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This book aims at providing an up-to-date report to cover key aspects of existing 
problems in the emerging field of targets in gene therapy. With the contributions 
in various disciplines of gene therapy, the book brings together major approaches: 
Target Strategy in Gene Therapy, Gene Therapy of Cancer and Gene Therapy of Other 
Diseases. This source enables clinicians and researchers to select and effectively utilize 
new translational approaches in gene therapy and analyze the developments in target 
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Preface 
Up to now, major diseases often attempted to be treated by gene therapy include 
cancer, cardiovascular disease and monogenic diseases. Despite many decades of gene
therapy research on these fatal diseases, most of the products fail to make it to market. 
One urgent problem is to identify the key targets for specific drugs.
The aim of our book is to cover key aspects of existing problems in the emerging field
of targets in gene therapy. With the contribution of leading experts and pioneers in
various disciplines of gene therapy, this book brings together major approaches: 
1. Target Strategy in Gene Therapy,  
2. Gene Therapy of Cancer, 
3. Gene Therapy of Other Diseases. 
The publication of this book was made possible by the efforts and collaboration of 
many individuals. We thank the contributors and section editors for generously 
sharing their expertise and scientific skills. 
We hope that this book will provide a realistic image of the huge potential, perspective 
and challenges facing the field of gene therapy in its quest to cure disease and prolong 
life.
Yongping You
Professor and Chief Physician 
Department of Neurosurgery 
The First Affiliated Hospital of Nanjing Medical University
China
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Choosing Targets for Gene Therapy 
Karina J. Matissek, Ruben R. Bender, 
James R. Davis and Carol S. Lim 
University of Utah 
USA 
1. Introduction 
Gene therapy is often attempted in fatal diseases with no known cure, or after standard 
therapies have failed. Targeting gene defects includes addressing a single mutation, 
multiple mutations in several genes, or even addressing missing or extra copies in a 
particular disease. A defect in one specific gene may impair normal function of the 
corresponding expressed protein. For example, in X-linked severe combined 
immunodeficiency (X-SCID), there is a mutation in the IL2 receptor γ gene. Another classic 
example occurs in thalassemia propagated by a defect in the β-globulin gene. Some diseases 
are caused by multiple mutations in several genes. For example, some cardiovascular 
diseases may manifest due to mutations in different chromosomes which are a result of 
inherited or environmental factors. Before approaching a disease using gene therapy, the 
key protein(s) and pathways involved in the disease should first be identified. However, in 
some cases an abnormal gene is formed that results in disease; such is the case for the Bcr-
Abl gene. The oncogenic Bcr-Abl protein is the causative agent of chronic myelogenous 
leukemia (CML) which could be blocked for CML treatment. Genomic sequencing 
information, microarrays, and biochemical assays can be used to determine up- or down-
regulated proteins involved in disease, and will help determine the function of these 
proteins. In the case of some cancers, the signal transduction pathways for oncogenesis have 
been mapped out, allowing hub proteins to be identified. Hub proteins are essential proteins 
that interact with multiple other proteins in signaling cascades. If selected properly, adding 
back a tumor-suppressing hub protein (such as p53), or blocking an oncogenic hub protein 
(such as survivin) could halt cancer or alter disease progression. Gene mutations can result 
in mislocalization of these key proteins which can cause cancer; this mislocalization can be 
exploited with gene therapy approaches. Further, new types of gene therapy are being 
developed in our lab to direct proteins to other cellular compartments where their function 
is altered. This chapter will summarize these and other known targets and also focus on 
choosing newer targets for gene therapy. 
2. Known targets for gene therapy 
The general aim of gene therapy is to introduce a well-defined DNA sequence into specific 
cells. Almost any disease can be targeted with gene therapy by replacing defective genes or 
imparting a new function. In fact, 85% of clinical trials in gene therapy have been conducted 
for cancer, cardiovascular diseases and for inherited monogenic diseases. In addition, 6.5% 
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of clinical trials have been conducted for infectious diseases (mainly HIV). Cancer, 
cardiovascular diseases and HIV are ideal gene therapy targets because of their enormous 
prevalence and the associated fatal consequences of these diseases, whereas monogenic 
disorders reflect the original idea of gene therapy which is replacement of a defective gene. 
Gene therapy offers a unique opportunity to cure patients with monogenic disorders. One 
third of clinical trials for monogenic disorders are for cystic fibrosis while about 20% are for 
SCID (Edelstein et al. 2004). This section highlights the advantages of gene therapy for 
multifactorial diseases such as cancer, vascular diseases, and HIV and describes the utility of 
gene therapy for monogenic diseases such as cystic fibrosis, SCID and β-thalassemia. 
2.1 Cancer 
Cancer was responsible for 7.6 million deaths in 2008 (WHO 2011) and is the largest target 
for gene therapy clinical trials. The complexity of cancer may make it difficult to bring a 
product to the market due to the number of genes involved compared to monogenetic 
disorders. However, gene therapeutics are not designed to correct these mutations by 
adding an enormous amount of DNA to the cells. Instead, they target critical proteins 
involved in signaling cascades such as the tumor suppressor p53. For example, the first gene 
therapy product was GendicineTM, an adenovirus containing the tumor suppressor p53. 
The tumor suppressor p53 is mutated in 40% of many types of cancers, and malfunction of 
p53 is the major contributor for chemotherapy resistance (Goh et al. 2011). Apoptosis can be 
triggered by transcriptionally active p53 in the nucleus (Taha et al. 2004) as well as by p53-
mediated transcriptionally independent mechanisms in the mitochondria (Vaseva et al. 
2009). Various animal studies have shown that p53 induces apoptosis even in advanced 
tumors such as lymphoma and hepatocellular carcinoma (Ventura et al. 2007; Palacios & 
Moll 2006; Xue et al. 2007).  
The first p53 based gene therapy in humans was conducted in 1996. This trial used a 
retroviral vector containing wild type p53 with an actin promoter for the treatment of non-
small cell lung carcinoma. In this study three patients showed tumor regression and three 
other patients showed tumor growth stabilization (Roth et al. 1996). China was the first 
country which approved a p53 adenovirus for gene therapy, GendicineTM SiBiono, in 
combination with radiotherapy for head and neck squamous cell cancer in 2004 (Shi & 
Zheng 2009). GendicineTM is a recombinant serotype 5 adenovirus with the E1 region 
replaced by the p53 expressing cassette (with a Rous sarcoma virus promoter). The 
adenovirus particles infect tumor target cells carrying therapeutic p53 (Peng 2005). Clinical 
trials for GendicineTM showed that in combination with radiation therapy it caused partial 
or complete tumor regression (Peng 2005; Xin 2006). There were also some clinical trials for 
GendicineTM in advanced liver cancer, lung cancer and other advanced solid tumors (Peng 
2005). It should be kept in mind that China’s State Food and Drug Administration (SFDA) 
has different standards for the approval of a cancer drug compared to the U.S. FDA and the 
European Medicine Agency (EMA). GendicineTM was approved in China on the basis of 
tumor shrinkage. The U.S. FDA and the EMA require novel cancer drugs to extend the 
lifetime of the treated patients (Guo & Xin 2006).  
Another p53 product is OncorineTM from Shanghai SunwayBiotech, an oncolytic virus. 
OncorineTM was approved for the treatment of head and neck cancer in China in 2006 (Yu & 
Fang 2007). It is a replicative adenovirus 2/adenovirus 5 hybrid with deletion in E1B55K 
and E3B (Raty et al. 2008). This oncolytic virus was expected to infect and lyse cancer cells 
only and not affect normal cells (Guo et al. 2008). Even though clinical studies showed that it 
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was not specific for cancer cells, it did, however, kill tumor cells preferentially (Garber 2006). 
Phase I/II trials showed little dose-limiting toxicity (Lockley et al. 2006) and the 
combination of OncorineTM with chemotherapy showed greater tumor shrinkage in patients 
with head and neck cancer, compared to chemotherapy alone. It should be kept in mind that 
like GendicineTM, OncorineTM was also approved by the SFDA based on objective response 
rate, not on survival (Garber 2006). Nevertheless, all the available data concerning p53 and 
its proven function as tumor suppressor qualifies it as an adjuvant treatment with 
radiotherapy or chemotherapy.  
Another approach to cancer gene therapy is gene-directed enzyme prodrug therapy 
(GDEPT).  GDEPT transfers an activating transgene into tumor cells followed by systemic 
treatment with a non-toxic drug which becomes activated only in cells expressing the 
transgene. CereproR is an adenovirus containing a herpes simplex type-1 thymidine kinase 
transgene under the cytomegalovirus promoter. CereproR is under phase I, II and III clinical 
trials in Europe for malignant glioma, a fatal form of brain cancer. In these clinical trials 
CereproR was injected multiple times into healthy brain tissues of patients following 
surgical removal of the solid tumor mass. Then the patients were treated with the prodrug 
ganciclovir, which is converted to its toxic form, deoxyguanosine, by thymidine kinase. This 
toxic metabolite affects newly dividing cells, thus it prevents new tumors from growing. In 
phase I and II trials, patients given CereproR showed a significant increase in survival. 
However, after phase III studies, the EMA rejected the marketing application for CereproR 
due to inadequate efficacy (van Putten et al. 2010; Cerepro 2009; Mitchell 2010; Raty et al. 
2008). Despite this particular failure, systemic side effects are avoided with the GDEPT 
concept. The general goal of GDEPT is the improvement of chemotherapy in terms of safety 
and efficiency using concomitant gene therapy (Edelstein et al. 2004).  
2.2 Cardiovascular diseases 
Cardiovascular diseases (CVD) encompass disorders of the heart and blood vessels and 
include hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular 
disease, heart failure, rheumatic heart disease, congenital heart disease and 
cardiomyopathies (Chiuve et al. 2006). Cardiovascular diseases are the largest health 
problem worldwide, claiming 17.1 million lives per year. Despite the complexity of 
cardiovascular disease, there is great potential for gene therapy especially in ischemia, 
angiogenesis, hypertension and hypercholesterolemia. Currently there is no gene therapy 
product on the market for CVD. Nevertheless, several clinical trials have been conducted 
(Edelstein et al. 2004; Edelstein et al. 2007). Most gene therapies for CVD aim to increase 
angiogenesis which is a mechanism to overcome ischemia. Ischemia is a condition in which 
the flow of blood is restricted to parts of the body. The response of the body is to form new 
blood vessels around the blockage, called angiogenesis, and is triggered by angiogenic 
proteins such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) 
and hepatocyte growth factor (HGF) (Abo-Auda & Benza 2003; Kass et al. 1992). The goal of 
introducing genes coding for these growth factors is to increase the local concentration of 
these factors to stimulate angiogenesis (Edelstein et al. 2004). Two companies are conducting 
phase III clinical trials using FGF. Bayer Schering Pharm AG has developed alferminogene 
tadenovec, which is a replication-deficient human adenovirus serotype 5 which encodes 
human FGF4. Since myocardial ischemia is linked to coronary artery disease, the therapeutic 
goal is to improve the reperfusion of ischemic myocardium. Phase IIb/III clinical trials 
showed that it is well-tolerated; a phase III trial is ongoing to prove its efficacy (Flynn & 
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was not specific for cancer cells, it did, however, kill tumor cells preferentially (Garber 2006). 
Phase I/II trials showed little dose-limiting toxicity (Lockley et al. 2006) and the 
combination of OncorineTM with chemotherapy showed greater tumor shrinkage in patients 
with head and neck cancer, compared to chemotherapy alone. It should be kept in mind that 
like GendicineTM, OncorineTM was also approved by the SFDA based on objective response 
rate, not on survival (Garber 2006). Nevertheless, all the available data concerning p53 and 
its proven function as tumor suppressor qualifies it as an adjuvant treatment with 
radiotherapy or chemotherapy.  
Another approach to cancer gene therapy is gene-directed enzyme prodrug therapy 
(GDEPT).  GDEPT transfers an activating transgene into tumor cells followed by systemic 
treatment with a non-toxic drug which becomes activated only in cells expressing the 
transgene. CereproR is an adenovirus containing a herpes simplex type-1 thymidine kinase 
transgene under the cytomegalovirus promoter. CereproR is under phase I, II and III clinical 
trials in Europe for malignant glioma, a fatal form of brain cancer. In these clinical trials 
CereproR was injected multiple times into healthy brain tissues of patients following 
surgical removal of the solid tumor mass. Then the patients were treated with the prodrug 
ganciclovir, which is converted to its toxic form, deoxyguanosine, by thymidine kinase. This 
toxic metabolite affects newly dividing cells, thus it prevents new tumors from growing. In 
phase I and II trials, patients given CereproR showed a significant increase in survival. 
However, after phase III studies, the EMA rejected the marketing application for CereproR 
due to inadequate efficacy (van Putten et al. 2010; Cerepro 2009; Mitchell 2010; Raty et al. 
2008). Despite this particular failure, systemic side effects are avoided with the GDEPT 
concept. The general goal of GDEPT is the improvement of chemotherapy in terms of safety 
and efficiency using concomitant gene therapy (Edelstein et al. 2004).  
2.2 Cardiovascular diseases 
Cardiovascular diseases (CVD) encompass disorders of the heart and blood vessels and 
include hypertension, coronary heart disease, cerebrovascular disease, peripheral vascular 
disease, heart failure, rheumatic heart disease, congenital heart disease and 
cardiomyopathies (Chiuve et al. 2006). Cardiovascular diseases are the largest health 
problem worldwide, claiming 17.1 million lives per year. Despite the complexity of 
cardiovascular disease, there is great potential for gene therapy especially in ischemia, 
angiogenesis, hypertension and hypercholesterolemia. Currently there is no gene therapy 
product on the market for CVD. Nevertheless, several clinical trials have been conducted 
(Edelstein et al. 2004; Edelstein et al. 2007). Most gene therapies for CVD aim to increase 
angiogenesis which is a mechanism to overcome ischemia. Ischemia is a condition in which 
the flow of blood is restricted to parts of the body. The response of the body is to form new 
blood vessels around the blockage, called angiogenesis, and is triggered by angiogenic 
proteins such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) 
and hepatocyte growth factor (HGF) (Abo-Auda & Benza 2003; Kass et al. 1992). The goal of 
introducing genes coding for these growth factors is to increase the local concentration of 
these factors to stimulate angiogenesis (Edelstein et al. 2004). Two companies are conducting 
phase III clinical trials using FGF. Bayer Schering Pharm AG has developed alferminogene 
tadenovec, which is a replication-deficient human adenovirus serotype 5 which encodes 
human FGF4. Since myocardial ischemia is linked to coronary artery disease, the therapeutic 
goal is to improve the reperfusion of ischemic myocardium. Phase IIb/III clinical trials 
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O'Brien 2008; CardioVascular BioTherapeutics). Sanofi-Aventis is developing a FGF gene 
therapy product called riferminogene pecaplasmide or NV1FGF (Riferminogene 
pecaplasmide  2010). It is a novel pCOR (conditional origin of replication) plasmid-based 
gene delivery system (Maulik 2009). NV1FGF is injected into muscle cells, and expresses 
FGF-1. The therapeutic goal is to treat chronic/critical limb ischemia since limb ischemia is 
linked to peripheral artery disease (Baumgartner et al. 2009). Phase III clinical trials are 
ongoing in 32 countries (Riferminogene pecaplasmide  2010). 
Another gene therapy approach to treat limb ischemia uses HGF. There are several animal 
studies showing that HGF can trigger formation of new blood vessels (Shigematsu et al. 
2010). The injection of the naked HGF gene is well-tolerated as shown in the first clinical 
trial conducted in Japan (Morishita et al. 2004). Another clinical trial in the U.S. showed that 
HGF injection increased tissue perfusion compared to placebo (Powell et al. 2008). Lastly, 
there is also a clinical trial to prove efficacy of HGF gene therapy, using reduction of ulcer 
size and decrease in rest pain (pain occurring during sleep) as objectives (Shigematsu et al. 
2010). 
2.3 HIV 
The human immunodeficiency virus (HIV) causes acquired immunodeficiency syndrome 
(AIDS), a severe disease characterized by profound negative effects on the immune system 
leading to life-threatening opportunistic infections. Although antiretroviral drugs have 
decreased the morbidity and mortality of HIV infected patients, currently there is no cure. 
However, new developments in gene therapy have focused on introducing genes encoding 
RNA or proteins which are capable of interfering with intracellular replication of HIV, so-
called intracellular immunization. So far, the approaches range from protein-based 
strategies such as fusion inhibitors or zinc finger nucleases to RNA-based approaches such 
as ribozymes, antisense or short hairpin RNA. Currently, a promising target is the 
chemokine receptor 5 (CCR5) which is needed for fusion of HIV with immune cells. Studies 
have shown that patients with mutated CCR5 have a higher long-term survival and slower 
progression of the disease. A homozygous defect in the CCR5 gene, a Δ32 deletion, resulting 
in a lack of functional CCR5 protein and confers resistance to HIV infection (Liu et al. 1996). 
An allogeneic stem-cell transplantation of CCR5 defective cells in a patient with HIV 
infection and acute myeloid leukemia resulted in both a negative HIV plasma viral load and 
no detection of HIV proviral DNA for more than 3.5 years after treatment (without the use 
of antiviral drugs). This result has been classified as a cure of HIV (Kitchen et al. 2011, and 
references therein; Symonds et al. 2010, and references therein). 
2.4 Monogenic diseases 
Monogenic diseases are prime targets for gene therapy due to their simple single gene 
mutations. Their disease causing mechanisms are easier to elucidate which is advantageous 
for choosing a target for gene therapy. In addition, the execution of therapy is more 
straightforward, since it is easier to transfer single genes into cells instead of several genes. 
Other important factors are the location and the type of cell in which the gene has to be 
transferred. Is the cell reachable with existing delivery systems? Is the cell already 
differentiated or is it a still dividing stem cell? Does gene transfer need to be repeated or is a 
one-time transfer sufficient? All these questions have to be considered in order to choose the 
right target for gene therapy, and it must be noted that not every disease caused by single 
gene mutations can be targeted. Three examples of well-studied diseases and attempts to 
treat these diseases using gene therapy will be discussed. 
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2.4.1 Cystic fibrosis 
Cystic fibrosis (CF) is a complex inherited disease affecting the lungs and digestive system. 
The cause of this disease is a defect in the cystic fibrosis transmembrane conductance 
regulator (CFTR), which is a chloride channel on the apical membrane of respiratory 
epithelia. This leads to reduced Cl- and increased Na+ permeability (Boucher et al. 1988). CF 
is caused by several different mutations in the CFTR gene located on chromosome 7 
(Knowlton et al. 1985). Of the hundreds of mutations that cause CF, the most common 
mutation, which occurs in approximately 70% of all cases, is the deletion of a phenylalanine 
residue at amino acid position 508 (ΔF508) (Kerem et al. 1989). CF results in decreased 
production of pancreatic enzymes leading to malnutrition, and also blocks the lung with 
unusually viscous mucus leading to life-threatening infections (Cystic Fibrosis Foundation; 
Wood 1997). It is possible to treat symptoms of CF to improve quality of life but there is no 
current cure for this disease. Mainstays for symptomatic treatment include enzymatic 
therapies (pancreatic enzymes and DNAse I) (McPhail et al. 2008), airway clearance and 
hypertonic saline for improved lung function, use of drugs that enhance Cl- secretion in 
airway epithelium (Cloutier et al. 1990) and anti-inflammatories involving ibuprofen or 
corticosteroids (Flume et al. 2010, and references therein). Despite a clear understanding of 
genetic links, gene therapy is not yet a standard treatment for CF, as recent attempts to cure 
patients with CF have not been successful. Moss et al. showed improvement in pulmonary 
function in a phase II clinical trial with 42 CF patients, of whom 20 received at least one dose 
of aerosolized adeno-associated serotype 2 virus carrying the CFTR gene. A significant 
enhancement in FEV1 (forced expiratory volume per second) was noted after 30 days 
compared to placebo. Furthermore, this study showed no adverse events demonstrating the 
safety of adeno-associated vectors (Moss et al. 2004). However, when this same group 
performed a second, larger phase IIb trial with 102 subjects, there was no significant 
improvement in FEV1 seen after 30 days compared with placebo (Moss et al. 2007). 
Expression of CFTR was noted in airway epithelium of 7 individuals with CF after the first 
administration but the effect lasted only 30 days. The second administration showed 
decreased expression. Finally, at the third administration, the expression fell to zero (Harvey 
et al. 1999). In conclusion, there is some indication that gene therapy could be used to cure 
CF, but no method has shown to be universally applicable. Further research is needed to 
find the right vector with repeatable administration and subsequent high expression while 
simultaneously being safe. Gene therapy for CF targets epithelial cells which have a limited 
life span and do not divide. Because of that, the gene has to be transferred repeatedly into 
new growing cells, which is problematic since repeated transfections have been ineffective.   
2.4.2 Severe combined immunodeficiency 
Severe combined immunodeficiency (SCID) is a rare, fatal syndrome with an incidence of 
24.3 cases per million live births (Ryser et al. 1988). The disease is characterized clinically by 
defects in humoral and cellular immunity due to profound deficiencies of T-and B-cell 
function, and if left untreated usually leads to death in infancy (Buckley et al. 1997). 
Mutations leading to SCID appear in various genes including Jak-3, adenosine deaminase, 
IL-7 receptor (Puel et al. 1998), tyrosine phosphatase CD45 (Kung et al. 2000), the 
interleukin-2 (IL-2) receptor γ chain (IL2-Rγ), the Artemis gene (Kobayashi et al. 2003) and 
recombinase activating genes 1 or 2 (Schwarz et al. 1996; Buckley et al. 1997, and references 
therein). The most frequently diagnosed form of SCID is X-SCID, which is characterized by 
a mutation in the IL2-Rγ gene located on the X chromosome. This disease shows a male 
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predominance, with a mean age of diagnosis of 6.6 months. The IL2-Rγ chain is a critical 
component of many cytokine receptors including those for IL-2, -4, -7, -9, -15 and 21, where 
defects may result in greatly decreased numbers of T and NK cells. The number of B cells is 
generally normal but their activity is abnormal (Buckley et al. 1997). After maternal 
antibodies have vanished, the extreme susceptibility to infection due to opportunistic 
microbes, persistent diarrhea and failure to thrive usually lead to death in the first year of 
life unless immunologic reconstruction can be achieved. 
Hematopoietic stem cell transplantation is the standard of care for all genetic types of SCID 
with a survival rate of nearly 80% with HLA-identical parental marrow (Antoine et al. 2003). 
Even with a matched donor, stem cell transplantation may lead to long-term clinical 
complications (De Ravin & Malech 2009). Thus, other treatments for SCID are needed. An ex 
vivo gene therapy trial with two X-SCID patients, aged 8 and 11 months, demonstrated that 
gene therapy has curative potential. Administration of a retroviral vector containing the 
correct IL2-Rγ gene resulted in T cell counts similar to that of age-matched controls after 105 
days. Furthermore, the immune system responded to tetanus toxin and polioviruses within 
the normal range after primary vaccination. Both patients later showed normal growth and 
psychomotor development (Cavazzana-Calvo et al. 2000). Other studies confirmed these 
results (Hacein-Bey-Abina et al. 2002; Thrasher et al. 2005). A separate study of gene therapy 
for X-SCID with children aged 2.5, 4 and 8 years old showed mixed results. Only the 
youngest patient experienced benefit from the treatment (Chinen et al. 2007). Another trial 
with two patients, aged 15 and 20 years old also failed (Thrasher et al. 2005). Despite the 
variable outcome from these studies, gene therapy may still potentially cure X-SCID and 
other SCIDs, in particular for younger patients. It is already possible to cure newborn 
children with this modern technique, if traditional methods like BMT fail. If the safety of 
gene therapy vectors can be improved to lower the risk of insertional mutagenesis, gene 
therapy will likely become first-line therapy for to the treatment of X-SCID. In contrast to 
CF, the presence of accessible stem cells in which the functional gene could be transferred 
would allow continuous expression of this gene, making X-SCID a good candidate for gene 
therapy. 
2.4.3 β–thalassemia 
β–thalassemia syndromes are a group of inherited blood disorders. Thalassemia major is 
the only transfusion-dependent type of β-thalassemia and manifests itself clinically 
between 6 and 24 months of life by paleness and failure to thrive. It is marked by reduced 
(β+) or absent (β0) beta globin chain synthesis caused by several different single gene 
mutations, resulting in reduced hemoglobin in red blood cells (Weatherall 1976). If left 
untreated, this disease results in growth retardation, pallor, jaundice, poorly developed 
musculature, skeletal changes and other consequences leading to death during infancy 
(Cao & Galanello 2010). Blood transfusion is the current standard therapy for β–
thalassamia and aims to correct the anemia from reduced hemoglobin (Cao & Galanello 
2010). This treatment, however, carries the risk of infection from blood borne diseases 
such as HIV and hepatitis and as well as the serious side effect of transfusional iron 
overload which is fatal if untreated. Currently, BMT offers the best chance for curing β-
thalassemia in both in children and adults if a HLA identical donor is found, but is limited 
by complications like graft-versus-host disease or finding suitable donors (Lucarelli & 
Gaziev 2008). 
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Gene therapy of human β-thalassemia is still in its infancy and requires the development of 
efficient, safe and high level gene transfer into target hematopoietic stem cells. It also 
requires regulation of erythroid lineage-specific expression and therapeutic levels of β-
globin expression (Malik & Arumugam 2005). Meeting these requirements may be difficult, 
but a successful gene therapy trial was achieved in 2007 when an 18 year-old patient was 
effectively treated using a β-globin-expressing lentiviral vector. The vector was transfected 
ex vivo into harvested CD34+ cells and then transplanted back into the patient’s bone 
marrow. The patient, who had no HLA-matched donors (making BMT impossible), was 
treated with high dose chemotherapy with intravenous busulfan to eliminate defective 
hematopoetic stem cells (HSC) prior to transplantation. This step was critical for the success 
of this treatment to prevent the defective HSC from diluting the corrected HSC. Three years 
post-transplant this patient no longer required blood transfusions and showed stable 
hemoglobin levels. However, mild anemia, compensatory expansion of red-blood-cell 
precursors in bone marrow, and other safety concerns have been raised (including 
development of cancers) (Cavazzana-Calvo et al. 2010). Although the long-term prognosis 
and outcome of gene therapy for β-thalassemia is currently unclear, it still has the same 
advantage of the presence of accessible stem cells as X-SCID. With this in mind, targeting 
stem cells may be more successful than differentiated cells, and may be sufficient to cure the 
disease. 
3. Identifying novel targets for gene therapy 
Before targeting a disease with gene therapy, the genetic basis of that disease should be 
identified. Strategies for finding disease genes have greatly improved in the last few years 
due to the Human Genome Project and the Hap Map Project. The Hap Map Project 
identifies and catalogs genetic similarities and differences in humans (Human Genome 
Project; The International Hap Map Consortium 2003) and supplies computerized databases 
to search through and identify new gene therapy targets (Hap Map Project 2003). To find 
genes the two most common options are candidate-gene studies and genome-wide studies. 
Candidate-gene association studies are based on prior biological knowledge of gene 
function or on significant findings in linkage studies. This method is based on a single 
polymorphism and haplotypes and compares allele or haplotype frequencies between the 
case and the control group. Genome-wide studies can be divided into linkage mapping and 
genome-wide association studies. Genetic linkage mapping studies are used to discover and 
identify new genes by using genetic and phenotypic data from families. The analysis is 
conducted without any prior knowledge about genetic basis of disease. Linkage analysis 
functions by comparing genotype polymorphic markers at known locations in the genome. 
Genome-wide association studies are the most recent technology. They search the whole 
genome for single nucleotide polymorphisms (SNPs). Each study can look at hundreds or 
thousands of SNPs at the same time (for an excellent review see (Hirschhorn & Daly 2005)). 
The results are plotted into biostatistics algorithms (Nakamura 2009; Hirschhorn & Daly 
2005). The proteins identified by genomic methods can be further characterized by standard 
molecular and biochemical assays. In addition, protein targets have been identified by 
individual labs using standard molecular and biochemical methods without a priori use of 
genomic information. With the growing understanding of genes associated with many 
diseases the future for new gene therapeutics shows promise.  
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Fig. 1. Finding Novel Gene Therapy Targets. Integration of standard and modern 
technologies for disease-causing targets for gene therapy. 
3.1 Methods to find gene therapy targets 
Microarrays lay the groundwork for the methods mentioned above. The two most important 
advantages of microarrays are their small scale (multi-well plate formats) and ability to 
detect thousands of different immobilized genes simultaneously (Duggan et al. 1999; 
Siegmund et al. 2003; NCBI 2007). There are three types of microarray technologies: 
comparative genomic hybridization, expression analysis and mutation/polymorphism 
analysis, though the principle remains the same for all. First, the DNA chip corresponding 
to the DNA of interest is selected. Then, isolated messenger RNA (mRNA) is used as a 
template to generate complementary DNA (cDNA), with a fluorescent tag. This mixture is 
incubated with the DNA chip. During this incubation, tagged cDNA can specifically bind to 
the complementary DNA template on the chip. Afterwards, the hybridized cDNA can be 
detected with lasers specific to different fluorophores followed by analysis using 
computational methods (NCBI 2007). 
The Human Genome Project and the HapMap project have provided the foundation for 
candidate gene and genome-wide studies. Using these methods may allow us to draw 
conclusions between gene abnormalities and diseases. For example, many different studies 
have been conducted to determine the genes associated with cardiovascular diseases. In fact 
many CVDs are linked to mutated genes. For example, there is evidence based on genetic 
linkage analysis that chromosomes 1, 2, 3, 13, 14, 16 and X are involved in myocardial 
infarction, which is the major killer world-wide. Additionally, myocardial infarction and 
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stroke are associated with mutations in chromosome 13q12-13 containing the ALOX5AP 
gene encoding arachidonate 5-lipoxygenase-activating protein. Furthermore, high LDL, low 
HDL and high triglycerides values are high risk factors for cardiovascular disease, with 
linkage results located in all autosomes except for 2 and 14 (Arnett et al. 2007, and references 
therein). 
Finding disease-causing genes may not only help to better understand the pathophysiology 
of the disease, but may improve the diagnosis of the disease by discovery of disease-specific 
marker genes. Importantly, identification of disease-causing genes will lead to new targets 
for improved therapeutics. Genome-wide association studies which scan markers across the 
entire genome can find single mutations causing monogenic disorders as well as different 
mutations in several genes, which may lead to more gene therapy-based cures for these 
diseases.  
3.2 Hub proteins 
Genomic sequencing information, microarrays, and molecular/biochemical assays are tools 
that can help determine which proteins are responsible for disease. This information can be 
analyzed to identify hub proteins involved in disease progression. Hub proteins are key 
proteins that signal to multiple other proteins in transduction cascades. They are highly 
connected to other proteins with multiple interaction partners. Hub proteins bind with 
several distinct binding sites to other proteins. Studying the binding interface of cancer-
related proteins maybe useful for better understanding of cellular function and biological 
processes (Keskin & Nussinov 2007; Kim et al. 2006).  
3.2.1 Tumor suppressor hub proteins   
3.2.1.1 p53 
The tumor suppressor p53 is an example of a hub protein involved in cancer which loses the 
ability to bind different other proteins due to mutations (Shiraishi et al. 2004). It induces 
transactivation of target genes which are responsible for cell cycle arrest, DNA repair and 
apoptosis. p53 is mutated in 40% of cancers (Goh et al. 2010). In normal, healthy cells p53 is 
rapidly degraded via the MDM2 pathway, but when stress signals occur, p53 accumulates 
dramatically in the cell, allowing it to accomplish its apoptotic functions. p53 stimulates 
multiple signaling mechanisms which lead to apoptosis: the extrinsic pathway through 
death receptors and the intrinsic pathway through the mitochondria (Haupt et al. 2003). As 
a transcription factor it binds to p53-responsive genes, and the expressed proteins trigger 
apoptosis, G1 arrest, as well as DNA repair through different mechanisms. In addition, p53 
translocates to the mitochondria and induces a rapid apoptotic response (Erster et al. 2004; 
Haupt et al. 2003). Consequently, p53 fulfills the requirements for an ideal hub protein for 
gene therapy. Indeed, p53 adenovirus has been used for cancer therapy, and was the first 
gene therapeutic on the market.  
3.2.1.2 BRCA1 and BRCA2 
Breast cancer susceptibility protein (BRCA)1 and BRCA2 are highly associated with breast 
and ovarian cancer. The lifetime risk of developing breast cancer for a person carrying 
mutations in both genes is 82%; mutations in BRCA1 account for 52% and BRCA2 for 23% of 
all cases. Furthermore, the risk for ovarian cancer is dramatically increased due to mutations 
in BRCA1 and/or BRCA2. Thus, it is important to identify patients with a probability of 
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having mutations in these proteins. BRCA1 and BRCA2 regulate cell cycle progression, 
DNA repair and gene transcription (Metcalfe et al. 2005).  Their export into the cytoplasm is 
associated with apoptosis. In cooperation with cellular partner BARD1 (BRCA1-associated 
RING domain protein), BRCA1 is able to enter the nucleus and accomplish its role in DNA 
repair, centrosome regulation and RNA processing (Henderson 2005; Rodriguez et al. 2004). 
When the sensitive balance between BARD1 and BRCA1 is defective due to cancer-
promoting mutations in both, they remain as a dimer which results in nuclear 
compartmentalization leading to dramatic reduction of their apoptotic activity (Davis et al. 
2007; Rodriguez et al. 2004). Silencing BRCA1 expression using RNA-mediated interference, 
results in increased cytoplasmic levels of BARD1 and causes apoptosis in breast cancer cell 
lines (Rodriguez et al. 2004). BARD1 translocates to the mitochondria and causes 
oligomerization of Bax which results in apoptosis (Tembe & Henderson 2007). Therefore, 
targeting BRCA1 is a viable gene therapy-based approach.  
3.2.2 Hub proteins that promote cancer 
3.2.2.1 Survivin 
In addition to adding back hub tumor suppressors for gene therapy, oncogenic hub proteins 
can be blocked as well. The oncogene survivin is nearly universally expressed in various 
types of cancer and is almost undetectable in most adult tissue. Survivin is a unique member 
of the inhibitor of apoptosis protein (IAP) family and plays a major role as a mitotic 
regulator (Altieri 2001, and references therein). It is involved in multiple cancer-promoting 
mechanisms, particularly inhibition of apoptosis. Various parallel pathways, such as 
intervention in mitochondrial function, inhibition of caspases, and influence on gene 
expression are responsible for survivin’s anti-apoptotic function (Altieri 2008, and references 
therein). For example,  survivin and its binding partners act to prevent caspase activation; 
activated caspase 9 is required to activate effector caspase 3 and caspase 7, which execute 
mitochondrial-induced apoptosis (Li & Yuan 2008). Also, a splice variant of survivin, 
survivin ΔEx-3, translocates to the mitochondria where it interacts with proteins from the 
Bcl-2 family. These proteins are inhibitors of permeabilization of the mitochondrial outer 
membrane which is essential for cytochrome c release. Stabilization of Bcl-2 proteins 
prevents cytochrome c release, thus resulting in the inhibition of caspase 9 and caspase 3 
(Altieri 2008, and references therein). Furthermore, survivin’s role as a mitotic regulator is 
related to its inhibition of apoptosis. Survivin expression is upregulated at the G2/M phase 
to localize to the mitotic apparatus and is downregulated in interphase via ubiquitin-
dependent destruction (Li, Ambrosini, et al. 1998; Zhao et al. 2000). High survivin 
expression was detected in various types of cancers including breast, lung, colon, stomach, 
esophagus, pancreas, uterus, ovary and liver (Altieri 2008, and references therein). Dramatic 
overexpression of survivin correlates with more aggressive and invasive clinical phenotypes 
which means a poor prognosis compared to survivin-negative tumors, an increased rate of 
recurrence and chemotherapy resistance (Kato et al. 2001; Grossman & Altieri 2001). The 
differential expression and function of survivin make it an excellent target for cancer 
therapy (Altieri 2003). There are many gene-based strategies to inhibit survivin in cancer 
cells, with some in phase I and II clinical trials. One gene-based method uses survivin 
antisense oligonucleotides to prevent expression in cancer cells. Two phase II trials and one 
phase I trial by Eli Lilly and Co. are ongoing for relapsed or refractory acute myeloid 
leukemia, hormone refractory prostate cancer and advanced hepatocellular carcinoma (Ryan 
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et al. 2009). Furthermore, Alteri et al. created a replication-deficient adenovirus containing a 
dominant negative survivin mutant where threonine 34 is mutated to alanine. This mutation 
abrogates phosphorylation of threonine which impairs survivin’s ability act as a mitotic 
regulator, as only phosphorylated survivin is able to localize to the mitotic apparatus 
(O'Connor et al. 2000). Injection of adenovirus containing survivin mutant triggers apoptosis 
by cytochrome c release which leads to caspase 3 activation. Alteri et al. demonstrated in 
several cancer cell lines that this mutant causes apoptosis and confirmed these results in 
three xenograft breast cancer mice models. Interestingly, this survivin mutant was not able 
to cause apoptosis in proliferating normal human cells (Mesri et al. 2001). 
3.2.2.2 Ras 
The RAS supergene family is divided into six subfamilies RAS, RHO, RAB, ARF, RAN and 
RAD which code for more than 50 structurally related proteins. Their main function is to 
transmit signals from cell-surface receptors to the cell interior. All proteins have a guanosine 
triphosphate (GTP) binding motif in common and participate in signaling cascades. The 
RAS subfamily functions in proliferation and differentiation which makes it a prime target 
for anti-cancer therapy. The localization of Ras on the cell membrane, and binding to GTP 
are essential for its function. When Ras binds to GTP, it initiates the signaling pathway for 
cell proliferation and differentiation. However, when Ras-GTP is hydrolyzed to Ras-GDP by 
GTPase-activating proteins (GAPs), it is unable to activate its signal transduction pathway. 
This sensitive regulation process is out of balance in cancer cells due to different mutations 
in the RAS gene. Most of these mutations occur in the Ras gene itself and in the regulatory 
proteins of the Ras pathway. These mutations cause Ras to stay in the active Ras-GTP form 
and prevent conversion into the inactive Ras-GDP form. Mutated Ras protein is hyperactive 
and triggers cancer development. Hyperactive Ras is associated with different types of solid 
tumors such as pancreatic, cervical, thyroid, colon, skin, and lung tumors as well as with 
hematopoietic malignancies such as chronic myelomonocytic leukemia, acute myelogenous 
leukemia and multiple myeloma to list a few. Ras is an excellent gene therapy target due to 
its involvement in various cancers (Beaupre & Kurzrock 1999, and references therein). 
Recently it has been shown that knocking out Ras with an anti-Ras mRNA plasmid-
mediated short-hairpin RNA in combination with clinical drug vincristine resulted in 
inhibition of the growth of human hepatoma HepG2 in vivo (Sun et al. 2009). This illustrates 
once again that the combination of gene therapy with standard chemotherapy is a promising 
approach for treatment of cancer.  
3.2.2.3 AKT 
AKT, a serine/threonine kinase, plays an essential role in oncogenesis. The AKT family 
consists of three cellular homologues AKT1, AKT2 and AKT3. The encoded proteins have a 
similar structure consisting of an amino-terminal pleckstrin homology domain, a short α-
helical linker and a carboxy-terminal kinase domain. Tissues have different expression 
levels of the three homologues AKT1, AKT2 and AKT3, which is why it is not surprising 
that the three different variants of AKT are overexpressed in different types of cancers. For 
example, AKT1 is overexpressed in gastric cancer and is associated with poor prognosis in 
breast and prostate cancer; AKT2 is overexpressed in ovarian and pancreatic cancer. AKT3 
is overexpressed in estrogen receptor-deficient breast cancer and in androgen-insensitive 
prostate cancer which implies that AKT3 contributes to aggressive steroid hormone-
insensitive cancer. AKT acquires growth signal autonomy and inhibits apoptosis in cancer 
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cells. It promotes cell survival through its phosphorylation of MDM2, which enhances 
nuclear accumulation of MDM2. MDM2 inhibits the transcriptional activity of p53 and 
promotes its degradation by the proteasome (Testa & Bellacosa 2001). AKT gene therapy has 
been conducted with an aerosol delivery system consisting of nano-sized glucosylated 
polyethylenimine (GPEI). It has been shown that this aerosol is capable of delivering AKT 
wild-type and kinase deficient genes into the lung of mice (Tehrani et al. 2007). Dominant 
negative alleles of AKT directly injected into lung carcinoma cells have also been shown to 
block cell survival and proliferation (Li, Simpson, et al. 1998). 
3.3 Protein-protein interactions 
A protein dimer or oligomer is a macromolecular structure formed by two (dimer) or 
several (oligomer) proteins of either same origin (homo-oligomers) or different origins 
(hetero-oligomers). For several proteins the formation of oligomers or dimers is essential in 
order to form functional systems. Both Bcr-Abl and p53 proteins function in the homo-
oligomeric form. On the other hand, hemoglobin forms hetero-oligomers consisting of two α 
and two β subunits to form a functional structure. If one of these subunits is defective or 
missing, the protein cannot master its tasks leading to diseases such as the previously 
described β-thalassemia. Mutations in the oligomerization domain can lead to loss of 
function. Dimer or oligomer formation is governed by non-covalent interactions, including 
salt bridges, hydrogen bonds and hydrophobic interactions. A common structural motif for 
dimerization is a coiled coil consisting of usually two to five α-helices that wind around one 
another like strands of a rope, meshed together like “knobs-into-holes.” They contain a 
characteristic seven-residue sequence repeat (Mason & Arndt 2004; Crick 1952). Coiled coil 
motifs play an important role in the function of several different proteins ranging from 
transcription factors such as Jun and Fos which are responsible for cell growth and 
proliferation (Glover & Harrison 1995) to the oncoprotein Bcr-Abl which leads to cancer 
(McWhirter et al. 1993). A subgroup of the coiled coil motif is represented by the “leucine 
zipper”, an unusually long α-helix with protruding leucine residues in periodic repetition. 
The leucine residues from one peptide interact with leucine residues from a second peptide, 
forming a molecular zipper (Landschulz et al. 1988). Another important dimerization 
interface for proteins is the helix-loop-helix (HLH) motif. Characterized by two α-helices 
connected by a short loop, this structure is highly conserved in many diverse organisms. 
Proteins containing this structure are transcription factors that are only functional as homo- 
or hetero-dimers (Murre et al. 1994, and references therein). Important HLH family 
members are myc proteins which play an essential role in cell proliferation, differentiation, 
cell growth, and apoptosis, but are also involved in development of numerous kinds of 
cancer (Vita & Henriksson 2006). Finally, another interaction motif is the zinc finger motif, 
containing several subgroups such as C2H2, Gag knuckle, treble clef, zinc ribbon, 
Zn2/Cys6, TAZ2 domain like, zinc binding loops and metallothionein (Krishna et al. 2003). 
The C2H2 zinc finger represents the most prevalent motif and contains a zinc ion 
coordinated by cysteines and histidines (Wolfe et al. 2000). Although most C2H2 fingers 
apparently contribute to protein-DNA or protein-RNA interactions, examples for protein-
protein interactions also exist. One example is Ikaros, a transcription factor participating in 
gene silencing and activation in hematopoietic cells. In this protein, dimerization is 
important for its activity and affinity to DNA (McCarty et al. 2003, and references therein). 
In addition, more complex oligomerization structures exist. For example, p53 forms a dimer 
with an antiparallel β-sheet and an antiparallel helix-helix interface. Two dimers associate as 
a parallel helix-helix to form a tetramer (Jeffrey et al. 1995). 
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Gene therapy may be used to enhance or inhibit dimerization interfaces. Currently, small 
molecule drugs are unable to re-establish the ability of proteins to form dimers with the aim 
of restoring their natural function. In contrast, gene therapy can supply dimerization-
capable and functional proteins. On the other hand, if the formation of a dimer is unwanted, 
it is possible to disrupt the dimerization interface of a disease-causing protein by 
introducing proteins into the cell which compete for dimerization. Normal dimerization of 
the disease-causing protein is then blocked, hence stopping the disease. 
3.3.1 Homo-oligomerization for apoptotic activity 
The classic example of a protein that is only functional as a homo-oligomer is p53. The 
protein p53 is 393 amino acids long and contains a transactivation domain (amino acids 1-
43) and a proline-rich domain (amino acids 61-94), a DNA-binding domain (amino acids 
110-286), a tetramerization domain (amino acids 326-355) and a regulatory region (amino 
acids 363-393) (Chene 2001). As already mentioned, mutations of TP53, the gene encoding 
for p53, occur in a large proportion of human cancers. Some of these mutations may prevent 
the formation of tetramers, which lead to loss of p53 function (Vogelstein et al. 2000). Not 
only does the site-specific binding to DNA depend on oligomerization , but so do a number 
of post-translational modifications of p53 which are believed to be important regulators of 
p53 activity (Chene 2001, and references therein). Reintroducing tetramerization-capable 
p53 using gene therapy may allow treatment of cancers which are caused by mutations in 
this region of TP53. So far 49 mutations in the tetramerization domain of p53 have been 
described, even though not all mutations prevent dimerization or tetramerization. Most of 
these occurring mutants still form tetrameric structures like wild-type p53 but with reduced 
stability (Kamada et al. 2011).  
Another example where protein oligomerization yields functionality occurs with DJ-1. This 
protein bears cytoprotective functions within cells and protects neurons from stressful 
stimulants. A L166P mutation in the DJ-1 gene may prevent its ability to homodimerize, and 
it has been speculated that this can lead to neurodegeneration in autosomal recessive early 
onset Parkinsonism (Gorner et al. 2007, and references therein). Re-introduction of 
dimerization-capable DJ-1 with gene therapy is therefore a possible treatment option. 
3.3.2 Disruption of disease-causing homo-oligomerization  
Like p53, Bcr-Abl is also a protein that functions as a homo-oligomer (dimer of dimers). 
However, Bcr-Abl derives oncogenic function rather than tumor suppression from 
oligomerization. Bcr-Abl results from the fusion of the breakpoint cluster region (Bcr) gene 
on chromosome 22 and the Abelson leukemia oncogene (Abl) on chromosome 9. This results 
in an abnormal shortened chromosome called the Philadelphia chromosome. Bcr-Abl 
functions as an oncoprotein leading to increased cell proliferation and inhibition of 
apoptosis due to the constitutive activation of tyrosine kinase activity and causes 95% of all 
cases of chronic myeloid leukemia (CML) (Sawyers 1999, and references therein). The 
oligomerization of Bcr-Abl is essential for the activation of the tyrosine kinase activity of 
Bcr-Abl (McWhirter et al. 1993). Destroying the ability of Bcr-Abl to form tetramers or using 
the dimerization domain to disrupt Bcr-Abl activity would be a possible gene therapy 
approach for CML (Dixon et al. 2009). 
Finally, serpins (serine protease inhibitors) such as serpin α1-antitrypsin function aberrantly 
as oligomers/polymers (Silverman et al. 2001; Lomas & Mahadeva 2002). In fact, the 
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cells. It promotes cell survival through its phosphorylation of MDM2, which enhances 
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wild-type and kinase deficient genes into the lung of mice (Tehrani et al. 2007). Dominant 
negative alleles of AKT directly injected into lung carcinoma cells have also been shown to 
block cell survival and proliferation (Li, Simpson, et al. 1998). 
3.3 Protein-protein interactions 
A protein dimer or oligomer is a macromolecular structure formed by two (dimer) or 
several (oligomer) proteins of either same origin (homo-oligomers) or different origins 
(hetero-oligomers). For several proteins the formation of oligomers or dimers is essential in 
order to form functional systems. Both Bcr-Abl and p53 proteins function in the homo-
oligomeric form. On the other hand, hemoglobin forms hetero-oligomers consisting of two α 
and two β subunits to form a functional structure. If one of these subunits is defective or 
missing, the protein cannot master its tasks leading to diseases such as the previously 
described β-thalassemia. Mutations in the oligomerization domain can lead to loss of 
function. Dimer or oligomer formation is governed by non-covalent interactions, including 
salt bridges, hydrogen bonds and hydrophobic interactions. A common structural motif for 
dimerization is a coiled coil consisting of usually two to five α-helices that wind around one 
another like strands of a rope, meshed together like “knobs-into-holes.” They contain a 
characteristic seven-residue sequence repeat (Mason & Arndt 2004; Crick 1952). Coiled coil 
motifs play an important role in the function of several different proteins ranging from 
transcription factors such as Jun and Fos which are responsible for cell growth and 
proliferation (Glover & Harrison 1995) to the oncoprotein Bcr-Abl which leads to cancer 
(McWhirter et al. 1993). A subgroup of the coiled coil motif is represented by the “leucine 
zipper”, an unusually long α-helix with protruding leucine residues in periodic repetition. 
The leucine residues from one peptide interact with leucine residues from a second peptide, 
forming a molecular zipper (Landschulz et al. 1988). Another important dimerization 
interface for proteins is the helix-loop-helix (HLH) motif. Characterized by two α-helices 
connected by a short loop, this structure is highly conserved in many diverse organisms. 
Proteins containing this structure are transcription factors that are only functional as homo- 
or hetero-dimers (Murre et al. 1994, and references therein). Important HLH family 
members are myc proteins which play an essential role in cell proliferation, differentiation, 
cell growth, and apoptosis, but are also involved in development of numerous kinds of 
cancer (Vita & Henriksson 2006). Finally, another interaction motif is the zinc finger motif, 
containing several subgroups such as C2H2, Gag knuckle, treble clef, zinc ribbon, 
Zn2/Cys6, TAZ2 domain like, zinc binding loops and metallothionein (Krishna et al. 2003). 
The C2H2 zinc finger represents the most prevalent motif and contains a zinc ion 
coordinated by cysteines and histidines (Wolfe et al. 2000). Although most C2H2 fingers 
apparently contribute to protein-DNA or protein-RNA interactions, examples for protein-
protein interactions also exist. One example is Ikaros, a transcription factor participating in 
gene silencing and activation in hematopoietic cells. In this protein, dimerization is 
important for its activity and affinity to DNA (McCarty et al. 2003, and references therein). 
In addition, more complex oligomerization structures exist. For example, p53 forms a dimer 
with an antiparallel β-sheet and an antiparallel helix-helix interface. Two dimers associate as 
a parallel helix-helix to form a tetramer (Jeffrey et al. 1995). 
 
Choosing Targets for Gene Therapy 
 
15 
Gene therapy may be used to enhance or inhibit dimerization interfaces. Currently, small 
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stimulants. A L166P mutation in the DJ-1 gene may prevent its ability to homodimerize, and 
it has been speculated that this can lead to neurodegeneration in autosomal recessive early 
onset Parkinsonism (Gorner et al. 2007, and references therein). Re-introduction of 
dimerization-capable DJ-1 with gene therapy is therefore a possible treatment option. 
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However, Bcr-Abl derives oncogenic function rather than tumor suppression from 
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polymerization of serpin α1-antitrypsin is known to cause hepatocellular carcinoma and 
liver cirrhosis due to accumulation in the endoplasmatic reticulum of the liver (Lomas & 
Mahadeva 2002). Disruption of polymerization could also be targeted for gene therapy, 
using an exogenously added polymerization domain that could compete for binding to 
serpin α1-antitrypsin. 
3.4 Cell compartments 
Targeting a gene therapy product to a specific subcellular compartment is another way to 
overcome disease. There are many diseases associated with protein malfunction in different 
organelles of the cell (Davis et al. 2007). For example, certain cancers can arise when a 
protein localizes to the wrong compartment. The typical example is cytoplasmically 
mislocalized p53. When p53 is in the cytoplasm, it cannot act as tumor suppressor since it is 
a transcription factor that needs to be in the nucleus in order to function (Kau et al. 2004; 
Wurzer et al. 2001). In addition to mislocation from the nucleus, the incorrect localization of 
proteins normally destined for lysosomes, peroxisomes, Golgi apparatus, endoplasmic 
reticulum (ER) or mitochondria can also lead to disease. Directing gene therapy products to 
specific subcellular compartments represents not only novel targets but a new way to 
approach gene therapy (Mossalam et al. 2010).  
3.4.1 Lysosomes 
Lysosomes degrade unused cellular constituents, receptors and release active enzymes 
extracellularly and are involved in post-translational maturation of proteins. Dysfunction of 
lysosomal hydrolases leads to loss of cell growth control and results in chemotherapy 
resistance as well as high metastatic potential (Castino et al. 2003). Furthermore, lysosome 
and lysosome-related organelles are associated with Lysosomal Storage Disease (LSD), 
Alzheimer’s disease and development of several types of tumors. LSD is collective term for 
40 genetic disorders due to single or multi enzyme deficiency which results in 
neurodegenerative disorders. Therapy options are limited to BMT and enzyme replacement. 
The disadvantages of BMT are morbidity and mortality as well as incomplete response to 
therapy. Enzyme replacement fails because of fast degradation of the enzyme from 
bloodstream. Due to these limitations, gene therapy represents a potential alternative. 
Currently, gene therapy is focused on using cargo proteins that deliver proteins to the 
lysosome. Since clathrin-dependent receptor-mediated endocytosis (RME) is the main 
transport mechanism for delivery to the lysosome, it is thought that all forms of LSDs can be 
treated with gene therapy (Bareford & Swaan 2007, and references therein).  
3.4.2 Peroxisomes 
Peroxisomes are multifunctional organelles which are involved in biochemical and 
metabolic processes such as oxidation of fatty acids, plasmalogen biosynthesis and 
glyoxylate detoxification. Malfunction of or defects in peroxisomes are associated with a 
variety of diseases which can be classified as Zellweger spectrum peroxisome biogenesis 
disorders or rhizomelic chondrodysplasia punctate. Defects in peroxisome biogenesis 
proteins (peroxins, encoded by PEX genes) can lead to eye anomalies, extreme hypotension, 
and hepatomegaly (to name a few), and usually are fatal by age 1-2. In general deficiencies 
in a single peroxisomal enzyme (PEX) are associated with a variety of diseases. The therapy 
approaches are focused on protein therapeutics, peroxisomal enzymes and gene therapy. 
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One possible gene therapy target is the antioxidant enzyme, catalase. A modified catalase 
molecule was transduced into hypocatalasemic fibroblasts and reduced hydrogen peroxide 
levels dramatically. This resulted in the restoration of oxidative balance, which may have 
cytoprotective effects (Terlecky & Koepke 2007). The cytoprotective role of catalase makes it 
an excellent gene therapy target, because many diseases such as cardiovascular diseases are 
linked to high hydrogen peroxide levels (Gong et al. 2010). 
3.4.3 Proteasome 
Targeting the proteasome, the cell’s degradation machinery, represents another possible 
target for gene therapy. The general inhibition of the proteasome is already used for 
treatment of inflammatory disease and cancer (Nalepa et al. 2006) while the activation of the 
proteasome can be used for neurodegenerative diseases and cardiac diseases (Dahlmann 
2007). Targeting disease-specific components of the ubiquitin-proteasome system provides 
the possibility for directed therapy approaches (Nalepa et al. 2006). The E3 ubiqitin ligases 
are important for specificity of proteasomal degradation because they recognize the proteins 
which should be destroyed (Nalepa et al. 2006). More classical drug targets are the 
ubiquitin-activation and the actual degradation step which occurs in the proteasome. A new 
approach suggested by our lab involves capturing oncogenic proteins such as survivin and 
sending them to the proteasome for degradation. This could be achieved by including a 
gene therapy construct that has a survivin dimerization domain and a proteasomal 
degradation domain, capable of capturing endogenous survivin and sending it to the 
proteasome (Mossalam et al. 2010). 
3.4.4 Mitochondria 
Mitochondria are essential for production of cellular ATP. The mitochondria consist of the 
outer membrane, the inner membrane, intermembrane space, cristae and mitochondrial 
DNA. Mutations in mitochondrial DNA are associated with muscle and central nervous 
system dysfunction, but only if most of the DNA is mutated. An interesting gene therapy 
approach is to tag mitochondria targeting signals to endonucleases which are able to 
degrade the mutated mitochondrial DNA. This mutant DNA contains the T8399G mutation 
which creates a unique restriction site and allows the restriction enzyme to distinguish 
between normal DNA and mutated DNA. It provides new therapy options for neuropathy, 
ataxia and retinitis pigmentosa (Srivastava & Moraes 2001). In addition, the mitochondrion 
is also essential in cellular apoptosis. Proteins such as p53 can be sent to the mitochondria, 
eventually resulting in cytochrome c release and apoptosis. Indeed, p53 targeted to the 
mitochondria has shown to cause apoptosis in different cancer cell lines (Palacios & Moll 
2006).  
3.4.5 Endoplasmic reticulum 
The endoplasmic reticulum (ER) produces almost all cellular lipids, and the majority of 
proteins are synthesized on the cytosolic surface of the ER. A wide range of diseases occur 
due to mistakes in protein folding/assembly in the ER such as CF and neurodegenerative 
diseases. CF is a classic gene therapy target with one single mutation which can be targeted 
by replacing the defect gene. Unfortunately, all gene therapy approaches for CF have failed 
thus far. Certain neurodegenerative diseases are affected by mutations in proteins involved 
in ER assembly. Mutations in Parkin, which is an E3 ligase responsible for ubiquitinylation 
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therapy. Enzyme replacement fails because of fast degradation of the enzyme from 
bloodstream. Due to these limitations, gene therapy represents a potential alternative. 
Currently, gene therapy is focused on using cargo proteins that deliver proteins to the 
lysosome. Since clathrin-dependent receptor-mediated endocytosis (RME) is the main 
transport mechanism for delivery to the lysosome, it is thought that all forms of LSDs can be 
treated with gene therapy (Bareford & Swaan 2007, and references therein).  
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Peroxisomes are multifunctional organelles which are involved in biochemical and 
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glyoxylate detoxification. Malfunction of or defects in peroxisomes are associated with a 
variety of diseases which can be classified as Zellweger spectrum peroxisome biogenesis 
disorders or rhizomelic chondrodysplasia punctate. Defects in peroxisome biogenesis 
proteins (peroxins, encoded by PEX genes) can lead to eye anomalies, extreme hypotension, 
and hepatomegaly (to name a few), and usually are fatal by age 1-2. In general deficiencies 
in a single peroxisomal enzyme (PEX) are associated with a variety of diseases. The therapy 
approaches are focused on protein therapeutics, peroxisomal enzymes and gene therapy. 
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One possible gene therapy target is the antioxidant enzyme, catalase. A modified catalase 
molecule was transduced into hypocatalasemic fibroblasts and reduced hydrogen peroxide 
levels dramatically. This resulted in the restoration of oxidative balance, which may have 
cytoprotective effects (Terlecky & Koepke 2007). The cytoprotective role of catalase makes it 
an excellent gene therapy target, because many diseases such as cardiovascular diseases are 
linked to high hydrogen peroxide levels (Gong et al. 2010). 
3.4.3 Proteasome 
Targeting the proteasome, the cell’s degradation machinery, represents another possible 
target for gene therapy. The general inhibition of the proteasome is already used for 
treatment of inflammatory disease and cancer (Nalepa et al. 2006) while the activation of the 
proteasome can be used for neurodegenerative diseases and cardiac diseases (Dahlmann 
2007). Targeting disease-specific components of the ubiquitin-proteasome system provides 
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ubiquitin-activation and the actual degradation step which occurs in the proteasome. A new 
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degradation domain, capable of capturing endogenous survivin and sending it to the 
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DNA. Mutations in mitochondrial DNA are associated with muscle and central nervous 
system dysfunction, but only if most of the DNA is mutated. An interesting gene therapy 
approach is to tag mitochondria targeting signals to endonucleases which are able to 
degrade the mutated mitochondrial DNA. This mutant DNA contains the T8399G mutation 
which creates a unique restriction site and allows the restriction enzyme to distinguish 
between normal DNA and mutated DNA. It provides new therapy options for neuropathy, 
ataxia and retinitis pigmentosa (Srivastava & Moraes 2001). In addition, the mitochondrion 
is also essential in cellular apoptosis. Proteins such as p53 can be sent to the mitochondria, 
eventually resulting in cytochrome c release and apoptosis. Indeed, p53 targeted to the 
mitochondria has shown to cause apoptosis in different cancer cell lines (Palacios & Moll 
2006).  
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The endoplasmic reticulum (ER) produces almost all cellular lipids, and the majority of 
proteins are synthesized on the cytosolic surface of the ER. A wide range of diseases occur 
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diseases. CF is a classic gene therapy target with one single mutation which can be targeted 
by replacing the defect gene. Unfortunately, all gene therapy approaches for CF have failed 
thus far. Certain neurodegenerative diseases are affected by mutations in proteins involved 
in ER assembly. Mutations in Parkin, which is an E3 ligase responsible for ubiquitinylation 
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and regulation of proteasomal degradation, is associated with juvenile Parkinsonism. The 
Parkin proteasomal pathway normally degrades Pael-R in dopaminergic neurons. Pael-R 
accumulates in brain cells when Parkin is mutated (Aridor et al. 2004, and references 
therein). Adding back functional Parkin would then be a possible gene therapy approach for 
juvenile Parkinsonism.  
3.4.6 Golgi apparatus 
In addition to the synthesis of carbohydrates, the Golgi apparatus (GA) sorts as well as 
dispatch proteins to the ER. SPCA1 is a protein found in the trans-Golgi. When mutations 
occur in the gene (ATP2C1) encoding SPCA1, a genetic disorder results called Hailey-Hailey 
disease. These various mutations result in skin lesions which are usually benign and lead 
only in a few cases into squamous cell carcinoma (Pizzo et al. 2011). Replacing mutated 
SPCA1 would be a possible gene therapy approach to treat Hailey-Hailey disease.  
3.4.7 Nucleus 
Many diseases are associated with problems in nuclear import and export. For example, 
various types of cancers are associated with p53 and FOXO mislocalization in the cytoplasm, 
while their normal localization is the nucleus. There are several examples of proteins that 
when mislocalized to different compartments lose their function or may become oncogenic. 
The control of compartmentalization of key proteins can be used to overcome disease. 
Besides, tumor suppressors such as p53, cell cycle inhibitors, G-protein coupled receptors 
and transcription factors can also lose their function when mislocalized (Chinen et al. 2007). 
p21WAF-1 is localized in the nucleus where it accomplishes its function as cell cycle inhibitor. 
When moved to the cytoplasm, it is associated with tumor progression (Davis et al. 2007; 
Keeshan et al. 2003). G-protein coupled receptors like rhodopsin, vasopressin V2, LDL and 
CFTR all require proper localization for function. For example, rhodopsin is found in the 
membrane sacs within the rods, and when mislocalized it is confined in the plasma 
membrane of photoreceptor cell body and causes retinitis pigmentosa (Edwards et al. 2000). 
Additional transcription factors such as NF-κB and FOXO are both associated with various 
types of cancer when mislocalized to different compartments. NF-κB is located in the 
cytoplasm of normal cells whereas nuclear accumulation causes cancer. In contrast FOXO is 
found in the nucleus of normal cells and cytoplasmic localization results in cancer (Davis et 
al. 2007, and references therein).  
There are several different gene therapy approaches for targeting mislocalized proteins. The 
standard method is to add back the protein which contains functional localization signals, 
such as the adenoviral p53 vectors GendicineTM and OncorineTM. On the other hand, 
blocking general nuclear import or export machinery has been attempted, but due to the 
non-specific blockage of import/export, these methods suffer from toxicity. Instead of 
general inhibition of import/export, the protein itself can be modified. Adding nuclear 
localization signals (NLS) or nuclear export signals (NES) to the genes encoding 
mislocalized proteins allows targeting of proteins directly to the desired compartments.  
The localization of proteins can be changed by using a protein switch developed in our 
laboratory (Kakar et al. 2007; Davis et al. 2007). The protein switch is a plasmid encoding a 
NES, a NLS and a ligand binding domain (LBD) from steroid hormone receptor. The LBD 
serves as a ligand-inducible nuclear localization switch. The protein switch is cytoplasm in 
the absence of ligand and translocates to the nucleus when ligand is added. The protein 
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switch has also been designed to contain dimerization domain that allows capture of an 
endogenous protein of interest. Upon ligand addition, the protein switch-endogenous 
protein complex will then translocate to the nucleus. Removal of the endogenous protein 
from the cytoplasm can result in decrease cytoplasmic signaling or increased apoptotic 
signaling in the nucleus, with potential use in cancer therapy (Kakar et al. 2007). 
4. Conclusions 
Some of the major diseases currently targeted by gene therapy include cancer, 
cardiovascular disease, HIV, and monogenic diseases. Despite many decades of gene 
therapy research on these diseases, there currently are very few products that have made it 
to market. The search for new gene therapy targets and improved methods are therefore 
warranted. The integration of new and standard technologies (genome sequencing, 
microarrays, improved analysis, and linkage to molecular and biochemical assays) recently 
have yielded methods to uncover new drivers of cancer (Akavia et al. 2010). In 2008, the 
NIH started its Undiagnosed Diseases Program. These NIH investigators first try to 
diagnose an illness by first looking at known genetic markers, followed by standard 
molecular and biochemical assays. If no candidate genes are revealed, they then use state-of-
the-art genetic analyses that can sequence the entire exome (all exons in the human genome) 
of a patient and their family; high resolution microarrays can genotype the rest of the 
genome to "bring genomics to the clinic." After comparison to family data and a reference 
sequence (from the Human Genome Project), the gene causing a particular rare disease may 
be discovered (Maxmen 2011). Currently patients enrolled in this program are not cured; the 
candidate gene and corresponding protein are only identified. Small molecule inhibitors of 
these proteins can take years or decades to screen, therefore making replacement of these 
defective or mutant genes prime candidates for gene therapy treatment in patients with a 
rare disease.  
Further analysis of the protein can uncover the molecular basis of the disease. Is this protein 
a hub protein which interacts with many other proteins? What are the protein-protein 
interactions that govern its activity? Are there any cell compartmentalization abnormalities 
that promote disease? With this information in mind, more modern gene therapy 
approaches can be developed. In our laboratory, we have designed a protein switch 
designed to capture and change location of a harmful protein in a cell. This altered location 
could be exploited for disease therapy. For example, the Bcr-Abl protein is oncogenic in the 
cytoplasm, but causes apoptosis when moved to the nucleus (Dixon et al. 2009). A protein 
switch against Bcr-Abl is being developed in our laboratory that can dimerize to wild type 
(wt) Bcr-Abl by virtue of a coiled-coil dimerization domain (Mossalam et al. 2010). The 
protein switch also contains a ligand-inducible domain that can move the protein from the 
cytoplasm to the nucleus upon the addition of ligand (Kakar et al. 2007). Therefore, after 
capture, wt Bcr-Abl is dragged to the nucleus, where apoptosis ensues. Understanding the 
molecular mechanisms that govern protein activity can therefore be used as the next phase 
in gene therapy, where altered protein location can completely change the function of a 
protein. Other emerging modern gene therapy-based approaches including anti-gene 
therapies (antisense, siRNA, ribozymes) and immunotherapy are desired to have a 
significant impact on disease treatment. 
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accumulates in brain cells when Parkin is mutated (Aridor et al. 2004, and references 
therein). Adding back functional Parkin would then be a possible gene therapy approach for 
juvenile Parkinsonism.  
3.4.6 Golgi apparatus 
In addition to the synthesis of carbohydrates, the Golgi apparatus (GA) sorts as well as 
dispatch proteins to the ER. SPCA1 is a protein found in the trans-Golgi. When mutations 
occur in the gene (ATP2C1) encoding SPCA1, a genetic disorder results called Hailey-Hailey 
disease. These various mutations result in skin lesions which are usually benign and lead 
only in a few cases into squamous cell carcinoma (Pizzo et al. 2011). Replacing mutated 
SPCA1 would be a possible gene therapy approach to treat Hailey-Hailey disease.  
3.4.7 Nucleus 
Many diseases are associated with problems in nuclear import and export. For example, 
various types of cancers are associated with p53 and FOXO mislocalization in the cytoplasm, 
while their normal localization is the nucleus. There are several examples of proteins that 
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Besides, tumor suppressors such as p53, cell cycle inhibitors, G-protein coupled receptors 
and transcription factors can also lose their function when mislocalized (Chinen et al. 2007). 
p21WAF-1 is localized in the nucleus where it accomplishes its function as cell cycle inhibitor. 
When moved to the cytoplasm, it is associated with tumor progression (Davis et al. 2007; 
Keeshan et al. 2003). G-protein coupled receptors like rhodopsin, vasopressin V2, LDL and 
CFTR all require proper localization for function. For example, rhodopsin is found in the 
membrane sacs within the rods, and when mislocalized it is confined in the plasma 
membrane of photoreceptor cell body and causes retinitis pigmentosa (Edwards et al. 2000). 
Additional transcription factors such as NF-κB and FOXO are both associated with various 
types of cancer when mislocalized to different compartments. NF-κB is located in the 
cytoplasm of normal cells whereas nuclear accumulation causes cancer. In contrast FOXO is 
found in the nucleus of normal cells and cytoplasmic localization results in cancer (Davis et 
al. 2007, and references therein).  
There are several different gene therapy approaches for targeting mislocalized proteins. The 
standard method is to add back the protein which contains functional localization signals, 
such as the adenoviral p53 vectors GendicineTM and OncorineTM. On the other hand, 
blocking general nuclear import or export machinery has been attempted, but due to the 
non-specific blockage of import/export, these methods suffer from toxicity. Instead of 
general inhibition of import/export, the protein itself can be modified. Adding nuclear 
localization signals (NLS) or nuclear export signals (NES) to the genes encoding 
mislocalized proteins allows targeting of proteins directly to the desired compartments.  
The localization of proteins can be changed by using a protein switch developed in our 
laboratory (Kakar et al. 2007; Davis et al. 2007). The protein switch is a plasmid encoding a 
NES, a NLS and a ligand binding domain (LBD) from steroid hormone receptor. The LBD 
serves as a ligand-inducible nuclear localization switch. The protein switch is cytoplasm in 
the absence of ligand and translocates to the nucleus when ligand is added. The protein 
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switch has also been designed to contain dimerization domain that allows capture of an 
endogenous protein of interest. Upon ligand addition, the protein switch-endogenous 
protein complex will then translocate to the nucleus. Removal of the endogenous protein 
from the cytoplasm can result in decrease cytoplasmic signaling or increased apoptotic 
signaling in the nucleus, with potential use in cancer therapy (Kakar et al. 2007). 
4. Conclusions 
Some of the major diseases currently targeted by gene therapy include cancer, 
cardiovascular disease, HIV, and monogenic diseases. Despite many decades of gene 
therapy research on these diseases, there currently are very few products that have made it 
to market. The search for new gene therapy targets and improved methods are therefore 
warranted. The integration of new and standard technologies (genome sequencing, 
microarrays, improved analysis, and linkage to molecular and biochemical assays) recently 
have yielded methods to uncover new drivers of cancer (Akavia et al. 2010). In 2008, the 
NIH started its Undiagnosed Diseases Program. These NIH investigators first try to 
diagnose an illness by first looking at known genetic markers, followed by standard 
molecular and biochemical assays. If no candidate genes are revealed, they then use state-of-
the-art genetic analyses that can sequence the entire exome (all exons in the human genome) 
of a patient and their family; high resolution microarrays can genotype the rest of the 
genome to "bring genomics to the clinic." After comparison to family data and a reference 
sequence (from the Human Genome Project), the gene causing a particular rare disease may 
be discovered (Maxmen 2011). Currently patients enrolled in this program are not cured; the 
candidate gene and corresponding protein are only identified. Small molecule inhibitors of 
these proteins can take years or decades to screen, therefore making replacement of these 
defective or mutant genes prime candidates for gene therapy treatment in patients with a 
rare disease.  
Further analysis of the protein can uncover the molecular basis of the disease. Is this protein 
a hub protein which interacts with many other proteins? What are the protein-protein 
interactions that govern its activity? Are there any cell compartmentalization abnormalities 
that promote disease? With this information in mind, more modern gene therapy 
approaches can be developed. In our laboratory, we have designed a protein switch 
designed to capture and change location of a harmful protein in a cell. This altered location 
could be exploited for disease therapy. For example, the Bcr-Abl protein is oncogenic in the 
cytoplasm, but causes apoptosis when moved to the nucleus (Dixon et al. 2009). A protein 
switch against Bcr-Abl is being developed in our laboratory that can dimerize to wild type 
(wt) Bcr-Abl by virtue of a coiled-coil dimerization domain (Mossalam et al. 2010). The 
protein switch also contains a ligand-inducible domain that can move the protein from the 
cytoplasm to the nucleus upon the addition of ligand (Kakar et al. 2007). Therefore, after 
capture, wt Bcr-Abl is dragged to the nucleus, where apoptosis ensues. Understanding the 
molecular mechanisms that govern protein activity can therefore be used as the next phase 
in gene therapy, where altered protein location can completely change the function of a 
protein. Other emerging modern gene therapy-based approaches including anti-gene 
therapies (antisense, siRNA, ribozymes) and immunotherapy are desired to have a 
significant impact on disease treatment. 
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1. Introduction  
Since non-viral gene therapy was developed and employed in different in vitro and in vivo 
experimental systems as an effective way to control and modify gene expression, RNA has 
been considered as a molecular target of great relevance (Li &Huang, 2008, López-Fraga et 
al., 2008). In combination with standard chemotherapy, the siRNA therapy can reduce the 
chemoresistance of certain cancers, demonstrating its potential for treating many malignant 
diseases. Examples of RNA sequences to be targeted for therapeutic applications are 
mRNAs coding oncoproteins or RNA coding anti-apoptotic proteins for the development of 
anti-cancer therapy.  
In the last years, progresses in molecular biology have allowed to identify many genes 
Coding for small non coding RNA molecules, microRNA (miRNAs or miRs), able to 
regulate gene expression at the translation level (Huang et al., 2008, Shrivastava & 
Shrivastava, 2008, Sahu et al. 2007, Orlacchio et al., 2007, Williams et al., 2008, 
Papagiannakopoulos & Kosik, 2008). Accordingly, an increasing number of reports associate 
the changed expression with specific phenotypes and even with pathological conditions 
(Garzon & Croce, 2008, Mascellani et al., 2008, Sontheimer & Carthew, 2005, Filipowicz et 
al., 2005, Alvarez-Garcia & Miska, 2005). Interestingly, microRNAs play a double role in 
cancer, behaving both as oncogenes or tumor suppressor genes. In general, miRs promoting 
cancer targets mRNA coding for tumor-suppression proteins, while microRNAs exhibiting 
tumor-suppression properties usually target mRNAs coding oncoproteins. MicroRNAs 
which have been demonstrated to play a crucial role in the initiation and progression of 
human cancer are defined as oncogenic miRNAs (oncomiRs) (Cho, 2007). The oncomiR 
expression profiling of human malignancies has also identified a number of diagnostic and 
prognostic cancer signals (Cho, 2007, Lowery et al., 2008). Moreover, microRNAs have been 
firmly demonstrated to be involved in cancer metastasis (metastamiRs).  
Examples of metastasis-promoting microRNAs are, miR-10b (Calin et al., 2006), miR-373 and -
520c (Woods et al., 2007), miR-21, -143 and -182 (Hayashita et al., 2005; Si et al., 2007; Zhu et al., 
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2007). Reviews on metastamiR has been recently published Hurst et al. (Hurst et al. 2009, 
Edmonds et al. 2009). Reviews on metastamiRs has been recently published by Hurst et al. 
Table 1 shows examples of microRNAs involved in cancer onset and progression. 
 
MicroRNAs Tumor Target mRNA Reference(s) 
miR-17-92 Lung cancer, lymphoma E2F1 Woods et al., 2007 
miR-21 
Breast cancer, cholangiocarcinoma, 




Iorio et al.,  2005; 
Zhu et al., 2007 




Costinean et al., 2006; 
Kong et al., 
2010; 
Pedersen et al., 2009 
miR-221 Glioblastoma PUMA Ciafre et al., 2005; Zhang et al., 2010 
miR-222 Thyroid carcinoma P27Kip1 Visone et al., 2007 
miR-31 Lung cancer LATS2 Liu et al., 2010 
Table 1. Examples of microRNAs involved in cancer onset and their putative targets. 
Thus, therapeutic strategies involving miRNA silencing could be proposed based on the 
roles of these small non-coding RNAs as oncogenes. For these reasons, the development of 
molecules able to specifically recognize microRNA target sequences is of particular interest, 
from both a diagnostic and a therapeutic point of view.  
Indeed, miRNAs can be antagonized in vivo by highly-affine oligonucleotides (Lowery et al., 
2008, Stenvang & Kauppinen, 2008). Up to now synthetic oligonucleotides have been used 
for targeting microRNAs, although with several problems, including delivery and stability. 
However, the use of oligonucleotide analogues has recently been proposed to be effective 
for the inhibition of miR expression and, accordingly, as a potent tool for the regulation of 
gene expression (Kota & Balasubramanian, 2010). 
Peptide nucleic acids (PNAs) (figure 1) are DNA analogues in which the sugar-phosphate 
backbone is replaced by N-(2-aminoethyl)glycine units (Nielsen et al., 1991, Nielsen and 




















DNA PNA  
Fig. 1. Structure of DNA and PNA 
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These molecules efficiently hybridize with complementary DNA and RNA, forming 
Watson-Crick double helices. In addition, they can generate triple helix structures with 
double stranded DNA and perform strand invasion. Accordingly, they have been proposed 
for antisense and anti-gene therapy in a great number of studies (Larsen and Nielsen, 1996, 
Gambari, 2004, Nielsen 2005, 2006, Yin et al. 2008). PNAs are very promising for RNA 
recognition, since they have a higher affinity for RNA than for DNA, are more specific and 
are resistant to DNAses and proteases (Demidov et al 1994). 
PNAs can be modified in order to achieve better performances in terms of cellular 
permeation, higher affinity, and specificity for the target DNA and RNA sequences 
(Corradini et al., 2004, 2007, Sforza et al., 2000, 2007, 2010, Tedeschi et al., 2005 a,b,c,  
Wojciechowski and Hudson, 2007, Dragulescu-Andrasi 2005, Rapireddy 2007). 
In this chapter we will describe the recent results reported in the literature by using PNAs as 
anti-miR agents  and  the perspectives of this technology for future development. 
2. MiR targeting: therapeutic significance 
MicroRNAs are a family of small (19 to 25 nucleotide in length) noncoding RNAs that 
regulate gene expression by sequence-selective targeting of mRNAs, leading to a 
translational repression or mRNA degradation, depending on the degree of 
complementarity between miRNAs and the target sequences (Krol et al., 2010).  






















Fig. 2. Pathways of miR production and action. The primary transcript microRNA (pri-miR) is 
processed by DROSHA in combination with other factors such as DGCR8 to yield an hairpin 
structure called pre-miR, which is then exported by exportin 5 to the cytoplasm where it is 
cleaved by DICER in combination with other factors. The mature 21-23nt long dsRNA is 
processed by incorporation of the guiding strand into the miRISC complex, which act as 
inhibitor of translation, by either degradation of the mRNA bearing the target sequence or by 
incorporation of the miRISC-mRNA complex into the P-body, leading to inactivation. 
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Fig. 1. Structure of DNA and PNA 
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These molecules efficiently hybridize with complementary DNA and RNA, forming 
Watson-Crick double helices. In addition, they can generate triple helix structures with 
double stranded DNA and perform strand invasion. Accordingly, they have been proposed 
for antisense and anti-gene therapy in a great number of studies (Larsen and Nielsen, 1996, 
Gambari, 2004, Nielsen 2005, 2006, Yin et al. 2008). PNAs are very promising for RNA 
recognition, since they have a higher affinity for RNA than for DNA, are more specific and 
are resistant to DNAses and proteases (Demidov et al 1994). 
PNAs can be modified in order to achieve better performances in terms of cellular 
permeation, higher affinity, and specificity for the target DNA and RNA sequences 
(Corradini et al., 2004, 2007, Sforza et al., 2000, 2007, 2010, Tedeschi et al., 2005 a,b,c,  
Wojciechowski and Hudson, 2007, Dragulescu-Andrasi 2005, Rapireddy 2007). 
In this chapter we will describe the recent results reported in the literature by using PNAs as 
anti-miR agents  and  the perspectives of this technology for future development. 
2. MiR targeting: therapeutic significance 
MicroRNAs are a family of small (19 to 25 nucleotide in length) noncoding RNAs that 
regulate gene expression by sequence-selective targeting of mRNAs, leading to a 
translational repression or mRNA degradation, depending on the degree of 
complementarity between miRNAs and the target sequences (Krol et al., 2010).  






















Fig. 2. Pathways of miR production and action. The primary transcript microRNA (pri-miR) is 
processed by DROSHA in combination with other factors such as DGCR8 to yield an hairpin 
structure called pre-miR, which is then exported by exportin 5 to the cytoplasm where it is 
cleaved by DICER in combination with other factors. The mature 21-23nt long dsRNA is 
processed by incorporation of the guiding strand into the miRISC complex, which act as 
inhibitor of translation, by either degradation of the mRNA bearing the target sequence or by 
incorporation of the miRISC-mRNA complex into the P-body, leading to inactivation. 
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Since their discovery and first characterization, the number of microRNA sequences 
deposited in the miRBase databases is significantly growing (Kozomara & Griffiths-Jones, 
2010). On the other hand, considering that a single miRNA can target several mRNAs and a 
single mRNA might contain in the 3’UTR sequence several signals for miRNA recognition, it 
can be calculated that at least 10-40% of human mRNAs are targets for microRNAs (He & 
Hannon, 2004). Therefore, a great interest is concentrated on the identification of validated 
targets of microRNAs. This specific field of research has confirmed that the complex 
networks constituted by miRNAs and RNA targets coding for structural and regulatory 
proteins leads to the control of highly regulated biological functions, such as differentiation 
(Masaki et al., 2007), cell cycle (Wang & Blelloch, 2009) and apoptosis (Subramanian & Steer, 
2010).  
More in detail, and considering the role of microRNAs, a low expression of a given miR is 
expected to be linked with a potential accumulation of targets mRNAs; conversely, a high 
expression of miRNAs is expected to be responsible for a low expression of the target 
mRNAs. 
However, since a single 3’UTR of a given mRNA contains signal sequences for several 
microRNAs, which microRNA should be targeted in order to achieve alteration of the 
expression of the gene should be experimentally evaluated. With respect to the possible 
effects of the expression of other mRNA targets, it should be clearly stated that alteration of 
a single microRNA might retain multiple effects. Finally, multiple targeting of several 
microRNAs  might be considered for achieving strong biological effects. Whatever strategy 
is considered, several examples of biological effects of targeting microRNA involved in 
human pathologies are already available in the literature. 
3. MiR targets relevant in gene therapy  
The number of known microRNAs which regulate gene expression is continuously growing, 
with 1048 sequences present to date in the miRbase for humans (as available on march 30th, 
2011 at http://www.mirbase.org/cgi-bin/mirna_summary.pl?org=hsa). 
Although the discovery of new miRNA is presently carried out using massive sequencing 
technologies (Kozomara & Griffiths-Jones, 2010), the miR targets important in biochemical 
processes rely on comparison schemes. As a general rule, selection of the target miRNA can 
be achieved using the microarray approach by quantitative analyisis of the miR profile in a 
particular cellular state compared to a control lineage. MiR specific RT-PCR protocols can be 
used, followed by hybridization to specialized miR microarrays. This analysis has been used 
to identify miR targets which are over- or, more frequently, under-expressed under 
pathological conditions. Moreover, several very important miR targets have been addressed 
by many studies on account of the fact that they were able to act as critical points in the 
regulation of pathological states. 
Chemically engineered oligonucleotides, termed 'antagomirs', are efficient and specific 
silencers of endogenous miRNAs in mice. Silencing of microRNAs in vivo with 'antagomirs' 
is a very interesting strategy, supporting studies on the involvement of miRs in gene 
expression and providing new tools for non-viral gene therapy (Czech, 2006). 
MiR-155 is one of the first known miR to be overexpressed in cancers, especially in those 
occurring in B-cells; high level of this miR have been associated to several neoplastic states 
and to autoimmune diseases, since it leads to the suppression of a large number of genes 
involved in the control of cellular proliferation. Therefore miR-155 has been identified as 
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possible target for gene therapy associated to lymphomas and chronic lymphocytic 
leukemias and colorectal cancer (Zhang et al., 2007, Kota & Balasubrasmanian, 2010). 
Furthermore, miR-155 was shown to control inflammatory response to microbes (Ceppia et 
al., 2009).  
MiR-21 overexpression was shown to be associated to several solid tumours (lung, breast, 
colon, gastric and prostate carcinomas and endocrine pancreatic tumours) as well as to 
cholangiocarcinoma and glioblastoma, since it is correlated to inhibition of apoptosis (Calin 
& Croce, 2006, Papagiannakopoulos et al., 2008). Knock down of this miR by locked nucleic 
acids (LNA) oligonucleotides, associated with neural precursor cells (NPC) expressing a 
secretable variant of the cytotoxic agent tumor necrosis factor–related apoptosis inducing 
ligand (S-TRAIL), was shown to have high antitumor activity (Corsten et al., 2007).  
MiR-122 is another very important target: it is a well characterized liver-specific microRNA 
exhibiting particular therapeutic interest, since it is related to cholesterol levels in plasma, 
and it has been shown not only to facilitate Hepatitis C RNA replication (Jopling et al., 2005)  
but also to be up-regulated in HIV-1 infected cells (Triboulet et al., 2007). Krützfeldt and 
coworkers (Krützfeldt et al., 2005) demonstrated that intravenous administration of 
antagomirs against several miRs, including miR-122, resulted in a marked reduction of the 
corresponding miRNA levels in liver, lung, kidney, heart, intestine, fat, skin, bone marrow, 
muscle, ovaries and adrenals. The silencing of endogenous miRNAs by this novel method is 
specific, efficient and long-lasting. The biological significance of silencing miRNAs with the 
use of antagomirs was studied with miR-122. Gene expression and bioinformatic analysis of 
messenger RNA from antagomir-treated animals revealed that the 3' untranslated regions of 
upregulated genes are strongly enriched in miR-122 recognition motifs, whereas down-
regulated genes are depleted of these motifs. These findings show that antagomirs are 
powerful tools to silence specific miRNAs in vivo and may represent a therapeutic strategy 
for silencing miRNAs in disease. This was confirmed by Elmén et al. (Elmén et al., 2008a), 
who demonstrated that antagonism of microRNA-122 in mice, systemically treated with 
LNA-antimiR, leads to up-regulation of a large set of predicted target mRNAs in the liver. 
These results were also confirmed in non-human primates (Elmén et al.,2008b), showing 
that lowering of plasma cholesterol could be achieved without signs of toxicity. 
That interest on this target has been recently boosted by a report which showed increased 
resistance to chronic hepatitis C virus (HCV) in primates was achieved by targeting miR122 
with LNA, with long-lasting suppression of HCV viremia, with no evidence of viral 
resistance or side effects in the treated animals (Landfrod et al., 2010).  
MiR-221 and mir-222 have been shown to be associated to the suppression of p27Kip1 , a cell 
cycle inhibitor and tumor suppressor; high levels of these miRs are present in glioblastoma 
(Le Sage et al 2007) and have been proposed as very important therapeutic targets. 
More recently, miR-210 was identified as an highly expressed miR in the erythroid 
precursor cells from a patient exhibiting hereditary persistence of fetal haemoglobin 
(HPFH). When RT-PCR was performed on mithramycin-induced K562 cells and erythroid 
precursor cells, miR-210 was found to be induced in time-dependent and dose-dependent 
fashion, together with increased expression of the fetal -globin genes (Bianchi et al., 2009). 
Thus miR-210 plays a crucial role in the erythroid differentiation pathway, by limiting the 
expression of genes whose down-modulation might be associated with the progression of 
erythroid differentiation. 
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Since their discovery and first characterization, the number of microRNA sequences 
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processes rely on comparison schemes. As a general rule, selection of the target miRNA can 
be achieved using the microarray approach by quantitative analyisis of the miR profile in a 
particular cellular state compared to a control lineage. MiR specific RT-PCR protocols can be 
used, followed by hybridization to specialized miR microarrays. This analysis has been used 
to identify miR targets which are over- or, more frequently, under-expressed under 
pathological conditions. Moreover, several very important miR targets have been addressed 
by many studies on account of the fact that they were able to act as critical points in the 
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possible target for gene therapy associated to lymphomas and chronic lymphocytic 
leukemias and colorectal cancer (Zhang et al., 2007, Kota & Balasubrasmanian, 2010). 
Furthermore, miR-155 was shown to control inflammatory response to microbes (Ceppia et 
al., 2009).  
MiR-21 overexpression was shown to be associated to several solid tumours (lung, breast, 
colon, gastric and prostate carcinomas and endocrine pancreatic tumours) as well as to 
cholangiocarcinoma and glioblastoma, since it is correlated to inhibition of apoptosis (Calin 
& Croce, 2006, Papagiannakopoulos et al., 2008). Knock down of this miR by locked nucleic 
acids (LNA) oligonucleotides, associated with neural precursor cells (NPC) expressing a 
secretable variant of the cytotoxic agent tumor necrosis factor–related apoptosis inducing 
ligand (S-TRAIL), was shown to have high antitumor activity (Corsten et al., 2007).  
MiR-122 is another very important target: it is a well characterized liver-specific microRNA 
exhibiting particular therapeutic interest, since it is related to cholesterol levels in plasma, 
and it has been shown not only to facilitate Hepatitis C RNA replication (Jopling et al., 2005)  
but also to be up-regulated in HIV-1 infected cells (Triboulet et al., 2007). Krützfeldt and 
coworkers (Krützfeldt et al., 2005) demonstrated that intravenous administration of 
antagomirs against several miRs, including miR-122, resulted in a marked reduction of the 
corresponding miRNA levels in liver, lung, kidney, heart, intestine, fat, skin, bone marrow, 
muscle, ovaries and adrenals. The silencing of endogenous miRNAs by this novel method is 
specific, efficient and long-lasting. The biological significance of silencing miRNAs with the 
use of antagomirs was studied with miR-122. Gene expression and bioinformatic analysis of 
messenger RNA from antagomir-treated animals revealed that the 3' untranslated regions of 
upregulated genes are strongly enriched in miR-122 recognition motifs, whereas down-
regulated genes are depleted of these motifs. These findings show that antagomirs are 
powerful tools to silence specific miRNAs in vivo and may represent a therapeutic strategy 
for silencing miRNAs in disease. This was confirmed by Elmén et al. (Elmén et al., 2008a), 
who demonstrated that antagonism of microRNA-122 in mice, systemically treated with 
LNA-antimiR, leads to up-regulation of a large set of predicted target mRNAs in the liver. 
These results were also confirmed in non-human primates (Elmén et al.,2008b), showing 
that lowering of plasma cholesterol could be achieved without signs of toxicity. 
That interest on this target has been recently boosted by a report which showed increased 
resistance to chronic hepatitis C virus (HCV) in primates was achieved by targeting miR122 
with LNA, with long-lasting suppression of HCV viremia, with no evidence of viral 
resistance or side effects in the treated animals (Landfrod et al., 2010).  
MiR-221 and mir-222 have been shown to be associated to the suppression of p27Kip1 , a cell 
cycle inhibitor and tumor suppressor; high levels of these miRs are present in glioblastoma 
(Le Sage et al 2007) and have been proposed as very important therapeutic targets. 
More recently, miR-210 was identified as an highly expressed miR in the erythroid 
precursor cells from a patient exhibiting hereditary persistence of fetal haemoglobin 
(HPFH). When RT-PCR was performed on mithramycin-induced K562 cells and erythroid 
precursor cells, miR-210 was found to be induced in time-dependent and dose-dependent 
fashion, together with increased expression of the fetal -globin genes (Bianchi et al., 2009). 
Thus miR-210 plays a crucial role in the erythroid differentiation pathway, by limiting the 
expression of genes whose down-modulation might be associated with the progression of 
erythroid differentiation. 
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Other highly expressed miRs (such as miR-142-3p) are very important tools in gene therapy 
protocols since specific targets can be inserted in gene constructs in order to suppress 
toxicity associated to viral vectors or to inhibit immune response against a transgene, but 
they are not easily used as targets for specific inhibition of a pathological state (Brown & 
Naldini, 2009). 
4. MiR targeting by PNAs 
PNAs are very promising tools for RNA recognition, since they have a higher affinity for 
RNA than for DNA (Nielsen, 2004), are more specific and are resistant to DNases and 
proteases (Demidov et al 1994). 
As far as their role in targeting mRNAs in the antisense strategy, it should be underlined 
that, unlike oligonucleotide (ON) molecules, PNAs do not activate the RNAse H mediated 
degradation (Bonham et al., 2005). However, since the RNAse H degradation was shown not 
to be effective in the inhibition of miR by oligonucleotides, the steric block mechanism, i.e. 
the base pairing of the therapeutic ON with one of the strands of the miR target, should be 
one of the possible mechanisms, although a degradation of the miR target by a still 
unknown mechanism has been proposed for some ON derivatives (Krutzfeldt et al., 2007). 
The steric block mechanism is highly efficient when using PNAs, due to their high affinity 
for RNA,  and the high stability to both chemical and enzymatic degradation (Demidov et 
al., 1994).  
However, very few works have been reported so far concerning the use of PNAs as anti-miR 
agents, showing good performances (table 2). One of the reasons is the lack of cellular 
permeation by simple unmodified PNA, or segregation in lysosomes of some PNA-peptide 
conjugates, which can prevent the access to the target miRNA. However, these problems can 
be easily circumvented by using appropriate carriers, as shown by our own experience and 
by other  examples reported in the next paragraph.  
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Table 2. Works reporting PNA induced miR suppression. 
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The first example of targeting microRNAs using PNA-based molecules is provided by miR-
122. Fabani and Gait demonstrated, using PNAs and PNA-peptide conjugates, that these 
oligonucleotide analogs, evaluated for the first time in microRNA inhibition, are more 
effective than standard 2'-O-methyl oligonucleotides in binding and inhibiting microRNA 
action (Fabani & Gait, 2009). In their experiments, PNAs were delivered by electroporation.  
Inhibition of miR-122 was evaluated by Northern blot and by the up-regulation effect upon 
both chemical and enzymatic degradation.  
Interestingly, these authors showed that microRNA inhibition can be achieved without the 
need for transfection or electroporation, by conjugating the PNA to the cell-penetrating 
peptide R6-Penetratin, or merely by linkage to four Lys residues, highlighting the potential 
of PNAs for future therapeutic applications as well as for studying microRNA function. 
Both LNA/OMe and PNA oligomers were found to be much more effective than 2’-O-
methyl RNA oligonucleotides usually used as anti-miR agents. The target miR disappeared 
from the Northen-blot analysis of the PNA-treated sample, suggesting a still unknown 
mechanism of degradation or segregation induced by PNA. 
In a parallel work, Oh et al. described the effectiveness of miR targeting by PNA-peptide 
conjugates, using a series of cell penetrating peptides (CPP) as carriers, including R6 pen, 
Tat, a four Lys sequence, and transportan ( Oh, et al., 2009). The best conditions were 
obtained with cationic peptides, and in particular with the Tat-modified peptide 
RRRQRRKKRR. In this study, cells were transfected with a plasmid containing a luciferase 
gene carrying a target site for each miR tested. Inhibition of the miR activity was monitored 
by expression of the luciferase gene. Inhibition of miR-16, which regulates Bcl-2 expression, 
and of miR-21 activity could be monitored in this way. PNAs were found to be more 
effective than LNAs and 2’-OMe oligonucleotides (Figure 3 A). Furthermore, PNAs showed 
no cytotoxicity at the concentration used, unlike LNAs which showed a reduction in cell 
viability (Figure 3 B). Furthermore PNAs were found to be more resistant to degradation 
than LNAs, even if stored at room temperature, suggesting better performances of the 
former class as candidate drugs. 
More recently, a PNA targeted against miR-155 has been used in cellular systems and in 
mice (Fabani et al., 2010). In this study, the induction of miR-155 by bacterial 
lipopolysaccharide (LPS) was reduced by using a PNA matching the miR target and linked 
to four lysine residues. Mice challenged with sub-lethal dose of LPS were treated with 50 mg 
PNA/kg/day for 2 days and 24 h after the last injection (At which time the miR-155 
expression is maximal) they were sacrified and their spleen tissue was  analysed. Complete 
suppression of miR-155 induction was observed. Genome-wide analysis of gene expression 
revealed a profile of normal mice treated with LPS and then with anti-miR PNA similar to 
transgenic miR-155-deficient animals receiving control PBS buffer. 
This study revealed important clues on the miR-155 regulation of B-cells and suggested a 
possible use of anti-miR PNA in the treatment of diffuse large B-cell lymphoma (DLBCL). 
In a recent study we evaluated the activity of a PNA targeting microRNA-210, which is 
firmly associated to hypoxia and is modulated during erythroid differentiation, in leukemic 
K562 cells (Fabbri et al., 2010). The major conclusions of our study were that a PNA against 
miR-210 conjugated with a polyarginine peptide (R-pep-PNA-a210): (a) is efficiently 
internalized within the target cells; (b) strongly inhibits miR-210 activity; (c) deeply alters 
the expression of raptor and -globin genes. Unlike commercially available antagomiRs, 
which need continuous administrations, a single administration of R-pep-PNA-a210 was 
sufficient to obtain the biological effects.  
 
Targets in Gene Therapy 
 
34
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revealed a profile of normal mice treated with LPS and then with anti-miR PNA similar to 
transgenic miR-155-deficient animals receiving control PBS buffer. 
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Fig. 3. A, B: Comparison of the PNA-based anti-miR activity  and cellular toxicity with other 
oligonucleotide mimics as reported by Oh and coworkers (data from Oh et al., 2009). A) 
Effect of anti-miR on HeLa cells transfected with 200 nM of PNA, LNA-modified 
oligonucleotide, and a 2′-OMe-modified oligonucleotide (2′-OMe) specific for miR-24; a 
luciferase assay was performed to evaluate the effect anti-miR oligonucleotide mimics. B) 
Cell viability of  HeLa cells after incubation with 200nm of PNA, LNA and 2’OMe 
oligonucleotides.  (C-E) Cellular delivery and anti-miR210 activity of fluoresceinated R8-
PNA. C. FACS analysis showing the uptake of fluoresceinated R8 peptide (R-pep), anti-miR-
210 PNA (PNA-a210), and R8-PNA (R-pep-PNA-a210) after 48 hours incubation of K562 
cells at a 2 M concentration. D. Intracellular distribution of K562 cells cultured for 48 hours 
with 2 M of Fluoresceinated Rpep-PNA-a210 and then analyzed using a fluorescence 
microscope. The picture is the merged analysis of the fluorescence and of the staining of the 
same cell population with Hoechst 33258 (selectively staining nuclei). E. Effects of the 
treatment with Rpep, PNA-a210, Rpep-PNA-a210 on the miR-210 content in K562 cells.  
Interestingly, cellular uptake was found to be crucial in order to obtain biological activity, 
since the PNA lacking of the polyarginine tail (PNA-a210), despite being able to hybridize to 
target nucleotide sequences, displayed very low activity on cells (Figure 3 C-E).  
5. Modified PNAs can improve miR targeting  
The major limit in the use of PNAs for the alteration of gene expression is the low uptake by 
eukaryotic cells (Rasmussen et al., 2006). In order to remove this drawback, several 
approaches have been considered, including the delivery of PNA analogues with liposomes 
and microspheres (Nastruzzi et al., 2000, Cortesi et al., 2004, Borgatti, 2002). One of the 
possible strategy is to link PNAs to polylysine (K) or a polyarginine (R) tails, based on the 
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observation that this cell-membrane penetrating oligopeptides are able to facilitate uptake of 
conjugated molecules (Abes et al., 2008).  
Since their discovery, many modifications of the original PNA backbones have been 
proposed in order to improve performances in term of affinity and specificity. 
Modification of the PNA backbone with positively charged groups (figure 4) has also been 
demonstrated to enhance cellular uptake and consequently PNA efficiency (Corradini et al., 
2007, Zhou et al., 2003, 2006). 
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The insertion of one chiral monomeric unit in a PNA strand has resulted in increased DNA 
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PNA:DNA duplex stability was found to be dependent on stereochemistry: PNAs carrying a 
monomer with a stereocenter derived from a D-amino acid at the C2 position bound 
complementary antiparallel DNA strands with higher affinity than the corresponding PNA 
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Therefore, the affinity of chiral PNAs for complementary DNA emerged to be a contribution 
of different factors: electrostatic interactions, steric hindrance and, most interestingly, 
enantioselectivity with a preference for the D-configuration at the 2 position of the 
monomer. A PNA:DNA duplex, in which three adjacent chiral monomers based on 2D-
lysine ("chiral box") were present in the middle of the PNA strand, was characterized by X-
ray diffraction, and the results showed that the D-lysine-based chiral PNA-DNA 
heteroduplex adopts the so-called P-helix conformation, with helical parameters 
significantly different from those of the canonical DNA helical forms (Menchise et al., 2003). 
The P-helix is characterized by a small twist angle, a large x-displacement and a wide, deep 
major groove. The 2D-lysine "chiral box" PNA showed also an increased sequence 
selectivity, both in terms of direction control and of recognition of a single base mismatch 
(Sforza et al., 2000). Therefore, this type of structures was found ideal for targeting point 
mutations in genes of diagnostic interest (Corradini et al., 2004, Tedeschi et al., 2005a,b). 
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studied (Sforza et al., 2007, Manicardi et al., 2010).76 The strongest directing factor was found 
to be the L-stereogenic center at position 5 derived from L-lysine. This preference (L-
configuration at position 5) and the former (D-configuration at position 2) are related to the 
ability to form a preferred right-handed helicity of PNA and therefore a preferential 
preorganization for binding right-handed DNA.  
More recently, three consecutive different chiral monomers, respectively modified with 2D-
Arg, with 5L,2D-Arg and with 5L-Arg, were used by our group in order to build an 
"extended chiral box" PNA.  Such PNA, analogously to the above mentioned "chiral box" 
PNA, showed very good mismatch discrimination towards DNA, was even more specific in 
RNA recognition, showing that PNA modifications can also be used in order to tailor PNA 
recognition towards RNA (Calabretta et al., 2011). 
Recently, Ly and co-workers reported the synthesis and uptake properties of  γGPNA, in 
which the PNA backbone had a homo-arginine side chain at the 5-position (or γ position) 
(Sahu et al., 2009), showing an excellent cellular uptake. 
Substitution at both C2 and C5 carbons of the PNA backbone with amino acid side chains 
leads to ambivalent structures having properties of DNA or RNA mimic on one side and 
peptide mimics on the other side, thus allowing recognition by specific receptors, as shown 
very recently by a short PNA mimicking the function of a nuclear localization peptide (NLS) 
(Sforza et al., 2010). Thus, and to obtain PNAs with both peptide properties and RNA 
binding ability. This strategy can be used to further improve the efficiency of PNAs for miR 
targeting. In fact, the use of peptides as carriers represents a “Achille’s heel” of the potential 
PNA-based drug candidates, since the peptide part might be subjected to enzymatic 
degradation, whereas the incorporation of the peptide signal into the PNA backbone does 
not lead to enzymatic degradation, even in the presence of highly active proteases. 
PNAs bearing modified nucleobases able to induce additional interactions providing high 
improvement in RNA and DNA binding affinities have also been described (Wojciechowski 
et al., 2009). Combination of modified nucleobases and backbone modification with C2 or C5 
modified residues was found to be the best approach in order to achieve strand invasion 
into mixed DNA sequences (Ishizuka et al., 2008, 2009, Chenna  et al., 2008), a strategy 
which could also be very fruitful in challenging double-stranded miRs.   
6. Conclusions and perspectives 
PNAs are very promising tools for the inhibition of miR activities, and this effect can be very 
important for obtaining gene modulation in a relatively simple way, with very important 
applications in gene therapy and in drug development. 
The issue of the correct delivery of PNAs to their targets is still open, although efficient 
strategies have already been described, including conjugation with carrier peptides and 
backbone modification. 
The very high affinity of PNAs for RNA and the very strong chemical and enzymatic 
stability of these compounds (especially the backbone-modified version) make them ideal 
candidates as miR inhibitors with long-lasting effect. 
The first data available already indicate that this technology is likely to succeed, despite the 
limited number of targets studied so far. Apart from model systems, PNAs have the 
potentiality to perform like (and eventually outperform) other anti-miR agents such as 2’-
OMe oligonucleotides and LNAs. 
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Furthermore, the possibility to introduce functional groups along the chain of the PNA 
strand by chemical synthesis allows to envisage strategies in which the PNA can be 
endowed of catalytic sites, thus leading to molecules not only capable of binding, but also of 
cleaving, leading to miR specific nuclease models. 
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3 
Effective Transgene Constructs to Enhance 
Gene Therapy with Trichostatin A 




Gene therapy has been proposed as a strategy for the treatment of intractable human 
diseases since the early 1990s. For the expression of a specific transgene in desired cells or 
tissues with the proper timing, many vectors carrying transgenes have been developed 
(Mátrai et al., 2010; Nayak & Herzog, 2010; Sliva & Schnierle, 2010).  Retroviral, lentiviral, 
adenoviral, and adeno-associated viral vectors are used in various ways to achieve these 
goals. However, the introduced transgenes frequently become silenced in the host cells 
(Harbers et al., 1981; Jähner et al., 1982; Palmer et al., 1991). We searched for bioactive 
substances from Actinomycetes that enhance transgene expression, and found that 
trichostatin A (TSA), a histone deacetylase inhibitor (HDACi), enhanced several promoter 
activities remarkably (Y. Ma et al., 2009).  
HDACis have been used as anti-cancer drugs, because they have various effects on tumor cells 
to arrest cell growth, induce apoptosis, inhibit metastasis, and enhance anti-tumor immunity, 
by regulating the expression of the relevant genes (Bolden et al., 2006; Haberland et al. 2009; X. 
Ma et al., 2009; Mai et al., 2005). Here, we developed effective TSA-inducible killer constructs 
to enhance the anti-cancer effects of TSA, by identifying the TSA-responsive element of the 
herpes simplex virus thymidine kinase (hsvTK) promoter, and TSA-dependently activating 
some cell-death-inducing genes. We determined the most relevant regions responsive to TSA, 
and constructed chimeric promoters with higher fold-increases and greater induced strengths 
with TSA, by replacing the weak TSA-responsible region (TSA2) of the CMV promoter with 
two or three copies of the TSA-responsible sites (TSA1) of the hsvTK promoter. In addition, the 
synthetic intron sequence (0.2kb) from the pRL-TK vector and the long 3’-untranslated region 
(1.0kb) from the pSV2-neo vector, including the SV40 late polyA site, were important for the 
basal expression of the transgene and the TSA-induction, respectively.  
To create the TSA-inducible killer constructs, we placed the hsvTK gene for combination 
therapy with the prodrug Ganciclovir, and some strong death-inducing molecules (Bax, 
caspase8, and TRIF) under the control of the TSA-responsible chimeric promoters. They 
effectively killed the cells in which they were introduced, in a TSA-dependent manner. To 
evaluate the utility of the killer constructs for cancer gene therapy, the TSA-dependent 
death-inducing constructs were transferred to retroviral and adenoviral vectors. 
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2. TSA-induced transgene activation 
2.1 Screening of actinomycetes products to enhance the transgene 
Actinomycetes are the prime candidates in screens for new natural products as antitumor 
and antimicrobial bioactive agents, and the achievements have been well reviewed (Jensen 
et al., 2005; Park et al., 2008; Zheng et al., 2000). We screened the Actinomycetes products for 
substances that enhance the transgene promoter, using the luciferase reporter, pRL-TK 
vector (Promega). In the vector, the 0.75kb promoter region of hsvTK was placed upstream 
of the reporter Renilla luciferase gene. We found that a methanol extract of the MK616-mF5 
strain increased the luciferase activity significantly, by about 41-fold, as compared to the 
control among 2,448 Actinomycetes products. The methanol extract from the Actinomycetes 
MK616-mF5 strain was purified by chromatography on a silica column and a C18 reverse-
phase HPLC column, by monitoring the effects on the hsvTK-driven luciferase activities. 
Based on NMR and mass spectrometry analyses, we concluded that the natural product is 
TSA. TSA is a histone deacetylase inhibitor (HDACi), and some HDACis have recently been 
used in clinical trials for cancer treatment (Hoshino & Matsubara, 2010; X. Ma et al, 2009; 
Wagner et al., 2010). HDACi is thought to work by changing the acetylation status of core 
histones and thus modulating the gene expression patterns, including the genes associated 
with cell cycle arrest, apoptosis, and differentiation. Modifications of the N-terminal tails of 
core histones (the core histone is an octamer, consisting of an H3-H4 tetramer and two H2A-
H2B dimers) play a crucial role in chromatin packing and gene expression. The acetylation 
of the core histone is illustrated in Fig. 1, although other modifications, including 
methylation, phosphorylation, and ubiquitination, also affect the chromatin remodeling 
(Gasper-Maia, et al., 2011; Mai et al., 2005). Generally, the positively-charged lysine residues 
in the N-terminal core histone tails, which protrude from the surface of the nucleosome, are 
tightly bound to the phosphate backbone of the DNA, thus maintaining the chromatin in a 
transcriptionally silent state (closed chromatin). The acetylation status of the core histone is 
controlled by the competitive activities of histone acetyl transferase (HAT) and histone 
deacetylase (HDAC). Acetylation neutralizes the positive charges on the core histone, and 
converts the chromatin to a more open state, enhancing the access of the transcriptional 
machinery, including RNA polymerase II, to the promoter region for gene expression. 
HDACis have been used as anti-cancer drugs, because they activate the expression of the 
TRAIL, Fas, Bid, and p53 genes to induce growth arrest and/or apoptosis of cancer cells 
(Bandyopadhyay et al., 2004; Nakata et al., 2004; Ogawa et al., 2004; Ruefli et al., 2001; 
Sonnemann et al., 2007) by inhibiting HDAC activities, and they also have anti-angiogenic 
and anti-metastatic effects (Bolden et al., 2006). In addition, HDACi can enhance anti-tumor 
immunity, either by directly affecting malignant cells to make them more attractive immune 
targets, or by altering immune cell activity and/or cytokine production. HDACi reportedly 
augments the immunogenicity of tumor cells by upregulating the expression of the major 
histocompatibility complex (MHC) class I and II proteins and co-stimulatory/adhesion 
molecules, such as CD40, CD80, CD86 and intercellular adhesion molecule-1 (ICAM-1) 
((Maeda et al.,2000; Magner et al., 2000).  
On the other hand, HDACis have been used to reactivate virally transduced genes and to 
amplify the expression of transgenes encoded by recombinant adenoviral or retroviral 
vectors (Chen et al., 1997; Dion et al., 1997; Khalighinejad et al., 2008; Kikuchi et al., 2007). 
However, the induction levels of the silenced transgenes were not sufficient to achieve 
satisfactory results.  
 



































Fig. 1. Effects of HDAC inhibitors on chromatin structure and gene expression. In general, 
the acetylation of the positively-charged lysine residues within the N-terminal core histone 
tails, by histone acetyl transferase (HAT), converts the chromatin to a more open form for 
the access of the transcriptional machinery, including RNA polymerase II, to activate gene 
expression. In turn, when the acetylation is removed by histone deacetylase (HDAC), the 
chromatin returns to a closed form (transcriptionally silent). By inhibiting HDAC activities, 
the HDACi can alter the chromatin structure to an open form, to activate gene expression. 
―+: positively-charged lysine residues at N-terminal core histone, ―Ac: acetylated lysine 
residues. 
To develop effective vectors exhibiting high sensitivities to TSA and sustained strong 
activities in the presence of TSA, we examined the responsiveness of various promoters to 
TSA. HeLa cells were treated with 1.0 g/ml of TSA for 24 hours, after transfections with 
various Renilla luciferase constructs. The TSA treatment induced remarkable transgene 
expression with all of the tested promoters, as shown in Fig. 2. The hsvTK promoter 
exhibited the highest fold-increase, and the RSV and SV40 promoters also showed relatively 
high fold-increases. The responses of the CMV and -actin promoters to TSA were poor. In 
contrast, the CMV promoter showed the greatest strength, but the hsvTK promoter activity 
was weak, even in the presence of TSA. 
2.2 Analyses of the TSA-responsive elements in the hsvTK and CMV promoters 
To assess which region of the hsvTK promoter is responsible for the TSA stimulation, we 
created a series of deletion mutants within the 0.7kb promoter region of the hsvTK gene. 
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2. TSA-induced transgene activation 
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To develop effective vectors exhibiting high sensitivities to TSA and sustained strong 
activities in the presence of TSA, we examined the responsiveness of various promoters to 
TSA. HeLa cells were treated with 1.0 g/ml of TSA for 24 hours, after transfections with 
various Renilla luciferase constructs. The TSA treatment induced remarkable transgene 
expression with all of the tested promoters, as shown in Fig. 2. The hsvTK promoter 
exhibited the highest fold-increase, and the RSV and SV40 promoters also showed relatively 
high fold-increases. The responses of the CMV and -actin promoters to TSA were poor. In 
contrast, the CMV promoter showed the greatest strength, but the hsvTK promoter activity 
was weak, even in the presence of TSA. 
2.2 Analyses of the TSA-responsive elements in the hsvTK and CMV promoters 
To assess which region of the hsvTK promoter is responsible for the TSA stimulation, we 
created a series of deletion mutants within the 0.7kb promoter region of the hsvTK gene. 
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Fig. 2. Treatment with purified TSA leads to the induction of cellular and viral promoters. 
HeLa cells in a 96-well plate were transfected with 40ng of various constructs in FuGene 6 
transfection mixtures. The transfected HeLa cells were treated with/without 1.0 g/ml of 
TSA for 24hr, and the reporter assay was performed using a Renilla luciferase assay kit 
(Promega), according to the manufacturer’s instructions. (a) Luciferase activities. (b) Fold 
increase: the ratio of the luciferase activities in HeLa cells with or without TSA treatment. 
Promoters: hsvTK, herpes simplex virus thymidine kinase promoter; CMV, cytomegalovirus 
promoter; SV40, Simian Virus 40 early promoter; and RSV, Rous sarcoma virus LTR 
promoter. Values are means  SD. This figure was reproduced from Int. J. Integ. Biol., 5: 108-
115, 2009. 
They were transfected into HeLa cells, and the Renilla luciferase activities were measured 
after a 24 hr treatment with 1.0 g/ml of TSA. The responses to TSA were reduced by the 
deletion of the region between 231 and 111. Therefore, this region is important for the 
activation of the HSV-tk promoter by TSA, and we named this region TSA1. The TSA1 
region contained an octamer motif (ATTTGCAT), an NF-Y binding site (CCAAT), and a GC 
box. These elements are also reportedly important for the TSA-activation of other promoters 
(Hirose et al., 2003), consistent with our results. The TSA treatment also increased the gene 
expression by the CMV promoter, although the fold-increase was low. The reporter 
construct deletion mutant –77 almost lost its basal and TSA-induced activities. The region –
281 ～ –77 is important for weak activation by TSA, and thus we named it TSA2. The weak 
TSA-stimulation may be related to the degenerate octamer motif (ATTTGCgT), the partial 
NF-Y binding site (CCAAg), and the GC box in the TSA2 region. 
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2.3 Development of chimeric promoters that significantly enhance transgene 
expression 
A strong, drug-inducible promoter is urgently needed for cancer treatments, such as suicide 
gene therapy. The TSA1 site within the hsvTK promoter was important for the highest fold-
increase. On the other hand, the CMV promoter showed the greatest induced strength, and 
the TSA2 site was relevant to the weak responsiveness to TSA. We succeeded in 
constructing chimeric promoters with a higher fold-increase and greater induced strength to 
TSA, by replacing the weak TSA2 site of the CMV promoter with two or three copies of the 
TSA1 sites of the hsvTK promoter. A schematic representation of the chimeric promoters is 
shown in Fig. 3a. The reporter assay revealed that the chimeric promoter HC1, containing 
two copies of TSA1, and the chimeric promoter HC3, containing three copies of TSA1, 
amplified transgene expression in response to TSA by 220.7-fold and 94.2-fold, respectively 




Fig. 3. The chimeric promoter of hsvTK and CMV enhanced transgene expression. (a) 
Schematic representations of the chimeric promoters. The open horizontal box represents 
the regulatory region in the hsvTK promoter (shown as a thin line) responsive to TSA 
(TSA1); the stippled horizontal box represents the regulatory region in the CMV promoter 
(shown as a thick line) responsive to TSA (TSA2); and the HC1 and HC3 chimeric promoters 
containing TSA1 and fragments of the CMV promoter are shown as a thick line. The 
restriction enzyme sites used to make the mutants are indicated. (b) Reporter assay of 
chimeric promoters. HeLa cells in a 96-well plate were transfected with 40ng of the various 
constructs in FuGene 6 transfection mixtures. The transfected HeLa cells were treated 
with/without 1.0 g/ml of TSA for 24hr, and the Renilla luciferase activities were 
measured. Experiments were performed in triplicate. Values are means  SD. (c) Fold 
increase: the ratio of luciferase activities in HeLa cells with or without TSA treatment. This 
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activation of the HSV-tk promoter by TSA, and we named this region TSA1. The TSA1 
region contained an octamer motif (ATTTGCAT), an NF-Y binding site (CCAAT), and a GC 
box. These elements are also reportedly important for the TSA-activation of other promoters 
(Hirose et al., 2003), consistent with our results. The TSA treatment also increased the gene 
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As shown in Fig. 4, we also found that a synthetic intron (0.2kb) from the pRL-TK vector 
and the long 3’-untranslated region (1.0kb) from the pSV2-neo vector are important for the 
basal expression of the transgene and the TSA-induction, respectively. The long 3’-
untranslated region lowered the basal transgene activities in the HC3-L construct, and 
enhanced the TSA-stimulated transgene activities in all of the constructs (CMV-L, HC1-L, 
and HC3-L).  
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Fig. 4. Development of a modified CMV construct with intron and polyA sequences. (a) 
Transgene constructs modified with a synthetic intron and short and long 3’-untranslated 
regions. The closed solid horizontal box ( ) represents Renilla luciferase. The open 
horizontal box ( ) and the striped horizontal box ( ) represent the short and long 3’-
untranslated regions (UTR), respectively. The broken line ( ) represents the synthetic 
intron. The solid arrow ( ), open arrow ( ), and striped arrow ( ) represent the 
CMV, HC1, and HC3 chimeric promoters, respectively. (b) Reporter assay of the constructs. 
HeLa cells in a 96-well plate were transfected with 40ng of the various constructs in FuGene 
6 transfection mixtures. The transfected HeLa cells were treated with/without 1.0 g/ml of 
TSA for 24 hr, and the Renilla luciferase activities were measured. Experiments were 
performed in triplicate. Values are means  SD. (c) Fold increase: the ratio of luciferase 
activities in HeLa cells with or without TSA treatment. This figure was reproduced from Int. 
J. Integ. Biol., 5: 108-115, 2009. 
2.4 TSA-dependent induction of the stably integrated transgene under the chimeric 
promoters to kill target cells by different mechanisms. 
Considering the various escape mechanisms employed by cancer cells, we introduced the 
molecules that can activate different cell death-inducing mechanisms. We placed the hsvTK 
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gene for combination therapy with the prodrug Ganciclovir, and some strong death-
inducing molecules (Bax, caspase8, and TRIF) under the TSA-responsible chimeric 
promoters. Suicide gene therapy has been proposed as a strategy for the treatment of cancer 
for many years (Culver et al., 1992; Fillat et al., 2003; Mooleten et al., 1990). One of the most 
widely used prodrug-activating gene therapies is the thymidine kinase gene of the herpes 
simplex virus (hsvTK), in combination with the non-toxic prodrug Ganciclovir (GCV) (Fig. 
5). The principal effect of the hsvTK/GCV system is to generate GCV triphosphate (GCV-
PPP) from the non-toxic prodrug GCV, by the introduced hsvTK and several cellular 
kinases, including guanylate kinase. The produced GCV-PPP inhibits the mammalian DNA 
polymerase due to its analogy with deoxyguanosine triphosphate, and leads to cell death. 
The hsvTK is required for the formation of GCV-PPP; however, the GCV treatment 
eradicated the majority of the population, even though only 10% of the cell population was 
expressing hsvTK (Freeman et al., 1993). The killing of hsvTK-negative cells by adjacent 

































Fig. 5. Principle of suicide gene therapy with bystander effects. The non-toxic prodrug 
Ganciclovir (GCV) is assimilated into the target hsvTK-transduced cell, and is converted 
into the toxic triphosphorylated GCV (GCV-PPP) by hsvTK and several cellular kinases. 
GCV-PPP inhibits the mammalian DNA polymerase due to its analogy with 
deoxyguanosine triphosphate, and leads to cell death. In addition, GCV-PPP is transferred 
to the neighboring hsvTK-non-expressing cell via the gap junction, and the neighboring cell 
is also killed by the toxic GCV-PPP (Bystander killing effects). 
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gene for combination therapy with the prodrug Ganciclovir, and some strong death-
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junction formation, and has been established as a potentially powerful tool in cancer gene 
therapy (Fick et al., 1995; Denning & Pitts, 1997; Mesnil et al., 1996). To enhance the killing 
effects on cancer cells, the hsvTK suicide gene therapy is employed with other anti-cancer 
treatments, such as chemotherapy, radiotherapy, and immunotherapy. Especially, the 
combination therapy of hsvTK/GCV and HDAC inhibitors (HDACi) including TSA is 
promising for cancer therapy (Ammerpohl et al., 2004; Yamamoto et al., 2003), because 
HDACis have anti-cancer effects by inducing tumor cells to undergo differentiation, growth 
arrest and/or apoptosis, and by enhancing anti-tumor immunity, by altering gene 
expression through chromatin structure remodeling. 
Other molecules (Bax, Caspase8, and TRIF) that induce apoptosis by activating different 
pathways should be beneficial for the treatment of various tumors, because each cancer 
employs various strategies to escape from the host immune surveillance and to gain growth 
advantages (Liu et al., 2011; Luo et al., 2009; Pavet et al., 2011). As shown in Fig. 6, two core 
pathways for inducing apoptosis exist: the extrinsic and intrinsic pathways. In the intrinsic 
pathway, the mitochondrion plays a central role. The mitochondrial membrane integrity is 
controlled by pro-apoptotic molecules (Bax, Bak, Bid, etc.) and anti-apoptotic molecules (Bcl-
2, Bcl-xL, etc.). The disruption of the membrane integrity by various stimuli, including DNA-
damaging agents, increases the permeability and allows the release of cytochrome c and 
second mitochondria-derived activator of caspase (Smac)/direct IAP binding protein with 
low pH (DIABLO). The cytochrome c forms an apoptosome with apoptotic protease-
activating factor-1 (Apaf-1) and caspase9 in the cytosol, and the Smac/DIABLO antagonizes 
the inhibitor of apoptosis proteins (IAPs) to enhance the activation of caspse9 and caspase3. 
As a result, the executioner caspase3 is effectively activated, to induce cell death. Actually, 
Bax overexpression has been reported to cause cell death in various cell types (Kitanaka et 
al., 1997; Tamm et al., 1998; Xiang et al., 1996). Caspase8 is the key enzyme in the extrinsic 
pathway. When the death receptors (Fas, DR3, DR4, etc.) are activated by their ligands, they 
recruit caspase8 via an adaptor molecule, Fas-associated death domain (FADD), and form 
the death-inducing signaling complex (DISC) to activate caspase8. The activated caspase8 
not only activates caspase3 directly, but also activates the intrinsic pathway by removing the 
N-terminal region of Bid, thus producing its active, truncated form (tBid). Both signals work 
together to induce cell death by activating the executioner caspase3. TIR domain-containing 
adaptor protein (TRIF) is a key molecule that mediates the signals from pathogens via Toll-
like receptor3 (TLR3) and TLR4, to trigger type I interferon production and inflammatory 
responses via interferon regulatory factor3 (IRF3) and Nuclear factor B (NFB), 
respectively (Kawai & Akira, 2010). Among these molecules related to the innate immune 
system, TRIF is a strong death-inducing molecule that activates caspse8 via receptor 
interacting proteins (RIPs) and FADD (Kaiser & Offermann et al., 2005). 
To evaluate the utility of these TSA-responsive killer constructs for cancer gene therapy, we 
introduced the TSA-inducible hsvTK gene constructs to a well-characterized retroviral 
vector. Retroviral vectors are useful tools for the long-term expression of stably integrated 
transgenes in target cells, although there are risks due to insertional mutagenesis and the 
generation of replication competent retroviruses. We used a retroviral vector, pQC 
(Clontech) that self-inactivates the 5' LTR to avoid promoter interference, and to reduce the 
risk of transactivation of genome sequences around the integration site. The hsvTK, Bax, 
Caspase8, and TRIF genes were placed downstream of the chimeric promoters (PHC1, and 
PHC3), with the PPGK-driven puromycin selection marker (Fig. 7).  
 




























Fig. 6. Apoptosis pathways activated by Bax, Caspase8, and TRIF. Bax activates the intrinsic 
pathway of apoptosis by antagonizing the anti-apoptotic molecules (Bcl-2, Bcl-xL, etc.) and 
increasing the permeability of the mitochondrion. The cytochrome c released from the 
intermembrane space of the mitochondrion forms an apoptosome with Apaf-1 and caspase9 
in the cytosol, and leads to cell death by activating the executioner caspase3. Caspase8 is the 
key enzyme in the extrinsic pathway, where death receptors (Fas, DR4, DR5, etc.) activated 
by their ligands form the death-inducing signaling complex (DISC) with FADD and 
caspase8. The activated caspase8 leads to cell death by activating the executioner caspase3. 
TRIF is not only a key molecule that mediates the signal from pathogens via TLR3 and TLR4 
to trigger type I interferon production and an inflammatory response, but also a strong 
death-inducing molecule by activating caspse8 via RIPs and FADD. Apaf-1, apoptotic 
protease-activating factor-1; DR4, Death receptor 4; FADD, Fas-associated death domain; 
TRIF, TIR domain-containing adaptor protein; TLR3, Toll-like receptor 3; RIP, receptor 
interacting proteins.       : stimulatory siganal.  : inhibitory signal. 
To verify the activities of the constructs, we examined whether the cells in which these 
constructs were transiently introduced are killed by TSA treatment. The 293T cells with the 
PHC1- or PHC3-hsvTK gene showed TSA- and GCV-dependent cell death. The cells with the 
PHC1- or PHC3-driven Bax, Caspase8, or TRIF genes were also killed with 0.1~0.3 g/ml TSA 
treatment. Among them, TRIF triggered the most effective cell death. To examine the effects 
of TSA on the stably-introduced transgene expression, we obtained stable clones to express 
the death-inducing molecules under the control of the HC1 and HC3 promoters, by selection 
with puromycin for several weeks after the retroviral infection. The 293T cells containing the 
PHC1-TRIF gene showed drastic cell death (apoptosis) upon a treatment with 0.1g/ml TSA 
for 24h, as compared to the control 293T cells containing PCMV only (Fig. 8). The chimeric 
promoter PHC1 maintained the TSA-responsiveness after becoming stably-integrated into the 
genome DNA. 
 
Targets in Gene Therapy 
 
54
junction formation, and has been established as a potentially powerful tool in cancer gene 
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Fig. 6. Apoptosis pathways activated by Bax, Caspase8, and TRIF. Bax activates the intrinsic 
pathway of apoptosis by antagonizing the anti-apoptotic molecules (Bcl-2, Bcl-xL, etc.) and 
increasing the permeability of the mitochondrion. The cytochrome c released from the 
intermembrane space of the mitochondrion forms an apoptosome with Apaf-1 and caspase9 
in the cytosol, and leads to cell death by activating the executioner caspase3. Caspase8 is the 
key enzyme in the extrinsic pathway, where death receptors (Fas, DR4, DR5, etc.) activated 
by their ligands form the death-inducing signaling complex (DISC) with FADD and 
caspase8. The activated caspase8 leads to cell death by activating the executioner caspase3. 
TRIF is not only a key molecule that mediates the signal from pathogens via TLR3 and TLR4 
to trigger type I interferon production and an inflammatory response, but also a strong 
death-inducing molecule by activating caspse8 via RIPs and FADD. Apaf-1, apoptotic 
protease-activating factor-1; DR4, Death receptor 4; FADD, Fas-associated death domain; 
TRIF, TIR domain-containing adaptor protein; TLR3, Toll-like receptor 3; RIP, receptor 
interacting proteins.       : stimulatory siganal.  : inhibitory signal. 
To verify the activities of the constructs, we examined whether the cells in which these 
constructs were transiently introduced are killed by TSA treatment. The 293T cells with the 
PHC1- or PHC3-hsvTK gene showed TSA- and GCV-dependent cell death. The cells with the 
PHC1- or PHC3-driven Bax, Caspase8, or TRIF genes were also killed with 0.1~0.3 g/ml TSA 
treatment. Among them, TRIF triggered the most effective cell death. To examine the effects 
of TSA on the stably-introduced transgene expression, we obtained stable clones to express 
the death-inducing molecules under the control of the HC1 and HC3 promoters, by selection 
with puromycin for several weeks after the retroviral infection. The 293T cells containing the 
PHC1-TRIF gene showed drastic cell death (apoptosis) upon a treatment with 0.1g/ml TSA 
for 24h, as compared to the control 293T cells containing PCMV only (Fig. 8). The chimeric 
promoter PHC1 maintained the TSA-responsiveness after becoming stably-integrated into the 
genome DNA. 
 






































Fig. 7. Retroviral constructs. The retroviral vector, pQC (Clontech), that self-inactivates the 5' 
LTR to avoid promoter interference, was used to construct the expression plasmids. 5' LTR, 
the hybrid long terminal repeat, consists of the CMV type I enhancer and the mouse 
sarcoma virus promoter; , packaging signal; PHC1, PHC3, and PCMV: the CMV, HC1, and 
HC3 chimeric promoters, respectively; Intron, the synthetic intron; PPGK-Puror, PGK (murine 
phosphoglycerate kinase) promoter-driven puromycin resistance gene; 3' LTR, the Moloney 
murine leukemia virus LTR deleted in the U3. The death inducing genes (Bax, Caspase8, 
TRIF, and hsvTK) are boxed. 
 














Fig. 8. TSA-induced cell death in the cells stably containing the PHC1-TRIF transgene. The 
HEK293T cells introduced with the PHC1-TRIF gene, or the control PCMV promoter only, were 
selected in medium containing 1g/ml puromycin for more than two weeks to obtain stable 
clones. The cells were then treated with 0.1g/ml TSA for 24h to activate the PHC1 promoter. 
To detect the apoptotic cells, FITC-conjugated Annexin V was used according to the 
manufacturer’s instructions. The HEK293T cells containing the PHC1-TRIF gene showed 
drastic cell death (apoptosis), as compared to the control 293T cells containing PCMV only. 
On the other hand, adenoviral or adeno-associated viral vectors are preferable to retroviral 
or lentiviral vectors, to avoid insertional mutagenesis by the transgene in target cells. In 
addition, the vectors can be inserted with the long 3’-untranslated region (UTR), to enhance 
the TSA-responsiveness between the inverted terminal repeats (ITRs). We constructed 
several adenoviral vectors containing the death-inducing genes (Bax, Caspase8, TRIF, and 
hsvTK) under the chimeric promoters (PHC1 and PHC3) with the long 3’ UTR sequence (Fig. 
9). To monitor the transfection and infection efficiencies easily, we added the EF1 
promoter-driven GFP. The recombinant adenovirus constructs were transferred from a 
shuttle vector (Clontech) with the specific homing endonucleases I-CeuI and PI-SceI, and 
showed GFP expression in the HEK293 packaging cells. 
/P -Puror 
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Fig. 9. Adenoviral constructs. The recombinant adenovirus constructs were created by 
transferring the fragments from a shuttle vector, pTRE-Shuttle2 (Clontech), with the specific 
homing endonucleases I-CeuI and PI-SceI to an adenoviral vector deleted in the E1 and E3 
regions, pAdeno-X (Clontech). PHC1, PHC3, and PCMV: the CMV, HC1, and HC3 chimeric 
promoters, respectively; Intron, the synthetic intron; PPGK-Puror, PGK (murine 
phosphoglycerate kinase) promoter driving the puromycin resistance gene; Long UTR, long 
3’-untranslated region. The death inducing genes (Bax, Caspase8, TRIF, and hsvTK) are 
boxed. 
3. Specific delivery of transgenes to target cells 
Another challenge is to deliver the transgene to the desired cells or tissues. Some specific 
delivery systems have been developed by engineering the viral envelope proteins of 
Lentivirus or Retrovirus, in a procedure referred to as pseudotyping, and incorporating 
specific antibodies and ligands (Mátrai et al., 2010). The pseudotyping with vesicular 
stomatitis virus glycoprotein (VSV-G) as a viral envelope protein has broadened the natural 
tropism of the virus to infect basically all human and murine cell types (Burns et al., 1993). 
Using various viral envelopes, the recombinant viruses can be introduced into different 
target cells, including lymphocytes and nerve cells (Colin et al., 2009; Funke et al., 2009; 
Miletic et al., 2004). Some viruses have two envelope proteins with distinct functions, to 
bind to the host receptor and to fuse with the membrane for entry (Buchholz et al., 2009). 
The E1 and E2 proteins of Sindbis virus (Morizono et al., 2005; Yang et al., 2006), and the H 
and F proteins of measles virus (Frecha et al. 2008; Funke et al., 2008) have been well 
 
Effective Transgene Constructs to Enhance Gene Therapy with Trichostatin A 
 
59 
characterized for the recombinant virus to infect a desired target cell (retargeting) with high 
transduction efficiency. The principle of retargeting using the measles H and F proteins is 
illustrated in Fig. 10. The natural receptor recognition of the measles H protein is ablated, 
and a ligand is attached that recognizes the cognate receptor on the target cell. Subsequent 
virus entry is mediated by the F protein pH-independently at the plasma membrane, and 
the transgene is delivered into the target cell. Using specific markers on target cells (specific 
epitope and antibody binding, or ligand and receptor binding), the transgene will be 
retargeted to the desired cell type. By combining this specific delivery system with a suicide 
gene, selective cell death of the target cells was achieved (Funke et al., 2008). Our TSA-
responsible killer gene constructs can be applied to this retargeting system. 
Finally, these TSA-responsible killer gene constructs can be used to eliminate the 
undesirable cells generated by inadvertent insertional mutagenesis in the process of gene 



















Fig. 10. Specific delivery of a transgene. The natural receptor recognition of the measles H 
protein is ablated, and a ligand is attached that recognizes the cognate receptor on the target 
cell. The virus entry is mediated by the F protein pH-independently at the plasma 
membrane, and the transgene is delivered into the target cell. Using specific epitope and 
antibody binding, or ligand and receptor binding, the transgene is delivered to the desired 
target cells. 
4. Conclusions  
Considering the various anti-cancer effects of TSA, an HDACi with the ability to reactivate 
silenced transgenes by altering the chromatin structure, we have developed TSA-inducible 
cell death systems to enhance the anti-cancer effects of TSA. The chimeric promoters PHC1 
and PHC3 showed high TSA-responsiveness to express the death-inducing genes (hsvTK, 
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Bax, Capase8, and TRIF), and the cells in which the killer constructs were introduced 
showed TSA-dependent cell death. Combined with specific delivery systems to target 
cancer cells, these killer constructs will be beneficial for cancer gene therapy. We are 
planning to investigate the killer efficacies of other HDACis besides TSA, because various 
HDACis are now available for cancer therapy. The in vivo trials of these constructs with 
HDACis will be the crucial next step. 
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1. Introduction 
Suicide gene therapy for cancer treatment proposed by Moolten [1] started more than 25 
years ago and has gained momentum with little variations in the original technology. At the 
current statistics, worldwide 1550 clinical trials of gene therapy have been reported 
(http://www.wiley.co.uk/genmed/clinical) among them 7% using suicide gene therapy. 
HSV-TK is the most well characterized suicide gene used for cancer therapy and in other 
diseases without inducing significant systemic toxicity [2] [3]. Chemotherapeutic drugs used 
for cancer therapy are problematic because they do not discriminate in their mode of action. 
Currently available drugs in the market are not cancer specific so functional concentration 
level in tumors cannot be reached without off-target toxicity level. This is specifically true 
for solid tumors where vascularization is poor and necrotic at the center of the tumor due to 
low oxygen and nutrient supply [4][5]. However, when the drug is activated by locally 
enzymatic reactions in a timely fashion, the metabolite is toxic for the tissue. The most 
widely used suicide genes are Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK), and 
Cytosine Deaminase (CD) from the virus Herpes simplex or the bacterium Escherichia coli 
respectively [6][7]. 
Prior research has focused on the mechanism of initiation and development of tumors. It 
starts with the mutation of 1 or several genes, then gradually attains more genetic mutation 
and genomic instability during the evolution of tumor/cancer. Almost all the genes fall in 2 
categories – oncogenes (derived from proto-oncogene) and tumor suppressor genes. There 
are many ways to treat various tumors ranging from benign to metastatic. Among them 
surgery followed by chemotherapeutic drug treatments is the widely used method of choice 
that damages the DNA and renders the cells apoptotic. Additionally, tumors can be cured 
by more subtle ways by restoring the function of tumor suppressor genes or disabling 
oncogenes, to prime the immune cells to act and down-regulate angiogenesis and metastatic 
activities. Solid tumors can be treated by intra-tumor delivery of suicide genes. The protein 
product of these genes catalyzes the formation of highly toxic metabolites following the 
application of some lesser toxic prodrugs. This leads to apoptosis or programmed cell death 
of the treated cells [8]. The apoptotic cells invite immune cells that further clear the tumor 
zone by phagocytosis. 
Suicide gene therapy is also known as Gene Directed Enzyme/Prodrug therapy (GDEPT) or 
as Gene Prodrug Activation Therapy (GPAT). GDEPT can either take the form of CBT (cell 
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zone by phagocytosis. 
Suicide gene therapy is also known as Gene Directed Enzyme/Prodrug therapy (GDEPT) or 
as Gene Prodrug Activation Therapy (GPAT). GDEPT can either take the form of CBT (cell 
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based therapy) where nearby cells of the tumor are modified to express suicide gene or the 
tumor itself expresses the suicide gene therapy. GDEPT can also be used for viral vectors 
which itself carries the suicide gene. GDEPT (Molecular chemotherapy) has advantages over 
classical therapy. As only tumor cells posses the enzyme that converts prodrug to active 
metabolites, it increases the toxicity level several fold inside the tumor whereas the vast 
majority of the host cells are unaffected. By using tumor specific regulatory elements 
(promoter) drugs can be activated only in tumor cells [9][10] has used the technique where 
the drug is only preferentially activated in the hypoxic regions of the tumor. By harnessing 
the bystander effects, more destruction of tumor cells have been rendered. 
2. Properties of suicide gene 
To be considered as a suicide gene, the product enzyme should be either absent or present 
in low concentrations (low expression) in the host. It should have a high catalytic activity, so 
that tumor cells can convert this prodrug even in low substrate concentration (high KCAT, 
low Km). To be considered as an ideal therapeutic agent, it should have/possess the 
following criteria. 1) The drug should be non-toxic or minimally toxic prior to activation and 
highly toxic after enzymatic activation. 2) The prodrug should be able to effectively 
penetrate the tumor, distributed and taken up by individual cells. 3) It should have a high 
affinity for the transduced suicide gene and low affinity for cellular enzyme. The HSV-TK 
enzyme has 1000 times more affinity for the substrate GCV than the host cell TK [11]. 4) The 
metabolite should have a half-life that extends long enough to kill the tumor so that drug is 
not lost before reaching its concentration.  
3. Types of suicide genes for therapy 
There are several suicide gene therapies. Among them HSV1-TK and cytodine deaminase 
are important. Cytidine Deaminase: Cytosine Deaminase (CD) is an enzyme found in some 
bacteria and fungi that deaminates cytosine to uracil [12]. It can also convert the nontoxic 5-
fluorocytosine (5-FC) into the toxic compound 5-fluorouracil (5-FU) [13]. Mammalian cells 
do not contain CD. This property allows the drug to be used for suicide gene therapy 
especially for the treatment of cancer. The sensitivity of tumor to CD drug depends on dose, 
duration etc. This review will mainly focus on HSV-TK gene therapy. 
HSV-TK: TK converts GCV into a toxic metabolite that kills cells widely used for cancer 
therapy. HSV1-TK can also phosphorylate various nucleoside analogs of GCV such as 
acyclovir, ganciclovir, and penciclovir. 
4. Mode of action of HSV-TK 
HSV-1 encodes about 70 genes some are immediate early genes. TK is one of the immediate 
early (IE) genes that give rise to a 376 amino acid long protein. IE genes can be defined as 
genes that show rapid and transient expression in the absence of de novo protein synthesis; 
some viruses posses IE genes. HSV1 virus is neurotropic (preferentially attacks nerve cells to 
avoid immune cells) and TK is necessary when the virus goes into the lytic cycle from a 
dormant stage in the neural cells. During TK suicide gene therapy, GCV is injected 
systemically way and upon reaching the tumor area, the drug is monophosphorylated by 
HSV-TK, and further phosphorylation is done by the host cell kinase. This triphosphate 
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form of GCV (deoxythymidine triphosphate) is an analog of purine which inhibits DNA 
polymerase and is the most toxic. Cancer cells are actively proliferating and synthesizing 
DNA; the purine analogs GCV triphosphate competes with triphosphate substrate for DNA 
polymerase and are incorporated in the nascent DNA. This results the DNA polymerase 
enzyme stall and termination of nuclear and mitochondrial DNA synthesis initiating the 
cascades of apoptosis paths. [14][1]. The mechanism for cell death with HSV-TK is not 
completely known. Apoptosis induction or the sensitization of CD95- L, TNF, and TNF-
related apoptosis-inducing ligands may contribute to cell death [15]. Yang et al. suggested 
that apoptosis occurred as a result of GCV-induced cell cycle arrests rather than direct 
chemical effects [16]. Depletion of the T-cells had no effect on the response [17]. The 
bystander effect causes local inflammation and the apoptotic cells invites dendritic cells and 
immune effectors (immune response) and further clears the tumor [18][19]. 
5. Bystander effect mediated by gap junctions 
The bystander effect can amplify the effect of toxic drugs several fold. The toxic form of the 
drug should have diffusible property so that it can kill the non-transduced tumor cells 
through the bystander effect; in case of absence of diffusion, it should be taken up by 
surrounding cells by active transport. The action/effect of drug should also be cell cycle 
independent. Although cancer cells are highly proliferating, at a particular given time only a 
fraction of cells are dividing. In these cases drug distribution by diffusion is helpful. 
Moreover, in case of solid tumors only 10% of the cells can be transduced; in that case tumor 
ablation is mainly dependent on the bystander effect. Phospho-GCV is about a 500 daltons 
molecule. Such a small molecule should spread to surrounding cells by diffusion. But 
phospho-GCV is not dissolved in the cell lipid membrane. So, they spread to neighboring 
cells by gap junction that mainly consists of connexin family of proteins among them 
connexin-43 is the most studied. Gap junctions are a narrow connecting channel (2-3 nm 
diameter) between cells that facilitates the exchange of small molecules less than 1.5 kd in 
size. The gap is bridged by connexins, a family of 21 proteins. Gap junction exchanges small 
metabolites, second messengers and electric signals through a procedure called Gap 
Junctional Intercellular Communication (GJIC) [20]. Gap junction allows the ablation of the 
entire tumor although all cells in the tumor do not contain the suicide gene. This 
phenomenon is known as bystander effect and has boosted/amplified the toxic effect. Many 
kinds of cells express gap junction and are connected with neighboring cells. Some of the 
brain tumors (gliomas) do not express gap junctions or downregulate gap junctions [21]. 
Several studies have been done to deliver connexin-43 with the suicide gene so that the 
bystander effect through diffusion of active drug can take place. This was attempted by the 
pharmacological administration of cAMP analogs, hydroxyurea etc. [22]. Various reports of 
using connexin-26 and connexin-43 for the augmentation of the bystander effect have been 
published [23][9]. Solid tumors from both humans and rodents express lower amount of 
connexin and gap junction [24]. Established cell lines derived from tumors also 
downregulate expression of connexin and sometimes lack gap junction. Fusion proteins 
consisting of HSVtk and 11 amino acids from HIV-1 TAT protein have been demonstrated to 
provide gap-junction independent intercellular trafficking [25]. 
6. Variations of original HSV-TK approach 
HSV1-TK suicide gene therapy is used for glioma [26], prostate cancer [27], leukemia [28] 
and lymphoma. Potency of original HSV-TK has been improved by the application of 
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various strategies. An approach was made to deliver fusion protein of TK and viral 
tegument protein VP22 (to increase the bystander effect) [29] and by the use of fusion 
protein of HIV TAT and TK (that is more stable than wild type TK) [30]. Cerepro 
(sitimagene ceradenovec) is a recombinant adenoviral vector consisting of HSV-TK and 
replication deficient (where E1 and part of E3 genes have been deleted). After the brain 
surgery, this vector was injected immediately. Upon intra-peritoneal administration of GCV, 
the volume of the tumor was reduced [31]. It is found that GCV is a substrate for ABCG2 
(ATP-binding cassette sub-family G member 2, also known as the breast cancer resistance 
protein) and glioblastoma side population can pump out small molecule drugs like GCV 
rendering it resistant to therapy whereas non-side populations are susceptible [32]. Due to 
toxicity of the surrounding healthy tissue especially liver parenchyma cells in liver tumor, 
the use of TK has limited its clinical usefulness [33]. This problem has been improved by 
injecting the vector inside the tumor or using engineered HSV-TK under tumor specific 
promoter like α-fetoprotein. [34]. Ad.TK was injected intratumorally in hepatocellular 
carcinoma (HCC) and it did not show any toxicity in normal liver tissue and the therapy 
was well tolerated. Ad.TK can be safely used in HCC patient upto 2X1012 viral 
Particles/patient [35]. The HSV-TK gene has been successfully transferred into hepatoma 
cells (BEL-7402), and the growth potential of these cells was significantly inhibited by the 
application of GCV [36]. The bystander effect was further boosted by a combination therapy 
of co-expression of TK and E-cadherin genes in adenoviral vector. E-cadherin expression 
modulates the gap junction by connexin expression. It is assumed that E-cadherin 
expression facilitates connexin transport to the plasma membrane thus connexin stabilized 
and minimize connexin internalization and degradation by lysosomes and proteosome 
mediated degradation [37]. The role of E-cadherin in suicide gene therapy is established in 
an in vivo model of pancreatic ductal adenocarcinoma. This way it was possible to increase 
the bystander effect by treating the tumor with HSV-TK+E-cad [38]. Additionally, the 
increase of E-cad  expression. also down regulates bcl-2 (an anti-apoptotic gene) rendering 
cell death. Non-human primate marmoset is used as a transgenic model for preclinical 
studies. HSV-TK knock-in marmoset stem cell line (cmES) was established using RMCE (Cre 
recombinase-mediated cassette exchange). From the cmES cell line-generated tumor cells 
were effectively destroyed by GCV treatment. Thus, HSV-TK and GCV treatment may 
ensure safety of stem cell therapy [39]. In NSCLC (non-small cell lung cancer), human 
telomerase reverse transcriptase hTERT is up-regulated. Thus hTERT promoter controlled 
E1A (Ad.hTERT-E1A-TK /GCV) gene expression in NSCLC, efficiently killed different 
types of tumor cells and could be used a safe and potent therapy for NSCLC [40]. One group 
has used piggyBack vector for HSV-TK delivery and GCV treatment for gene therapy of 
cervical cancer [41]. Co-transfection of insulin like growth factor-I (IGF-I) and HSVTK by 
liposome promotes wound healing and minimizes the scar formation [42]. Adenoviral 
vectors containing HSVTK were transfected into T47D human breast cancer cells [43]. When 
grown in nude mice, administration of GCV markedly demonstrated regression of tumors 
over control animals [44]. Fong et al. demonstrated that ablation of CT26 tumor cells in situ 
was achieved by directly injecting high-titer HSV-TK retroviral vector preparations into the 
site of tumor cell inoculation followed by intra-peritoneal delivery of GCV [45]. 
Chondrosarcoma cells implanted into nude mice were injected with HSV-TK. After 4 weeks, 
the growth of tumors was significantly prevented [46]. Suicide gene therapy can be used as 
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a tool for molecular biology research. Evans G et al. have used HSV-TK suicide gene therapy 
to shut down Nerve Growth Factor (NGF) when its intended job is done i.e. the bridging of 
nerve gaps have been achieved [47]. Suicide gene was used as a molecular off switch for 
growth factor expression in a tissue engineered construct after the successful healing of the 
defect, both morphologically and functionally. NGF-producing HEK-293 called as hNGF-
EcR-293 cells were genetically modified to incorporate HSV-TK gene as a suicide gene for 
cell kill upon treatment with GCV. The combination of the inducible NGF expression system 
with the HSV-TK system offers regulation of time and presumed dose-dependent NGF 
expression at the site of the lesion with a subsequent elimination of genetically engineered 
cells within the conduit. 
 
 
Fig. 1. Conversion of Ganciclovir by HSV-TK and cellular kinase to Ganciclovir 
triphosphate. The drug GCV is monophosphorylated by HSV-TK, and further 
phosphorylation is done by the host cell kinase. This triphosphate form of GCV 
(deoxythymidine triphosphate) is an analog of purine which inhibits DNA polymerase and 
is the most toxic. The bystander effect is mediated by the intercellular gap junctions present 
in many kinds of tissues and tumors.  
One particular problem with the gene therapy is that retroviral vectors integrate in the 
genome randomly consequently it may potentially activate a proto-oncogene or silent a 
tumor suppressor gene rendering the cell to tumorigenesis. Insertion induced mutagenesis 
is a rare event at a frequency between 10-6 and 10-8 per insertion event [48]. Adenine 
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Deaminase (ADA) and Severe Combined Immuno-Deficiency (SCID) are genetic (inherited) 
disorders where the babies are born with immune deficiency and are vulnerable to common 
infections that others can resist in their everyday life. Several gene therapy approaches were 
used to deliver the corrected version of the gene in SCID patients by retroviral delivery. 
Patients regained immunity within 2-5 months but surprisingly several patients died due to 
cancer. Upon investigation, it was found that the virus has a preponderance to integrate in 
the vicinity of the human T-cell oncogene, LMO2 [49]. This probably due to retroviral 
transgene that has cotransforming role in leukemogenesis by giving advantages of increased 
cell proliferation or decreased apoptosis. As a cautionary measure, further trial of gene 
therapy was stopped. Delivery of HSV-TK fused with the therapeutic gene of interest into 
the therapeutic vector can be used for gene therapy. When the therapeutic gene has done its 
intended job, the cells harboring the gene and HSV-TK can be selectively eliminated by the 
administration of GCV. Thus killing the cells after gene therapy can be protective before the 
oncogene can do any harm. The GCV system has also been utilized in the non-oncologic 
setting. In vivo transduction with HSV-TK adenoviral vector followed by GCV treatment 
significantly inhibited the development of posterior capsule opacification from hyperplasia 
of the lens epithelium in the rabbit. Further, HSV-TK plasmid DNA has been injected into 
the joint space of rabbits with antigen-induced arthritis and when treated with GCV, results 
demonstrated a reduction in joint swelling in the HSV-TK–transduced knees [50]. Barbier et 
al. in an open and single-arm study on 48 patients, demonstrated that intracerebral injection 
of HSV-TK carrying cells into glioblastoma multiforme (GBM) did not result in any adverse 
effects [51]. HSV-TK has also been injected into the white matter of the right frontal lobe in 
two rhesus monkeys, with no clinical symptoms observed [52]. Murata et al. have 
demonstrated that like the Muristerone A–inducible system, the HSV-TK suicide gene 
allows for dose- and time-dependent regulation of cell death upon the application of  
GCV [53]. 
HSV-TK was modified to be able to migrate to neighboring cells and expand the expression 
of TK positive cells. A secreting form of HSV-TK was constructed by adding Igkappa leader 
peptide in the TK gene. An endoplasmic reticulum export signal was added to further 
increase the secretion. This resulted in the 70% of total protein secreted. However, enzyme 
activity of the secreted protein was decreased. This may present a hurdle for the 
development of a transmitted form of TK [54]. Microbubble destruction by ultrasound 
increases the efficiency of HSV-TK transfection [55]. HCC induces intrahepatic metastatic 
growth which is difficult to treat and prognosis is poor. A novel approach to introduce 
chemokine ligand 2/monocyte chemoattractant protein-1 (CCL2/MCP-1) and HSV-TK 
together increases the efficiency of gene therapy. CCL2/MCP-1 attracts T helper 1-polarized 
antitumor activity without inducing tumor angiogenesis [56]. By using an IRES sequence, a 
plasmid was constructed with 2 suicide genes driven by PSMA promoter. The genes are 
FCY1 and HSV-TK for metabolizing the drug. Introducing the combination of 5-FC and 
GCV drugs inhibited the growth of prostate tumor compared to each drug individually. In a 
xenograft mouse model, retarded tumor growth was also observed. This suggests that the 
combination of multiple suicide genes may be more effective in prostate tumor [57]. 
Adenovirus mediated HSV-TK is a promising adjuvant therapy for patient’s having high 
grade glioma. This is a choice as surgery for malignant glioma is difficult due to its location 
and non-metastatic nature of glioma. The HSV-TK attacks the dividing tumor cells without 
harming healthy neurons which are non-dividing [58]. Pancreatic tumor was treated with 
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mesenchymal stem cells (MSC) containing a CCL5 promoter. Homing of MSC cells into 
primary pancreatic tumor stroma and activation of the CCL5 promoter takes place. About 
one week later after stem cell treatment tumor size reduced to 50% and metastasis reduced 
significantly [59]. Use of undifferentiated embryonic stem (ES) cells may form teratomas 
thus limiting the use of stem cells in clinical setting. However, HCV-TK with Oct4 promoter 
construct was injected to ES cells. Upon treatment with GCV, undifferentiated cells die but 
differentiated cells are free from harm [60]. Combination gene therapy using multidrug 
resistance (MDR1) shRNA and HPV-TK [61], targeting angiogenesis of hepatocellular 
carcinoma with GCV treatment has been done [62]. Transfection of wild type p53 makes C6 
glioma cells more susceptible to GCV treatment [63]. HIV-1 transactivator protein 
transduction domain (TAT PTD) can penetrate the cell. Cytotoxicity of GCV was enhanced 
by the fusion of HSV-TK and TAT PTD [64]. Fusion of mutant HSV-TK (with improved 
GCV activation) and guanylate kinase enhances prodrug sensitivity [65]. 
7. Disadvantage or drawback 
GCV has toxic side effects especially on bone marrow cells. So, it is administered in lower 
concentrations [66] and has been used in animal model studies. The disadvantage of using 
GCV is that although GCV is readily diffusible, its metabolite triphosphate is membrane 
insoluble and can’t diffuse to surrounding cells. However, the bystander effect of the close 
proximity/neighboring cells happen as triphosphate is transported to nearby cells through 
the gap junctions.  
8. Conclusion 
Suicide gene therapy is a method of choice to ablate cells in many diseases including cancer. 
But like other techniques this method is not fully safe and efficacious. HSV-TK gene therapy 
is still evolving and the method has been tinkered to be applicable in various cell 
background and different goal. More works need to be done for future applications. 
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Deaminase (ADA) and Severe Combined Immuno-Deficiency (SCID) are genetic (inherited) 
disorders where the babies are born with immune deficiency and are vulnerable to common 
infections that others can resist in their everyday life. Several gene therapy approaches were 
used to deliver the corrected version of the gene in SCID patients by retroviral delivery. 
Patients regained immunity within 2-5 months but surprisingly several patients died due to 
cancer. Upon investigation, it was found that the virus has a preponderance to integrate in 
the vicinity of the human T-cell oncogene, LMO2 [49]. This probably due to retroviral 
transgene that has cotransforming role in leukemogenesis by giving advantages of increased 
cell proliferation or decreased apoptosis. As a cautionary measure, further trial of gene 
therapy was stopped. Delivery of HSV-TK fused with the therapeutic gene of interest into 
the therapeutic vector can be used for gene therapy. When the therapeutic gene has done its 
intended job, the cells harboring the gene and HSV-TK can be selectively eliminated by the 
administration of GCV. Thus killing the cells after gene therapy can be protective before the 
oncogene can do any harm. The GCV system has also been utilized in the non-oncologic 
setting. In vivo transduction with HSV-TK adenoviral vector followed by GCV treatment 
significantly inhibited the development of posterior capsule opacification from hyperplasia 
of the lens epithelium in the rabbit. Further, HSV-TK plasmid DNA has been injected into 
the joint space of rabbits with antigen-induced arthritis and when treated with GCV, results 
demonstrated a reduction in joint swelling in the HSV-TK–transduced knees [50]. Barbier et 
al. in an open and single-arm study on 48 patients, demonstrated that intracerebral injection 
of HSV-TK carrying cells into glioblastoma multiforme (GBM) did not result in any adverse 
effects [51]. HSV-TK has also been injected into the white matter of the right frontal lobe in 
two rhesus monkeys, with no clinical symptoms observed [52]. Murata et al. have 
demonstrated that like the Muristerone A–inducible system, the HSV-TK suicide gene 
allows for dose- and time-dependent regulation of cell death upon the application of  
GCV [53]. 
HSV-TK was modified to be able to migrate to neighboring cells and expand the expression 
of TK positive cells. A secreting form of HSV-TK was constructed by adding Igkappa leader 
peptide in the TK gene. An endoplasmic reticulum export signal was added to further 
increase the secretion. This resulted in the 70% of total protein secreted. However, enzyme 
activity of the secreted protein was decreased. This may present a hurdle for the 
development of a transmitted form of TK [54]. Microbubble destruction by ultrasound 
increases the efficiency of HSV-TK transfection [55]. HCC induces intrahepatic metastatic 
growth which is difficult to treat and prognosis is poor. A novel approach to introduce 
chemokine ligand 2/monocyte chemoattractant protein-1 (CCL2/MCP-1) and HSV-TK 
together increases the efficiency of gene therapy. CCL2/MCP-1 attracts T helper 1-polarized 
antitumor activity without inducing tumor angiogenesis [56]. By using an IRES sequence, a 
plasmid was constructed with 2 suicide genes driven by PSMA promoter. The genes are 
FCY1 and HSV-TK for metabolizing the drug. Introducing the combination of 5-FC and 
GCV drugs inhibited the growth of prostate tumor compared to each drug individually. In a 
xenograft mouse model, retarded tumor growth was also observed. This suggests that the 
combination of multiple suicide genes may be more effective in prostate tumor [57]. 
Adenovirus mediated HSV-TK is a promising adjuvant therapy for patient’s having high 
grade glioma. This is a choice as surgery for malignant glioma is difficult due to its location 
and non-metastatic nature of glioma. The HSV-TK attacks the dividing tumor cells without 
harming healthy neurons which are non-dividing [58]. Pancreatic tumor was treated with 
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mesenchymal stem cells (MSC) containing a CCL5 promoter. Homing of MSC cells into 
primary pancreatic tumor stroma and activation of the CCL5 promoter takes place. About 
one week later after stem cell treatment tumor size reduced to 50% and metastasis reduced 
significantly [59]. Use of undifferentiated embryonic stem (ES) cells may form teratomas 
thus limiting the use of stem cells in clinical setting. However, HCV-TK with Oct4 promoter 
construct was injected to ES cells. Upon treatment with GCV, undifferentiated cells die but 
differentiated cells are free from harm [60]. Combination gene therapy using multidrug 
resistance (MDR1) shRNA and HPV-TK [61], targeting angiogenesis of hepatocellular 
carcinoma with GCV treatment has been done [62]. Transfection of wild type p53 makes C6 
glioma cells more susceptible to GCV treatment [63]. HIV-1 transactivator protein 
transduction domain (TAT PTD) can penetrate the cell. Cytotoxicity of GCV was enhanced 
by the fusion of HSV-TK and TAT PTD [64]. Fusion of mutant HSV-TK (with improved 
GCV activation) and guanylate kinase enhances prodrug sensitivity [65]. 
7. Disadvantage or drawback 
GCV has toxic side effects especially on bone marrow cells. So, it is administered in lower 
concentrations [66] and has been used in animal model studies. The disadvantage of using 
GCV is that although GCV is readily diffusible, its metabolite triphosphate is membrane 
insoluble and can’t diffuse to surrounding cells. However, the bystander effect of the close 
proximity/neighboring cells happen as triphosphate is transported to nearby cells through 
the gap junctions.  
8. Conclusion 
Suicide gene therapy is a method of choice to ablate cells in many diseases including cancer. 
But like other techniques this method is not fully safe and efficacious. HSV-TK gene therapy 
is still evolving and the method has been tinkered to be applicable in various cell 
background and different goal. More works need to be done for future applications. 
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1. Introduction 
The liver is a central organ in many metabolic processes. Multiple inherited metabolic 
disorders have their origin in this organ. Therefore, hepatocytes are a key target for gene 
therapy directed at correction of inborn errors of metabolism and of hemophilia. Inborn 
errors of metabolism lead to accumulation of toxic products in hepatocytes and extensive 
hepatotoxicity, as observed in disorders like 1-antitrypsin deficiency, type I tyrosinemia, or 
Wilson disease1. In other metabolic disorders, such as in Crigler-Najjar syndrome type I, 
ornithine transcarbamylase deficiency, familial hypercholesterolemia, and hemophilia A 
and B, manifestations are primarily extrahepatic1. In addition, the liver is a target for gene 
therapy of acquired diseases such as liver cancer and hepatitis2, 3.  
Insights into the determinants of gene transfer efficiency to hepatocytes are therefore 
required to evaluate the potential of gene therapy for inborn errors of metabolism and for 
acquired liver diseases. These determinants include innate and adaptive immune responses, 
cellular and biochemical determinants of hepatocyte transduction such as ligand receptor 
interactions, and anatomical and histological factors. Here we will first focus on the role of 
liver sinusoidal cells and sinusoidal fenestrae as determinants of the efficiency in 
hepatocyte-directed gene transfer. Uptake of gene transfer vectors by Kupffer cells and liver 
sinusoidal endothelial cells limits hepatocyte transduction4-11. However, the presence of 
fenestrae in liver sinusoidal endothelial cells provides a direct access to the space of Disse 
and microvillous surface of hepatocytes and may allow transcellular migration of vectors. In 
the following paragraphs, we provide substantial evidence that the interplay between these 
opposing forces, i.e. uptake by non-parenchymal liver cells and transcellular migration 
through fenestrae, is a critical determinant of gene transfer efficiency into hepatocytes.  
Before discussing the different parameters that influence the efficiency of hepatocyte-
directed gene transfer, it is important to point out that the process of gene transfer to 
parenchymal liver cells using replication-defective virus-derived vectors or non-viral 
vectors is fundamentally different from infection of hepatocytes by hepatotropic viruses. 
After successful infection, viruses replicate, leading to an exponential local increase of viral 
load. Consequently, a very small inoculum may be sufficient to induce hepatitis. In contrast, 
the number of transgenes carried by viral gene transfer vectors that pass through fenestrae 
cannot be amplified in hepatocytes since these vectors are replication defective. The number 
of vector particles that pass through fenestrae and are subsequently taken up by hepatocytes 
is therefore a critical determinant of transgene DNA copy number in these cells and of 
transgene expression levels.  
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2. Liver anatomy and histology 
The liver is the largest internal organ of the human body, weighs about 1.5 kg, and is located 
in the upper right quadrant of the abdomen. The liver is highly vascularised and the total 
blood flow through the liver can reach up to 25% of the cardiac output. Approximately 75% 
of the blood that enters the liver derives from the portal vein that carries oxygen-poor blood. 
Oxygenated blood entering the liver via the hepatic artery constitutes the remaining 25% of 
blood supply. The portal vein, the hepatic artery, lymphatic vessels, nerves, and bile ducts 
enter the liver at the hilus. From the hilus, continuous branching of the hepatic artery and 
portal vein results in an intricate network of intertwining capillaries, called sinusoids. 
Histologically, the liver is divided into lobuli, hexagonal functional units formed by 
hepatocytes and sinusoids surrounding a central vein. Neighbouring lobules are 
surrounded by portal triads, consisting of branches of the bile duct, the portal vein, and the 
hepatic artery.  
A human liver comprises 4.5 x 1011 cells12, 13. A murine liver contains approximately 1.6 x 108 
cells12 whereas a rabbit liver counts about 1.5 x 1010 cells. These data allow to calculate the 
ratio of transgene copies contained in a given vector dose versus the number of hepatocytes, 
which can be calculated as 66% of the total number of liver cells. Empirical determination of 
the transgene DNA copy number per hepatocyte is hampered by the fact that copy numbers 
per diploid genome do not accurately reflect transgene DNA copy numbers per hepatocyte. 
Indeed, hepatocytes are frequently tetraploid or even octoploid and may also have a 
binuclear nucleus. 
3. Liver sinusoidal cells 
Sinusoidal cells constitute approximately 33% of the number of resident liver cells whereas 
parenchymal liver cells or hepatocytes comprise the remaining cells14-16. Sinusoidal cells are 
a compilation of endothelial cells, Kupffer cells (resident liver macrophages), fat-storing 
cells (also called stellate cells or Ito cells), and pit cells (natural killer cells). Liver sinusoidal 
endothelial cells comprise 70%, Kupffer cells 20%, stellate cells 10%, and pit cells less than 
1% of the number of sinusoidal cells14, 16, 17. In the context of hepatocyte-directed gene 
transfer, we focus here on the role of Kupffer cells and liver sinusoidal endothelial cells that 
constitute together the reticulo-endothelial cells of the liver. Kupffer cells account for 80% to 
90% of resident macrophages in the entire body18. They have a diameter of 10-15 m 
whereas liver sinusoidal endothelial cells are smaller with a diameter of 7-9 m14. Sinusoidal 
endothelial cells are scavenger cells that are able to internalize particles up to 0.23 µm under 
physiologic conditions in vivo19. Larger particles are taken up by Kupffer cells19. Since most 
gene transfer vectors have a diameter below 0.23 µm, uptake of vectors by both Kupffer cells 
and liver sinusoidal endothelial cells may attenuate the efficiency of hepatocyte-directed 
gene transfer.  
Most experimental work on the role of liver reticulo-endothelial cells in relation to 
hepatocyte transduction has been performed with adenoviral vectors. These studies support 
the dual role of liver reticulo-endothelial cells in hepatocyte-directed gene transfer. On the 
one hand, the high endocytotic capacity of these cells limits hepatocyte transduction, on the 
other hand, the presence of fenestrae facilitates hepatocyte transduction20. The relevance of 
these observations for other types of vectors and other modes of gene transfer will 
subsequently be discussed.  
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4. In vitro and in vivo transduction by adenoviral vectors 
Efficient hepatocyte transduction by adenoviral vectors requires that two clearly distinct 
conditions are met. First, adenoviral vectors should have a facilitated access to the space of 
Disse via sufficiently large sinusoidal fenestrae. Second, vectors in the space of Disse must 
be able to bind to cellular receptors on hepatocytes for internalisation and transduction. 
Thus, both the anatomical access of vectors to the space of Disse and the potential for 
interaction with hepatocyte receptors in vivo are necessary but not always sufficient for 
hepatocyte transduction in vivo. Before going into the anatomical access of vectors to the 
space of Disse, we will first discuss differences between adenoviral transduction in vitro and 
transduction of hepatocytes in vivo.  
For humans, 51 adenovirus serotypes have been identified, and these serotypes are 
classified into 6 species (A-F). In vitro, uptake of most Ad serotypes belonging to species A, 
C, D, E, and F, is initiated by binding of the adenovirus fiber protein to coxsackie and 
adenovirus receptor (CAR) on the cell surface21, 22. CD46, a complement regulatory protein 
that is ubiquitously expressed in humans23, but only in the testis in mice24, is a cellular 
receptor for group B adenoviruses23. Human species C adenovirus serotype 5 (Ad5) is the 
most common viral vector used in clinical studies worldwide25. In vitro, Ad5 infects cells 
through binding of the fiber to CAR, followed by binding of an arginine-glycine-aspartic 
acid (RGD)-motif on the Ad5 penton base with cellular integrins (mainly v3 and v5) 
which initiates receptor-mediated endocytosis via clathrin coated pits26, 27. However, CAR 
binding ablation28, 29 and v integrin binding ablation29, 30 do not significantly reduce liver 
transduction by adenoviral vectors in vivo. The direct Ad binding to hepatic heparan sulfate 
proteoglycans via the KKTK motif within the fiber shaft domain has been suggested to be 
the major mechanism of hepatocyte transduction in vivo31, 32. However, mutation of the 
KKTK motif in the Ad5 fiber shaft renders the fiber inflexible and prevents internalisation of 
Ad5 though steric hindrance33, 34. In vitro and in vivo infectivity studies of Ad5-based vectors 
possessing long Ad31- (species A) or Ad41- (species F) derived fiber shaft domains that lack 
the KKTK motif, have shown that these vectors transduce hepatocytes with similar 
efficiency compared to Ad5 vectors35, consistent with the absence of a critical role of the 
KKTK motif in hepatocyte transduction.  
An important difference between in vitro transduction and in vivo transduction of liver cells 
after intravenous injection is that adenoviral vectors are in contact with blood proteins. 
Treatment of mice with the vitamin K antagonist warfarin, which inactivates several 
proteins of the coagulation cascade (factor II, factor VII, factor IX, factor X) as well as the 
anticoagulant protein C, abrogates transduction of hepatocytes by adenoviral serotype 5 
vectors8, 36-38. These studies suggested that a coagulation protein or coagulation proteins 
have a bridging function in the entry of liver cells by adenoviral vectors. Only factor X could 
rescue liver transduction in warfarin anticoagulated mice39. Recently, it has been shown that 
the -carboxyglutamic acid domain of factor X binds in a calcium-dependent manner to 
hexon protein in adenovirus serotype 525, 39, 40. Factor X binds at the cup formed by the 
center of each hexon trimer. Serotypes with a high affinity for factor X, such as the species C 
serotypes Ad2 and Ad5, have been shown to efficiently transduce hepatocytes following 
intravenous administration41, 42. In contrast, species B Ad35 and species D Ad26 bind to 
factor X weakly or not at all, and fail to transduce hepatocytes39, 43, 44. More specifically, 
factor X binds to the adenovirus hexon hypervariable regions (HVRs). Liver infection by the 
factor X-Ad5 complex is mediated through a heparin-binding exosite in the factor X serine 
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4. In vitro and in vivo transduction by adenoviral vectors 
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serotypes Ad2 and Ad5, have been shown to efficiently transduce hepatocytes following 
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protease domain. Substitution of HVR5 or HVR7 from Ad5 with sequences from the non-
factor X binding serotype Ad26 substantially lowered factor X binding and liver 
transduction in vivo45. An Ad5 mutant containing an insertion in HVR5 was shown to bind 
factor X in vitro with 10 000-fold reduced affinity compared with unmodified vector and 
failed to deliver the red fluorescent protein transgene in vivo25. Taken together, factor X 
binding to hexon trimer is a necessary prerequisite for hepatocyte transduction in vivo39. 
5. Liver trapping of adenoviral vectors 
Previous studies have shown that different adenoviral serotypes are rapidly sequestered in 
the liver after intravenous delivery, independent of their potential to effectively transduce 
hepatocytes43, 46, 47. Trapping of adenoviral vectors in the liver is comparable between wild-
type mice and mice treated with warfarin, which shows that factor X-facilitated adenoviral 
vector entry into hepatocytes is not required for trapping of vectors in the liver8. 
Demonstration of liver sequestration using whole livers does not make a distinction 
between the presence of vectors extracellularly (in the vascular lumen of the sinusoids or in 
the space of Disse) or intracellularly (in the non-parenchymal liver cells of the parenchymal 
liver cells). Cellular uptake of adenoviral vectors after systemic gene transfer occurs 
predominantly in non-parenchymal liver cells (i.e. mainly liver sinusoidal endothelial cells 
and Kupffer cells)4-7. Kupffer cells may bind adenoviral vectors via multiple mechanisms 
including scavenger receptor-A, complement, and natural antibodies9-11 and this uptake is 
independent of factor X10, 11. Interactions of adenoviral vectors with platelets in blood may 
contribute significantly to sequestration in the reticuloendothelial system of the liver9. 
Nevertheless, the exact mechanisms of adenoviral vector uptake in Kupffer cells have not 
been elucidated. The amount of Ad vector DNA after intravenous administration was nearly 
identical in wild-type mice and scavenger receptor-A deficient mice11 consistent with the 
presence of multiple pathways leading to Kupffer cell sequestration10. 
Recently, Di Paolo et al.11 showed that simultaneous treatment of mice with warfarin and 
clodronate liposomes, that deplete Kupffer cells, results in only a minor reduction of 
sequestration of adenoviral vectors in the liver 1 hour after gene transfer. Transmission 
electron microsopy showed the presence of vectors in the space of Disse, consistent with 
anatomical sequestration of vectors. We suggest that the presence of fenestrae is crucial in 
the liver targeting of adenoviral vectors. In other words, the targeting of adenoviral vectors 
to the liver reflects predominantly or exclusively anatomical targeting. This also implies that 
molecular strategies directed at liver detargeting of adenoviral vectors should take into 
account the existence of anatomical targeting to the liver. 
6. Uptake of gene transfer vectors by reticulo-endothelial cells of the liver 
reduces hepatocyte transduction 
Both Kupffer cells and liver sinusoidal endothelial cells take up the large majority of 
adenoviral vectors after systemic gene transfer7. Uptake of vectors by non-parenchymal liver 
cells (i.e. mainly liver sinusoidal endothelial cells and Kupffer cells) inversely correlates with 
transduction of parenchymal liver cells7. The transgene DNA copy number in the non-
parenchymal liver cells at one hour after transfer in Balb/c mice was nearly 6-fold higher 
than in C57BL/6 mice7. This difference in scavenging of vectors between both strains is a 
major determinant of the approximately 3-fold higher transgene DNA levels in hepatocytes 
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and higher transgene expression levels in C57BL/6 mice compared to Balb/c mice7. Based 
on more refined experiments with isolation of Kupffer cells and liver sinusoidal endothelial 
cells, we showed that the transgene DNA copy number per diploid genome at 1 hour after 
transfer in C57BL/6 mice was 2.9-fold higher in liver sinusoidal endothelial cells than in 
Kupffer cells7. In contrast, the copy number in Kupffer cells was 2.6-fold higher than in liver 
sinusoidal endothelial cells in Balb/c mice. These data indicate that the relative contribution 
of liver sinusoidal endothelial cells and Kupffer cells to adenoviral vector clearance may be 
highly dependent on the specific genetic context. One explanation for this difference of 
uptake of adenoviral vectors by the liver reticulo-endothelial cells of C57BL/6 and Balb/c 
mice may be the differential modulation of the function of these cells by humoral factors 
produced by spleen cells. Indeed, a significantly reduced transgene DNA copy number was 
observed in the liver reticulo-endothelial cells one hour after adenoviral transfer in 
splenectomized Balb/c mice and in Balb/c rag-2-/- mice compared to control Balb/c mice7. 
This was accompanied by a significantly higher transgene DNA copy number in 
hepatocytes of splenectomized Balb/c mice and of Balb/c rag-2-/- mice than in hepatocytes 
of wild-type Balb/c mice7. Splenectomy in Balb/c rag-2-/- mice did not result in an 
incremental effect7. This suggests that humoral factors produced by spleen lymphocytes 
may affect the clearance of adenoviral vectors by liver reticulo-endothelial cells in Balb/c 
mice. In contrast, no such effects on intrahepatic transgene DNA distribution were observed 
in splenectomized C57BL/6 mice and in C57BL/6 rag-1-/- mice, suggesting highly 
heterogeneous effects of humoral factors produced by spleen lymphocytes on liver reticulo-
endothelial cells. 
Further evidence for a major role of liver reticulo-endothelial cells as a determinant of 
hepatocyte transduction comes from experiments with clodronate liposomes. Depletion of 
Kupffer cells and macrophages in the spleen by intravenous administration of clodronate 
liposomes results in significantly increased transgene DNA levels in parenchymal liver cells7 
and in increased transgene expression6, 7, 48, 49. Since liver sinusoidal endothelial cell function 
may be modified by Kupffer cells50, 51, it cannot be excluded that part of the effect of 
clodronate liposomes is due to reduced activation of liver sinusoidal endothelial cells by 
Kupffer cells. Besides clodronate liposomes, pre-administration of polyinosinic acid, a 
scavenger receptor A ligand, before gene transfer has been shown to prevent sequestration 
of adenoviral vectors in Kupffer cells and to enhance parenchymal liver cell transduction52. 
Transient saturation of the reticulo-endothelial system with phosphatidylcholine liposomes 
or with Intralipid® also reduces uptake of vectors in the non-parenchymal liver cells and 
augments hepatocyte transduction7. Taken together, various interventions that result in 
reduced uptake of adenoviral vectors in liver reticulo-endothelial cells consistently enhance 
hepatocyte transduction.  
7. Liver sinusoidal endothelial fenestrae 
Liver sinusoids are highly specialized capillaries with two critical features: the thin 
endothelium contains open fenestrae, whereas a basal lamina is lacking53. Fenestrae are 
clustered in sieve plates and provide an open pathway between the sinusoidal lumen and 
the space of Disse, in which numerous microvilli from parenchymal liver cells protrude53, 54. 
Sinusoidal fenestrae have no diaphragm and visualisation requires perfusion fixation with 
glutaraldehyde. Scanning electron microscopy analysis has shown that sinusoidal fenestrae 
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uptake of adenoviral vectors by the liver reticulo-endothelial cells of C57BL/6 and Balb/c 
mice may be the differential modulation of the function of these cells by humoral factors 
produced by spleen cells. Indeed, a significantly reduced transgene DNA copy number was 
observed in the liver reticulo-endothelial cells one hour after adenoviral transfer in 
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clodronate liposomes is due to reduced activation of liver sinusoidal endothelial cells by 
Kupffer cells. Besides clodronate liposomes, pre-administration of polyinosinic acid, a 
scavenger receptor A ligand, before gene transfer has been shown to prevent sequestration 
of adenoviral vectors in Kupffer cells and to enhance parenchymal liver cell transduction52. 
Transient saturation of the reticulo-endothelial system with phosphatidylcholine liposomes 
or with Intralipid® also reduces uptake of vectors in the non-parenchymal liver cells and 
augments hepatocyte transduction7. Taken together, various interventions that result in 
reduced uptake of adenoviral vectors in liver reticulo-endothelial cells consistently enhance 
hepatocyte transduction.  
7. Liver sinusoidal endothelial fenestrae 
Liver sinusoids are highly specialized capillaries with two critical features: the thin 
endothelium contains open fenestrae, whereas a basal lamina is lacking53. Fenestrae are 
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comprise 6–8% of the sinusoidal surface55. Compared to the centrilobular area, the diameter 
of fenestrae is larger but the frequency of fenestrae is lower in the periportal area55, 56.  
The open communication between the sinusoidal lumen and the space of Disse through 
fenestrae represents a unique route that provides direct access for gene transfer vectors to 
the surface of hepatocytes. However, fenestrae act as a sieve and will mechanically restrict 
the transport of gene transfer vectors according to their size. Thus, two parameters must be 
taken into account when considering the access of gene transfer vectors to hepatocytes 
namely the diameter of both fenestrae and gene transfer vectors. 
8. Species variation of the average diameter of fenestrae 
Fenestrae generally measure between 100 nm and 200 nm and significant species differences 
in their size exist53-55. However, the interpretation of the existing literature on species 
variations of the size of sinusoidal fenestrae is hampered by differences in preparatory 
methods applied by different investigators. Standardised protocols within one group of 
investigators are therefore a conditio sine qua non for reliable species and strain comparisons. 
A direct comparative study of the diameter of sinusoidal fenestrae in five species using 
scanning electron microscopy was performed by Higashi et al.57. The average diameter of 
sinusoidal endothelial fenestrae in this study was 45 nm in cows, 52 nm in sheep, 66 nm in 
guinea pigs, 82 nm in pigs, and 131 nm in dogs57. However, these results are based on 
scanning electron microscopy preparations and are therefore subject to a shrinkage effect in 
the order of 30% caused by dehydration and drying of the tissue58. Accurate measurements 
of fenestrae can only be obtained by gradually replacing cellular water by plastic during 
preparation for transmission electron microscopy59. Previous studies have shown that this 
method of preparation leads to accurate measurements of cellular details, such as fenestrae. 
Visualisation of fenestrae in transmission electron microscopy sections requires that 
endothelial cells and their sieve plates are cut tangentially so that fenestrae become visible 
as holes. Using this technology and standardized protocols, it has previously been shown 
that the average diameter of fenestrae is significantly larger in Sprague Dawley rats (150 nm 
in the pericentral area and 175 nm in the periportal area)55 and C57BL/6 mice (141 nm)60 
than in New Zealand White rabbits (103 nm)60, Fauve de Bourgogne rabbits (105 nm)61, and 
humans with a healthy liver (107 nm)62. The diameter in Dutch Belt rabbits was intermediate 
(124 nm)61. Taken together, this species comparison demonstrates that the diameter of 
fenestrae in humans is similar to New Zealand White rabbits and significantly smaller 
compared to mice and rats, two species that are most frequently used in gene transfer 
studies. The occurrence of major shrinkage effects in scanning electron microscopy samples 
is indicated by the significantly lower diameters reported for New Zealand White rabbits (49 
nm)63 and Sprague Dawley rats (89 nm)63 as compared to diameters obtained in 
transmission electron microscopy studies55, 60. Transmission electron microscopy studies 
consistently show that the interindividual variation of the average diameter of fenestrae 
within the same species or strain is low, as indicated by coefficients of variation between 3-
8%. In contrast, as will be discussed in the next paragraph, the intraindividual variation of 
diameters of fenestrae is high. 
9. Intraindividual variation of the diameter of fenestrae 
The intraindividual variation of the diameter of fenestrae is an important parameter that 
may complicate investigations on the relation between the diameter of fenestrae and gene 
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transfer efficiency to hepatocytes. The distribution of the diameters of fenestrae within one 
individual or within one animal follows a Gaussian function with some skewing to the 
right20. 
Two opposing processes will determine the entrance of vectors into the space of Disse: on 
the one hand passage through sinusoidal fenestrae and on the other hand endocytosis by 
Kupffer cells and endothelial cells. Species and strain differences in transendothelial passage 
will be determined by intrinsic differences of the function of liver reticulo-endothelial cells 
(e.g. C57BL/6 versus Balb/c mice) as well as the rate passage of vectors through fenestrae. 
Based on these considerations, one can predict that the ratio of transgene DNA copy number 
in parenchymal liver cells versus the copy number in sinusoidal liver cells will correlate 
positively with the diameter of fenestrae. After reviewing data on the diameters of different 
gene transfer vectors, we will present several lines of experimental evidence that support 
the critical role of the diameter of fenestrae in hepatocyte transduction. 
10. Diameters of gene transfer vectors 
To put the importance of the size of fenestrae for hepatocyte-directed gene transfer into 
perspective, accurate knowledge of the diameter of gene transfer vectors is required. To 
avoid bias in the measurement of the diameter of adenoviral vectors, we previously vitrified 
a sample of adenoviral vectors using VitrobotTM technology and determined the diameter by 
cryo-electron microscopy60. Adenoviral serotype 5 virions were shown to have a diameter of 
93 nm with protruding fibers of 30 nm60. Using the same imaging techniques, the diameter 
of a vesicular stomatitis virus-G pseudotyped human immunodeficiency virus-1 derived 
lentiviral vector was found to be 150 nm60. Adeno-associated viral serotype 2 vectors have 
an average diameter of 22 nm64. Herpes simplex virions have been reported to be as large as 
180 nm65. The diameter of liposomes used for non-viral gene transfer varies between 50 nm 
and 1000 nm and is highly dependent on production parameters66, 67. 
11. Experimental evidence for a critical role of sinusoidal fenestrae in 
hepatocyte transduction following adenoviral gene transfer 
Based on our prior studies in different strains of rabbits and in different species60-62, the 
correlation coefficient between the average diameter of sinusoidal fenestrae in these 
different strains and species and human apo A-I expression at day 7 after transfer with an 
adenoviral vector containing a hepatocyte-specific expression cassette was found to be 0.94 
(p<0.01). This strongly suggests that the diameter of sinusoidal fenestrae is an important 
determinant of gene transfer efficiency to hepatocytes.  
To demonstrate that the difference of human apo A-I plasma levels reflects differences of 
transgene DNA levels in parenchymal liver cells, we isolated parenchymal and non-
parenchymal liver cells at day 3 after transfer in C57BL/6 mice and New Zealand White 
rabbits. Transgene DNA levels in parenchymal liver cells were much higher in C57BL/6 
mice than in New Zealand White rabbits whereas the reverse pattern was observed in non-
parenchymal liver cells60. Considering the small average diameter of fenestrae in New 
Zealand White rabbits (103 nm), it appears that the sinusoidal wall constitutes a histological 
barrier for adenoviral vectors in this species leading to increased uptake by liver reticulo-
endothelial cells. In contrast, the larger fenestrae in C57BL/6 mice (141 nm) facilitate access 
to hepatocytes, leading to increased uptake into hepatocytes and to reduced scavenging by 
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transfer efficiency to hepatocytes. The distribution of the diameters of fenestrae within one 
individual or within one animal follows a Gaussian function with some skewing to the 
right20. 
Two opposing processes will determine the entrance of vectors into the space of Disse: on 
the one hand passage through sinusoidal fenestrae and on the other hand endocytosis by 
Kupffer cells and endothelial cells. Species and strain differences in transendothelial passage 
will be determined by intrinsic differences of the function of liver reticulo-endothelial cells 
(e.g. C57BL/6 versus Balb/c mice) as well as the rate passage of vectors through fenestrae. 
Based on these considerations, one can predict that the ratio of transgene DNA copy number 
in parenchymal liver cells versus the copy number in sinusoidal liver cells will correlate 
positively with the diameter of fenestrae. After reviewing data on the diameters of different 
gene transfer vectors, we will present several lines of experimental evidence that support 
the critical role of the diameter of fenestrae in hepatocyte transduction. 
10. Diameters of gene transfer vectors 
To put the importance of the size of fenestrae for hepatocyte-directed gene transfer into 
perspective, accurate knowledge of the diameter of gene transfer vectors is required. To 
avoid bias in the measurement of the diameter of adenoviral vectors, we previously vitrified 
a sample of adenoviral vectors using VitrobotTM technology and determined the diameter by 
cryo-electron microscopy60. Adenoviral serotype 5 virions were shown to have a diameter of 
93 nm with protruding fibers of 30 nm60. Using the same imaging techniques, the diameter 
of a vesicular stomatitis virus-G pseudotyped human immunodeficiency virus-1 derived 
lentiviral vector was found to be 150 nm60. Adeno-associated viral serotype 2 vectors have 
an average diameter of 22 nm64. Herpes simplex virions have been reported to be as large as 
180 nm65. The diameter of liposomes used for non-viral gene transfer varies between 50 nm 
and 1000 nm and is highly dependent on production parameters66, 67. 
11. Experimental evidence for a critical role of sinusoidal fenestrae in 
hepatocyte transduction following adenoviral gene transfer 
Based on our prior studies in different strains of rabbits and in different species60-62, the 
correlation coefficient between the average diameter of sinusoidal fenestrae in these 
different strains and species and human apo A-I expression at day 7 after transfer with an 
adenoviral vector containing a hepatocyte-specific expression cassette was found to be 0.94 
(p<0.01). This strongly suggests that the diameter of sinusoidal fenestrae is an important 
determinant of gene transfer efficiency to hepatocytes.  
To demonstrate that the difference of human apo A-I plasma levels reflects differences of 
transgene DNA levels in parenchymal liver cells, we isolated parenchymal and non-
parenchymal liver cells at day 3 after transfer in C57BL/6 mice and New Zealand White 
rabbits. Transgene DNA levels in parenchymal liver cells were much higher in C57BL/6 
mice than in New Zealand White rabbits whereas the reverse pattern was observed in non-
parenchymal liver cells60. Considering the small average diameter of fenestrae in New 
Zealand White rabbits (103 nm), it appears that the sinusoidal wall constitutes a histological 
barrier for adenoviral vectors in this species leading to increased uptake by liver reticulo-
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Kupffer cell and liver sinusoidal endothelial cells. In other words, the size of fenestrae 
determines the distribution of vectors between sinusoidal and parenchymal liver cells. 
Although the relation between the diameter of sinusoidal fenestrae and transgene 
expression after adenoviral gene transfer may be confounded by substantial differences in 
genetic background, we showed that interventions that increase the diameter of fenestrae 
result in New Zealand White rabbits significantly increased transgene expression60, 61. These 
two intervention studies support the view that the correlation between the diameter of 
fenestrae and transgene expression after adenoviral transfer reflects a causal relationship. 
Based on the high degree of similarity of the distribution of the diameter of fenestrae 
between humans and New Zealand White rabbits20, 68, one would predict a low efficiency of 
gene transfer into hepatocytes after adenoviral transfer in humans. In the ornithine 
transcarbamylase deficiency trial, low levels of gene transfer in hepatocytes were indeed 
observed69. The authors concluded that the level of transgene expression was lower than 
what would have been predicted based on preclinical animal models69. Although 
histological alterations of the livers in patients with partial ornithine transcarbamylase 
deficiency may have contributed to low hepatocyte transduction, we speculate that a much 
smaller size of fenestrae in humans compared to mice and rats is likely the most critical 
factor in the observed species difference of hepatocyte transduction. On the other hand, the 
small diameter of fenestrae in humans may be beneficial for the efficacy of molecular 
strategies directed at liver detargeting of adenoviral vectors since anatomical targeting to 
the liver will be limited. 
Recently, Brunetti-Pierri et al.70 developed a minimally invasive procedure that significantly 
improves the efficiency of hepatocyte-directed transfer in nonhuman primates. A balloon 
occlusion catheter was percutaneously positioned in the inferior vena cava to occlude hepatic 
venous outflow70. Gene transfer of gutted vectors was performed via a percutaneously 
placed hepatic artery catheter with an infusion time of 7.5 minutes or 15 minutes. This 
procedure resulted in approximately 10-fold higher transgene expression levels compared to 
systemic gene transfer. Increased intrahepatic pressure following occlusion of hepatic 
outflow of the liver may increase the diameter of fenestrae, similar as observed following 
hydrodynamic injections in mice71, and this may contribute to the beneficial effects of this 
procedure in monkeys. 
12. Potential relevance of sinusoidal fenestrae for other modes of 
hepatocyte-directed gene transfer 
Based on the data obtained with adenoviral vectors, it is likely that the large diameter of 
lentiviral vectors is an important limitation for hepatocyte-directed gene transfer and may 
restrict passage of vectors even in mice and rats. Indeed, gene transfer efficiency in mice and 
rats is low after in vivo lentiviral gene transfer72-75. Although other factors like technological 
challenges to obtain high titer vector stocks may play a role, it is likely that the large 
diameter of lentiviral vectors is a limitation for hepatocyte-directed gene transfer. Since this 
anatomical limitation does not exist for adeno-associated viral vectors, gene transfer 
efficiency into hepatocytes with this type of vectors will be solely dependent on cellular and 
molecular determinants of hepatocyte transduction.  
Fenestrae may also play a role in naked DNA transfer. Liu et al.76 showed that the murine 
liver can rapidly extract up to 25 µg of plasmid DNA from the blood during a single pass 
after simple intravenous injection. Moreover, this study showed that naked DNA is 
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primarily taken up by the liver endothelial cells, but not by Kupffer cells, and that 
transfection of hepatocytes can be improved by mechanical massage of the liver, which 
increases the size of liver sinusoidal fenestrae76. Substantial amounts of plasmid DNA are 
degraded by nucleases in the blood following simple intravenous injection, which can be 
overcome by hydrodynamic gene transfer. It has also been proposed that fenestrae play a 
role in the transport of naked DNA into hepatocytes during hydrodynamic gene transfer71. 
Although the exact mechanism of hepatocyte transfection following hydrodynamic gene 
transfer remains to be elucidated, a general consensus is that the injected volume induces 
right heart volume overload. This results in a retrograde flow through the vena cava and in 
particular in a retrograde flow into the hepatic veins. As a result, intrahepatic pressure 
increases and the DNA containing solution is forced out of the hepatic sinusoids into the 
parenchymal liver cells. Following systemic hydrodynamic gene transfer in mice and rats, 
the majority of the injected DNA (i.e. >90%) can be retrieved in the liver77. In addition, 
microscopic analysis has indicated that transfected hepatocytes are predominantly located 
in the pericentral region78. This predilection may be explained by the fact that sinusoids are 
wider and straighter and contain more fenestrae per unit of surface in the pericentral area 
than in the periportal area56, 77.  
13. Sinusoidal fenestrae and hepatocyte transduction in diseased livers 
The unique morphological features of liver sinusoidal endothelial cells may change in 
pathological conditions. Liver fibrosis and cirrhosis lead to a decreased number of 
fenestrae79 and capillarization and perisinusoidal fibrosis leads to the development of a 
basal lamina, found to be absent in normal sinusoids. A significant reduction in the number 
of fenestrae and porosity of the sinusoidal endothelial cells was observed in alcoholic liver 
disease without cirrhosis80. In a comparative study, decreased transduction by adenoviral 
vectors has been observed in cirrhotic rat livers compared to normal livers81. Furthermore, 
hydrodynamic gene transfer was significantly less efficient in rats with a fibrotic liver 
compared to rats with a healthy liver82. Sinusoidal capillarization also occurs in 
hepatocellular carcinoma83, 84. This may constitute a major obstacle for efficient gene therapy 
for liver cancers. 
14. General perspective 
Preclinical viral and non-viral gene transfer studies should consider scavenging of vectors 
by liver reticulo-endothelial cells and as well as the diameter of sinusoidal fenestrae as 
important determinants of gene transfer efficiency into hepatocytes. Although the diameter 
of fenestrae may be modulated to some extent, there is currently no safe pharmacological 
intervention that results in a significant enlargement of fenestrae. The small diameter of 
fenestrae in humans and alterations of liver sinusoidal endothelial cells in liver disease may 
constitute a significant and potentially insurmountable obstacle for efficient gene transfer 
into hepatocytes with several vectors. Both anatomical access of vectors to the space of Disse 
on the one hand and the potential of vectors for interaction with hepatocyte receptors in vivo 
on the other hand are necessary for efficient hepatocyte transduction in vivo. A model on 
hepatocyte transduction should therefore take into account that both an anatomical 
prerequisite and a molecular prerequisite have to be met. 
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15. Innate and adaptive immune responses: an introductory perspective 
The use of non-viral gene therapy vectors, including naked DNA and liposomes, results in 
very low to suboptimal expression levels with the possible exception of hydrodynamic gene 
transfer85-87. However, this latter method is only successful in mice and rats and attempts for 
implementation of this methodology in larger species have resulted in very low gene 
transfer efficiencies88-90. Therefore, our strategic point of view is that only viral vectors 
constitute sufficiently potent gene delivery platforms to treat genetic and acquired diseases. 
Although viral vectors are non-replicative in contrast to wild-type viruses, the immune 
system is efficient to fight off what it perceives as invading pathogens. Innate immune 
responses are initiated by recognition of pathogen-associated molecular patters by pattern 
recognition receptors like Toll-like receptors on the surface of professional antigen 
presenting cells. Subsequent production of inflammatory cytokines stimulates maturation of 
antigen presenting cells, enhances their endocytic activity, and upregulates expression of 
molecules required for antigen processing and presentation and for costimulation. Viral 
capsid proteins not only elicit innate immunity but are also viable targets for host adaptive 
immune responses that do not necessarily require de novo viral gene expression. Adaptive 
immune responses against vector-derived antigens may reduce the efficacy of in vivo gene 
transfer and may prevent readministration. Furthermore, many vectors are derived from 
parent viruses that humans have encountered through natural infection, resulting in pre-
existing antibodies and possibly in memory responses against vector antigens. Taken 
together, adaptive immune responses represent one the most challenging remaining hurdles 
for the development of viral hepatocyte-directed gene transfer strategies with a sufficient 
therapeutic index. Besides the issue of adaptive immune responses against the vector and 
the potential problem of pre-existing immunity, immune responses against the transgene 
product also constitute a hurdle. 
16. Innate immune responses after viral gene transfer 
Adenoviral vectors efficiently transduce liver cells after systemic gene transfer and 
expression levels are generally significantly higher as compared to non-viral, adeno-
associated viral, and lentiviral transfer. However, recognition of molecular patterns on 
adenoviral capsids by pattern recognition receptors on macrophages and dendritic cells 
triggers innate immune responses and induces the production of several cytokines and 
chemokines6, 91-96. Severe activation of the innate immune system, as observed in patients 
with systemic microbial infections, severe trauma, or after major surgery, may lead to a 
systemic inflammatory response syndrome, or even to multiple system organ failure and 
shock. The development of systemic inflammatory response syndrome and multiple system 
organ failure after adenoviral transfer is dose and species dependent69, 94, 97. Schnell et al.94 
demonstrated significant species variation in innate immune responses after adenoviral 
gene transfer. Mice did not develop clinical symptoms of systemic inflammatory response 
syndrome at any dose of vector whereas rhesus monkeys developed liver necrosis and 
coagulopathy at a dose of 1013 particles/kg of an E1-deleted vector94. The sensitivity of 
humans to adverse effects of innate immune responses after adenoviral transfer is 
significantly higher than in rhesus monkeys as significant side-effects have been observed at 
doses of 6 × 1011 particles/kg or even lower69.  
Interleukin (IL)-6 is not only produced by macrophages and T cells but also by liver 
sinusoidal endothelial cells98 and possibly by spleen sinusoidal endothelial cells. 
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Notwithstanding the fact that Kupffer cells are by large the most numerous population of 
resident macrophages in the body, we have shown that the predominant source of IL-6 after 
adenoviral transfer in C57BL/6 mice is the spleen and not the liver or lungs99. This finding is 
based both on gene transfer experiments in splenectomized mice as well as on quantification 
of IL-6 mRNA levels in different organs following adenoviral transfer99.  
Innate immune responses following adenoviral transfer are dependent on both Toll like 
receptor (TLR) 2 and TLR9100. TLR2 and TLR9 are expressed in Kupffer cells but also in the 
spleen101-103 as well as in liver sinusoidal endothelial cells102.  
Depletion of tissue macrophages and dendritic cell subpopulations in liver and spleen by 
the administration of liposomes encapsulating dichloromethylene-biphosphonate results in 
reduced plasma levels of IL-6, IL-12, and tumor necrosis factor (TNF)-93. However, this 
cytotoxic strategy is unlikely to be applicable in humans. Conjugation of adenoviral vectors 
with activated monomethoxypolyethylene glycols (MPEG) has been shown to reduce IL-6 
plasma levels after adenoviral transfer99, 104. In addition, we have shown that the 
combination of PEGylation of adenoviral vectors and administration of methylprednisolone 
completely suppresses elevations of IL-6 levels after transfer with E1E3E4-deleted 
adenoviral vectors at a dose of 4 x 1012 particles/kg99. This combined strategy also inhibits 
chemokine expression in the liver, abrogates neutrophil infiltration and T-lymphocyte 
infiltration in the liver, and reduces elevations of serum transaminases in the early phase 
after adenoviral transfer99.  
Since dose reduction represents an additional means to attenuate innate immune responses 
against adenoviral vectors, strategies to enhance the efficiency of hepatocyte transduction 
are required to obtain therapeutic expression levels at lower doses. Brunetti-Pierri et al.70 
developed a minimally invasive procedure that significantly improves the therapeutic index 
of hepatocyte-directed transfer in nonhuman primates. A balloon occlusion catheter was 
percutaneously positioned in the inferior vena cava to occlude hepatic venous outflow70. 
Gene transfer of gutted vectors was performed via a percutaneously placed hepatic artery 
catheter with an infusion time of 7.5 minutes or 15 minutes. This procedure resulted in 
approximately 10-fold higher transgene expression levels compared to systemic gene 
transfer. At vector doses of 1 x 1010 or 3 x 1010 particles/kg, IL-6 levels were consistently 
below 100 pg/ml70.  
In contrast to adenoviral gene transfer, adeno-associated viral gene transfer induces very 
weak or absent innate immune responses to viral capsids both in mice95 and monkeys105. 
Serum levels of five major inflammatory cytokines (TNF-, interferon-, IL-6, IL-10, and IL-
12) were not elevated in macaques after gene transfer with vectors based on adeno-
associated virus serotypes 2, 7, and 8105. These data suggest that very weak or absent innate 
immune responses to adeno-associated viral capsids may be a general observation in 
different species. Nevertheless, some level of innate immune activation occurs even with 
adeno-associated viral vectors106. 
17. Adaptive immune responses after hepatocyte-directed gene transfer 
T helper cell activation is complex. Besides signalling via pattern recognition receptors 
(signal 0), T cell activation requires interaction of the T cell receptor CD3 complex with 
antigen presented in Major Histocompatibility Complex II (MHCII) (signal 1), engagement 
of costimulatory molecules such as CD80/86 on antigen presenting cells with CD28 on T 
cells or CD40 on antigen presenting cells with CD40 ligand on T cells (signal 2), and a 
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specific cytokine milieu (signal 3) that primes a T helper 1 (Th1) or a T helper 2 (Th2) 
response. Immunological tolerance is a state in which the immune system is not capable to 
activate the appropriate cellular or humoral immune responses following antigen exposure. 
In absence of signal 1, naive T cells are never primed, resulting in immunological ignorance. 
In the absence of adequate costimulation (signal 2), immunological tolerance is based on 
anergy/deletion: antigen-specific T cells are primed but are functionally deficient with 
regard to proliferation and cytokine production. In the absence of signal 3, regulatory T cells 
(Tregs) may develop. Tregs actively suppress adaptive immune effectors. Taken together, 
there are multiple requirements for adequate priming of T cells, which offers perspectives 
for induction of antigen specific tolerance. 
Immune responses in mice are highly strain dependent. C57BL/6 mice preferentially 
develop a predominantly Th1-type immune response whereas Balb/c mice develop a Th2-
type immune response107. Nevertheless, we have shown that cellular immune responses 
against adenoviral epitopes do not play a role in transgene DNA kinetics in C57BL/6 
mice108. This implies that, in the absence of an adaptive immune response against the 
transgene product, non-immune mechanisms are responsible for the decrease of transgene 
DNA over time. Whether this is also the case in Balb/c mice, is unknown. Taken together, 
episomal stability of non-integrated transgenes is an important issue. This is further 
highlighted by our observations that the persistence of transgene DNA is dependent on the 
expression cassette design109-111. 
Treatment of genetic diseases by gene replacement therapy is hampered by adaptive 
immune responses against the transgene product. The risk of antibody formation against the 
transgene product may be limited in the specific setting of hepatocyte-directed gene 
transfer112-114 and specifically by restricting transgene expression to hepatocytes by use of 
hepatocyte-specific expression cassettes115, 116.  
We consistently observed the absence of antibodies against human apolipoprotein (apo) A-I 
in all investigated murine strains after gene transfer with vectors containing a hepatocyte-
specific expression cassette110, 115. This absence of a humoral immune response has also been 
observed after gene transfer with the same vector in rats117. However, this observation 
cannot be robustly extrapolated to other species. In contrast to findings in mice and rats, we 
have previously observed a vigorous humoral immune response against human apo A-I in 
three different rabbit strains following transfer with AdA-I leading to the disappearance of 
detectable human apo A-I levels within 14 days61.  
18. Development of expression cassettes for hepatocyte-directed gene 
transfer 
The development of potent hepatocyte-specific expression cassettes for gene transfer offers 
several advantages. First, a therapeutic effect may be obtained at a lower vector dose, thus 
providing a means to improve the therapeutic index of vectors. Second, hepatocyte-specific 
expression cassettes represent a very efficient way to restrict transgene expression to 
hepatocytes, i.e. transcriptional targeting108, 111, 115. In contrast, targeting vectors to 
hepatocytes is significantly more difficult to realise. Third, hepatocyte-specific expression 
cassettes may lead to immunological unresponsiveness to an immunogenic transgene 
product via immunological ignorance or immunological tolerance110, 114, 115, 118, 119.  
Optimalisation of transgene expression may be achieved by modulating all levels of 
expression including transcription, post-transcriptional modification of RNA, RNA export, 
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RNA stability, and translation. Expression cassettes for hepatocyte-directed transfer have 
been improved by using new promoter-enhancer combinations109, 111, 119-123, inclusion of 
introns109, 124-127, and inclusion of additional transcriptional sequences like scaffold matrix 
attachment regions (SMAR) and hepatic control regions (HCR)126, 128-132. In a series of 
studies87, 108-111, 115, 133, we have performed a direct in vivo comparison of nearly 50 different 
expression cassettes in the context of gene transfer with E1-deleted or E1E3E4-deleted 
adenoviral vectors using human apo A-I plasma levels in C57BL/6 mice as end-point. These 
studies represent a continuous improvement of expression cassettes. The conclusion of these 
investigations is that the DC172 promoter, consisting of an 890 bp human 1-antitrypsin 
promoter and two copies of the 160 bp 1-microglobulin enhancer, upstream of the genomic 
human apo A-I sequence and 2 copies of the HCR-1, represents at present the most potent 
expression cassette. After gene transfer with a moderate dose (5 x 1010 particles) of an 
E1E3E4-deleted vector containing this expression cassette, human apo A-I levels in C57BL/6 
mice were more than 3-fold higher than physiological plasma levels in humans87. In 
addition, hydrodynamic gene transfer of minicircles containing this expression cassette 
resulted in sustained plasma levels in C57BL/6 mice that were equivalent to physiological 
levels in humans87. 
19. General conclusion 
The limited external validity of experimental gene transfer studies with regard to several of 
the parameters discussed in this review provides a framework to understand why clinical 
translation of hepatocyte-directed gene transfer is such a major challenge. It is inherent to 
gene transfer technologies that a wide variety of biological processes affect the ultimate 
outcome of these interventions. This number of biological determinants is significantly 
higher compared to classical pharmaceutical therapies or to protein infusion therapies. 
Species or strain variation of any of these multiple determinants of the outcome of 
hepatocyte-directed gene transfer hinders the process of clinical translation. Considering the 
relative small size of fenestrae in humans, one important parameter that should be 
considered is the diameter of gene transfer vectors. A progressive increase of fundamental 
insights into species variations of determinants of the success of hepatocyte-directed gene 
transfer may provide a solid base for technological advances that may result in more robust 
technologies and finally in clinical translation. At the present time, it is our view that 
hepatocyte-directed adeno-associated viral gene transfer has the greatest potential for 
clinical translation. This view is based on two fundamental properties of these vectors: (1) 
their size is small enough to pass through human fenestrae that are characterised by a much 
smaller diameter than those of rodents and (2) innate immune responses are very weak after 
adeno-associated viral gene transfer. Taken together, the current review contains multiple 
elements that are a foundation to make stable progress in this field and that provide a 
realistic perspective on the future of hepatocyte-directed gene transfer. 
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specific cytokine milieu (signal 3) that primes a T helper 1 (Th1) or a T helper 2 (Th2) 
response. Immunological tolerance is a state in which the immune system is not capable to 
activate the appropriate cellular or humoral immune responses following antigen exposure. 
In absence of signal 1, naive T cells are never primed, resulting in immunological ignorance. 
In the absence of adequate costimulation (signal 2), immunological tolerance is based on 
anergy/deletion: antigen-specific T cells are primed but are functionally deficient with 
regard to proliferation and cytokine production. In the absence of signal 3, regulatory T cells 
(Tregs) may develop. Tregs actively suppress adaptive immune effectors. Taken together, 
there are multiple requirements for adequate priming of T cells, which offers perspectives 
for induction of antigen specific tolerance. 
Immune responses in mice are highly strain dependent. C57BL/6 mice preferentially 
develop a predominantly Th1-type immune response whereas Balb/c mice develop a Th2-
type immune response107. Nevertheless, we have shown that cellular immune responses 
against adenoviral epitopes do not play a role in transgene DNA kinetics in C57BL/6 
mice108. This implies that, in the absence of an adaptive immune response against the 
transgene product, non-immune mechanisms are responsible for the decrease of transgene 
DNA over time. Whether this is also the case in Balb/c mice, is unknown. Taken together, 
episomal stability of non-integrated transgenes is an important issue. This is further 
highlighted by our observations that the persistence of transgene DNA is dependent on the 
expression cassette design109-111. 
Treatment of genetic diseases by gene replacement therapy is hampered by adaptive 
immune responses against the transgene product. The risk of antibody formation against the 
transgene product may be limited in the specific setting of hepatocyte-directed gene 
transfer112-114 and specifically by restricting transgene expression to hepatocytes by use of 
hepatocyte-specific expression cassettes115, 116.  
We consistently observed the absence of antibodies against human apolipoprotein (apo) A-I 
in all investigated murine strains after gene transfer with vectors containing a hepatocyte-
specific expression cassette110, 115. This absence of a humoral immune response has also been 
observed after gene transfer with the same vector in rats117. However, this observation 
cannot be robustly extrapolated to other species. In contrast to findings in mice and rats, we 
have previously observed a vigorous humoral immune response against human apo A-I in 
three different rabbit strains following transfer with AdA-I leading to the disappearance of 
detectable human apo A-I levels within 14 days61.  
18. Development of expression cassettes for hepatocyte-directed gene 
transfer 
The development of potent hepatocyte-specific expression cassettes for gene transfer offers 
several advantages. First, a therapeutic effect may be obtained at a lower vector dose, thus 
providing a means to improve the therapeutic index of vectors. Second, hepatocyte-specific 
expression cassettes represent a very efficient way to restrict transgene expression to 
hepatocytes, i.e. transcriptional targeting108, 111, 115. In contrast, targeting vectors to 
hepatocytes is significantly more difficult to realise. Third, hepatocyte-specific expression 
cassettes may lead to immunological unresponsiveness to an immunogenic transgene 
product via immunological ignorance or immunological tolerance110, 114, 115, 118, 119.  
Optimalisation of transgene expression may be achieved by modulating all levels of 
expression including transcription, post-transcriptional modification of RNA, RNA export, 
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RNA stability, and translation. Expression cassettes for hepatocyte-directed transfer have 
been improved by using new promoter-enhancer combinations109, 111, 119-123, inclusion of 
introns109, 124-127, and inclusion of additional transcriptional sequences like scaffold matrix 
attachment regions (SMAR) and hepatic control regions (HCR)126, 128-132. In a series of 
studies87, 108-111, 115, 133, we have performed a direct in vivo comparison of nearly 50 different 
expression cassettes in the context of gene transfer with E1-deleted or E1E3E4-deleted 
adenoviral vectors using human apo A-I plasma levels in C57BL/6 mice as end-point. These 
studies represent a continuous improvement of expression cassettes. The conclusion of these 
investigations is that the DC172 promoter, consisting of an 890 bp human 1-antitrypsin 
promoter and two copies of the 160 bp 1-microglobulin enhancer, upstream of the genomic 
human apo A-I sequence and 2 copies of the HCR-1, represents at present the most potent 
expression cassette. After gene transfer with a moderate dose (5 x 1010 particles) of an 
E1E3E4-deleted vector containing this expression cassette, human apo A-I levels in C57BL/6 
mice were more than 3-fold higher than physiological plasma levels in humans87. In 
addition, hydrodynamic gene transfer of minicircles containing this expression cassette 
resulted in sustained plasma levels in C57BL/6 mice that were equivalent to physiological 
levels in humans87. 
19. General conclusion 
The limited external validity of experimental gene transfer studies with regard to several of 
the parameters discussed in this review provides a framework to understand why clinical 
translation of hepatocyte-directed gene transfer is such a major challenge. It is inherent to 
gene transfer technologies that a wide variety of biological processes affect the ultimate 
outcome of these interventions. This number of biological determinants is significantly 
higher compared to classical pharmaceutical therapies or to protein infusion therapies. 
Species or strain variation of any of these multiple determinants of the outcome of 
hepatocyte-directed gene transfer hinders the process of clinical translation. Considering the 
relative small size of fenestrae in humans, one important parameter that should be 
considered is the diameter of gene transfer vectors. A progressive increase of fundamental 
insights into species variations of determinants of the success of hepatocyte-directed gene 
transfer may provide a solid base for technological advances that may result in more robust 
technologies and finally in clinical translation. At the present time, it is our view that 
hepatocyte-directed adeno-associated viral gene transfer has the greatest potential for 
clinical translation. This view is based on two fundamental properties of these vectors: (1) 
their size is small enough to pass through human fenestrae that are characterised by a much 
smaller diameter than those of rodents and (2) innate immune responses are very weak after 
adeno-associated viral gene transfer. Taken together, the current review contains multiple 
elements that are a foundation to make stable progress in this field and that provide a 
realistic perspective on the future of hepatocyte-directed gene transfer. 
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1. Introduction  
Gene-replacement gene therapy has been under development for a number of years. In spite 
of the large amount of research invested into developing gene therapy for the treatment of 
recessive genetic disorders only a limited number of patients world-wide have received the 
benefits. In addition, several high profile adverse events in gene therapy trials have lead to 
an increasing awareness of the challenges facing gene therapy treatments before they 
become established in the clinic. This has necessitated the development of novel advances in 
gene therapy vector design and delivery. This chapter will focus on the development of 
gene expression vectors incorporating native genomic regulatory elements that ensure 
transgene expression is physiologically relevant. Three main advances will be discussed 
here in detail; the use of whole genomic DNA loci to ensure physiologically-regulated 
transgene expression; development of viral vectors based on the herpes simplex virus type 1 
for delivery of whole genomic DNA loci; and the development of genomic mini-gene 
vectors that contain native regulatory regions for the physiologically-regulated expression 
of cDNA mini-genes.  
The principal aim of gene-replacement gene therapy is to complement the loss of function of 
an endogenous gene by supplying an exogenous ‘working’ copy in trans. The conventional 
approach to this is to supply a wild-type cDNA copy of the gene in a small vector in which 
transgene expression is controlled by a strong heterologous promoter, such as the 
immediate early promoter of cytomegalovirus (pCMV). The advantage of this approach is 
that the vectors are easy to use, have high levels of transgene expression, and fit easily into 
most viral delivery systems such as lentivirus and adenovirus. However, expression from 
these vectors is characteristically short-term and wide-spread with no tissue specificity or 
temporal regulation. One alternative to heterologous expression vectors for gene therapy is 
to utilise native genomic DNA regulatory elements to ensure gene expression that is both 
spatially and temporally regulated. A highly effective means of achieving gene expression 
that is physiologically-regulated is through the use of whole genomic loci which contain all 
introns, exons and regulatory regions in the correct genomic context. Expression from whole 
genomic loci has been proven to recapitulate endogenous expression. In the context of gene 
therapy, delivery of whole genomic loci using bacterial artificial chromosomes (BAC) has 
been shown to be an effective means of complementing gene deficiencies. Delivery of BAC 
vectors carrying complete loci encoding, for example, the genes for the human low density 
lipoprotein receptor (LDLR), the Friedreich's ataxia (FRDA) frataxin protein (FXN), 
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genomic loci has been proven to recapitulate endogenous expression. In the context of gene 
therapy, delivery of whole genomic loci using bacterial artificial chromosomes (BAC) has 
been shown to be an effective means of complementing gene deficiencies. Delivery of BAC 
vectors carrying complete loci encoding, for example, the genes for the human low density 
lipoprotein receptor (LDLR), the Friedreich's ataxia (FRDA) frataxin protein (FXN), 
 
Targets in Gene Therapy 
 
100 
microtubule associated protein tau (MAPT) and hypoxanthine phosphoribosyltransferase 
(HPRT) effectively rescue gene deficiencies in vitro. It has also been shown that the 
complementation of gene deficiency is responsive to changes in the cellular milieu, an 
important point for conditions where gene expression is controlled by cellular signalling 
pathways and where over-expression of the gene is toxic.  
Historically, BAC vectors have been discounted for gene therapy purposes as there was no 
viral delivery system with the transgene capacity for a whole genomic locus which may be 
≥100 kb. Recently, viral vectors based on the herpes simplex virus type (HSV-1) amplicons 
have been developed and shown to have a transgene capacity of over 100 kb and a broad 
cell tropism making them an attractive means of delivering large transgenes for the 
purposes of gene therapy. Currently HSV-1 amplicons have been used in a number of gene 
complementation studies which will be reviewed in detail here.  
Recent work in our laboratory has adapted the genomic locus approach for the treatment of 
familial hypercholesterolaemia (FH). FH is a condition caused by mutations in the LDLR 
gene and represents a unique challenge in gene therapy. Over-expression of the LDL 
receptor leads to a toxic accumulation of intracellular cholesterol. It is therefore essential 
that LDLR transgene expression is appropriately regulated. We have generated gene 
expression vectors in which expression of the LDLR cDNA was controlled by 10 kb of 
genomic DNA encompassing key regulatory regions in the LDLR genomic DNA promoter. 
These regulatory regions sense the levels of intracellular cholesterol. When cholesterol levels 
in the cell are high, LDLR expression is low; when the cholesterol stores become depleted, 
expression of the LDL receptor is high. Delivery of the LDLR mini-gene expression vectors 
in vitro and in vivo lead to efficient and prolonged LDLR gene expression in vivo that is 
sensitive to changes in cellular cholesterol and resulted in a decrease in circulating 
cholesterol in receptor deficient mice.   
2. Physiologically-relevant gene expression vectors: use of a complete 
genomic locus 
The central aim of gene-replacement gene therapy is to complement the loss of function of 
an endogenous gene by supplying a working copy of that gene in trans. Classically this was 
achieved using cDNA coding for the endogenous gene under the expression control of 
constitutively active exogenous promoters such as the immediate early promoter from the 
cytomegalovirus (pCMV). In general transgene expression levels from these vectors are 
characteristically high and therefore therapeutic effect is seen in some conditions. Clinical 
trials have demonstrated that these vectors are effective in ameliorating the symptoms of 
conditions such as haemophilia (Manno et al. 2006) and several severe combined 
immunodeficiencies (SCID) such as X-linked SCID (Cavazzana-Calvo et al. 2000), adenosine 
deaminase deficiency (Aiuti et al. 2009) and chronic granulomatous disease (Ott et al. 2006). 
The SCID trials also demonstrated that delivery of transgenes in the context of small cDNA 
vectors with no native expression control did have a number of issues including cell 
transformation. 
2.1 Complete genomic locus ensures gene expression in the correct genomic context 
There are several issues which may confound the use of cDNA expression cassettes to 
complement the loss of function of an endogenous gene: aberrant spatial expression 
dynamics resulting in gene expression in ‘off-target’ cells; aberrant temporal dynamics 
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resulting in continuous expression of a transgene with possible cytotoxic consequences; 
transgene over-expression at supra-physiological levels; and, the inability to produce 
multiple splice variants. 
Transgenic mice offer an interesting insight into the benefits of using native genomic loci 
over cDNA expression systems to investigate the function of genes. For some genes it is 
essential that they are expressed in the correct spatial, developmental and temporal context 
to ensure functionality. The β-globin gene cluster is an excellent example of this. This 
genomic locus consists of five separate genes (5’-ε-Gγ-Aγ-δ-β-3’) that are expressed at 
different developmental stages (Huang et al. 2000). The γ genes are expressed in foetal 
erythroid tissues while the δ and β are expressed in adult haematopoietic cells of the 
erythroid lineage. The expression of these genes in under the control of a region called the 
locus control region (Huang, Liu et al. 2000). In mice expressing the β-globin from a cDNA 
expression plasmid without the locus control region, low levels of protein are detected with 
no tissue-specificity (Magram et al. 1985; May et al. 2000; Vadolas et al. 2005). The use of the 
entire genomic locus of the β-globin gene cluster which included the locus control regions 
resulted in spatial and temporal expression profiles that mimicked the native profile (Porcu 
et al. 1997; Vadolas, Wardan et al. 2005).  
Further examples of the advantages of using the complete genomic locus comes from mice 
lacking either the frataxin (Fxn) gene (Cossee et al. 2000; Miranda et al. 2002) or the cystic 
fibrosis transmembrane conductance regulator (Cftr) gene (Zhou et al. 1994; Manson et al. 
1997), mouse models of Friedrich’s ataxia and cystic fibrosis, respectively. Mice lacking 
frataxin die at embryonic day six and crossing heterozygous knock-out mice with mice 
expressing the full genomic locus of the human FXN gene from a bacterial artificial 
chromosome (BAC) rescues the phenotype and expression patterns of mRNA and protein 
was physiological (Sarsero et al. 2004). Transgenic mice lacking the endogenous Cftr gene 
but expressing the full 200 kb of the human CFTR gene in a yeast artificial chromosome 
(YAC) show correct expression of CFTR protein in the appropriate spatial and temporal 
context (Manson, Trezise et al. 1997). 
Other examples include comparisons between mice expressing the amyloid precursor 
protein (APP) as either a cDNA construct or as a complete locus within a YAC. The APP 
gene is involved with the development of Alzheimer’s disease. It is a complex genomic locus 
comprising 18 exons that are alternatively spliced to give rise to four distinct transcripts 
(Hsiao et al. 1996). Mice expressing the APP cDNA vector do not express APP protein in the 
correct genomic context limiting the relevance of biological information obtained from these 
animals (Lamb 1995; Lamb et al. 1997). Mice expressing APP from the YAC construct 
displayed physiologically-relevant APP protein expression making them a far superior tool 
for the study of how APP might contribute to the development of Alzheimer’s disease 
(Lamb, Call et al. 1997). 
The advantages of using BAC plasmids to generate transgenic mice is now widely accepted. 
BAC transgenics have been shown, for example, to rescue knockout phenotypes in mice 
lacking the Pkd1 gene involved in polycystic kidney disease (Pritchard et al. 2000) and mice 
lacking β-globin genes (Vadolas et al. 2002; Jamsai et al. 2005; Vadolas, Wardan et al. 2005; 
Jamsai et al. 2006). BACs have also been useful in investigating novel genomic expression 
control regions. A negative regulatory region in the Wilson’s disease gene was characterised 
using BAC plasmids (Bochukova et al. 2003). BACs were also used to characterise the locus 
control regions responsible for the differential expression of Myf5 in skeletal muscle 
(Carvajal et al. 2001; Zammit et al. 2004). In addition to this, insertion of reporter genes into 
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(HPRT) effectively rescue gene deficiencies in vitro. It has also been shown that the 
complementation of gene deficiency is responsive to changes in the cellular milieu, an 
important point for conditions where gene expression is controlled by cellular signalling 
pathways and where over-expression of the gene is toxic.  
Historically, BAC vectors have been discounted for gene therapy purposes as there was no 
viral delivery system with the transgene capacity for a whole genomic locus which may be 
≥100 kb. Recently, viral vectors based on the herpes simplex virus type (HSV-1) amplicons 
have been developed and shown to have a transgene capacity of over 100 kb and a broad 
cell tropism making them an attractive means of delivering large transgenes for the 
purposes of gene therapy. Currently HSV-1 amplicons have been used in a number of gene 
complementation studies which will be reviewed in detail here.  
Recent work in our laboratory has adapted the genomic locus approach for the treatment of 
familial hypercholesterolaemia (FH). FH is a condition caused by mutations in the LDLR 
gene and represents a unique challenge in gene therapy. Over-expression of the LDL 
receptor leads to a toxic accumulation of intracellular cholesterol. It is therefore essential 
that LDLR transgene expression is appropriately regulated. We have generated gene 
expression vectors in which expression of the LDLR cDNA was controlled by 10 kb of 
genomic DNA encompassing key regulatory regions in the LDLR genomic DNA promoter. 
These regulatory regions sense the levels of intracellular cholesterol. When cholesterol levels 
in the cell are high, LDLR expression is low; when the cholesterol stores become depleted, 
expression of the LDL receptor is high. Delivery of the LDLR mini-gene expression vectors 
in vitro and in vivo lead to efficient and prolonged LDLR gene expression in vivo that is 
sensitive to changes in cellular cholesterol and resulted in a decrease in circulating 
cholesterol in receptor deficient mice.   
2. Physiologically-relevant gene expression vectors: use of a complete 
genomic locus 
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achieved using cDNA coding for the endogenous gene under the expression control of 
constitutively active exogenous promoters such as the immediate early promoter from the 
cytomegalovirus (pCMV). In general transgene expression levels from these vectors are 
characteristically high and therefore therapeutic effect is seen in some conditions. Clinical 
trials have demonstrated that these vectors are effective in ameliorating the symptoms of 
conditions such as haemophilia (Manno et al. 2006) and several severe combined 
immunodeficiencies (SCID) such as X-linked SCID (Cavazzana-Calvo et al. 2000), adenosine 
deaminase deficiency (Aiuti et al. 2009) and chronic granulomatous disease (Ott et al. 2006). 
The SCID trials also demonstrated that delivery of transgenes in the context of small cDNA 
vectors with no native expression control did have a number of issues including cell 
transformation. 
2.1 Complete genomic locus ensures gene expression in the correct genomic context 
There are several issues which may confound the use of cDNA expression cassettes to 
complement the loss of function of an endogenous gene: aberrant spatial expression 
dynamics resulting in gene expression in ‘off-target’ cells; aberrant temporal dynamics 
 
Physiologically-Regulated Expression Vectors for Gene Therapy 
 
101 
resulting in continuous expression of a transgene with possible cytotoxic consequences; 
transgene over-expression at supra-physiological levels; and, the inability to produce 
multiple splice variants. 
Transgenic mice offer an interesting insight into the benefits of using native genomic loci 
over cDNA expression systems to investigate the function of genes. For some genes it is 
essential that they are expressed in the correct spatial, developmental and temporal context 
to ensure functionality. The β-globin gene cluster is an excellent example of this. This 
genomic locus consists of five separate genes (5’-ε-Gγ-Aγ-δ-β-3’) that are expressed at 
different developmental stages (Huang et al. 2000). The γ genes are expressed in foetal 
erythroid tissues while the δ and β are expressed in adult haematopoietic cells of the 
erythroid lineage. The expression of these genes in under the control of a region called the 
locus control region (Huang, Liu et al. 2000). In mice expressing the β-globin from a cDNA 
expression plasmid without the locus control region, low levels of protein are detected with 
no tissue-specificity (Magram et al. 1985; May et al. 2000; Vadolas et al. 2005). The use of the 
entire genomic locus of the β-globin gene cluster which included the locus control regions 
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et al. 1997; Vadolas, Wardan et al. 2005).  
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lacking either the frataxin (Fxn) gene (Cossee et al. 2000; Miranda et al. 2002) or the cystic 
fibrosis transmembrane conductance regulator (Cftr) gene (Zhou et al. 1994; Manson et al. 
1997), mouse models of Friedrich’s ataxia and cystic fibrosis, respectively. Mice lacking 
frataxin die at embryonic day six and crossing heterozygous knock-out mice with mice 
expressing the full genomic locus of the human FXN gene from a bacterial artificial 
chromosome (BAC) rescues the phenotype and expression patterns of mRNA and protein 
was physiological (Sarsero et al. 2004). Transgenic mice lacking the endogenous Cftr gene 
but expressing the full 200 kb of the human CFTR gene in a yeast artificial chromosome 
(YAC) show correct expression of CFTR protein in the appropriate spatial and temporal 
context (Manson, Trezise et al. 1997). 
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comprising 18 exons that are alternatively spliced to give rise to four distinct transcripts 
(Hsiao et al. 1996). Mice expressing the APP cDNA vector do not express APP protein in the 
correct genomic context limiting the relevance of biological information obtained from these 
animals (Lamb 1995; Lamb et al. 1997). Mice expressing APP from the YAC construct 
displayed physiologically-relevant APP protein expression making them a far superior tool 
for the study of how APP might contribute to the development of Alzheimer’s disease 
(Lamb, Call et al. 1997). 
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lacking β-globin genes (Vadolas et al. 2002; Jamsai et al. 2005; Vadolas, Wardan et al. 2005; 
Jamsai et al. 2006). BACs have also been useful in investigating novel genomic expression 
control regions. A negative regulatory region in the Wilson’s disease gene was characterised 
using BAC plasmids (Bochukova et al. 2003). BACs were also used to characterise the locus 
control regions responsible for the differential expression of Myf5 in skeletal muscle 
(Carvajal et al. 2001; Zammit et al. 2004). In addition to this, insertion of reporter genes into 
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BAC plasmids has enabled the understanding of spatial and temporal expression dynamics 
of many genes such as Nkx2-5 (Chi et al. 2003). Recently BAC transgenesis has been used in 
studies of immunomodulation (Kulik et al. 2011), blood vessel development (Ishitobi et al. 
2010) and in generating mouse models of Parkinson’s disease that more closely recapitulate 
deficits in the human disease (Li et al. 2009). These studies represent a small sub-section of 
the work being performed using whole genomic loci to better understand gene function. 
They demonstrate that the use of native regulatory regions can yield more biologically-
relevant data than over-expression studies. This is important in the generation of mouse 
models of disease and also in the development of therapeutic protocols to treat genetic 
disease.  
2.2 Complete genomic locus for therapy 
Transgenic animals offer extensive evidence that the use of cDNA expression vectors often 
does not result in physiologically-relevant expression patterns. In terms of gene therapy the 
use of these cDNA vectors may not be appropriate for diseases where the correct 
physiological expression of the transgene is vital for therapeutic effect and to protect cells 
from ectopic or cytotoxic over-expression, where proteins expressed with no control result 
in pathological changes in the transduced cell.  
The use of a complete genomic DNA region in the design of gene therapy vectors is still a 
relatively new field. Manipulation and use of such large pieces of DNA can be challenging. 
Success has been seen however with a range of genes using a number of different techniques 
to isolate and deliver the locus. In vitro studies demonstrated that it was possible to achieve 
gene expression following non-viral BAC plasmid delivery. The gene involved in Lesh-
Nyan syndrome, hypoxanthine phosphoriribosyltransferase (HPRT) was delivered to HPRT 
deficient fibroblasts and resulted in sustained physiological levels of HPRT (Wade-Martins 
et al. 2000). Lipofection and an integrin targeting peptide were used to deliver a 143 kb BAC 
encompassing the locus of Nijmegen breakage syndrome gene (NBS1) resulting in 
expression of the NBS1 gene product, nibrin (White et al. 2003). BACs have also been 
generated that contain the CFTR locus (Kotzamanis et al. 2009) delivery of which to CMT-93 
cells resulted in mRNA expression that was correctly spliced (Kotzamanis, Abdulrazzak et 
al. 2009).   
In vivo non-viral delivery of plasmids containing large genomic DNA inserts has been 
achieved in two studies. In the first study hydrodynamic tail vein injection or lipofection 
was used to successfully deliver plasmids containing 150 kb of non-gene specific DNA 
(Magin-Lachmann et al. 2004). We have also demonstrated efficient delivery of a 135 kb 
genomic insert containing the full human low density lipoprotein receptor (LDLR) genomic 
locus for the treatment of Familial Hypercholesterolaemia (FH). We showed that up to 4 
months following hydrodynamic tail vein injection, human LDLR protein was detectible in 
the livers of recipient mice (Hibbitt et al. 2007).  
Alternatives to BAC plasmids for delivery of large genomic inserts are also being 
investigated. Human artificial chromosomes (HACs) for example offer advantages over the 
bacterial counterparts. HAC vectors are able to replicate and segregate without integration 
into the host-cell chromosomes and are capable of carrying very large amounts of DNA. 
HACs have been shown to be an effective means of generating transgenic mice (Suzuki 
2006).  They have also been used to express HPRT (Moralli et al. 2006) and CFTR complete 
genes (Rocchi et al. 2010).  In addition a HAC containing the entire 2.4 Mb genomic locus of 
the human dytrophin gene was used to stably maintain expression of human dystrophin in 
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mouse embryonic stem cells (Hoyshiya 2009) without any integration into the host cell 
chromosomes. These cells were used to generate chimeric mice analysis of which showed 
correct tissue-specific dystrophin expression. As the HACs are stable they could be useful in 
cell therapies in the future.  
Viral vectors have also been developed to achieve infectious delivery of large genomic 
sequences. A gutless adenovirus with a transgene capacity of 36 kb was used to deliver the 
whole locus of the human α1 antitrypsin gene (SERPINA1) to mice (Schiedner et al. 1998). 
Vectors based on the Epstein Barr virus have also been used to deliver 120 kb of genomic 
DNA to cells of lymphoblast and B-cell lineage (White et al. 2002). Other viral systems have 
been under investigation, such as CMV which has a very large transgene capacity of around 
210 kb and a strong haematopoietic cell tropism (Borst and Messerle 2000; Borst and 
Messerle 2003). However, the best characterised is amplicon vectors based on Herpes 
Simplex 1 (HSV-1). 
2.3 Infectious delivery of a complete genomic locus – HSV-1 amplicons 
The large size of a compete genomic locus precludes their use with most viral vector 
systems which typically have a transgene capacity of less than 20 kb. Vectors based on the 
herpes virus family however have a much larger transgene capacity. HSV-1 in particular is 
well described and widely used. Wild-type HSV-1 infects mucosa and establishes a latent 
phase in sensory neurons. HSV-1 infection produces cold sores in symptomatic infected 
individuals and 90% of the population has circulating antibodies (Corey and Spear 1986; 
Bowers et al. 2003). The HSV-1 genome consists of 152 kb of double stranded DNA. Of this 
only two non-coding regions are required for the packaging of DNA plasmids into HSV-1 
virions (Spaete and Frenkel 1982; Spaete and Frenkel 1985).  Inclusion of these two 
packaging signals, the OriS and pac, into DNA plasmids will promote their packaging into 
HSV-1 virions in the presence of the HSV-1 genome in trans. Plasmids are packaged head to 
tail in concatemers up to 150 kb. The average size of a human genomic locus is around 40 kb 
and the 150 kb capacity of HSV-1 amplicons potentially allows delivery of up to 90% of 
genomic loci as infectious particles, making the vector a highly versatile viral packaging 
system (Senior and Wade-Martins 2005; Hibbitt and Wade-Martins 2006).  
HSV-1 amplicons are capable of infecting dividing and non-dividing cells including, but not 
limited to; neurons, such as those of the dorsal root ganglion (Marsh et al. 2000), thalamus 
(Costantini et al. 1999), cortex (Agudo et al. 2002), hippocampus (Adrover et al. 2003), glial 
cells (Marsh, Dekaban et al. 2000), gliomas (Shah et al. 2004), skeletal muscle (Wang et al. 
2000; Wang et al. 2002) and osteoblasts (Xing et al. 2004). HSV-1 amplicons also retain their 
ability for retrograde transport in neuronal axons allowing for the possibility of peripheral 
delivery for centrally located targets. For example inoculation of the foot pad in diabetic rats 
with HSV-1 amplicons expressing nerve growth factor (NGF) resulted in NGF expression in 
the dorsal root ganglion and protected against diabetes associated peripheral neuropathy 
(Goss et al. 2002). 
One of the key concerns with any viral vector system is safety. HSV-1 amplicons are non-
integrating viruses which thus avoids issues of cell transformation by insertional 
mutagenesis. The packaging of OriS and pac containing plasmids into HSV-1 amplicons 
requires the presence of the HSV-1 genome in trans. To improve vector safety helper virus-
free HSV-1 amplicon packaging systems have been developed. The supply of the HSV-1 
genome in trans has been achieved by the use of BAC plasmids encompassing the full 
genome and lacking the packaging signal (Saeki et al. 1998; Stavropoulos and Strathdee 
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Alternatives to BAC plasmids for delivery of large genomic inserts are also being 
investigated. Human artificial chromosomes (HACs) for example offer advantages over the 
bacterial counterparts. HAC vectors are able to replicate and segregate without integration 
into the host-cell chromosomes and are capable of carrying very large amounts of DNA. 
HACs have been shown to be an effective means of generating transgenic mice (Suzuki 
2006).  They have also been used to express HPRT (Moralli et al. 2006) and CFTR complete 
genes (Rocchi et al. 2010).  In addition a HAC containing the entire 2.4 Mb genomic locus of 
the human dytrophin gene was used to stably maintain expression of human dystrophin in 
 
Physiologically-Regulated Expression Vectors for Gene Therapy 
 
103 
mouse embryonic stem cells (Hoyshiya 2009) without any integration into the host cell 
chromosomes. These cells were used to generate chimeric mice analysis of which showed 
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Viral vectors have also been developed to achieve infectious delivery of large genomic 
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Vectors based on the Epstein Barr virus have also been used to deliver 120 kb of genomic 
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been under investigation, such as CMV which has a very large transgene capacity of around 
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Simplex 1 (HSV-1). 
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systems which typically have a transgene capacity of less than 20 kb. Vectors based on the 
herpes virus family however have a much larger transgene capacity. HSV-1 in particular is 
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phase in sensory neurons. HSV-1 infection produces cold sores in symptomatic infected 
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packaging signals, the OriS and pac, into DNA plasmids will promote their packaging into 
HSV-1 virions in the presence of the HSV-1 genome in trans. Plasmids are packaged head to 
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and the 150 kb capacity of HSV-1 amplicons potentially allows delivery of up to 90% of 
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ability for retrograde transport in neuronal axons allowing for the possibility of peripheral 
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with HSV-1 amplicons expressing nerve growth factor (NGF) resulted in NGF expression in 
the dorsal root ganglion and protected against diabetes associated peripheral neuropathy 
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One of the key concerns with any viral vector system is safety. HSV-1 amplicons are non-
integrating viruses which thus avoids issues of cell transformation by insertional 
mutagenesis. The packaging of OriS and pac containing plasmids into HSV-1 amplicons 
requires the presence of the HSV-1 genome in trans. To improve vector safety helper virus-
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genome in trans has been achieved by the use of BAC plasmids encompassing the full 
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Targets in Gene Therapy 
 
104 
1998). Further safety mechanisms were then added to the system. One recent packaging 
BAC now widely used has both the packaging signal (pac) and the essential gene, ICP27, 
deleted, and is also oversized to preclude its inclusion into HSV-1 virions (Saeki et al. 2003). 
It has also been demonstrated that this packaging system is an efficient means of generating 
infectious BAC (iBAC) particles that have been successfully used for gene expression in vivo 
and in vitro. Overall, helper virus-free packaging systems for HSV-1 amplicons result in 
vector stocks with a much reduced immune-response in vivo (Olschowka et al. 2003).  
 
 
Fig. 1. Packaging of HSV-1 amplicons. 
Schematic showing packaging of OriS and pac containing plasmids into HSV-1 virions. A) 
AniBAC plasmid containing the gene of interst (GOI) is packaged using packaging virus to 
supply  the HSV-1 genome in trans. This results in viral stocks that contain virions only 
carrying the iBAC GOI plasmid and wild-type-like virus. B) An improved packaging system 
using two plasmids in place of the wild-type-like virus. An oversized, ICP27 deleted BAC 
plasmid and a small plasmid that contains ICP27. This results in viral stocks that only 
contain virions with GOI containing iBAC. 
HSV-1 delivers DNA to the cell as an extrachromosomal element and hybrid vectors have 
been designed to promote persistence of episomal vector DNA (Figure 2). The best 
described of these is the HSV-1/EBV hybrid vectors. The inclusion of the EBV latent origin 
of replication OriP and the EBV nuclear antigen (EBNA-1) promotes replication and 
segregation of DNA during cell division (Wang and Vos 1996; Wade-Martins et al. 2001; 
Wade-Martins et al. 2003; Muller et al. 2005). Mammalian-based systems have also been 
investigated. The inclusion of scaffold matrix attachment regions (SMARs) to an iBAC 
containing the human LDLR gene resulted in the establishment of stable, episomal LDLR 
expression in cell lines (Lufino et al. 2007). Successful delivery and establishment of HACs 
has been shown in cells transduced with iBAC vectors carrying alpha satellite DNA inserts 
(Moralli, Simpson et al. 2006).  
 




A BAC plasmid containing complete genomic locus can be retrofitted using cre-LoxP recombination 
with small plasmids containing elements essential for extrachromosomal maintance of delivered 
plasmids. Suggested in this figure is the incorpation of a CMV-green fluorescence protein (CMVGFP) 
reporter gene cassette to allow for assessment of delivery. The HSV-1 packaging signals (pac and oriS)  
and retention elements. ; 1) Contains the episomal  retention elements from the Epstein Barr virus 
(EBNA-1 and oriP), 2) contains the S/MAR retention elements, 3) Alpha satelite DNA promotes the 
generation of human artificial chromosomes following delivery. 
Fig. 2. Extrachromosomal retention elements.  
The use of iBAC vectors in gene therapy is still evolving and a number of studies have 
demonstrated that these vectors are capable of efficient delivery and genetic 
complementation. Recent work has used the delivery and expression of the complete 
genomic of two genes key to the development of Alzheimer’s disease and Parkinson’s 
disease, microtubule associated protein tau (MAPT) and alpha synuclein (SNCA) to study 
gene function. Amplicon iBAC vectors carrying the 143 kb MAPT locus or the 135 kb SNCA 
locus were used to infect cellular models of neurodegeneration (Peruzzi et al. 2009). 
Expression of MAPT and SNCA in cells infected with the iBAC vectors was similar to 
endogenous human levels. It was found by comparing transgene expression in primary 
neuronal and glial cultures that expression from the MAPT locus was strictly regulated by 
developmental time-point and cell type. Multiple transcripts were observed which 
mimicked the expression pattern seen in humans. Infection of MAPT-deficient neurons in 
culture with the MAPT iBAC vector rescued the cellular phenotype, restoring the normal 
response to Aβ-peptide (Peruzzi, Lawler et al. 2009). This delivery system provides an 
effective means of investigating neurodegeneration in cell models. 
Success had already been seen previously using iBAC vectors coding for the HPRT (Wade-
Martins, Smith et al. 2001) as described in Section 2.2 or bone morphogenic protein 2 (BMP2) 
(Xing, Baylink et al. 2004) loci. The role of BMP2 in osteoblast formation was investigated 
using iBAC delivery of the complete BMP2 locus (Xing, Baylink et al. 2004). BMP2 has been 
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demonstrated that these vectors are capable of efficient delivery and genetic 
complementation. Recent work has used the delivery and expression of the complete 
genomic of two genes key to the development of Alzheimer’s disease and Parkinson’s 
disease, microtubule associated protein tau (MAPT) and alpha synuclein (SNCA) to study 
gene function. Amplicon iBAC vectors carrying the 143 kb MAPT locus or the 135 kb SNCA 
locus were used to infect cellular models of neurodegeneration (Peruzzi et al. 2009). 
Expression of MAPT and SNCA in cells infected with the iBAC vectors was similar to 
endogenous human levels. It was found by comparing transgene expression in primary 
neuronal and glial cultures that expression from the MAPT locus was strictly regulated by 
developmental time-point and cell type. Multiple transcripts were observed which 
mimicked the expression pattern seen in humans. Infection of MAPT-deficient neurons in 
culture with the MAPT iBAC vector rescued the cellular phenotype, restoring the normal 
response to Aβ-peptide (Peruzzi, Lawler et al. 2009). This delivery system provides an 
effective means of investigating neurodegeneration in cell models. 
Success had already been seen previously using iBAC vectors coding for the HPRT (Wade-
Martins, Smith et al. 2001) as described in Section 2.2 or bone morphogenic protein 2 (BMP2) 
(Xing, Baylink et al. 2004) loci. The role of BMP2 in osteoblast formation was investigated 
using iBAC delivery of the complete BMP2 locus (Xing, Baylink et al. 2004). BMP2 has been 
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implicated in the differentiation of osteoblasts by altering alkaline phosphatase activity in 
precursor cells (Thies et al. 1992). When the iBAC-BMP2 vector was used to infect a 
preosteoblast cell line differentiation was observed consistent with appropriate BMP2 
expression (Xing, Baylink et al. 2004).  
Small cDNA-based vectors are not suitable to express loci which undergo complex splicing, 
such as the MAPT locus discussed above. Another example is the human CDKN2 genomic 
locus, an especially complex region. Expression from the CDKN2 locus results in five 
different genes from only six exons (Sharpless and DePinho 1999). Two of the genes p16INK4a 
and p14ARF are particularly complex. Two separate promoter regions control expression of 
each gene. Separate first exons are spliced with second and third exons which are shared 
between the two transcripts (Sharpless and DePinho 1999). Both of these genes are involved 
in cell cycle control. They are being investigated as potential targets for cancer gene therapy. 
The 132 kb CDKN2 locus was delivered as a iBAC vector to CDKN2 knockout glioma cells. 
Cells transduced with the iBAC vector has physiological levels of expression and correct 
splicing of three gene products of the CDKN2 locus, p15, p16INK4a and p14ARF (Inoue et al. 
2004). Cells also displayed a phenotype of reduced growth consistent with expression of cell 
cycle arrest genes (Inoue, Moghaddam et al. 2004).  
HSV-1 amplicons have been used to deliver the complete genomic locus of the LDLR gene to 
cell models of FH (Wade-Martins, Saeki et al. 2003; Lufino et al. 2007; Lufino, Manservigi et 
al. 2007). It was shown that delivery of the LDLR locus as an iBAC to Ldlr deficient CHO 
cells and FH patient fibroblasts lead to attenuation of the cellular phenotype as seen by 
normalisation of uptake and internalisation of LDL (Wade-Martins, Saeki et al. 2003; Lufino, 
Manservigi et al. 2007). Long-term expression was achieved by the use of the EBV episomal 
retention elements (Wade-Martins, Saeki et al. 2003) or scaffold matrix attached regions 
(Lufino, Manservigi et al. 2007). Both episomal retention systems promoted efficient 
establishment of the LDLR locus as a extrachromosomal element (Wade-Martins, Saeki et al. 
2003; Lufino, Manservigi et al. 2007). Expression from this locus was down-regulated by 
sterol treatment through interaction with response elements in the promoter region (Wade-
Martins, Saeki et al. 2003; Lufino, Manservigi et al. 2007).  
The first example of in vivo infectious delivery of a whole genomic locus using the iBAC 
delivery system was recently described (Gimenez-Cassina et al. 2011). The entire 135 kb 
FXN gene was delivered as an iBAC directly to mouse cerebellum using intracranial 
injection. Analysis of expression of the LacZ reporter gene expressed from within the FXN 
locus showed large numbers of transduced cells in the cerebellum up to 75 days post-
injection. This was also compared to reporter gene expression from the viral HSV-1 IE4/5 
promoter which was short-lived in vivo from the same vector. This work is an elegant 
demonstration of the potential of BAC plasmid delivery in vivo to result in high-level 
sustained transgene expression. 
The LDLR expression and FXN iBAC delivery studies represent an interesting proof of 
principle in the use of complete genomic regions to treat genetic disease via gene therapy. 
Delivery of the whole genomic locus is an elegant way to provide the therapeutic gene in its 
correct genomic context, ensuring that complementation can be physiologically-relevant, 
cell-specific and temporally-regulated. This has the potential effect of decreasing 
genotoxicity and improving the safety and efficacy of gene therapy vectors. However, the 
use of large genomic inserts can be technically challenging. Work is underway to develop 
gene expression vectors that combine the gene-regulation of a large insert with the 
convenience of a small mini-gene vector. 
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4. Physiologically-relevant gene expression vectors: use of native regulatory 
regions 
Whole genomic loci represent an excellent means of ensuring physiologically-relevant 
expression in target cells. However, the large size of BAC plasmids precludes their use in all 
but a few viral vector systems. Although, non-viral systems such as hydrodynamic tail vein 
injection offer excellent means of delivery to target certain tissues, for many applications 
BAC-sized plasmids may not be practical. Many studies have attempted to combine the 
advantages of cDNA vectors (small size, high transduction or transfection efficiency, and 
high levels of protein expression) with an advantage of a whole genomic locus, being 
regulated physiologically-relevant expression. Depending on the gene of interest it may be 
necessary only to ensure expression of the transgene is restricted to a particular cell type; 
alternatively, it may be necessary to ensure transgene expression also tracks changes in cell 
physiology to ensure therapeutic and not pathologic transgene expression. 
There has been extensive research into targeting gene expression to desired tissues using 
transcriptional restriction. Such work uses well-characterised promoters and enhancer 
regions that limit transgene expression to certain desired cell types where they are active. 
Liver-directed gene expression for example has been achieved using the promoter regions 
from either the albumin (Follenzi et al. 2002) or α1 antitrypsin genes (Le et al. 1997) to target 
expression of clotting factors to the liver to treat the haemophilia family of diseases. 
Targeting gene expression to cells in vascular wall is possible using endothelial cell 
restricted expression through the use of promoter such as VE-cadherin or VEGFR-1 (Quinn 
et al. 2000; Nicklin et al. 2001). Vascular smooth muscle specific expression has been 
achieved using promoters like the SM22 promoter (Imai et al. 2001) and was successfully 
used to target expression of heme oxygenase 1 to the vascular endothelium.  
For some diseases it is not enough to limit expression to cell type. The temporal dynamics of 
gene expression is also important. One novel way of achieving physiological expression 
using small cDNA vectors is to generate a genomic mini-gene construct that uses native 
gene expression elements with a cDNA transgene. Wiskott-Aldrich syndrome (WAS) is an 
excellent example of the need for native regulatory elements to ensure correct expression 
dynamics. WAS is an X-linked recessive disease caused by mutations in the WAS protein 
gene (WAS) and defined by thrombocytopenia. WAS is expressed in haematopoietic cells at 
different concentrations depending on the cell type (Toscano et al. 2008). Over-expression in 
non-haematopoietic cells has been shown to be cytotoxic (Toscano, Frecha et al. 2008). 
Lentiviral delivery of WAS cDNA vectors where expression is governed by different 
fragments of the WAS gene promoter ranging from 500 bp to 1600 bp has demonstrated 
restricted expression of WASP in haematopoietic cells (Dupre et al. 2004; Martin et al. 2005; 
Leuci et al. 2009). These vectors were also able to correct the genetic defect in Was knockout 
mice and transduce haematopoietic cells from WAS patients. However, these relatively 
small promoter fragments were unable to achieve complete physiological regulation and 
some target cell types did not exhibit correct transgene expression profiles (Frecha et al. 
2008). This may be because the promoter fragment was too small to contain all necessary 
machinery for all target cells.  
One example in which clinical success has been seen with a vector containing native 
regulatory elements is in treatment of Leber’s congenital amaurosis, a group of recessive 
congenital rod-cone dystrophies. Mutations in a retinal pigment epithelium specific gene 
called RPE65 causes impaired vision from birth that degenerates to complete blindness later 
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demonstration of the potential of BAC plasmid delivery in vivo to result in high-level 
sustained transgene expression. 
The LDLR expression and FXN iBAC delivery studies represent an interesting proof of 
principle in the use of complete genomic regions to treat genetic disease via gene therapy. 
Delivery of the whole genomic locus is an elegant way to provide the therapeutic gene in its 
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in life.  An adeno-associated virus was constructed that contained the RPE65 cDNA under 
the expression control of 1600 bp human RPE65 promoter (Le Meur et al. 2007). The use of 
the native promoter region of the RPE65 gene effectively targeted expression to the retinal 
epithelium. This was shown to be effective at improving vision in a naturally occurring 
animal model; the Swedish Briard dog. This vector is now in clinical trials to treat this 
condition in humans (Bainbridge et al. 2008).  
These two examples use only a minimal promoter region, which may be appropriate for 
those genes where regulatory elements are located in a small region proximal to the start of 
the coding region. However, as was seen in the WAS example, a larger portion of genomic 
DNA may be necessary for full physiological regulation. In our laboratory we have 
investigated the use of a 10 kb piece of genomic DNA to ensure fully physiological 
expression of the low density lipoprotein receptor gene (LDLR) for functional 
complementation in vitro and in vivo for the treatment of familial hypercholesterolaemia 
(FH). FH is caused by mutations in the LDL receptor which binds and internalises LDL 
cholesterol in response to low intracellular cholesterol levels. Gene therapy for FH been 
under investigation for a number of years with many published investigations reporting 
lowering of plasma cholesterol following delivery of cDNA vectors where expression is 
driven by heterologous promoters and delivery is achieved by virus-mediated liver-directed 
transduction with retrovirus (Miyanohara et al. 1988; Wilson et al. 1988; Chowdhury et al. 
1991; Grossman et al. 1995; Kankkonen et al. 2004), adenovirus (Ishibashi et al. 1993; 
Kozarsky et al. 1994; Li et al. 1995; Kozarsky et al. 1996; Nomura et al. 2004; Jacobs et al. 
2008; Van Craeyveld et al. 2011) and adeno-associated virus (Lebherz et al. 2004; Kassim et 
al. 2010). These previous studies included a clinical trial (Grossman, Rader et al. 1995) that 
showed no evidence of long-term therapeutic effect.  
FH represents a significant challenge for gene therapy due to the regulation of LDLR. There 
are three issues that need to be overcome by a therapeutic protocol. Firstly, cholesterol 
biosynthesis in the liver is constitutive. This means any gene therapy protocol needs to 
supply an agent that is not only capable of clearing cholesterol already present in the serum, 
it needs to clear all future cholesterol that will be synthesised by the liver. This puts huge 
demands on the transduced cells. The second issue is that the LDLR locus is tightly 
regulated by a negative feedback system. Expression from the LDLR genomic locus is 
controlled by levels of intracellular cholesterol. When intracellular levels of cholesterol fall 
LDLR expression is triggered by the binding of sterol response element binding proteins 
(SREBP) to the sterol response elements in the promoter region (Sudhof et al. 1987; Briggs et 
al. 1993; Horton et al. 2002). This drives expression of the LDL receptor which binds and 
internalises LDL particles from the circulation. As cellular cholesterol stores become replete 
the SREBP become less active and expression from the LDLR locus is repressed. There is 
evidence that suggests hepatocytes are only metabolically able to deal with a certain amount 
of cholesterol influx. Delivery of cDNA vectors with strong viral promoters driving LDLR 
expression into cells, and animals, using adenovirus results in immediate, dramatic 
lowering of cholesterol. The initial lowering of cholesterol is slowly eroded over time as 
intracellular cytotoxic accumulation of cholesterol leads to apoptotic cell death and loss of 
the transduced population of cells.  The third confounding factor is the physiological 
expression itself. It is apparent that physiologically-relevant expression of the LDLR is 
important for the function of the hepatocytes and the nature of the expression plasmid may 
limit its ability to clear large amounts of cholesterol from the blood. As the cholesterol stores 
 
Physiologically-Regulated Expression Vectors for Gene Therapy 
 
109 
in transduced cells become replete the expression of the LDLR transgene will be repressed 
effectively ‘switching off’ that particular cell’s cholesterol processing ability, this could 
reduce the therapeutic effectiveness of physiological vectors.   
We have previously shown that an iBAC vector containing the 135 kb LDLR genomic locus 
encompassing all 18 exons, intervening introns, sterol response elements and other 
regulatory elements all in the correct genomic context was capable of rescuing the genetic 
defect in cell models of FH (Wade-Martins, Saeki et al. 2003; Lufino, Manservigi et al. 2007). 
When we moved the focus of the work into animal models of FH we found that non-viral 
gene transfer via hydrodynamic tail vein injection to be an efficient means of vector 
delivery. Delivery of the LDLR BAC using hydrodynamic tail vein injection resulted in long-
term expression of human LDLR in the liver over the full four month course of the 
experiment (Hibbitt, Harbottle et al. 2007). However, the level of hepatocyte transduction 
was insufficient to result in therapeutic lowering of cholesterol.  
The challenge was to maintain physiologically-regulated expression while improving 
transfection efficiency using hydrodynamic tail vein injection. We built genomic DNA mini-
gene vectors that contained 10 kb of genomic DNA encompassing the full genomic DNA 
promoter of the human LDLR gene (Hibbitt et al. 2010). This consisted of the 5′ untranslated 
region, three sterol response elements, the transcription initiation sequence and eight kb 
upstream of genomic DNA that may contain as yet undescribed enhancer elements (Figure 
3a). This genomic DNA promoter region was used to drive the cDNA of either the luciferase 
or human LDLR genes. We have shown in vitro that the 10 kb LDLR promoter provides 
stable, long-term, physiological expression and provides functional complementation in cell 
culture in Ldlr deficient CHO cells and FH patient fibroblasts (Figure 3b). Physiological 
LDLR promoter induction was demonstrated using either luciferase expression, or specific 
LDL binding and internalisation assays in the presence of modifiers of receptor expression, 
sterols or statins. Statins are specific inhibitors of the de novo cholesterol synthesis pathway. 
They act on the LDL receptor by decreasing the amount of cholesterol in the cell thereby up-
regulating expression from the LDLR promoter. Incubation of cells with statins lead to a 
five-fold up-regulation of expression from the 10 kb promoter element. Sterols down-
regulate LDL receptor expression through association with sterol response elements in the 
LDLR promoter region. Incubation with sterols lead to a 50% down-regulation of expression 
from the 10 kb promoter element.  
Liver-directed delivery of LDLR mini-gene vectors in vivo using hydrodynamic tail vein 
injection resulted in expression from the LDLR promoter element that was sensitive to drug 
administration in vivo. Pravastatin administration resulted in a five-fold increase in 
luciferase expression five days after delivery (Figure 3c). The inclusion of EBV episomal 
retention elements ensured long-term expression up to 240 cell cycles in vitro and 9 months 
in vivo (Hibbitt, McNeil et al. 2010).  
This work describes the successful combination of genomic DNA regulatory elements with a 
mini-gene cDNA vector. Expression from this vector is physiologically-regulated by 
intracellular cholesterol levels. Delivery of the smaller-sized mini-gene vector is more 
efficient than with the full BAC and highlights the possibility of combining gene 
replacement gene therapy with traditional medical treatments. Combining gene delivery 
with treatment that will reduce the amount of cholesterol being synthesised by the liver 
could increase the power of the gene delivery ensuring efficient binding and internalisation 
of LDL to reduce plasma cholesterol levels. We have demonstrated in vivo that treatment 
with statin drugs increases the activity of the LDLR promoter. We have also investigated the 
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mini-gene cDNA vector. Expression from this vector is physiologically-regulated by 
intracellular cholesterol levels. Delivery of the smaller-sized mini-gene vector is more 
efficient than with the full BAC and highlights the possibility of combining gene 
replacement gene therapy with traditional medical treatments. Combining gene delivery 
with treatment that will reduce the amount of cholesterol being synthesised by the liver 
could increase the power of the gene delivery ensuring efficient binding and internalisation 
of LDL to reduce plasma cholesterol levels. We have demonstrated in vivo that treatment 
with statin drugs increases the activity of the LDLR promoter. We have also investigated the 
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feasibility of using a more targeted approach. Statins work by inhibiting the conversion of 
HMG CoA to mevalonate by 3-hydroxy-3-methylglutaryl Coenzyme A reductase 
(HMGCR), the rate limiting step in cholesterol synthesis inhibitors. We have investigated 
whether knock-down of HMGCR might have a more specific effect leading to a greater 
reduction in cholesterol synthesis and therefore greater induction of LDLR. We have 
demonstrated that treatment with HMGCR-specific small-interferring RNAs and synthetic 
microRNAs leads to a ten-fold induction of the LDLR promoter in vitro and in vivo which 
resulted in a greater reduction in circulating LDL cholesterol in Ldlr knockout mice (Hibbitt 
et al. Accepted).  
 
 
Generation of LDLR genomic mini-gene vectors. A) A 10kb Icece of genomic DNA encompassing the 
LDLR promoter the promoter region (UTR) and 8kb upstream of genomic DNA was cloned into vectors 
containing the cDNA of either luciferase or LDLR.  B) Following delivery of LDLR cDNA containing 
vectors to patient fibroblasts binding and internalisation of LDL was observed. Increased binding was 
seen after cells were treated with statins. Decreased binding was observed with cells treated with 
sterols. Cells transduced with a control vector that did not contain the LDLR expression cassette 
showed no binding and internalisation of LDL. C) Animals injected with luciferase expressing vectors 
and treated with statins show a 5 fold induction of LDLR promoter activity compared to animals no 
treated with statin. Results were obtained using live animal luciferase imaging. Figure modified from 
(Hibbitt et. al.,2010). 
Fig. 3. Genomic mini-gene vectors 
3. Conclusion  
Gene replacement gene therapy has been under investigation for a number of years and is 
emerging as a potentially potent tool to treat genetic disease.  Most gene therapy protocols 
involve the use of small cDNA vectors where expression of the transgene is constitutive and 
unregulated. While for some conditions this may be adequate, others will require the 
expression of therapeutic genes to be regulated spatially, temporally and physiologically to 
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circumvent issues with genotoxicity, loss of expression, and lack of therapeutic effect in 
animal models. 
Several advances have been made in recent years to address these issues. The use of 
transcriptional restriction is now wide-spread with many studies employing cell-specific 
promoters to ensure gene expression is limited to target cells. There have also been 
developments in the use of whole genomic DNA loci transgenes. This opens the possibility 
of using vectors for gene therapy which completely recapitulate endogenous expression. 
Advances in viral vectors based on helper virus-free HSV-1 amplicons mean that viral 
delivery of large genomic loci >100 kb  is now possible in vivo. Finally, the development of 
novel vectors which incorporate genomic DNA elements to achieve physiological 
expression in a mini-gene vector format will push the use of genomic regulatory elements in 
gene therapy vectors closer to a clinical reality. 
A greater body of work in vivo is now needed using genomic regulatory vectors. Work is 
currently underway in our laboratory to assess the feasibility of using genomic mini-gene 
vectors to correct genetic defects in vivo long-term. We believe that these vectors represent a 
major addition to the gene therapy field and will be applicable to a wide range of genetic 
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microRNAs leads to a ten-fold induction of the LDLR promoter in vitro and in vivo which 
resulted in a greater reduction in circulating LDL cholesterol in Ldlr knockout mice (Hibbitt 
et al. Accepted).  
 
 
Generation of LDLR genomic mini-gene vectors. A) A 10kb Icece of genomic DNA encompassing the 
LDLR promoter the promoter region (UTR) and 8kb upstream of genomic DNA was cloned into vectors 
containing the cDNA of either luciferase or LDLR.  B) Following delivery of LDLR cDNA containing 
vectors to patient fibroblasts binding and internalisation of LDL was observed. Increased binding was 
seen after cells were treated with statins. Decreased binding was observed with cells treated with 
sterols. Cells transduced with a control vector that did not contain the LDLR expression cassette 
showed no binding and internalisation of LDL. C) Animals injected with luciferase expressing vectors 
and treated with statins show a 5 fold induction of LDLR promoter activity compared to animals no 
treated with statin. Results were obtained using live animal luciferase imaging. Figure modified from 
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circumvent issues with genotoxicity, loss of expression, and lack of therapeutic effect in 
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delivery of large genomic loci >100 kb  is now possible in vivo. Finally, the development of 
novel vectors which incorporate genomic DNA elements to achieve physiological 
expression in a mini-gene vector format will push the use of genomic regulatory elements in 
gene therapy vectors closer to a clinical reality. 
A greater body of work in vivo is now needed using genomic regulatory vectors. Work is 
currently underway in our laboratory to assess the feasibility of using genomic mini-gene 
vectors to correct genetic defects in vivo long-term. We believe that these vectors represent a 
major addition to the gene therapy field and will be applicable to a wide range of genetic 
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1. Introduction 
The evolution on the field of biotechnology and proteomics create a novel therapeutic field 
(Enzymo-therapy) for treatment of various types of disease, particularly in the last fifty 
years. Exploitation of enzymes as anticancer, anti-cardiovascular, anticoagulants, 
antimicrobials and antioxidants (Vellard, 2003) was absolutely approved by Food and Drug 
Administration (FDA). Practically, almost of tumor cells were reported to be auxotrophs for 
L-methionine, glutamine, asparagine and arginine, due to the absence of intrinsic enzymatic 
systems synthesizing these amino acids, thus it depends for their growth and proliferation 
on the exogenous supply of these amino acids, that usually from diets (Hoffman and Erbe, 
1976, Mecham et al., 1983, Pasut et al., 2007, El-Sayed, 2010). Consequently, L-methioninase, 
L-glutaminase, L-asparaginase and arginine deiminase were frequently used as common 
anticancer agents by sequestering their corresponding amino acids from the blood plasma 
(Hoffman, 1985, Klimberg and McClellan, 1996, Agrawal et al., 2003, Cheng et al., 2005).  
Additionally, hyperaccumulation of certain metabolic intermediates as homocysteine and 
cystathionine usually associated with various cardiovascular diseases and complex 
disorders (Zou and Banerjee, 2005, Wang and Hegele, 2003). Cystathionine β-synthase and 
cystathionine γ-lyase are potential for sequestering homocysteine and cystathionine via 
transsulfuration metabolic pathways for production of glutathione and other antioxidants, 
so, these enzymes were described as anti-cardiovascular agents (Stipanuk, 2004, Zhu et al., 
2008).  
Unlike traditional approaches, Enzymo-therapy seems to be the promising therapeutic 
technology for their great specificity and affinity towards a clue substrate on specific 
metabolic pathway. However, the structural and conformational complexity of these 
enzymes makes it more vulnerable to extrinsic parameters, modulators, immunogenicity 
and proteolysis (Tan et al., 1996, Sun et al., 2003, Pasut et al., 2007). In addition, purification 
and formulation of these therapeutic enzymes, due to the economic expenses may add 
further complications.      
Therefore, the various approaches for stabilization of these enzymes in situ and decreasing 
their immunogenicity were the objective of this context. The structural and catalytic identity 
of pyridoxal phosphate enzymes, molecular aspects to enhance their therapeutic 
potentiality, in addition to our prospectives will be exploited.      
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2. Pyridoxal 5'-phosphate dependent enzymes: classification and catalytic 
identities 
Pyridoxal 5'-Phosphate (PLP) dependent enzymes, a group of versatile enzymes including 
about 145 distinct enzyme, 4% of the total cellular enzymatic activities (www.brenda.com) 
(Thornton et al., 2000, Percudani and Peracchi, 2003) which mainly uses PLP as covalent co-
enzyme. PLP is an active phosphorylated derivative of vitamin B6 (pyridoxine) (Heyl et al., 
1951). According to the international biochemical, molecular classification of enzymes 
(Enzyme Commission) (www.chem.qmul.ac.uk/iubmb), PLP-dependent enzymes were 
distributed in to five groups; 1- Oxido-reductase (EC 1; one enzyme), 2-Transferase (EC 2; 
eighty enzymes), 3- Hydrolase (EC 3; two enzymes), 4-Lyase (EC 4; Forty nine enzyme), and 
5-Isomerase (EC 5; Thirteen enzyme) as totally 145 enzyme (Grishin et al., 1995, Percudani 
and Peracchi, 2003) as shown in Fig.1.     
Practically, all the PLP-dependent-enzymes are mainly involved in amino acids 
transformation as decarboxylation, transamination, racemization, β, γ-elimination and β, γ-
substitution (Percudani and Peracchi, 2003). The multiple functional catalytic modes of PLP-
enzymes according to the position of net reaction were summarized in Table 1. PLP 
coenzyme has a pivotal role in catalysis of various enzymatic reactions. Pyridoxal phosphate 
can be synthesized de novo from preexisting precursor in bacteria (Brewke and Leistner, 
2001), fungi (Bean et al., 2001, Ehrenshaft and Daub, 2001) and plants (Galperin and Koonin, 
1997) from erythrose 4-phosphate, pyruvate and D-glyceraldhyde 3-phosphate. However, in 
human PLP cannot be synthesized de novo, it must be supplemented from the diet as 
pyridoxine, pyridoxamine and/or pyridoxal. PLP can be formed from pyridoxal via 
phosphorylation by action of kinase (PdxK; EC. 2.7.1.35), from oxidation of pyridoxamine/ 
pyridoxine by oxidase (EC. 1.4.3.5) (Choi et al., 1983, Bahn et al., 2002). Structurally, 
aldehyde group of PLP are bound covalently as internal aldimine (Schiff base)/ imine 
linkage to the Ɛ-amino group of lysine residues, close to N-terminus (Lopez et al., 2010) as in 
Fig. (2).      
The role of PLP, during catalysis, is to reduce the energy for conversion of amino acids 
substrates to a zwitterionic carbonion (Richard and Amyes, 2004), substantially the 
apoenzyme catalyze the cleavage of substrate target bond yielding the product as reviewed 
by Richard et al. (2011). Regarding to the native internal aldimine of PLP-enzyme, the 
catalytic process started with formation of external aldimine linkage of amino group of 
substrate and pyridoxal phosphate coenzyme forming coenzyme-substrate Schiff base, 
replacing the Ɛ-amino group of lysine-enzyme (Schirch et al., 1993).This external aldimine of 
Co-enzyme-substrate Schiff base is the common intermediate for all PLP-dependent 
enzymes. Interestingly, pyridoxal phosphate without apo-enzyme, can slowly mediate 
many of reactions while the enzyme can ensure the substrate specificity and catalysis 
(Toney, 2005, Lopez et al., 2010), that justifies the lack of apoenzyme activity, with 
potentiality to recover its catalytic state upon supplementation by external PLP (El-Sayed, 
2011). Since the formation of external aldimine, the pyridoxal phosphate is bounded tightly 
to the apoenzyme via nine hydrogen bonds (Johnson et al., 1990, Palm et al., 1990). The PLP 
extremely withdraw electrons, stabilizing the negative charge at α-carbon (carbanion) of the 
substrate as transition state that commonly referred as Quinonoid intermediates (Metha and 
Christen, 2000, Hult and Berglund, 2007). The catalytic promiscuity of PLP-dependent 
enzymes mainly depends on the mechanistic consequence of quinonoid intermediates 
(Alexander et al., 1994, Toney, 2005) as shown in Fig. (3).   
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Depending of crystallographic structures and topological studies, PLP-dependent enzymes 
were categorized in to five distinct folds (I-V) (Alexander et al., 1994, John, 1995, Jansonius, 
1998) as illustrated in Table 2. The five independent fold types of PLP-enzymes were: Fold 
type I; Aspartate Aminotransferase (AAT) family; the most functionally diverse type 
containing α and γ-families of PLP-enzymes in which the internal aldimine was formed at 
lysine of N-terminus of the short helix at β-strand (Percudani and Peracchi, 2003). On AAT 
family, pyridine nitrogen is protonated and stabilized by interaction with enzyme aspartic 
and glutamic acid (Casanovas et al., 2009). Methionine γ-lyase, cystathionine β-synthase, 
cystathionine γ-lyase were belongs to this family. Fold type II; Tryptophan Synthase β-
family, this family represented tryptophan synthase (Hyde et al., 1988), threonine 
deaminase (Gallagher et al., 1998) and O-acetylserine sulfhydrylase (Burkhard et al., 1998). 
The internal aldimine was at lysine residues of α-helix on the N-terminal domain. The 
apoenzyme was stabilized by interaction of its serine and threonine residues with pyridine 
ring of PLP (Percudani and peracchi, 2003). Fold type III; Alanine Racemase family; that 
represented by alanine racemase (Shaw et al., 2000), ornithine decarboxylase (Kern et al., 
1999). Physically, the pyridine ring PLP, coenzyme, was interacted with NH moiety of 
arginine residues of apo-enzyme (Le-Magueres et al., 2005). Fold type IV; D-Amino Acid 
Aminotransferase family, that involve D-amino acid aminotransferase (Sugio, 1995), 
branched chain amino acid amino transferase (Okada et al., 1997) and 4-amino-4-
deoxychorismate lyase (Nakai et al., 2000) as reviewed by Denesyuk et al. (2002). Like Type 
I, pyridine of PLP was interacted with glutamic acid of apoenzyme by hydrogen bonds 
(Sugio, 1995). Fold type V; Glycogen Phosphorylase Family; that contains glycogen 
phosphorylase (Sprang and Fletterick, 1979, Palm et al., 1990) and maltodextrin 
phosphorylase (Watson et al., 1999). 
 
 
PLP-dependent enzymes were within five classes according to enzyme classification system (Enzyme 
Commission (EC) 1-Oxidoreductases, one enzyme (Red), 2-Transferase, 80 enzyme (faint blue), 3-
Hydrolase, two enzymes (faint red), 4-Lyase, 49 enzyme (yellow) and 5-Isomearse, 13 enzyme (green). 
The catalytic diversity of PLP-dependent enzymes was described by Thornton et al. (2000) and 
Percudani and Peracchi (2003).    
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Fig. 2. Internal and External aldimine linkage of Pyridoxal Phosphate with enzyme and 






Fig. 3. Mechanism of PLP-enzyme catalysis via Quinonoid intermediates. 
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Table 1. Functional catalytic modes of PLP-enzymes according to the position of net reaction  
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No. Fold Type I No.
1 Glycine dehydrogenase 50 Tyrosine decarboxylase  
2 Glycine hydroxymethyltransferase 51 Glutamate decarboxylase b
3 Threonine aldolase 52 Histidine decarboxylase b
4 Trptophanase 53 Ornithine decarboxylase 1
5 Tyrosine phenol lyase 54 Arginine decarboxylase 1
6 Selenocysteine lyase 55 Lysine decarboxylase 
7 Glyoxylate aminotransferase 56 Allinase 
8 Serine aminotransferase 
9 Phosphoserine aminotransferase 
10 Amino ketobutyrate CoA ligase Fold Type II
11 Aminolevulinate Synthase 1 Aminocyclopropane-carboxyl deaminase 
12 Amino oxononanoate synthase 2 Tryptophan synthase β
13 Serine palmitoyltransferase 3 Cystathionine β-synthase
14 Kvnureninase 4 O-Acetylserine sulfhydrylase 
15 Isopenicillin N-epimerase 5 D-Serine dehydratase
16 Cysteine desulfurase 6 L-serine dehydratase
17 Splicing protein SPL1 7 Threonine dehydratase
18 Cystathionine γ-Synthase 8 Threonine synthase 1
19 O-Succinylhomoserine sulhydrase 9 Diaminopropionate lyase
20 Methionine γ-Lyase 10 Threonine synthase 2
21 Cystathionine γ-Lyase 11 D-Alanine aminotransferase 
22 Cystathionine β-Lyase 12 Amino deoxychorismate lyase 
23 Aspartate aminotransferase a 13 Branched amino acid aminotransferase 
24 Aromatic amino acid 
aminotransferase 
25 Tyrosine aminotransferase 
26 Alanine aminotransferase Fold Type III
27 malY gene product 1 Ornithine decarboxylase 2
28 Phenylpuruvate aminotransferase 2 Diaminopimelate decarboxylase 
29 Aminocyclopropane carboxylate 
synthase 
3 Arginine decarboxylase
30 Rhizopine regulatory protein alanine racemase
31 Aspartate aminotransferase b
32 Aspartate aminotransferase c
33 Histidinol phosphate 
aminotransferase 
Fold Type IV
34 cobC gene product 1 D-amino acid aminotransferase 
35 Valine-Pyruvate aminotransferase 2 branched chain amino acid amino 
transferase
36 Acetylornithine aminotransferase 3 4-amino-4-deoxychorismate lyase 
37 Succinylornithine aminotransferase 
38 Ornithine aminotransferase 
39 Alanine glyoxylate 
aminotransferase 
40 Dialkylglycine decarboxylase Fold type V
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41 Alanine pyruvate aminotransferase 1 Glycogen phosphorylase
42 Aminooxononanoate 
aminotransferase 
2 Maltodextrin phosphorylase 
43 DNTP hexose aminotransferase
44 Glutamate semialdehyde 
aminomutase 
45 Aminobutyrate aminotransferase 
46 Lysine Ɛ-aminotransferase 
47 Diaminobutanoate 
aminotransferase 
48 Glutamate decarboxylase a
49 Histidine decarboxylase a
Table 2. Families of Pyridoxal Phosphate dependent enzymes 
No hydrogen bonds between pyridine nitrogen and apoenzyme (Percudani and Percacchi, 
2003). The systematic and catalytic promiscuity of the five fold types PLP-dependent 
enzymes as adopted by Metha and Christen (2000) and Percudani and Peracchi (2003), were 
illustrated in Table 2. 
Regarding to our previous work (Khalaf and El-Sayed, 2009, El-Sayed, 2009, 2010, 2011a, b), 
the subsequent section was focused on the metabolic interactions of sulfur containing amino 
acid by PLP-dependent enzymes of Aspartate Aminotransferase Family.  
3. Metabolic interactions of sulfur-containing amino acids by PLP-dependent 
enzymes: Biochemical identity of normal and tumor cells 
Sulfur-containing amino acids are pivotal compounds for almost of metabolic cellular 
process. In contrary to humans, plants and microorganisms can synthesize their sulfur 
containing amino acids from the inorganic precursor as sulfate, sulfite and sulfide via 
reduction or activation (Beinert, 2000, Kessler, 2006). In humans, methionine and cysteine 
were described as conditional essential amino acids for normal various biological aspects 
(Baylin et al., 1998, Davis and Uthus, 2004). The prominent sulfur containing amino acids on 
living cell are cysteine and methionine, that crucially incorporated on the synthesis of Co-
enzyme, vitamins, epigenetic DNA modulators, DNA stabilizers and antioxidants (El-Sayed, 
2010 and Cellarier et al., 2003). Additionally, cysteine is the essential source for H2S 
biogenesis that critically acts as neuro-modulators, cardio-protector, relaxing muscle 
regulators, and vasodiolator for vascular system (Wang, 2002, Kimura, 2010, Predmore and 
Lefer, 2010 and Gadalla and Snyder, 2010). The general metabolic interactions of sulfur 
containing amino acids and their derivative by PLP-enzymes were illustrated in Fig. (3). 
Methionine can be metabolized via different ways that collectively regulated by PLP-
dependent enzymes as methionine γ-lyase, cystathionine β, γ-synthases and cystathionine β, 
γ-lyases. In plants and microbes, methionine can be undergoes oxidative deamination/ 
demethiolation forming methanethiol, α-ketobutyrate and ammonia (Tanaka et al., 1977) via 
the action of L-methioninase. L-Methioninase was frequently reported as a substrate 
induced extracellular enzyme for various microbial cultures (Tanaka et al., 1977, Soda et al., 
1983; Nikulin et al., 2008, Khalaf and El-Sayed, 2009), while it is absent in mammalian cells 
(Cooper, 1983). Biochemically, methionine was activated by methionine adenosyltransferase 
forming S-adenosylmethionine as a key intermediate for the following metabolic pathways; 
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4. Transmethylation pathway and methionine synthesis  
S-Adenosylmethionine undergoes de-methylation by glycine-N-methyltransferase forming 
S-adenosyl homocysteine (Luka et al., 2006). This reaction is the source for more than 100 
biological methylation reactions including epigenetic DNA regulation and protein 
posttranslational modifications, in living cell (Choi and Mason, 2002) Moreover, in microbial 
cells, the methyl group from adenosylmethionine can switch the formation of Siroheme via 
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Fig. 3. Metabolic Interactions of sulfur-containing amino acids, as supplied from the diet or 
intracellular, via different cellular pathways. Except human, L-methionine was undergoes 
oxidative deamination and demethiolation by L-methioninase (EC 4.4.1.11) in various 
microorganisms and plants. In all living cells, adenosyl methionine, activated form of L-
methionine, was implicated in various pathways: 1- Transmethylation, adenosylmethionine 
by glycine N-methyltransferase is demethylated to adenosyl-homocysteine that involved in 
methylation of DNA, RNA, and protein. 2- Transsulfuration pathway, forming glutathione 
and trypanothione as cellular antioxidants, cysteine was involved on formation of several S-
containing compounds. 3- Polyamine synthesis, S-adenosylmethionine was decarboxylated 
by decarboxylase forming adenosyl methylpropylamine that condensate with putrescine 
forming spermidine by spermidine synthase, then forming spermine by spermine synthase.    
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al., 1997). Physiologically, tumors are genetically abnormal cells with uncontrolled rapidly 
growth and proliferation, for mutation on some genes encoding amino acids metabolizing 
enzymes, comparing to the corresponding normal cells (Hoffman, 1985). Elevated 
requirements of methionine are the common biochemical criteria by tumor cells comparing 
to corresponding normal ones, to fulfill their high protein synthesis and regulation of DNA 
expression (Stern et al., 1984, Swisher et al., 2009). Practically, hypermethylation of DNA is 
usually correlates with transcriptional silencing of many of tumor suppressor genes, P53 
genes, thus disrupting DNA repairing systems and cell signaling modulators (Jones and 
Baylin, 2002, Santini et al., 2001) as reviewed by El-Sayed (2010). Also, methylation of tumor 
DNA change the identity of CpG islands, thus altering the expression of DNA repairing and 
apoptosis controlling genes (Sun et al., 1997, Matsukura et al, 2003) and changing of CpG 
islands (Swisher et al., 2009). On other hand, suppression of methionine synthase genes are a 
reliable cellular criteria in various cells as bladder, breast, kidney, lung and hematological 
tumors (Mecham et al., 1983, Hoffman, 1985, Kreis and Goodenow, 1978), thus it described 
as methionine dependent cells. In contrast, the normal cells have an active methionine 
synthase with the ability to form methionine from homocysteine in the presence of methyl 
tetrahydro folate and betaine as methyl group donors (Kenyon et al., 2002). Consequently, 
the tumor cells have no ability to grow on homocysteine, comparing to the normal growth 
of healthy cells. The different argumentations for methionine dependency of tumor cells and 
biochemical identity of L-methioninase as therapeutic agent were comprehensively 
interpreted by our previous studies (El-Sayed, 2010). 
5. Polyamines synthesis  
S-Adenosylmethionine was decarboxylated by adenosylmethionine decarboxylase forming 
S-adenosyl-methylpropylamine (Gilmour, 2007) that subsequently reacts with putrescine 
forming spermidine by spermidine synthase (Fig. 3). Subsequently, S-adenosyl-methyl 
propylamine react with spermidine forming spermine by action of spermine synthase 
(Martinez-Lopez et al., 2008). Putrescine residues are catabolically products of ornithine/ 
arginine as intermediates of urea cycle by action of decarboxylases. Polyamines are biogenic 
molecules that tightly bound to the poly-anionic macromolecules as DNA, RNA and 
phospholipids (Igarashi et al., 1982), regulating the gene expression and protein processing. 
Biochemically, it crucially involved in stabilization of DNA: Chromatin conformational 
structures (Davidson et al., 1999), reprogramming of some genes by translational frame-
shifting mechanism and expression of the targeted overlapped open reading frames (such as 
nuclear phospholipids P53) (Coffino, 2000). Also, it essentially interact with membrane 
phospholipids regulating the membrane linked enzyme transporters (Moruzzi et al., 1993), 
maintaining the proper membrane potentials. In contrast, high levels of polyamines usually 
associated with high carcinogenesis of skin, breast, liver, kidney (O'Brien, 1976, Pegg, 1988) 
and over apoptosis (Hoet and Nemery, 2000). Practically, elevated levels of ornithine 
decarboxylase a pyridoxal phosphate-dependent enzyme, is significantly correlates with 
high ratio of polyamines that usually used as relevant carcinogenesis marker (Persson et al., 
1998).  
6. Transsulfuration pathway 
Transsulfuration is the main metabolic pathway for transformation of homocysteine to 
glutathione, and trypanothione (Cellarier et al., 2003), involving two pyridoxal phosphate 
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to corresponding normal ones, to fulfill their high protein synthesis and regulation of DNA 
expression (Stern et al., 1984, Swisher et al., 2009). Practically, hypermethylation of DNA is 
usually correlates with transcriptional silencing of many of tumor suppressor genes, P53 
genes, thus disrupting DNA repairing systems and cell signaling modulators (Jones and 
Baylin, 2002, Santini et al., 2001) as reviewed by El-Sayed (2010). Also, methylation of tumor 
DNA change the identity of CpG islands, thus altering the expression of DNA repairing and 
apoptosis controlling genes (Sun et al., 1997, Matsukura et al, 2003) and changing of CpG 
islands (Swisher et al., 2009). On other hand, suppression of methionine synthase genes are a 
reliable cellular criteria in various cells as bladder, breast, kidney, lung and hematological 
tumors (Mecham et al., 1983, Hoffman, 1985, Kreis and Goodenow, 1978), thus it described 
as methionine dependent cells. In contrast, the normal cells have an active methionine 
synthase with the ability to form methionine from homocysteine in the presence of methyl 
tetrahydro folate and betaine as methyl group donors (Kenyon et al., 2002). Consequently, 
the tumor cells have no ability to grow on homocysteine, comparing to the normal growth 
of healthy cells. The different argumentations for methionine dependency of tumor cells and 
biochemical identity of L-methioninase as therapeutic agent were comprehensively 
interpreted by our previous studies (El-Sayed, 2010). 
5. Polyamines synthesis  
S-Adenosylmethionine was decarboxylated by adenosylmethionine decarboxylase forming 
S-adenosyl-methylpropylamine (Gilmour, 2007) that subsequently reacts with putrescine 
forming spermidine by spermidine synthase (Fig. 3). Subsequently, S-adenosyl-methyl 
propylamine react with spermidine forming spermine by action of spermine synthase 
(Martinez-Lopez et al., 2008). Putrescine residues are catabolically products of ornithine/ 
arginine as intermediates of urea cycle by action of decarboxylases. Polyamines are biogenic 
molecules that tightly bound to the poly-anionic macromolecules as DNA, RNA and 
phospholipids (Igarashi et al., 1982), regulating the gene expression and protein processing. 
Biochemically, it crucially involved in stabilization of DNA: Chromatin conformational 
structures (Davidson et al., 1999), reprogramming of some genes by translational frame-
shifting mechanism and expression of the targeted overlapped open reading frames (such as 
nuclear phospholipids P53) (Coffino, 2000). Also, it essentially interact with membrane 
phospholipids regulating the membrane linked enzyme transporters (Moruzzi et al., 1993), 
maintaining the proper membrane potentials. In contrast, high levels of polyamines usually 
associated with high carcinogenesis of skin, breast, liver, kidney (O'Brien, 1976, Pegg, 1988) 
and over apoptosis (Hoet and Nemery, 2000). Practically, elevated levels of ornithine 
decarboxylase a pyridoxal phosphate-dependent enzyme, is significantly correlates with 
high ratio of polyamines that usually used as relevant carcinogenesis marker (Persson et al., 
1998).  
6. Transsulfuration pathway 
Transsulfuration is the main metabolic pathway for transformation of homocysteine to 
glutathione, and trypanothione (Cellarier et al., 2003), involving two pyridoxal phosphate 
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dependent enzymes, cystathionine β-synthase and γ-lyase (Fig. 3). By cystathionine β-
synthase, homocysteine condensates with serine moiety forming cystathionine, that 
subsequently oxidized to cysteine, α-ketobutyrate and ammonia by cystathionine γ-lyase 
(Zou and Baerjee, 2005). Biochemically, transsulfuration pathway contributes in maintaining 
the cellular balance of cysteine-homocysteine pool that participates in about 50% of total 
antioxidant formation (Zhu et al., 2008). Practically, inactivation of cystathionine β-synthase 
causes hyperaccumulation of homocysteine that is a visual risk of cardiovascular diseases, 
damage to vascular endothelia (De Bree et al., 2002, Wald et al., 2002) and Alzheimer's 
disease (Morris, 2003). Moreover, the deficiency of cystathionine γ-lyase results in 
accumulation of cystathionine, known as Cystathioninuria that usually accompanied with 
diabetes, Down's syndrome, neuroblastoma (Wang and Hegele, 2003, Zhu et al., 2008). 
Glutathione was synthesized by γ-glutamylation (El-Sayed et al., 2010) of cysteine by γ-
glutamyl cysteine synthetase, then complexation with glycine forming glutathione by 
glutathione synthetase (Cellarier et al., 2003) as reviewed by El-Sayed (2010). Trypanothione 
as dimmer of glutathione molecules joined by sperimidine linker, as powerful antioxidants 
against stress (Tover et al., 2003).  
7. Rationality of PLP dependent enzymes as antitumor and anti-
cardiovascular agents 
The absolute dependence of tumor cells on the exogenous supply of plasma L-methionine, 
not homocysteine, due to their lacks to active methionine synthase is the biochemical target 
for many therapeutic strategies (Cellarier et al., 2003). Unlike the inactivity of methionine 
synthase in tumor cells, this enzyme was very active in normal cells ensuring their ability 
for synthesizing required methionine from homocysteine (Anderson, 1998). The 
argumentation of biochemical dependence of tumors on methionine synthase or their 
coenzymes for various cell lines corresponding to the normal cells was comprehensively 
documented (Liteplo et al., 1991; Fiskerstrand et al., 1994, El-Sayed, 2010). Several 
approaches were designed for triggering the methionine dependency of tumor cells, for 
example, starvation of the tumor cells from methionine using methionine-free diets that 
displays a reliable efficacy against various types of tumor cells (Goseki et al. 1992). 
However, this strategy is practically inefficient for many technical, therapeutical and 
economical considerations (Hoffman, 1985, Tan et al., 1996, Hoshiya et al., 1997). 
Consequently, application of L-methioninase for removal of plasma L-methionine is the 
potent justifiable strategy towards various methionine dependent tumor cells (Anderson, 
1998 and Kokkinakis, 2006). Methionine depletions cause arresting of tumor cell growth on 
the late of S-G2 phase undergoing eventually apoptosis (Guo et al., 1993, Nagahama et al., 
1998). Biochemically, nutrients with depleted or enriched specific amino acid affect on the 
growth of normal/tumor cells, according to Harper's concept of amino acid balance. 
Malnutrition of patient is closely associated with severe amino acid metabolic disorders, 
uncorrectable nitrogen balance with low activity of immune system (Nitenberg and 
Raynard, 2000). Interestingly, methionine/ valine depleted, tyrosine lowered and arginine 
enriched was the most rationalized form for inhibition of tumor growth (Chen et al., 2001, 
He et al., 2003). L-Methioninase was extensively tested a potent anti-proliferative enzyme 
towards Lewis lung (Yoshioka et al., 1998), human colon (Tan et al., 1998), glioblastoma 
(Kokkinakis et al., 2001), neuroblastoma (Hu and Cheung, 2009) as reviewed by Sato and 
Nozaki (2009) and El-Sayed (2010). Recently, Parenteral nutrition is a common co-
supportive strategy for various aspects of tumor therapy (Buchman et al., 2006).      
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L-Methioninase was purified and characterized from different bacterial isolates (Hoffman 
and Erbe, 1976; Tanaka et al., 1977, Soda et al., 1983, Nikulin et al., 2008), particularly, 
Pseudomonas putida enzyme that extensively structurally studied via crystallographic studies 
(Ito et al., 1976, Tanaka et al., 1977, Nakayama et al., 1984, Lishko et al., 1993, Motoshima et 
al., 2000, Kudou et al., 2007). However, the therapeutic response of bacterial enzymes 
usually associated with high immunogenic reactions, rapid plasma clearance and 
proteolysis especially with multiple dosing (Tan et al., 1996; Sun et al., 2003), making the 
patient is more vulnerable to secondary immunogenic disorders by opportunistic 
pathogens. Also, as result of deaminating activity of this enzyme, extra amounts of 
ammonia (hyper-ammoniemia) was released during the course of tumor therapy, causing 
additional hazardous effects to the kidney and liver, as observed for many of anticancer 
deaminating enzymes (Balcao et al., 2001). Biochemically, hyperaccumulation of ammonia 
anticipates on formation of extra amounts of arginine and ornithine, via urea cycle, 
promoting the polyamines synthesis that indirectly induces tumorgenesis (Pegg, 1988, 
Gerner and Meyskens, 2004). The immunogenic reactions of bacterial enzyme could be 
attributed to their structural stereo-conformation during the enzyme posttranslational 
modifications, prokaryotic nature, making distinct epitopes immunogenic sites on the 
surface of the enzyme as assumed from the phylogenetic analysis of their amino acids (El-
Sayed, 2010). Depending on database, the structural amino acid identity of Arabidopsis 
thaliana L-methioninase was similar to that of Pseudomonas putida by less than 25 %, 
suggesting the differences on the surface amino acid constitution (El-Sayed, 2010). 
Accordingly, L-methioninase was classified structurally in two forms; First, Pseudomonas-
Trichomonas group that contain six subgroups namely; Pseudomonas, Bacillus, Brevibacterium, 
Trichomonas, Rhizobium and Aeromonas. Second; Arabidopsis group which represented by A. 
thaliana. Interestingly, the similarity of amino acid composition of L-methioninase is closely 
related to the systematic morphological and physiological position of the organism. 
Actually, the amino acid composition of the fungal L-methioninase open reading frame, nor 
crystallographic studies was not studied. Therefore, regarding to the therapeutic 
implications of currently applied L-methioninase, the searching for a novel enzyme with 
less immunogenic activity and high therapeutic potentiality or modifications of the 
currently used enzymes is a challenge for many biotechnologists. 
8. Different approaches to increase the therapeutic potentiality of l-
methioninase 
8.1 PEGylation of L-methioninase  
Immobilization of the therapeutic enzymes on polyethylene glycol (PEG), PEGylation, is one 
of the most successful strategies that originated in 1970 (Abuchowski et al., 1977). 
PEGylation of albumin and catalase was the milestone for the development and 
globalization of this technique, as efficient method for modification of the structural and 
immunogenic identities of proteins (Abuchowski et al., 1977). Polyethylene glycol is a 
neutral, water soluble, hydrophilic polyether with less immunogenicity that ensure various 
pharmacological properties as increasing half-life time, reducing the kidney clearance, 
protecting protein from proteolysis by via steric hindrance, reduce the immunogenicity of 
protein, increasing the solubility of target therapeutic agent (Reddy, 2000, Veronese and 
Pasut, 2005, Fee and Van Alsteine, 2004, Pasut and Veronese, 2009). The therapeutic 
behavior of PEGylated-enzyme was illustrated (Fig. 4). PEGylated-enzyme have a reduced 
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synthase, homocysteine condensates with serine moiety forming cystathionine, that 
subsequently oxidized to cysteine, α-ketobutyrate and ammonia by cystathionine γ-lyase 
(Zou and Baerjee, 2005). Biochemically, transsulfuration pathway contributes in maintaining 
the cellular balance of cysteine-homocysteine pool that participates in about 50% of total 
antioxidant formation (Zhu et al., 2008). Practically, inactivation of cystathionine β-synthase 
causes hyperaccumulation of homocysteine that is a visual risk of cardiovascular diseases, 
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synthase in tumor cells, this enzyme was very active in normal cells ensuring their ability 
for synthesizing required methionine from homocysteine (Anderson, 1998). The 
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coenzymes for various cell lines corresponding to the normal cells was comprehensively 
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approaches were designed for triggering the methionine dependency of tumor cells, for 
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displays a reliable efficacy against various types of tumor cells (Goseki et al. 1992). 
However, this strategy is practically inefficient for many technical, therapeutical and 
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Consequently, application of L-methioninase for removal of plasma L-methionine is the 
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the late of S-G2 phase undergoing eventually apoptosis (Guo et al., 1993, Nagahama et al., 
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growth of normal/tumor cells, according to Harper's concept of amino acid balance. 
Malnutrition of patient is closely associated with severe amino acid metabolic disorders, 
uncorrectable nitrogen balance with low activity of immune system (Nitenberg and 
Raynard, 2000). Interestingly, methionine/ valine depleted, tyrosine lowered and arginine 
enriched was the most rationalized form for inhibition of tumor growth (Chen et al., 2001, 
He et al., 2003). L-Methioninase was extensively tested a potent anti-proliferative enzyme 
towards Lewis lung (Yoshioka et al., 1998), human colon (Tan et al., 1998), glioblastoma 
(Kokkinakis et al., 2001), neuroblastoma (Hu and Cheung, 2009) as reviewed by Sato and 
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pathogens. Also, as result of deaminating activity of this enzyme, extra amounts of 
ammonia (hyper-ammoniemia) was released during the course of tumor therapy, causing 
additional hazardous effects to the kidney and liver, as observed for many of anticancer 
deaminating enzymes (Balcao et al., 2001). Biochemically, hyperaccumulation of ammonia 
anticipates on formation of extra amounts of arginine and ornithine, via urea cycle, 
promoting the polyamines synthesis that indirectly induces tumorgenesis (Pegg, 1988, 
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attributed to their structural stereo-conformation during the enzyme posttranslational 
modifications, prokaryotic nature, making distinct epitopes immunogenic sites on the 
surface of the enzyme as assumed from the phylogenetic analysis of their amino acids (El-
Sayed, 2010). Depending on database, the structural amino acid identity of Arabidopsis 
thaliana L-methioninase was similar to that of Pseudomonas putida by less than 25 %, 
suggesting the differences on the surface amino acid constitution (El-Sayed, 2010). 
Accordingly, L-methioninase was classified structurally in two forms; First, Pseudomonas-
Trichomonas group that contain six subgroups namely; Pseudomonas, Bacillus, Brevibacterium, 
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thaliana. Interestingly, the similarity of amino acid composition of L-methioninase is closely 
related to the systematic morphological and physiological position of the organism. 
Actually, the amino acid composition of the fungal L-methioninase open reading frame, nor 
crystallographic studies was not studied. Therefore, regarding to the therapeutic 
implications of currently applied L-methioninase, the searching for a novel enzyme with 
less immunogenic activity and high therapeutic potentiality or modifications of the 
currently used enzymes is a challenge for many biotechnologists. 
8. Different approaches to increase the therapeutic potentiality of l-
methioninase 
8.1 PEGylation of L-methioninase  
Immobilization of the therapeutic enzymes on polyethylene glycol (PEG), PEGylation, is one 
of the most successful strategies that originated in 1970 (Abuchowski et al., 1977). 
PEGylation of albumin and catalase was the milestone for the development and 
globalization of this technique, as efficient method for modification of the structural and 
immunogenic identities of proteins (Abuchowski et al., 1977). Polyethylene glycol is a 
neutral, water soluble, hydrophilic polyether with less immunogenicity that ensure various 
pharmacological properties as increasing half-life time, reducing the kidney clearance, 
protecting protein from proteolysis by via steric hindrance, reduce the immunogenicity of 
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kidney excretion, with more plasma half-life time for the increasing of its molecular size 
(hydrodynamic radii), masking the sensitive amino to chemical modification, shielding the 
critical surface active sites from proteolysis, antibodies recognition and/or interaction with 
inhibitors (Harris, 1991; Zalipsky, 1995; Harris et al., 2001; Veronese and Harris, 2002), 
comparing to free enzyme. Also, PEGylation reduce the protein opsonization and adhesion 
to liposomes, microparticles (Fee and Van Alstine, 2004). Currently, PEGylation become a 
well developed technique for formulations of biopharmaceuticals for improving their 
solubility, bioavailability and decreasing their immunogenic properties as approved by FDA 
organization (Pasut et al., 2007). PEGylated forms of therapeutic enzymes as Escherichia coli 
asparaginase (Abuchowski et al., 1979), arginine deiminase (Izzo et al., 2007), Bacillus subtilis 
arginase (Cheng et al., 2005), Aspergillus flavus uricase (Bayol et al., 2002) displays affordable 
therapeutic potentialities comparing to corresponding free enzymes, as declared by FDA. 
PEGylation of Pseudomonas putida L-methioninase was extensively studied (Tan et al., 1998 
and Sun et al., 2003). The half-life time of PEG-L-methioninase was increased to 160 min, 
comparing to 80 min to the unmodified enzyme. However, the activity of L-methioninase 
was relatively not inhibited by PEGylation as appeared from the IC50 values against human 
lung and kidney tumors (Tan et al., 1998). In addition, PEGylation enhance the half-life 
times of the recombinant L-methioninase by about 20 fold and rate of serum methionine 
depletion by about 12 fold (Sun et al., 2003). Apparently, the degree of enzyme PEGylation 
usually correlate with the decreasing on enzyme immunogenicity and prolonged half-life 
time, in vivo. For example, the in vivo half-life times was increased from 12, 18 to 38 h upon 
degree of PEGylation of L-methioninase by 30/1, 60/1 and 120/1 molar ratios, respectively, 
comparing to the 2 h for the naked L-methioninase. PEGylation decreases the titer of IgG by 
about 10 and 10000 fold for PEG-rMETase 30/1 and 120/1 molar ratios, degree of 
PEGylation comparing to free enzyme (Sun et al., 2003).  Also, administration of external 
pyridoxal phosphate remarkably confers the half-life times and activity of PEG-rMETase. 
The significant decrease on the enzyme immunogenicity was appeared from the titer of anti-
PEG-METase as significantly reduced comparing to the native enzyme. As could be 
deduced, the more degree of PEGylation, the more masking of the superficial antigenic, 
epitopes, sites of the enzyme (Sun et al., 2003, Yang et al., 2004). The decrease on the 
activities of native of PEG-L-methioninase in vivo may attributed to dissociation of PLP Co-
enzyme (Yang et al., 2004), that being confirmed by our results in vitro (El-Sayed, 2011). 
However, L-methioninase and co-enzyme being easily re-associate upon external 
supplementation of pyridoxal phosphate as appeared by A420/280 ratio parallel to 
spectroscopic analysis for determination of the enzyme activity (El-Sayed, 2011). Thus, the 
combination of PEG-L-methioninase and pyridoxal phosphate infusion, or periodical 
supplementation of PLP by external osmotic pump, may exhibit a new strategy for 
prolonging the half-life time, for maximum enzyme therapeutic exploitation. L-
Methioninase displays two absorption maxima at 280 nm, as aromatic amino acids 
containing protein, and at 420 nm due to the internal aldimine linkage of the aldhyde group 
of pyridoxal phosphate and Ɛ-amino group of lysine N-terminal domain of PLP-enzyme. 
The absorption spectra of bacterial and fungal L-methioninase (Tanaka et al., 1977, Johnston 
et al., 1979, El-Sayed, 2011) are typically to other pyridoxal-dependent enzymes (Bertoldi et 
al., 2002; Saha et al., 2009). The pyridoxal phosphate co-enzyme was dissociate from the apo-
enzyme by incubation with 10 mM hydroxylamine, giving one peak at 280nm, with 
disappearance of the 420 nm peak due to the dissociation of the PLP and hydrolysis of the 
internal aldimine bond. To evaluate the structural reconstitution potentiality of fungal L-
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methioninase, different doses of PLP was supplemented to the apo-enzyme, the structural 
and catalytical efficiency was monitored. The ratio of A280/420 was decreased from 4.01 to 
1.7, upon addition of pyridoxal phosphate (0.2 mM) to the apo-enzyme, indicating the full 
reconstitution of the active holo-enzyme (El-Sayed, 2011) (Fig.5). Johnston et al. (1979) 
reported that upon freezing and thawing the ratio of A280/420 of Pseudomonas ovalis L-
methioninase was increased from 3.90 to 4.7, due to the dissociation of pyridoxal phosphate. 
P. ovalis L-methioninase lacks the ability to restore its original activity by dialysis against 
pyridoxal phosphate (Johnston et al., 1979), while that of Trichomonas vaginalis enzyme 
restore more than 90 % of its activity by 0.1mM PLP (Lockwood and Coombs, 1991). 
However, A. flavipes L-methioninase has the ability to reconstitute its fully structural 
catalytic state upon addition of pyridoxal phosphate (0.2mM), similarly to cystathionine γ-
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methioninase, different doses of PLP was supplemented to the apo-enzyme, the structural 
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Fig. 5. Absorption spectra of holo and apo-methioninase from A. flavipes (El-Sayed, 2011). 
Apo-methioninase obtained by preincubation of the holo-enzyme (2.2 mg/ml) in potassium 
phosphate buffer (pH 7.8) with 10 mM hydroxylamine. Reconstruction of the holo-enzyme 
by incubation of the apo-methioninase with 0.04 mM PLP (1), 0.08 mM PLP (2), 0.1 mM PLP 
(3), 0.15 mM PLP (4) and 0.2 mM PLP (5).  
9. Combination between L-methioninase and chemotherapeutic agents  
Synergism between L-methioninase and chemotherapeutic agents present a new strategy 
against various types of tumors (Yoshioka et al., 1998). Biochemically, starvation of the 
tumor cells to L-methionine, by action of L-methioninase or L-methionine depleted diets 
usually make the tumor cells more vulnerable to any biochemical modulator as reviewed by 
El-Sayed (2010). Methionine starvation and simultaneous phase-specific chemotherapeutic 
agent is an overall concept for all therapeutic strategies. 5-Fluorouracil, common 
biochemical modulator, an analogue to thiamine, that competitively bind to thymidylate 
synthetase, causing prompted suppression to DNA synthesis of tumor cells (Poirson-Bichat 
et al., 1997). The sensitivity of Lewis lung carcinoma to L-methioninase was increased by 
about 4.5 fold by addition of 5-fluorouracil (Hoshiya et al., 1997, Tan et al., 1998, Yoshioka et 
al., 1998). Similarly, doxorubicin as intercalating agent blocks the cell cycle, greatly improves 
the activity of L-methioninase against human lung carcinoma H460 (Gupta et al., 2003). 
Ethionine, as methionine analogue, in combination with methionine starved diets display a 
potent activity against human colon and lung tumors, that attributed to inhibition of 
methyltransferase leading to DNA, RNA, protein hypomethylation (Razin and Riggs, 1980 
and Poirson-Bichat et al., 2000). Also, methionine free diets potentiality against human 
prostate and glioma was strongly augmented by supplementation of ethionine that 
attributed to reduction of ATP pool and glutathione synthesis (Guo et al., 1996, Poirson-
Bichat et al., 1997). Also, methionine deprivation induce the hypomethylation reactions that 
lowers the glutathione and alters folate metabolism causing selective arresting to the cell 
cycle in the late of S/G2 phase, strongly modulate the efficiency of Cisplatin against human 
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breast carcinoma (Hoshiya et al., 1996). However, continuous starvation of human serum to 
methionine may exert hazardous implications to liver (Kokkinakis, 2006). Biochemically, 
combination of methioninase with various therapeutic agents, for methionine starvation, as 
doxorubicin (Stern et al., 1984), 5-fluoruracil, mitomycin C (Goseki et al., 1992), nitrosoureas 
(Kokkinakis et al., 2001) and BCNU (Kokkinakis et al. 1997), display a new approach for 
treatment of methionine dependent tumor cells.         
10. L-Methioninase gene therapy and selenomethionine as prodrugs 
Introduction of the L-methioninase encoding genes to tumor cells with regulating their 
expression one of the recent challenges for treating of tumor cells as reviewed by El-Sayed 
(2010). Transduction of bacterial L-methioninase gene via developed adenoviral vector, with 
exogenous L-methioninase, display a powerful activity towards human ovarian cancer cells 
(Miki et al., 2000a). The potentiality of gene therapy for methionine dependent tumors based 
on deprivation of the tumor cells from the intrinsic L-methionine, so this technique 
significantly intensified by combination with external L-methioninase, to remove the serum 
L-methionine. A plausible anti-proliferative activity towards human lung cancer by 
transduction of P. putida L-methioninase gene via retroviral vectors, in combination with 
methioninase treatment, was observed (Miki et al., 2000b). Transduction of P. putida L-
methioninase gene to human lung carcinoma using retroviral victors and their therapeutic 
implications were extensively studied by Tan et al., 1997, Miki et al., 2000a,b, 2001). In 
contrary to hypomethylation by extrinsic starvation of L-methionine, introduction of p53 
genes using retroviral, adenoviral, lipid based delivery, displays an efficient strategy against 
various types of p53 regulated tumors (Miki et al., 2001). Unfortunately, different genetic 
therapeutical trials is rarely occurred without signs of biochemical implications as low 
clinical efficiency and lethal toxicity (Fox, 1999), due to the production of some anti-apoptic 
mitochondrial proteins that counteract the introduced methioninase gene (Yamamoto et al., 
2003). Mitochondrial protein (Bc1-2) is the common released anti-apoptotic proteins that 
hinder the release of mitochondrial cytochrome c to cytosol thus counteracting different 
gene therapeutic approaches (Hamel et al., 1996, Carsten et al., 2000). Additionally, the low 
transduction efficiency by retroviral L-methioninase gene hinders their therapeutic 
potentiality. Recently, a novel strategy for reduction the clinical hazardous and 
augmentation of the pharmacokinetic impact of this enzyme via combination of gene 
therapy and selenomethionine as prodrugs as reported by Miki et al. (2001) and Yamamoto 
et al. (2003). In addition to intracellular and extracellular depletion of L-methionine, 
introduction of selenomethionine, as non-toxic prodrug, plausibly maximize the therapeutic 
potentiality of this approach, against tumor cells. Selenomethionine, methionine analogue, is 
a prodrug that under γ-elimination forming a powerful toxic methylselenol, α-ketobutyrate 
and ammonia (El-Sayed, 2010). Subsequently methylselenol catalyzes thiols oxidation 
generating reactive oxygen species as superoxide causing mitochondrial swelling, releasing 
cytochrome c, activation of caspase inducing prompt cell apoptosis (Green and Reed, 1998, 
Miki et al., 2001, Yamamoto et al., 2003). Methylselenol released from L-methioninase gene 
transduced tumor cell can easily adsorbed by surrounding cells, bystander effect, generating 
the same toxicity on mitochondrial system (Miki et al., 2001) as reviewed by El-Sayed (2010). 
Unlike the sensitivity of tumor cells to methylselenol, the normal human cells were not 
being affected for their lack to L-methioninase (Hoffman, 1984). The sensitivity of tumor 
cells to transduction by adenovirus methioninase gene and selenomethionine as prodrug 
was increased by 1000 fold (Miki et al., 2000a) comparing to only gene transduced cells.  
 











Fig. 5. Absorption spectra of holo and apo-methioninase from A. flavipes (El-Sayed, 2011). 
Apo-methioninase obtained by preincubation of the holo-enzyme (2.2 mg/ml) in potassium 
phosphate buffer (pH 7.8) with 10 mM hydroxylamine. Reconstruction of the holo-enzyme 
by incubation of the apo-methioninase with 0.04 mM PLP (1), 0.08 mM PLP (2), 0.1 mM PLP 
(3), 0.15 mM PLP (4) and 0.2 mM PLP (5).  
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al., 1998). Similarly, doxorubicin as intercalating agent blocks the cell cycle, greatly improves 
the activity of L-methioninase against human lung carcinoma H460 (Gupta et al., 2003). 
Ethionine, as methionine analogue, in combination with methionine starved diets display a 
potent activity against human colon and lung tumors, that attributed to inhibition of 
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breast carcinoma (Hoshiya et al., 1996). However, continuous starvation of human serum to 
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doxorubicin (Stern et al., 1984), 5-fluoruracil, mitomycin C (Goseki et al., 1992), nitrosoureas 
(Kokkinakis et al., 2001) and BCNU (Kokkinakis et al. 1997), display a new approach for 
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10. L-Methioninase gene therapy and selenomethionine as prodrugs 
Introduction of the L-methioninase encoding genes to tumor cells with regulating their 
expression one of the recent challenges for treating of tumor cells as reviewed by El-Sayed 
(2010). Transduction of bacterial L-methioninase gene via developed adenoviral vector, with 
exogenous L-methioninase, display a powerful activity towards human ovarian cancer cells 
(Miki et al., 2000a). The potentiality of gene therapy for methionine dependent tumors based 
on deprivation of the tumor cells from the intrinsic L-methionine, so this technique 
significantly intensified by combination with external L-methioninase, to remove the serum 
L-methionine. A plausible anti-proliferative activity towards human lung cancer by 
transduction of P. putida L-methioninase gene via retroviral vectors, in combination with 
methioninase treatment, was observed (Miki et al., 2000b). Transduction of P. putida L-
methioninase gene to human lung carcinoma using retroviral victors and their therapeutic 
implications were extensively studied by Tan et al., 1997, Miki et al., 2000a,b, 2001). In 
contrary to hypomethylation by extrinsic starvation of L-methionine, introduction of p53 
genes using retroviral, adenoviral, lipid based delivery, displays an efficient strategy against 
various types of p53 regulated tumors (Miki et al., 2001). Unfortunately, different genetic 
therapeutical trials is rarely occurred without signs of biochemical implications as low 
clinical efficiency and lethal toxicity (Fox, 1999), due to the production of some anti-apoptic 
mitochondrial proteins that counteract the introduced methioninase gene (Yamamoto et al., 
2003). Mitochondrial protein (Bc1-2) is the common released anti-apoptotic proteins that 
hinder the release of mitochondrial cytochrome c to cytosol thus counteracting different 
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transduction efficiency by retroviral L-methioninase gene hinders their therapeutic 
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augmentation of the pharmacokinetic impact of this enzyme via combination of gene 
therapy and selenomethionine as prodrugs as reported by Miki et al. (2001) and Yamamoto 
et al. (2003). In addition to intracellular and extracellular depletion of L-methionine, 
introduction of selenomethionine, as non-toxic prodrug, plausibly maximize the therapeutic 
potentiality of this approach, against tumor cells. Selenomethionine, methionine analogue, is 
a prodrug that under γ-elimination forming a powerful toxic methylselenol, α-ketobutyrate 
and ammonia (El-Sayed, 2010). Subsequently methylselenol catalyzes thiols oxidation 
generating reactive oxygen species as superoxide causing mitochondrial swelling, releasing 
cytochrome c, activation of caspase inducing prompt cell apoptosis (Green and Reed, 1998, 
Miki et al., 2001, Yamamoto et al., 2003). Methylselenol released from L-methioninase gene 
transduced tumor cell can easily adsorbed by surrounding cells, bystander effect, generating 
the same toxicity on mitochondrial system (Miki et al., 2001) as reviewed by El-Sayed (2010). 
Unlike the sensitivity of tumor cells to methylselenol, the normal human cells were not 
being affected for their lack to L-methioninase (Hoffman, 1984). The sensitivity of tumor 
cells to transduction by adenovirus methioninase gene and selenomethionine as prodrug 
was increased by 1000 fold (Miki et al., 2000a) comparing to only gene transduced cells.  
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Currently, in a revolution of biotechnology in the fight against cancer, directing of the 
enzyme via antibodies to the target tumor cells for removal of extracellular methionine in 
addition to transduced enzyme gene and selenomethionine as prodrug is the promising 
strategy against various types of tumors (Napier et al., 2000, Zhao et al., 2006). This novel 
approach referred as Antibody Directed Enzyme Prodrug Therapy (ADEPT) that is reliable 
strategy to avoid the systemic clinical and therapeutical limitations of the traditional 
approaches (Sharma et al., 2005). However, several trials for construction of enzyme 
antibodies models (Bagshawe, 1987, Stener and Springer, 2001, Bagshawe et al., 2004) were 
experimented. However, the design of enzyme-antibody without interactions on the enzyme 
catalytic sites and specific to receptors on the surface of tumor cells is main challenge by 
biotechnologists, for approving this strategy. After transduction of L-methioninase gene to 
the target tumor cells, the enzyme-antibody was introduced to the human plasma followed 
by injection of selenomethionine as planned by several trials as reviewed by El-Sayed (2010).                          
11. Exploitation of L-methioninase as a target for antimicrobial drugs  
Uniqueness distribution of L-methioninase as intracellular enzyme among all microbial 
pathogens, but not humans makes this enzyme is a novel target for antibacterial, antifungal 
and anti-protozoal therapies (Ali and Nozaki, 2007, Sato and Nozaki, 2009). 
Trifluoromethionine (TFM), a fluorinated methionine that undergoes β, γ-elimination 
forming trifluoro-methanethiol (CF3SH) that converted to carbonothionic difluoride which 
subsequently interacted with primary amino groups of the enzymes lysine moieties, causing 
cellular toxicities (Alston and Bright, 1983, Sato et al., 2008). TFM was reported as a potent 
antibacterial agent towards the growth of Mycobacterium smegmatis, M. phlei and Candida 
lipolytica  (Zygmunt and Tavormina, 1966, Sato and Nozaki, 2009), P. gingivalis, F. nucleatum 
(Yoshimura et al., 2002) and antiprotozoal agent Entaemoba histolytica (Coombs and 
Mottram, 2001). Also, TFM is highly effective against many anaerobic bacteria as Clostridium 
botulinum (botulism), C. difficile (colitis), Porphyromonas sp (tooth decay) and Bacteroides sp 
(intra-abdominal infections) (Finegold and Wexler, 1996). Methionine and TFM was 
activated by methionine adenosyltransferase for further metabolic biochemical pathways. 
Mammalian cystathionine γ-lyase doesn’t affected by the presence of TFM (Alston and 
Bright, 1983). Myrsinoic acid B and terpeno-benzoic acid extracted from Myrisine seguinii, 
were reported as potent anti-methioninase, anti-inflammatory and anti-edema agents 
(Hirota et al., 2002, Ito et al., 2008). Myrsinoic acid exhibits a significant activities against F. 
nucleatum (IC50 0.39 µm), T. denticoal (IC50 30.3 µM) and P. gingivalis (IC50 82.4 µM), it used as 
powerful anti-malodor and periodontal disease (Sato and Nozaki, 2009). Propargylglycine 
as cysteine analogues, was widely reported as suicide L-methioninase catalytic inhibitor, in 
vitro (El-Sayed, 2011), with relatively low deleterious effect on whole growth of amoebic 
trophozites, E. histolytica (Ali and Nozaki, 2007), suggesting alternative shunt for sulfur 
amino acid metabolism other than L-methioninase (Coombs and Mottram, 2001). Thus, for 
unique distribution of L-methioninase as intracellular enzyme among pathogenic microbes, 
the searching for various inhibitors with reliable specificity to this enzyme will be a 
justifiable new trend of antimicrobials agents.         
12. Pyridoxal phosphate-dependent enzymes deficiency and cardiovascular 
diseases  
Biochemically, transsulfuration and reverse-transsulfuration pathways are the pivotal 
mechanisms for proper accumulation of homocysteine and cystathionine. As shown in Fig. 
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(3), these pathways are controlled by four PLP-dependent enzymes namely; cystathionine β, 
γ-synthases and cystathionine γ, β-lyases. Inactivation of transsulfuration enzymes as 
cystathionine β-synthase causes hyperaccumulation of homocysteine (homocysteinuria) that 
is a visual risk of cardiovascular diseases, damage to vascular endothelia, increases to the 
risk of abnormal blood clots and skeletal abnormalities (De Bree et al., 2002; Wald et al., 
2002) and Alzheimer's disease (Morris, 2003). Also, homocysteinuria usually associated with 
intellectual disability, seizures and megaloblastic anemia (Mudd et al., 1985). Practically, it 
commonly reported as genetic or metabolic disorders that affect on the metabolism of 
protein, generally one to 200,000 babies are born with genetic disorders. Homocysteinuria is 
a biochemically disorder due to the deficiency of cystathionine β-synthase, owing to the 
genetically inborn error of the transsulfuration pathway that increases the homocysteine 
and methionine, with crucial decreasing to the cysteine pool (Mudd et al., 1985). The major 
clinical implication of homocysteinuria includes mental retardation, dislocation of the optic 
lenses, skeletal abnormalities (Schuh et al., 1984). Dietary therapy relying of deprivation of 
methionine and supplementation of cysteine display a reliable positive result in delaying the 
clinical manifestations (Pullon, 1980). However, supplementation of cystathionine β-
synthase was the potent relevant therapy for dramatically conversion of homocysteine to 
cystathionine (Zhu et al., 2008). Since cystathionine β-synthase is a PLP-dependent enzyme 
and the rapid dissociation of PLP as coenzyme from the apoenzyme is a common structural 
and catalytic criteria (El-Sayed, 2010, 2011), external supplementation of pyridoxal 
phosphate, vitamin B6 gave a plausible results for decreasing the amount of homocysteine, 
assuming the reassociation of apo-cystathionine β-synthase forming the holo-enzyme 
(Barber and Spaeth, 1967). Moreover, the deficiency of cystathionine γ-lyase results in 
accumulation of cystathionine (Cystathioninuria) that usually accompanied with diabetes, 
Down's syndrome, neuroblastoma (Wang and Hegele, 2003) as reviewed by Zhu et al. 
(2008).  
13. Industrial application of l-methioninase: methanethiol production 
Methanethiol has enormous biotechnological applications such as key gradient in gas 
odorants, jet fuel additives and coke formation in steel mill furnaces (Welirnan 1966). 
Recently, it is used for preparation of modified gold biosensors, manufacturing of plastics 
and pesticides (Jin et al. 2005, Nakamura et al. 2006). Also, it is the precursor for 
dimethyltrisulfide, S-methylthio-esters and 2,4-dithiapentane production (Chin and Lindsay 
1994, Amarita et al. 2004), as presulfiding, hydrocracking catalysts, extracting solvents, 
manufacturing of ion-exchange resins and as modifier of Nylon fibers (Herschler 1962; 
Stewart and Lasis 1965) (www.gaylardchemical.com).   
Chemically, methanethiol can be synthesized by reaction of methanol with hydrogen sulfide 
(Scott et al., 1955). The reaction was preceded at 380°C (716°F) in the presence of 
K2MoSO4/SiO2 as catalyst and 2MPa. By chemical methods usually methanethiol 
accompanied with formaldehyde, requiring more steps for purification, especially with 
higher solubility of methanethiol in water (Yang et al., 1998). Commercially, the price of 
methanethiol salt is about eighteen fold higher than L-methionine, also one gram of sodium 
methanethiolate is 3.6 folds more than one liter of methanol (Sigma-Aldrich Co 2010).  
Consequently, the enzymatic method, using L-methioninase seems to be a plausible process 
for large scale production of methanethiol from the technical and economical point of views. 
For the high expense of enzyme purification from the microbial cultures, immobilization is a 
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Currently, in a revolution of biotechnology in the fight against cancer, directing of the 
enzyme via antibodies to the target tumor cells for removal of extracellular methionine in 
addition to transduced enzyme gene and selenomethionine as prodrug is the promising 
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as cysteine analogues, was widely reported as suicide L-methioninase catalytic inhibitor, in 
vitro (El-Sayed, 2011), with relatively low deleterious effect on whole growth of amoebic 
trophozites, E. histolytica (Ali and Nozaki, 2007), suggesting alternative shunt for sulfur 
amino acid metabolism other than L-methioninase (Coombs and Mottram, 2001). Thus, for 
unique distribution of L-methioninase as intracellular enzyme among pathogenic microbes, 
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(3), these pathways are controlled by four PLP-dependent enzymes namely; cystathionine β, 
γ-synthases and cystathionine γ, β-lyases. Inactivation of transsulfuration enzymes as 
cystathionine β-synthase causes hyperaccumulation of homocysteine (homocysteinuria) that 
is a visual risk of cardiovascular diseases, damage to vascular endothelia, increases to the 
risk of abnormal blood clots and skeletal abnormalities (De Bree et al., 2002; Wald et al., 
2002) and Alzheimer's disease (Morris, 2003). Also, homocysteinuria usually associated with 
intellectual disability, seizures and megaloblastic anemia (Mudd et al., 1985). Practically, it 
commonly reported as genetic or metabolic disorders that affect on the metabolism of 
protein, generally one to 200,000 babies are born with genetic disorders. Homocysteinuria is 
a biochemically disorder due to the deficiency of cystathionine β-synthase, owing to the 
genetically inborn error of the transsulfuration pathway that increases the homocysteine 
and methionine, with crucial decreasing to the cysteine pool (Mudd et al., 1985). The major 
clinical implication of homocysteinuria includes mental retardation, dislocation of the optic 
lenses, skeletal abnormalities (Schuh et al., 1984). Dietary therapy relying of deprivation of 
methionine and supplementation of cysteine display a reliable positive result in delaying the 
clinical manifestations (Pullon, 1980). However, supplementation of cystathionine β-
synthase was the potent relevant therapy for dramatically conversion of homocysteine to 
cystathionine (Zhu et al., 2008). Since cystathionine β-synthase is a PLP-dependent enzyme 
and the rapid dissociation of PLP as coenzyme from the apoenzyme is a common structural 
and catalytic criteria (El-Sayed, 2010, 2011), external supplementation of pyridoxal 
phosphate, vitamin B6 gave a plausible results for decreasing the amount of homocysteine, 
assuming the reassociation of apo-cystathionine β-synthase forming the holo-enzyme 
(Barber and Spaeth, 1967). Moreover, the deficiency of cystathionine γ-lyase results in 
accumulation of cystathionine (Cystathioninuria) that usually accompanied with diabetes, 
Down's syndrome, neuroblastoma (Wang and Hegele, 2003) as reviewed by Zhu et al. 
(2008).  
13. Industrial application of l-methioninase: methanethiol production 
Methanethiol has enormous biotechnological applications such as key gradient in gas 
odorants, jet fuel additives and coke formation in steel mill furnaces (Welirnan 1966). 
Recently, it is used for preparation of modified gold biosensors, manufacturing of plastics 
and pesticides (Jin et al. 2005, Nakamura et al. 2006). Also, it is the precursor for 
dimethyltrisulfide, S-methylthio-esters and 2,4-dithiapentane production (Chin and Lindsay 
1994, Amarita et al. 2004), as presulfiding, hydrocracking catalysts, extracting solvents, 
manufacturing of ion-exchange resins and as modifier of Nylon fibers (Herschler 1962; 
Stewart and Lasis 1965) (www.gaylardchemical.com).   
Chemically, methanethiol can be synthesized by reaction of methanol with hydrogen sulfide 
(Scott et al., 1955). The reaction was preceded at 380°C (716°F) in the presence of 
K2MoSO4/SiO2 as catalyst and 2MPa. By chemical methods usually methanethiol 
accompanied with formaldehyde, requiring more steps for purification, especially with 
higher solubility of methanethiol in water (Yang et al., 1998). Commercially, the price of 
methanethiol salt is about eighteen fold higher than L-methionine, also one gram of sodium 
methanethiolate is 3.6 folds more than one liter of methanol (Sigma-Aldrich Co 2010).  
Consequently, the enzymatic method, using L-methioninase seems to be a plausible process 
for large scale production of methanethiol from the technical and economical point of views. 
For the high expense of enzyme purification from the microbial cultures, immobilization is a 
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promising technique for enzyme stabilization and continuous production of methanethiol 
(El-Sayed and Shindia, 2011). Among the tested methods, polyacrylamide (42.2%), Ca-
alginate (40.9%) and chitin (40.8%) displaying the highest A. flavipes L-methioninase 
immobilization efficiency. Chitin-enzyme gave a plausible stability till 4th cycle for 
production of methanethiol under controlled system. Applying GC and HNMR analysis, 
methanethiol has identical chemical structure to the standard compound. A new method for 
continuous production of pure methanethiol using a simple low expense enzymatic method 
was developed (El-Sayed and Shindia, 2011).   
14. Prospectives for improving the therapeutic potentiality of PLP-dependent 
enzymes 
Regarding to publications describing the structural and catalytic identities of PLP-
dependent enzymes and their wide therapeutic and pharmaceutical applications, the 
immunogenicity and relative instability were the common limitations from pharmacokinetic 
point of view. Actually, all of these enzymes that receive considerable attention as 
therapeutic agent were of bacterial sources as reviewed by El-Sayed (2010). However, the 
crystallographic and biochemical studies for various therapeutic enzymes reveal a reliable 
distinction on the enzyme conformational structural of surface amino acids and 
immunogenic sites, from prokaryotes to eukaryotes (Kusakabe et al., 1979). Unlike the 
extensive studies of bacterial PLP-dependent enzymes, no more publications for 
biochemical characterization and crystal structures of these enzymes from eukaryotes, in 
spite of their distinct structural identity from eukaryotes as revealed from amino acid 
constitution (El-Sayed, 2010). Thus, further biochemical and crystallographic studies to 
elucidate the catalytic identity and tertiary structure of eukaryotic PLP-enzymes for the 
maximum therapeutic exploitation of these enzymes need to be resolved. The plausible re-
association of PLP coenzyme with the apo-L-methioninase with full activity, comparing to 
lower to inability to re-association of the corresponding enzymes from prokaryotes, is an 
obscure, and their authorization with greatly participates in explanation of their catalytic 
and immunogenic identities. In addition, immobilization and co-immobilization studies of 
these enzymes will significantly maximize their biotechnological and therapeutical 
applications. Regarding to gene therapy, PEGylation and directing of these enzymes to 
specific tumors via targeting by modified antibodies or nao-particles is the main challenge 
for our ongoing research.        
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promising technique for enzyme stabilization and continuous production of methanethiol 
(El-Sayed and Shindia, 2011). Among the tested methods, polyacrylamide (42.2%), Ca-
alginate (40.9%) and chitin (40.8%) displaying the highest A. flavipes L-methioninase 
immobilization efficiency. Chitin-enzyme gave a plausible stability till 4th cycle for 
production of methanethiol under controlled system. Applying GC and HNMR analysis, 
methanethiol has identical chemical structure to the standard compound. A new method for 
continuous production of pure methanethiol using a simple low expense enzymatic method 
was developed (El-Sayed and Shindia, 2011).   
14. Prospectives for improving the therapeutic potentiality of PLP-dependent 
enzymes 
Regarding to publications describing the structural and catalytic identities of PLP-
dependent enzymes and their wide therapeutic and pharmaceutical applications, the 
immunogenicity and relative instability were the common limitations from pharmacokinetic 
point of view. Actually, all of these enzymes that receive considerable attention as 
therapeutic agent were of bacterial sources as reviewed by El-Sayed (2010). However, the 
crystallographic and biochemical studies for various therapeutic enzymes reveal a reliable 
distinction on the enzyme conformational structural of surface amino acids and 
immunogenic sites, from prokaryotes to eukaryotes (Kusakabe et al., 1979). Unlike the 
extensive studies of bacterial PLP-dependent enzymes, no more publications for 
biochemical characterization and crystal structures of these enzymes from eukaryotes, in 
spite of their distinct structural identity from eukaryotes as revealed from amino acid 
constitution (El-Sayed, 2010). Thus, further biochemical and crystallographic studies to 
elucidate the catalytic identity and tertiary structure of eukaryotic PLP-enzymes for the 
maximum therapeutic exploitation of these enzymes need to be resolved. The plausible re-
association of PLP coenzyme with the apo-L-methioninase with full activity, comparing to 
lower to inability to re-association of the corresponding enzymes from prokaryotes, is an 
obscure, and their authorization with greatly participates in explanation of their catalytic 
and immunogenic identities. In addition, immobilization and co-immobilization studies of 
these enzymes will significantly maximize their biotechnological and therapeutical 
applications. Regarding to gene therapy, PEGylation and directing of these enzymes to 
specific tumors via targeting by modified antibodies or nao-particles is the main challenge 
for our ongoing research.        
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Fusing the FasL to Del1 Protein Domains 
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1. Introduction  
Gene delivery, transfection, cytotoxicity, and many other factors influence the ability of gene 
therapy to treat cancer. In addition, as with pharmacologic agents, longer exposure to higher 
concentrations of gene products should intensify their effects (Wada et al., 2007). Cytotoxic 
gene products, such as FasL and TRAIL, may remain in tissues after the death of the 
transfected cells, and they are known to induce apoptosis in both transfected cells and 
neighbouring cells (Hyer et al., 2003; Kagawa et al., 2001). They have been examined for use 
in cancer gene therapy and its effects have been examined in vitro and in vivo (Elojeimy et 
al., 2006; Griffith et al., 2009). FasL delivered via a viral vector can reduce tumour size and 
improve prognosis in an explanted tumour model. 
 
 
a. Immunohistochemical staining for Del1 in a 14.5 dpc (days post coitum) mouse embryo. Sections 
were stained with anti-Del1 antibody, followed by an alkaline phosphatase-conjugated secondary 
antibody and naphthol red as a colorimetric substrate. Immunoreactive protein appears red. Staining 
for Del1 appeared in the subendocardial region. b. The domain structure of Del1 protein. The RGD 
sequence in the second EGF motif is indicated. 
Fig. 1. Expression and structure of Del1 protein 
Currently, multiple injections with a gene therapeutic agent are needed because it is 
unlikely for a single injection to eliminate a cancer. Therefore, gene therapeutic agents need 
to be not only safe but inexpensive. Non-viral vectors represent a possible safe and 
inexpensive way of delivering genes for gene therapy (Lungwitz et al., 2005). However, the 
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Currently, multiple injections with a gene therapeutic agent are needed because it is 
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inexpensive way of delivering genes for gene therapy (Lungwitz et al., 2005). However, the 
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gene transfer efficiency of non-viral vectors remains low. New non-viral vectors that are 
non-carcinogenic, non-immunogenic, and highly efficient are currently being developed. 
Here, we discuss the use of non-viral vectors encoding Del1 in cancer gene therapy. Del1 is 
an extracellular matrix (ECM) protein expressed by embryonic endothelial cells and 
hypertrophic chondrocytes (Fig. 1a) (Hidai et al., 1998). We examined the biological 
functions of Del1 domains by generating non-viral vectors encoding fragments of the Del1 
gene. 
2. Del1 and its application in cancer gene therapy 
Del1 is a 480-amino acid protein made up of five regions, including three epidermal growth 
factor (EGF) repeats (E1-3) at its N-terminus and two discoidin domains (C1 and C2) at its 
C-terminus (Fig. 1b). The C1 domain is essential for the deposition of Del1 in the ECM, and 
E3 enhances the ECM deposition mediated by C1 (Hidai et al., 2007). Proteins fused to the 
E3 and C1 domains are deposited in the ECM, where they accumulate. The E3 domain can 
also increase the endocytosis of transfected genes, and at high concentrations, E3 induces 
apoptosis (Kitano et al., 2008, 2010). We therefore examined the possible application of Del1 
in cancer gene therapy by transfecting a squamous cell carcinoma line with cDNA encoding 
a FasL-E3C1 fusion protein. This protein was deposited in ECM, increased apoptosis, and 
enhanced the efficiency of a following second transfection in vitro. 
2.1 E3 enhances the efficiency of gene transfection 
Although viral vectors are highly efficient for gene transfer, they can be carcinogenic and 
immunogenic (Check, 2002). They also require more time and are more expensive than non-
viral vectors. However, non-viral vectors are less efficient for gene transfer. Various 
methods have been made to improve the efficiency of non-viral vectors. For example, novel 
chemical transfection reagents have been developed to improve extracellular binding. Also, 
vectors have been modified with chemicals, growth factor peptides, extracellular matrix 
proteins, and viral proteins to improve uptake via receptor-mediated endocytosis (Al-Taei et 
al., 2006; Kikuchi et al., 1996; Nam et al., 2009; Oba et al., 2007). 
Although the characteristics of the transfection reagents are important, differences between 
cell types are a more important determinant of transfection efficiency; some cells are always 
more easily transfected than others (Von Gersdorff et al., 2006). In this regard, the biological 
state of a given cell type, such as which endocytic pathways are functional in the cell prior to 
treatment, may be an important factor in endocytosis-mediated gene transfer. Molecules 
that initiate and enhance endocytosis are needed to improve endocytosis as a method for 
delivering exogenous molecules. 
Del1 protein is one such a factor that increases the efficiency of transfection in vitro and in 
vivo (Kitano et al., 2008). We have found that conditioned medium containing Del1 increases 
LacZ gene transfection using several non-viral gene transfer systems, including lipoplex and 
polyplex systems. Experiments using deletion mutants and fragments of Del1 have shown 
that domain E3 of Del1 mediates the enhancement of gene transfer. Incubation of culture 
cells with as low as 16 pM of recombinant E3 is sufficient to enhance transfection, and 1 nM 
recombinant E3 enhances the transfection 12-fold. This effect of E3 was observed in every 
cell type tested. E3 enhanced transfection even when it was administrated to the cell culture 
medium before transfection. The effects of Del1 on gene transfer are inhibited by both of 
nystatin, an inhibitor of caveolin-dependent endocytosis, and chlorpromazine, an inhibitor 
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of clathrin-dependent endocytosis. Furthermore, the addition of E3 to cell culture medium 




a. Confluent COS-7 cells were cultured with 1-μm diameter fluorescent beads (Invitrogen, Carlsbad, 
CA) and 1 nM of an alkaline phosphatase (AP)-E3 fusion protein (left side of panel a) for 1 h, washed 
with PBS, and visualized by fluorescence microscopy. AP protein was used as a negative control (right 
side of panel a). b. Fluorescence intensity evaluated using image analysis software (AquaCosmos, 
Hamamatsu photonics, Hamamatsu, Japan). Fluorescence was normalized by the control samples. 
Results represent means ± SEM (n=6). The results show that recombinant E3 increases phagocytosis. 
Fig. 2. Effect of recombinant E3 on phagocytosis 
 
 
Fig. 3. Effect of recombinant E3 on gene transfer in vivo 
The effects of Del1 on gene transfer were observed in vivo. We found two-fold higher serum 
alkaline phosphatase activity following transfection with a heat-stable alkaline phosphatase 
(AP) cDNA in mice over-expressing Del1 compared wild-type littermates (Fig. 3). These 
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results suggest that the E3 fragment of Del1 in ECM can be used as a general enhancer of 
non-viral gene transfer. 
Del1 over-expressing mice (TG) and wild-type mice (WT) were intravenously injected with a 
cDNA encoding AP using jet-PEI (Polyplus-transfection, San Marco, CA, USA). Mice 
injected with an empty vector were used as negative controls. After 24 h, serum AP activity 
was measured. AP activities were normalized by the AP activity of wild-type mice. Results 
represent means ± SEM (n=6). N.S., not significant. These results revealed that Del1 
increased the susceptibility to gene transfer in vivo. 
2.2 E3 induces apoptosis 
Del1 is present in branchless cavities, such as the heart and umbilical veins, as well as in 
avascular tissue with hypertrophic chondrocytes in developing embryos (Hidai et al., 1998). 
In transgenic mice, constitutive expression of Del1 decreases the total volume of the vascular 
bed (Hidai et al., 2005). These findings suggest that Del1 is inhibits angiogenesis activity. 
However, some evidence suggests that Del1 promotes angiogenesis. Zhong et al. reported 
that Del1 can stimulate angiogenesis in animal models of ischemia (Zhong et al., 2003). 
Additionally, Del1 can accelerate tumor growth by enhancing vascular formation (Aoka et 
al., 2002). Del1 has seemed to have ambiguous characteristics. 
We have found that Del1 induces cell death in vitro (Fig. 4) (Kitano et al., 2010). Treatment of 
cells with Del1 results in chromatin condensation and DNA laddering, suggesting 
apoptosis. Experiments using TUNEL and annexin V staining also suggest that Del1 induces 
apoptosis. The apoptosis-inducing activity of Del1 is localized in E3. As little as 25 pM 
recombinant E3 is sufficient to induce apoptosis, and we have found that E3 induces 
apoptosis in all adhesive cell types examined. Because of this ability to induce cell death, the 
E3 domain of Del1 might be useful for cancer gene therapy. 
 
 
COS-7 cells were transfected with Del1 cDNA (a) or an empty vector. (b). After 24 h, fragmented DNA 
was detected with a TACS2 TdT-blue label in situ apoptosis detection kit (Trevigen, Gaithersburg, MD, 
USA). Cells were counterstained with Nuclear Fast Red. Bar , 20 μm. 
Fig. 4. In situ detection of DNA fragmentation induced by a recombinant E3 
The C1 domain of Del1 also mediates apoptosis. Hanayama et al. reported that the C1 
domain binds to phosphatidylserine (PS), a component of the plasma membrane 
(Hanayama et al., 2004). In healthy cells, PS is maintained on the inner leaflet of the plasma 
membrane lipid bilayer. However, in apoptotic cells, PS is present in the outer leaflet. Del1 
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may link phagocytes with apoptotic cells via the integrin-binding RGD sequence in the E2 
domain and the PS-binding C1 domain, which can bind to apoptotic cells. Thus, Del1 can 
both initiate apoptosis and enhance the elimination of apoptotic cells. 
2.3 C1 as a deposition domain 
The ECM is a critical factor in morphogenesis (Fujiwara et al., 2011; Sakai et al., 2003). 
Because the organization of the ECM directly influences the structure of tissues and organs, 
determining how ECM organization is regulated can help clarify the process of 
morphogenesis. We therefore investigated how Del1 is assembled in the ECM using an AP-
Del1 fusion protein. We found that the fusion protein is secreted from cells and deposited in 
the ECM (Fig. 5). 
 
 
Fig. 5. Del1 deposition domain can immobilize AP protein 
CHO cells were cultured and transfected with cDNA of an AP-Del1 fusion protein. Cells 
were removed from tissue culture plates with EDTA and the ECM remaining was collected 
with a cell scraper, followed by centrifugation. Collected ECM pellets were incubated with 
p-nitrophenyl phosphate in microcentrifuge tubes. The ECM pellet on the left was collected 
from wild-type cells, the pellet in the middle from cells transfected with a cDNA encoding 
AP, and the pellet on the right from cells transfected with cDNA encoding the AP-Del1 
fusion protein. The pellet on the right was stained purple indicating that the AP-Del1 fusion 
protein was present in the ECM. 
Using various Del1 deletion mutants, we have found that the C-terminus of the C1 
domain, which contains a lectin-like structure, mediates ECM deposition (Hidai et al., 
2007). The efficiency of deposition is influences by the presence of other domains in Del1. 
A fragment containing E3 and C1 (E3C1) had the highest level of ECM deposition, with 
approximately 70% of the secreted AP fusion protein deposited in the ECM. In contrast, 
fragments containing C2, which is highly homologous to C1, were present at much lower 
levels in the ECM. The E3C1 fragment was deposited in the ECM by all cell types 
examined, although the efficiency varied. Digestion of the ECM with bovine testis 
hyaluronidase released Del1 from ECM, suggesting that glycosaminoglycans are involved 
in the deposition of Del1. 
In vivo gene transfer experiments in mice showed that the deposition domain of Del1 
dramatically alters the distribution of exogenous proteins. The AP activity in liver was 8 times 
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higher and the serum activity 30 times lower in mice injected intravenously with a cDNA 
encoding an AP-E3C1 fusion protein than in mice injected with a cDNA encoding AP alone.  
In addition to AP protein, the E3C1 sequence of Del1 can immobilize several proteins, 
including yellow fluorescent protein (YFP) (Fig. 6). Therefore, the E3C1 sequence should be 
a powerful tool for targeting therapeutic proteins to target tissues and thereby increasing the 
efficacy and decreasing side-effects.  
 
 
a COS-7 cells were transfected with cDNA encoding YFP fused with E3C1. After 48 h, cells were 
removed with EDTA and observed by fluorescence microscope. Bar, 10 μm. Specific staining of the 
ECM was observed. b. Fluorescence intensity in the ECM. Values were corrected by the fluorescence 
from unconditioned ECM. Values were normalized to the fluorescence from cells expressing cDNA 
encoding YFP alone. Results represent mean ± SEM (n=6). The data indicate that E3C1 can immobilize 
YFP protein in ECM. 
Fig. 6. YFP-E3C1 fusion stains the ECM 
To examine whether the E3C1 domain interferes with the function of fused enzymes, we 
fused it to 3α-hydorxysteroid dehydrogenase and expressed it in the prostatic cancer-
derived, androgen-dependent cell line LNCap (Hidai et al., 2009). The 3α-hydorxysteroid 
dehydrogenase-E3C1 fusion protein was localized in the ECM and metabolized 
dihydrotestosterone in the medium, inhibiting cell growth. Thus, the E3C1 domain can 
target proteins to the ECM without interfering with their function. 
2.4 Potential of a FasL-E3C1 fusion protein in cancer gene therapy 
We next considered fusing the E3C1 domain to FasL, a cytotoxic protein that has been 
studied for cancer gene therapy. A FasL-E3C1 fusion protein was deposited and 
concentrated in the ECM and enhanced the efficiency of subsequent transfections with the 
same plasmid (Fig. 7). 
SCCKN oral squamous cell carcinoma cells (Urade et al., 1992) were transfected with a non-
viral vector encoding a FasL-E3C1 fusion protein or encoding FasL alone (control). Three 
days later, the cells were transfected with a cDNA encoding AP. E3C1 was expected to 
target FasL to the ECM, increase cytotoxicity, and increase the efficiency of the secondary 
transfection with AP. 
 




Fig. 7. Scheme describing repetitive gene therapy using a FasL-E3C1 fusion protein.  
2.4.1 The E3C1 sequence of Del1 targets FasL to the ECM 
2.4.1.1 Materials and methods 
Cell culture 
CHO cells were purchased from ATCC and grown in α-minimum essential medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen). The 
human oral squamous cell carcinoma cell line, SCCKN, a gift from Dr. Hayashido, 
Hiroshima university, was grown in RD medium (45% Dulbecco's modified Eagle's medium 
[Invitrogen], 45% RPMI 1640 medium (Invitrogen), and 10% fetal bovine serum. Cells were 
cultured in 5% CO2 at 37°C. 
DNA constructs 
Mouse FasL cDNA was a gift of Dr. Tagawa, Chiba cancer center. Mouse Del1 cDNA in 
pcDNA3 (Invitrogen, Carlsbad, CA) was a gift from Dr. Quertermous, Stanford university. 
First, a cDNA fragment encoding the mouse FasL gene was amplified by reverse 
transcriptase-PCR using the forward primer 5’- 
TACCGAGCTCGGATCCATGCAGCAGCCCATGAATTAC and the reverse primer 5’- 
GGCACTGTGCTGGATATCAAGCTTATACAAGCCGAA and then cloned into pcDNA3D 
(Invitrogen), resulting in pFasL. Next, a fragment encoding the E3 and D1 sequence (E3D1, 
amino acids 122–316 of mouse Del1) was amplified with the forward primer 5’-
TGTGAAGCTGAGCCTTGCAGAATGGCCGGA and the reverse primer 5’- 
ACAGCCTGAGAGCTCACAGCCAAGAAGTT and cloned into the 3’-end of the FasL gene 
in pFasL, resulting in pFasL-E3D1. The recombinant proteins expressed by these constructs 
also had a V5 epitope tag at their C-terminal ends. 
Immunoblotting 
Immunoblotting was used to determine whether E3C1 can target FasL protein to the ECM. 
CHO cells were used for the experiment because they are more efficiently transfected than 
SCCKN cells. CHO cells was cultured in 60-mm tissue culture plates and transfected with 
pFasL-E3D1, pFasL, or a empty vector using jet-PEI (PolyPlus-transfection; San Marcos, 
CA). Six hours later, the medium was replaced with 3 ml of fresh medium. After 72 h, cells 
were harvested by incubation with 10 mM EDTA and then solubilized with SDS-sample 
buffer. Next, the remaining ECM was fixed with 1 ml of 10% trichloroacetic acid in PBS 
(Wako, Osaka, Japan) and harvested with a cell scraper. One-fourth of the protein from the 
samples was analyzed by SDS-polyacrylamide gel electrophoresis, after which protein was 
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transferred to a poluvinylidene difluoride membrane (ATTO, Tokyo, Japan). After blocking 
and incubation with anti-V5 antibody (Invitrogen), anti-laminin antibody (Sigma, Saint 
Louis, MO), or anti-tubulin antibody (Oncogene, San Diego, CA), and HRP conjugated 
secondary antibody (Cell signaling technology, Denvers, MA). an ECL advance western 
blotting detection kit (Amersham, Piscataway, NJ) was used to detect immunoreactive 
protein. 
2.4.1.2 Results 
Immunoblotting of cell lysate showed that the recombinant FasL and FasL-E3C1 fusion 
proteins had the expected sizes (Fig. 8a). Immunoblotting of conditioned ECM remaining 
after cell removal showed that FasL-E3C1 fusion protein but not FasL was present in the 
ECM (Fig. 8b). 
 
 
Fig. 8. Immunoblotting 
Immunoblotting of cell lysate (a) and ECM (b) from CHO cells transfected with empty 
vector, pFasL, or pFasL-E3C1. Immunoblotting for tubulin and laminin was used to confirm 
equal loading. 
2.4.2 The E3C1 fragment of Del1 improved the effects of FasL 
2.4.2.1 Materials and methods 
Induction of apoptosis by FasL fusion proteins 
SCCKN cells were plated on a 24-weel plate at 30% confluency. After 1 or 4 days, cells were 
transfected with an empty vector, pFasL, or pFasL-E3C1. Cells were co-transfected with 
pAP-tag4 (GenHunter, Nashville, TN) as a control for transfection efficiency. After 48 h, cell 
death was analyzed by measuring lactate dehydrogenase (LDH) in the cell medium using a 
LDH cytotoxicity detection kit (Takara) according to the manufacturer’s protocol (Decker 
and Lohmann-Matthes, 1988; Legrand et al., 1992). Percent cell death was calculated as 100% 
x [(LDH activity for the test condition – LDH activity for the negative control)/LDH activity 
in cells treated with 1% Triton X-100 (positive control)]. LDH activity was normalized to the 
heat stable AP activity, which was measured as follows. Conditioned medium (20 μl/well) 
was added to a 96-well plate, heated at 65ºC for 30 min to inactivate endogenous AP 
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activity, and mixed with 200 μl/well of 1 mg/ml p-nitrophenyl phosphate (Sigma, St Louis, 
MO) in 1 mM MgCl2 and 1 M diethanolamine, pH 9.8. The absorbance at 405 nm was 
measured after 30 to 60 min. 
2.4.2.2 Results 
In a first set of experiments, cells were transfected with plasmids 1 day after plating (Fig. 9a). 
In this experiment, expression of the FasL-E3C1 fusion protein was as cytotoxic as FasL. 
Because the deposition activity of Del1 varies between cells, possibly because of the 
composition and amount of ECM, we repeated the experiment with transfection 4 days after 
plating to allow them to produce sufficient ECM (Fig. 9b). Under these conditions, transfection 
with pFasL-E3C1 was twice as effective as transfection with pFasL at inducing cell death. 
 
 
Fig. 9. Effect of E3C1 on the cytotoxicity of FasL 
KN cells were transfected 1 (a) or 4 (b) days after plating with an empty vector, pFasL, or 
pFasL-E3C1. Results represent means ± SEM (n=8). N.S., not significant. Asterisk, P<0.01. 
2.4.3 The E3C1 fragment of Del1 enhances the efficiency of a following transfection 
2.4.3.1 Materials and methods 
Evaluation of the effects of FasL-E3C1 on the efficiency of a second gene transfer 
SCCKN cells were cultured at 30% confluency in 96-well plates for 4 days. The cells were 
transfected with 1 μg of pFasL, pFasL-E3C1, or empty vector (negative control) using jet-
PEI. After the cells were cultured for 72 h, the cells that survived the first transfection were 
transfected with pAPtag-4. Next, the cells were cultured for 24 h before analysis. The AP 
activity in medium was measured as described above. To count the number of cells, cells 
were harvested with trypsin EDTA, stained with Trypan blue, and counted using a counting 
chamber. The AP activity was calculated as the total AP activity in medium/cell numbers. 
2.4.3.2 Results 
The efficiency of the second transfection was evaluated by measuring the secreted AP 
activity per cells (Fig. 10). Efficiency increased in the following order: empty vector < pFasL 
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Louis, MO), or anti-tubulin antibody (Oncogene, San Diego, CA), and HRP conjugated 
secondary antibody (Cell signaling technology, Denvers, MA). an ECL advance western 
blotting detection kit (Amersham, Piscataway, NJ) was used to detect immunoreactive 
protein. 
2.4.1.2 Results 
Immunoblotting of cell lysate showed that the recombinant FasL and FasL-E3C1 fusion 
proteins had the expected sizes (Fig. 8a). Immunoblotting of conditioned ECM remaining 
after cell removal showed that FasL-E3C1 fusion protein but not FasL was present in the 
ECM (Fig. 8b). 
 
 
Fig. 8. Immunoblotting 
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vector, pFasL, or pFasL-E3C1. Immunoblotting for tubulin and laminin was used to confirm 
equal loading. 
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< pFasL-E3C1. Because cells transfected with empty vector during the first transfection were 
cultured for 8 days without significant cell death, they may have been too dense to allow for 
an efficient second transfection, which could explain the higher efficiency of secondary 
transfection in the pFasL-transfected cells than in the control cells. 
 
 
Fig. 10. Effect of E3C1 on secondary transfection with AP 
Results represent mean ± SEM (n=8). N.S., not significant. Asterisk, P<0.01. 
2.5 Discussion 
Expression of Del1 is cell- and tissue-specific. As some reports suggest that Del1 promotes 
angiogenesis, whereas other reports suggest that it inhibits it, Del1 may be bifunctional. 
Furthermore, the E3 and C1 domains of Del1 have distinct functions and can act on a variety 
of cells, and they might be useful as fusion partners to enhance gene therapy using FasL or 
other proteins. 
Neck and esophageal cancer can cause obstruction. Although they can be treated using 
radiation therapy, its use is limited by the total dosage. As an alternative treatment, we 
designed a fusion protein of FasL and E3C1 to allow multiple rounds of cancer gene therapy 
with non-viral vectors. Further study of this fusion protein in the treatment of cancer needs 
is warranted and should be explored in vivo using an explanted tumor model. 
3. Conclusion 
The E3C1 fragment of Del1 can substantially improve the efficiency of cancer gene therapy 
using FasL. 
4. Acknowledgment 
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1. Introduction 
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor β 
superfamily and have the unique ability to control the differentiation of mesenchymal stem 
cells into osteoblastic cells [1]. Bone morphogenetic protein-2 (BMP-2), an osteoinductive 
member of the BMP family, plays an important role in bone growth and regeneration [2], 
and the clinical applications of recombinant human BMP-2 (rhBMP-2) are being investigated 
[3,4]. However, a large quantity of the recombinant protein and carrier are necessary, and 
the carriers often have problems with antigenicity, biocompatibility, biodegradability, and 
infection. An alternative, more efficient approach, gene transfer, may be able to target 
specific cells with specific promoters, and appropriate vectors to attain sustained gene 
expression. BMP-2 gene transfer with adenovirus have been investigated extensively [5-7]. 
Although the adenovirus vector is very efficient, potential toxicity and immunogenicity may 
limit its clinical application [8]. Furthermore, its therapeutic application would require 
efficient and reliable manufacture of viral vectors that are free of helper viruses and a 
reduction in immunogenicity. On the other hand, nonviral methods are safe and do not 
require immunosuppression for successful gene delivery, but suffer from lower transfection 
efficiencies. DNA injection followed by application of electric fields (electroporation) has 
been more effective for introducing DNA into muscle tissue than the use of simple 
intramuscler DNA injection [9]. Although this method should have the highest potential for 
clinical application, there is a concern that the electric pulse causes tissue damage. In 
addition, this method requires special equipment, and optimization of the parameters is 
necessary. Recently, ultrasound-enhanced gene transfer (sonoporation) has been 
investigated [10]. We recently reported osteoinduction by microbubble enhanced 
transcutaneous sonoporation of BMP-2 plasmid DNA [11]. Although this method seems to 
be safer than electroporation, it also requires special equipment and it is necessary to 
optimize the parameter of ultrasound. In this chapter, we report the human BMP-2 gene 
transfer using an ultra-fine needle and describe the feasibility of BMP-2 gene therapy using 
this new apparatus.  
2. Materials and methods 
To obtain human BMP-2 cDNA, a polymerase chain reaction (PCR) was performed using a 
pUC BMP-2 plasmid [12] and the following primers: 5’-AGA GAG AG GAATTC G TCG 
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1. Introduction 
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor β 
superfamily and have the unique ability to control the differentiation of mesenchymal stem 
cells into osteoblastic cells [1]. Bone morphogenetic protein-2 (BMP-2), an osteoinductive 
member of the BMP family, plays an important role in bone growth and regeneration [2], 
and the clinical applications of recombinant human BMP-2 (rhBMP-2) are being investigated 
[3,4]. However, a large quantity of the recombinant protein and carrier are necessary, and 
the carriers often have problems with antigenicity, biocompatibility, biodegradability, and 
infection. An alternative, more efficient approach, gene transfer, may be able to target 
specific cells with specific promoters, and appropriate vectors to attain sustained gene 
expression. BMP-2 gene transfer with adenovirus have been investigated extensively [5-7]. 
Although the adenovirus vector is very efficient, potential toxicity and immunogenicity may 
limit its clinical application [8]. Furthermore, its therapeutic application would require 
efficient and reliable manufacture of viral vectors that are free of helper viruses and a 
reduction in immunogenicity. On the other hand, nonviral methods are safe and do not 
require immunosuppression for successful gene delivery, but suffer from lower transfection 
efficiencies. DNA injection followed by application of electric fields (electroporation) has 
been more effective for introducing DNA into muscle tissue than the use of simple 
intramuscler DNA injection [9]. Although this method should have the highest potential for 
clinical application, there is a concern that the electric pulse causes tissue damage. In 
addition, this method requires special equipment, and optimization of the parameters is 
necessary. Recently, ultrasound-enhanced gene transfer (sonoporation) has been 
investigated [10]. We recently reported osteoinduction by microbubble enhanced 
transcutaneous sonoporation of BMP-2 plasmid DNA [11]. Although this method seems to 
be safer than electroporation, it also requires special equipment and it is necessary to 
optimize the parameter of ultrasound. In this chapter, we report the human BMP-2 gene 
transfer using an ultra-fine needle and describe the feasibility of BMP-2 gene therapy using 
this new apparatus.  
2. Materials and methods 
To obtain human BMP-2 cDNA, a polymerase chain reaction (PCR) was performed using a 
pUC BMP-2 plasmid [12] and the following primers: 5’-AGA GAG AG GAATTC G TCG 
 
Targets in Gene Therapy 
 
160 
ACC ATG GTG GCC GGG ACC CGC T (ATG, initial codon) and human BMP-2 reverse 
primer, 5’-AGA GAG AG GAATTC CTA GCG ACA CCC ACA ACC CTC CAC AA (CTA, 
stop codon). Both primers had EcoRI recognition sites (italicized). The PCR protocol 
consisted of 25 cycles of 15 sec at 98ºC, 2 sec at 65ºC, and 30 sec at 74ºC with KOD DNA 
polymerase (Toyobo, Osaka, Japan). The PCR product was digested using EcoRI and ligated 
into the EcoRI-digested cloning site of the pCAGGS expression vector, which contains CAG 
(cytomegalovirus immediate-early enhancer/chicken β-actin hybrid) promoter [13], to yield 
pCAGGS-BMP-2. The 1197-bp insert sequence was confirmed by DNA sequencing. As a 
control, pCAGGS-lacZ, which causes the cytoplasmic expression of E.coli β-galactosidase 
[13], was used. The plasmid vectors were grown in Escherichia coli DH5α and prepared 
with a Qiagen Plasmid Giga Kit (Qiagen GmbH, Hilden, Germany) according to the 
manufacturer’s protocol. To verify the identity and purity of the plasmid vectors, agarose-
gel electrophoresis was performed after restriction endonuclease digestion. The plasmid 
DNA concentration was determined using a UV/visible spectrophotometer (DU-530, 
Beckman, Fullerton, CA). 
To determine the effect of the ultra-fine needle transfection on mammalian cells, C3H10T1/2 
(passage 9-10), a mouse fibroblastic cell line, was obtained from RIKEN Cell Bank (Tsukuba, 
Japan). The cells were maintained in DMEM supplemented with 10% fetal bovine serum 
and penicillin, streptomycin and ampicillin (PSA). The cell cultures were grown at 37C in a 
humidified atmosphere of 95% air-5% CO2. Once confluent, the cells were reseeded into 35-
mm glass bottom dishes and incubated 24 hours. Then the medium is replaced with Hank’s 
balanced salt solution (HBSS) supplemented with the plasmid DNA (0.1, 0.2, and 0.3 
mg/ml) to be delivered. The cells cultured on a dish were set on a stage and pierced the 
plasma membrane with the apparatus.  
In the present study, we used the ultra-fine needle transfection apparatus SU100 (Olympus, 
Tokyo, JAPAN) attached to an inverted confocal microscope (IX81, Olympus, Tokyo, Japan). 
This apparatus was attached to an inverted microscope. A target cell was placed under the 
needle by the x-y stage controller. To pierce the cell membrane, the needle was lowered 
vertically by z-stage controller. The needle tip stayed inside the cell for one second. Then, 
cells were washed with fresh culture medium a few times, followed by incubation in a CO2. 
First, to optimize the amount of the plasmid DNA in the medium, the lacZ gene, which 
causes the cytoplasmic expression of E.coli β-galactosidase, was transferred using pCAGGS-
lacZ. As many as 100 cells were transfected under various concentration of the lacZ-
encoding plasmid. On day 2 after transfection, the cells were fixed for 5 min in 2% 
formaldehyde and 0.2% glutaraldehyde in phosphate-buffered saline (PBS) at room 
temperature. They were subsequently washed with PBS and stained for 2 hours at 37ºC in 5-
Bromo-4chloro-3-indolyl-β-D-galactopyranoside (X-gal) staining solution containing 1 
mg/ml X-gal, 2 mM MgCl2, 5 mM K3Fe(CN)6 and 5 mM K4Fe(CN)6 ּ◌3H2O in PBS (pH 7.4). 
Experiments were performed in triplicate. Cells expressing β-galactosidase were counted 
and the results were presented as the mean and standard deviation Difference in the β-
galactosidase activity was assessed by analysis of variance.  
Next, BMP-2 gene transfer was performed using pCAGGS-BMP-2 and pCAGGS-LacZ as a 
control. The cells were harvested one day after transfection. RNA was isolated from the cells 
using a Qiagen RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany). Human BMP-2 mRNA 
and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) mRNA were detected by 
reverse transcription-polimerase chain reaction (RT-PCR) using the following primers: 
human BMP-2 forward, 5’-TCTGACTGACCGCGTTACTC-3’; human BMP-2 reverse, 5’-
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TCTCTGTTTCAGGGCCGAACA-3’ ; GAPDH forward, 5’-ACTCCACTCACGGCAAATTC-
3’; and GAPDH reverse, 5’-CCTTCCACAATGCCAAAGTT-3’. The human BMP-2 forward 
primer was designed to hybridize with the sequence immediately downstream of the 
transcriptional start site of the CAG promoter to ensure that the PCR products were not 
contaminated by plasmid DNA and genomic DNA. The PCR products were analyzed by 2% 
agarose gel electrophoresis to detect the 285-bp human BMP-2 mRNA and 682-bp GAPDH 
mRNA. In addition, to determine early osteoblastic differentiation, alkaline phosphatase 
(ALP) staining was performed using a Sigma diagnostic ALP kit (Sigma, St.Louis, MO) on 7 
days after transfection. Moreover, to confirm the terminal differentiation of osteoblast, von 
Kossa staining, which stains phosphates and the carbonates deposited in mineralized tissue, 
was performed on 21 days after transfection. For von Kossa staining, cells in dishes were 
fixed with 4% paraformaldehyde and were then soaked in 0.1M AgNO3 solution for 15 min. 
After exposure to ultraviolet light at least 5 min, the dishes were washed with PBS. 
3. Results 
On day 2 after lacZ gene transfer, we found that X-gal positive cells were present in all of 
the groups performed transfection (Figure 1). In 0.1 mg/ml group, transfection efficiency 
reached 40.2±22.4%. In addition, 0.2 mg/ml group, the transfection efficiency significantly 
enhanced (p<0.05 versus 0.1mg/ml group) and reached 71.2±16.8%. In 0.3mg/ml group, 
moreover, transfection efficiency significantly (p<0.01 versus 0.1mg/ml group) and reached 
100%. It was suggested that when 0.3 mg/ml of plasmid DNA was used, gene transfer was 
performed most efficiently. 
According to the results of lacZ gene transfer, we performed transfection with BMP-2-
encoding plasmid DNA at the concentration of 0.3 mg/ml. We detected human BMP-2 
mRNA expression by RT-PCR one day after transfection (Figure 2). On day 7 after 
transfection, ALP-positive cells were found (Figure 3). Furthermore, on day  21 after gene 
transfer, von Kossa positive areas were also found (Figure 4). 
4. Discussion 
We have demonstrated the transfer of the human BMP-2 gene to mouse fibroblastic cells by 
cell membrane perforation with an ultra-fine needle, and have shown that it caused the 
expression of human BMP-2 mRNA one day after transfection. On day 7 after transfection, 
we saw an increase in ALP activity. On day 21 after transfection, moreover, calcification was 
seen. It is known that rhBMP-2 can induce the differentiation of non-osteogenic cell lines 
into osteoblastic cells, indicating that the BMP-2 gene could be transfected into C3H10T1/2 
cells with an ultra-fine needle to induce the differentiation of fibroblast into osteoblast.  
Our previous studies demonstrated that implantation of rhBMP-2 with a carrier matrix [14], 
in vivo adenovirus-mediated gene transfer [15], and in vivo plasmid DNA-mediated gene 
transfer, such as electroporation [16], sonoporation [11], or repeat plasmid injection [17], 
could cause osteoinduction. However, the above techniques showed some limitations in 
practical usage. The purification of rhBMP-2 was laborious and expensive, and carrier 
matrices created problems with antigenicity, biocompatibility, biodegradability, and 
infection. In addition, surgical procedures were required in order to implant a carrier 
matrix. The direct delivery of human BMP-2 genes using adenoviral vectors caused an 
immune response that needed to be systemically or locally suppressed. Non-viral gene 
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transfer using naked plasmid DNA is a useful technique to reduce the side effect of gene 
therapy. However, the low transfection efficiency is a major obstacle to the clinical 
application. Numerous attempts have been made to overcome the relatively low 
transfection efficiency, including the application of electric pulses and / or ultrasonic 
devices. Although these techniques are efficient to some degree,  using a large amount of 
plasmid DNA is needed to enhanced the effect [11, 17]. In addition, direct injection of naked 
plasmid DNA into the animal or human body is associated with toxicity and 
immunogenicity [18]. However, this technique is also limited due to the low transfection 
efficiency. It is necessary to repeat the transfection procedure to raise the efficiency [11, 17].  
There are two general strategies in BMP-2 gene therapy: BMP-2-encoding vector is directly 
delivered to the body (in vivo) or genetically transduced cells by BMP-2-encoding vector are 
transplanted (ex vivo). In the case of the in vivo approach, it is difficult to control the specific 
cell population transduced genetically [19] and significant antibody response to the vector 
can be caused [20]. Concerning this issue, an ex vivo approach has the ability to overcome 
these problems. Previous studies showed that transfer of BMP-2-encoding vector into a 
mesenchymal cell line stimulated the osteogenic pathway via autocrine and paracrine 
mechanisms in vitro [21] and in vivo [22], and that cell mediated BMP-2 gene transfer using 
the stably transfected mesenchymal progenitor cell line C3H10T1/2 resulted in enhanced 
bone defect repair in a mice nonunion fracture model [23]. Another previous ex vivo gene 
transfer experiment suggested that neighbouring cells including periosteal cells and non-
transfected mesenchymal stem cells were affected by paracrine mechanisms, and BMP-2-
producing cells may themselves differentiate into osteoprogenitor cells in an autocrine 
activity [24]. In this study, we demonstrated efficient gene transfer without using chemical 
reagent and / or physical energy. This technique was simple to pierce the plasma membrane 
and resulted in extremely high efficiency, with the efficiency reaching to 100%. Thus, human 
BMP-2 gene transfer using an ultra-fine needle may be a feasible method for the ex vivo gene 
therapy of musculoskeletal disorders. However this technique is low-throughput. Future 
improvement of this apparatus in order to raise the throughput is indicated. In addition, 
injection of transfected cells is necessary and can cause damage to the target tissue. Injection 
of transfected cells with naked plasmid DNA into target tissue causes various degrees of 
damage and inflammatory reaction, depending on factors such as the needle size, the nature 
of solutions. One of the purposes for local growth factor application by gene delivery is 
production of growth factor at a defined site, thereby avoiding potentially negative effects 
on other organs and immune reactions. However, after direct injection, extensive spread of 
the vector DNA was observed. In the liver and in the spleen, reporter gene expression could 
be detected histochemically in several cells. In both of these organs as well as the lung, 
vector DNA was detected by nested PCR in all animals examined at 3 days and at 14 days 
after direct intraarticular injection. This indicated a broad systemic distribution of viral 
particles. Nevertheless, it was reported that no external DNA could be detected in the lung, 
the liver, or the spleen of most animals that have received cells infected ex vivo [20]. 
Our results suggest that BMP-2 gene transfer using an ultra-fine needle may allow gene 
delivery to be used for bone regeneration. The response to the procedure could be 
monitored with clinical examinations (e.g., X-ray). These findings showed that transfection 
using an ultra-fine needle with BMP-2-encoding plasmid caused the expression of the 
human BMP-2 gene in transfected cells, which demonstrated a feasibility of initiating the 
cascade of events to enhance  bone induction. This study has suggested the possibility of the 
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clinical application of gene therapy using an ultra-fine needle. Furthermore, the clinical 


















Fig. 1. Beta-galactosidase expression in C3H10T1/2 cells using an ultra-fine needle 
apparatus. X-gal staining was performed two days after transfection. Blue-stained cells were 
counted to examine the transfection efficiency and the maximum efficiency reached to 100%. 
Scale bar: 250 μm. 
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Fig. 1. Beta-galactosidase expression in C3H10T1/2 cells using an ultra-fine needle 
apparatus. X-gal staining was performed two days after transfection. Blue-stained cells were 
counted to examine the transfection efficiency and the maximum efficiency reached to 100%. 
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Fig. 2. Expression of the human BMP-2 transgene following the ultra-fine needle transfection 









Fig. 3. ALP activity was observed in the region of the transfected cells. ALP staining was 
performed 7days after transfection. Skale bar: 100 μm 
 




Fig. 4. Von Kossa staining was performed 21 days after transfection. Calcium deposition was 
confirmed in the region of the transfected cells.  Skale ber: 100μm 
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1. Introduction 
Cancer is one of the most lethal diseases in the world. Traditional methods for cancer 
treatment are surgery, chemotherapy and radiotherapy. Early stage cancer patients may be 
cured by radical surgery and (or) chem(radio-)therapy. However, advanced cancer patients 
usually suffer from chem(radio-)resistance or metastasis, most of which can not be 
controlled by current therapy. Furthermore, traditional chem(radio-)therapy will bring 
patients with severe side effects as they not only kill cancer cells, but also normal cells.  
Many investigators believe the potential to make great progress in cancer treatment lies in 
understanding the molecular biology of cancer and exploiting effective agents targeting 
abnormal molecules which regulate the growth and metastasis of tumor (Ku and Ilson, 
2010). This is called targeting therapy, which can selectively kill cancer cells with minor side 
effects. Effective targeting therapy lies on good targets chosen and the methods used to 
deliver targets into the tumor mass safely and efficiently. During the past decades, various 
important tumor targets were exploited. 
2. Targeting tumors by dysfunctional pathways 
Overexpression of receptors and the abnormal activation of intracellular kinase mutations, 
resulting downstream of signaling pathways enhanced, leading to cell transformation, 
proliferation, resistance to apoptosis and eventually promote tumorigenesis. Therefore, 
signaling pathway has become a potential therapeutic target for cancer. 
2.1 Targeting the EGFR signaling pathway 
EGFR pathway mediates many important physiological processes in both normal and 
cancerous cells. Because of the function of the EGFR pathway, a number of therapeutic 
agents have been developed aiming to target EGFR. To date, five EGFR-targeted agents 
have been approved by the FDA for treating cancer patients. Erlotinib (OSI-774, Tarceva) 
was approved to treat metastatic non-small cell lung cancer (NSCLC) as single agent and to 
be used in combination with gemcitabine for pancreatic cancer. Another small molecule 
EGFR kinase inhibitor, Gefitinib (ZD1839, Iressa), is being used for locally advanced and 
metastatic NSCLC (Lo). Lapatinib (GW572016, Tykerb/Tyverb) is an EGFR/HER2-dual 
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targeting small molecule inhibitor, it used in combination with other drugs, for patients 
with advanced or metastatic breast cancer whose cancer is HER2 positive and has failed to 
respond to other drugs (Moy et al., 2007).  
2.2 Targeting the NF-κB pathway  
Many cancer cells show aberrant or constitutive NF-κB activation which mediates resistance 
to chemo- and radio-therapy. Based on the pivotal role of the NF-κB pathway in the tumor 
progression, the NF-κB signaling pathway has become a potential target for 
pharmacological intervention. Strategies for blocking NF-κB include a NF-κB targeting 
strategy and an upstream strategy. The NF-κB targeting strategy involves blocking the 
activation of NF-κB signaling pathway, includes: (a) glucocorticoids used to block the 
transactivation of NF-κB (D'Acquisto et al., 1998). (b) decoy oligodeoxynucleotides (ODNs) 
used to block the DNA binding of NF-κB (Karin et al., 2004). On the other hand, the 
upstream strategy includes: (a) IKK inhibitors NSAIDs, sulfasalazine, arsenic trioxide, 
curcumin, thalidomide; (b) proteasome inhibitors PS-341, MG132; (c) the recombinant 
adenovirus-mediated overexpression of the IκBα gene. (d) cell-permeable peptides SN-50; 
(e) antioxidants disulram, glutathione (Chen et al., 2002; Tomita et al., 2003). 
2.3 Targeting the PTEN/PI3K/AKT signaling pathway  
PTEN/PI3K/AKT constitutes an important pathway regulating the signaling of cell 
proliferation, survival, apoptosis, and metabolism. Many components of this pathway have 
been described as causal forces in cancer. Once the activity of mTOR induced by disfunction 
of PTEN/PI3K/AKT pathway, the promotion of tumor proliferation and growth are 
achieved through its downstream targets. A number of basic research studies and clinical 
trials have investigated that rapamycin, the potential of the selective mTOR inhibitor could 
inhibit activity of both mTOR and AKT, suggesting that it may be an effective therapeutic 
blockade of PI3K signaling (Guertin and Sabatini, 2007). PI3K inhibitors, TGX115, LY294002 
derivatives have shown to have greater solubility, lower toxicity, improved 
pharmacodynamics, and more specific PI3K selectivity than LY294002 (Granville et al., 
2006). In addition, PX-866a, wortmannin derivative has more potent and less toxic effects 
than wortmannin (Jiang and Liu, 2008). SF1126 is a small molecule inhibitor that can inhibit 
all isoforms of PI3K class. In preclinical studies, it has been identified to be effective for 
tumor treatment in a variety of mouse tumor models, including prostate, breast, lung, 
multiple myeloma, and other cancers (Hennessy et al., 2005). Lipid-based inhibitors of Akt 
were the first group of inhibitors to be developed. Perifosine is the best-characterized Akt 
inhibitor, which inhibits the translocation of Akt to the cell membrane. It can inhibit the cell 
growth in different solid tumors (Martelli et al., 2003). Several other Akt inhibitors such as 
the indazole-pyri-dine A-443654 and 9-methoxy-2-methylellipticinium acetate (API-59-OMe) 
have been identified. A-443654 was shown to increase the effect of paclitaxel treatment both 
in vitro and in vivo (Han et al., 2007). API-59-OMe can inhibit cell growth and induce 
apoptosis of several different human cancer cells, including prostate, breast, endometrial 
and ovarian cancers (Jin et al., 2004; Tang et al., 2006). 
2.4 Targeting the MAPK signaling pathway  
The RAS–mitogen activated protein kinase (MAPK) signaling pathway not only promotes 
cell proliferation, but also mediates cell survival. The activity of this pathway was reported 
to be upregulated in a broad spectrum of human tumors. In this signalling pathway, RAS, 
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RAF and MEK proteins have unique features that make it a good therapeutic target. By 
inhibiting the post-translational addition of farnesyl group to RAS by farnesyltransferase, it 
was thought that Farnesyltransferase inhibitors (FTIs)would be able to target human tumors 
in which RAS was constitutively activated (Sebolt-Leopold and Herrera, 2004). Several FTIs 
such as BMS-214662, Sarasar and Zarnestra have been studied in patients diagnosed with a 
range of cancers. FTIs could be specific and effective therapeutic agents, however, clinical 
data obtained so far leads us to conclude that these agents do not represent a viable 
approach to blocking signal transduction through the RAS–MAPK pathway. Therefore, 
several small molecule RAF inhibitors have now been reported. According to published 
reports, only BAY 43-9006 has reached the clinical testing stage. It has completed Phase I 
and Phase II trials. It has been reported that this agent is generally well tolerated. However, 
the toxicities involving the gastrointestinal track and the skin have existed. Phase III trials to 
be focusing on patients with renal-cell carcinoma indicated that BAY 43-9006 lack of 
specificity. So, although BAY 43-9006 has promise as an anticancer agent, it is difficult to 
assess the impact of RAF inhibition on observed clinical outcomes. The first MEK inhibitor 
reported to inhibit tumor growth in vivo was CI-1040 (Sebolt-Leopold et al., 1999). There was 
evidence of antitumor activity in the Phase I trial, however, similar results were not 
observed in Phase II trials, so PD0325901, which is structurally highly similar to CI-1040, 
was subsequently developed. The anticancer activity of PD0325901 was improved compared 
with CI-1040. The longer duration and greater solubility leading to improved bioavailability, 
and increased metabolic stability. Therefore, PD0325901 viewed as a significantly more 
potent MEK inhibitor (Sebolt-Leopold and Herrera, 2004).  
 
 
Fig. 1. Targeting the PTEN/PI3K/AKT and MAPK signaling pathway 
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3. Targeting tumors with tumor suppress gene p53 
Clinical studies have shown that p53 is a tumor suppressor which mutates in about 50% of 
human cancers, and where the gene itself is not mutated, its signal pathway functionally 
inactivated. Three decades of researches in p53 have reached an understanding of p53 
playing a key role in the regulations of many different genes in response to a wide variety of 
epigenetic stresses.  
3.1 Regulation of p53 expression 
In normal cells, p53 restrains its expression and function to maintain normal homeostasis. 
Critical for the control of p53 function are its two main negative regulators: Mdm2 and 
Mdmx. Duplicated from a single ancestral gene, Mdm2 and Mdmx have similar sequences. 
They bind to p53 via an N-terminal hydrophobic pocket, thus inhibiting transactivation 
function of p53 (Kruse and Gu, 2009). The C-terminal of both Mdm2 and Mdmx contain a 
RING domain which has intrinsic E3 ubiquitin ligase activity and it targets p53 for 
ubiquitin-dependent degradation by proteasome both in nucleus and cytoplasm (Deshaies 
and Joazeiro, 2009). Mdm2 and Mdmx also induce the exportation of p53 from the nucleus 
to the cytoplasm. Thus, these two proteins negatively regulate p53 by both suppression of 
transactivation and post-translational destabilization.  
 
 
Fig. 2. Targeting tumors with tumor suppress gene p53 
3.2 Conformation of p53 
The p53 protein contains three main functional domains: N-terminal harbors transcriptional 
activation domain 1 (TAD1, residues 20-40), TAD2 (residues 40-60) which interacts with 
Mdm2 and Mdmx, and the proline domain (PP, residues 60-90); in the middle lies the 
central core sequence-specific DNA-binding domain (DAD, residues 100-300), it interacts 
with its target genes or proteins; and C-terminal contains the tetramerization domain (Tet, 
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residues 325-356) and lysine-rich basic C-terminal domain (++, residues 363-393) which 
regulates DNA-binding. Interacts mainly with sequence-specific DNA binding sites of its 
target agents, p53 starts series of cellular responses: cell-cycle arrest, apoptosis, DNA-repair 
and so on. For example, Brn3A and Hzf with DAD, C-Abl with Tet, YB1 and p18/Hamlet 
with ++ selectively induce p53 activation of cell-cycle arrest genes like p21. Conversely, 
ASPPs with DAD and Brn3b, and so on with the p53 C-terminal selectively induce apoptotic 
genes like PUMA and Bax (Vousden and Prives, 2009). 
3.3 Function of p53 
Here comes to questions: When do cells perform cell-cycle arrest, and when do they bring 
about senescence and apoptosis? Some researches hypothesis that the outcome of p53 
activation mostly depends on the type of tissue and stress, how severe the stress is, the 
microenvironment, and the post-transcriptional modification. With mild impact to DNA, 
p53 may stabilize the genes, including DNA repair and activating anti-oxidant genes. As a 
result, p53 acts as a protector by preventing the generation of oncogenic lesions. Conversely, 
once severe stress happens, like oncogene activation, lethal DNA damage or hypoxia, p53 
may start senescence and apoptosis, eliminating badly injured cells which cannot be rescued 
by cell-cycle arrest (Vousden and Lu, 2002).  
3.4 Wild-type p53 in cancers 
In tumors which have wild-type p53 reduced, disturbing the interaction between p53 and 
Mdm2/Mdmx may rationally restore p53 function and may enhance sensitivity of tumors to 
chemotherapy and radiotherapy.  
Nutlins, a well studied inhibitor family of the Mdm2-p53 complex, are highly selective for 
Mdm2 and they can tightly bind to their receptors (Dickens et al.). In the Nutlin family there 
is Nutlin-3, it competes for binding to Mdm2, so displaces p53 protein and releases it to 
function normally in cancer cells derived from hematologic malignancies (Secchiero et al., 
2008). The molecular pathways in the Nutlin-3 induced responses still wait to be explored. 
A small molecular compound, RITA, induces wild-type p53 activation and accumulation 
thus programs apoptosis in different tumor cell lines of colon, lung, breast, etc both in vitro 
and in vivo. It prevents interaction between p53 and Mdm2 through binding to the 1-63 
residues of the p53 protein N-terminal (Issaeva et al., 2004).  
3.5 Mutant p53 in cancers 
A large-scale sequencing of various tumor cells proved that p53 mutations, mostly DNA 
binding domain mutations are common events.  
Small molecular compounds for mutant p53 reactivation via different mechanisms have 
been identified in recent years. CP-31398, stabilizes the conformation of DNA binding 
domain to restore the function of several p53 mutants. Foster. et al reported that CP-31398 
suppressed the growth of both human tumor cells in vitro and xenograft tumors in mice 
(Foster et al., 1999).  
Similar with CP-31398, PRIMA-1 also serves to suppress tumor cell growth by reactivating 
the transcriptional function of mutant p53 and inducing cofactors responsible in p53-
mediated apoptosis like PUMA, Noxa, and Bax, which induce caspase activation, especially 
caspase-2 (Bykov et al., 2002). Rescue tumor suppression function of p53 will pave the way 
for future anti-cancer therapy. 
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For the purpose of inducing p53 activities in a desirable way, a wide range of unknown 
fields from the p53 posttranscriptional modifications, cofactors to network of targeted 
agents wait to be fetched. 
4. Targeting tumors by anti-angiogenesis 
Cytotoxic approaches to killing tumor cells, based on their increased rate of proliferation 
relative to normal cells, have been the mainstay of cancer therapy for decades. However, 
over 30 years ago, as proposed by Folkman in 1971, angiogenesis is required for tumor, so 
targeting angiogenesis is a significant approach in inhibiting solid tumor growth and hence, 
limit cancer progression (Folkman, 1971).  
Angiogenesis is the formation of new blood vessels from pre-existing ones. The 
understanding of the angiogenic mechanisms and the successful use of several angiogenesis 
inhibitors in animal models, have led to clinical applications of anti-angiogenic therapy. This 
strategy has several advantages over traditional chemotherapy, in principle, including side 
effects and less toxicity, a reduced risk for development of resistance, and a general broad 
spectrum of activity. More important, anti-angiogenic approaches can efficiently target both 
low and high proliferating tumor cells, so unlike conventional cytotoxic chemotherapies that 
are more effective against fast growing tumors, anti-angiogenic therapy could act against a 
broader range of cancers. The expected results are different from traditional cancer 
therapies, the first aim of anti angiogenesis is to stabilize the disease rather than to eradicate 
the tumor mass, unlike radiotherapy or chemotherapy; however these strategy can be used 
in concert (Bisacchi et al., 2003). 
4.1 Potential anti-angiogenic factors for gene therapy 
Induction of the angiogenic switch depends on a local change in the balance between 
inhibitors and activators of angiogenesis. The switch to an angiogenic phenotype of tumor 
requires downregulation of angiogenesis inhibitors and upregulation of  angiogenic factors 
(Dell'Eva et al., 2002). Until now, many angiogenic peptides have been identified, including 
vascular endothelial growth factor (VEGF) and vascular permeability factor (VPF), basic and 
acidic fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet-derived 
epidermal cell growth factor (PD-ECGF), platelet-derived growth factor (PDGF), insulin-like 
growth factors (IGFs), interleukin-8 (IL-8),transforming growth factor-α and β (TGF-α and -
β), heparin growth factor, granulocyte colony stimulating factor, E-selectin, angiogenin, 
tumor necrosis factor-α (TNF-α). Angiogenic factors released by tumor cells stimulate 
endothelial cells (EC) which become activated, providing growth factors (FGF-1,-2) and 
matrix metalloproteinases (MMPs). Proteolytic activities of the MMPs degrade the 
surrounding tissue and vascular membrane, leading to EC proliferation, migration and new 
capillary formation. 
Thus, the goal of anti-angiogenic gene therapy is to switch the local balance between 
angiogenic factors and angiogenic inhibitors in tumor microenvironment to the anti-
angiogenic phenotype, targeting one or more events of angiogenesis cascade. The more 
attractive angiosuppressive factors for clinical trials are: naturally occurring inhibitors of 
angiogenesis, agents that interfere with vascular basement membrane and extracellular 
matrix MMP inhibitors, angiostatic steroids and others, anti-adhesion molecules antibodies 
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and miscelllaneous drugs that modulate angiogenesis by diverse mechanisms of action 
(O'Reilly et al., 1997).  
4.2 Clinical trials targeting tumor angiogenesis 
The greatest clinical success with the antiangiogenic strategy to date, has been achieved with 
bevacizumab, the antibody to VEGF. Bevacizumab blocks the binding of VEGF-A to its 
receptors, VEGFR-1 and VEGFR-2. In rectal cancer patients, this VEGF signaling inhibitor 
reduced tumor microvessel density, blood flow and interstitial pressure, and increased the 
percentage of vessels covered by pericytes (Willett et al., 2004). 
Endostatin is a 20-kDa proteolytic COOH-terminal fragment derived from collagen XVIII58. 
Endostatin reduces endothelial cell proliferation and migration, significantly reduces 
invasion of endothelial as well as tumor cells into the reconstituted basement membrane and 
acts as a potent inhibitor of angiogenesis and tumor growth. In preclinical studies, 
expression of endostatin decreased tumor vascularization 3-fold with a concomitant 3-fold 
increase in the number of apoptotic cells. Endostatin is the first endogenous angiogenesis 
inhibitor to enter clinical trials. The earliest phase Ⅰ trials were published in 2002 and 2003 
at The University of Texas M.D. Anderson Cancer Center. The final results show that the 
anti-angiogenic drug was safe and reduced blood flow in patients. There was some 
shrinkage of tumors among the participants, and two patients showed encouraging results 
(Thomas et al., 2003). A Chinese phase Ⅲ trial using recombinant endostatin in combination 
with chemotherapy in NSCLC has exhibited a significant increase in response rates and time 
to progression. Another potent angiogenesis inhibitor is angiostatin (38kDa), which is 
generated as a result of proteolytic cleavage of plasminogen and comprises the first four 
triple loop disulphide-linked structures of plasminogen, termed kringle domains (O'Reilly et 
al., 1994). Currently, phase II/III clinical trials of endostatin and angiostatin are ongoing, 
and preliminary data analysis show minimal toxicities but anti-tumor results are 
inconsistent.  
Now, more than 300 anti-angiogenic molecules targeting different signalling pathways and 
over 20 angiogenic growth factors are being tested for their potential anti-cancer efficacies at 
preclinical and clinical stages. Eight new drugs in which anti-angiogenic activity is 
considered to be central to their therapeutic effects have been approved by the FDA in the 
United States for the treatment of cancer (Table 1) (Park and Dilda).   
4.3 Perspectives 
Antiangiogenic methods have changed the landscape in traditional cancer therapy after the 
initial clinical success of bevacizumab in 2004. Future development of antiangiogenic drugs 
targeting various pathways with different principles, particularly in combination therapy 
settings, is expected to significantly improve therapeutic efficacies. One of the important 
approaches of increasing therapeutic efficacy is to optimize the drug delivery systems that 
enable accurate drug release only in malignant tissues, persistent release and tightly 
controlled release of antiangiogenic agents. Long-term delivery is particularly advantageous 
for clinical benefits as withdrawal of these drugs might cause a rebound angiogenic activity 
in tumors. However, persistent release of the same drug in cancer patients might elicit 
evasive refractoriness to antiangiogenic therapy. This dilemma may be resolved using a 
smart microchip delivery system that simultaneously or sequentially releases multiple drugs 
targeting different pathways. 
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Angiogenic inhibitor Target FDA approved for 
Avastin/bevacizumab 
(Genentech) VEGF 
Non-small cell lung carcinoma, 
metastatic colorectal cancer and 
breastcancer 
Cetuximab/Erbitux (Bristol-
Myers Squibb ImClone) 
EGFR 
 
Metastatic colorectal carcinoma and 
head and neck cancer 
Panitumumab/Vectibix 
(Amgen) EGFR 
Metastatic colorectal carcinoma 
 
Erlotinib/Tarceva (Genentech 
OSI  Roche) EGFR 














Advanced renal cell carcinoma and 
advanced hepatocellular carcinoma 
Table 1. Anti-angiogenic therapeutics FDA approved for the treatment of cancer. 
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5. Targeting tumors with monocloning antibody  
For several decades, antibodies has been hoped to become a ‘magic bullets’ to cure patients, 
and this vision came true with the development of hybridoma technology by Kohler and 
Milstein (Kohler and Milstein, 1975). The antibodies are Y-shaped proteins with two 
identical light chains and two identical heavy chains. The arms of the Y identify antigens, 
and the stem of Y alerts and recruits the components to attack the molecular targets once 
bounded.  
Present, more than 400 mAbs entered commercial clinical development and anticancer 
mAbs comprised almost half of the total mAbs (Reichert et al., 2005).  To date, a dozen of 
anticancer mAbs have been approved for marketing by FDA. There are two modes that 
mAbs destroy the target tumor cells, one is direct way by conjugating radioactive toxins or 
triggering apoptosis. Another is the indirect way through activating immune system 
components or blockade of critical receptors.  
The conjugated mAbs can increase the specificity of chemo- or radiation therapy. Drugs 
composed of the conjugate can be produced by chemical linkers, while the proteins can be 
produced by either chemosynthesis or genetic engineering. However, some challenges exist 
in the development of immunotoxins since the protein toxins can lead to immunogenic 
action in human and the drug toxins which may lack potency for the little doses degrade in 
the way to the tumor site. Another limitation is that immunotoxins require internalization to 
gain a cytotoxic effect on tumor cells. 
In the recent data, over half of the mAbs are unmodified mAbs. The characteristics like 
average half-life, vary with the isotype of the unmodified mAbs are determined to be the 
crystallizablefragment (Fc) region. A common mode of mAbs function is to activate the 
components of the human immune system attacking the target cancer cells. Once binding to  
target, mAbs can call up effector cells to activate the complement. These actions are known 
as antibody-dependent cell cytotoxicity (ADCC) and complement-dependent cytotoxicity 
(CDC), and they are mediated by the Fc portion of mAbs. 
5.1 Targets in solid tumors  
EGFR family includes EGFR(c-erbB-1), HER2/neu (c-erbB-2), HER3(c-erbB-3), and HER4 (c-
erbB-4). EGFR overexpressed in many solid tumors, such as non-small cell lung cancer, 
colorectal cancer, breast cancer, head and neck cancer, and prostate cancer. Some anti-EGFR 
mAbs can inhibit tumor cell growth and activate tyrosine kinases. Cetuximab, a chimeric 
form of anti-EGFR antibody can objective anti-tumor responses alone, or in combination 
with other treatment strategies for the overexpressing EGFR cancers. A second EGFR-
targeted mAbs, Panitumumab, was produced in a muse while the genes of antibody came 
from human (Mendez et al., 1997).  
bold (HER2/neu) is overexpressed in 25% of breast cancer cells, and in other 
adenocarcinomas of the ovary, lung, prostate and gastrointestinal tract (Baselga et al., 1996). 
Trastuzumab is a humanized mAb that derived from the murine mAb4D5, which combined 
with chemotherapy in the randomized phase 3 trial shows a 25% increase in survival after 
29 months than chemotherapy alone. It had also been shown activity in Trastuzumab 
combination with small- molecule drugs such as vinorelbine, docetaxel and paclitaxel.  
 Ep-CAM (epithelial cell adhesion molecule) is highly expressed in colorectal, non-small cell 
lung and prostatic cancer and so on. Edrecolomab, came from murine and transformed into 
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human chimeric construct, is a manual antibody for Ep-CAM. The clinical testing showed 
the chimeric construct increased mononuclear cell-mediated ADCC and prolonged half-life 
than the murine mAb. In addition, it develops no human anti-mouse antibodies (Hartung et 
al., 2005). 
5.2 Targets in lymphomas 
The mAb direct against human B cell lymphoma–associated antigen have shown enormous 
power on clearance circulating tumor cells with rare objective clinical responses. The 
mechanisms underlying responses to these mAb are complex and have not been completely 
elucidated now, while the main mechanisms could include ADCC and disturbance 
transductional signals. Another target, CD52, a glycopeptides exists on T and B 
lymphocytes, has been tested as a target for mAb in the treatment of numerous lymphomas 
which decreased the response from allogeneic transplant grafts.  
5.3 Toxicity of mAb 
mAb are paid more attention as the clinical tests were shown with less toxicity than the 
normal cytotoxic chemotherapy and radiotherapy. But cytotoxic always emergence through 
two ways, one is mechanism-dependent and the other is mechanism-independent. 
Mechanism-independent occur for the mAb proteins produced by the xenogeneic gene. The 
primary toxicity of mAbs is mechanism-dependent toxicity that exaggerated pharmacology 
of blocking or enhancing the activities of the target cells or tissues target molecule. Toxicity 
is also resulted from binding to the target in normal tissues other than cancer tissues alone. 
Treatment with cetuximab can cause the skin toxicity (acneiform rash) and the cardiotoxicity 
observed with trastuzumab due to skin and cardiac muscle respectively expressing the same 
target antigens.  
 
 
Fig. 4. Targets in solid tumors and lymphomas 
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5.4 Further exploration 
Nowadays mAbs have achieved significantly success compared with the disappointment of 
failure in decades ago. Despite these accomplishments, the clinical response remains, such 
as the toxicity on the normal cells. Regardless of these challenges, each new anticancer mAb 
approved represents more choice and potential benefit to patients. With the development of 
biotechnology, the efficient and safe mAb for cancer patients may be produced. “We have a 
long way to go before the story is finished,” says Winter (Gura, 2002). 
6. Viral vector for gene delivery 
Cancer is a multigenic disorder involving activation of oncogenes and inactivation of 
suppressor genes. Many data has suggested that cancer can be arrested or reversed by 
treatment with gene transfer vectors that carrying therapeutic genes. The vectors used for 
gene therapy include viral or non-viral vectors. Viruses have been the most common vectors 
for gene therapy and about 70% of gene therapy clinical trials use viral vectors. The main 
viral vectors used in clinic include retroviruses, adenovirus, adeno-associated virus, 
herpesvirus and poxvirus.  
Retrovirus is an enveloped RNA virus. The genome of retrovirus contains two identical 
single-stranded RNAs about 7-10 kb. There are three open reading frames, gap, pol and env, 
and two long terminal repeats (LTRs) in retroviral genome (Baum et al., 2006). Replication-
defective retroviral vectors (RDR) lack genes required for self-replication and the capability 
of cell-to-cell spreading. RDR vectors have used to deliver therapeutic genes into 
immunodeciency disease. Replication-competent retrovirus (RCR) vectors can duplicate in 
dividing cells and result cell lysis. Retrovirus may randomly integrate to host genome and 
results insertional mutagenesis. Many methods has been explored to improve the safety of 
RCR vectors, such as using tissue-specic regulatory sequences replace the viral promoter 
elements; using inducible regulatory sequences to control transcription.  
Lentivirus is a kind of slow viruses of the Retroviridae family. In contrast with simple 
retrovirus, lentivirus has evolved the ability to infect nondividing cells (Cockrell and Kafri, 
2007). Recently, the inducible tet-on/off lentivirus expression system has been structured by 
researchers. Using this system, researchers can control gene expression, so this system is a 
powerful tool to research transgene expression.  
Adenovirus is a linear, double-stranded and non-enveloped DNA virus. The genome of 
adenovirus is about 36 kb. Over 50 serotypes of human Adenovirus have been identified, 
among which Ad5 is the most commonly used vector. Unlike the retrovirus, adenovirus 
genomes do not integrate into the host chromosome, so it is a safe vector for transient 
transgene expression. Replication-defective adenoviruses have been used to transfer tumor-
suppressor genes, anti-angiogenesis genes, immunostimulatory genes, prodrug-activating 
genes. In 2004, replication-deficient recombinant adenovirus (Ad)-p53 was approved to use 
for head and neck squamous cell carcinoma (HNSCC) by China’s State Food and Drug 
Administration. In china another cancer gene therapy agentia Ad-endostatin (E10A) has 
been finished the classⅠ clinical trial for solid cancers and no dose-limiting toxicity was 
developed (Lin et al., 2007).  
Adeno-Associated Virus (AAV) is a small, nonenveloped DNA virus. Its genome is a linear 
single-stranded DNA of 4.7 kb. AAV produces infection only in the presence of adenovirus 
or herpesvirus. In the absence of helper virus, AAV can set up latency by integrating into 
chromosome 19q13.4 (Lai et al., 2002). AAV vectors have successfully delivered targeting 
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genes into varieties of dividing and quiescent cells, including in the muscle, liver, lung, 
brain, eye, retina and heart. The therapeutic genes that AAV vectors contain are no more 
than 5kb. Researchers invent a new AAV vectors system which uses head-to-tail 
heterodimers of the two rAAV vectors form via recombination in the ITRs, which can 
improves the packaging capacity of AAV vectors to 10 kb. This vector has been successfully 
used for gene expression in the retina, lung and muscle diseases. 
Herpes Simplex Virus (HSV) is double-strand DNA virus. HSV-1 is the common vector in 
gene therapy. The genome of HSV includes long and short unique regions, each anked by 
inverted repeats. The neurotropic ability of HSV makes this vector for the design of gene 
therapies that target cancers of the CNS (Shen and Nemunaitis, 2006). The replication-
defective HSV vector lacks one or several essential immediate-early (IE) genes. Some 
researchers have used replication-defective HSV vector with suicide genes, such as 
thymidine kinase (TK) gene or cytosine deaminase (CD), treat CNS malignant tumors. 
Conditionally replicating HSV vector delete some genes for virus replication, but this vector 
can duplicate in cancer cells where it gains the enzymes of replication. This vector is an 
oncolytic HSV vector and has widely used to treat the squamous cancers in head and neck, 
malignant glioma, colorectal cancer, pancreatic cancer and prostate cancer.      
Poxvirus is a kind of complex DNA virus. The genome is linear double-stranded DNA and 
the size of the different poxvirus species is variable from 130kb to 160kb. The dsDNA 
molecule contains the open reading frame (ORF) and the inverted terminal repeats (ITRs) in 
the terminal regions of the genome (Lefkowitz et al., 2006). Poxvirus as a transgene vector 
with tumor-associated antigens or tumor-specific antigens has been used in cancer therapy, 
which can improve hose anti-cancer ability. 
7. Nonviral vector for gene delivery 
During the past two decades, gene therapy has gained rapid development as a promising 
therapeutic modality for the treatment of genetic and acquired disorders (Al-Dosari and 
Gao, 2009). However, the rate-limiting step is lack of a suitable vector for gene delivery. 
Although viral vectors are attractive in initial research due to its high efficiency, nonviral 
gene-delivery carriers have gained increasing attention in recent years because their safety 
and easy preparation advantages over viral vectors. 
Nonviral vectors for gene therapy have been categorized as expression vector and delivery 
vector. Among the nonviral vectors, the most widely used expression vector is plasmid 
DNA. Methods of nonviral gene delivery contained direct injection of naked plasmid DNA, 
physical and chemical approaches (Gao et al., 2007). Physical approaches employing 
mechanical (particle bombardment or gene gun), electric (electroporation), ultrasonic, or 
hydrodynamic (hydrodynamic gene transfer) have been explored in recent years. Chemical 
methods mediate gene uptake by membrane fusion and/or receptor-mediated endocytosis. 
Chemical vectors such as cationic lipids and cationic polymers form condense complexes 
with negatively charged DNA through electrostatic interactions (Al-Dosari and Gao, 2009; 
Ohlfest et al., 2005).   
7.1 Nonviral therapeutics in clinical trials 
Although adenoviral- and retroviral-mediated transfections are currently the most widely 
used strategies for gene therapy in clinical trials, there are more than 400 clinical trials using 
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nonviral vectors so far (www.wiley.co.uk/genmed/clinical). Lipid and polymer-mediated 
gene delivery has been used to successfully target both genetic diseases as well as cancer. 
With extensive effort being put into designing nonviral vectors with higher gene transfer 
efficiency, synthetic gene carriers may become superior to viral analogues in clinical trials in 
the near future. 
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8. Future direction and challenge   
Single targeted cancer therapy can not be expected to yield optimal outcomes as 
tumorigenesis is a multistep process and its molecular pathogenesis is not linked to the 
defect of a single target. Therefore, multi-targeted therapy through the combination of 
agents targeting distinct molecules might be the goals for targeting therapy in the near 
future. This could overcome the issues of tumour heterogeneity and maintain the selectivity 
of treatment at the same time. In addition, monotherapy is further evolving to single 
inhibitor which can target several molecules simultaneously. It seems promising that with 
our better understanding of tumor biology, more efficacious combinations for targeted 
therapy will emerge in the immediate future (Imai and Takaoka, 2006). 
Another new aspect of cancer-targeted therapy is employing cancer stem cells as the target. 
It was reported that mTOR inhibition by rapamycin selectively eliminated leukaemic stem 
cells without affecting normal haematopoietic stem cells (Zhang et al., 2006). Therefore, 
targeting abnormal signalling pathway in cancer stem cells might offer an effective 
approach for targeting therapies. Besides, it is of great importance to identify predictive 
markers for the response to targeted therapy (Swain, 2011). Beyond its obvious clinical 
benefits for cancer patients, the identification of predictive markers can also reduce the costs 
of cancer treatments (Warren et al., 2008).  
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A characteristic feature of solid tumours is the presence of cells under very low oxygen 
tensions, hypoxia. These cells, so called hypoxic tumour cells, express a transcription factor, 
hypoxia-inducible factor 1 (HIF-1), which induces the expression of more than one hundred 
genes related to angiogenesis, invasion, metastasis, and resistance to conventional 
treatments such as chemotherapy and radiotherapy. However, because hypoxia is unique to 
locally advanced malignant tumours, it provides the opportunity to develop tumour-
specific targeting strategies. Such an approach has been applied to gene therapy; for 
example, hypoxia-activated gene therapy using HIF-1-dependent promoters resulted in the 
selective expression of therapeutic genes and anti-tumour effects with minimum side effects 
in normal tissues. Here, I review recent advances in the development of cancer gene therapy 
strategies targeting hypoxic/HIF-1-active tumour cells. 
2. A tumour-specific microenvironment, hypoxia, as a therapeutic target 
Most human tumours are highly heterogeneous and involve diverse microenvironments. A 
typical microenvironment seen in solid tumours is hypoxia, low-oxygen conditions under 
physiological level (Thomlinson & Gray, 1955; Vaupel, Kallinowski, & Okunieff, 1989). 
Tumour hypoxia is a concern in cancer therapy because it increases the metastatic and 
angiogenic potential of cancer cells (Erler et al., 2006; Forsythe et al., 1996; Yang et al., 2008) 
and can render cancer cells resistant to radiation and chemotherapy (Brown & Wilson, 2004; 
Teicher, 1994; Thomlinson & Gray, 1955). 
2.1 What is tumour hypoxia and how does it occur in solid tumours? 
A typical feature of cancer cells is an extraordinarily accelerated proliferation caused by the 
activation of oncogenes and/or disruption of tumour suppressor genes (Hanahan & 
Weinberg, 2000). It leads to an imbalance in the supply and consumption of O2 in a solid 
tumour. This disequilibrium along with the inadequate diffusion of molecular oxygen can 
cause a dynamic gradient of O2 content in a solid tumour (Thomlinson & Gray, 1955; Vaupel 
et al., 1989). Tumour cells proliferate and grow actively only if supplied with enough 
oxygen and nutrients from tumour blood vessels; therefore, malignant solid tumours grow 
as a conglomerate of so-called “tumour cords” in each of which a blood vessel is 
sequentially surrounded with well-oxygenated viable cells (normoxic cells), dormant cells 
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under low oxygen conditions (hypoxic cells), and dead cells (necrotic cells) Fig. 1(Hall, 
1994). Because of the distance that O2 can diffuse, hypoxic cells exist 70-100 μm from a 
tumour blood vessel in a tumour cord (Hall, 1994). Hypoxic conditions are usually defined 
as < 2% O2, and anoxic conditions (severe hypoxia) as < 0.02% O2. 
 
 
Fig. 1. Spatial relationship between blood vessels and hypoxia in a malignant solid tumour. 
Chronic hypoxic regions (red) exist 70-100 μm from tumour blood vessels. Acute/cycling 
hypoxia caused by fluctuations in tumour blood flow occurs proximal to tumour blood 
vessels. 
In addition to areas of chronic hypoxia, malignant tumours contain cancer cells which are 
temporally exposed to low oxygen conditions for minutes to hours and then reoxygenated 
(Brown, 1979). This phenomenon, called “acute hypoxia”, frequently reoccurs during 
tumour growth, leading to “cycling hypoxia”. The occurrence of acute and cycling hypoxia 
is attributed to the fact that tumour blood vessels are quite immature and tortuous; and 
therefore, tumour blood flow fluctuates dramatically during tumour growth (Brown & 
Wilson, 2004).  
2.2 Chemo-resistance of cancer cells under hypoxic conditions 
Cancer cells are known to become chemo-resistant in hypoxic regions of locally advanced 
solid tumours through multiple mechanisms (Kizaka-Kondoh, Inoue, Harada, & Hiraoka, 
2003; Teicher, 1994). First, because hypoxic regions occur far from functional vasculatures, 
the diffusion and delivery of most anticancer drugs are not extensive enough to have a 
cytotoxic effect (Durand, 1994; Hicks et al., 2006; Tannock, 1998). Second, the cytotoxicity of 
some anticancer drugs is known to depend on molecular oxygen. For example, bleomycin is 
reported to chelate metal ions, produce a pseudoenzyme that reacts with oxygen and 
 
Gene Therapy Strategy for Tumour Hypoxia 
 
187 
generates superoxide and hydroxide free radicals, and then cleave DNA. Therefore, the 
cytotoxic effect of the drug dramatically decreases in the absence of O2 (Batchelder, Wilson, 
Hay, & Denny, 1996; Teicher, Lazo, & Sartorelli, 1981). Third, alkylating agents and 
antimetabolites are also less effective under hypoxic conditions. These kinds of drugs are the 
most effective against highly proliferating cancer cells, and therefore, hypoxic tumour cells, 
which are known to be dormant/less proliferating, can tolerate them (Tannock, 1968). 
Fourth, hypoxia upregulates the expression of genes involved in drug resistance, including 
the gene for p-glycoprotein (Comerford et al., 2002; Wartenberg et al., 2003). Finally, there is 
evidence that hypoxia can enhance genetic instability in tumour cells (N. Chan et al., 2008), 
thus allowing a more rapid development of drug resistance. 
2.3 Radio-resistance of cancer cells under hypoxic conditions 
Ionizing radiation produces DNA damage, such as DNA double/single strand breaks, DNA 
base damage, and DNA-DNA and DNA-protein crosslinks (Hall, 1994). The presence or 
absence of molecular oxygen influences the damage and death of cancer cells (Brown & 
Wilson, 2004; Thomlinson & Gray, 1955). This phenomenon, the so-called oxygen effect, was 
first identified in 1912 with the observation that the skin reaction to a radium applicator 
dramatically decreased when the applicator was pushed tightly onto the skin and 
consequently decreased blood flow there. The breakthrough linking the effect of oxygen 
with radioresistance of cancer cells was made by Thomlinson and Gray in 1955 (Thomlinson 
& Gray, 1955). They proposed that oxygen levels decreased in a solid tumour through 
successive layers of cancer cells distal to blood vessels, and cancer cells a distance of about 
10 cell diameters from vessels are viable but radioresistant. Actually, cancer cells become 2-3 
times more radioresistant under hypoxic conditions than normoxic conditions (Brown & 
Wilson, 2004).  
The hypoxia-mediated radioresistance is attributed to both chemical and biological 
mechanisms. Ionizing radiation induces ionization in or close to the genomic DNA of target 
cells and produces radicals (Brown & Wilson, 2004). The DNA radicals are subjected to 
oxidation in the presence of oxygen, leading to fixation of the damage. In the absence of 
oxygen, however, the DNA radicals are reduced by compounds containing sulfhydryl 
groups (SH groups), which restore the DNA to its original form. Therefore, DNA damage, 
especially irreparable double stranded breaks, is significantly less severe in the absence of 
molecular oxygen. Biological mechanisms are also important. It has been elucidated that 
hypoxic stimuli trigger changes in both the “DNA damage repair pathway” (Bindra, 
Crosby, & Glazer, 2007) and the “cell death/survival signaling pathway”. Moreover, recent 
advances in molecular and cellular biology revealed an important role for a transcription 
factor, hypoxia-inducible factor 1 (HIF-1), in tumour radioresistance (see Section 3 for 
details) (Harada & Hiraoka, 2010).  
2.4 Increase in metastatic and angiogenic potential under hypoxic conditions  
In addition to mediating resistance to conventional treatments, hypoxia is known to increase 
the metastatic and angiogenic potential of tumour cells. Cancer patients with relatively more 
hypoxic regions have a tendency to suffer from distant metastasis as well as local recurrence 
regardless of whether the initial treatment is surgery or radiation therapy (Brizel et al., 
1996). Recent molecular biological analyses have revealed that hypoxia stimulates the 
expression of a number of genes involved in metastatic cascades, such as lysyl oxidase and 
the chemokine receptor, CXCR4, osteopoetin (D. A. Chan & Giaccia, 2007; Erler et al., 2006; 
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thus allowing a more rapid development of drug resistance. 
2.3 Radio-resistance of cancer cells under hypoxic conditions 
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Wilson, 2004; Thomlinson & Gray, 1955). This phenomenon, the so-called oxygen effect, was 
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10 cell diameters from vessels are viable but radioresistant. Actually, cancer cells become 2-3 
times more radioresistant under hypoxic conditions than normoxic conditions (Brown & 
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mechanisms. Ionizing radiation induces ionization in or close to the genomic DNA of target 
cells and produces radicals (Brown & Wilson, 2004). The DNA radicals are subjected to 
oxidation in the presence of oxygen, leading to fixation of the damage. In the absence of 
oxygen, however, the DNA radicals are reduced by compounds containing sulfhydryl 
groups (SH groups), which restore the DNA to its original form. Therefore, DNA damage, 
especially irreparable double stranded breaks, is significantly less severe in the absence of 
molecular oxygen. Biological mechanisms are also important. It has been elucidated that 
hypoxic stimuli trigger changes in both the “DNA damage repair pathway” (Bindra, 
Crosby, & Glazer, 2007) and the “cell death/survival signaling pathway”. Moreover, recent 
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expression of a number of genes involved in metastatic cascades, such as lysyl oxidase and 
the chemokine receptor, CXCR4, osteopoetin (D. A. Chan & Giaccia, 2007; Erler et al., 2006; 
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Rofstad, 2000). Also, cancer cells under hypoxic conditions trigger angiogenesis in order to 
improve surrounding conditions and obtain enough oxygen and nutrients for their survival 
(Folkman, 1971). HIF-1 is known to play a pivotal role in the hypoxia-mediated increase in 
both the metastatic and angiogenic potential of cancer cells. 
3. Hypoxia-inducible factor 1 (HIF-1) 
Molecular and cellular biological research has identified HIF-1 as an important transcription 
factor in hypoxia-mediated angiogenesis, metastasis, and resistance to chemo/radiotherapy. 
3.1 Regulation of HIF-1 expression and activity 
HIF-1 is a heterodimeric transcription factor composed of alpha (HIF-1α) and beta (HIF-
1β/ARNT) subunits (Wang, Jiang, Rue, & Semenza, 1995). Its hypoxia-dependent activity is 
mainly regulated through the stabilization and modification of the HIF-1α subunit (Fig. 2). 
 
 
Fig. 2. Molecular mechanism behind the activation of HIF-1 under Hypoxic conditions.  
The best-characterized regulatory mechanism is that modulating HIF-1α’s stability. Under 
well-oxygenated normoxic conditions, prolyl hydroxylation (by prolyl hydroxylases 
[PHDs]) and subsequent ubiquitination (by von-Hippel Lindau (VHL)-containing E3 
ubiquitin-protein ligase) of the oxygen-dependent degradation (ODD) domain of HIF-1α 
leads to rapid degradation of HIF-1α with a half life of 5-8 min. Consequently, HIF-1 is 
inactive under normoxic conditions (Berra, Roux, Richard, & Pouyssegur, 2001; Hirota & 
Semenza, 2005; Jaakkola et al., 2001; Maxwell et al., 1999; Semenza, 2001). On the other hand, 
under oxygen-deprived hypoxic conditions, HIF-1α becomes stable because oxygen-
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depletion directly decreases the PHDs’ activity (Jaakkola et al., 2001). Then, HIF-1α interacts 
with HIF-1β, forms a heterodimer, HIF-1 (Wang et al., 1995), binds to its cognate DNA 
sequence, the hypoxic-responsive element (HRE), and finally induces the expression of 
various genes related to angiogenesis, metastasis, glycolysis and so on (D. A. Chan & 
Giaccia, 2007; Erler et al., 2006; Forsythe et al., 1996; Kim, Gao, & Dang, 2007; Rofstad, 2000). 
In addition to the regulation of HIF-1α’s stability, another post-translational modification of 
HIF-1α is known to function in the regulation of the transactivational activity of HIF-1. 
Under normoxic conditions, factor inhibiting HIF-1 (FIH-1) becomes active and 
hydroxylates an asparagine residue (N803) of HIF-1α (Hirota & Semenza, 2005; Mahon, 
Hirota, & Semenza, 2001; Semenza, 2001). The asparaginyl hydroxylation blocks the 
interaction of HIF-1α with the transcriptional co-factor p300 and CBP, resulting in the 
suppression of HIF-1’s transactivational activity. Because oxygen is a substrate of FIH-1 as 
well as PHDs, HIF-1’s transactivational activity is restored under oxygen-deprived hypoxic 
conditions. 
3.2 Function of HIF-1 in cancer cells 
In cancer cells, HIF-1 plays pivotal roles in the adaptation to (metabolic reprograming), 
evasion from (invasion and metastasis), and improvement of (angiogenesis) severe hypoxic 
conditions (D. A. Chan & Giaccia, 2007; Erler et al., 2006; Forsythe et al., 1996; Semenza, 
2007, 2008). Concerning angiogenesis in locally advanced malignant tumours, an up-
regulation of HIF-1 activity caused by intratumoural hypoxia is associated with the 
overexpression of vascular endothelial growth factor (VEGF), a glycoprotein responsible for 
angiogenesis and vasculogenesis (Forsythe et al., 1996). Concerning the metabolic 
reprogramming of cancer cells, HIF-1 induces the expression of genes encoding glucose 
transporters and glycolytic enzymes to facilitate glycolysis (Semenza, 2009; Wood et al., 
1998). At the same time, HIF-1-dependent genes decrease both mitochondrial metabolism 
(Fukuda et al., 2007; Semenza, 2007) and mitochondrial mass (Semenza, 2008; H. Zhang et 
al., 2008). These functions of HIF-1 are responsible for both the efficient production of ATP 
even under oxygen-deprived conditions and the decrease in the cytotoxic reactive oxygen 
species (ROS) produced through incomplete oxidative phosphorylation under hypoxic 
conditions (Fukuda et al., 2007; Semenza, 2007, 2009). Concerning invasion and metastasis, 
HIF-1 is known to trigger various pathways including epithelial-mesenchymal transition 
(EMT) and expression of the Met protooncogene and lysyl oxidase, which function in 
tumour metastasis (Erler et al., 2006; Pennacchietti et al., 2003). 
3.3 Function of HIF-1 in tumour radioresistance 
Preclinical studies have found that inhibition of intratumour HIF-1 activity by a 
pharmacological HIF-1 inhibitor, YC-1, or by a dominant negative mutant of HIF-1α and the 
knockdown of HIF-1α expression by short hairpin RNA or short interfering RNA 
significantly delayed tumour growth after radiation (Harada et al., 2009; Moeller, Cao, Li, & 
Dewhirst, 2004; Moeller et al., 2005; X. Zhang et al., 2004). It was also confirmed through 
clinical studies that HIF-1α expression correlates with a poor prognosis after radiation 
therapy (Aebersold et al., 2001; Irie, Matsuo, & Nagata, 2004; Ishikawa et al., 2004). These 
results imply that HIF-1 has a certain biological function to increase tumour radioresistance. 
Actually, HIF-1-mediated radioresistance has been recently revealed: 1) radiation activates 
HIF-1 in a solid tumour, 2) HIF-1 induces the expression of VEGF, 3) VEGF protects 
endothelial cells from the cytotoxic effects of radiation, and 4) the radio-protected tumour 
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Dewhirst, 2004; Moeller et al., 2005; X. Zhang et al., 2004). It was also confirmed through 
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blood vessels assure the supply of oxygen and nutrients to tumour cells and promote 
tumour growth (Harada et al., 2009; Moeller et al., 2004; Zeng et al., 2008). 
4. Development of gene therapy strategies targeting tumour hypoxia 
Because hypoxic/HIF-1-active cells are known to mediate tumour malignancy and 
resistance to conventional treatments, and because hypoxia has been recognized as a 
tumour-specific microenvironment, recent studies have tried to exploit hypoxic cells as 
targets for cancer therapy (Brown & Wilson, 2004; Harris, 2002; Semenza, 2003). Dachs et al. 
were the first to apply this concept to gene therapy (Dachs, Patterson, et al., 1997).  Since 
they demonstrated the effectiveness of hypoxia-specific gene therapy strategy using the 
HIF-1/HRE system, extensive efforts have been devoted to developing genetically 
engineered hypoxia-responsive promoters. 
4.1 Development of HIF-1-dependent promoters 
Various HREs, such as murin phosphoglycerate kinase-1 (PGK-1) HRE, human enolase 
(ENO) HRE, murin lactate dehydrogenase (mLDH-A) HRE, human erythropoietin (EPO) 
HRE, and human VEGF HRE, have been used to develop artificial hypoxia-responsive 
promoters (Table 1) (Binley, Iqball, Kingsman, Kingsman, & Naylor, 1999; Boast et al., 1999; 
Dachs, Patterson, et al., 1997; Harada et al., 2007; Rinsch et al., 1997; Shibata, Akiyama, 
Noda, Sasai, & Hiraoka, 1998; Shibata, Giaccia, & Brown, 2000). The number of HREs and 
combination with the basal promoter influence the hypoxia/HIF-1-responsiveness of each 
HRE-containing promoter (Table 1). 
Above all, the combination of five repeats of a HRE derived from the human VEGF 
promoter and the human cytomegarovirus (CMV) minimal promoter (mp), the so-called 
“the 5HRE promoter“, showed intense hypoxia-responsiveness and exhibited a more than 
500-fold increase in luciferase activity in response to hypoxic stimuli (Shibata et al., 2000). 
Moreover, the absolute level of luciferase activity from the 5HRE promoter under hypoxic 
conditions reached the same level as that from the constitutively active CMV-driven 
promoter under normoxic conditions (Shibata et al., 2000).  
However, the 5HRE promoter still has problems relating to the development of gene 
therapy. It shows a certain level of unwanted gene expression even when oxygen is 
available under normoxic conditions (Harada et al., 2007), which would cause high basal 
expression of therapeutic genes and result in side effects in well-oxygenated normal tissues. 
In order to decrease leakage under normoxic conditions, I and my colleagues came up with 
the idea of utilizing the ODD domain of HIF-1α. We fused the coding sequence of the ODD 
domain to that of luciferase, and inserted the fusion gene downstream of the 5HRE 
promoter. The resultant 5HREp-ODD-luc gene showed little leakage under normoxic 
conditions. Leakage from the conventional 5HREp-luc gene was 1.4 × 103 (arbitary units), on 
the other hand, that from the novel 5HREp-ODD-luc gene was just 1.5 × 101 (arbitary units), 
almost the same as the background level. Moreover, the oxygen-dependent destabilizing 
effect of the ODD domain contributed to an increase in the hypoxia-responsiveness to about 
4.7 × 104.  
The potential of hypoxia/HIF-1-dependent promoters in vivo has been proved through 
immunohistochemical analyses and optical imaging experiments. The human melanoma cell 
line, Be11, was stably transfected with a plasmid expressing a derivative of EGFP, d2EGFP, 
under the control of the 5HRE promoter, and transplanted into immunodeficient nude mice 
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HRE Basal Promoter Reporter Gene Induction Ratio References 
3 × mPGK-1 mPGK-1 CD2 1.4-1.9 
Dachs, 1997 3 × mPGK-1 minHSV TK CD2 2.2-2.33 
3 × mPGK-1 9-27 gene CD2 2.2-4.1 
mPGK-1 mPGK-1 hEPO 2.7 Rinsch, 1997 
hVEGF hVEGF luciferase 3.3-8.5 
Shibata, 1998 
hEPO SV40 luciferase 2-5 
5 × hVEGF hVEGF luciferase 20 
5 × hVEGF hVEGF+ minE1b luciferase  44 
3 × hENO SV40 luciferase 120 
Boast, 1999 
3 × hENO SV40 luciferase 63 
2 × mLDHA SV40 luciferase 81 
4 × mLDHA SV40 luciferase 65 
4 × hEPO SV40 luciferase 255 
3 × hENO SV40 luciferase  146 
3 × mPGK-1+
VEGF 3' UTR SV40 luciferase 300 
mPGK-1 SV40 β-gal 8.5-50 Binley, 1999 
5 or 10 × hVEGF SV40 luciferase 54-57 
Shibata, 2000 
5 or 10 × hVEGF+ 
5' VEGF UTR SV40 luciferase 23-27 
5-10 × hVEGF+ 
5' VEGF UTR E1b luciferase 56-60 
5 × hVEGF+ 
5' VEGF UTR E1b luciferase 131 
5 × hVEGF+ 
5' VEGF UTR+ 
3' VEGF UTR 
E1b luciferase 193 
5 × hVEGF hCMV-mp luciferase 524 
5 × hVEGF hCMV-mp luciferase 47,000 Harada, 2007 
Table 1. Genetically engineered hypoxia-responsive promoters. 
(Liu et al., 2005). Resultant tumour xenografts showed heterogeneous, partition-dependent 
and weak green fluorescence. Immunohistochemical analyses confirmed that d2EGFP-
positive cells were located at the boundary between well-oxygenated viable regions and 
necrotic regions, which were stained with a hypoxia marker, pimonidazole (Raleigh et al., 
1998). When human cervical cancer cells, HeLa cells, transfected with the 5HREp-luc or 
5HREp-ODD-luc gene were transplanted into nude mice, the resultant xenografts showed 
intense bioluminescence after the tumour-bearing leg was ligated and the blood flow to the 
xenograft decreased (Harada, Kizaka-Kondoh, & Hiraoka, 2005; Harada et al., 2007).  
4.2 Hypoxia-targeted gene-directed enzyme/prodrug therapy using a HIF-1-dependent 
promoter  
To exploit tumour hypoxia/HIF-1 active cells as a tumour-specific therapeutic target, 
several approaches have been examined including (1) hypoxia-targeting using 
hypoxia/HIF-1-responsive promoters combined with Gene-Directed Enzyme Prodrug 
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promoter. The resultant 5HREp-ODD-luc gene showed little leakage under normoxic 
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positive cells were located at the boundary between well-oxygenated viable regions and 
necrotic regions, which were stained with a hypoxia marker, pimonidazole (Raleigh et al., 
1998). When human cervical cancer cells, HeLa cells, transfected with the 5HREp-luc or 
5HREp-ODD-luc gene were transplanted into nude mice, the resultant xenografts showed 
intense bioluminescence after the tumour-bearing leg was ligated and the blood flow to the 
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To exploit tumour hypoxia/HIF-1 active cells as a tumour-specific therapeutic target, 
several approaches have been examined including (1) hypoxia-targeting using 
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Therapies (GDEPT) (Greco, Marples, Joiner, & Scott, 2003; Liu, Harada, Ogura, Shibata, & 
Hiraoka, 2007; Ogura et al., 2005; Patterson et al., 2002; Shibata, Giaccia, & Brown, 2002), and 
(2) hypoxia-specific replication of adenovirus (Hernandez-Alcoceba, Pihalja, Qian, & Clarke, 
2002; Post & Van Meir, 2003) (Table 2). 
 
Delivery System Hypoxia-specific Strategy Result Reference 
NA (Transfected 
cancer cell line) 
GDEPT: 5 x VEGF-HRE-
containing promoter driven NTR 
gene expression in HT1080 cells 







cancer cell line) 
GDEPT: 5 x VEGF-HRE-
containing promoter-driven HSV-
TK gene expression and i.p. 





cancer cell line) 
GDEPT: PGK-1 HRE/SV40 
chimeric promoter-driven P450R 
gene expression and i.p. injection 
of the 2-nitroimidazole 




Adenovirus GDEPT: optimized hypoxia 
response promoter using PGK-1 
HRE-driven human cytochrome 
P450 (CYP2B6) gene expression 
and i.p. injection of 
cyclophosphamide 
Delay in tumour 
growth 
Binley, 2003 
Adenovirus  3XHRE/5XERE-regulated E1A 
expression and hTERT (AdEHT2) 
or E2F-1 (AdEHE2F) promoter-









GDEPT: 5 x VEGF-HRE-
containing promoter-driven 
bacterial cytosine deaminase 
(BCD) gene expression and i.p. 






Adenovirus human VEGF promoter-driven 




cell growth in 
vitro 
Kaliberov, 2002 
Table 2. Gene therapy strategies for tumour hypoxia examined so far.  
NA, not applicable; HSV-TK, the herpes simplex virus thymidine kinase; GCV, ganciclovir; 
GDEPT, Gene-Directed Enzyme Pordrug Therapy; NTR, nitroreductase; CRAD, 
conditionally replicative adenoviruses; ER, estrogen receptor; ERE, estrogen response 
element; hTERT, human telomerase reverse transcriptase; CD, cytosine deaminase; VEGF, 
Vascular Endthelial Growth Factor, 5-FU, 5-fluorouracil; 5-FC, 5-flucytosine; 
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4.2.1 Gene-directed enzyme prodrug therapy (GDEPT) with HIF-1-dependent 
promoters   
GDEPT involves the delivery to target cells of a foreign gene, which is non-toxic but 
activates prodrugs to toxic agents and induces anti-tumour effects (Fig. 3 Dachs, Dougherty, 
Stratford, & Chaplin, 1997; Greco et al., 2003). HIF-1 activity is detected at high levels in 
hypoxic tumour cells but generally not in normal tissues as mentioned above; therefore, 
HIF-1-dependent promoters provide a chance to accomplish tumour-specific GDEPT. The 
target-specificity and therapeutic effects of GDEPT with HIF-1-dpendent promoters have 
been examined in experimental tumour systems either by administering viral vectors 
(Binley et al., 2003; Liu et al., 2007) or by using unique tumour xenografts prepared by 
transplanting cancer cells which express a prodrug-activating enzyme under the control of a 
HIF-1-dependent promoter (Ogura et al., 2005; Patterson et al., 2002; Shibata et al., 2002). 
Examples of enzyme/prodrug combinations in GDEPT are the bacterial nitroreductase 
(NTR)/anticancer prodrug CB1954, the cytochrome P450 reductase (P450R)/RSU1069, the 
herpes simplex virus thymidine kinase (HSV-TK)/ganciclovir (GCV), and the bacterial 
cytosine deaminase (BCD)/anti-herpes viral agent 5- fluorocytosine (5-FC).  
 
 
Fig. 3. Concept of GDEPT targeting tumour hypoxia. 
Using HREs derived from the VEGF promoter, Shibata et al. generated vectors expressing a 
bacterial NTR gene in a HIF-1-dependent manner, and established stable transfectants of a 
human fibrosarcoma cell line, HT1080 (Shibata et al., 2002). Hypoxia-induced expression of 
the NTR protein correlated with increased sensitivity of HT1080 cells to the prodrug CB1954 
(Shibata et al., 2002). Growth delay assays with established tumour xenografts derived from 
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Therapies (GDEPT) (Greco, Marples, Joiner, & Scott, 2003; Liu, Harada, Ogura, Shibata, & 
Hiraoka, 2007; Ogura et al., 2005; Patterson et al., 2002; Shibata, Giaccia, & Brown, 2002), and 
(2) hypoxia-specific replication of adenovirus (Hernandez-Alcoceba, Pihalja, Qian, & Clarke, 
2002; Post & Van Meir, 2003) (Table 2). 
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human fibrosarcoma cell line, HT1080 (Shibata et al., 2002). Hypoxia-induced expression of 
the NTR protein correlated with increased sensitivity of HT1080 cells to the prodrug CB1954 
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the same cells showed that significant antitumour effects were achieved with intraperitoneal 
injections of CB1954 (Shibata et al., 2002). In addition, respiration of 10% O2 increased the 
hypoxic fraction in the tumour xenograft in vivo and enhanced the antitumour effects 
(Shibata et al., 2002). 
A one-electron reductase, such as P450R, can be used for prodrug-activation. Patterson et al. 
reported that selective hypoxia-targeting could be accomplished by using an optimized 
PGK-1 HRE/SV40 chimeric promoter to regulate the expression of P450R. HT1080 cells 
stably transfected with the gene produced a 3.4-fold increase in P450R activity as a result of 
anoxic incubation, leading to a 30-fold enhancement of the cytotoxicity of the 2-
nitroimidazole bioreductive prodrug, RSU1069 (Patterson et al., 2002).  
As for HSV-TK/GCV gene therapy, Ogura et al. demonstrated that promoters containing 5 
copies of the VEGF HRE assured the expression of the HSV-TK gene in a HIF-active renal 
cell carcinoma, resulting in GCV-dependent tumour growth suppression (Ogura et al., 
2005). An important point of their study is that HIF-dependent HSV-TK/GCV gene therapy 
can target not only hypoxic but also normoxic renal cell carcinoma (RCC) cells because the 
VHL gene, which triggers the destruction of HIF-1α and HIF-2α during normoxia, is 
inactive in 33–57% of sporadic clear-cell RCCs, which accounts for 75% of RCCs.  
Binley et al. used an optimized hypoxia-responsive promoter (OBHRE) with the PGK-1 HRE 
and investigated hypoxia-targeted gene expression in vivo in the context of an adenoviral 
vector (Binley et al., 2003). The OBHRE promoter showed limited activity in the liver or 
spleen such that expression was 1000-fold lower than that driven by the strong CMV/IE 
promoter (Binley et al., 2003). However, in the context of the tumour microenvironment, the 
OBHRE promoter achieved expression levels comparable to that of the CMV/IE promoter. 
Moreover, they showed that an adenovirus expressing the human cytochrome P450 
(CYP2B6) regulated by the OBHRE promoter delays tumour growth in response to the 
prodrug cyclophosphamide (CPA) (Binley et al., 2003).  
As for CD/5-FC gene therapy, Liu et al. constructed an adenoviral vector in which the 5HRE 
promoter was responsible for the HIF-1-dependent expression of CD (Liu et al., 2007). 
Administration of the adenovirus resulted in the expression of CD in hypoxic regions of 
solid tumours, leading to 5- FC-dependent tumour growth suppression and enhancement of 
the therapeutic effect of radiation therapy (See Section 4.4 for details about the radio-
enhancing effect).  
In general, GDEPT is thought to have two advantages: amplification of its therapeutic effect 
and a bystander therapeutic effect. The former is due to the ability of each prodrug-
activating enzyme to activate a number of prodrug molecules. The latter advantage results 
from an extension of the killing effects of the activated/converted drug to surrounding 
cancer cells, which don’t express the therapeutic gene and don’t convert the prodrug to the 
active anticancer drug. Therefore, even if systemic delivery of the therapeutic genes is not 
effective Fig. 3, tumour eradication may still be achieved. 
4.2.2 Other gene therapy strategies targeting tumour hypoixia   
4.2.2.1 Gene therapy using a cytotoxic gene and HIF-1-dependent promoter 
An alternative GDEPT uses cytotoxic proteins instead of prodrug-activating enzymes 
expressed in a HIF-1-dependent manner (Table 2). Kaliberov et al. prepared an adenovirus, 
AdVEGFBAX, which expressed an inducer of apoptosis, BAX, under the control of a VEGF 
promoter (Kaliberov et al., 2002). They confirmed the potential therapeutic application of 
VEGF promoter–driven cancer-specific expression of the pro-apoptotic Bax gene.  
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4.2.2.2 Gene therapy using a hypoxia/HIF-dependent oncolytic adenovirus  
The lytic cycle of adenoviruses is known to result in the death of infected cells, and thus this 
property has been exploited as a therapeutic strategy against cancer. Post and Van Meir 
have developed a hypoxia/HIF-dependent replicative adenovirus (HYPR-Ad) that exhibits 
HIF-1-dependent E1A expression and conditional cytolysis of hypoxic cells but not 
normoxic cells (Post & Van Meir, 2003). This is the first evidence that an attenuated oncolytic 
adenovirus that selectively lyses hypoxic tumour cells can be generated. 
4.3 Side effect of hypoxia-targeting gene therapies   
To measure the damage to normal tissue after gene therapy targeting tumour hypoxia, 
Binley et al. evaluated the activity of lactate dehydrogenase (LDH) as an indicator of liver 
dysfunction after their hypoxia-responsive thymidine kinase/ganciclovir (TK/GCV) suicide 
gene therapy (Binley et al., 2003). Hypoxia-dependent TK expression and subsequent GCV 
treatment caused no irregularity in LDH levels. On the other hand, constitutive TK 
expression from a CMV promoter and GCV treatment significantly elevated LDH levels in 
mice. These results suggest that a hypoxia-responsive promoter would facilitate target 
specificity and so reduce the side effects on well-oxygenated normal tissues, meaning an 
increased therapeutic window for cytotoxic cancer gene therapies.  
Liu et al observed no obvious side effects after hypoxia-targeting gene therapy with a 5HRE 
promoter-mediated BCD/5-FC strategy (Liu et al., 2007). On the other hand, after the 
Ad/EFp-BCD/5-FC treatment, which constitutively expresses BCD regardless of 
surrounding oxygen conditions, they observed significant weight loss and severe diarrhea 
(Liu et al., 2007). These results strengthen the argument that we can exploit tumour hypoxia 
as a tumour-specific target of cancer gene therapy, and that hypoxia/HIF-1-dependent 
therapeutic gene expression helps to avoid side effects in normal tissues. 
4.4 Improvement of the effect of radiotherapy by hypoxia/HIF-1-targeting gene 
therapies 
As tumour hypoxia and HIF-1 activity are responsible for tumour radioresistance 
(Aebersold et al., 2001; Harada et al., 2009; Irie et al., 2004; Ishikawa et al., 2004; Moeller et 
al., 2004; Moeller et al., 2005; X. Zhang et al., 2004), the specific targeting of tumour hypoxia 
and/or HIF-1 activity by gene therapy strategies may improve the efficacy of radiotherapy. 
Actually, Patterson et al. demonstrated that the therapeutic effect of radiation can be 
enhanced by a hypoxia-targeting gene therapy strategy (Patterson et al., 2002). They 
transfected HT1080 cells with a hypoxia-regulated expression vector encoding the human 
P450 reductase (HRE-P450R). Xenografts of HRE-P450R and empty vector transfectants had 
comparable hypoxic fractions and were refractive to a single dose of radiotherapy of up to 
15 Gy. However, combining a prodrug RSU1069 with a reduced dose of radiotherapy (10 
Gy) cured 50% of mice bearing HRE-P450R xenografts by 100 days after the treatment. On 
the other hand, one hundred percent mortality was observed by day 44 in the empty vector 
control xenografts treated using the same protocol.  
Liu et al. treated HeLa tumour xenografts with adenovirus-mediated hypoxia-targeting 
cytosine deaminase gene therapy (Ad/5HREp-BCD/5-FC) and/or radiotherapy (IR), and 
carried out growth delay assays (Liu et al., 2007). They intentionally chose a low dose of 
Ad/5HREp-BCD/5-FC, which had minimal effects on the tumour growth rate compared to 
that after sham-treatment. Combined with IR, the gene therapy strikingly suppressed 
tumour growth as compared to radiotherapy alone. The period taken for tumour growth to 
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the same cells showed that significant antitumour effects were achieved with intraperitoneal 
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Moreover, they showed that an adenovirus expressing the human cytochrome P450 
(CYP2B6) regulated by the OBHRE promoter delays tumour growth in response to the 
prodrug cyclophosphamide (CPA) (Binley et al., 2003).  
As for CD/5-FC gene therapy, Liu et al. constructed an adenoviral vector in which the 5HRE 
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4.2.2.2 Gene therapy using a hypoxia/HIF-dependent oncolytic adenovirus  
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carried out growth delay assays (Liu et al., 2007). They intentionally chose a low dose of 
Ad/5HREp-BCD/5-FC, which had minimal effects on the tumour growth rate compared to 
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increase two-fold from the initial volume (tumour growth doubling time: TGDT) was 13.2 ± 
5.6 days after gene therapy alone, which is not significantly longer than that after sham-
treatment (8.2 ± 3.1 days). On the other hand, the combination of gene therapy with 
radiotherapy prolonged the TGDT to 47.2 ± 16.8 days, which was about 2.4-fold longer than 
that after radiotherapy alone (19.4 ± 4.8 days). Similar results were observed after 
fractionated irradiation (3 Gy × 5 fractions). The TGDT after gene therapy alone was 13.0 ± 
4.4 days, which is not significantly longer than that after sham treatment (9.8 ± 5.8 days). On 
the other hand, the TGDT after the fractionated radiotherapy was 17.0 ± 3.7 days, which was 
significantly delayed by the combination with the gene therapy to 43.3 ± 23.8 days. These 
results also lead to a conclusion that hypoxia-targeting gene therapy combined with 
radiotherapy is a promising approach to cancer treatment. 
5. Conclusion 
Cancer cells under hypoxic conditions/HIF-1-active cancer cells have been recognized as 
crucial and excellent targets for cancer therapy not only because they mediate tumour 
malignancy and resistance to conventional treatments but also because they are only seen in 
malignant tumours, not in normal tissues. Several approaches have been used to target these 
cell populations; hypoxia-targeting using hypoxia-responsive promoters combined with 
GDEPT, and hypoxia-specific replication of adenovirus as well as hypoxic cytotoxins and 
HIF-1 inhibitors. Hypoxia/HIF-1-targeting gene therapy is a promising tumour-specific 
approach with few side effects in normal tissues, and has the potential to enhance the effect 
of radiation therapy. Some approaches are now in clinical trials and are expected to lead to 
breakthroughs in cancer therapy. 
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One of the most trying pathological conditions of the central nervous system is the 
malignant glial development of the brain. The major malignancy is the glioblastoma 
multiforme, GBM, which almost uniformly leads to the patient’s demise: mortality is still 
close to 100 %, and median survival 8 – 11 months. All currently used therapies - surgery, 
radiotherapy, chemotherapy and pharmacology – have not given satisfactory results; the 
median survival, using an immune- or chemotherapy is 15 months, rarely 18 months (Stupp 
et al., 2006). The search for new approaches based on gene molecular biology/immunology 
techniques, is therefore a necessary step. In the presented chapter we highlight to 
biomedical researchers and physicians not only the importance of the glioblastoma problem 
but the fact that we are currently successfully progressing in the studies and the treatment 
of this pathology. The most recent approaches for the treatment of malignant tumors and 
especially of gliomas are now focusing on the use of different types of inhibitors. More 
specifically gene therapy approach using anti - gene technology including antisense strategy 
is considered to target as well growth factors (IGF-I, EGF, VEGF, TGF) as their receptors and 
related downstream steps of signal transduction pathways (IRS-1, PI3K, AKT, PKC, Bcl-2, 
GSK3, glycogen synthase GS) (Helene, 1994; Beckner et al., 2005; Trojan et al., 2007a). Among 
growth factors, IGF-I plays a principal role during development of the brain reappearing in 
malignant glial differentiation (Pollak et al., 2004). This hypothesis has strongly underlined 
the usefulness of techniques permitting to target and stop the expression of growth factors 
present in tumoral development by anti – gene strategies, particularly antisense approach.  
The ”discovery” of the antisense approach, AS, was made in 1984/1985 (Rubenstein et al., 
1984; Weintraub et al., 1985). The AS approach, as a concept, was created to study basic 
problems of gene regulation, particularly useful in developmental biology investigations, 
bypassing inherent limitations of functional studies dependent upon natural mutant cells or 
artificially mutagenized cells (Izant & Weintraub, 1985). Antisense technique was 
particularly used to target tumor antigens, which arrest of expression was not efficiently 
stopped using antibodies or other inhibitors (Dias & Stein, 2002). The demonstration of AS 
technology as a efficient gene therapy tool, simultaneously suppressing the targeted protein 
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One of the most trying pathological conditions of the central nervous system is the 
malignant glial development of the brain. The major malignancy is the glioblastoma 
multiforme, GBM, which almost uniformly leads to the patient’s demise: mortality is still 
close to 100 %, and median survival 8 – 11 months. All currently used therapies - surgery, 
radiotherapy, chemotherapy and pharmacology – have not given satisfactory results; the 
median survival, using an immune- or chemotherapy is 15 months, rarely 18 months (Stupp 
et al., 2006). The search for new approaches based on gene molecular biology/immunology 
techniques, is therefore a necessary step. In the presented chapter we highlight to 
biomedical researchers and physicians not only the importance of the glioblastoma problem 
but the fact that we are currently successfully progressing in the studies and the treatment 
of this pathology. The most recent approaches for the treatment of malignant tumors and 
especially of gliomas are now focusing on the use of different types of inhibitors. More 
specifically gene therapy approach using anti - gene technology including antisense strategy 
is considered to target as well growth factors (IGF-I, EGF, VEGF, TGF) as their receptors and 
related downstream steps of signal transduction pathways (IRS-1, PI3K, AKT, PKC, Bcl-2, 
GSK3, glycogen synthase GS) (Helene, 1994; Beckner et al., 2005; Trojan et al., 2007a). Among 
growth factors, IGF-I plays a principal role during development of the brain reappearing in 
malignant glial differentiation (Pollak et al., 2004). This hypothesis has strongly underlined 
the usefulness of techniques permitting to target and stop the expression of growth factors 
present in tumoral development by anti – gene strategies, particularly antisense approach.  
The ”discovery” of the antisense approach, AS, was made in 1984/1985 (Rubenstein et al., 
1984; Weintraub et al., 1985). The AS approach, as a concept, was created to study basic 
problems of gene regulation, particularly useful in developmental biology investigations, 
bypassing inherent limitations of functional studies dependent upon natural mutant cells or 
artificially mutagenized cells (Izant & Weintraub, 1985). Antisense technique was 
particularly used to target tumor antigens, which arrest of expression was not efficiently 
stopped using antibodies or other inhibitors (Dias & Stein, 2002). The demonstration of AS 
technology as a efficient gene therapy tool, simultaneously suppressing the targeted protein 
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expression, changing a morphologic phenotype of cultured neoplastic cells, and stopping in 
vivo a growth of experimentally established tumors, was done for the first time using AS 
anti IGF-I approach for glioma treatment (Trojan et al., 1993). We can also consider the 
1992/3 years as the beginning of gene therapy of gliomas exploring either strategy of AS 
anti IGF-I using episomal vector (Trojan et al., 1992), or strategy of retroviral vector with 
gene encoding TK -HSV (Culver et al., 1992) (only the first approach – AS anti IGF-I - has 
shown valuable results in ulterior clinical trials). The first clinical cases of glioblastoma were 
treated with AS strategies - anti IGF-I and anti IGF-I receptor - in 2000/1 (Wongkojornsilp et 
al., 2001; Andrews et al., 2001). Since the past decade,  we observe a significant increase of AS 
approach for the treatment of tumors and especially of gliomas. Recently, other targets than 
IGF-I, as TGFbeta and their downstream signal transduction pathway elements as GS 
among others were proposed for treatment of malignant gliomas using AS technology 
(Schlingensiepen, R. et al., 2005; Ardourel et al., 2007). The approach of AS TGF-beta, 
similarly to that of AS IGF-I, has given satisfactory clinical results.  
2. Anti - genes 
Since twenty years different approaches of the treatment of tumours, including 
glioblastoma, were considered. For example, the treatment of liver cancer with antibodies to 
AFP was widely used. Unfortunately these techniques were not specific  for the treated 
tissues. Actually, the “anti-gene” strategies offer new possibilities for cancer therapy. The 
anti-genes can be classified into three categories, as follows: 1) the antisense molecules 
(Rubenstein et al., 1984; Weintraub et al., 1985; Galderisi et al., 1999; Stein, 2001; Dias & Stein, 
2002; Biroccio et al., 2003;  Kalota et al., 2004) targeted to the complementary sequence in 
mRNA, including antisense RNA, antisense oligodeoxynucleotides and ribozymes; 2) the 
triple helix-forming oligomers (Dervan, 1992; Helene, 1994; Shevelev et al., 1997) targeted to 
the double stranded DNA gene; and 3) the sense oligodeoxynucleotides designed to act as 
decoys to trap regulatory proteins (Morishita et al., 1998). The “antisense” and “triple helix” 
techniques seem very promising, stopping the protein synthesis at transcription level (Green 
et al., 1986), and translation level (Derwan, 1992), respectively.  
Other recently introduced technologies include those of triple helix, TH (Dervan, 1992; 
Helene, 1994), as well as potentially useful siRNA (Boado, 2005; Pai et al., 2006) and  miRNA 
(microRNA) (Berezikov et al., 2006). The role of 21-23 mer double-stranded RNA (si RNA) in 
the silencing of genes is strongly similar to that of the TH DNA mechanism, which also 
involves 23 mer RNA (Helene, 1994). As to miRNAs, they are noncoding RNA molecules of 
21 to 24 nucleotides that can regulate gene expression at the post-transcriptional level. 
Moreover, miRNA may play a fundamental role in tumorigenesis, controlling cell 
proliferation and apoptosis; in gliomas, the miRNA (microRNA-21) level has been reported 
to be elevated (Corsten et al., 2007). Whether or not siRNA technology or miRNA 
knockdown will supplant the AS oligodeoxynucleotide approaches remains in question at 
this time, because we do not yet have final clinical results (Dias & Stein, 2002; Pai et al., 2006; 
Corsten et al., 2007).  
2.1 Antisense approach 
The “discovery” of antisense approach was done by the groups of F. Jacob and R.M. 
Harland (Rubinstein et al., 1984; Weintraub et al., 1985). This event has been suggested to 
physiologically occur as the regulation mechanism of gene expression in cells. Some years 
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ago, regulating activities of untranscribed DNA strand (“antisense” strand) has been 
suggested (Ring & Roberts, 1994). It has also been widely proven that a lot of genes present 
an open reading frame on the antisense strand (Merino et al., 1994; Yomo & Urabe, 1994; 
Campbell et al., 1994). The role of this natural antisense RNA is not yet understood. More 
recently, it was found that mouse thymidine kinase (Tk) gene expression is regulated by 
antisense transcription: a putative promoter in intron 3 of the murine Tk will transcribe this 
antisense RNA. However, concerning natural antisense RNA in prokaryotes, it has been 
shown that they could play a regulatory role in replication, transcription or translation steps 
of some genes; it was demonstrated that the translation of the bacterial enzyme transposase 
was controlled by an antisense RNA (Weintraub et al., 1985). 
An antisense RNA, hybridized on its complementary sequence in a mRNA blocks the 
ribosome progression during the translation of the mRNA. This observation constitutes the 
“starting point” of the antisense or non-sense approach (Rubinstein et al., 1984) based on 
antisense RNA or antisense oligonucleotides to modulate artificially and specifically the 
expression of genes involved in important cellular processes. The mRNA complementary 
sequence is introduced in the cell either by a plasmid vector (dsDNA) coding for an 
antisense RNA or by a single stranded oligonucleotide form. The plasmid vector allows the 
intracellular transcription of antisense RNA which can strongly hybridize to the mRNA and 
stop the translation. Generally, an effective inhibition demands a high copy number of 
antisense RNA relative to mRNA . The antisense oligodeoxynucleotides, once in the cell, can 
stimulate the ribonuclease H after hybridization with target RNA. This enzyme, which is 
implicated in DNA replication, damages RNA moiety of the hybrids formed in the cell. On 
the other hand, the antisense oligonucleotide can remain as nondegraded, hybridizing to 
another messenger and inducing the degradation of this mRNA. In this way, in the presence 
of RNAse H, the antisense oligonucleotide acts in a catalytic marrow, with the enzyme 
potentiating the antisense effect (Hélène, 1990). 
The chemical stability of plasmid-derived antisense RNA seems much more efficient than 
that of antisense oligonucleotides delivered directly into cells. The antisense 
oligonucleotides are exposed to intra- and extracellular nuclease actvity. Antisense 
oligomers action can be reinforced by association with polycations like polyethyleneimin 
(PEI), polylysine or cationic lipids (DOTMA, DOTAP) facilitating endocytosis of oligomers 
(Galderisi et al., 1999). These positively charged molecules are also used for transfection of 
cells with plasmids encoding antisense RNA.  
The first antisense oligonucleotide used in clinical pharmacology was as anti-
cytomegalovirus therapy (VitraveneTM) (Vitravene Study Group, 2002). The antisense 
strategy was then largely used in order to analyze gene expression and intron splicing. The 
phosphorothioates are the most widely studied oligonucleotides, because of their nuclease 
stability are highly soluble and have excellent antisense activity. These data have led to the 
introduction of phosphorothioate oligonucleotides into clinical therapeutic trials (melanoma, 
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A good example of a new generation oligonucleotide is the N3' P5’ PN. The PN exhibits 
highly selective and specific antisense activity in vitro and in vivo. An 11-mer PN, 
complementary to junction region of the bcr-abl mRNA (thought to be a determinant of the 
chronic myelogenous leukemia phenotype) efficiently inhibited the growth of treated BV173 
cells (Gryaznow et al., 1996). Another exemple of new generation oligonucleotides concerns 
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expression, changing a morphologic phenotype of cultured neoplastic cells, and stopping in 
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cell line SGC 7901 (Yang et al., 2004). ASODN caused a statistically significant reduction of 
cell viability and the cell growth was significantly inhibited. A significant loss of survivin 
mRNA was also presented, and the protein level was significantly decreased. ASODN may 
provide a novel approach to therapy of gastric cancer. 
The antisense technology was used to study several protein actions: the alpha subunit of 
human chorionic gonadotrophin in choriocarcinoma cells (Cao et al., 1995); the regulating 
protein E2F-1, in S cellular cycle phase, and its action on genes linked to proliferation (Sala et 
al., 1994); nerve growth factor (NGF) in skin of transgenic mice, and its relationship with 
response to mechanical stimuli (Davis et al., 1993). Lately, the antisense strategy is 
“classically” used to analyze gene expression and intron splicing. The same technology was 
employed to study the function of the heat shock protein hsp70, overexpressed in mouse 
fibrosarcoma cells; a direct correlation was found between hsp70 overexpression and 
tumorigenicity of cells. Cells which express high rates of hsp70 are resistant in vitro to 
cytotoxic cells and macrophages (Jaattela, 1995). 
The action of IGF-I - BP-4, insulin-like growth factor I – binding protein 4, has also been 
studied using antisense strategy. The IGF-I – BP-4 was shown to inhibit the mitogenic effect 
of exogenous IGF on IIT29 tumor cells (Singh et al., 1994). The same antisense strategy was 
applied to study p27kipl protein. The quiescent state of cells needs the p27. The inhibition of 
p27 expression induces the progression of cell cycle and the cyclin D1 promoter activity. 
Hamster fibroblasts transformed in this way grow faster than non-treated cells, even in 
serum free medium (Rivard et al., 1996).  
In “antisense” anti-tumor experimental therapy different strategies were applied coming 
from 1992. Among them were strategies based on : 
 antisense oncogenes  (i.e. Okabe et al., 1993);  
 antisense of genes encoding enzymes (i.e. Ahmad et al., 1994); 
 antisense of protein related to MHC expression (i.e. Lichtenstein et al., 1992) and  
 antisense of genes encoding growth factors (i.e. Trojan et al, 1992); the last antisense 
strategy seems to constitute the most promoting approach in clinical trials. Some 
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2.2 Triple helix approach 
Since the 1990's, in parallel with antisense strategy, another approach – triple helix strategy 
is starting to be successfully introduced in experimental and clinical gene therapy trials 
(Scaggiante et al., 1994; Postel et al., 1991; Thomas et al., 1995). The triple helix (TH) 
technology is the new approach, which belongs together with antisense approach to anti-
gene strategies sensu lato, i.e. the techniques targeting the expression of respective up-
regulated gene. The TH technology was “discovered” by groups of P.B. Derwan (Derwan, 
1992) and of C. Helene (Helene, 1994). Its action is well defined by gene inhibition at the 
translation level. In brief, the short specific oligonucleotides (so called triple-helix forming 
oligonucleotides, TFOs) are delivered to cells both by cell transfection with chemical carriers 
and via vector plasmid that can drive the synthesis of TFO RNA. TFOs link to genomic 
double-strand DNA, form triple-helix structure with target gene and strongly inhibit its 
expression at transcriptional level. A triple-helical structure on DNA is considered to block 
transit of RNA polymerase. TFOs are usually targeted against polypurine/polypyrimidine 
sequences located in control regions (promoters) of the genes of interest (Derwan, 1992).  
The examples of the inhibitory activity of triplex-forming oligonucleotides on target genes 
involved in tumorigenesis are now available (i.e.  Giovannangeli & Hélène, 1997; Vasquez & 
Wilson, 1998). Most of the TFOs are targeted to polypurine-polypyrimidine sequences 
located in control regions of the gene of interest and are cell delivered via transfection with 
various chemical carriers. An alternative way to introduce TFOs in cells is to use a plasmid 
vector that can drive the synthesis of an RNA triplex-forming oligonucleotide inside the 
cells. This TFO generated in situ is therefore protected from degradation by nucleases and 
could reach its DNA target without being trapped in lysosomal vesicles. Obviously, it could 
be transfected in cells via either standard cell transfection procedures or via ways similarly 
used in virus-based gene therapy. An application of this triplex-based approach has been 
used for the inhibition of the IGF-I which plays a major role in tumorigenesis (Shevelev et al., 
1997). 
Triple helix strategy was also applied to the ras oncogenes which are the most frequently 
activated oncogenes in human cancer. In vitro transcription of human Ha-ras was inhibited 
by triplex-forming oligonucleotides targeted to sequences recognized by the Sp I tran-
cription factor (Mayfield et al., 1994). Growth factors are known to play a role in 
tumorigenesis, and thereby represent relevant targets for antigene therapies. The synthesis 
of human tumor necrosis factor (TNF), which acts as an autocrine growth factor in various 
tumor cell lines including neuroblastoma and glioblastoma, has been blocked by 
triplex-forming oligonucleotide treatment (Aggarwal et al., 1996 
2.3 Biotechnological limitations 
Human gene therapy is defined as a medical intervention based on the administration of 
genetic material in order to modify or manipulate the expression of a gene product or to 
alter the biological properties of living cells. Cells may be modified ex vivo for subsequent 
administration or altered in vivo by gene therapy products given directly to the subject. 
Example that falls under this definition includes use of antisense oligonucleotides to block 
gene transcription or use of sequence-specific oligonucleotides to correct a genetic mutation 
(Miller & Simek, 2000). 
The specificity of antisense mechanism of action should be verified by: a proof of cellular 
uptake, the use of multiple control oligonucleotide sequences and direct measurement of 
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target mRNA or protein levels. Anyway, phosphorothioate oligonucleotides are in general 
able to produce a wide spectrum of nonspecific effects, especially at high concentration. 
Fortunatelly non-antisense effects can be therapeutically useful although their 
unpredictability can confound research applications of these biologically active 
molecules in human gene therapy (Lebedeva & Stein, 2002).  
Antisense oligonucleotides have been widely employed as a method to decrease tumor cell 
viability and chemoresistance and to induce apoptosis in vitro and in vivo. The “weakness” 
of oligonucleotides is not only their sensitivity to nuclease digestion, which affects 
their half-life in culture and in vivo, but also their inappropriate intracellular 
compartmentalization. It seems that the most reliable way to choose an antisense 
sequence is the "mRNA walking" method (i.e. in bcl-2 antisense) (Lebedeva & Stein, 
2002).  
Undesirable properties have been identified for phosphorothioate oligodeoxynucleotides. 
When dosed at high levels it is possible to identify toxicities in rodents and primates. 
However, at doses currently under evaluation in the clinic, phosphorothioate 
oligodeoxynucleotides have been well tolerated. Extensive medicinal chemistry efforts 
have been successfully focused on identifying improved antisense oligonucleotides. 
Oligonucleotide modifications have been identified that exhibit increased resistance to 
serum and cellular nucleases, enabling use of oligonucleotides that do not have phospho-
rothioate linkages (Benett et al., 2000). The tissue distribution of oligonucleotides may be 
altered with either chemical modifications or formulations. The modified oligonucleotides 
have been described that potentially exhibited less toxicity than first-generation 
phosphorothioate oligodeoxynucleotides. Because experience with these modified 
oligonucleotides is rather limited, it remains to be seen whether they will have a distinct 
toxicity profile. The data also suggest that oral delivery of antisense oligonucleotides 
may be feasible, which would increase the utility of the technology. Identification of second- 
and third-generation oligonucleotides should ameliorate therapies for patients (Benett et al., 
2000).   
3. IGF-I and tumorigenicity 
There is a convergence between ontogenesis and cancerogenesis and the same specific 
antigens (oncoproteins) are present in embryo/fetal tissues and in corresponding neoplastic 
developing tissues. The development of the brain is related to appearance of specific 
antigens. These disappear in mature brain and reappear in the development of neoplastic 
nervous tissue development. Gene expression during neoplastic brain development 
concerns oncoproteins (such as alpha-fetoptrotein, as well as serum albumin) (Trojan et al., 
1984), growth factors and their respective receptors (i.e. IGF-I, EGF, FGF, VEGF, TGF-alpha 
and -beta) (Baserga, 1994). Their down stream proteins and glycogen signalling elements 
including glycogen synthase (GS), are also involved (Patel et al., 2004; Trojan et al., 2007).  In 
1992 Trojan and his co-workers have demonstrated that an Insulin-like growth factor 1, IGF-
I, is present in glioma cells but absent in neuroblastoma cells (Trojan et al., 1992). Using 
teratocarcinoma model, Trojan and his co-workers have shown that neoplastic hepatocytes 
express IGF-I and IGF-II, and neuroblastic cells express IGF-II (Trojan et al., 1994). These 
observations permitted to study separetly, using IGF-I and IGF-II as the oncoprotein 
markers, different groups of diseases: of glial, neural and digestive tube and hepatocyte 
origin. 
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IGF-I is a 70-amino acid polypeptide involved in cell and tissue differentiation (Daughaday 
et al., 1972; Froesch et al., 1985; Baserga, 1994; Trojan et al., 1994) coded by IGF-I gene 
(Sussenbach et al., 1992). IGF-I plays an important role in growth as a mediator of growth 
hormone, GH, and a locally acting stimulator (Froesch et al., 1985; Le Roith et al., 2001). The 
action of IGF-I on cellular metabolism depends on binding proteins, IGFBP, which prolong 
the half life of this factor and modify its interaction with receptor (i.e. Rosen, 1999). IGF-I 
acts via specific IGF-I receptor and subsequent activation of a protein tyrosine phosphorylic 
signal transduction cascade, similar to that of insulin action (Werner and Le Roith, 2000). 
Through its binding to IGF-I-R, which activates a protein tyrosine phosphorylic signal 
transduction cascade, PI3K/AKT/GSK3, similar to that of insulin action (Adams et al., 
2000), IGF-I has been reported to block the apoptosis pathway (IRS/PI3K/AKT/Bcl or 
GSK3 or Ca++ or caspases). Such a blockade occurs at the cytoplasmic and nuclear 
levels in a variety of cell lines, including neuronal and glial cells ( D’Mello et al., 1993;  
Baserga, 1994;  Mason et al., 2000, Chrysis et al., 2001). The anti-inflammatory and anti-
apoptotic effects of IGF-I are established through an increase of phosphatidylinosotol 3’ 
kinase (PI3 kinase) activity and a maintain of Bcl-2 survival proteins. PI3 kinase is directly 
related to insulin receptor substrate (IRS-1), the latter following the tyrosine kinase (IGF-I 
receptor) (D’Ambrosio et al., 1996). IGF-I being known as a factor protecting cells from 
apoptosis, different researchers have tried to stop apoptotic effect using the approach of 
antisense IGF-I receptor (Resnicoff et al., 1994). The block of IGF-I synthesis, induces 
apoptotic and also immunogenic phenomenons (Upegui-Gonzalez et al., 1998). 
The human IGF-I gene is located within a region of over 85 kb on the chromosome 12 - 
12p22 (Daughaday and Rotwein, 1989; Sussenbach et al., 1992).  Deregulated expression of 
growth factors and/or their receptors, and especially of IGF-I, is associated as well with 
growth as with pathology of different diseases, including tumors (Trojan et al., 1993; 
Baserga, 1994; Rubin and Baserga, 1995). Since last Symposium “IGFs and Cancer”, held in 
Halle in Germany (15-17.09.2000), IGF-I is considered as a diagnostic marker and a 
biological modulator in different types of tumors, especially in brain tumors (Zumkeller & 
Westphal, 2001).  
4. Methodology 
Described methodology established for an experimental preclinical research was applied for 
clinical research.  
4.1 Plasmids 
The episome based plasmid pMT-Anti IGF-I was constructed as previously described 
(Trojan et al., 1992). The vector pMT-EP, under the control of the metallothionein, MT-I, 
inducible promotor was used as its base. The casette contains the Epstein-Barr Virus origin 
of replication and the gene encoding nuclear antigen I which together drive 
extrachromosomal replication. Down-stream of the insertion site is a poly A termination 
signal followed by the hygromycin B and ampilicin resistance genes. Comparatively, the 
same plasmid was prepared containing either CMV or HS (heat shock) promotors. The 
vector expressing IGF-I triple helix (pMT-AG triple helix) was constructed as previously 
described (Shevelev et al., 1997). This cassette consists of a 23 bp DNA fragment cloned into 
the vector pMT-EP which transcribes a third RNA strand forming a triple helix structure 
within the target region of the human IGF-I gene, between its transcription and translation 
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initiation sites. The vector pMT-EP with either the lac-Z reporter gene, or cDNA expressing 
IGF-II antisense RNA as insert was used in control experiments (Trojan et al., 1994).  
Vectors encoding MHC-I or B-7 antisense cDNA were constructed in the laboratory of J. Ilan 
(CWRU, Cleveland) using pMT-EP containing the neomycine (G418) resistance gene instead 
of the hygromycin B resistance gene, and the MHC-I or B7 insert in antisense orientation in 
place of the IGF-I gene sequence.  
4.2 Cell culture 
Human primary glioma cell lines (Anthony et al., 1998; Trojan et al., 2003),  were cultured in 
DMEM+F12 (v/v) (GIBCO-BRL) supplemented with 10 % FCS, 2mM glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin, at 37° C and 5 % C02. Hygromycin B (Boehringer 
Mannheim) at a concentration of 0,005 mg/ml was added 48 hours after transfection to 
select for transfected cells. Then the concentration of hygromycin for cell culture was 
determined as previously described (Anthony et al., 1998). B-104 rat neuroblastoma cell line 
(obtained from ATCC) was used as a negative control (Trojan et al., 1992). 
Primary cell cultures of human glioma were derived from tumors of glioblastoma patients 
during surgical resection in the University Hospital of Cleveland, OH, Hopital Val-de-
Grace, Paris and the Medical University Hospital of Bydgoszcz (5 to 6 cases from every 
hospital). Surgical sections approximately 3x3 mm X 1-2 cm in length were placed in DMEM 
containing high glucose concentration, 100 U/ml penicillin and 100 U/ml streptomycin. 
Specimens were then transferred to phosphate buffered saline (PBS) containing no Ca2+ or 
Mg2+ and dissected into 1-2 mm fragments. The tissue was then centrifuged at 1500 rpm x 5 
min. The pellet was resuspended in DMEM containing 20 % FCS supplemented with 2mM 
glutamine, 100 U/ml penicillin, 100 microg/ml streptomycin and 10 ng/ml EGF. Cell 
suspensions were adjusted to a concentration of 2 million cells / well in 6-well plates and 
incubated at 37 C and 5 % C02 in culture medium containing 10 ng/ml EGF (Sigma) 
(GIBCO). After two days, dead cells were removed and incubation was continued in DMEM 
containing 10% FCS, and no EGF, for three additional days. The medium was then changed 
to DMEM minus FCS and incubation was continued x 48 hours. Following this first week, 
cells were maintained in 5% FCS / DMEM / 10% C02 / 37° C until stable transfection was 
established (approximately 4 weeks).  
4.3 Transfection 
Cultures of cells, 60-80 % confluent, were transfected in 6-well plates utilizing a ratio of 1 µg 
plasmid DNA per 400 000 cells. The FuGENE 6 Transfection Reagent (Boehringer 
Mannheim) was used according to the supplier's instructions. To determine the efficiency of 
transfection, the process was carried out using the pMT-EP construct containing lac-Z as a 
reporter gene. Cell cultures were washed in PBS and incubated at 37° C in the presence of 
the staining solution which contained 5mM K3Fe(CN)6, 2mM MgCl2, 0,8 mg/ml X-gal 
made in PBS. The selected IGF-I « antisense » or « triple helix » cell clones (expressing MHC-
I and B7) were co-transfected with vectors either encoding MHC-I or B7 antisense cDNA , in 
the presence of 0,4 mg/ml of G-418 .  
4.4 Northern blot 
Content of IGF-I antisense RNA was determined in 50 % confluent cell cultures. Cells were 
deprived of serum and cultured overnight in DMEM containing 0,1 % BSA ; 60 µM Zn S04 
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initiation sites. The vector pMT-EP with either the lac-Z reporter gene, or cDNA expressing 
IGF-II antisense RNA as insert was used in control experiments (Trojan et al., 1994).  
Vectors encoding MHC-I or B-7 antisense cDNA were constructed in the laboratory of J. Ilan 
(CWRU, Cleveland) using pMT-EP containing the neomycine (G418) resistance gene instead 
of the hygromycin B resistance gene, and the MHC-I or B7 insert in antisense orientation in 
place of the IGF-I gene sequence.  
4.2 Cell culture 
Human primary glioma cell lines (Anthony et al., 1998; Trojan et al., 2003),  were cultured in 
DMEM+F12 (v/v) (GIBCO-BRL) supplemented with 10 % FCS, 2mM glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin, at 37° C and 5 % C02. Hygromycin B (Boehringer 
Mannheim) at a concentration of 0,005 mg/ml was added 48 hours after transfection to 
select for transfected cells. Then the concentration of hygromycin for cell culture was 
determined as previously described (Anthony et al., 1998). B-104 rat neuroblastoma cell line 
(obtained from ATCC) was used as a negative control (Trojan et al., 1992). 
Primary cell cultures of human glioma were derived from tumors of glioblastoma patients 
during surgical resection in the University Hospital of Cleveland, OH, Hopital Val-de-
Grace, Paris and the Medical University Hospital of Bydgoszcz (5 to 6 cases from every 
hospital). Surgical sections approximately 3x3 mm X 1-2 cm in length were placed in DMEM 
containing high glucose concentration, 100 U/ml penicillin and 100 U/ml streptomycin. 
Specimens were then transferred to phosphate buffered saline (PBS) containing no Ca2+ or 
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min. The pellet was resuspended in DMEM containing 20 % FCS supplemented with 2mM 
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suspensions were adjusted to a concentration of 2 million cells / well in 6-well plates and 
incubated at 37 C and 5 % C02 in culture medium containing 10 ng/ml EGF (Sigma) 
(GIBCO). After two days, dead cells were removed and incubation was continued in DMEM 
containing 10% FCS, and no EGF, for three additional days. The medium was then changed 
to DMEM minus FCS and incubation was continued x 48 hours. Following this first week, 
cells were maintained in 5% FCS / DMEM / 10% C02 / 37° C until stable transfection was 
established (approximately 4 weeks).  
4.3 Transfection 
Cultures of cells, 60-80 % confluent, were transfected in 6-well plates utilizing a ratio of 1 µg 
plasmid DNA per 400 000 cells. The FuGENE 6 Transfection Reagent (Boehringer 
Mannheim) was used according to the supplier's instructions. To determine the efficiency of 
transfection, the process was carried out using the pMT-EP construct containing lac-Z as a 
reporter gene. Cell cultures were washed in PBS and incubated at 37° C in the presence of 
the staining solution which contained 5mM K3Fe(CN)6, 2mM MgCl2, 0,8 mg/ml X-gal 
made in PBS. The selected IGF-I « antisense » or « triple helix » cell clones (expressing MHC-
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Content of IGF-I antisense RNA was determined in 50 % confluent cell cultures. Cells were 
deprived of serum and cultured overnight in DMEM containing 0,1 % BSA ; 60 µM Zn S04 
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(Sigma) was then added x 5 hours to induce the MTI promoter. The cells were then prepared 
for Northern blot. Labeling of human IGF-I cDNA and chicken beta actin cDNA and 
hybridizations were done according to Maniatis and procedures previously 
described (Trojan et al, 1992, 2003); the 770 bp human IGF-I cDNA and 500 bp rat IGF-I 
cDNA used as probes were a gift from J. llan (CWRU, Cleveland). The Northern blot was 
used also to verify expression of IGF-I in solid glioblastomas.  
4.5 Histology 
The removed human samples of tumours were fixed in 4% para-formaldehyde, and paraffin 
embedded sections were stained for IGF-I by immunoperoxidase technique (Vectastain ABC 
kit, Vector Laboratories, Burlingame, CA, USA).  
4.6 Immunocytochemistry and flow cytometry analysis (FACS)  
Immunocytochemical localization of IGF-I protein was done by the immunoperoxidase 
technique (Vectastain ABC kit, Vector Laboratories, Burlingame, CA, USA). Cells were fixed 
in 4 % paraformaldehyde. Polyclonal antibodies against rat and mouse IGF-I and against 
human IGF-I were purchased from Valbiotech (Paris, France).  
For FACS, paraformaldehyde-fixed cells were treated as described earlier (Trojan et al., 
1996). Stained cells were analyzed for MHC-I, MHC-II and B7 antigens, as well as for CD 
antigens of PBL cells, in a FACSCAN flow cytometer (Becton Dickinson).  
4.7 Fluorescein cell - death detection 
Apoptosis was determined by dUTP-fluorescein terminal transferase-labeling of nicked 
DNA (TUNEL apoptosis assay). The « In situ Cell Death Detection Kit, fluorescein » 
(Boehringer Mannheim) was used according to supplier's instructions.  
4.8 Preparation of cell membranes 
Human glioma cells membranes were prepared according to the method of M.A. Matlib 
with modifications (Matlib et al., 1988). The Na+-Ca2+ exchange system in vascular smooth 
muscle cell membrane vesicles isolated from cultured cells and from tissue is similar. 
Homogenization of tissues was performed on ice by Polytron homogenizer in 20 mM 
MOPS, 250 mM sucrose, 0.05% BSA, 0.25 mM PMSF, pH 7.5. Homogenates were centrifuged 
for 10 min at 1000 x g, and the supernatant was recentrifuged for 15 min at 10000 x g. 
Microsome membranes were sedimented from the supernatant by centrifugation for 60 min 
at 100000 x g. The pellet was resuspended in 20 mM MOPS, pH 7.5, layered on top of 0.8 M 
sucrose in 20 mM MOPS and centrifuged in SW-27 bucket rotor (60 min x 24000 rpm). The 
pellet was collected from the interphase and recentrifuged under the same conditions. 
Finally, the membrane pellet was resuspended in 20 mM MOPS, pH 7.5, frozen in liquid 
nitrogen and stored at -70oC. For treatment of glioblastoma patients, the membrane pellet 
resuspended in MOPS, was, one hour befor vaccination, ressuspended in PBS (0.9% NaCl, 
pH 7.5) in ratio 1: 100.  
4.9 Vaccination of glioblastoma patients  
Human glioma cell lines were transfected with the “triple helix” pMT–AG TH plasmid 
vector. Clones of transfected cells (down-regulated for IGF-I and expressing MHC-I and B7 
molecules) were selected after two months - coming from a day of transfection. Before 
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injection the cells were irradiated. The first injection was done using the membranes only of 
so prepared 1 mln cells - injected subcutaneously into the left arm of operated glioblastoma 
patients (The next 3 weeks permitted to prepare a sufficient number of 5 million cells for the 
second injection, and then for the third injection). The blood was collected before the first 
vaccination, and then 3 weeks after the first and the second injection. Peripheral blood 
lymphocyte (PBL) typing was performed using mouse monoclonal antibodies directed 
against the superficial cell antigens.  
The samples of monoclonal antibodies were used for flow cytometer analysis as follows: 
conjugated to FITC - (a) CD45, (b) CD 4, (c) CD3, (d) CD25, (e) CD45RO, (f) CD19, (g) CD8, (h) 
CD8CD11b+, (i) control antibody IgG1, and those conjugated to PE – (a) CD14, (b) CD8, (c) 
CD16+CD6, (d) CD4(CD8), (e) CD4(CD8), (f)CD5, (g) CD8CD11b-, (h) CD8CD28, (i)  IgG2.   
5. Results 
The approval for the gene therapy clinical trial (based on NIH clinical study n°1602, 
Bethesda, Maryland, 24. 11. 1993) was administrated by the Bioethical Commission of the L. 
Rydygier Medical University, Bromberg (Bydgoszcz), Poland (n° KB/176/2001, 28. 06. 2002) 
and registered by international Wiley Gene Therapy Clinical Trial database n° 635 and 636 
(J. Gene Med., updated 2002), and by NATO Science program (LST 980517). 
Primary glioma cell cultures were established from biopsies of human GBM (Trojan et al., 
1996). The established cell lines were transfected with “antisense” or “triple helix” IGF-I 
vector. The cells were down regulated in IGF-I and presented both MHC-I and B7.1 
molecules. The IGF-I antisense cells or “vaccine” were irradiated before injection into status 
post-surgically resected glioblastoma patients. The significant changes observed were 
primarily after the first vaccination (Fig. 1). The phenotypic changes in peripheral blood 
lymphocytes were as follows. There was an increase in the percentage of CD8+T cells with a 
characteristic CD8+CD11b-  and CD8CD28+ phenotype after each of three vaccinations, the 
alteration that may reflect the enhanced activation of T cytotoxic cells in blood (Fig. 2). 
Additionally, an increased percentage of the lymphocytes positive for superficial 
interleukine-2 receptor (CD25) was observed. No changes in other CD molecules were 
demonstrated (Trojan et al., 2003, 2007). In our work in progress (new protocol) 4th and 5th 
injections of IGF-I TH cells in glioblastoma patients have been introduced. After the 4th 
injection the blood of treated patients showed a progressive increase in CD8 and NK cells, as 
compared with the 1st and 2nd injections, which underlines the in vivo immune effect of 
injected IGF-I TH cells. An increase in CD25 after the 2nd and 3rd injections was also 
observed. Then, after the 4th and 5th injections this progression slowed down. The only side 
effect observed was a post-vaccination fever of 38°C, corresponding probably to a cellular 
immune response (induction of T lymphocytes). These alterations may reflect the enhanced 
activation of cytotoxic T cells (Trojan et al., 2007a). 
The promising results were obtained in six Phase-I patients at University Hospitals of 
Cleveland, USA, in two patients in Bangkock Thailand and in four patients at the University 
Hospital of Bromberg (Bydgoszcz), Poland. In these Phase I trials, no unacceptable 
complications in patients were observed from the treatment. The only complicating finding 
was transit increase in temperature to 38-38.5 0C lasting 24-48 hours (confirming the 
presence of immune anti-tumour response). This usually occurred by 12 hours and in 8 of 
the 12 GBM patients that were treated. In the patients treated in the United States study, and 
in those investigated in Bromberg, Poland, tumour burden at time of treatment was 
advanced. One patient who was treated at University Hospitals of Cleveland, had lived 24 
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Fig. 1. Schema of IGF-I antisense therapy. The tumor cells are cloned in vitro to obtain a cell line 
positive for IGF-I. *After transfection of the cell line with a vector containing IGF-I cDNA in 
antisens orientation, the cells express IGF-I antisens RNA, and become negatively stained 
for IGF-I and positively for MHC-I and B7. Moreover they become apoptotic. Both 
phenomenons, immune and apoptotic, are related to signal transduction pathway (the 
presented pathway is common for different growth factors as EGF, VEGF, TGF-beta or PDGF).  The 
injected transfected cells including apoptotic cells, together with APC cells induced in vivo, 
activate T lymphocytes (CTL CD8+CD28+); activated CTL produce immune anti tumot 
response (Beckner et al., 2005; Fontenau et al., 2002; Ly et al., 2001; Trojan et al., 2007a, 2010). 
Abréviations : TAP 1,2 (transporter associated with antigen processing antigen); TK 
(tyrosine kinase); PI3K (phosphatidyinositol 3 kinase); PDK1 (phosphoinositide-dependent 
kinase 1); AKT (PKB, protein kinase B); Bcl 2 (key molecule of apoptose); GSK3 (glycogene 
synthetase kinase 3); GS (glycogene synthetase); MAPK (MAP kinase – mitogen activated 
protein kinase); PKC (protein kinase C). 
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Fig. 2. Flow cytometric peripheral blood lymphocyte CD marker patterns following cellular 
anti - gene anti IGF-I therapy in glioblastoma multiforme. CD molecules were labelled in 
peripheral blood lymphocytes (PBL) obtained from prevaccinated and “vaccinated “ cancer 
patients.  Each of the first column (blue) corresponds to data obtained before vaccinations; 
each second and third column corresponds to data obtained after two successive cellular 
vaccinations. Two cases of glioblastoma were examined (every column represents the 
median value of two cases). The successive vaccinations consited of injections of 1.5x106 to 
2.0x106 transfected cells.   Interval between successive injections was four weeks. PBL were 
analyzed by flow cytometry analysis using FACScan Becton Dickinson cytometer. Double 
direct immunotyping with pairs of monoclonal antibodies conjugated with FITC and PE 
were used. Lymphocyte gate was defined according to the CD45 back gating. Data are 
expressed as percent of positive cells when compared to the isotype control. Difference in 
percentage of CD8+ CD11b-  and  CD8+ CD28+ subpopulations before and after vaccination 
was strongly significant with a range of p from 0.001 to 0.02 according to the Student’s t test,  
and weakly significant  concerning the decreasing CD8+ CD11b+ subpopulation from the 
relevant patients. Difference in percentage of NK, CD3, CD4  sub-populations before and 
after vaccinations was not significant.  
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months from time of diagnosis. He had been treated with conventional courses of 
combination chemotherapy followed by stem cell transplantation, prior to treatment with 
vaccine. Among five other patients treated in USA (University Hospitals of Cleveland), two 
of the treated patients forming a group of maximum median OS have both survived 19 
months. The therapy done in USA has shown that the number of cell vaccinations (between 
one and four) was not related to to the median OS. Other group of three patients treated in 
USA, have not responded as positively to the therapy. The patient had advanced disease 
with cerebral oedema at the time of first treatment with vaccine, and also were receiving 
treatment with high dose of decadron or related steroids to reduce the effect of CNS 
oedema. This of course has caused further jeopardy to the immune system, and can explain 
the relatively negative results in three treated cases (not published data). In two of the four 
patients with GBM treated in Bromberg (NATO Science Programme – U.S./France/Poland), 
life from time of diagnosis to time of demise was 19 and 24 months.  In two control treated 
patients, life was an average of 9,5-10 months (Trojan et al., 2010). The significant clinical 
results were published in 2006/2007, when it was shown that using AS approach following 
radio- and chemotherapy, the median survival of patients reached 21 months (Trojan et al., 
2007a, 2007b). In 2010 we have communicated, that this relatively high median survival of 
glioblastoma patients could be explained by immune response related to the increase of 
CD28 molecules in PBL cells shown after every of two successive  “vaccinations”. Moreover 
this phenomenon was observed also in other studied tumours (four cases of liver, colon, 
ovary, uterus and prostate cancers (Trojan et al., 2010). Histopathologic examination of 
resected glioblastoma tumours showed that subjects had developed peritumour necrosis 
and tissue bordering the necrotic tumour showed infiltration by lymphocytes consisting of 
both CD8+ T and CD4+ T cells (Wongkajornsilp et al., 2011). There was no difference before 
or after the vaccination in the CD3, CD16+CD56, CD19, CD5, CD45 and CD14 levels. 
6. Discussion 
The immunosuppression phenomenon was largely described in cancer patients (Brooks et 
al., 1981; Roszman et al., 1991). TGF-beta was identified as factor suppressing T lymphocytes 
in tumors (Couldwell et al., 1991). Surgery seems to diminish the immunosuppressive effect 
(Sawamura & de Tribolet, 1990). Immune response could be increased by different 
approaches as the injections of interferon, IL-2, activated lymphocytes, monoclonal 
antibodies or irradiated cells (i.e. Apuzzo & Mitchell, 1981) or using approach of IGF-I 
antisense treatment (Trojan et al., 1993; Ly et al., 2001). 
Previous results have shown that tumor cells of glioma, transfected with IGF-I antisense 
expression vector had no longer induced tumor formation, when injected into host 
recipients as compared to unmanipulated cells (Trojan et al., 1993). The mechanisms leading 
to this tumor inhibition in host animals could be drawn:  
Tumor cells treated by IGF-I antisense become immunogenic to the isogenic recipients 
whose immune system was triggered via the novo expression of MHC-I presenting antigen 
as well as B7 costimulation molecule (Trojan et al., 1996). The effects of antisense IGF-I and 
targetting to IGF-I on tumor growth could also be discussed at the molecular basis in 
considering the balance between survival versus death signals. Thus the role of insulin-like 
growth factor must also be analyzed for its inhibitotry effects on prototypical 
proinflammatory cytokine tumor necrosis factor alpha (TNF alpha) (Upegui-Gonzalez et al., 
2001). TNF alpha is a pleiotropic cytokine that promotes inflammation and signals of death.  
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The IGF-I antisense transfected cells, when co-transfected with vectors encoding MHC-I 
and/or and B-7 antisense cDNA, however maintained their previous IGF-I « antisense » 
morphology, the number of apoptotic cells in the cultures of the double co-transfected IGF-I 
antisense glioma cells decreased from 60-70 to 20-30 % (Ly et al., 2001). The observation 
suggests that a relation could exist between immunogenicity and apoptosis in IGF-I 
transfected cells. They also indicate that both antigens, B-7 and MHC-I, are necessary to 
« render » the IGF-I antisense or triple-helix glioma cells immunogenic. The role of both B-7 
and MHC-I antigens in the induction of T cell immunity against tumors has been 
extensively investigated (Chen et al., 1992). As far as B-7 appeararance in IGF-I antisense 
transfected cells is considered, the absence of IGF-I synthesis would be expected to lead to a 
higher activation of the receptor of IGF-I (tyrosine kinase). This in turn could lead to 
induction in the expression of B7 antigen; enhancement in B7 co-stimulation through a 
cAMP mechanism linked to tyrosine kinase of the CD 28 receptor has been previously 
reported (Schwartz, 1992). As to the MHC-I expression, down-regulation of MHC-I due to 
action of IGF-I has been reported for experiments with rat thyroid cells (Saji et al, 1992). This 
would be in agreement with results reported here concerning the inverse correlation 
between IGF-I and MHC-I protein expression in glioma cells. 
In tumor cells, the absence of IGF-I, when induced by IGF-I antisense technology, is 
associated with massive apoptosis. A qualitative relationship between the level of IGF-I 
receptor and tumorigenesis in nude mice, which correlates to the extent of apoptosis has 
been shown (Resnicoff et al., 1996). When the function of IGF-I receptor is decreased, glioma 
cells undergo massive apoptosis. It was concluded for the IGF-I-R result, that this receptor 
activated by its ligand plays a protective role against programmed cell death. This 
protection was even more striking in vivo than in vitro (Resnicoff et al., 1996). Another 
possible interpretation could be that an immune response occurring in the animals inhibits 
tumorigenesis. This is probably because nude mice do have a residual immune system 
containing both natural killer cells and B lymphocyte. The observation that C6 glioma cells 
transfected with IGF-I-R anti-gene approach express MHC-I (Szpechcinski et al., 2004) seems 
to  confirm that both apoptosis and an immune mechanism occur in the inhibition of tumour 
genesis. These IGF-I-R antisense and triple helix transfected C6 cells also express protease 
nexin I, which may reduce the tumourigenic potential of the C6 glioma cells injected into 
nude mice (Rininsland et al., 1997, Shevelev et al., 1997). 
A further elucidation of the relationship between the immune process, related to MHC-I or 
HLA system (Blanchet et al., 1996), and the apoptotic process is under investigation. 
Recently it was demonstrated that dendritic cells which are involved in tumor-
immunogenicity mechanisms by activation of lymphocytes CD8 in the context of MHC-I, 
recognize apoptotic cells (Matthew et al, 1998). The last data could suggest the following 
mechanism of IGF-I anti - gene therapy : suppression of IGF-I – induction of MHC-I and B7 
– Induction of apoptosis – involving of APC cells – induction of CD8 T cells. The 
relationship between two phenomenons, immunogenicity and apoptosis is crucial for the 
discussion of mechanism of IGF-I antisense gene therapy. Moreover, this point is capital for 
the selection of cell clones used in gene therapy of glioblastoma in clinical trial.  
The first clinical results obtained with glioblastoma using anti – gene anti IGF-I therapy are 
very promising. Comparatively, the most recent chemotherapy, proposing temozolomid 
combined with radiotherapy, has shown in recurrent glioma patients the median 
progression-free survival as 10 weeks, and median overall survival as 30 weeks, respectively 
(Stupp et al., 2005). However, median survival is the most important consideration to be 
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taken into account (Stupp reported a 14.6 months median survival). In some cases of 
glioblastoma a strong association between methylation of the promoter region of the gene 
for 06-methylguanin-DNA methyltransferase (MGMT) and a benefit from temozolomid has 
been demonstrated (Hegi et al., 2005). Patients whose tumours had methylation of the 
MGMT gene, and who received chemo-radiation, had a 2-year survival rate of 46% 
compared with a 2-year survival rate of less than 2% in patients whose tumours had an 
actively unmethylated MGMT gene. On the contrary, other studies do not support the 
correlation of MGMT promoter methylation. Both temozolomide/MGMT and IGF-I anti-
gene approaches strongly support the strategy of individualized therapy. In the case of the 
IGF-I anti-gene approach the verification of MHC-I and B7 in the “vaccine” of every patient 
is the sine qua non condition for success in obtaining maximum survival. 
Obviously, IGF-I was not the only growth factor target as an anti-gene approach for 
glioblastoma treatment. The recently studied TGF-2 antisense compound (AP 12009) gave 
satisfactory results in preclinical investigations, and was introduced in a clinical phase I/II 
study in malignant tumours, including glioblastoma (Kaminska et al., 2005, Schlingensiepen 
et al., 2006).  The important data have been presented in international trial since 2004: in 
three phase I/II dose escalation studies of GBM patients, the median overall survival time 
(mOS) from start of the first chemotherapy after recurrence was 44 weeks. The mOS for a 
patient subgroup that received temozolomide as chemotherapy before AP-12009 was 46.1 
weeks. In 2007 the mOS group was 28.6 months  (and 75% were still alive), and in the 
control group, survival was 20.2 months (and 42% remained alive). In another clinical AS 
TGF-beta study, a phase I clinical trial of GBM was performed using autologous tumor cells 
modified by a AS TGF-beta2 vector (Fakhrai et al., 1996). Six patients with progressive GBM 
were enrolled in the trial. Patients received 2-7 subcutaneous injections of transfected tumor 
cells. There were indications of humoral and cellular immunity induced by the vaccine. Two 
patients had partial regressions and two had stable disease following therapy. The oMS was 
68 weeks. mOS of the responding patients was 78 weeks (Fakhrai et al., 1996).  
The in vitro and in vivo “antisense” results obtained with IGF-I and its receptor seem more 
significant than those obtained with other growth factors. That is probably due to a special 
role playing by IGF-I among other growth factors (Pollak et al., 2004; Trojan et al., 2007a) – 
thus IGF-I via IGF-I-R, not only increases cell proliferation but ”supervises” mitogenic 
action of other growth factors (EGF, PDGF etc.) by its autocrine-paracrine stimulation, 
becoming somewhat of growth factors director. As to a clinical trial of glioblastoma using 
the antisense IGF-I-R strategy (Andrews et al., 2001) 12 patients with recurrent glioblastoma 
and anaplastic astrocytoma were treated using an antisense oligonucleotide directed against 
IGF-I-R (implantation into the rectus sheath of irradiated autologous glioma cells 
encapsulated in diffusion chambers, after incubation with antisense IGF-I-R). Three patients 
were re-treated later using the same dose of oligodeoxynucleotides. Treatment was 
associated with incidences of vein thrombosis, but also with a rather high rate of clinical and 
radiological improvements. Two complete responses and four partial responses were 
achieved. Two patients were alive at 168 and 134 weeks after antisense therapy. Histological 
analysis of tumours resected from patients with disease progression revealed lymphocytic 
infiltration and necrosis (Andrews et al., 2001). It seems that this therapy could be more 
efficient if the cell ”vaccines” used were prepared after cloning of IGF-I-R antisense cells for 
MHC-I expression (Szpechcinski et al., 2004). Currently, regarding IGF-I, about 400 articles 
are published a year, and since 2001, more than 2000 publications deal with  a relationship 
existing  between growth factors and gliomas. In this context, the treatment of gliomas using 
 
Gene Therapy of Glioblastoma:Anti – Gene Anti IGF-I Strategy 217 
different technologies targeting growth factors and their down stream elements, has 
produced a burst in use of the antisense approach, presenting almost 100 publications a year 
since 2005. 
7. Conclusion 
The presented chapter on gene therapy of GBM draws attention to the latest studies in the 
area of antisense cancer therapy (in relation with apoptotic and immune phenomena as well 
as signal transduction pathway) being among the most promising strategy of treatment of 
this malignant brain tumour. Although the number of "antisense" clinical trials is much 
lower than that of experimental preclinical therapies (Table 1), we would like to underline 
that every experimental therapy is a potential clinical trial, the later often depending on 
hospital/administrative logistics. The current clinical strategies of glioma treatment are 
generally a combination of chemotherapy with therapies using different types of inhibitors 
(imatinib, gefitinb) including antibodies (i.e. avastin) targeting growth factors and their 
receptors (i.e. Stupp et al. 2005; Reardon et al. 2006;  Wen et al. 2006). The most recent 
therapies are now focusing on antisense technology used alone or combined also with 
pharmacological treatment  (Dietrich et al. 2010). A pharmacologic strategy – the use of 
temozolomide, introduced by Dr R. Stupp, has offered a new hope for the treatment of this 
tumour. However, even though the median survival has reached almost two years, we are 
still far from victory (Hegi et al., 2005; Gorlia et al., 2008). Among the new strategies in efforts 
to successfully treat GBM, the use of AS approach targeting IGF-I, TGF-beta or VEGF, their 
receptors and their down stream transduction signalling elements (Trojan et al., 2007a; Pan 
et al., 2007; Hau et al., 2009), appears to offer hope for a promising solution.  
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thus IGF-I via IGF-I-R, not only increases cell proliferation but ”supervises” mitogenic 
action of other growth factors (EGF, PDGF etc.) by its autocrine-paracrine stimulation, 
becoming somewhat of growth factors director. As to a clinical trial of glioblastoma using 
the antisense IGF-I-R strategy (Andrews et al., 2001) 12 patients with recurrent glioblastoma 
and anaplastic astrocytoma were treated using an antisense oligonucleotide directed against 
IGF-I-R (implantation into the rectus sheath of irradiated autologous glioma cells 
encapsulated in diffusion chambers, after incubation with antisense IGF-I-R). Three patients 
were re-treated later using the same dose of oligodeoxynucleotides. Treatment was 
associated with incidences of vein thrombosis, but also with a rather high rate of clinical and 
radiological improvements. Two complete responses and four partial responses were 
achieved. Two patients were alive at 168 and 134 weeks after antisense therapy. Histological 
analysis of tumours resected from patients with disease progression revealed lymphocytic 
infiltration and necrosis (Andrews et al., 2001). It seems that this therapy could be more 
efficient if the cell ”vaccines” used were prepared after cloning of IGF-I-R antisense cells for 
MHC-I expression (Szpechcinski et al., 2004). Currently, regarding IGF-I, about 400 articles 
are published a year, and since 2001, more than 2000 publications deal with  a relationship 
existing  between growth factors and gliomas. In this context, the treatment of gliomas using 
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different technologies targeting growth factors and their down stream elements, has 
produced a burst in use of the antisense approach, presenting almost 100 publications a year 
since 2005. 
7. Conclusion 
The presented chapter on gene therapy of GBM draws attention to the latest studies in the 
area of antisense cancer therapy (in relation with apoptotic and immune phenomena as well 
as signal transduction pathway) being among the most promising strategy of treatment of 
this malignant brain tumour. Although the number of "antisense" clinical trials is much 
lower than that of experimental preclinical therapies (Table 1), we would like to underline 
that every experimental therapy is a potential clinical trial, the later often depending on 
hospital/administrative logistics. The current clinical strategies of glioma treatment are 
generally a combination of chemotherapy with therapies using different types of inhibitors 
(imatinib, gefitinb) including antibodies (i.e. avastin) targeting growth factors and their 
receptors (i.e. Stupp et al. 2005; Reardon et al. 2006;  Wen et al. 2006). The most recent 
therapies are now focusing on antisense technology used alone or combined also with 
pharmacological treatment  (Dietrich et al. 2010). A pharmacologic strategy – the use of 
temozolomide, introduced by Dr R. Stupp, has offered a new hope for the treatment of this 
tumour. However, even though the median survival has reached almost two years, we are 
still far from victory (Hegi et al., 2005; Gorlia et al., 2008). Among the new strategies in efforts 
to successfully treat GBM, the use of AS approach targeting IGF-I, TGF-beta or VEGF, their 
receptors and their down stream transduction signalling elements (Trojan et al., 2007a; Pan 
et al., 2007; Hau et al., 2009), appears to offer hope for a promising solution.  
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1. Introduction 
Hepatocellular carcinoma (HCC) is one of the most common and rapidly fatal malignancies 
worldwide and has been ranked the second highest cancer killer in China since the 1990s, 
particularly in the eastern and southern areas, including the inshore area of the Yangtze 
River (1). Multiple risk factors are associated with HCC disease etiology, with the highest 
incidence in patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV), 
although other factors such as genetic makeup and environmental exposure are involved 
(2~4). As a common malignant, solid tumor, HCC is characterized by fast infiltrating 
growth, early metastasis, high-grade malignancy, and poor therapeutic efficacy. It is a 
highly vascular tumor dependent on neovascularization and one of the most common and 
rapidly developing malignancies (5, 6). HCC treatment options are severely limited by the 
frequent presence of metastases (7～10, Fig.1).  
Multistep malignance of HCC progression with multigene alterations mostly accompany 
with chronic hepatitis and liver cirrhosis (11, 12). Hypoxia inducible factor-1 (HIF-1) is a 
basic-Helix–Loop–Helix Per-Arnt-Sim protein (bHLH-PAS) consisting of α and β subunits 
and a key transcription factor regulating cellular responses to hypoxia (13, 14), and can 
regulate neovascularization, activate expressions of many hypoxia-response genes, leading 
to closely associate with HCC ecosystem for tumor growth, infiltration, metastasis and 
prognosis (15~17). HIF-1α is an oxygen-dependent protein, which is degraded by poly 
ubiquitination and proteasomal degradation via the Von-Hippel-Lindau tumor suppressor 
protein under normoxic conditions (4, 18, 19). Here we briefly review the expression of rat 
hepatic HIF-1α and its gene during the malignant transformation of hepatocytes, the hepatic 
expression and circulating level of HIF-1α in patients with liver diseases for prospectively 
elucidating the relationship between HIF-1α level and the pathological features as well as 
the diagnosis and metastasis of HCC, and the effect of miRNA silencing HIF-1α gene on 
inhibition of HepG2 cell proliferation. 
2. HIF-1alpha expression and HCC development 
Hepatocarcinogenesis is a complex process requiring multiple factors and multiple steps. 
Chemical carcinogens can induce cancer development in liver cells in a short time, with 
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Fig. 1. HCC development and the role of hepatic HIF-1α. A, Model for the development of 
hepatocyte malignant transformation and the role of HIF-1α during liver tumorigenesis. The 
gradual replacement of cells during normal physiologic turnover is accomplished by the 
proliferation of the differentiated liver cells, in response to various forms of liver injury to 
canceration. In contrast, when parenchymal cells are unable to proliferate (e.g., in response 
to hepatocyte toxins), rare cells associated with the bile ducts known as oval cells expand 
and then differentiate to restore liver mass. The alterations of many genes result in 
hepatocyte and oval cell proliferation and the development of HCC. B, The role of hepatic 
HIF-1α. Regulation of the α-subunit is mediated by the oxygen dependent degradation 
domain (ODD), which contains two regulatory proline residues. Transcriptional activity of 
HIF-1 is facilitated by a N- vs. C-terminal transactivation domains (TAD-N vs. TAD-C) in 
HIF-1α. B1, Under normoxia O2 is available and hydroxylation via FIH-1 and PHDs 
proceeds. FIH-1 hydroxylates Asn 803 in the C-TAD of HIF-1α. This modification causes 
CBP/p300 to dissociate from HIF-1α, thus repressing HIF-1 transcriptional activity. PHDs 
hydroxylate Pro 402 and Pro 564 within the ODD of HIF-1α thereby making it available for 
the binding of pVHL. pVHL forms a E3-ubiquitin ligase complex with co-factors which 
subsequently facilitates poly-ubiquitination of HIF-1α and thus degradation by the 26S 
proteasome. B2, Scheme of the proposed role of HBx in the HIF-1-mediated angiogenesis of 
HCC. HBx interacts and stabilizes HIF-1 through inhibition of the interaction between 
pVHL and HIF-1 and the ubiquitin (Ub)-dependent degradation. Subsequently, HBx 
activates the HIF-1-dependent transcription and leads to angiogenesis. Under hypoxia O2 is 
limited and PHDs as well as FIH are inactive. In turn HIF-1α accumulates associates with 
the β-subunit and upon recruitment of the co-factor p300 forms the transcriptionally active 
HIF-1 complex. Activation of genes that contain HIF-responsive elements (HRE) in their 
promotor region follows 
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large-scale RNA transcription. The total RNA content gradually increases, and in the 
precancerous lesion, this can be significantly different from normal tissues. Angiogenesis is 
necessary for solid tumors larger than 1×1 mm, or the tumor remains dormant and does not 
metastasize. As soon as the angiogenesis stage arrives, potent metastasis is exhibited at once. 
The expression of HIF-1α plays important roles in angiogenesis, tumor growth, invasion, 
and metastasis in different cancers. We have investigated the expression of HIF-1α and its 
gene at the early stage of hepatocarcinogenesis, and provided the first evidence to show that 
HIF-1α is activated in preneoplastic hepatocytes during the early stage of carcinogenesis 
and long before the development of HCC.  
 
 
Fig. 2. Appearance of rat liver and morphological changes of rat hepatocytes during 2-FAA-
induced hepatocarcinogenesis. A-D: liver appearance of control rats, at the early, middle, 
and late stages during the malignant transformation of hepatocytes ; E-H: corresponding 
histopathological images confirming normal tissue, hepatocyte degeneration, precancerous, 
changes and HCC (original magnification ×100), respectively.  
Forty-eight male Sprague-Dawley rats, 6 weeks old, weighing 150-160 g, were purchased 
from the Experimental Animal Center, Nantong University, China. All animals were treated 
according to the guidelines of Nantong University for the Care and Use of Laboratory 
Animals. The rats were randomly divided into 8 groups with 6 rats per cage. One group was 
selected as controls while the others made up the experimental groups. Among the 7 
experimental groups one served as a substitute for accidental deaths. All rats were fed with 
general grain, except that the grain of the hepatoma model rats contained 0.05% 2-fluorenyl-
acetamide (2-FAA, Sigma Chemical Co., USA). All rats were housed under bio-clean 
conditions. One control rat and one experimental rat were sacrificed every 2 weeks. All 
surgical procedures were conducted under deep ether anesthesia. Four ml of blood was 
drawn from the heart and anticoagulated with EDTA-K2. Plasma and karyocytes were 
separated and kept at -80 ℃ for further analysis. After washing off the blood, one liver 
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sample was fixed in 10% neutral buffered formalin and embedded in paraffin for 
pathological examination and immunohistochemical staining, and the rest were kept at -80 
℃ until use. 
The changes of liver appearance and the pathohistology of hepatocytes during 2-FAA-
induced rat HCC development are shown in Fig. 2. Apparent morphological changes (Fig. 
2A-D) were confirmed pathohistologically examination (Fig. 2E-H). No pathological 
changes of rat hepatocytes were found in normal controls (Fig. 2E). During 2-FAA-induced 
hepatocarcinogenesis, granule-like degeneration in the cytoplasm of hepatocytes occurred at 
the early stage of hepatocarcinogenesis, with a few large and dysmorphic nuclei 
(degeneration group, n=18, Fig. 2F). An increase in the number of cell layers of hepatic 
plates was observed at the middle stage, at which there were more than 3 cell layers in some 
foci. Thickened chromatin in the nucleus was found, and the ratio of nucleus versus 
cytoplasm was elevated (precancerous group, n=9, Fig. 2G). At the late stage, the normal 
structure of liver tissue was completely destroyed, hepatocytes were rearranged to be nest-
like and crudely cord-like, cellular nuclei were moderate in size and chromatinthickened, 
the ratio of nucleus versus cytoplasm was elevated, and the liver tissues were confirmed as 
highly differentiated (cancerous group, n=9, Fig. 2H). 
Immunohistochemical staining confirmed positive expression of HIF-1α as clear and brown 
particles, mainly located in the cytosol and nuclei, with no staining of the plasma membrane 
(Fig. 3). The positive staining was mostly located in the border of hepatic terminal portal 
venules or near the central veins (Fig. 2A). With carcinogenesis, the rate of HIF-1α-positive 
expression increased and there was significantly higher intensity in the degeneration, 
precancerous, and cancerous groups than in the normal control (Table 1, P < 0.05), with a 




Fig. 3. Immunohistochemical staining with anti-HIF-1α in rat HCC. A: HIF-1α-positive 
expression in cytoplasm and cell membrane (S-P, original magnification ×200) in HCC focus 
from rat hepatoma; B: HIF-1α-negative expression, brown particles in cytoplasm and cell 
membrane (S-P, original magnification ×200) in control rats. 
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    Intensity of HIF-1α 
Group  n Positive (%)     
    - + ++ +++ 
Control  6 0 (0.0) 6 0 0 0 
Degeneration  18 14(77.8) 4 9 5 0 
Precancerous  9 8(88.9)* 1 2 5 1 
Cancerous  9 9(100)* 0 1 2 6 
<0.01, compared with the control group. 
Table 1. Comparative analysis of hepatic HIF-1α expression intensity at different stages of 
rat hepatocarcinogenesis 
Reverse-transcribed HIF-1α cDNA from hepatic HIF-1α mRNA during the malignant 
alteration of rat hepatocytes was amplified by nested-PCR, and the sizes of amplified 
fragments were identical to the original designed ones, i.e., the size of the PCR product was 
500 bp in the 1st PCR and 210 bp in the 2nd PCR (Fig. 4). The amplified fragments (210 bp) 
of the rat HIF-1α gene from the degeneration, the precancerous, and the cancerous livers 
were purified and confirmed by DNA sequencing. The alignments of their nucleotide 
sequences at the different stages of hepatocarcinogenesis by sequencing, and no alteration of 
the amplified gene fragment was found during the malignant alteration of rat hepatocytes. 
 
 
Fig. 4. Amplification and alteration of HIF-1α gene from rat hepatoma tissues. In order to 
obverse the alteration of HIF-1α at RNA level, HIF-1α mRNAs were synthesized to HIF-1α 
cDNA with random hexamers and moloney murine leukemia virus reverse-transcriptase, 
and detected with different primer pairs by nested PCR (210bp). The amplified positive 
fragments of HIF-1α gene were distinctly found in rat hepatoma tissues. HIF-1α mRNA in 
rat liver (Lanes. 1-4). Lane 1: control rat; lane 2: Degeneration rat; lane 3: precancerous rat; 
lane 4: HCC rat; marker: DNA molecular weight marker. 
The levels of total RNA and HIF-1α mRNA expression in rat liver tissues during the 
malignant alteration of hepatocytes are shown in Table 2. The expression of total RNA and 
HIF-1α mRNA with histological alteration of hepatocytes was observed in the rats after 
treatment with 2-FAA, progressing from granule-like degeneration to precancerous lesions 
to HCC. The levels increased markedly in the cancerous group and the precancerous lesion 
group, and the incidence of amplified HIF-1α mRNA dynamically increased as hepatocytes 
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expression in cytoplasm and cell membrane (S-P, original magnification ×200) in HCC focus 
from rat hepatoma; B: HIF-1α-negative expression, brown particles in cytoplasm and cell 
membrane (S-P, original magnification ×200) in control rats. 
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    Intensity of HIF-1α 
Group  n Positive (%)     
    - + ++ +++ 
Control  6 0 (0.0) 6 0 0 0 
Degeneration  18 14(77.8) 4 9 5 0 
Precancerous  9 8(88.9)* 1 2 5 1 
Cancerous  9 9(100)* 0 1 2 6 
<0.01, compared with the control group. 
Table 1. Comparative analysis of hepatic HIF-1α expression intensity at different stages of 
rat hepatocarcinogenesis 
Reverse-transcribed HIF-1α cDNA from hepatic HIF-1α mRNA during the malignant 
alteration of rat hepatocytes was amplified by nested-PCR, and the sizes of amplified 
fragments were identical to the original designed ones, i.e., the size of the PCR product was 
500 bp in the 1st PCR and 210 bp in the 2nd PCR (Fig. 4). The amplified fragments (210 bp) 
of the rat HIF-1α gene from the degeneration, the precancerous, and the cancerous livers 
were purified and confirmed by DNA sequencing. The alignments of their nucleotide 
sequences at the different stages of hepatocarcinogenesis by sequencing, and no alteration of 
the amplified gene fragment was found during the malignant alteration of rat hepatocytes. 
 
 
Fig. 4. Amplification and alteration of HIF-1α gene from rat hepatoma tissues. In order to 
obverse the alteration of HIF-1α at RNA level, HIF-1α mRNAs were synthesized to HIF-1α 
cDNA with random hexamers and moloney murine leukemia virus reverse-transcriptase, 
and detected with different primer pairs by nested PCR (210bp). The amplified positive 
fragments of HIF-1α gene were distinctly found in rat hepatoma tissues. HIF-1α mRNA in 
rat liver (Lanes. 1-4). Lane 1: control rat; lane 2: Degeneration rat; lane 3: precancerous rat; 
lane 4: HCC rat; marker: DNA molecular weight marker. 
The levels of total RNA and HIF-1α mRNA expression in rat liver tissues during the 
malignant alteration of hepatocytes are shown in Table 2. The expression of total RNA and 
HIF-1α mRNA with histological alteration of hepatocytes was observed in the rats after 
treatment with 2-FAA, progressing from granule-like degeneration to precancerous lesions 
to HCC. The levels increased markedly in the cancerous group and the precancerous lesion 
group, and the incidence of amplified HIF-1α mRNA dynamically increased as hepatocytes 
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changed from normal to granule-like denaturation to precancerous and cancerous lesions. 
Induction of HIF-1α mRNA expression was detected in all the liver tissues of the cancerous 
group and parts of the precancerous lesion and degeneration group, i.e., 44.4% in the 
hepatocyte degeneration group, 77.8% in the precancerous lesion group, and 88.9% in the 
HCC group. It was significantly higher in the cancerous group than in the degeneration and 
the control groups, and the precancerous lesion group was also significantly higher than the 
normal control. 
 
Group n Total RNA (μg/mg liver) HIF-1α mRNA (%) 
Control 6 1.58±0.49 0 (0.0) 
Degeneration 18 1.91±0.60 8 (44.4) 
Precancerous 9 2.00±0.21* 7 (77.8)* 
Cancerous 9 2.86±0.60* 8 (88.9)* 
*P<0.05, compared with the control group. 
Table 2. Dynamic alterations of total RNA and amplification of HIF-1α mRNA in liver 
tissues at different stages of rat hepatocarcinogenesis 
Nested PCR results revealed that HIF-1α mRNA was induced in hepatoma, precancerous 
and degenerative tissues, but was not expressed in normal tissues. During the course of 
cancer development, the levels of HIF1α mRNA in precancerous tissues were higher than in 
normal and degenerating tissues, and the levels of HIF-1α mRNA in HCC tissues were even 
higher than in precancerous tissues. The activation of HIF-1α gene transcription may 
participate in the signal transmission of cancer development. In the early stage, the 
expression of HIF-1α mRNA and HIF-1α was at low levels. In the advanced stage of cancer 
development, the expression of HIF-1α mRNA and HIF-1α was at high levels. The 
preneoplastic hepatic lesions showed increased levels of HIF-1α and HIF-1α mRNA 
compared with the normal liver. So the upregulation of hepatic HIF-1α protein synthesis 
and HIF-1α mRNA levels strongly suggest that HIF-1α participates in the development of 
HCC. The expression of HIF-1α gradually increased along with the histological changes, it 
was significantly higher in premalignant tissues than in the control group, and it may be 
related to the activation of signal pathways. 
The quantitative data of hepatic and circulating HIF-1α expression are shown in Table 3. 
The HIF-1α levels showed a tendency to increase with the histopathological changes: 
cancerous group > precancerous lesion group > hepatocyte degeneration group > control 
group. The levels were markedly higher in the cancerous and precancerous lesion groups 
than in the hepatocyte degeneration and normal control groups. As a result of its low 
molecular weight, HIF-1α is easily released into the blood, leading to a higher concentration 
there. Blood levels in the precancerous lesion group were higher than in the hepatocyte 
degeneration and normal control groups (P<0.05). The HIF-1α blood levels in the cancerous 
group were markedly higher than in any other group (P<0.05). An apparent positive 
correlation between the levels in blood and liver samples was found (r=0.474, P = 0.030). The 
expression level of HIF-1α gradually increased both in liver cells and blood. The increasing 
tendency of hepatic and circulating HIF-1α was synchronized, suggesting that the 
increasing expression of HIF-1α is closely related to the malignant transformation of 
hepatocytes.  
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Group n HIF-1α in blood (μg/mg NP) HIF-1α in liver (μg/mg) 
Control 6 206.3±18.6 9.8±2.9 
Degeneration 18 277.2±96.1 12.6±3.2 
Precancerous  9 401.6±178.8* 16.9±2.2* 
Cancerous 9 445.9±138.9* 23.5±8.7* 
*P<0.05, compared with the control group. 
Table 3. Quantitative analysis of HIF-1α dynamic expression in circulation and liver tissues 
at different stages of rat hepatocarcinogenesis 
Increasing evidence suggests that HIF-1 activation occurs in the early stages of 
carcinogenesis. HIF-1α genes are overexpressed in morphologically normal single cells, 
forming multicellular foci or microcysts similar to overt HCC. HIF-1α was also shown to be 
expressed in a few cells in ductal hyperplastic areas adjacent to invasive cancer, and their 
malignant counterparts. Furthermore, HIF-1α genes were shown to be overexpressed in 
hyperplastic and dysplastic lesions during multistage carcinogenesis. Recent new findings 
from several laboratories have implicated constitutive activation of the transcription factor 
NF-κB as one of the early key events involved in neoplastic progression of chronic liver 
disease. Further studies will permit us to analyze mechanism of human 
hepatocarcinogenesis and to know how to target HIF-1α sites or RNA interference-mediated 
suppression of HIF-1α expression for HCC therapy. However, the combination of the 
pathological features of HIF-1α expression and some of the biomarkers with high sensitivity 
and specificity for early HCC seems to be more practical so far. 
3. Expression difference in human HCC tissues 
The self-controlled HCC and para-cancerous specimens (2 cm to cancer) were collected from 
35 patients who underwent operations for liver cancer at the Affiliated Hospital of Nantong 
University. The specimens were immediately frozen in liquid nitrogen and kept at –85℃ 
until required. The patients included 28 men and 7 women, ranging in age from 22 to 70 
years. Prior written informed consent was obtained from all patients according to the World 
Medical Association Declaration of Helsinki, and the study received ethics board approval 
from the Affiliated Hospital of Nantong University. The histological types of all HCC 
specimens were graded in differentiation degrees as follows: well, 9; moderate, 12; and poor, 
14. Of these specimens, 20 showed single tumor tubercles and the rest multiple; 14 were 
stage II, 13 were stage III, and 8 were stage IV. Each specimen was analyzed by total RNA 
abstraction and pathologic examination. 
The expressions and cellular distribution of HIF-1α in HCC tissues and comparative 
analysis with their para-cancerous tissues are shown in Fig. 5. The positive HIF-1α was 
brown and granule-like, mainly presented in cytoplasm and few in nucleus, with obvious 
differences of HIF-1α positive expression intensity among different areas of tissues. HIF-1α 
staining in paracancerous tissues was showing significantly in the compressed hepatic cords 
and central veins. The intensity of HIF-1α expressions was significantly higher in 
paracancerous tissues than that in HCC, mainly due to more necrosis in the latter, 
representing that there is a very close relationship between high intensity of HIF-1α 
expressions and active proliferation or hypoxia microenvironment in paracancerous tissues. 
The distribution of positive cells was well-distributed and higher in adjacent areas of 
necrosis and tumor infiltration in HCC (Fig.5A), whereas it was showing significantly in the 
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changed from normal to granule-like denaturation to precancerous and cancerous lesions. 
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and HIF-1α mRNA levels strongly suggest that HIF-1α participates in the development of 
HCC. The expression of HIF-1α gradually increased along with the histological changes, it 
was significantly higher in premalignant tissues than in the control group, and it may be 
related to the activation of signal pathways. 
The quantitative data of hepatic and circulating HIF-1α expression are shown in Table 3. 
The HIF-1α levels showed a tendency to increase with the histopathological changes: 
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group. The levels were markedly higher in the cancerous and precancerous lesion groups 
than in the hepatocyte degeneration and normal control groups. As a result of its low 
molecular weight, HIF-1α is easily released into the blood, leading to a higher concentration 
there. Blood levels in the precancerous lesion group were higher than in the hepatocyte 
degeneration and normal control groups (P<0.05). The HIF-1α blood levels in the cancerous 
group were markedly higher than in any other group (P<0.05). An apparent positive 
correlation between the levels in blood and liver samples was found (r=0.474, P = 0.030). The 
expression level of HIF-1α gradually increased both in liver cells and blood. The increasing 
tendency of hepatic and circulating HIF-1α was synchronized, suggesting that the 
increasing expression of HIF-1α is closely related to the malignant transformation of 
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Medical Association Declaration of Helsinki, and the study received ethics board approval 
from the Affiliated Hospital of Nantong University. The histological types of all HCC 
specimens were graded in differentiation degrees as follows: well, 9; moderate, 12; and poor, 
14. Of these specimens, 20 showed single tumor tubercles and the rest multiple; 14 were 
stage II, 13 were stage III, and 8 were stage IV. Each specimen was analyzed by total RNA 
abstraction and pathologic examination. 
The expressions and cellular distribution of HIF-1α in HCC tissues and comparative 
analysis with their para-cancerous tissues are shown in Fig. 5. The positive HIF-1α was 
brown and granule-like, mainly presented in cytoplasm and few in nucleus, with obvious 
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and central veins. The intensity of HIF-1α expressions was significantly higher in 
paracancerous tissues than that in HCC, mainly due to more necrosis in the latter, 
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expressions and active proliferation or hypoxia microenvironment in paracancerous tissues. 
The distribution of positive cells was well-distributed and higher in adjacent areas of 
necrosis and tumor infiltration in HCC (Fig.5A), whereas it was showing significantly in the 
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compressed hepatic cords and the border of central veins in the para-cancerous tissues 
(Fig.5B). Moreover, the HIF-1α positive staining was significantly higher (P=0.017) in the 
para- cancerous group (100%, 35 of 35) than in the corresponding HCC group (80%, 28 of 
35). The intensity of hepatic HIF-1α expression was also higher in the para-cancerous tissues 
than in the HCC tissues (Z =4.728, P< 0.001, Table 4). 
 
 
Fig. 5. Immunohistochemical staining of HIF-1α, total RNA levels and amplification of HIF-
1α mRNA in HCC or their paracancerous tissues. Hepatic HIF-1α expression with brown 
particles in cytoplasm and cell membrane，A, the HCC tissue; B, the para-cancerous tissue 
(S-P, original magnification × 200). C, the levels of total RNA expression in HCC or their 
paracancerous tissues; D, the HIF-1α mRNA was synthesized to HIF-1α cDNA and 
amplified by nested PCR (349 bp), Line 1, 2, the amplified fragment of HIF-1αmRNA in 
HCC tissues; Line 3, 4, the amplified fragment of HIF-1αmRNA in para-cancerous tissues; 
M, DNA marker with molecular weight standard. HCC, the hepatocellular carcinoma 
tissues; Para-HCC, the para-cancerous tissues. 
HCC is mostly characterized by uncontrolled growth of tumor cells. Increasing oxygen 
consumption results in hypoxic microenvironment. HIF-1α expression is significantly high 
in adjacent areas of necrosis and tumor infiltration. Many factors, such as hypoxia, 
oncogenes activation, inactivation of tumor suppressors, growth factors, inflammatory 
factors, can up-regulate HIF-1α expressions, directly or indirectly promoting more than 2 % 
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human genes transcriptions, which are all related to oxygen and energy metabolism. 
Productive nucleic acids metabolism, abnormal gene expressions, development of HCC are 
closely associated with surrounding vessels state and hypoxic conditions (20).  
 
    HIF-1α intensity 
Group n Positive (％) P value*    Z value P value* 
    － ＋ ＋＋ ＋＋＋   
HCC 35 28 (80.0) 0.017 7 21 7 0 4.728 0.000 
Para-HCC  35 35 (100)  0 10 18 7   
*P value vs the paracancerous tissue group; HCC, the hepatocellular carcinoma tissues. 




Fig. 6. Alignment of the amplified fragments of HIF-1α gene and homology analysis of their 
sequences. The HIF-1α mRNA from cancerous tissue and para-cancerous tissue of HCC 
patients was synthesized to HIF-1α cDNA and amplified by nested PCR (349 bp) and 
confirmed by sequencing. No mutation was found between HCC tissues and para-cancerous 
tissue. HIF-1α: the cited sequence (349 bp, nt 2452-2800) of human HIF-1α genome 
(NM_001530); HCC, the amplified fragment of HIF-1α genome from HCC tissues; Para-
HCC, the amplified fragment of HIF-1α genome from their paracancerous tissues. 
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Productive nucleic acids metabolism, abnormal gene expressions, development of HCC are 
closely associated with surrounding vessels state and hypoxic conditions (20).  
 
    HIF-1α intensity 
Group n Positive (％) P value*    Z value P value* 
    － ＋ ＋＋ ＋＋＋   
HCC 35 28 (80.0) 0.017 7 21 7 0 4.728 0.000 
Para-HCC  35 35 (100)  0 10 18 7   
*P value vs the paracancerous tissue group; HCC, the hepatocellular carcinoma tissues. 




Fig. 6. Alignment of the amplified fragments of HIF-1α gene and homology analysis of their 
sequences. The HIF-1α mRNA from cancerous tissue and para-cancerous tissue of HCC 
patients was synthesized to HIF-1α cDNA and amplified by nested PCR (349 bp) and 
confirmed by sequencing. No mutation was found between HCC tissues and para-cancerous 
tissue. HIF-1α: the cited sequence (349 bp, nt 2452-2800) of human HIF-1α genome 
(NM_001530); HCC, the amplified fragment of HIF-1α genome from HCC tissues; Para-
HCC, the amplified fragment of HIF-1α genome from their paracancerous tissues. 
 
Targets in Gene Therapy 
 
234 
Hepatic total RNA was purified from human HCC or their para- cancerous tissues, the 
specific concentrations of total RNA were 12.4 ± 7.3 μg/mg wet liver in the HCC group, and 
53.8 ± 52.0 μg/mg wet liver in the para-cancerous group (Fig.5C), with significant difference 
between them (t = 3.05, P < 0.01). The final amplified fragment of hepatic HIF-1α gene was 
349 bp (Fig.5D), and the incidence was 85.7% in the HCC group and 100 % in the para-
cancerous group (P > 0.05). The amplified fragments of HIF-1α gene were confirmed by 
sequencing, with consistent completely with the cited sequence of human HIF-1α gene 
(Fig.6). The level of total RNA was obviously higher in paracancerous tissues than in HCC, 
indicating HIF-1αmRNA involved in cell proliferation, neovascularization and metastasis 
and could be a prime target for gene therapy. 
4. Expression of circulating HIF-1α in HCC 
One hundred thirty-one of HCC patients, 30 of chronic hepatitis, 22 of acute hepatitis, and 
37 of cirrhosis were diagnosed at the Affiliated Hospital of Nantong University, Nantong, 
China, and 27 healthy people obtained from the Nantong Central Blood Bank as controls 
(Table 5). All cases were diagnosed by blood biochemical tests, with negative hepatitis viral 
markers (HBsAg, and anti–HCV antibody), normal alanine aminotransferase (ALT) levels, 
and B-ultrasonic examination. All samples (5 mL of peripheral blood) were collected in the 
morning and sera were separated at once. The serum AFP concentrations exceeded 50 μg/L 
were taken as a positive result. The diagnosis of HCC and viral hepatitis was based on the 
criteria proposed by Chinese National Collaborative Cancer Research Group (21) and at the 



















































HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; AH, acute hepatitis; NC, 
normal control. 
Table 5. Patients’ data in the present study 
The levels of circulating HIF-1α expression in 220 patients with liver diseases are shown in 
Table 6. The circulating HIF-1α level was increased, especially in patients with chronic liver 
diseases. If the cutoff value of serum HIF-1α level was >50 μg/L, the incidence of HIF-1α 
abnormality was 100 % in HCC, 89.2% in LC, 66.7 % in CH, none in AH or NC, respectively; 
And the cutoff values rise to 100 μg/L, the abnormality of circulating HIF-1α level was 
90.8% in HCC and 27.0% in LC, none in CH or AH or NC, respectively. The level of serum 
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HIF-1α in HCC patients was significantly higher (P < 0.001) than those in cases with benign 
liver diseases.  
The prognosis of HCC is poor, and early detection is of the utmost importance. Treatment 
options are severely limited by the frequent presence of metastases. Although the 
mechanisms of hepatocarcinogenesis have not been elucidated, a long-lasting inflammation 
induced by hepatitis virus infection is a definite risk for neoplastic degeneration and 
accumulation of genetic alterations. The fragments of circulating HIF-1α could be detected 
in all patients with HCC with extrahepatic metastasis; like circulating IGF-II, these results 
argue for growth factor–dependent HCC development and could provide novel markers of 
severity and prognosis for HCC. The present data indicate that the expression levels of 
























136.3 ± 28.8 
84.6 ± 25.9* 
58.8 ± 14.5*a 
37.6 ± 5.3*bc 











*P < 0.001, vs the HCC group；aP < 0.001, vs the liver cirrhosis group (q = 4.39)；bP < 0.01 vs the chronic 
hepatitis group (q = 3.17)；cP < 0.001, vs the liver cirrhosis group (q = 7.31)；d P < 0.001, vs the chronic 
hepatitis group (q = 5.47)；eP < 0.001, vs the liver cirrhosis group (q = 9.99)；HCC, hepatocellular 
carcinoma; LC, liver cirrhosis; CH, chronic hepatitis; AH, acute hepatitis; NC, normal control. 
Table 6. Quantitative analysis of circulating HIF-1α level (mean ± SD) in patients with liver 
diseases 
The evaluation of serum HIF-1α and AFP levels for HCC diagnosis using the ROC curves is 
shown in Fig.7. The advantage of analyzing two markers over the whole range of 
sensitivities and specificities using the area (0.854 in AFP, 0.909 in HIF-1α) under ROC 
curves indicated that the abnormality of serum HIF-1α level could be a useful seroloical 
marker for HCC diagnosis. 
5. Quantitative detection of VEGF and Ang-2 
The levels of serum VEGF and Ang-2 were detected and the concentrations were calculated 
using a standard curve generated with specific standards. Inter and intra-assay variances 
were lower than 10%. The levels of circulating VEGF and Ang-2 expression in patients with 
chronic liver diseases are shown in Table 7. Like circulating HIF-1α expression, the 
circulating VEGF and Ang-2 levels were increased in patients with chronic liver diseases, 
especially in HCC patients. If the cutoff value with >280 μg/L for VEGF and >35 μg/L for 
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hepatitis group (q = 5.47)；eP < 0.001, vs the liver cirrhosis group (q = 9.99)；HCC, hepatocellular 
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diseases 
The evaluation of serum HIF-1α and AFP levels for HCC diagnosis using the ROC curves is 
shown in Fig.7. The advantage of analyzing two markers over the whole range of 
sensitivities and specificities using the area (0.854 in AFP, 0.909 in HIF-1α) under ROC 
curves indicated that the abnormality of serum HIF-1α level could be a useful seroloical 
marker for HCC diagnosis. 
5. Quantitative detection of VEGF and Ang-2 
The levels of serum VEGF and Ang-2 were detected and the concentrations were calculated 
using a standard curve generated with specific standards. Inter and intra-assay variances 
were lower than 10%. The levels of circulating VEGF and Ang-2 expression in patients with 
chronic liver diseases are shown in Table 7. Like circulating HIF-1α expression, the 
circulating VEGF and Ang-2 levels were increased in patients with chronic liver diseases, 
especially in HCC patients. If the cutoff value with >280 μg/L for VEGF and >35 μg/L for 
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Ang-2, the incidence of VEGF and Ang-2 were 87.0 % and 94.7 % abnormality in HCC, 12.7 
% and 2.9 % in LC, 13.3 % and 0% in CH, both none in NC, respectively.  
 
 
Fig. 7. The relationship between circulating HIF-1α and AFP levels and receiver operating 
characteristic (ROC) curves. A, the scatter diagram of circulating HIF-1α and AFP levels in 
HCC patients，and no significant relationship was found between circulating HIF-1α and 
AFP levels; B, ROC curves for circulating HIF-1α and AFP investigated markers for HCC. 
Sensitivity = true-positive rate; specificity = false-positive rate; and the area under ROC 
curves was 0.854 for AFP and 0.909 for HIF-1α. Sensitivity and specificity were calculated 
according to the following formulas: Sensitivity = a/(a+c); and Specificity = d/ (b+d), where 
a = true-positive cases, b = false-positive cases, c = false- negative cases, and d = true-
negative cases. ROC curves were constructed by calculating the sensitivities and specificities 
at several cutoff points, and indicated that both of circulating HIF-1α and AFP level be 
useful molecular markers for HCC diagnosis. 
HCC is known to contain aberantly vascularized regions characterized by severe hypoxia. 
Hypoxia can stimulate cell proliferation, induce angiogenesis, accelerate invasion and is also 
responsible for treatment resistance in HCC. Activation of oncogenes or inactivation of 
tumor suppressors can change signaling pathway and up-regulate HIF-1α expression, 
leading to HIF-1α activation. Under hypoxic conditions it can be stabilized, binding to the 
specific sites of hypoxia-response target genes, regulating proliferation on transcriptional 
level and activating expression of many hypoxia-response genes, which are closely relevant 
with energy metabolism, angiogenesis, infiltration, metastasis and prognosis. The frequency 
of circulating HIF-1α and its diagnostic value increased with distal metastases of HCC 
hepatocytes. The pathological characteristics of serum HIF-1α associated with the levels of 
circulating VEGF and Ang-2 expression, the size of tumor and extra-hepatic metastasis, and 
but not to patients’ gender, age, and AFP level. 
Mechanism of Hypoxia-Inducible Factor-1alpha Over- Expression  




 VEGF (μg/L)   >280 μg/L    Ang-2 (μg/L)   >35 μg/L 









462.7±119.2   114(87.0)      40.8±3.5    124(94.7) 
216.3±54.5*    6(16.2)*      25.5±5.8*    1(2.7)* 
160.9±98.2*    4(13.3)*      20.9±7.1*     0(0)* 
 140.9±54.5*     0(0)*        17.4±2.6*     0(0)* 
*P < 0.001, vs the HCC group；HCC, hepatocellular carcinoma; LC, liver cirrhosis; CH, chronic 
hepatitis; NC, normal control. 
Table 7. The levels of circulating VEGF and Ang-2 expression in patients with chronic liver 
diseases 
6. Clinicopathological features of HIF-1α expression  
The clinicopathological characteristics of circulating HIF-1α expression in HCC patients are 
shown in Table 8. Significant difference was found between high HIF-1α expression and 
tumor size (P=0.007) or HCC with extra-hepatic metastasis (P< 0.001), but not with patients’ 
gender, age, or AFP level. There was a very close relationship between circulating HIF-1α 
level and VEGF (r=0.937, P <0.001) or Ang-2 (r= 0.933, P < 0.001), suggesting that high 
expression of HIF-1α associated with HCC metastasis and poor prognosis. 
Clinical pathological features of HIF-1α expression indicated that HIF-1α expression 
intensity and positive rate was lower in HCC than in paracancerous tissues, which were in 
accordance with total RNA. HIF-1α positive rate was associated with tumor diameter, 
because they were usually singles, enveloped, well-differentiated, more diplonts and less 
heteromorphism when tumors were small. With tumors swelling, the biological 
characteristics have changed, developed into the opposite. Therefore, the invasion is 
strengthened, and tumor blood supply can not satisfy growth demand. HBx and HIF-1α are 
presented in cytoplasm in HCC. Moreover, HBx can up-regulate HIF-1α under normoxia or 
hypoxia, reinforce HIF-1α transcriptional activity via MAPK pathway, increase HIF-1α 
protein levels, induce neovascularization and contribute to metastasis. No correlation was 
found between HIF-1α and HBsAg positive in HCC and further studies whether it 
associates with HBV replication are required. 
7. Effect of miRNA silencing HIF-1α gene on HCC 
In order to investigate the effect of miRNA silencing HIF-1α gene on inhibition of HepG2 
cell proliferation. Recently, we constructed the eukaryotic expression plasmids of HIF-
1αmiRNA and report gene containing hypoxia-reponse element. After HepG2 cells 
transfection with plasmid, the expression of HIF-1α gene and protein were determined by 
real time-PCR or Western blotting. The expressions of HIF-1α, VEGF, and Ang-2 were 
quantitatively detected by ELISA. The alterations of cell cycles and apoptosis rate were 
quantitatively measured by flow cytometry or Annexin V-FITC/PI double dyeing assay. 
At 72h After HepG2 cell transfection with HIF-1αmiRNA, the down- regulation of HIF-1α 
was 87% at mRNA or 56% at protein level, and the decreasing of target gene was 46% in the 
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report gene, 54% in VEGF and 36% in Ang-2, respectively. The apoptotic ratio of HepG2 cells 
was 22.46 ± 0.61% (P < 0.01), and the cell cycle changed greatly at the ratio of G1 
(61.49±1.12%) and S phase (22.40± 0.58%, P < 0.01). After the cells combined with 
doxorubicin, the apoptotic ratio increased to 36.99 ± 0.88%. The ratio of G1 and S phase were 
upregulated to 65.68 ± 0.91% and 19.47 ± 1.34%. HIF-1αmiRNA or / and doxorubicin can 
regulate the growth cycle, promote apoptotic and inhibit proliferation of HepG2 cells. 
 
Group          n       HIF-1α(μg/L)           t value  P value      
HCC 
Sex         Male 
Female 
Age         ≥ 50y 
<50y 
Tumor size   ≥ 5.0 cm 
<5.0 cm 
AFP(μg/L)   ≥ 400.0 
< 400.0 
HBsAg       Positive 
Negative 















136.3 ± 28.8 
137.4 ± 28.7 
130.7 ± 29.0 
133.7 ± 30.1 
143.2 ± 24.0 
144.4 ± 26.3* 
130.8 ± 29.2 
136.9 ± 25.8 
135.9 ± 30.7 
137.9 ± 29.6 
129.2 ± 25.5 
152.5 ± 21.5** 

























*P < 0.01, vs the tumor size less than 5㎝ group; **P < 0.001, vs the non- extrahepatic metastasis group; 
HCC, hepatocellular carcinoma; EHT, Extra- hepatic metastasis. 
Table 8. The pathological characteristics of HIF-1α levels (mean ± SD) in sera of HCC 
patients. 
8. Perspectives 
HCCs exhibit numerous genetic abnormalities as well as epigenetic alterations including 
modulation of DNA methylation (23, 24). Molecular factors are involved in the process of 
HCC development and metastasis (25~27). Recent findings from several laboratories have 
implicated constitutive activation of the transcription factor NFkappa B as one of the early 
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key events involving in neoplastic progression of the liver. Further studies will permit us to 
analyze mechanism of human hepatocarcinogenesis and pay attention to these areas 
(28~31). However, the hepatic HIF-1α expression is associated with development and 
prognosis of HCC, and circulating HIF-1α level is a useful molecular marker in HCC 
diagnosis, and monitor prognosis (32~36). HIF-1α expression in hepatic tissues plays an 
important role in development and prognosis of HCC. HIF-1α, as an initial hypoxia 
moderator, should be a promising molecular-target for the development of anti-HCC agents 
(37~40). The intensity of HIF-1α expressions was significantly higher in paracancerous 
tissues than in HCC, mainly due to more necrosis in the latter, representing that there is a 
very close relationship between high intensity of HIF-1α expressions and active metabolism 
or hypoxia microenvironment in paracancerous tissues and HIF-1α could be a molecular-
target for gene therapy (41, 42).  
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NKG2D and FAS Pathways 




NKG2D (natural-killer group 2, member D) belongs to a sub-family of C type lectin-like 
receptors. NKG2D is a homodimeric, type II transmembrane glycoprotein (Wolan et al., 
2001). The NKG2D gene is located in the NK gene complex which is on chromosome 6 in the 
mouse (Ho et al., 1998) and chromosome 12 in human (Glienke et al., 1998). Like most 
activating receptors, NKG2D is a multi-subunit receptor complex. Signaling in NKG2D is 
mediated by specialized signaling adaptors. In mouse NKG2D associates with two distinct 
adaptors: DAP-10 and DAP-12/KARAP (Diefenbach et al., 2002a), while in human NKG2D 
exclusively uses DAP-10 (Rosen et al., 2004). Non-covalent interactions are responsible for 
these associations (Diefenbach et al., 2002b). One NKG2D homodimer associates with two 
DAP-10 dimers to form a hexameric complex (Garrity et al., 2005). Two distinct NKG2D 
isoforms (NKG2D-S and NKG2D-L) are expressed in mouse as a result of alternative exon 
usage and are responsible for differential adaptor associations. The short (NKG2D-S) and 
long (NKG2D-L) isoforms differ by their 13 NH2-terminal amino acids. While DAP-10 
associates with both NKG2D isoforms, the extended cytoplasmic domain of NKG2D-L 
prevents the association with DAP-12 (Diefenbach et al., 2002a; Rosen et al., 2004). NKG2D-
L is constitutively expressed in resting NK cells. In contrast, the abundance of NKG2D-S 
increases considerably upon NK cell stimulation with cytokines (Rabinovich et al., 2006).  
NKG2D has the ability to interact with a significant number of distinct ligands with 
affinities ranging from 4 to 800nM (Carayannopoulos et al., 2002a; O’Callaghan et al., 2001; 
Li et al., 2001). Both chains of the NKG2D homodimer contribute to the interaction with the 
different monomeric ligands, making contacts with either the α1 or α2 domain of the ligand. 
Thus, the symmetric, homodimeric NKG2D receptor binds asymmetric ligands, and the 
contribution of the individual NKG2D chains is unequal (Radaev et al., 2002; Mc Farland et 
al., 2003). It is surprising that mouse and human NKG2D, which are only 69% identical in 
their ectodomains, can recognize most ligands of the other species (Mc Farland et al., 2003). 
1.1 Expression of NKG2D receptor 
The NKG2D receptor is constitutively expressed on most innate immune effector cells of 
lymphoid origin, including NK cells, most TCR γδ T cells (Jamieson et al., 2002), and a large 
fraction of NKT cells (Jamieson et al., 2002; Gumperz et al., 2002). Functional NKG2D is also 
found on murine interferon producing killer dendritic cells (IKDC) which are of myeloid 
origin (Taieb et al., 2006) interferon producing killer dendritic cells (IKDC) which are of 
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myeloid origin (Taib et al., 2006; Chan et al., 2006). On adaptive immune system cells, 
NKG2D is constitutively expressed on all human CD8+ T cells and on activated and 
memory (but not on naive) CD8+ αß T cells in the mouse (Jamieson et al., 2002). NKG2D is 
not normally expressed on CD4+ T cells (Table 1).  
 
 Human Mouse 
NK cells 










All NK cells 
Naïve, activated and memory  
CD8+ T cells 
Subpopulation of Synovial and 
circulating CD4+ T cells in 
rheumatoid arthritis patients 





All NK cells 
Activated and memory CD8+ T cells 
Not express on naïve CD8+ T cells 
Not express on CD4+ T cells 
 
 
25% of splenic TCRγδ T cells 
Large fraction of NKT cells 
 
IKDC subset 
Only mRNA  
Table 1. Pattern of NKG2D receptor expression in human and in mouse. IEL: intestinal 
intraepithelial lymphocytes. IKDC: interferon producing killer dendritic cells. ND: not 
determined. (Coudert and Held, 2006). 
1.2 Function of NKG2D receptor 
Human NKG2D signals exclusively via DAP-10, while mouse NKG2D associates with both 
DAP-10 and DAP-12. Upon NKG2D engagement, DAP-12 recruits ZAP-70 and Syk protein 
tyrosine kinases with the help of its immunoreceptor tyrosine-based activation motif (ITAM) 
(Lanier et al., 1998). It has been observed that mouse deficient for DAP-12 retained 
significant NKG2D-dependent NK cell mediated killing (Diefenbach et al., 2002a; Zompi et 
al., 2003). Moreover, NK cells from Syk/ZAP-70 deficient mouse also retained significant 
lytic activity. In contrast, DAP-10 lacks an ITAM but instead contains a YINM motif. Upon 
engagement of human NKG2D, the recruitment of the p85 subunit of phosphatidylinositol 
3- kinase (PI3-K) (Wu et al., 1999) and of Grb2 to DAP-10 occurs (Chang et al., 1999). Both 
p85 and Grb2 have to be recruited to DAP-10 for full calcium flux and cell-mediated 
cytotoxicity (Upshaw et al., 2006). The residual lytic activity observed in DAP-12 deficient 
mice was abrogated when pharmacological blockade of Src family kinases and PI3-K, which 
act down-stream of DAP-10, were used (Colucci et al., 2002), indicating that DAP-10 is 
crucial for NK cell cytotoxicity. The NKG2D/DAP-10 complex triggers granule release and 
cytotoxicity following NKG2D crosslinking in human NK cells (Billadeau et al., 2003). Thus, 
ITAM-independent, DAP-10- dependent signaling triggers NKG2D-dependent cytotoxic 
function in NK cells. 
Besides NK cells, NKG2D receptors are constitutively expressed in human CD8+ T cells and 
upon activation in mouse CD8+ T cells. Since T cells generally lack DAP-12 expression, 
NKG2D signaling occurs exclusively via DAP-10 in humans and in mice. In T cells, NKG2D 
serves as co-stimulatory and in some instances, as primary activation function. In CD8+ T 
cells NKG2D engagement enhances T cell activation rather than induces activation (Groh et 
al., 2001; Maasho et al., 2005). Prolonged exposure of T cells derived from human intestinal 
epithelium to high amounts of IL-15 changes NKG2D function and expression by up-
regulating DAP-10 (Roberts et al., 2001).  
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1.3 NKG2D ligands  
NKG2D ligands are structurally similar to MHC class I molecules. The number of NKG2D 
ligands currently known stands at seven both in humans and mice. In humans these ligands 
are grouped into two families: the MHC-class-I-polypeptide related sequence A (MICA) and 
MICB protein family and the other family including cytomegalovirus UL16-binding protein 
(ULBP; also known as RAET1 proteins) consisting of five members (ULBP1–ULBP4 and 
RAET1G) (Bahram et al., 1994; Chalupny et al., 2003; Bacon et al., 2004). NKG2D ligands are 
variable in both their amino acid sequence and domain structure. MICA, for example, only 
shares 20–25% sequence identity with ULBP molecules (Radosavljevic et al., 2002). In mice 
there are five retinoic acid early transcript 1 (RAE1) proteins and the minor 
histocompatibility protein H60 and MULT (Diefenbach et al., 2003).  
All ligands share an MHC-class-I-like α1α2 domain that binds to NKG2D. The MICA and 
MICB proteins also have an additional α3 domain. The RAE1 proteins in mice and ULBP1, 
ULBP2 and ULBP3 in humans are glycosylphosphatidylinositol (GPI)- anchored receptors. 
By contrast, MICA, MICB, ULBP4, RAET1G, H60 and MULT1 possess transmembrane 
domains and cytoplasmic tails (Eagle and Trowsdale, 2007). The ULBP genes are clustered 
in the telomeric region of human chromosome 6; a corresponding region with NKG2D 
ligands is found on mouse chromosome 10. The MICA and MICB genes are localized within 
the human HLA locus on chromosome 6, which also harbors orthologous MHC class I 
related Rae genes (Radosavlievic et al., 2002). Some NKG2D ligands are polymorphic, over 
70 distinct alleles have been identified in MIC genes (Radosavljevic et al., 2002). Even 
though the number of NKG2D ligands in humans and mice are same, phylogenetic analysis 
shows that these ligands have almost certainly diversified independently from each other 
(Raulet et al., 2003). 
1.4 NKG2D ligand expression 
The expression of NKG2D ligands are induced by a wide variety of stimuli referred as 
“cellular stress”, which includes tumorigenesis (Gasser et al., 2005), infection by a variety of 
pathogens (Lodoen et al., 2006), classic cell-stress stimuli such as heat shock (Venkataraman 
et al., 2007) and, also, as a result of Toll-like receptor (TLR) signaling (Nedvetzki et al., 2007). 
The aberrant expression of NKG2D ligands has also been linked with autoimmune diseases, 
including rheumatoid arthritis, coeliac disease and autoimmune diabetes (Hue et al., 2004). 
Not much is know about the precise mechanisms that lead to upregulation of NKG2D 
ligands. In cancer, NKG2D ligand expression has been associated with activation of the 
DNA-damage response pathways by genotoxic stress (Gasser et al., 2005). The triggers for 
switching on of NKG2D-ligand expression during infection have not yet been well defined 
(Eagle and Trowsdale, 2007). 
1.5 NKG2D ligands and tumor 
A large fraction of tumor cells express NKG2D ligands constitutively. MICA/B expression is 
detected on many types of epithelial tumor cell lines of different tissue origins (Bauer et al., 
1999; Jinushi et al., 2003; Groh et al., 1999; Groh et al., 1998). In contrast, ULBPs are 
preferentially expressed on T cell leukemia cell lines (Pende et al., 2002) as well as on freshly 
isolated lymphoid leukemia cells. RAE-1 and H60 are up-regulated in skin treated with 
carcinogens (Girardi et al., 2001)  and are found on skin, renal and lung carcinoma cell lines 
(Girardi et al., 2001; Smyth et al., 2002). The murine NKG2D ligands H60 and RAE-1 are also 
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found on numerous hematopoietic tumor cell lines (Lowin-Kropf et al., 2002). In some cases, 
NKG2D ligand up-regulation has been observed to be associated with transformation, 
having both oncogene and tumor suppressor roles. Embryonic fibroblasts deficient for JunB 
show an enhanced expression of RAE-1є and MULT1. JunB exerts tumor suppressor activity 
through the negative regulation of c-jun function (Deng et al., 1993). The chronic activity of 
the DNA damage response pathways have also been implicated to be responsible for the 
constitutive expression of NKG2D ligands such as RAE-1, MULT1 in mouse lymphoid 
tumor cell lines (Gasser et al., 2005).  
1.6 MULT1 ligand 
Murine ULBP-like transcript 1 (MULT1) is a ligand of NKG2D receptor. NKG2D receptors 
present on the effector cells recognize and bind to MULT1 on target cells. The cDNA 
sequence of MULT1 consists of a full length open reading frame (ORF) of 1.1 Kb and 
encoding a protein with a molecular weight of 37.1 KD. MULT1 protein is a type I 
transmembrane protein with an N-terminal signal sequence of 25 aa, two class I MHC like α 
domains (89 aa and 91 aa, respectively), a transmembrane domain 17 aa and a cytoplasmic 
domain of 109 aa. Compare to other NKG2D ligands MULT1 lacks α3- like domain and the 
GPI trans amidation site (Diefenbach et al., 2003). 
MULT1 protein is a glycoprotein with two ectodomains containing four N-glycosylation 
sites and one O-glycosylation site. Sequence alignments of MULT1 with other known mouse 
NKG2D ligands such as H60, Rae1ß and other known human NKG2D ligands such as 
MICA, ULBP1 and MHC-1, reveals that MULT1 protein is distantly related to known 
NKG2D ligands, which are in turn distantly related to MHC class I proteins. The sequence 
identity of MULT1 with known human ligands like MICA and ULBP1, are 16.7% and 29.9% 
respectively, thus MULT1 is closely related to the members of human ULBP family 
(Diefenbach et al., 2003). 
1.6.1 Expression of MULT1 ligand 
MULT1 mRNA is detected in a wide variety of tissues such as thymus, spleen, lymph nodes, 
and to a lesser extent liver and heart, but is not detected in kidney or brain. However, 
surface expression of MULT1 is not detected in lymph node, liver or kidney cells, suggesting 
that MULT1 may be regulated post-transcriptionally (Diefenbach et al., 2003). 
MULT1 mRNA expression has been observed in multiple tumor cell lines like YAC-1, 
WEH17.1, A20, P815, S49.1, BW5147 and TRAMP-C1. In WEHI7.1, S49.1 and BW5147 T cell 
lymphomas, and the P815 mastocytoma, MULT1 is the only known NKG2D ligand 
expressed in the cells. Other cell lines such as A20 B cell lymphoma and TRAMP-C1 prostate 
carcinoma coexpress MULT1 and RAE1 ligands (Diefenbach et al., 2003). The finding that 
MULT1, like RAE1 and H60 family members, is expressed by multiple tumor cell lines 
suggests that MULT1 contributes to immune surveillance in tumors (Diefenbach et al., 
2002b). 
1.6.2 Function of MULT1 ligand 
High-level expression of NKG2D ligand on a tumor cell helps the tumor cell to overcome 
class 1-mediated inhibition of NK cells resulting in its cell lysis (Carayannopoulos et al., 
2002). Tumor cells expressing high levels of MULT1 are highly susceptible to NK mediated 
lysis and strongly induce IFN-γ production in freshly isolated, as well as IL-2 expanded, NK 
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cells. MULT1 also induces the production of nitric oxide in activated macrophages. When 
ectopically expressed by tumor cells, MULT1 induces a very potent antitumor response in 
vivo resulting in strong rejection of the transduced tumor cells in syngeneic B6 mice. 
Interestingly, the MULT1-transduced tumor cells have been observed to prime the mice, 
rendering them immune to the tumor antigens of the parental tumor cell (Diefenbach et al., 
2003). Tumor cells expressing different NKG2D ligands such as MULT1, RAE1ß and/or H60 
can induce protective immunity against multiple tumor cell lines such as RMA, B16-BL6 and 
EL4 (Hayakawa et al., 2002).  
MULT1 protein has a KD  of 6 nM and Koff of ~0.006 S-1 which is several times lower than 
RAE1є and H60 (KD ~ 10-30 nM ). MULT1 has a t 1/2 of ~ 2 min, longer than either H60 (~ 20 
s) or RAE1 α-δ (~ 5s). These results indicate that MULT1 binds NKG2D with the highest 
affinity of all known ligands and has a half life longer than all known NKG2D ligands 
(Carayannopoulos et al., 2002a). Thus, three distinct MHC class 1-like molecules in the 
mouse, H60, RAE1є and MULT1 bind NKG2D with high affinity despite low mutual 
sequence identity (<20%).  
Evolutionary advantage of selecting such a complicated receptor ligand system is two-fold. 
First, the functional consequences of NKG2D engagement are pleiotropic, involving T cell 
co-stimulation, NK cell activation, macrophage stimulation, and possibly regulation of fetal 
development (Diefenbach et al., 2000; Groh et al., 2001). Precise execution of these diverse 
functions requires multiple genes with distinct promoter/enhancer sequences, 
posttranslational controls, and even kinetics of binding. Second, microbes exert enormous 
selective pressure to diversify immune-related functions, albeit at differing rates (Klein et 
al., 1993; Khakoo et al., 2000). Recent evidence suggests that human CMV interferes with the 
NKG2D system using the UL16 gene product to bind ULBP1 and ULBP2 (Cosman et al., 
2001) also, mouse CMV gp40 downregulates H60 (Krmpotic et al., 2002). Pathogen-encoded 
factors such as these might have selected for NKG2D-binding partners which retain receptor 
specificity but lack susceptibility to interference or subversion (e.g., ULBP3, which does not 
bind to UL16), resulting in the current repertoire of dissimilar NKG2D ligands 
(Carayannopoulos et al., 2002). 
1.7 Escape mechanism by tumors 
Tumors have developed many distinct mechanisms that would allow them to escape the 
detection by NKG2D expressing effector cells. As cancer progresses, immune pressure on 
the tumor may lead to selection of cells devoid of NKG2D ligands. It has been observed in 
cancer patients that most primary tumors seem to express NKG2D ligands, whereas more 
advanced tumors and metastases express very low level ligand (Vetter et al., 2004; 
Raffaghello et al., 2005). This leads to selection of variants with low levels of NKG2D 
ligands. 
NKG2D ligand cleavage has been observed in some tumors. Metalloproteinases can cleave 
MICA/B off the cell surface of tumor cells (Doubrovina et al., 2003) reducing their cell 
surface levels and limiting recognition by NKG2D-expressing effector cells. In addition, 
soluble NKG2D ligands such as MICA in the serum, upon binding to NKG2D, induce the 
internalization and lysosomal degradation of the NKG2D receptor on CD8+ T cells and NK 
cells (Doubrovina et al., 2003; Jinushi et al., 2003), reducing the efficiency of NKG2D 
recognition.  
TGF-ß, a major immunosuppressive cytokine produced by tumor cells also decreases the 
surface expression of MICA, effecting tumor cell recognition by CD8+ T and NK cells (Friese 
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found on numerous hematopoietic tumor cell lines (Lowin-Kropf et al., 2002). In some cases, 
NKG2D ligand up-regulation has been observed to be associated with transformation, 
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through the negative regulation of c-jun function (Deng et al., 1993). The chronic activity of 
the DNA damage response pathways have also been implicated to be responsible for the 
constitutive expression of NKG2D ligands such as RAE-1, MULT1 in mouse lymphoid 
tumor cell lines (Gasser et al., 2005).  
1.6 MULT1 ligand 
Murine ULBP-like transcript 1 (MULT1) is a ligand of NKG2D receptor. NKG2D receptors 
present on the effector cells recognize and bind to MULT1 on target cells. The cDNA 
sequence of MULT1 consists of a full length open reading frame (ORF) of 1.1 Kb and 
encoding a protein with a molecular weight of 37.1 KD. MULT1 protein is a type I 
transmembrane protein with an N-terminal signal sequence of 25 aa, two class I MHC like α 
domains (89 aa and 91 aa, respectively), a transmembrane domain 17 aa and a cytoplasmic 
domain of 109 aa. Compare to other NKG2D ligands MULT1 lacks α3- like domain and the 
GPI trans amidation site (Diefenbach et al., 2003). 
MULT1 protein is a glycoprotein with two ectodomains containing four N-glycosylation 
sites and one O-glycosylation site. Sequence alignments of MULT1 with other known mouse 
NKG2D ligands such as H60, Rae1ß and other known human NKG2D ligands such as 
MICA, ULBP1 and MHC-1, reveals that MULT1 protein is distantly related to known 
NKG2D ligands, which are in turn distantly related to MHC class I proteins. The sequence 
identity of MULT1 with known human ligands like MICA and ULBP1, are 16.7% and 29.9% 
respectively, thus MULT1 is closely related to the members of human ULBP family 
(Diefenbach et al., 2003). 
1.6.1 Expression of MULT1 ligand 
MULT1 mRNA is detected in a wide variety of tissues such as thymus, spleen, lymph nodes, 
and to a lesser extent liver and heart, but is not detected in kidney or brain. However, 
surface expression of MULT1 is not detected in lymph node, liver or kidney cells, suggesting 
that MULT1 may be regulated post-transcriptionally (Diefenbach et al., 2003). 
MULT1 mRNA expression has been observed in multiple tumor cell lines like YAC-1, 
WEH17.1, A20, P815, S49.1, BW5147 and TRAMP-C1. In WEHI7.1, S49.1 and BW5147 T cell 
lymphomas, and the P815 mastocytoma, MULT1 is the only known NKG2D ligand 
expressed in the cells. Other cell lines such as A20 B cell lymphoma and TRAMP-C1 prostate 
carcinoma coexpress MULT1 and RAE1 ligands (Diefenbach et al., 2003). The finding that 
MULT1, like RAE1 and H60 family members, is expressed by multiple tumor cell lines 
suggests that MULT1 contributes to immune surveillance in tumors (Diefenbach et al., 
2002b). 
1.6.2 Function of MULT1 ligand 
High-level expression of NKG2D ligand on a tumor cell helps the tumor cell to overcome 
class 1-mediated inhibition of NK cells resulting in its cell lysis (Carayannopoulos et al., 
2002). Tumor cells expressing high levels of MULT1 are highly susceptible to NK mediated 
lysis and strongly induce IFN-γ production in freshly isolated, as well as IL-2 expanded, NK 
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cells. MULT1 also induces the production of nitric oxide in activated macrophages. When 
ectopically expressed by tumor cells, MULT1 induces a very potent antitumor response in 
vivo resulting in strong rejection of the transduced tumor cells in syngeneic B6 mice. 
Interestingly, the MULT1-transduced tumor cells have been observed to prime the mice, 
rendering them immune to the tumor antigens of the parental tumor cell (Diefenbach et al., 
2003). Tumor cells expressing different NKG2D ligands such as MULT1, RAE1ß and/or H60 
can induce protective immunity against multiple tumor cell lines such as RMA, B16-BL6 and 
EL4 (Hayakawa et al., 2002).  
MULT1 protein has a KD  of 6 nM and Koff of ~0.006 S-1 which is several times lower than 
RAE1є and H60 (KD ~ 10-30 nM ). MULT1 has a t 1/2 of ~ 2 min, longer than either H60 (~ 20 
s) or RAE1 α-δ (~ 5s). These results indicate that MULT1 binds NKG2D with the highest 
affinity of all known ligands and has a half life longer than all known NKG2D ligands 
(Carayannopoulos et al., 2002a). Thus, three distinct MHC class 1-like molecules in the 
mouse, H60, RAE1є and MULT1 bind NKG2D with high affinity despite low mutual 
sequence identity (<20%).  
Evolutionary advantage of selecting such a complicated receptor ligand system is two-fold. 
First, the functional consequences of NKG2D engagement are pleiotropic, involving T cell 
co-stimulation, NK cell activation, macrophage stimulation, and possibly regulation of fetal 
development (Diefenbach et al., 2000; Groh et al., 2001). Precise execution of these diverse 
functions requires multiple genes with distinct promoter/enhancer sequences, 
posttranslational controls, and even kinetics of binding. Second, microbes exert enormous 
selective pressure to diversify immune-related functions, albeit at differing rates (Klein et 
al., 1993; Khakoo et al., 2000). Recent evidence suggests that human CMV interferes with the 
NKG2D system using the UL16 gene product to bind ULBP1 and ULBP2 (Cosman et al., 
2001) also, mouse CMV gp40 downregulates H60 (Krmpotic et al., 2002). Pathogen-encoded 
factors such as these might have selected for NKG2D-binding partners which retain receptor 
specificity but lack susceptibility to interference or subversion (e.g., ULBP3, which does not 
bind to UL16), resulting in the current repertoire of dissimilar NKG2D ligands 
(Carayannopoulos et al., 2002). 
1.7 Escape mechanism by tumors 
Tumors have developed many distinct mechanisms that would allow them to escape the 
detection by NKG2D expressing effector cells. As cancer progresses, immune pressure on 
the tumor may lead to selection of cells devoid of NKG2D ligands. It has been observed in 
cancer patients that most primary tumors seem to express NKG2D ligands, whereas more 
advanced tumors and metastases express very low level ligand (Vetter et al., 2004; 
Raffaghello et al., 2005). This leads to selection of variants with low levels of NKG2D 
ligands. 
NKG2D ligand cleavage has been observed in some tumors. Metalloproteinases can cleave 
MICA/B off the cell surface of tumor cells (Doubrovina et al., 2003) reducing their cell 
surface levels and limiting recognition by NKG2D-expressing effector cells. In addition, 
soluble NKG2D ligands such as MICA in the serum, upon binding to NKG2D, induce the 
internalization and lysosomal degradation of the NKG2D receptor on CD8+ T cells and NK 
cells (Doubrovina et al., 2003; Jinushi et al., 2003), reducing the efficiency of NKG2D 
recognition.  
TGF-ß, a major immunosuppressive cytokine produced by tumor cells also decreases the 
surface expression of MICA, effecting tumor cell recognition by CD8+ T and NK cells (Friese 
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et al., 2004). In vitro experiments have shown that NK cells cultured in the presence of TGF-ß 
down-regulated NKG2D receptor expression (Lee et al., 2004). It has been reported that IFN-
γ can render certain susceptible target cells resistant to NK cell responses in vitro and in vivo. 
This has been attributed to an up-regulation of MHC class I molecules, which are recognized 
by inhibitory NK cell receptors (Bui et al., 2006).  
Research has also shown that sustained NKG2D ligand encounters can promote NK cell 
dysfunction in vitro and in vivo. The enforced constitutive expression of NKG2D ligands 
such as RAE-1ß, RAE-1є and MICA as transgenes in mice impair NKG2D functions in vivo 
(Wiemann et al., 2005). This observed NKG2D dysfunction also raises the possibility that 
CD8+ T cells and human NK cells may similarly be susceptible to inactivation. 
1.8 NKG2D ligands diversity  
Even though NKG2D ligands are not functionally equivalent, their roles are redundant to 
some extent (Komatsu et al., 1999). The evolutionary advantage for the presence of diverse 
NKG2D ligands can be explained with 3 possible reasons: 1) escaping immune recognition, 
2) evading tumor responses and 3) tissue specific function (Eagle and Trowsdale, 2007). 
1.8.1 Escaping immune recognition 
In nature, both host and pathogen are under natural selection pressure to diversify and 
refine their defense strategies in response to improvements made by their competitor. It has 
been observed that viruses, such as human cytomegalovirus (HCMV), MCMV, Influenza A, 
and Epstein–Barr virus, induce NKG2D ligands in infected cells (Draghi et al., 2007; 
Pappworth et al., 2007). As an escape mechanism HCMV deploys immunoevasin proteins 
such as UL16 that can bind to MICB, ULBP1, ULBP2 and RAET1G and prevent the 
expression of NKG2D ligands, helping the virus to escape immune recognition (Cosman et 
al., 2001; Chalupny et al., 2003; Bacon et al., 2004). Since viruses have evolved mechanisms to 
evade immune system, the host responds by developing variants of NKG2D ligands by gene 
duplication and going beyond the reach of the virus (Zhou et al., 2005; Chalupny et al., 
2006).  
1.8.2 Evading tumor responses 
One of the main functions of NKG2D is to participate in antitumour immune response and 
immune surveillance (Diefenbach et al., 2001; Smyth et al., 2005). Tumors have evolved 
many mechanisms that would allow them to avoid NKG2D-mediated immune attack. Some 
of these mechanisms are shedding soluble NKG2D ligands like MIC from their cell surface 
or down regulating MICA expression, producing TGF-β, effectively anergizing NKG2D-
mediated immune recognition, and switching off the expression of NKG2D ligands as they 
progress (Groh et al., 2002; Vetter et al., 2004). Possessing multiple NKG2D ligands under 
the control of different cancer-related stress-response would provide the host with a fail-safe 
alert mechanism. Since expression of an individual NKG2D ligand may be lost as part of a 
cancer immunoediting process, the advantage of having more than one NKG2D ligand is 
that it would be much more difficult for the cancer to switch off multiple NKG2D ligands at 
once and help a host in detecting tumors (Eagle and Trowsdale, 2007). 
1.8.3 Tissue specific functions 
In humans, MICA and RAET1G proteins are expressed constitutively in the polarized 
epithelial-cell layer of the gut where they are likely to come in contact with pathogens (Groh 
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et al., 1996). MICA and ULBP1–ULBP3 are expressed by normal airway epithelial cells 
(Borchers et al., 2006). RAE1 transcripts were reported in mouse embryonic tissues such as 
embryonic brain (Nomura et al., 1996). MICA has a specialized role in the gut, whereas 
ULBP4 may have a related but equally specialized role in the skin (Groh et al., 1996).  
NKG2D ligands, like RAE-1 or MICA/B are not expressed in most tissues in healthy adult 
mice and humans (Nomura et al., 1996; Groh et al., 1996). ULBP1-3 mRNA is expressed in 
various healthy tissues (Cosman et al., 2001) and ULBP4 mRNA expression is detected in the 
skin (Jan Chalupny et al., 2003). Likewise, MULT1 mRNA is expressed in a wide variety of 
tissues such as thymus, spleen, lymph node, liver and heart (Carayannopoulos et al., 2002b; 
Diefenbach et al., 2003). RAE-1ß and RAE-1δ mRNA expression is detected in the early 
embryos, particularly in the brain (Nomura et al., 2006). Bone marrow cells express low 
levels of RAE-1 and H60 but not MULT1 (Ogasawara et al., 2003). Some NKG2D ligands are 
constitutively expressed in a restricted number of normal cells, indicating that they may 
have evolved unique tissue-specific functions that are not necessarily relate to their role in 
immune surveillance. Hence, it seems that NKG2D-ligand diversity may have allowed for 
the evolution of individual ligands with functional specialties that are specific for different 
cell types and tissues (Eagle and Trowsdale, 2007). 
1.9 NKG2D dependent immunotherapy 
As NKG2D receptor recognizes ligands that are constitutively expressed on many 
transformed but not on most normal cells, this provides an opportunity for their use in 
immunotherapy of cancer. Many different therapeutic strategies are being developed using 
NKG2D receptor-ligand interactions (Coudert and Held, 2006). Chimeric anti-tumor 
mAb/NKG2D-ligand, with the antibody portion of the chimeric protein specific to tumor 
cell targeting, while the NKG2D ligand re-directs NKG2D-expressing effector cells to the 
site of tumor have been generated. An anti-CEA (carcinoembryonic antigen)/MICA chimera 
and H60/anti-CEA specifically bind CEA+ human tumor cells and enhanced the in vitro 
lysis by NK cells in a NKG2D-dependent manner (Zhou et al., 2005). NKG2D receptor fused 
to the cytoplasmic portion of CD3ζ has been expressed in splenic T cells. This chimeric 
NKG2D receptor/CD3ζ protein confers primary activation function to T cells in response to 
NKG2D ligand-bearing tumor cells in vitro and induces memory response to NKG2D 
ligand-negative tumor cells (Zhang et al., 2005).  
Cytokines, such as IL-21, IL-12 and IFN-α, exert anti-tumor effects by up-regulating NKG2D 
cell surface expression have been used in some tumor models with positive results. Mice 
treated with IL-21 have been observed to reject tumors cells more efficiently than control 
mice. IL-21 up-regulated NK cell mediated NKG2D-dependent tumor cell lysis in vitro and 
the rejection of grafted tumor cells in vivo (Takaki et al., 2005). Similar results were observed 
with IL-12 and IFN-α (Zhang et al., 2005). 
Irradiation or alkylating compounds commonly used in chemotherapy treatment of cancer 
activate the DNA damage response pathway and can induce the expression of NKG2D 
ligands in mouse and human cells. ULBP3 and MICA are up-regulated by transretinoic acid 
in patients with chronic B cell lymphocytic leukemia (B-CLL) (Poggi et al., 2004). These 
treatments rendered tumor cells susceptible to killing by autologous NKG2D expressing 
effector cells and can be used as part of the combination therapy regime with any of the 
above discussed approaches (Coudert and Held, 2006). 
NKG2D recognition of multiple stress-inducible host proteins is of considerable research 
interest since this system has potential to be manipulated for therapeutic purposes. Tumor 
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et al., 2004). In vitro experiments have shown that NK cells cultured in the presence of TGF-ß 
down-regulated NKG2D receptor expression (Lee et al., 2004). It has been reported that IFN-
γ can render certain susceptible target cells resistant to NK cell responses in vitro and in vivo. 
This has been attributed to an up-regulation of MHC class I molecules, which are recognized 
by inhibitory NK cell receptors (Bui et al., 2006).  
Research has also shown that sustained NKG2D ligand encounters can promote NK cell 
dysfunction in vitro and in vivo. The enforced constitutive expression of NKG2D ligands 
such as RAE-1ß, RAE-1є and MICA as transgenes in mice impair NKG2D functions in vivo 
(Wiemann et al., 2005). This observed NKG2D dysfunction also raises the possibility that 
CD8+ T cells and human NK cells may similarly be susceptible to inactivation. 
1.8 NKG2D ligands diversity  
Even though NKG2D ligands are not functionally equivalent, their roles are redundant to 
some extent (Komatsu et al., 1999). The evolutionary advantage for the presence of diverse 
NKG2D ligands can be explained with 3 possible reasons: 1) escaping immune recognition, 
2) evading tumor responses and 3) tissue specific function (Eagle and Trowsdale, 2007). 
1.8.1 Escaping immune recognition 
In nature, both host and pathogen are under natural selection pressure to diversify and 
refine their defense strategies in response to improvements made by their competitor. It has 
been observed that viruses, such as human cytomegalovirus (HCMV), MCMV, Influenza A, 
and Epstein–Barr virus, induce NKG2D ligands in infected cells (Draghi et al., 2007; 
Pappworth et al., 2007). As an escape mechanism HCMV deploys immunoevasin proteins 
such as UL16 that can bind to MICB, ULBP1, ULBP2 and RAET1G and prevent the 
expression of NKG2D ligands, helping the virus to escape immune recognition (Cosman et 
al., 2001; Chalupny et al., 2003; Bacon et al., 2004). Since viruses have evolved mechanisms to 
evade immune system, the host responds by developing variants of NKG2D ligands by gene 
duplication and going beyond the reach of the virus (Zhou et al., 2005; Chalupny et al., 
2006).  
1.8.2 Evading tumor responses 
One of the main functions of NKG2D is to participate in antitumour immune response and 
immune surveillance (Diefenbach et al., 2001; Smyth et al., 2005). Tumors have evolved 
many mechanisms that would allow them to avoid NKG2D-mediated immune attack. Some 
of these mechanisms are shedding soluble NKG2D ligands like MIC from their cell surface 
or down regulating MICA expression, producing TGF-β, effectively anergizing NKG2D-
mediated immune recognition, and switching off the expression of NKG2D ligands as they 
progress (Groh et al., 2002; Vetter et al., 2004). Possessing multiple NKG2D ligands under 
the control of different cancer-related stress-response would provide the host with a fail-safe 
alert mechanism. Since expression of an individual NKG2D ligand may be lost as part of a 
cancer immunoediting process, the advantage of having more than one NKG2D ligand is 
that it would be much more difficult for the cancer to switch off multiple NKG2D ligands at 
once and help a host in detecting tumors (Eagle and Trowsdale, 2007). 
1.8.3 Tissue specific functions 
In humans, MICA and RAET1G proteins are expressed constitutively in the polarized 
epithelial-cell layer of the gut where they are likely to come in contact with pathogens (Groh 
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et al., 1996). MICA and ULBP1–ULBP3 are expressed by normal airway epithelial cells 
(Borchers et al., 2006). RAE1 transcripts were reported in mouse embryonic tissues such as 
embryonic brain (Nomura et al., 1996). MICA has a specialized role in the gut, whereas 
ULBP4 may have a related but equally specialized role in the skin (Groh et al., 1996).  
NKG2D ligands, like RAE-1 or MICA/B are not expressed in most tissues in healthy adult 
mice and humans (Nomura et al., 1996; Groh et al., 1996). ULBP1-3 mRNA is expressed in 
various healthy tissues (Cosman et al., 2001) and ULBP4 mRNA expression is detected in the 
skin (Jan Chalupny et al., 2003). Likewise, MULT1 mRNA is expressed in a wide variety of 
tissues such as thymus, spleen, lymph node, liver and heart (Carayannopoulos et al., 2002b; 
Diefenbach et al., 2003). RAE-1ß and RAE-1δ mRNA expression is detected in the early 
embryos, particularly in the brain (Nomura et al., 2006). Bone marrow cells express low 
levels of RAE-1 and H60 but not MULT1 (Ogasawara et al., 2003). Some NKG2D ligands are 
constitutively expressed in a restricted number of normal cells, indicating that they may 
have evolved unique tissue-specific functions that are not necessarily relate to their role in 
immune surveillance. Hence, it seems that NKG2D-ligand diversity may have allowed for 
the evolution of individual ligands with functional specialties that are specific for different 
cell types and tissues (Eagle and Trowsdale, 2007). 
1.9 NKG2D dependent immunotherapy 
As NKG2D receptor recognizes ligands that are constitutively expressed on many 
transformed but not on most normal cells, this provides an opportunity for their use in 
immunotherapy of cancer. Many different therapeutic strategies are being developed using 
NKG2D receptor-ligand interactions (Coudert and Held, 2006). Chimeric anti-tumor 
mAb/NKG2D-ligand, with the antibody portion of the chimeric protein specific to tumor 
cell targeting, while the NKG2D ligand re-directs NKG2D-expressing effector cells to the 
site of tumor have been generated. An anti-CEA (carcinoembryonic antigen)/MICA chimera 
and H60/anti-CEA specifically bind CEA+ human tumor cells and enhanced the in vitro 
lysis by NK cells in a NKG2D-dependent manner (Zhou et al., 2005). NKG2D receptor fused 
to the cytoplasmic portion of CD3ζ has been expressed in splenic T cells. This chimeric 
NKG2D receptor/CD3ζ protein confers primary activation function to T cells in response to 
NKG2D ligand-bearing tumor cells in vitro and induces memory response to NKG2D 
ligand-negative tumor cells (Zhang et al., 2005).  
Cytokines, such as IL-21, IL-12 and IFN-α, exert anti-tumor effects by up-regulating NKG2D 
cell surface expression have been used in some tumor models with positive results. Mice 
treated with IL-21 have been observed to reject tumors cells more efficiently than control 
mice. IL-21 up-regulated NK cell mediated NKG2D-dependent tumor cell lysis in vitro and 
the rejection of grafted tumor cells in vivo (Takaki et al., 2005). Similar results were observed 
with IL-12 and IFN-α (Zhang et al., 2005). 
Irradiation or alkylating compounds commonly used in chemotherapy treatment of cancer 
activate the DNA damage response pathway and can induce the expression of NKG2D 
ligands in mouse and human cells. ULBP3 and MICA are up-regulated by transretinoic acid 
in patients with chronic B cell lymphocytic leukemia (B-CLL) (Poggi et al., 2004). These 
treatments rendered tumor cells susceptible to killing by autologous NKG2D expressing 
effector cells and can be used as part of the combination therapy regime with any of the 
above discussed approaches (Coudert and Held, 2006). 
NKG2D recognition of multiple stress-inducible host proteins is of considerable research 
interest since this system has potential to be manipulated for therapeutic purposes. Tumor 
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cells expressing NKG2D ligands have been shown to be susceptible to NK cell mediated 
lysis, to induce a very potent antitumor response, and to provide protective immunity in 
vivo (Carayannopoulos et al., 2002a; Carayannopoulos et al., 2002b; Diefenbach et al., 2003; 
Kotturi et al., 2008; Eagle and Trowsdale, 2007). NKG2D recognition system has potential as 
a promising entry point to induce and/or improve immune responses against cancer for the 
following reasons. First, NKG2D ligands are generally poorly and only transiently 
expressed on healthy tissues, while they are constitutively expressed at significant levels on 
tumor cells. Second, NKG2D ligands are expressed on a broad variety of tumor cells of 
distinct tissue origins. Third, in situations where NKG2D ligands are poorly expressed, it 
may be possible to enhance their expression using radiation and/or chemotherapies. Fourth, 
NKG2D is expressed on all NK cells and also on a substantial fraction of T lymphocytes, 
providing a large number of potential effector cells. Fifth, cytokines may be used to improve 
NKG2D function. Finally, NKG2D-mediated adoptive immunotherapy should, in principal, 
be applicable to all individuals as the NKG2D receptor is monomorphic (Coudert and Held, 
2006). 
A great deal has yet to be understood about the involvement of NKG2D ligands in disease. 
A lot is known about the function of MICA; however, investigation of the expression and 
function of other NKG2D ligands with transmembrane domains and cytoplasmic tails is 
needed. A better understanding of the differences in the functional properties of NKG2D 
ligands and the pathways that regulate NKG2D ligand expression could help us develop 
better therapeutic interventions that could induce NKG2D-mediated immune responses and 
more efficient therapeutic strategies in the future (Eagle and Trowsdale, 2007). 
1.10 Fas/CD95  
CD95/APO-1/Fas receptor is a member of the tumor necrosis factor (TNF) superfamily of 
receptors. Its main function in signaling is the induction of apoptosis (Schulze-Osthoff et al., 
1998). CD95/Fas receptor is expressed on various human cells, including myeloid cells, T 
lymphoblastoid cells, and diploid fibroblasts. Fas is a 48-kDa type I transmembrane receptor 
of 319 amino acids with a single transmembrane domain of 17 amino acids, an N-terminal 
cysteine-rich extracellular domain and a C-terminal cytoplasmic domain containing 145 
amino acids relatively abundant in charged amino acids. The cytoplasmic portion of Fas 
contains a domain called “death domain” of about 85 amino acids. The “death domain” is very 
crucial as it plays a role in transmitting the death signal from the cell’s surface to 
intracellular pathways and mediates signaling through protein–protein interactions 
(Nagata, 1997). The tertiary structure of the Fas death domain consists of six antiparallel, 
amphipathic α helices. Helices α1 and α2 are centrally located and flanked on each side by 
α3/α4 and α5/α6. This leads to an unusual topology in which the loops connecting α1/α2 
and α4/α5 cross over each other. The presence of a high number of charged amino acids in 
the death domain is responsible for interactions between death domains (Mollinedo and 
Gajate, 2006). CD95 receptors are expressed on the surface of cells as preassociated 
homotrimers (Siegel et al., 2000). These interactions were found to be mediated by a domain 
in the N-terminus, within the first of the cysteine-rich domains called PLAD (preligand 
binding assembly domain) (Siegel et al., 2000). CD95 receptors only function as trimers 
(Kischkel et al., 1995). 
CD95 contains a protein–protein interaction domain in its cytoplasmic region termed the 
death domain (DD) (Peter et al., 1999). When the preassociated receptor is ligated, CD95 
becomes competent to form the death-inducing signaling complex (DISC). In the DISC, the 
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adaptor molecule Fas-associated DD containing protein (FADD) binds to CD95 through 
homotypic interaction of its DD with the DD of CD95 (Kischkel et al., 1995). In addition to 
its DD, FADD contains another protein–protein interaction domain at its N-terminus, 
termed the death effector domain (DED). This domain recruits caspases containing these 
DED domains to the DISC. Both the DD and DED enable proteins containing the same 
domains to interact with one another. FADD interacts with procaspase-8 through its DED 
(Boldin et al., 1996). Thus, activation of Fas results in receptor aggregation and formation of 
DISC (Kischkel et al., 1995), containing trimerized Fas, FADD and procaspase-8. The 
apoptotic caspases perform different roles. The effector caspases, which include caspases 3, 
7, and 6 are responsible for most of the cleavage of proteins characteristic of apoptosis and 
are responsible for cleavage of proteins which induce the major morphological changes 
observed during programmed cell death (Ernshaw et al., 1999). Caspase-8 is a main initiator 
caspase and transduces the first signals of apoptosis in CD95 signaling and is expressed as 
two isoforms, caspase-8/a and -8/b, which are both recruited to the activated CD95 receptor 
(Scaffidi et al., 1997). Two molecules (FADD and caspase-8) are the key components of the 
CD95 DISC. Once procaspase-8 associates with FADD, the high local concentration of 
procaspase-8 leads to its autoproteolytic cleavage and activation (Salvesan and Dixit, 1999). 
Following the autoproteolytic cleavage of the enzyme, caspase-8 is released from the DISC 
as an active heterotetramer (Peter and Krammer, 2003).  
1.11 Fas ligand (FasL) 
FasL belongs to the TNF family and can be found as a 40-kDa membrane-bound or a 26-kDa 
soluble protein (Nagata, 1997). Rat FasL has no signal sequence at the N-terminus, but has a 
domain of hydrophobic amino acids in the middle of the molecule, indication that it is a 
type 11 membrane protein with the COOH-terminal region outside the cell. Mouse and 
human FasL are 76.9% identical at the amino acid sequence level and are functionally 
interchangeable. A stretch of about 150 amino acids in the extracellular region of FasL show 
significant homology to the corresponding region of other members of the TNF family 
which includes TNF, lymphotoxin (LT), CD40 ligand, CD27 ligand, CD30 ligand and OX40 
ligand. A single FasL gene is located on human and mouse chromosome 1 in the 
neighborhood of the OX40 ligand gene. Fas/FasL system is the major regulator of apoptosis 
at the cell membrane in mammalian cells through a receptor/ligand interaction (Mollinedo 
and Gajate, 2006).  
1.11.1 Expression of fasL 
FasL has been found to be expressed on cells of the lymphoid/myeloid lineage, including 
activated T cells and natural killer (NK) cells, where it plays an important role in immune 
homeostasis, T cell and NK cell-mediated toxicity (Brunner et al., 2003). FasL is also found to 
be expressed in sites such as the eye (Griffith et al., 1995) and testis (Bellgrau et al., 1995) 
contributing to immune privilege by inducing apoptosis of infiltrating proinflammatory 
immunocytes (Houston and O’Connell, 2004). FasL expression has also been observed in a 
variety of tumor cells indicating a possibility that FasL could mediate immune privilege in 
human tumors by inducing apoptosis of anti-tumor lymphocytes and also, stimulate 
proliferation of tumor cells (Houston and O’Connell, 2004). Tumor expression of FasL was 
first demonstrated in the colon carcinoma cell line SW620, where it could induce apoptosis 
of Fas-sensitive lymphoid cells in vitro (O’Connell et al., 1996). A functional FasL expression 
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cells expressing NKG2D ligands have been shown to be susceptible to NK cell mediated 
lysis, to induce a very potent antitumor response, and to provide protective immunity in 
vivo (Carayannopoulos et al., 2002a; Carayannopoulos et al., 2002b; Diefenbach et al., 2003; 
Kotturi et al., 2008; Eagle and Trowsdale, 2007). NKG2D recognition system has potential as 
a promising entry point to induce and/or improve immune responses against cancer for the 
following reasons. First, NKG2D ligands are generally poorly and only transiently 
expressed on healthy tissues, while they are constitutively expressed at significant levels on 
tumor cells. Second, NKG2D ligands are expressed on a broad variety of tumor cells of 
distinct tissue origins. Third, in situations where NKG2D ligands are poorly expressed, it 
may be possible to enhance their expression using radiation and/or chemotherapies. Fourth, 
NKG2D is expressed on all NK cells and also on a substantial fraction of T lymphocytes, 
providing a large number of potential effector cells. Fifth, cytokines may be used to improve 
NKG2D function. Finally, NKG2D-mediated adoptive immunotherapy should, in principal, 
be applicable to all individuals as the NKG2D receptor is monomorphic (Coudert and Held, 
2006). 
A great deal has yet to be understood about the involvement of NKG2D ligands in disease. 
A lot is known about the function of MICA; however, investigation of the expression and 
function of other NKG2D ligands with transmembrane domains and cytoplasmic tails is 
needed. A better understanding of the differences in the functional properties of NKG2D 
ligands and the pathways that regulate NKG2D ligand expression could help us develop 
better therapeutic interventions that could induce NKG2D-mediated immune responses and 
more efficient therapeutic strategies in the future (Eagle and Trowsdale, 2007). 
1.10 Fas/CD95  
CD95/APO-1/Fas receptor is a member of the tumor necrosis factor (TNF) superfamily of 
receptors. Its main function in signaling is the induction of apoptosis (Schulze-Osthoff et al., 
1998). CD95/Fas receptor is expressed on various human cells, including myeloid cells, T 
lymphoblastoid cells, and diploid fibroblasts. Fas is a 48-kDa type I transmembrane receptor 
of 319 amino acids with a single transmembrane domain of 17 amino acids, an N-terminal 
cysteine-rich extracellular domain and a C-terminal cytoplasmic domain containing 145 
amino acids relatively abundant in charged amino acids. The cytoplasmic portion of Fas 
contains a domain called “death domain” of about 85 amino acids. The “death domain” is very 
crucial as it plays a role in transmitting the death signal from the cell’s surface to 
intracellular pathways and mediates signaling through protein–protein interactions 
(Nagata, 1997). The tertiary structure of the Fas death domain consists of six antiparallel, 
amphipathic α helices. Helices α1 and α2 are centrally located and flanked on each side by 
α3/α4 and α5/α6. This leads to an unusual topology in which the loops connecting α1/α2 
and α4/α5 cross over each other. The presence of a high number of charged amino acids in 
the death domain is responsible for interactions between death domains (Mollinedo and 
Gajate, 2006). CD95 receptors are expressed on the surface of cells as preassociated 
homotrimers (Siegel et al., 2000). These interactions were found to be mediated by a domain 
in the N-terminus, within the first of the cysteine-rich domains called PLAD (preligand 
binding assembly domain) (Siegel et al., 2000). CD95 receptors only function as trimers 
(Kischkel et al., 1995). 
CD95 contains a protein–protein interaction domain in its cytoplasmic region termed the 
death domain (DD) (Peter et al., 1999). When the preassociated receptor is ligated, CD95 
becomes competent to form the death-inducing signaling complex (DISC). In the DISC, the 
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adaptor molecule Fas-associated DD containing protein (FADD) binds to CD95 through 
homotypic interaction of its DD with the DD of CD95 (Kischkel et al., 1995). In addition to 
its DD, FADD contains another protein–protein interaction domain at its N-terminus, 
termed the death effector domain (DED). This domain recruits caspases containing these 
DED domains to the DISC. Both the DD and DED enable proteins containing the same 
domains to interact with one another. FADD interacts with procaspase-8 through its DED 
(Boldin et al., 1996). Thus, activation of Fas results in receptor aggregation and formation of 
DISC (Kischkel et al., 1995), containing trimerized Fas, FADD and procaspase-8. The 
apoptotic caspases perform different roles. The effector caspases, which include caspases 3, 
7, and 6 are responsible for most of the cleavage of proteins characteristic of apoptosis and 
are responsible for cleavage of proteins which induce the major morphological changes 
observed during programmed cell death (Ernshaw et al., 1999). Caspase-8 is a main initiator 
caspase and transduces the first signals of apoptosis in CD95 signaling and is expressed as 
two isoforms, caspase-8/a and -8/b, which are both recruited to the activated CD95 receptor 
(Scaffidi et al., 1997). Two molecules (FADD and caspase-8) are the key components of the 
CD95 DISC. Once procaspase-8 associates with FADD, the high local concentration of 
procaspase-8 leads to its autoproteolytic cleavage and activation (Salvesan and Dixit, 1999). 
Following the autoproteolytic cleavage of the enzyme, caspase-8 is released from the DISC 
as an active heterotetramer (Peter and Krammer, 2003).  
1.11 Fas ligand (FasL) 
FasL belongs to the TNF family and can be found as a 40-kDa membrane-bound or a 26-kDa 
soluble protein (Nagata, 1997). Rat FasL has no signal sequence at the N-terminus, but has a 
domain of hydrophobic amino acids in the middle of the molecule, indication that it is a 
type 11 membrane protein with the COOH-terminal region outside the cell. Mouse and 
human FasL are 76.9% identical at the amino acid sequence level and are functionally 
interchangeable. A stretch of about 150 amino acids in the extracellular region of FasL show 
significant homology to the corresponding region of other members of the TNF family 
which includes TNF, lymphotoxin (LT), CD40 ligand, CD27 ligand, CD30 ligand and OX40 
ligand. A single FasL gene is located on human and mouse chromosome 1 in the 
neighborhood of the OX40 ligand gene. Fas/FasL system is the major regulator of apoptosis 
at the cell membrane in mammalian cells through a receptor/ligand interaction (Mollinedo 
and Gajate, 2006).  
1.11.1 Expression of fasL 
FasL has been found to be expressed on cells of the lymphoid/myeloid lineage, including 
activated T cells and natural killer (NK) cells, where it plays an important role in immune 
homeostasis, T cell and NK cell-mediated toxicity (Brunner et al., 2003). FasL is also found to 
be expressed in sites such as the eye (Griffith et al., 1995) and testis (Bellgrau et al., 1995) 
contributing to immune privilege by inducing apoptosis of infiltrating proinflammatory 
immunocytes (Houston and O’Connell, 2004). FasL expression has also been observed in a 
variety of tumor cells indicating a possibility that FasL could mediate immune privilege in 
human tumors by inducing apoptosis of anti-tumor lymphocytes and also, stimulate 
proliferation of tumor cells (Houston and O’Connell, 2004). Tumor expression of FasL was 
first demonstrated in the colon carcinoma cell line SW620, where it could induce apoptosis 
of Fas-sensitive lymphoid cells in vitro (O’Connell et al., 1996). A functional FasL expression 
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has also been reported on numerous tumors of varying origin including colon (Okada et al., 
2000), gastric (Zheng et al., 2003), lung (Niehans et al., 1997) carcinoma, and astrocytoma 
(Saas et al., 1997). Tumor cells expressing FasL demonstrated the ability to kill Fas-sensitive 
target cells when co-cultured in vitro. Apoptosis of tumor-infiltrating lymphocytes (TILs) 
has also been detected in situ within FasL-expressing human tumors such as esophageal 
carcinoma (Houston and O’Connell, 2004; Okada et al., 2000; Zheng et al., 2003; Niehans et 
al., 1997).  
FasL expression was found to be higher in metastatic tumors than in primary ones. In breast 
and cervical tumors, high FasL expression was significantly associated with lymph node 
metastases (Kase et al., 2003) whereas, stronger FasL expression was found in liver 
metastases of colon cancer relative to the primary tumor (Houston and O’Connell, 2004). 
1.11.2 Inhibition of apoptosis  
One of the hallmarks of cancer is resistance to apoptosis (Hanahan and Weinberg, 2000). 
Most cancer cells are relatively resistant to apoptosis mediated through Fas. Fas-mediated 
apoptosis can be inhibited at different points in the apoptotic signaling pathway. Cells may 
secrete soluble ‘decoy’ receptors, such as sFasL or DcR3, which can bind to FasL and inhibit 
FasL-induced apoptosis (Pitti et al., 1998). FADD-like interleukin-1ß-converting enzyme 
inhibitory protein (cFLIP) binds to the DISC and prevents the activation of caspase-8 (Irmler 
et al., 1997). Reduced expression of FADD (Tourneur et al., 2003) or caspase-8 (Fulda et al., 
2001) can also inhibit Fas signaling. IAPs present in the cytosol can bind to and inhibit 
caspases and upregulation of Bcl-2 or Bcl-xL can render type II cells resistant to Fas-
mediated apoptosis. Cytochrome c and inhibitor-of-apoptosis protein (IAP) can inhibit 
apoptosis (Igney and Krammer, 2002). Thus, because of their insensitivity to Fas-mediated 
apoptosis, tumor cells can express FasL without undergoing apoptosis (Houston et al., 
2003). It has been observed that resistance to Fas-mediated apoptosis protects tumor cells 
not only from tumor-expressed FasL but also from FasL expressed as a cytotoxic mediator 
by infiltrating anti-tumor T cells and NK cells (Houston and O’Connell, 2004). 
1.12 Immunotherapy 
Death receptors are members of the tumor necrosis factor (TNF) receptor gene superfamily, 
consisting of more than 20 proteins with a broad range of biological function, including 
regulation of cell death, survival, differentiation or immune regulation (Debatin and 
Krammer, 2004). Death receptors share regions of high homology including cysteine-rich 
extracellular domains and a cytoplasmic domain of about 80 amino acids called death 
domain (DD), which plays a crucial role in transmitting the death signal from the cells 
surface to intracellular signaling pathways (Mollinedo and Gajate, 2006). 
The death receptors which have potential to induce apoptosis are Fas, TNF receptor 1 
(TNFR1), TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), TRAIL-R2, death 
receptor 4 (DR4) and death receptor 5 (DR5). Due to their potential to induce apoptosis, 
ligands such as TNF, Fas ligand (FasL) and TRAIL are interesting candidates for antitumor 
therapy (Shankar and Srivastava, 2004; Mollinedo and Gajate, 2006). However, ligands of 
the TNF family and their cognate receptors have been found to play a key role in liver 
pathogenesis and have become a major challenge for the clinical application of death 
receptor-targeted therapy (Hohenberger and Tunn, 2003; Ogasawara et al., 1993; Nesterov et 
al., 2002).  
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Conventional chemotherapy is based on the perception that malignant cells have 
uncontrolled proliferation. The rather modest impact of antiproliferative drugs in the clinic 
is not surprising since many tumors have a low growth capacity. In addition, exposure of 
normal tissues that have a high rate of cellular proliferation, such as the bone marrow, the 
gastrointestinal epithelial cells and the cells of the hair follicles, to anti-proliferative drugs 
leads to major toxicities. The effectiveness of anticancer drugs reflects the ability of tumor 
cells to detect and respond to the perturbation induced by the drug (Mashima and Tsuruo, 
2005). The failure of some tumor cells to die following drug treatment and their resistance to 
drugs is due to their resistance to apoptosis as tumors cells have defects in triggering their 
own death by apoptosis (Mollinedo and Gajate, 2006). If liver toxicity could be 
circumvented, Fas would be a worthy anticancer target due to its potent proapoptotic 
activity and widespread expression in tumor cells (Mollinedo and Gajate, 2006). 
1.13 Adenovirus and cancer gene therapy 
Different viral vectors like lentivirus, retrovirus, pox virus, herpes simplex virus-1, vaccinia 
virus, adeno-associated virus (AAV) and adenovirus have been used for experimental 
cancer gene therapy (Young et al., 2006). These viral vectors have been used individually 
and in combination with conventional therapies to treat cancers that are refractory to just 
conventional therapy (surgery, radiation, and chemotherapy). Of all the vectors used, 
adenoviruses are one of the most widely accepted viral agents for cancer gene therapy. The 
features of adenovirus that make them well suited for gene therapy are: its capacity for gene 
transfer (up to 7-8 Kb), in vivo stability, inability to integrate into host genome, ability to 
transduce dividing and non dividing cells, a well characterized genome and relative ease of 
production, purification and manipulation. From a clinical point of view, adenovirus is 
endemic in the human population and its natural pathogenicity is associated with mild 
respiratory infections, and therefore, manifests a well defined safety profile (Gomes and 
Tong, 2006; Young et al., 2006). 
Adenovirus was first isolated and cultured from human tonsils and adenoid tissues (Garnett 
et al., 2002). Currently, 51 human adenovirus serotypes have been identified and grouped 
into six subgroups (A-F) of which the most widely studied serotype are group C types 2 and 
5. Adenovirus is a non-enveloped icosohedral particle which carries a 36 Kb double 
stranded DNA genome. The capsid consists of three main components: hexon, penton and 
fiber. Hexon is the most abundant structural protein which appears to play a role in coating 
the virus. The pentameric structure called penton is known to mediate viral internalization. 
The fiber protrudes from the penton bases and appears to play a role in viral attachment to 
the cellular receptor namely coxsackie adenovirus receptor (CAR). Attachment via knob-
CAR interactions is followed by interactions between cellular integrins and an arginine-
glycine aspartic acid motif (RGD-motif) located at the penton base. This binding leads to the 
formation of endosomes, viral internalization, disassembly and the release of viral nucleic 
acid. Thereafter viral DNA is transported to the nucleus where the genes are expressed and 
viral replication occurs. The adenoviral genome can be divided into immediately early 
(E1A), early (E1B, E2, E3, E4), intermediate (IX, IVa2) and late genes. The early genes are 
expressed prior to viral replication consisting of mainly regulatory proteins that prepare the 
host cell for virus DNA replication and block antiviral mechanisms. The late viral genes 
encode for viral structural proteins. Importantly, E3 region encodes a variety of proteins 
involved in immune response evasion. Adenoviruses with deletions in E1 and/or E3 regions 
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has also been reported on numerous tumors of varying origin including colon (Okada et al., 
2000), gastric (Zheng et al., 2003), lung (Niehans et al., 1997) carcinoma, and astrocytoma 
(Saas et al., 1997). Tumor cells expressing FasL demonstrated the ability to kill Fas-sensitive 
target cells when co-cultured in vitro. Apoptosis of tumor-infiltrating lymphocytes (TILs) 
has also been detected in situ within FasL-expressing human tumors such as esophageal 
carcinoma (Houston and O’Connell, 2004; Okada et al., 2000; Zheng et al., 2003; Niehans et 
al., 1997).  
FasL expression was found to be higher in metastatic tumors than in primary ones. In breast 
and cervical tumors, high FasL expression was significantly associated with lymph node 
metastases (Kase et al., 2003) whereas, stronger FasL expression was found in liver 
metastases of colon cancer relative to the primary tumor (Houston and O’Connell, 2004). 
1.11.2 Inhibition of apoptosis  
One of the hallmarks of cancer is resistance to apoptosis (Hanahan and Weinberg, 2000). 
Most cancer cells are relatively resistant to apoptosis mediated through Fas. Fas-mediated 
apoptosis can be inhibited at different points in the apoptotic signaling pathway. Cells may 
secrete soluble ‘decoy’ receptors, such as sFasL or DcR3, which can bind to FasL and inhibit 
FasL-induced apoptosis (Pitti et al., 1998). FADD-like interleukin-1ß-converting enzyme 
inhibitory protein (cFLIP) binds to the DISC and prevents the activation of caspase-8 (Irmler 
et al., 1997). Reduced expression of FADD (Tourneur et al., 2003) or caspase-8 (Fulda et al., 
2001) can also inhibit Fas signaling. IAPs present in the cytosol can bind to and inhibit 
caspases and upregulation of Bcl-2 or Bcl-xL can render type II cells resistant to Fas-
mediated apoptosis. Cytochrome c and inhibitor-of-apoptosis protein (IAP) can inhibit 
apoptosis (Igney and Krammer, 2002). Thus, because of their insensitivity to Fas-mediated 
apoptosis, tumor cells can express FasL without undergoing apoptosis (Houston et al., 
2003). It has been observed that resistance to Fas-mediated apoptosis protects tumor cells 
not only from tumor-expressed FasL but also from FasL expressed as a cytotoxic mediator 
by infiltrating anti-tumor T cells and NK cells (Houston and O’Connell, 2004). 
1.12 Immunotherapy 
Death receptors are members of the tumor necrosis factor (TNF) receptor gene superfamily, 
consisting of more than 20 proteins with a broad range of biological function, including 
regulation of cell death, survival, differentiation or immune regulation (Debatin and 
Krammer, 2004). Death receptors share regions of high homology including cysteine-rich 
extracellular domains and a cytoplasmic domain of about 80 amino acids called death 
domain (DD), which plays a crucial role in transmitting the death signal from the cells 
surface to intracellular signaling pathways (Mollinedo and Gajate, 2006). 
The death receptors which have potential to induce apoptosis are Fas, TNF receptor 1 
(TNFR1), TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), TRAIL-R2, death 
receptor 4 (DR4) and death receptor 5 (DR5). Due to their potential to induce apoptosis, 
ligands such as TNF, Fas ligand (FasL) and TRAIL are interesting candidates for antitumor 
therapy (Shankar and Srivastava, 2004; Mollinedo and Gajate, 2006). However, ligands of 
the TNF family and their cognate receptors have been found to play a key role in liver 
pathogenesis and have become a major challenge for the clinical application of death 
receptor-targeted therapy (Hohenberger and Tunn, 2003; Ogasawara et al., 1993; Nesterov et 
al., 2002).  
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Conventional chemotherapy is based on the perception that malignant cells have 
uncontrolled proliferation. The rather modest impact of antiproliferative drugs in the clinic 
is not surprising since many tumors have a low growth capacity. In addition, exposure of 
normal tissues that have a high rate of cellular proliferation, such as the bone marrow, the 
gastrointestinal epithelial cells and the cells of the hair follicles, to anti-proliferative drugs 
leads to major toxicities. The effectiveness of anticancer drugs reflects the ability of tumor 
cells to detect and respond to the perturbation induced by the drug (Mashima and Tsuruo, 
2005). The failure of some tumor cells to die following drug treatment and their resistance to 
drugs is due to their resistance to apoptosis as tumors cells have defects in triggering their 
own death by apoptosis (Mollinedo and Gajate, 2006). If liver toxicity could be 
circumvented, Fas would be a worthy anticancer target due to its potent proapoptotic 
activity and widespread expression in tumor cells (Mollinedo and Gajate, 2006). 
1.13 Adenovirus and cancer gene therapy 
Different viral vectors like lentivirus, retrovirus, pox virus, herpes simplex virus-1, vaccinia 
virus, adeno-associated virus (AAV) and adenovirus have been used for experimental 
cancer gene therapy (Young et al., 2006). These viral vectors have been used individually 
and in combination with conventional therapies to treat cancers that are refractory to just 
conventional therapy (surgery, radiation, and chemotherapy). Of all the vectors used, 
adenoviruses are one of the most widely accepted viral agents for cancer gene therapy. The 
features of adenovirus that make them well suited for gene therapy are: its capacity for gene 
transfer (up to 7-8 Kb), in vivo stability, inability to integrate into host genome, ability to 
transduce dividing and non dividing cells, a well characterized genome and relative ease of 
production, purification and manipulation. From a clinical point of view, adenovirus is 
endemic in the human population and its natural pathogenicity is associated with mild 
respiratory infections, and therefore, manifests a well defined safety profile (Gomes and 
Tong, 2006; Young et al., 2006). 
Adenovirus was first isolated and cultured from human tonsils and adenoid tissues (Garnett 
et al., 2002). Currently, 51 human adenovirus serotypes have been identified and grouped 
into six subgroups (A-F) of which the most widely studied serotype are group C types 2 and 
5. Adenovirus is a non-enveloped icosohedral particle which carries a 36 Kb double 
stranded DNA genome. The capsid consists of three main components: hexon, penton and 
fiber. Hexon is the most abundant structural protein which appears to play a role in coating 
the virus. The pentameric structure called penton is known to mediate viral internalization. 
The fiber protrudes from the penton bases and appears to play a role in viral attachment to 
the cellular receptor namely coxsackie adenovirus receptor (CAR). Attachment via knob-
CAR interactions is followed by interactions between cellular integrins and an arginine-
glycine aspartic acid motif (RGD-motif) located at the penton base. This binding leads to the 
formation of endosomes, viral internalization, disassembly and the release of viral nucleic 
acid. Thereafter viral DNA is transported to the nucleus where the genes are expressed and 
viral replication occurs. The adenoviral genome can be divided into immediately early 
(E1A), early (E1B, E2, E3, E4), intermediate (IX, IVa2) and late genes. The early genes are 
expressed prior to viral replication consisting of mainly regulatory proteins that prepare the 
host cell for virus DNA replication and block antiviral mechanisms. The late viral genes 
encode for viral structural proteins. Importantly, E3 region encodes a variety of proteins 
involved in immune response evasion. Adenoviruses with deletions in E1 and/or E3 regions 
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have been developed to provide cloning sites for transgene insertion (Gomes and Tong, 
2006). 
1.14 Conditional replicative and oncolytic adenovirus for cancer therapy 
Research has shown that adenovirus can be safely used for gene delivery. Adenoviruses 
have been modified by replacing early genes, E1A and E1B or E3 with the gene of interest. 
Since the E1 unit is essential for viral replication, the recombinant vector is replicative 
defective and its replication requires helper functions provided by a packaging cell line with 
complementing E1 genes. However, these recombinant constructs have been useful mainly 
at local/ regional stage. Their therapeutic limitation has been the incomplete infection of 
tumor cells, transient expression of the transgene, and a lack of systemic efficacy. Recently, 
conditional replicative oncolytic adenoviruses have been shown to replicate and kill tumor 
cells without harming normal cells. The tumor specificity of these viruses has been 
manifested through the incorporation of tissue or tumor specific promoters that limit viral 
gene (Tong, 2006; Gomes and Tong, 2006). 
A recent study indicates that the use of adenoviral vectors for clinical gene therapy is 
widespread. As of July 2006, adenoviral vectors are used in 26% of the 1,192 current 
worldwide gene therapy clinical trials. Of the 301 clinical trials involving the use of Ad 
vectors, 76% are for the treatment of cancer followed by vascular disease and monogenic 
disorders at 14% and 7%, respectively (http://www.wiley.co.uk/ genetherapy /clinical/) 
(Campos and Barry. 2007). 
Adenoviral gene therapy approaches have shown promising results in clinical trials. 
Adenovirus mediated delivery of NTR (nitroreductase enzyme) from E. Coli by direct 
intratumoural injection in patients with primary or secondary liver cancer showed 
appropriate levels of NTR expression in tumor cells. The early clinical trial data of the 
NTR/CB1954 system in patients with liver cancer or prostate cancer are extremely 
encouraging (Palmer et al., 2004). Adenoviral delivery of TRAIL (tumor necrosis factor-
related apoptosis-inducing ligand) showed significant anti-tumor efficacy in animal models 
of aggressive primary and metastatic cancer (Ma et al., 2005). Clinical trials of a recombinant 
adenovirus expressing interleukin-12 (IL-12) in patients with advanced digestive tumors 
have produced evidence of antitumor effects (Sangro et al., 2004). 
2. Hypothesis and objectives  
2.1 Hypothesis 
A novel fusion protein consisting of MULT1 extracellular domain and Fas transmembrane 
and intracellular domains (MULT1E/FasTI) when expressed on a cell, would activate 
NKG2D expressing cells such as NK cells from its MULT1E extracellular region, upon 
binding of MULT1E to NKG2D receptor on NK cells. At the same time the engagement of 
the fusion protein with NKG2D receptor would send death signals into the cells that express 
the fusion protein and induce apoptosis of the cell (Fig.1).  
2.2 Objectives 
The work presented here is a two pronged approach of using a novel fusion protein 
consisting of MULT1 extracellular domain and Fas transmembrane and intracellular 
domains for cancer therapy. First, the construction and expression of MULT1E/FasTI fusion 
protein is examined. Second, in vitro and in vivo activity of the fusion protein is tested. 
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Finally, the adenoviral vector mediated delivery and in vivo therapeutic effect of the novel 
fusion protein is evaluated.  
 
 
Fig. 1. Schematic representation of proposed mechanism of novel fusion protein MULT1E 
/FasTI.  
3. Construction and evaluation of fusion protein MULT1E/FasTI 
3.1 Plasmid construction of pMULT1E/FasTI 
Thymus glands from 4-day old newborn C57BL/6J mice were removed and stored in liquid 
nitrogen. The glands were homogenized using a tissue homogenizer and total RNA was 
extracted using TRIzol reagent (Invitrogen, Carlsbad, CA). Primers were designed for 
amplification of the extracellular domain of MULT1 (Genebank accession # NM_029975) 
from 236bp to 868bp. The sequence of the 5’ primer is CCCAAGCTTATGGAGCTG 
ACTGCCAGTAACAAGGTCC and that of the 3’ primer is CGGGATCCGGTACTGAAA 
GATCCTGCAGGCTCCAG. At the 5’ end of the upstream primer, a HindIII enzyme site 
was created and at the 5’ end of downstream primer, a BamHI site was created. cDNA was 
synthesized from the extracted total RNA using an RT-PCR kit (Promega, Madison, WI). 
The fragment was excised and gel purified using a Qiagen gel purification kit (Valencia, 
CA). Double enzyme digestion was performed on the purified fragment using HindIII and 
BamHI. The enzyme digested fragment was then ligated into a pcDNA3.1 (+) vector 
(Invitrogen, CA). The full MULT1 cDNA sequence in the new vector, pMULT1E, was 
confirmed by DNA sequencing.  
The cDNA clone of the Fas receptor in pDNR-LIB (ATCC # 10088798) was purchased from 
American Type Collection Centre (ATCC, Manassas, VA). A pair of primers was designed 
for amplification of the transmembrane and intracellular domains of Fas from 524 bp to 
1013bp (Genebank accession# BC061160). The 5’ primer used was CGGGATCCCCC AGAA 
ATCGCCTATGGTTGTTGTTGACC and the 3’ primer was CGGAATTCTCACTCCAGACA 
TTGTCCTTCATTTTC. At the 5’ end of upstream primer, a BamHI enzyme site was created 
and at the 5’ end of downstream primer, an EcoRI enzyme site was created. DNA PCR was 
performed to amplify the Fas transmembrane and intracellular domains from pDNR-LIB. 
The gel purified fragment was treated with BamHI and EcoRI enzymes and ligated into the 
pcDNA3.1 (+)/Zeo vector to create pFasTI. The DNA sequence of the transmembrane and 
intracellular domains of Fas in vector pFasTI was confirmed by DNA sequencing.  
The cDNA fragment encoding the MULT1 extracellular domain was cut out from pMULT1E 
by HindIII and BamHI enzyme digestion and ligated into the pFasTI. The resulting vector 
was named pMULT1E/FasTI (Fig.2) and used for transfection. 
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have been developed to provide cloning sites for transgene insertion (Gomes and Tong, 
2006). 
1.14 Conditional replicative and oncolytic adenovirus for cancer therapy 
Research has shown that adenovirus can be safely used for gene delivery. Adenoviruses 
have been modified by replacing early genes, E1A and E1B or E3 with the gene of interest. 
Since the E1 unit is essential for viral replication, the recombinant vector is replicative 
defective and its replication requires helper functions provided by a packaging cell line with 
complementing E1 genes. However, these recombinant constructs have been useful mainly 
at local/ regional stage. Their therapeutic limitation has been the incomplete infection of 
tumor cells, transient expression of the transgene, and a lack of systemic efficacy. Recently, 
conditional replicative oncolytic adenoviruses have been shown to replicate and kill tumor 
cells without harming normal cells. The tumor specificity of these viruses has been 
manifested through the incorporation of tissue or tumor specific promoters that limit viral 
gene (Tong, 2006; Gomes and Tong, 2006). 
A recent study indicates that the use of adenoviral vectors for clinical gene therapy is 
widespread. As of July 2006, adenoviral vectors are used in 26% of the 1,192 current 
worldwide gene therapy clinical trials. Of the 301 clinical trials involving the use of Ad 
vectors, 76% are for the treatment of cancer followed by vascular disease and monogenic 
disorders at 14% and 7%, respectively (http://www.wiley.co.uk/ genetherapy /clinical/) 
(Campos and Barry. 2007). 
Adenoviral gene therapy approaches have shown promising results in clinical trials. 
Adenovirus mediated delivery of NTR (nitroreductase enzyme) from E. Coli by direct 
intratumoural injection in patients with primary or secondary liver cancer showed 
appropriate levels of NTR expression in tumor cells. The early clinical trial data of the 
NTR/CB1954 system in patients with liver cancer or prostate cancer are extremely 
encouraging (Palmer et al., 2004). Adenoviral delivery of TRAIL (tumor necrosis factor-
related apoptosis-inducing ligand) showed significant anti-tumor efficacy in animal models 
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adenovirus expressing interleukin-12 (IL-12) in patients with advanced digestive tumors 
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2. Hypothesis and objectives  
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the fusion protein and induce apoptosis of the cell (Fig.1).  
2.2 Objectives 
The work presented here is a two pronged approach of using a novel fusion protein 
consisting of MULT1 extracellular domain and Fas transmembrane and intracellular 
domains for cancer therapy. First, the construction and expression of MULT1E/FasTI fusion 
protein is examined. Second, in vitro and in vivo activity of the fusion protein is tested. 
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Fig. 2. Construction of the MULT1E/FasTI plasmid.  
3.2 Expression of pMULT1E/FasTI 
Lung carcinoma TC-1 tumor cells were transfected with pMULT1E/FasTI. Three clones that 
were zeocin resistant were selected and labeled as L-5, L-7 and L-10. An in vitro cell growth 
study showed that all the clones grew at a similar rate as TC-1 cells. The cells of these clones 
were stained with anti-mouse MULT1 antibody and analyzed by fluorescence-activated cell 
sorting (FACS). The result showed that TC-1 cells and clone L-7 cells were negative, whereas 
clones L-5 and L-10 cells were strongly positive (Fig. 3). To confirm that MULT1E of the 
fusion protein can indeed bind to NKG2D, the cells were incubated with NKG2D/Fc, a 
recombinant fusion protein, and then stained with anti-mouse NKG2D antibody conjugated 
with fluorescein isothiocyanate (FITC). TC-1 cells and clone L-7 cells were dimly positive, 
whereas clones L-5 and L-10 cells were strongly positive (Fig. 4) with L-10 cells the 
strongest. The results indicate that clones L-5 and L-10 are MULT1E/FasTI-positive clones, 
whereas TC-1 and clone L-7 are negative for the fusion protein, but express some 
endogenous MULT1 protein. 
 
 
Fig. 3. FACS analysis of MULT1E/FasTI expression. A total of 5x105 cells of TC-1 and clones 
L5, L7 or L10 were stained with purified rat anti-mouse MULT1 antibody followed by goat 
anti-mouse IgG F(ab’)-FITC. The dashed lines are isotype controls.  
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Fig. 4. FACS analysis of MULT1E/FasTI expression. A total of 1x106 cells of TC-1 and clones 
L-5, L-7 or L-10 were first treated with NKG2D/Fc and then stained with anti-mouse 
NKG2D antibody conjugated with FITC. The cells were analyzed on FACS Calibur with 
CellQuest software. Dashed lines are controls without NKG2D/Fc incubation.  
3.3 Fusion protein MULT1E/FasTI induces apoptosis of cells 
To confirm the concept that when bound to its ligand NKG2D fusion protein 
MULT1E/FasTI can send death signals through its Fas portion into the cells, TC-1 cells and 
clones L-5, L-7, L-10 were treated with recombinant protein NKG2D/Fc and analyzed by 
Annexin V staining and caspase-3 activation assay. The treatment of NKG2D/Fc increased 
both Annexin V-positive cells and Annexin V/propidium iodide (PI) double-positive cells in 
clones L-5 and L-10, but not in TC-1 cells or clone L-7 (Fig. 5). After the NKG2D/Fc 
treatment, not only apoptotic cells (Annexin V-positive cells and Annexin V/PI double- 
positive cells), but also the necrotic cells (PI-positive/Annexin V-negative cells) in clone L-5 
and L-10 were significantly higher than those of TC-1 or clone L-7 (Fig. 6A and 6B). 
Similarly, caspase-3 activities in cells of clones L-5 and L-10 were significantly higher than 
those of TC-1 or clone L-7 (Fig. 6C). The treatment of NKG2D/Fc induced more apoptotic 
cells in clone L-10 than clone L-5 (Fig. 6A and 6C). 
3.4 Cells expressing MULT1E/FasTI activate NK cells 
It is critical to know whether fusion protein MULT1E/FasTI can activate NKG2D-expressing 
cells, such as NK cells. Cells from TC-1 or clones L-5, L-7 and L-10 were co-cultured with 
NK cells isolated from mouse spleen. Intracellular interferon-γ (IFN- γ) was detected by 
FACS analysis (Fig. 7A). The percentage of the NK cells that express IFN- γ was significantly 
increased in wells that contained cells of clone L-5 or L-10 compared to those co-cultured 
with TC-1 (P<0.05). Although the percentage of NK cells expressing IFN-γ in wells that 
contained cells of clone L-7 increased slightly compared to those co-cultured with TC-1 cells, 
it was not statistically significant (Fig. 7B). 
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Fig. 5. MULT1E/FasTI induces apoptosis. A total of 1x106 cells of TC-1 and clones L-5, L-7 
and L-10 were treated with 1 µg/ml NKG2D/Fc for 16 h. The cells were then analyzed for 








Fig. 6. MULT1E/FasTI induces apoptosis. A total of 1x106 cells of TC-1 and clones L-5, L-7 
and L-10 were treated with 1 µg/ml NKG2D/Fc for 16 h. The cells were then analyzed for 
apoptosis and necrosis using Annexin V staining (A, B) or caspase-3 assay (C). The statistical 
analyses were conducted between the controls (open bars) and NKG2D/Fc-treated cells 
(solid bars) using two-way analysis of variance (ANOVA). The difference between 
NKG2D/Fc-treated L-5 cells and NKG2D/Fc-treated L-10 cells was also compared using 
Student’s t-test. *P<0.05; **P<0.01 and ***P<0.001. 
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Fig. 7. MULT1E/FasTI activates natural killer (NK) cells. A total of 1x106 cells of TC-1 and 
clones L-5, L-7 and L-10 were co-cultured with NK cells for 3 h. The cells were stained with 
anti-NK1.1-FITC and were then permeabilized and fixed, and stained with antimouse IFN-
γ-PE. The cells were analyzed on FACS Calibur with CellQuest software. (A) represents an 
example of the FACS data and (B) is the summery of the data from three separate 
experiments. *P<0.05. 
3.5 In vivo antitumor effect of fusion protein MULT1E/FasTI 
The in vivo therapeutic effect of the fusion protein was evaluated in a subcutaneous tumor 
model as well as a pulmonary metastasis model. Two hundred thousand cells of TC-1 and 
clones L-5, L-7 and L-10 in 0.2 ml Hank’s balanced salt solution (HBSS) were injected 
subcutaneously into 6- to 8-week-old mice and tumor size was measured twice weekly with 
a caliper and tumor volume was calculated. The tumor growth of clone L-7 was slightly, but 
not significantly (P>0.05) slower when compared to that of TC-1 cells. At day 18, the growth 
of clones L-5 and L-10 was significantly slower (P<0.01, P<0.01) when compared to that of 
TC-1 cells. At day 24, the difference of tumor growth between TC-1 and clone L-10 was even 
more significant (P<0.001), whereas the difference of tumor growth between TC-1 and clone 
L-5 remained the same (P<0.01; Fig. 8). An even better antitumor effect of the fusion protein 
was observed in the pulmonary metastasis model. Four weeks after i.v. tumor cell injection, 
the mice were euthanized and lungs were excised (Fig. 9A). The total weight of the lungs 
with the tumors was measured (Fig. 9B) and the tumor nodules on the surface of the lungs 
were counted (Fig. 9C). The lungs isolated from mice injected with TC-1 cells were fully 
covered with tumors and weighed an average 0.82 g. All the four lungs have more than 200 
tumor nodules each. The lungs isolated from mice injected with clone L-7 cells are covered 
with many tumors as well and weighed averagely 0.48 g. There are 118, 89, 67, 125 tumor 
nodules on the lungs. The lungs isolated from mice injected with clones L-5 and L-10 were 
almost tumor free and weighed much less (0.15 and 0.14 g, respectively) than those of mice 
injected with either TC-1 cells or clone L-7 cells. The average weight of lungs from normal 
mice was 0.14 g. 
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the mice were euthanized and lungs were excised (Fig. 9A). The total weight of the lungs 
with the tumors was measured (Fig. 9B) and the tumor nodules on the surface of the lungs 
were counted (Fig. 9C). The lungs isolated from mice injected with TC-1 cells were fully 
covered with tumors and weighed an average 0.82 g. All the four lungs have more than 200 
tumor nodules each. The lungs isolated from mice injected with clone L-7 cells are covered 
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Fig. 8. Subcutaneous tumor study. A total of 2x105 tumor cells of TC-1 or clones L-5, L-7 and 
L-10 in 0.2 ml HBSS were subcutaneously injected into C57BL/6J mice (four mice per 
group). Tumor growth was measured and presented as 1/2LW2. **P<0.01; ***P<0.001.    
 
 
Fig. 9. Pulmonary metastatic tumor study. A total of 2x105 tumor cells of TC-1 or clones L-5, 
L-7 and L-10 in 0.5 ml HBSS were i.v. injected into C57BL/6J mice (four mice per group). 
Four weeks after tumor cell injection, mice were killed and their lungs were dissected (A). 
The lungs were weighted (B) and the tumor nodules on the lungs were counted (C). *P<0.05; 
***P<0.001. 
3.6 Construction of adenoviral vectors 
In order to effectively deliver the fusion protein into cells, especially tumor cells, adenovirus 
vectors were chosen. Ad-MULT1E/FasTI, Ad-MULT1E and Ad-Lac-Z adenovirus were 
generated using the ViraPower Adenoviral Expression System (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s instructions. The full-length cDNAs of MULT1E/FasTI or 
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MULT1E (Section 3.1) were cloned into the pCR ®8/GW/TOPO® vector.  The pCR 
®8/GW/TOPO®  vector with MULT1E/FasTI or MULT1E inserts  were used as entry clone 
vectors and transferred into the destination vector pAd/CMV/V5-DEST (Invitrogen, 
Carlsbad, CA) using the Gateway LR Clonase II enzyme mix according to the 
manufacturer’s directions (Invitrogen, Carlsbad, CA) to generate pAd/CMV/ 
MULT1E/FasTI/V5 and pAd/CMV/MULT1E/V5. The vectors were linearized with PacI 
enzyme and transfected into 293A cells using LipofectamineTM 2000 reagent as per 
manufacturer’s directions. The 293A cells were maintained in DMEM medium until a 
cytophathic effect was apparent 5–7 days post-transfection. Cells were collected and lysed 
by subjecting them to four freeze/thaw cycles. The cell debris was pelleted at 3000 x g for 15 
min and the supernatant was collected and stored at -80 °C as crude viral lysate.  Fifty 
microliters of crude viral lysate were added into each 293A cell culture dish and incubated 
for 2-3 days until an 80-100% cytophathic effect was observed. Two recombinant 
adenoviruses (Ad-MULT1E/FasTI and Ad-MULT1E) were harvested and purified using the 
Adeno-X TM virus Mini Purification Kit according to the manufacturer’s directions 
(Clontech, Mountain View, CA) and stored at -80 0C. Ad-Lac-Z was purchased directly from 
the manufacturer (Clontech) and amplified as per the above method.  Titers of Ad-
MULT1E/FasTI, Ad-MULT1E and Ad-Lac-Z stocks were determined using an Adeno-X TM 
Rapid Titer Kit as per manufacturer’s directions (Clontech). 
3.7 Adenoviral vector effectively delivers MULT1E/FasTI into cultured TC-1 cells 
Three adenoviral vectors were constructed: 1) Ad-MULT1E/FasTI containing the full fusion 
protein sequence of MULT1E extracellular domain and FasTI transmembrane and 
intracellular domains; 2) Ad-MULT1E containing only the MULT1E extracellular domain; 3) 
Ad-Lac-Z containing the Lac-Z gene as control adenoviral vector. The adenoviral vectors 
were linearized using Pac1 and transfected into 293A cells to generate adenoviral stocks. The 
titer of these adenoviral stocks are in the range of 1010 PFU/ml. 
TC-1 tumor cells were infected with Ad-MULT1E/FasTI viral particles with different 
multiplicities of infection (MOI): 500, 250, 100, 25, and 0 for 24 hours. The fusion gene 
expression was detected by RT-PCR (Fig. 10) and FACS analysis (Fig. 11). Both assays not 
only demonstrate the fusion gene expression in the infected cells, but also show a clear dose 
dependent expression manner.  
 
 
Fig. 10. RT-PCR analysis of AD-MULT1E/FasTI expression at different MOIs. RNAs were 
isolated from infected cells and RT-PCR was performed. Lanes  2, 4, 6, 8, 10 and 12 are 
1134bp RT-PCR product of total RNA from TC1 cells infected with Ad-MULT1E/ FasTI at 
MOIs 500, 250, 100, 50, 25 and 0, amplified with MULT1E forward and Fas reverse primers; 
Lanes 3, 5, 7, 9, 11 and 13 are ß-actin controls; and lanes 1 and 14 are 1 kb markers.  
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MULT1E (Section 3.1) were cloned into the pCR ®8/GW/TOPO® vector.  The pCR 
®8/GW/TOPO®  vector with MULT1E/FasTI or MULT1E inserts  were used as entry clone 
vectors and transferred into the destination vector pAd/CMV/V5-DEST (Invitrogen, 
Carlsbad, CA) using the Gateway LR Clonase II enzyme mix according to the 
manufacturer’s directions (Invitrogen, Carlsbad, CA) to generate pAd/CMV/ 
MULT1E/FasTI/V5 and pAd/CMV/MULT1E/V5. The vectors were linearized with PacI 
enzyme and transfected into 293A cells using LipofectamineTM 2000 reagent as per 
manufacturer’s directions. The 293A cells were maintained in DMEM medium until a 
cytophathic effect was apparent 5–7 days post-transfection. Cells were collected and lysed 
by subjecting them to four freeze/thaw cycles. The cell debris was pelleted at 3000 x g for 15 
min and the supernatant was collected and stored at -80 °C as crude viral lysate.  Fifty 
microliters of crude viral lysate were added into each 293A cell culture dish and incubated 
for 2-3 days until an 80-100% cytophathic effect was observed. Two recombinant 
adenoviruses (Ad-MULT1E/FasTI and Ad-MULT1E) were harvested and purified using the 
Adeno-X TM virus Mini Purification Kit according to the manufacturer’s directions 
(Clontech, Mountain View, CA) and stored at -80 0C. Ad-Lac-Z was purchased directly from 
the manufacturer (Clontech) and amplified as per the above method.  Titers of Ad-
MULT1E/FasTI, Ad-MULT1E and Ad-Lac-Z stocks were determined using an Adeno-X TM 
Rapid Titer Kit as per manufacturer’s directions (Clontech). 
3.7 Adenoviral vector effectively delivers MULT1E/FasTI into cultured TC-1 cells 
Three adenoviral vectors were constructed: 1) Ad-MULT1E/FasTI containing the full fusion 
protein sequence of MULT1E extracellular domain and FasTI transmembrane and 
intracellular domains; 2) Ad-MULT1E containing only the MULT1E extracellular domain; 3) 
Ad-Lac-Z containing the Lac-Z gene as control adenoviral vector. The adenoviral vectors 
were linearized using Pac1 and transfected into 293A cells to generate adenoviral stocks. The 
titer of these adenoviral stocks are in the range of 1010 PFU/ml. 
TC-1 tumor cells were infected with Ad-MULT1E/FasTI viral particles with different 
multiplicities of infection (MOI): 500, 250, 100, 25, and 0 for 24 hours. The fusion gene 
expression was detected by RT-PCR (Fig. 10) and FACS analysis (Fig. 11). Both assays not 
only demonstrate the fusion gene expression in the infected cells, but also show a clear dose 
dependent expression manner.  
 
 
Fig. 10. RT-PCR analysis of AD-MULT1E/FasTI expression at different MOIs. RNAs were 
isolated from infected cells and RT-PCR was performed. Lanes  2, 4, 6, 8, 10 and 12 are 
1134bp RT-PCR product of total RNA from TC1 cells infected with Ad-MULT1E/ FasTI at 
MOIs 500, 250, 100, 50, 25 and 0, amplified with MULT1E forward and Fas reverse primers; 
Lanes 3, 5, 7, 9, 11 and 13 are ß-actin controls; and lanes 1 and 14 are 1 kb markers.  
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Fig. 11. FACS analyses of AD-MULT1E/FasTI expression at different MOIs. 5 x 105 TC1 cells 
were harvested from each group that were infected with Ad-MULT1E/FasTI at MOIs 500, 
250, 100, 50, 25, 0 and stained with purified rat anti-mouse MULT1 antibody followed by 
goat anti IgG F(ab’)-FITC. Dashed lines represent un-infected TC-1 cells. 
3.8 MULT1E/FasTI delivered by adenoviral vector induces apoptosis in TC-1 cells 
To confirm the activity of adenoviral vector delivered MULT1E/FasTI fusion protein in TC-
1 cells, recombinant NKG2D/Fc ligand was added to the infected cells. As MULT1E binds to 
its ligand NKG2D, the binding would send apoptotic signal through its FasTI region into 
TC-1 cells (Kotturi et al., 2008). When TC-1 cells were infected with 100 MOI of Ad-
MULT1E/FasTI and treated with NKG2D/Fc, their caspase 3 activity was significantly 
higher (p<0.001) than the cells that were also infected by Ad-MULT1E/FasTI but not treated 
with NKG2D/Fc. Ad-MULT1E or Ad-Lac-Z infection showed slightly increased caspase 3 
activity (p>0.05) compared with non-infected TC-1 cells (Fig. 12A). The caspase activity in 
Ad-MULT1E/FasTI infected and NKG2D treated TC-1 cells is adenoviral particle dose 
  
 
Fig. 12. Ad-MULT1E/FasTI infection induces apoptosis in vitro. A) TC-1 (5x105) cells were 
infected with Ad-MULT1E/FasTI, Ad-MULT1E and Ad-Lac-Z at 100 MOI. Twenty-four 
hour after infection, cells were treated with 1µg/ml NKG2D/Fc for 16 hrs.  The cells were 
then analyzed for apoptosis by caspase-3 assay. B) TC-1 (5x105) cells were infected with Ad-
MULT1E/FasTI at different MOIs: 500, 250, 100, 50, 25. Twenty-four hour after infection, 
cells were treated with 1µg/ml NKG2D/Fc for 16 hrs.  The cells were then analyzed for 
apoptosis by caspase-3 assay. The data represented are summaries of three separate 
experiments. *p< 0.05; **p< 0.01 and ***p< 0.001. 
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dependent: 500 MOI infection generated the highest caspase activity, while a 25 MOI 
infection did not show any increased caspase 3 activity compared with un-infected TC-1 
cells (Fig. 12B). 
3.9 Intratumor delivery of MULT1E/FasTI by adenoviral vector 
To observe the antitumor activity of MULT1E/FasTI delivered by adenoviral vector, 
subcutaneous TC-1 tumors were grown in C57BL/6J mice. When the tumor reached about a 
size of 40 mm3, Ad-MULT1E/FasTI, Ad-MULT1E or Ad-Lac-Z at a dose of 1x109 pfu/tumor 
in 0.05ml HBSS was injected into the tumors. Control mice received HBSS only. The 
injections were repeated every other day for 4 times. The size of the tumors was measured 
every two days. At day 22 after tumor cell injection, the mice were sacrificed and the tumors 
were collected and measured. Although tumors received Ad-MULT1E or Ad-Lac-Z grew 
slightly slower than tumors received only HBSS, tumors received Ad-MULT1E/FasTI 
showed the slowest growth rate (Fig. 13A). The end point tumor measurement confirmed 
the conclusion that Ad-MULT1E/FasTI treatment significantly slowed the tumor growth 
(P<0.01, Fig. 13B). 
 
 
Fig. 13. MULT1E/FasTI delivered by adenoviral vector inhibits in vivo tumor growth. TC-1 
cells (2 x 105) in 0.2ml HBSS were subcutaneously injected into flanks of C57BL/6J mice (n = 
6).  One week after tumor cell injection, various viral vectors at a dose of 1 x 109 pfu/tumor 
were intratumorally injected on every other day for a total of 4 injections. Control animals 
received injections of 50µl HBSS. Tumor growth was measured and presented as 1/2LW2 
(A). At the end of this experiment, the mice were sacrificed and tumors were harvested and 
measured (B). *P< 0.05 
3.10 MULT1E/FasTI delivered by adenoviral vector induces apoptosis in tumor 
In order to confirm that MULT1E/FasTI delivered by adenoviral vector slows tumor growth 
by inducing tumor cell to undergo apoptosis, two days after last adenoviral particle 
injection, some mice were i.v. injected with FLIVOTM in vivo apoptosis detection reagent. 
Thirty minutes later, the tumor tissues were collected and 7 µm frozen sections were 
produced. The slides were examined under fluorescent microscope and the green 
fluorescent cells were counted. The number of apoptotic cells in tumors receiving Ad-
MULT1E/FasTI is significantly higher than that of tumors receiving either Ad-MULT1E or 
Ad-Lac-Z. There are no significantly more apoptotic cells in tumors receiving Ad-MULT1E 
or Ad-Lac-Z when compared with tumors that received just HBSS (Fig. 14).  
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dependent: 500 MOI infection generated the highest caspase activity, while a 25 MOI 
infection did not show any increased caspase 3 activity compared with un-infected TC-1 
cells (Fig. 12B). 
3.9 Intratumor delivery of MULT1E/FasTI by adenoviral vector 
To observe the antitumor activity of MULT1E/FasTI delivered by adenoviral vector, 
subcutaneous TC-1 tumors were grown in C57BL/6J mice. When the tumor reached about a 
size of 40 mm3, Ad-MULT1E/FasTI, Ad-MULT1E or Ad-Lac-Z at a dose of 1x109 pfu/tumor 
in 0.05ml HBSS was injected into the tumors. Control mice received HBSS only. The 
injections were repeated every other day for 4 times. The size of the tumors was measured 
every two days. At day 22 after tumor cell injection, the mice were sacrificed and the tumors 
were collected and measured. Although tumors received Ad-MULT1E or Ad-Lac-Z grew 
slightly slower than tumors received only HBSS, tumors received Ad-MULT1E/FasTI 
showed the slowest growth rate (Fig. 13A). The end point tumor measurement confirmed 
the conclusion that Ad-MULT1E/FasTI treatment significantly slowed the tumor growth 
(P<0.01, Fig. 13B). 
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3.10 MULT1E/FasTI delivered by adenoviral vector induces apoptosis in tumor 
In order to confirm that MULT1E/FasTI delivered by adenoviral vector slows tumor growth 
by inducing tumor cell to undergo apoptosis, two days after last adenoviral particle 
injection, some mice were i.v. injected with FLIVOTM in vivo apoptosis detection reagent. 
Thirty minutes later, the tumor tissues were collected and 7 µm frozen sections were 
produced. The slides were examined under fluorescent microscope and the green 
fluorescent cells were counted. The number of apoptotic cells in tumors receiving Ad-
MULT1E/FasTI is significantly higher than that of tumors receiving either Ad-MULT1E or 
Ad-Lac-Z. There are no significantly more apoptotic cells in tumors receiving Ad-MULT1E 
or Ad-Lac-Z when compared with tumors that received just HBSS (Fig. 14).  
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Fig. 14. MULT1E/FasTI delivered by adenoviral vector induces apoptosis in vivo. Two days 
after the last intratumor virus injection, 100µl of FLIVOTM in vivo apoptosis detection reagent 
(green) was injected into mice. Thirty minutes later, the mice were sacrificed and tumors 
collected. Frozen sections were made from the tumor tissues and examined under 
fluorescent microscope. The data presented are the sum of apoptotic cells from 12 random 
fields of each section. *** P < 0001   
4. Conclusion 
Tumor cells have developed multiple mechanisms to subvert and suppress immune 
responses by regulating cell-surface expression of Fas (Ivanov et al., 2003) and Fas ligand 
(Zheng et al., 2003) and shedding NKG2D ligands such as MULT1 (Raffaghello et al., 2004), 
resulting in escape from killing by infiltrating antitumor NK cells and T cells (Elsasser-Beile 
et al., 2003). As NKG2D ligand surface levels critically determine the susceptibility to 
NKG2D-mediated NK cell lysis, stable expression of NKG2D ligands on tumors would help 
increase NK cell lysis of tumors (Diefenbach and Raulet, 2001). In this study, we enhanced 
the cell-surface expression of MULT1, one of the mouse NKG2D ligands, by anchoring the 
extracellular domain of MULT1 on tumor cells using a transmembrane sequence of Fas. We 
also introduced the DD of Fas in the intracellular domain of the fusion protein 
MULT1E/FasTI, hoping to develop a bifunctional chimeric protein that can send an 
apoptosis signal to the tumor cells and at the same time activate NKG2D-expressing 
immune cells such as NK cells. 
We cloned the cDNA encoding the extracellular domain of MULT1 gene from thymus of 
new born mice and ligated it to the transmembrane and intracellular domains of mouse fas 
cDNA. The resulting fusion cDNA was inserted into a mammalian cell expressing vector 
under the control of CMV promoter.  The vector was then transfected into mouse TC-1 lung 
epithelial cancer cells, and stable cell lines expressing the fusion protein were established. 
The transcription of the novel fusion protein MULT1E/FasTI in the transfected cells was 
confirmed by RT–PCR and its expression was characterized by surface FACS analysis.   
One of the key features of the designed fusion protein is to send apoptosis signals into the 
cells expressing the fusion protein, upon binding to its ligand, NKG2D. Although we do not 
have direct evidence supporting that the binding of NKG2D can form DISC inside tumor 
cells, a clear apoptosis signal is sent to the cells as indicated by the increased caspase-3 
activity and increased Annexin V-positive cells after treatment with recombinant 
NKG2D/Fc. Our data shows that fusion protein MULT1E/FasTI, when expressed on cells, 
not only sends apoptotic signals into cells expressing it, but also activates immune cells that 
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express receptors for MULT1 like NK cells. When co-culutred with NK cells isolated from 
spleen, the fusion proteins expressing clones activated NK cells by producing IFN-γ. 
This study shows that fusion protein MULT1E/FasTI has antitumor activity in vivo. We 
used a subcutaneous tumor model and a pulmonary metastatic tumor model in this study. 
In the subcutaneous tumor study, MULT1E/FasTI expressing clones formed smaller tumors 
compared to controls; and in the pulmonary metastasis study, mice completely rejected 
tumor cells expressing the fusion protein. We showed that the fusion protein had a much 
stronger antitumor effect in the pulmonary metastasis setting than in the subcutaneous 
setting. This is in agreement with a study demonstrating that NK cells are more effective 
against blood borne metastasis (Smyth et al., 2002). Previous studies have shown that tumor 
cells ectopically expressing NKG2D ligands such as MULT1 are potently rejected by 
NKG2D-expressing lymphocytes (Diefenbach et al., 2001). Our data shows that adding Fas 
to the MULT1 has a clear additional antitumor effect. 
A significant challenge facing cancer gene therapy is how to specifically deliver tumor-
killing genes into tumor cells efficiently. The recent development of adenovirus as gene 
delivery vectors opens a new window for cancer gene therapy (Cohen and Rudin, 2001; Ries 
and Korn, 2002). We used adenoviruses to deliver the fusion protein MULT1E/FasTI into 
tumor cells. The findings of this study demonstrate the therapeutic effect of adenovirus-
mediated gene therapy of novel fusion protein MULT1E/FasTI. The most encouraging 
finding from a preclinical viewpoint is that mice receiving treatment with Ad-
MULTE/FasTI showed more apoptosis in vivo, formed smaller tumors, and survived longer.   
NK cell function is regulated by a balance between activating and inhibiting receptor signals 
(Trinchieri, 1989; Diefenbach and Raulet, 2001). Several types of inhibitory NK cell receptors 
recognize MHC class I molecules on target cells and prevent NK cell cytotoxicity toward 
normal cells (Yokoyama et al., 1995). The expression of ligands for activating receptor on 
target cells tips the balance toward activation of NK cells and induces NK cell cytotoxicity 
by formation of NK cell lytic synapse. NK cell cytotoxicity involves the secretion of cytolytic 
effector molecules known as lytic granules. The induction of NK cell effector functions, such 
as cytotoxicity, requires the contact between the NK cell and its target cell. The events that 
occur following the interaction between a cytolytic cell and its target cell, and the formation 
of the NK cell lytic synapse can be divided into three main stages: 1) initiation stage, 2) 
effector stage, and 3) termination stage. Initiation stage includes adhesion and initial 
signaling for cell activation. Effector stage involves actin reorganization, receptor clustering, 
raft formation, polarization of the microtubule-organizing centre (MTOC) and lytic granule 
fusion with the plasma membrane. Termination stage includes a period of inactivity and 
detachment.  
Fas receptor activation can occur through different mechanisms. Binding of homotrimers of 
FasL to Fas can homotrimerize Fas receptor (Papoff et al., 1999; Siegel et al., 2000). A death 
domain-independent oligomerization domain in the extracellular region of the Fas, mapping 
to the N-terminal 49 amino acids, can also mediate homo- and heterooligomerization of the 
death receptor (Papoff et al., 1999). Apoptosis can be triggered in the absence of FasL by 
overexpression of the Fas cytoplasmic domain or Fas lacking the N-terminal 42 amino acids 
(Papoff et al., 1999), suggesting that the extracellular oligomerization domain of Fas is not 
required to initiate signaling and that self-association of the death domain is necessary and 
sufficient to induce cell death. The intracellular death domains of death receptors show a 
high tendency to self-associate, and when overexpressed by gene transfer in eukaryotic cells, 
trigger apoptotic signaling (Boldin et al., 1996). These findings indicate that the Fas receptor 
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Fig. 14. MULT1E/FasTI delivered by adenoviral vector induces apoptosis in vivo. Two days 
after the last intratumor virus injection, 100µl of FLIVOTM in vivo apoptosis detection reagent 
(green) was injected into mice. Thirty minutes later, the mice were sacrificed and tumors 
collected. Frozen sections were made from the tumor tissues and examined under 
fluorescent microscope. The data presented are the sum of apoptotic cells from 12 random 
fields of each section. *** P < 0001   
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immune cells such as NK cells. 
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epithelial cancer cells, and stable cell lines expressing the fusion protein were established. 
The transcription of the novel fusion protein MULT1E/FasTI in the transfected cells was 
confirmed by RT–PCR and its expression was characterized by surface FACS analysis.   
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express receptors for MULT1 like NK cells. When co-culutred with NK cells isolated from 
spleen, the fusion proteins expressing clones activated NK cells by producing IFN-γ. 
This study shows that fusion protein MULT1E/FasTI has antitumor activity in vivo. We 
used a subcutaneous tumor model and a pulmonary metastatic tumor model in this study. 
In the subcutaneous tumor study, MULT1E/FasTI expressing clones formed smaller tumors 
compared to controls; and in the pulmonary metastasis study, mice completely rejected 
tumor cells expressing the fusion protein. We showed that the fusion protein had a much 
stronger antitumor effect in the pulmonary metastasis setting than in the subcutaneous 
setting. This is in agreement with a study demonstrating that NK cells are more effective 
against blood borne metastasis (Smyth et al., 2002). Previous studies have shown that tumor 
cells ectopically expressing NKG2D ligands such as MULT1 are potently rejected by 
NKG2D-expressing lymphocytes (Diefenbach et al., 2001). Our data shows that adding Fas 
to the MULT1 has a clear additional antitumor effect. 
A significant challenge facing cancer gene therapy is how to specifically deliver tumor-
killing genes into tumor cells efficiently. The recent development of adenovirus as gene 
delivery vectors opens a new window for cancer gene therapy (Cohen and Rudin, 2001; Ries 
and Korn, 2002). We used adenoviruses to deliver the fusion protein MULT1E/FasTI into 
tumor cells. The findings of this study demonstrate the therapeutic effect of adenovirus-
mediated gene therapy of novel fusion protein MULT1E/FasTI. The most encouraging 
finding from a preclinical viewpoint is that mice receiving treatment with Ad-
MULTE/FasTI showed more apoptosis in vivo, formed smaller tumors, and survived longer.   
NK cell function is regulated by a balance between activating and inhibiting receptor signals 
(Trinchieri, 1989; Diefenbach and Raulet, 2001). Several types of inhibitory NK cell receptors 
recognize MHC class I molecules on target cells and prevent NK cell cytotoxicity toward 
normal cells (Yokoyama et al., 1995). The expression of ligands for activating receptor on 
target cells tips the balance toward activation of NK cells and induces NK cell cytotoxicity 
by formation of NK cell lytic synapse. NK cell cytotoxicity involves the secretion of cytolytic 
effector molecules known as lytic granules. The induction of NK cell effector functions, such 
as cytotoxicity, requires the contact between the NK cell and its target cell. The events that 
occur following the interaction between a cytolytic cell and its target cell, and the formation 
of the NK cell lytic synapse can be divided into three main stages: 1) initiation stage, 2) 
effector stage, and 3) termination stage. Initiation stage includes adhesion and initial 
signaling for cell activation. Effector stage involves actin reorganization, receptor clustering, 
raft formation, polarization of the microtubule-organizing centre (MTOC) and lytic granule 
fusion with the plasma membrane. Termination stage includes a period of inactivity and 
detachment.  
Fas receptor activation can occur through different mechanisms. Binding of homotrimers of 
FasL to Fas can homotrimerize Fas receptor (Papoff et al., 1999; Siegel et al., 2000). A death 
domain-independent oligomerization domain in the extracellular region of the Fas, mapping 
to the N-terminal 49 amino acids, can also mediate homo- and heterooligomerization of the 
death receptor (Papoff et al., 1999). Apoptosis can be triggered in the absence of FasL by 
overexpression of the Fas cytoplasmic domain or Fas lacking the N-terminal 42 amino acids 
(Papoff et al., 1999), suggesting that the extracellular oligomerization domain of Fas is not 
required to initiate signaling and that self-association of the death domain is necessary and 
sufficient to induce cell death. The intracellular death domains of death receptors show a 
high tendency to self-associate, and when overexpressed by gene transfer in eukaryotic cells, 
trigger apoptotic signaling (Boldin et al., 1996). These findings indicate that the Fas receptor 
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plays an active role in its own clustering and that its oligomerization can be achieved in the 
absence of FasL. 
We hypothesize that, when NKG2D expressing cells such as NK cells come in contact with 
TC-1 cells expressing the MULT1E/FasTI fusion protein, an NK cell lytic synapse would be 
formed as a result of the receptor-ligand interaction between NK cells and fusion protein 
expressing target cells. At this NK cell lytic synapse, activated NKG2D receptors bind to 
MULT1 ligands, cluster together and form lipid rafts. Formation of lipid rafts consisting of 
receptor-ligand complexes would result in activation of NK cells and NK cell cytotoxicity 
with the release of lytic granules consisting of granzymes and IFN-γ at the immunological 
synapse. Binding of NKG2D to the MULT1E region of the fusion protein causes clustering of 
the fusion protein, and through death domain interactions would trigger formation of 
microaggregates resulting in larger clusters of FasTI, formation of DISC, caspase-8 activation 
and apoptosis in cell. Hence, our fusion protein approach is a two pronged approach for 
activating NK cells as well as inducing apoptosis, when the fusion protein binds to NKG2D 
receptors. Even though we do not have evidence of the formation of lytic synapses with NK 
cells and DISC formation in fusion protein expressing cells, our IFN-γ assay using NK cells 
and caspase-3 ELISA assay confirm the functionality of both MULT1E and FasTI regions in 
our fusion protein and the dual role of MULT1E/FasTI.               
In summary, a bi-functional chimeric protein containing the extracellular domain of MULT1 
and the transmembrane and intracellular domains of Fas is created. It may provide a 
potential avenue for new cancer therapies and supports further investigation of therapeutic 
strategies using other NKG2D ligands combined with Fas transmembrane and intracellular 
domains for treating cancer. When combined with adenovirus gene delivery vectors, 
especially the oncolytic adenovirus vectors, the fusion protein will provide a robust anti-
cancer agent. 
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plays an active role in its own clustering and that its oligomerization can be achieved in the 
absence of FasL. 
We hypothesize that, when NKG2D expressing cells such as NK cells come in contact with 
TC-1 cells expressing the MULT1E/FasTI fusion protein, an NK cell lytic synapse would be 
formed as a result of the receptor-ligand interaction between NK cells and fusion protein 
expressing target cells. At this NK cell lytic synapse, activated NKG2D receptors bind to 
MULT1 ligands, cluster together and form lipid rafts. Formation of lipid rafts consisting of 
receptor-ligand complexes would result in activation of NK cells and NK cell cytotoxicity 
with the release of lytic granules consisting of granzymes and IFN-γ at the immunological 
synapse. Binding of NKG2D to the MULT1E region of the fusion protein causes clustering of 
the fusion protein, and through death domain interactions would trigger formation of 
microaggregates resulting in larger clusters of FasTI, formation of DISC, caspase-8 activation 
and apoptosis in cell. Hence, our fusion protein approach is a two pronged approach for 
activating NK cells as well as inducing apoptosis, when the fusion protein binds to NKG2D 
receptors. Even though we do not have evidence of the formation of lytic synapses with NK 
cells and DISC formation in fusion protein expressing cells, our IFN-γ assay using NK cells 
and caspase-3 ELISA assay confirm the functionality of both MULT1E and FasTI regions in 
our fusion protein and the dual role of MULT1E/FasTI.               
In summary, a bi-functional chimeric protein containing the extracellular domain of MULT1 
and the transmembrane and intracellular domains of Fas is created. It may provide a 
potential avenue for new cancer therapies and supports further investigation of therapeutic 
strategies using other NKG2D ligands combined with Fas transmembrane and intracellular 
domains for treating cancer. When combined with adenovirus gene delivery vectors, 
especially the oncolytic adenovirus vectors, the fusion protein will provide a robust anti-
cancer agent. 
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1. Introduction 
Despite the early discovery of interferon (IFN) in 1957, some members of the IFN family 
were just identified during the recent years.  Interferon was discovered and characterized by 
Isaacs & Lindenmann during their study of viral infection and the biology of interference 
(Isaacs and Lindenmann, 1957). The authors used chick membranes infected with influenza 
viruses, and found that those cells released into the medium a substance which rendered 
other cells resistant to viral infection. The authors named this substance interferon. 
Subsequent studies demonstrated that interferon is not a virus particle but a protein 
released by the cells during viral infection.  
Early studies have defined three different subfamilies of interferons, depending on their cell 
origin (Stewart et al., 1973). IFN-α was characterized from virus-infected leukocytes, IFN-β 
from fibroblasts and IFN-γ produced by transformed lymphocytes, which was first 
designated as an immune interferon. Other properties such as hydrophobicity, antigenicity 
and heat/pH sensitivity were also investigated to distinguish between IFN molecules. By 
probing on several hydrophobic adsorbents, one group demonstrated that the fibroblast 
interferon is more hydrophobic than leukocyte interferon (Jankowski et al., 1975). Rabbit 
antiserum prepared against the leukocyte IFN was found to contain two populations of 
neutralizing antibodies specific for leukocytes and fibroblasts populations and the authors 
concluded that two antigenic species of IFN were present (Havell et al., 1975). However, this 
rabbit antiserum preparation was shown to be less active against immune interferon (IFN-
γ), which was also found to be relatively unstable at pH 2 and at 56 degrees (Valle et al., 
1975). In the last 30 years, IFN-α, β and γ were purified and receptor binding assays using 
radio-labeled ligands were performed. The data clearly indicated that IFN-α and IFN-β 
interacted with the same binding site, which was distinct from IFN-γ (Littman et al., 1985; 
Merlin et al., 1985). Subsequently, characterization of the IFN receptor, followed by the 
production of IFN knockout mice, clearly showed that IFN-α/β signal through a receptor 
that is completely distinct from IFN-γ receptor (Ding et al., 1993; Muller et al., 1994). As a 
result of all these studies, IFNs were classified as two types.  Type I IFN family is composed 
of several members, which include IFN-α, IFN-β and other related IFNs such as IFN-ω, IFN-
ε and IFN-κ.  The type II IFN family only includes IFN-γ (Pestka, 2007).  In 2003, another 
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IFN family (type III) was identified and its members designated as IFN-λ (Kotenko et al., 
2003; Sheppard et al., 2003) (Figure 1). 
The new IFN members identified in human were designated as IFN-λs, by Kotenko's group 
(Kotenko et al., 2003), or IL-28A, IL-28B and IL-29 by Sheppard and coll. (Sheppard et al., 
2003). IFN-λs demonstrate structural features that are similar to the IL-10-related cytokine 
family II [CRFII] but possess antiviral activity (Langer et al., 2004; Pestka et al., 2004). In 
2005, the International Community of Interferon and Cytokine Research designated IFN-λs 
as type III IFNs, which include three distinct IFN-λ proteins, called IFN-λ1 (IL-29), IFN-λ2 
(IL-28A) and IFN-λ3 (IL-28B). The genes encoding all three type III IFNs are clustered on 
human chromosome 19. The IFN-λ3 gene is transcribed in the opposite direction to the IFN-
λ1 and IFN-λ2 genes. The coding region of each of the genes is divided into five exons (exon 
1-5). The overall intron/exon structure of the IFN-λ genes correlates well with the common 
conserved architecture of the genes encoding IL-10-related cytokines (Kotenko, 2002). It is 
thought that the human IFN-λs genes derived from a common predecessor fairly recently. 
This is based on the fact that there is a great deal of homology between human IFN-λs   It is 
also suggested that during the divergence of the IFN-λ1 and IFN-λ2 genes, occurred a more 
recent duplication event in which a fragment containing the IFN-λ1 and IFN-λ2 genes was 
copied and integrated back into the genome in a head-to-head orientation with the IFN-λ1-
IFN-λ2 segment. It is speculated that this duplication may have created the IFN-λ3 gene, 
which is nearly identical to the IFN-λ2 gene in terms of the upstream and downstream 
flanking sequences and coding region. Therefore, the promoters of the genes for IFN-λ2 and 
IFN-λ3 share a great similarity and have many common elements with the IFN-λ1 promoter 
(Kotenko et al., 2003; Sheppard et al., 2003). Based on this, it is suggested that the IFN-λ 
genes are regulated in a similar fashion.  
The members of this new IFN family were found to interact through unique receptors that 
are distinct from type I and type II IFN receptors. The receptor for type III IFN is composed 
of the unique IFN-λR1 chain and the IL-10R2 chain, which is shared with IL-10, IL-22 and 
IL-26 receptor complexes. Although type III IFNs bind to a specific receptor, the 
downstream signaling is similar to that induced by type I IFNs. Both type I and type III IFNs 
stimulate common signaling pathways, consisting of the activation of JAK1 and TYK2 
kinases and leading to the activation of the IFN-stimulated gene factor 3 (ISGF3) 
transcription complex.  ISGF3 is composed of STAT1 and STAT2, and the interferon 
regulatory factor IRF9 (ISGF3-γ or p48). 
This complex translocates into the nucleus and interacts with a specific DNA sequence 
designated IFN stimulated response element (ISRE), present upstream of the genes 
stimulated by the IFNs. The Type II IFN activates cell signaling through another pathway. 
After the interaction with IFNGR, JAK1 and JAK2 are activated and phosphorylate STAT1, 
which dimerizes, translocates into the nucleus, binds to the gamma activated sequence 
(GAS) and induces gene expression. 
Although there are three genes encoding highly homologous but distinct human IFN-λ 
proteins (IFN-λ1, IFN-λ2, and IFN-λ3), our search of the mouse genome revealed the 
existence of only two genes, representing mouse IFN-λ2 and IFN-λ3 gene orthologues, 
located in chromosome 7 and encoding intact proteins. The mouse IFN-λ1 gene orthologue 
is a pseudogene containing some variations in addition to a stop codon in the first exon and 
does not code  for an active protein (Lasfar et al., 2006). We have cloned the mouse IFN-λs 
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(mIFN-λ2 and mIFN-λ3) and IFN-λ receptor (mIFN-λR1) orthologues and found them to be 
quite similar to their human counterparts. Experiments showed that similar to their human 
counterparts, mIFN-λ2 and mIFN-λ3 signal through the IFN-λ receptor complex, activate 
ISGF3, and are capable of inducing antiviral protection and MHC class I antigen expression 
in several cell types. The results showed that murine type III IFNs (IFN-λs) engage a unique 
receptor complex, composed of IFN-λR1 and IL-10R2 subunits, to induce signaling and 
biological activities similar to those of type I IFNs. Interestingly, in contrast to type I and 
type II IFNs, type III IFNs demonstrate less specie specificity. This characteristic of type III 




Fig. 1. Interferons, interferon receptors and cell signaling.  
2. Characteristics of the IFN- λ receptor 
2.1 The human IFN-λ receptor (hIFN-λR1) 
The human IFN-λR1 (hIFN-λR1) consists of 520 amino acids, including a signal peptide of 20 
amino acids. In SDS-PAGE (Sodium Dodecyl Sulfate PolyAcrylamide Gel Electrophoresis), 
the IFN-λR1 protein was estimated at around 70 kD, much higher than the theoretical 
molecular weight calculated at 56 KD, implying the existence of post-translational 
modifications (Witte et al., 2009). Although the extracellular domain presents 4 putative N-
linked glycosylation sites and 1 O-linked glycosylation site, effective IFN-λR1 glycosylation 
has not been definitely established. The intracellular domain of IFN-λR1 contains three 
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tyrosine residues. Tyrosines 343 and 517 are essential for STAT2 and STAT5 activation 
(Dumoutier et al., 2004). The existence of splice variants of IFN-λR1 has been reported. 
Shepard and coll. suggested the presence of one splice variant lacking a part of exon VII 
(Sheppard et al., 2003). However, we did not confirm yet the existence of these splice 
variants. Another splice variant lacking exon VI was first described in 2003 (Dumoutier et 
al., 2004), and its existence has been recently confirmed. This variant was designated sIFN-
λR1 for soluble IFN-λR1 or sIL-28R1 for soluble IL-28R1 (Witte et al., 2009). The cloning and 
protein expression analysis of the soluble IFN-λR1, sIFN-λR1, were performed and the 
ligand binding studies showed the aptitude of this soluble receptor to inhibit the IFN-λ 
response. However, high concentrations of sIFN-lR1 were used and only partial inhibition 
was achieved, suggesting that the described form of sIFN-λR1 may not play an important 
role in the regulation of IFN-λ response. However, we cannot rule out the induction of other 
post-translational modifications of the IFN-λR1 that may modulate the activity of sIFN-λR1 
by increasing its inhibitory effects on circulating IFN-λs in normal or pathologic situations. 
Witte and coll. (Witte et al., 2009) showed the presence of sIFN-λR1 in all cells expressing 
IFN-λR1, with high levels in immune cells such as B, T and NK cells and suggested a 
correlation between the level of sIFN-λR1 and the lack of response to IFN-λ. 
2.2 The mouse IFN-λ receptor and comparison to the human counterpart 
After the identification of the human IFN-λ system, we cloned the mouse IFN-λR1 (mIFN-
λR1) chain and found it around 67% similar to its human counterpart. The mIFN-λR1 is 
encoded on mouse chromosome 4D3. Although the mouse and human IFN-λR1 sequences 
are very similar, only two of three tyrosine residues of the human receptor intracellular 
domain are conserved in the mouse orthologue. In addition, the mouse receptor contains 
three additional tyrosine residues. There is also a stretch of negatively charged residues 
close to the end of the human receptor intracellular domain. This region in the mouse 
receptor is significantly altered by a short insertion and substitutions of several amino acid 
residues, resulting in a longer and more negatively charged region in the mouse receptor (18 
of 20 amino acids are negatively charged). Two tyrosines, Tyr343 and Tyr517, of hIFN-λR1 can 
independently mediate STAT2 activation by IFN-λs. Interestingly, the Tyr341-based motif of 
mIFN-λR1 (YLERP) shows similarities with that surrounding Tyr343 of hIFN-λR1 (YIEPP). In 
addition, the COOH-terminal amino acid sequence of mIFN-λR1 containing Tyr533 
(YLVRstop) is very similar to the COOH-terminal amino acid sequence of hIFN-λR1 
containing Tyr517 (YMARstop). Therefore, both the mouse and human IFN-λR1 chains 
contain similar docking sites for STAT2 recruitment and activation, YΦEXP and YΦXRstop 
(where Φ is hydrophobic). Thus, Tyr341- and Tyr533-based motifs on mIFN-λR1 are also likely 
to mediate STAT2 recruitment and, therefore, mediate ISGF3 activation, which is 
responsible for most of the IFN-λ-induced biological activities. Interestingly, by using 
hamster cells transfected with chimeric human IFN-λR1/γR1 and IL-10R2 expression 
vectors, we demonstrated that the cells were responsive to both human and mouse IFN-λs, 
as measured by STAT1 activation in electromobility shift assay and up-regulation of MHC 
class I antigen expression (Lasfar et al., 2006). However, expression of murine IFN-λR1/γR1 
alone rendered hamster cells responsive to both human and mouse IFN-λs, implying that 
hamster IL-10R2 can dimerize with murine IFN-λR1 to mediate signaling in response to 
either human or mouse IFN-λs. As controls, we did not detect any response of parental 
hamster cells to either human or mouse IFN-λ (Lasfar et al., 2006). Therefore, the mouse and 
human IFN-λs are not specie specific.   
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3. Distribution of IFN-λR1 and responsiveness to IFN- λ  
The functional IFN-λR is formed by two chains, IFN-λR1 (also called IL-28R1) and IL-10R2. 
IFN-λR1 is unique for the IFN-λs and its tissue distribution is highly restricted. In contrast to 
IFN-λR1, IL-10R2 is shared by IL-10, IL-22 and IL-26 and ubiquitously expressed in all 
tissues. Unlike IFN-α, only few cell types respond to IFN-λ (Figure 2) . In contrast to the 
epithelial-like cells, fibroblasts and endothelial cells were completely unresponsive to IFN-λ 
(Lasfar et al., 2006). Although the hematopoeitic system is not the primary target of IFN-λ, 
the response of some subpopulations to IFN-λ is not excluded. In mice, we found that IFN-λ 
induces STAT1 activation in both plasmacytoid and myeloid dentritic cells (Abushahba et 
al., 2010). These results are in accordance with Mennechet and Uze (Mennechet and Uze, 
2006), who proposed the acquisition of an IFNλ response by the monocytes after their 
differentiation into dentritic cells. Therefore, the response to IFN-λ may be controlled by the 
induction of the IFN-λR1 expression. Recently, Witte and coll. found different levels of IFN-
λR1 in different tissues (Witte et al., 2009). The highest levels were found in the 
gastrointestinal tract and lung. The brain showed the lowest level. The IFN-λR1 expression 
 
 
Fig. 2. Cellular targets for type I and type III IFNs. Cells from different origins were tested 
for IFN-α and IFN-λ response by measuring the IFN induced-cell signaling (Stat activation) 
and biological activity (MHC class I antigen stimulation).  
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3. Distribution of IFN-λR1 and responsiveness to IFN- λ  
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IFN-λR1, IL-10R2 is shared by IL-10, IL-22 and IL-26 and ubiquitously expressed in all 
tissues. Unlike IFN-α, only few cell types respond to IFN-λ (Figure 2) . In contrast to the 
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the response of some subpopulations to IFN-λ is not excluded. In mice, we found that IFN-λ 
induces STAT1 activation in both plasmacytoid and myeloid dentritic cells (Abushahba et 
al., 2010). These results are in accordance with Mennechet and Uze (Mennechet and Uze, 
2006), who proposed the acquisition of an IFNλ response by the monocytes after their 
differentiation into dentritic cells. Therefore, the response to IFN-λ may be controlled by the 
induction of the IFN-λR1 expression. Recently, Witte and coll. found different levels of IFN-
λR1 in different tissues (Witte et al., 2009). The highest levels were found in the 
gastrointestinal tract and lung. The brain showed the lowest level. The IFN-λR1 expression 
 
 
Fig. 2. Cellular targets for type I and type III IFNs. Cells from different origins were tested 
for IFN-α and IFN-λ response by measuring the IFN induced-cell signaling (Stat activation) 
and biological activity (MHC class I antigen stimulation).  
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was also analyzed in different cell types. The expression of cell populations isolated from 
human skin showed a high expression of IFN-λR1 in keratinocytes and melanocytes. 
However, dermal fibroblasts, endothelial cells and sub-dermal adipocytes did not express 
significant amounts of IFN-λR1. Significant expression of IFN-λR1 was detected in primary 
human hepatocytes in comparison with the condrocytes, isolated from the hyaline cartilage 
of the knee joint (Witte et al., 2009; Wolk et al., 2008). Although the expression of IFN-λR1 
was significantly high in lymphoid tissues, the IFN-λ response was very weak, implying the 
presence of specific mechanisms on the lymphoid tissues that may inhibit the IFN-λ 
response. For example, IFN-λR1 levels in B cells are three fold those detected in 
keratinocytes, which exhibit one of the highest response to IFN-λ. Witte and coll. proposed 
the potential role of sIFN-λR1, highly released by the immune cells, in this weak response to 
IFN-λ (Witte et al., 2009).  
Although all the IFN-λs interact with the same receptor, IFN-λR1, the binding characteristics 
for each ligand are still under investigation. In the future, it will be important to analyze the 
IFN-λ activity in the light of the IFN-λ binding to the cells and understand particularly the 
role of IFN- λ3, which possesses the highest activity as compared with the other IFN-λs 
(Dellgren et al., 2009). Analysis of the ligand binding in combination with the activity 
induced by IFN-λ will be also important in understanding the role of IFN-λ in epithelial 
cells, particularly in comparison with the immune cells expressing IFN-λR1. Besides several 
carcinomas, originating from epithelial cells, which respond to IFN- λ, other tumors not 
arising from epithelial cells may become more sensitive to IFN-λ. It was reported that 
multiple myeloma cells, which originate from B cell plasmocytes, showed high binding and 
response to IFN-λ (Novak et al., 2008). Studying the IFN-λ binding in transformed cells 
versus normal cells may be very helpful for tumor targeting and for the establishment of the 
optimum dose of IFN- λ to be used for the in vivo treatment. IFN-λ can also be used as a 
drug carrier, to specifically target a drug to tumors expressing high IFN-λ binding sites. 
4. Biological and clinical activities of IFN-λ 
4.1 Comparative studies between type I and type III IFN (IFN- λs) 
To date, every cell line responding to IFN-λ also responded to type I IFNs. However, the cell 
signaling induced by type III IFNs appeared to be significantly weaker as compared to type 
I IFNs. Interestingly, the intensity of cell signaling induced by IFN-λ, as assessed by STAT 
activation, is not always correlated with the level of biological activity, as determined by 
MHC class I expression (Figure 3).   
Antiviral studies performed in vitro and in vivo have shown that both IFN-α and IFN-λ 
contribute to the overall host antiviral defense system (Ank et al., 2008; Ank et al., 2006; 
Kotenko et al., 2003; Kugel et al., 2009; Mordstein et al., 2008; Sheppard et al., 2003).  It has 
been demonstrated that IFN-λ induces antiviral activity against VSV (vesicular stomatitis 
virus) and EMCV (encephalomyocarditis) in many cell types (Kotenko et al., 2003; Li et al., 
2009; Sheppard et al., 2003; Uze and Monneron, 2007). Several studies demonstrated that 
type III IFNs can also inhibit replication of Hepatitis C Virus (HCV) and Hepatitis B Virus 
(HBV) in vitro (Hong et al., 2007; Lazaro et al., 2007; Marcello et al., 2006; Robek et al., 2005; 
Uze and Monneron, 2007). These studies were important since they underlined the fact that 
IFN-λ could be used as an alternative to IFN-α for HCV patients who are resistant to IFN-α 
treatment.  Just recently, it has been reported that IFN-λ has the ability to inhibit human 
immunodeficiency virus type 1 (HIV-1) infection of blood monocyte-derived macrophages 
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that expressed IFN-λ receptors (Hou et al., 2009).  However, in most other cases, the 
antiviral potency of IFN-λ against several viruses seems to be lower than that of IFN-α 
(Kotenko et al., 2003; Li et al., 2009; Marcello et al., 2006; Meager et al., 2005; Mordstein et al., 
2008; Sheppard et al., 2003).  In addition, IFN-λ and IFN-α may induce distinct signal 
transduction and gene regulation kinetics (Maher et al., 2008; Marcello et al., 2006).   
 
 
Fig. 3. Intensity of the IFN signaling and biological activity induced by IFN-α and IFN-λ. 
B16 melanoma cells were treated with IFN-α or IFN-λ followed by STAT1 activation (A) and 
MHC class I antigen expression (B and C) analysis.  
Moreover, Type I IFN-α activates a plethora of innate and adaptive immune mechanisms 
that help eliminate tumors and viral infections. IFN-α immunoregulatory functions include 
major histocompatibility complex (MHC) class I expression in normal and tumor cells, 
activation of NK cells, dendritic cells (DCs) and macrophages, resulting in the promotion of 
adaptive immune responses against tumors and virally infected cells (Biron, 2001; Le Bon 
and Tough, 2002). The role of IFN-λ in the immune system is currently being investigated by 
several groups.  So far, data suggests that IFN-λ exerts immunomodulatory effects that 
overlap those of type I IFN. It has been recently demonstrated that human IFN-λ1 (IL-29) 
modulates the human cytokine response (Jordan et al., 2007a).  IFN-λ1 treatment of whole 
peripheral blood mononuclear cells (PBMC) up-regulated the expression of IL-6, IL-8, and 
IL-10 but not IL-1 or TNF.  This IFN-λ-induced cytokine production was inhibited by IL-10. 
By examination of purified cell populations, it was also shown that IFN-λ1 activated 
monocytes and macrophages, rather than lymphocytes, resulting in the secretion of the 
above panel of cytokines, suggesting that IFN-λ1 may be an important activator of innate 
immune responses particularly at the site of viral infections (Jordan et al., 2007a).  IFN-λ1 
was also shown to possess immunoregulatory functions on T helper 2 (Th2) responses by 
markedly inhibiting IL-13. However, only moderate effect was observed on IL-4 and IL-15, 
the other important cytokines in the Th2 response. (Dai et al., 2009; Jordan et al., 2007b; 
Srinivas et al., 2008). This immunoregulatory function was enhanced through the expression 
of IFN-λR1 on CD4+ T cells (Dai et al., 2009).  These findings correlate with data suggesting 
that IFN-λ may have an immunoprotective role against asthma, the allergy disease caused 
by an exaggerated Th2 response (Bullens et al., 2008; Johnston, 2007; Li et al., 2009).   
Similar to IFN-α, IFN-λ produced by DCs, in response to Toll-like receptor (TLR) 
stimulation, was found to have specific effects on DC differentiation and maturation (Coccia 
et al., 2004), which include only partial maturation of DCs, upregulation of MHC class I and 
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et al., 2004), which include only partial maturation of DCs, upregulation of MHC class I and 
 
Targets in Gene Therapy 
 
282 
II molecules, and no induction of co-stimulatory molecules (Li et al., 2009; Mennechet and 
Uze, 2006). During their differentiation from monocytes, DCs acquire IFN-λ responsiveness 
through the expression of IFN-λR1. Interestingly, DCs treated with IFN-λ promoted the 
generation of tolerogenic DCs and the IL-2 dependent proliferation of Foxp3-expressing 
CD4+CD25+ regulatory T cells (Tregs) (Mennechet and Uze, 2006). More recently, Morrow 
and coll. have demonstrated through DNA vaccination with plasmids encoding IFN-λ3 (IL-
28B) and IL-12, that IFN-λ3, just like IL-12, is able to enhance adaptive immunity. However, 
in contrast to IL-12, IFN-λ3 reduces regulatory T-cell populations.  They also showed that 
unlike IL-12, IFN-λ3 is able to increase the percentage of splenic CD8+ T cells in vaccinated 
animals and that IFN-λ3 can completely protect mice from death following a lethal influenza 
challenge (Morrow et al., 2009). These studies altogether highlight the strong candidacy of 
IFN-λ as a potential novel immunotherapeutic agent. 
In addition to antiviral and immunomodulatory activities, type I IFNs demonstrate 
antiproliferative activities in most cell lines, while this activity seems to be restricted with 
IFN-λs (Li et al., 2009; Meager et al., 2005). Type I IFNs have been shown to induce apoptosis 
in tumor cells.  Yet, the molecular mechanisms mediating cell death in response to these 
IFNs remain to be fully explained.  By binding to their corresponding cellular receptor 
complexes, IFNs induce a quick and potent signaling which leads to the expression of more 
than 300 IFN-stimulated genes (ISGs) (Der et al., 1998; Doyle et al., 2006; Marcello et al., 
2006). Many ISGs encode proteins that have been implicated in apoptosis (Clemens, 2003; 
Kalvakolanu, 2004). Unlike IFN-α, IFN-λs do not inhibit the proliferation of several cell lines 
including Daudi cells (a B-lymphoblastoid cell line from Burkitt’s lymphoma), which 
strongly respond to type I IFNs in an antiproliferative assay (Kotenko et al., 2003; Meager et 
al., 2005; Sheppard et al., 2003; Uze and Monneron, 2007). However, it was demonstrated 
that IFN-λs do inhibit the proliferation of few tumor cell lines, such as the LN319 human 
glioblastoma cell line (Meager et al., 2005) and of cells constitutively expressing high levels 
of IFN-λR1 (Dumoutier et al., 2004). The antiproliferative effects of IFN-λ have been 
demonstrated in various tumor cell lines that express ectopic or endogenous IFN-λ receptors 
(Brand et al., 2005; Meager et al., 2005; Zitzmann et al., 2006). Therefore, the ability of IFN-λs 
to induce antiproliferative activity in cells depends on the level of IFN-λR1 expression. 
It has been reported that IFN-λ signaling in colorectal adenocarcinoma HT29 cells led to 
caspase activation, externalization of phosphatidylserine (PS), and DNA fragmentation, 
resulting in subsequent apoptosis (Li et al., 2008).  This study provided evidence for the first 
time that type III IFNs, alone or in combination with other stimuli, have the potential to 
induce apoptosis.  Moreover, another recent study revealed that IFN-α and IFN-λ differ in 
their antiproliferative effects and this was correlated with a difference in the duration of 
JAK/STAT signaling activity between the two IFNs and prolonged ISG expression upon 
IFN-λ treatment (Maher et al., 2008). Using the human keratinocyte HaCaT cell line that 
expresses receptors for both IFN-α and IFN-λ, they found that IFN-λ induced a more 
pronounced growth inhibitory effect than IFN-α. IFN-λ was also more efficient than IFN-α 
in inducing an antiproliferative effect that overlapped with the activation of apoptosis. 
Prolonged duration of IFN-λ-induced STAT activation and ISG expression could account for 
the enhanced antiproliferative and pro-apoptotic effects observed in HaCaT cells, effects not 
seen upon treatment with high doses of IFN-α (Maher et al., 2008).  Interestingly, a study 
has shown that IFN-λ can induce the growth of multiple myeloma cells and antagonize the 
dexamethasone-induced cell death in these cells (Novak et al., 2008). IFN-λ-mediated cell 
growth of multiple myeloma cells was MAPK dependent (Novak et al., 2008). High level of 
 
Emergence of IFN-lambda as a Potential Antitumor Agent 
 
283 
IFN-λ was found in the malignant bone marrow microenvironment, implying that IFN-λ 
may play a direct role on multiple myeloma development.  
4.2 Role of endogenous IFN-λ in viral protection 
The availability of IFN-λR1 knock-out mice allowed to investigate the role of type III IFNs in 
vivo. By using those mice, Mordstein and coll. showed for the first time the contribution of 
IFN-λ in the innate immunity against the influenza virus (Mordstein et al., 2008). Later, they 
found that IFN-λ played an important role in the defense against other pathogens that infect 
the respiratory tract, such as the respiratory syncitial virus, the metapneumovirus and the 
severe acute respiratory syndrome (SARS) coronavirus. However, the lassa fever virus 
which replicates in the liver, was not affected by the lack of IFN-λR1 (Mordstein et al., 2010). 
Although this study clearly demonstrated that IFN-λ played an important role in protecting 
the respiratory and gastrointestinal tracts against virus infection, in comparison with type I 
IFN, the protection provided by type III IFN remains limited. However, in combination, 
type I and type III may provide a better viral protection. When the response to both type I 
and type III is deficient, the mice are not able to clear the SARS coronavirus from the 
intestine as compared with mice in which type I or type III remains functional, implying that 
IFN-λ may strengthen the antiviral activity by acting as a first line of defense for the mucosa 
(Mordstein et al., 2008, 2010). 
4.3 Clinical application of IFN-λ 
The first use of IFN-λ in the clinic has started for hepatitis C. The phase 1b study has been 
conducted in patients with chronic genotype 1 hepatitis C virus infection ((HCV) (Muir et 
al., 2010)). Pegylated IFN-λ1 in combination or not with ribavirin (RBV, which belongs to a 
class of antiviral medications called the nucleoside analogues) has been used in this study to 
assess the efficacy and the potential cytotoxicity. The study was performed in 3 parts. The 
first part evaluated the pegylated IFN-λ as single agent for relapsed patients after IFN-α-
based treatment. The second part concerned the combination of pegylated IFN-λ and RBV in 
treatment-relapse patients. The third part evaluated pegylated IFN-λ in combination with 
RBV in treatment-naïve patients. In addition, different doses (from 0.5 to 3 microg/kg) of 
pegylated IFN-λ were used. Fifty-six patients were enrolled. 24, 25 and 7 patients were used 
respectively for part 1 to 3. The data showed an antiviral activity in all doses of pegylated 
IFN-λ tested. 29% of treatment-naïve patients achieved rapid virological response. As 
expected, due to the limited IFN-λR1 distribution, the treatment was well tolerated with few 
adverse effects. Minimal flu-like symptoms and limited hematologic suppression were 
reported. In summary, the authors concluded that weekly PEG-IFN-λ with or without daily 
RBV for 4 weeks is associated with a clear antiviral activity in patients with chronic HCV. 
However, this study lacks a direct comparison between IFN-λ and IFN-α and the influence 
of viral and patient genotypes. Now it is well accepted that the response to IFN-α or the 
natural clearance of HCV infection is depending on single nucleotide polymorphisms 
(SNPs), upstream of IFN-λ3, that could be used as biomarkers to help determine the 
treatment outcome (Kelly et al., 2011). The first genome-wide association studies (GWAS) in 
HCV infection were reported by Ge and coll. They evaluated the treatment outcome in a 
group of 1671 patients of mixed ethnicity, receiving pegylated-IFN-α and ribavirin. An 
association was discovered between sustained viral response (SVR) to treatment and a 
cluster of seven SNPs linked to the IFN-λ3 gene, with the most significant SNP (rs12979860) 
demonstrating high statistical significance (Ge et al., 2009). Many other studies have 
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replicated these findings, demonstrating the high link between IFN-λ3 and treatment 
outcome (Labie and Gilgenkrantz, 2010; Mangia et al., 2010; McCarthy et al., 2010; Montes-
Cano et al., 2010; Mosbruger et al., 2010; Rauch et al., 2010; Suppiah et al., 2009; Tanaka et 
al., 2009). However the mechanisms explaining this link remain to be determined. It is not 
clear yet if this SNP is associated with a constitutive production of IFN-λ that may play a 
role in HCV clearance and the success of IFN-α treatment. These results also suggest the 
therapeutic potential of the IFN-α and IFN-λ combination therapy as demonstrated for the 
hepatocellular carcinoma (HCC) mouse model (Lasfar et al., 2008). 
5. Emergence of IFN-λ as a new antitumor agent 
5.1 First report in animal model 
Although they engage distinct receptors, IFN-α and IFN-λ induce similar cell signaling 
(Figure 1). Since IFN-α is widely used in clinic to treat cancer, we have investigated the 
potential antitumor activity of IFN-λ by using the mouse B16 melanoma model. We have 
chosen this cancer model because melanoma is a very aggressive cancer and one of the 
therapeutic agents frequently used in the treatment of melanoma is IFN-α. Significant 
improvements in relapse-free and overall survival, with postoperative adjuvant IFN-α 
therapy, have been reported by large and randomized studies (Kirkwood et al., 1996, 2001; 
Moschos et al., 2005). However, the beneficial effect of IFN-α was only obtained when the 
patients received high doses (20 MIU/m2 intravenously five times per week). Studies with 
low doses of IFN-α have not shown significant increase in overall survival (Cascinelli et al., 
2001; Kleeberg et al., 2004). Usually, the dose for optimal antitumor activity is higher than 
the maximally tolerated dose. This dose-dilemma profoundly affects the acceptance of IFN-
α treatment by both the clinicians and the patients. The adverse effects associated with high 
doses of IFN-α include myelosuppression and nervous system disorders. These effects often 
compromise the beneficial antitumor effect, with premature discontinuation of the treatment 
or the reduction of the dose of IFN-α. Since virtually all the cells of the body respond to IFN-
α, it is not surprising that the patients develop numerous side effects. Making a dissection 
between the beneficial and harmful effects of IFN-α is a very challenging task, which 
requires more investigation of the interferon system. To investigate the antitumor effect of 
IFN-λ in melanoma, we  used a gene therapy approach, consisting on the delivery of the 
IFN-λ gene to tumor cells. Gene transfer into tumor cells is a very useful approach to test the 
effectiveness of cytokines in animal cancer models. This approach does not require a 
production and the purification of the protein. The secretion of constant amounts of various 
cytokines by transduced tumor cells at the site of tumor growth could elicit more effective 
antitumor responses by acting directly on the tumor microenvironment. Another advantage 
of the cytokine gene transfer into tumor cells versus systemic administration is the potential 
of inducing the antitumor effect without eliciting the side effects associated with the 
systemic administration of high doses of cytokines.  
To investigate the potential antitumoral role of IFN-λ, we first evaluated the response of B16 
melanoma cells to IFN-λ, by analyzing STAT1 activation and MHC class I antigen 
expression.  In comparison with IFN-α, we have found that IFN-λ induces weak STAT1 
phosphorylation but strong stimulation of MHC class I antigen expression, indicating a 
difference between IFN-α and IFN-λ in the link intensity of cell signaling/biological activity 
(Figure 3). This result warrants further investigation, by comparing the response to IFN-α 
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and IFN-λ. As shown in this figure, although IFN-λ induces weak STAT1 activation, the 
biological activity can be very strong. By using gene transfer as illustrated in Figure 4, we 
next engineered B16 cells, which constitutively produced mIFN-λ (B16.IFN-λ cells). In 
response to their secretion of IFN-λ, B16.IFN-λ cells exhibited constitutively high levels of 
MHC class I antigen expression. All the C57BL/6 syngeneic mice injected with parental B16 
cells developed tumors. However, the constitutive production of mIFN-λ by B16.IFN-λ cells 
markedly affected tumorigenicity of the cells. B16.IFN-λ cells were either rejected by the 
host or grew at a slower rate than control parental B16 cells. The antitumor effect of IFN-λ 
was dose dependent. B16.IFN-λ cells also inhibited the growth of parental B16 cells when 
both cell types were injected together (Lasfar et al., 2006). We also used B16.IFN-λ Res. cells 
which in addition to their constitutive IFN-λ secretion,  are completely resistant to IFN-λ as 
demonstrated by the lack of IFN-λ–induced MHC class I antigen expression (Table 1). 
Interestingly, similar to B16.IFN-λ cells, we have found a reduction of the tumorigenicity of 




Fig. 4. IFN-λ gene transfer. Tumor cells were engineered to constitutively produce IFN-λ. 
Immunocompetent syngeneic mice were injected subcutaneously with the engineered tumor 
cells and monitored for tumor development.  
Following our report on the characterization of the mouse IFN-λ system and the potent 
antitumor activity of IFN-λ in the B16 mouse melanoma model, independent groups 
confirmed the role of IFN-λ as antitumoral agent in melanoma and other tumor models. To 
demonstrate the antitumor activity of IFN-λ, Sato and coll. (Sato et al., 2006) used the mouse 
melanoma B16F0 and B16F10 and the Colon26 cell lines transfected with IFN-λ2 cDNA. The 
IFN-λ-transduced B16F0 cells showed an increased activity of caspase 3/7, an induction of 
p21 and a dephosphoryation of Rb, which triggered a cell cycle arrest and apoptosis. These 
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events obtained in vitro, were apparently associated with a tumor growth delay, observed in 
vivo after the injection of the B16F0 cells, transduced with IFN-λ. A delay in tumor growth 
was also observed after the administration of the Colon26 cells transduced with IFN-λ.  By 
using the B16F10 cell line, which represents metastatic mouse melanoma cells, the authors 
showed that the overexpression of IFN-λ significantly inhibited lung metastasis. In another 
study, to evaluate the antitumor activity of IFN-λ, Numasaki and coll. (Numasaki et al., 
2007) first transduced the mouse fibrosarcoma cells, MCA2005, with the retroviral vector 
PA317IL-28 (IFN-λ2). Following the injection of the engineered tumor cells to mice, the 
authors observed a significant antitumor and antimetastatic effect in mice inoculated with 
the MCA2005IL-28 in comparison with those injected with the parental tumor cells. 
 
 
Table 1. Constitutive production of IFN-λ-induced tumor alteration. In vitro (Top) and in 
vivo (Bottom) analysis of the engineered B16 cells constitutively producing IFN-λ (B16.IFN-λ 
cells and B16.IFN-λ Res. cells). In contrast to the parental B16 and B16.IFN-λ cells, B16.IFN-λ 
Res. cells are completely resistant to IFN-λ, as indicated by MHC class I antigen expression 
unaffected by the presence of IFN-λ. HPF (High-Powered Field) 
5.2 Investigation of the antitumor activities of IFN-λ in comparison with those of IFN-α 
in a BNL mouse model of hepatocellular carcinoma (HCC) 
HCC is the most prevalent type of liver cancer.  It is the fifth most common solid tumor and 
the third leading cause of cancer-related death worldwide.  It is also the second most lethal 
cancer with the five-year survival rate below 9% (Farazi and DePinho, 2006; Lau and Lai, 
2008; Sherman, 2005).  Treatment options for HCC are limited mainly because of the 
inefficiency of existing anticancer chemotherapeutic drugs against HCC.  Unfortunately, 
due to a lack of biomarkers and screening for HCC, most patients are diagnosed at 
advanced stages of the disease and do not meet strict selection criteria for potentially 
curative surgical tumor resection or orthotopic liver transplantation (OLT) (Mazzaferro et 
al., 2008, 2009; Taketomi et al., 2008) In patients with unresectable HCC and preserved liver 
function, transarterial chemoembolization (TACE) has been shown to prolong survival.  
However TACE is rarely curative, and progression-free survival beyond 24 months is not 
frequent (Georgiades et al., 2008; Lau and Lai, 2008). For patients with advanced disease, 
systemic chemotherapy is of limited benefit because of the resistance of HCC to existing 
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anticancer drugs and the fact that about 50% of patients with HCC die secondary to liver 
failure from cirrhosis (Di Bisceglie et al., 1998; Nagai and Sumino, 2008). HCC occurs most 
frequently in patients with cirrhosis as a result of chronic HBV and HCV infections, and 
alcohol abuse (El-Serag, 2002; Sherman, 2005).  Although the link between the cancer and 
the viral infection is not fully understood yet, there is some suggestion that viral infection 
interferes with signal transduction and consequently, disrupts the normal, controlled 
growth of cells. 
Since IFN-α is used in the clinic for the treatment of chronic HCV  and HBV  infections, 
several studies evaluated the effect of IFN treatment on the incidence of HCC (Sherman, 
2005). It was previously shown that the systemic administration of high doses and long-term 
IFN-α into nude mice bearing human HCC with high metastatic potential, following 
curative resection, inhibited tumor metastasis and recurrence (Wang et al., 2003).  The 
majority of clinical studies also concluded that IFN therapy, alone or in combination with 
ribavirin, decreased the incidence of HCC, particularly in patients with sustained virological 
response (Fattovich et al., 1998; Lin et al., 2007; Omata et al., 2005; Yu et al., 2006). Therefore, 
IFN alone or, perhaps, in combination with other drugs can be used as a preventive therapy 
against the development of HCC in HCV and HBV-infected patients.  However, numerous 
side effects limit the overall tolerability of IFN-α, particularly in patients with cirrhosis 
(Llovet et al., 2000; Lo et al., 2007; Ueshima et al., 2008). 
In the following part of this section, we describe our findings on the antitumor properties of 
IFN-λ on the BNL mouse model of HCC. To evaluate the antitumor activities of both IFN-λ 
and IFN-α, we used a gene therapy approach as previously described (Lasfar et al., 2006). 
We expressed IFN-λ and IFN-α genes under a strong constitutive promoter in BNL cells and 
selected stable cell lines, BNL-IFN-λ and BNL-IFN-α, constitutively expressing IFN-λ and 
IFN-α (Abushahba et al., 2010). Since the constitutive expression of IFN-λ at the tumor site 
was found to affect the tumorigenicity of B16 melanoma cells in vivo (Lasfar et al., 2006), we 
examined whether similar effects of IFN-λ would be displayed in the case of BNL hepatoma. 
Mice injected with BNL.vector or parental BNL cells developed tumors in 4 to 6 weeks, 
whereas the tumor appearance for BNL.IFN-λ cells was significantly delayed.  Similar 
effects were obtained in mice inoculated with BNL.IFN-α cells.  These experiments 
demonstrated that constitutive expression of IFNs at the tumor site resulted in the delay of 
tumor growth in vivo. Interestingly, we found that IFN-α and IFN-λ exhibited similar 
antitumor activities (Abushahba et al., 2010). 
6. Antitumor mechanisms of IFN-α and IFN-λ 
6.1 Antitumor mechanisms of IFN-α 
Despite the antiproliferative effects of IFN-α on cells, it seems that the direct effects on 
tumor cells may not be the major mechanism by which IFN-α displays its antitumor activity. 
IFN-α can act indirectly on the tumor by inhibiting angiogenesis which is induced by the 
tumors and is required to promote their growth and metastasis (Sidky and Borden, 1987). In 
mice bearing human tumors, it was clearly demonstrated that the antitumor activity of IFN-
α is associated with the inhibition of tumor angiogenesis in bladder carcinoma (Dinney et 
al., 1998) and prostate cancer (Dong et al., 1999). The involvement of the immune system in 
the antitumor mechanism of IFN-α was strongly suggested by Gresser and coll. Early 
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events obtained in vitro, were apparently associated with a tumor growth delay, observed in 
vivo after the injection of the B16F0 cells, transduced with IFN-λ. A delay in tumor growth 
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studies in tumor models have shown that an intact immune system was essential in IFN-α-
induced antitumor activities.  The inhibition of FLC (Friend Leukemia Cells) by IFN-α in 
mice was shown to depend on the activation of host cells, such as NK cells and macrophages 
(Gresser et al., 1994). Both host humoral and cellular immune mechanisms were involved in 
the continued suppression of Friend erythroleukemia metastases after IFN-α treatment in 
mice (Gresser, 1991). In addition, effective adaptive immunotherapy was observed in a T-
cell lymphoma model, after the injection of tumor-sensitized spleen cells and IFN-α. By 
using antibodies against different immune cell populations, it has been shown that CD4+ T 
lymphocytes and CD8+ T lymphocytes were the major effectors in the antitumor activities 
induced by IFN-α (Kaido et al., 1994; 1995). 
6.2 Antitumor mechanism of IFN-λ  
Although IFN-α and IFN-λ signal quite similarly (Figure 1), the mechanisms underlying the 
antitumor activity of IFN-λ may be qualitatively different from IFN-α. As previously 
described, we initially investigated whether type III IFNs also possessed antitumor activities 
utilizing a gene therapy approach in the B16 melanoma model.  B16 melanoma cells that 
were engineered to constitutively secrete IFN-λ and were either sensitive or resistant to IFN-
λ, were transplanted into two groups of mice. Potent antitumoral activity was observed for 
both groups of mice.  Since secreted IFN-λ did not affect the proliferation rate of B16 
melanoma cells in vitro, studies in the B16 melanoma model suggested that IFN-λ acted 
through host mechanisms to elicit its antitumor activity (Lasfar et al., 2006).  However, we 
did not observe a significant long-lasting immunity, implying that there may be a lack of 
effective adaptive immunity in the mice which rejected the tumor.  On the other hand, we 
noticed a reduction in tumor vascularity in the presence of IFN-λ, suggesting a potential role 
of IFN-λ in the tumor microenvironment (Lasfar et al., 2006). Since we found that 
keratinocytes are highly sensitive to IFN-λ and they are known to interact with melanocytes, 
the cells from which the melanoma originates, we suggested that IFN-λ delivery to the 
tumor microenvironment may affect the function of the keratinocytes as well as other 
stroma cells thereby promoting inhibition of tumor growth (Lasfar et al., 2006) (Figure 5).   
Natural Killer (NK) cells, the major effectors of innate immunity, could also be recruited to 
the tumor microenvironment and help destroy the tumor cells. Two groups have reported 
that NK cells played a role in the antitumor mechanisms of IFN-λ. Sato and coll. (Sato et al., 
2006) have described the involvement of NK cells in melanoma and colon cancer antitumor 
responses. They have shown that transient transduction of B16 cells with mouse IFN-λ 
cDNA, enhanced MHC class I and Fas expression, suppressed cell proliferation by inducing 
increased caspase-3/7 activity and increased p21Waf1/Cip1 levels and dephosphorylated Rb 
(Ser780) in vitro (Sato et al., 2006).  This meant that IFN-λ was able to induce cell cycle arrest 
and apoptotic cell death in vitro.  In addition, they have demonstrated that overexpression of 
IFN-λ inhibited local and pulmonary metastatic tumor formation in vivo.  Depletion of NK 
cells, by injecting an anti-asialo GM1 antibody before tumor cells injection, revealed that NK 
cells are important in this IFN-λ-mediated tumor growth inhibition in vivo, suggesting that 
IFN-λ activated the innate immune response (Sato et al., 2006). Numasaki and coll. 
(Numasaki et al., 2007) have also implicated NK cells, polymorphonuclear neutrophils and 
CD8+ T cells in the antitumoral activity induced by IFN-λ in the MCA205 murine 
fibrosarcoma mouse model. Inoculation of MCA205-IFN-λMCA205-IFN-λ cells, into mice 
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enhanced IFN-γ production and cytotoxic T cell activity in the spleen.  The antitumor 
activity of IFN-λ was partially dependent on IFN-γ. In addition, IFN-λ increased the total 
number of splenic NK cells in severe combined immunodeficiency (SCID) mice, enhanced 
IL-12-induced IFN-γ production in vivo, and expanded spleen cells in C57BL/6 mice. 
Furthermore, they reported that IL-12 augmented the IFN-λ-mediated antitumor activity in 
the presence or absence of IFN-γ. Based on their findings, they suggested that IFN-λ is able 
to induce both innate and adaptive immune responses to suppress in vivo tumor growth 
(Numasaki et al., 2007).  
 
 
Fig. 5. Potential role of IFN-λ in the tumor, microenvironment. The IFN-λ delivered to the 
tumor microenvironment may induce its potent antitumor activity by modulating the 
interaction between the tumor cells and the normal cells, including the recruited immune 
cells. 
Our recent study in the BNL hepatoma model also revealed that NK cells are implicated in 
the antitumor activity induced by IFN-λ and probably more potently than in the antitumor 
activity induced by IFN-α.  However, in contrast to IFN-α, we did not detect any response 
after in vitro treatment of NK cells by IFN-λ, suggesting that IFN-λ may activate other cells, 
which then mediate NK cell activation (Abushahba et al., 2010). There was also a marked 
NK cell infiltration in IFN-λ producing tumors.  In addition, IFN-λ and, to a lesser extent, 
IFN-α enhanced immunocytotoxicity of splenocytes primed with irradiated BNL cells.  
Splenocyte cytotoxicity against BNL cells was dependent on IL-12 and IFN-γ, and mediated 
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studies in tumor models have shown that an intact immune system was essential in IFN-α-
induced antitumor activities.  The inhibition of FLC (Friend Leukemia Cells) by IFN-α in 
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lymphocytes and CD8+ T lymphocytes were the major effectors in the antitumor activities 
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melanoma cells in vitro, studies in the B16 melanoma model suggested that IFN-λ acted 
through host mechanisms to elicit its antitumor activity (Lasfar et al., 2006).  However, we 
did not observe a significant long-lasting immunity, implying that there may be a lack of 
effective adaptive immunity in the mice which rejected the tumor.  On the other hand, we 
noticed a reduction in tumor vascularity in the presence of IFN-λ, suggesting a potential role 
of IFN-λ in the tumor microenvironment (Lasfar et al., 2006). Since we found that 
keratinocytes are highly sensitive to IFN-λ and they are known to interact with melanocytes, 
the cells from which the melanoma originates, we suggested that IFN-λ delivery to the 
tumor microenvironment may affect the function of the keratinocytes as well as other 
stroma cells thereby promoting inhibition of tumor growth (Lasfar et al., 2006) (Figure 5).   
Natural Killer (NK) cells, the major effectors of innate immunity, could also be recruited to 
the tumor microenvironment and help destroy the tumor cells. Two groups have reported 
that NK cells played a role in the antitumor mechanisms of IFN-λ. Sato and coll. (Sato et al., 
2006) have described the involvement of NK cells in melanoma and colon cancer antitumor 
responses. They have shown that transient transduction of B16 cells with mouse IFN-λ 
cDNA, enhanced MHC class I and Fas expression, suppressed cell proliferation by inducing 
increased caspase-3/7 activity and increased p21Waf1/Cip1 levels and dephosphorylated Rb 
(Ser780) in vitro (Sato et al., 2006).  This meant that IFN-λ was able to induce cell cycle arrest 
and apoptotic cell death in vitro.  In addition, they have demonstrated that overexpression of 
IFN-λ inhibited local and pulmonary metastatic tumor formation in vivo.  Depletion of NK 
cells, by injecting an anti-asialo GM1 antibody before tumor cells injection, revealed that NK 
cells are important in this IFN-λ-mediated tumor growth inhibition in vivo, suggesting that 
IFN-λ activated the innate immune response (Sato et al., 2006). Numasaki and coll. 
(Numasaki et al., 2007) have also implicated NK cells, polymorphonuclear neutrophils and 
CD8+ T cells in the antitumoral activity induced by IFN-λ in the MCA205 murine 
fibrosarcoma mouse model. Inoculation of MCA205-IFN-λMCA205-IFN-λ cells, into mice 
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enhanced IFN-γ production and cytotoxic T cell activity in the spleen.  The antitumor 
activity of IFN-λ was partially dependent on IFN-γ. In addition, IFN-λ increased the total 
number of splenic NK cells in severe combined immunodeficiency (SCID) mice, enhanced 
IL-12-induced IFN-γ production in vivo, and expanded spleen cells in C57BL/6 mice. 
Furthermore, they reported that IL-12 augmented the IFN-λ-mediated antitumor activity in 
the presence or absence of IFN-γ. Based on their findings, they suggested that IFN-λ is able 
to induce both innate and adaptive immune responses to suppress in vivo tumor growth 
(Numasaki et al., 2007).  
 
 
Fig. 5. Potential role of IFN-λ in the tumor, microenvironment. The IFN-λ delivered to the 
tumor microenvironment may induce its potent antitumor activity by modulating the 
interaction between the tumor cells and the normal cells, including the recruited immune 
cells. 
Our recent study in the BNL hepatoma model also revealed that NK cells are implicated in 
the antitumor activity induced by IFN-λ and probably more potently than in the antitumor 
activity induced by IFN-α.  However, in contrast to IFN-α, we did not detect any response 
after in vitro treatment of NK cells by IFN-λ, suggesting that IFN-λ may activate other cells, 
which then mediate NK cell activation (Abushahba et al., 2010). There was also a marked 
NK cell infiltration in IFN-λ producing tumors.  In addition, IFN-λ and, to a lesser extent, 
IFN-α enhanced immunocytotoxicity of splenocytes primed with irradiated BNL cells.  
Splenocyte cytotoxicity against BNL cells was dependent on IL-12 and IFN-γ, and mediated 
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by dendritic cells.  In contrast to NK cells, isolated from spleen, CD11c+ and mPDCA+ 
dendritic cells responded directly to IFN-λ, suggesting that the effects of IFN-λ on NK cells 
are mediated by other IFN-λ-responsive cells, such as DCs (Abushahba et al., 2010).  On the 
other hand, a significant decrease in CD4+CD25+Foxp3+ Tregs was observed in mice 
inoculated with BNL cells secreting IFN-α, whereas the moderate decrease in Tregs 
observed in mice receiving BNL cells secreting IFN-λ was not statistically significant 
(Abushahba et al., 2010).  Therefore, antitumor mechanisms activated by IFN-α and IFN-λ 
may differ; IFN-λ increased the number of NK cells at the tumor site whereas IFN-α had a 
stronger effect on Tregs in the BNL model. 
These studies altogether suggest that although IFN-α and IFN-λ signal quite similarly 
(Figure 1), differences exist in their biological potency, kinetics and the sets of target cells 
sensitive to IFN-λ and IFN-α. Therefore, these two types of IFNs may have distinct 
physiological functions. 
7. IFN-λ as a potential ally rather than alternative to IFN-α 
Unlike IFN-α, only a small subset of cells are sensitive to IFN-λ, implying that its potential 
clinical use may be associated with limited side effects. This presumption raises the question 
whether IFN-λ could be an alternative to IFN-α in cancer therapy. However, despite the 
severe and numerous side effects inherent to IFN-α treatment (Moschos et al., 2005), we 
believe that alternative treatment to IFN-α should be weighed first against the real benefits 
to patients in terms of overall survival and their tumor clearance. We have, demonstrated in 
the BNL hepatoma model that the combination of IFN-λ and IFN-α could achieve a stronger 
antitumor activity in comparison with the use of each IFN alone (Lasfar et al., 2008). The 
benefits of the combination therapy of IFN-λ and IFN-α have been demonstrated by both a 
gene therapy approach and  direct administration of IFNs to the mice bearing the tumors. 
The mice injected with BNL cells secreting both IFN-λ and IFN-α can completely reject the 
tumor, in contrast to the mice that only received the BNL.IFN-λ cells or the BNL.IFN-α cells. 
Furthermore, mice bearing established tumors and treated with exogenous IFN-λ and IFN-
α, showed a drastic tumor repression. This effect was observed when the IFNs were 
delivered locally and even at low doses. Therefore, we believe that IFN-λ is not simply 
acting like IFN-α, with reduced side effects, but can be combined with IFN-α to achieve 
efficient antitumor activity. Combination of IFN-λ with low doses of IFN-α, which are sub-
therapeutic but less toxic (Kleeberg et al., 2004), may improve IFN therapy and benefit 
cancer patients. Combinational therapy of IFN-λ and IFN-α may achieve ultimate antitumor 
activity by inducing complementary mechanisms directly on the tumor cells or by indirectly 
modulating the tumor microenvironment, thereby leading to the stimulation of the immune 
response against the tumor and the inhibition of tumor angiogenesis. By acting with 
different intensities on the same targets, IFN-λ and IFN-α may generate a high level of 
synergy, leading to a potent antitumor activity.  
8. Conclusion 
Similarly to IFN-α, IFN-λ has been shown to play an important role in cancer and viral 
disease treatment. Although the two IFNs act through an identical signaling pathway in the 
cell, the pattern of their activity seems to be different in vivo, implying that IFN-λ and IFN-α 
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are not redundant cytokines. By acting on some targets with different intensity, we believe 
that IFN-λ and IFN-α act in concert to better control tumor development in vivo. Therefore, 
to achieve better treatments for viral diseases or cancers, we believe that the development of 
a combination therapy rather than the use of each IFN alone will be more beneficial for the 
patients.  The combination of IFNs with other cytokines, growth factors, or their antagonists 
could also be a viable strategy for the improvement of the IFN therapy. Transforming 
Growth Factor-beta (TGFβ) which plays a dual role in cancer, mediating tumor suppresive 
activities at early stages and prooncogenic activities at later stages of tumor progression 
(Javelaud et al., 2008), could represent one potentially important modulator or mediator of 
the IFN response. In different cancers, inculding melanoma, several cellular pathways 
modulate the activity of TGFβ (Lasfar and Cohen-Solal, 2010). Understanding the potential 
crosstalks between IFN-α, IFN-λ and other cytokines or growth factors, such as TGFβ, could 
be rewarding and lead to new preclinical studies in animal models and new clinicals trials 
resulting in better cancer treatments. 
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1. Introduction 
In the last two decades an enormous progress has been made in research of gene therapy, 
translating this new therapeutic approach from preclinical level to a large number of clinical 
trials, which presented encouraging results in treatment of a number of different diseases, 
from a single gene disorders to a more complex diseases, such as cancer. According to the 
Journal of Gene Medicine, at present more than 1400 human clinical trials investigating 
effects of gene therapy have been conducted, over 2/3 for therapy of cancer 
(www.wiley.com/genmed/clinical). With the advances in the field of gene therapy, this 
new therapeutic tool is steadily gaining its acceptance also in clinical veterinary medicine. In 
the last decade, a number of gene therapy clinical trials have been conducted on companion 
animals, employing both viral and nonviral vectors and evaluating its effects primarily in 
oncologic, haematologic, musculoskeletal and cardiovascular diseases (Bergmann et al., 
2003; Bodles-Brakhop et al., 2008; Dow et al., 2005; Draghia-Akli et al. 2002; Herzog et al., 
2001; Huttinger et al., 2008; Jahnke et al., 2007; Kamstock et al., 2006; Kornegay et al., 2010; 
Ohshima et al., 2009; Pavlin et al., 2011; Siddiqui et al., 2007; Sleeper et al., 2010; Z. Wang et 
al., 2007). Such clinical trials on companion animals not only play an essential role for 
progress of veterinary medicine, but also provide invaluable data for human clinical 
research, which cannot be gained from strictly preclinical research on experimental animals. 
With gene therapy having versatile applications, different approaches have been developed, 
utilizing delivery of therapeutic genes into a variety of target tissues. The first reports on 
using skeletal muscle as a target for gene delivery have been published in the 1990's and 
since then, extensive evidence has been presented that skeletal muscle is a suitable target 
tissue for gene therapy (Wolff et al., 1990). The main advantages of skeletal muscle are high 
capacity of protein synthesis and post-mitotic status of muscle fibers which enable long-
lasting transgene expression. Muscle targeted transgene delivery can lead to either local 
intramuscular secretion or systemic delivery of transgene products, thus having potential 
for treatment of both muscular and non-muscular disorders. The clinical applications of 
muscle targeted gene therapy are mainly correction of gene deficits in the muscle tissue (e.g. 
muscle dystrophies), intravascular release of therapeutic proteins resulting in expansion of 
this therapy on systemic level (e.g.immunomodulation) and DNA vaccination against tumor 
antigens or infectious agents. Intramuscular gene therapy in veterinary medicine has 
already been successfully applied for a variety of indications in a number of different animal 
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species, for example in cattle and sheep (Howell et al., 2008; Mena et al., 2001; Tollefsen et 
al., 2003), horses (Brown et al., 2008), pigs (Brown et al., 2004; Gravier et al., 2007) as well as 
cats (Brown et al., 2009; Ross et al., 2006; Walker et al, 2005) and dogs. In dogs mainly ex vivo 
delivery approach and viral vectors have been used in different disease models, primarily 
for treatment of hemophilia B, muscle dystrophies and in therapy of ischemic heart disease 
(Arruda et al. 2010; Banks & Chamberlain, 2008; Dixon & Spinale, 2009; Hasbrouck & High, 
2008; Haurigot et al., 2010; Herzog et al., 2001; Katz et al., 2010; Ohshima et al., 2009; L. 
Wang & Herzog, 2005; Z. Wang et al., 2007, 2009). 
The most straightforward introduction of foreign transgenes into skeletal muscle is simple 
intramuscular injection of naked plasmid DNA, which can result in a sustained transgene 
expression (Budker et al., 2000; Lu et al., 2003; Wolff et al., 1990). The main disadvantage of 
this method, which severely limits its therapeutic potential, is low transfection efficiency 
and pronounced variability of inter-individual levels of gene expression (Mir et al., 1999). 
Both described limitations of this gene delivery technique can be ameliorated by different 
methods, one of them being electroporation. 
Electroporation is a physical method for delivery of various molecules into the cells by 
transiently increasing permeability of cell membrane with application of controlled external 
electrical field to the target cells (Neumann et al., 1982). It displays effectiveness for a broad 
spectrum of applications, in both in vitro and in vivo settings. In vitro it is already routinely 
used as a method for intracellular delivery of a variety of molecules, e. g. RNA, DNA, dyes, 
ions, chemotherapeutic drugs, etc. In vivo it has shown a great potential for two prospective 
therapeutic approaches in oncology, electrochemotherapy and electrogene therapy (EGT), 
both already used in clinical practice in both human and veterinary medicine (Cemazar et 
al., 2008; Daud et al. 2008; Kodre et al., 2005; Mir et al., 1998; Pavlin et al., 2011; Reed et al., 
2010; Sersa et al., 2000; Tozon et al., 2001, 2005). This method of transgene delivery can be 
applied to almost any tissue in a living organism, with research focused primarily on tumor 
tissue, skin and skeletal muscle (Cemazar & Sersa, 2007). Electroporation based transfection 
of skeletal muscle or muscle targeted EGT has been proven to be one of the most efficient 
and simple methods among different nonviral delivery methods currently under 
investigation (Cemazar & Sersa, 2007; Gehl et al., 1999). It combines injection of therapeutic 
plasmid DNA into the muscle with subsequent electroporation of the target tissue, resulting 
in dramatically, up to 2000-times, increased long-term local gene expression lasting more 
than one year (Aihara & Miyaziki et al., 1998; Mir et al., 1999; Tevz et al., 2008).  
In the last few years, the number of reports on successful intramuscular EGT in dogs is 
steadily increasing. Therapeutic genes, delivered into canine skeletal muscle with this 
technique are genes encoding growth hormone releasing hormone (GHRH) (Bodles-
Brakhop et al., 2008; Brown et al., 2009; Draghia-Akli et al., 2002), human coagulation factor 
IX (hF.IX) (Fewell et al., 2001) and interleukin-12 (IL-12) (Pavlin et al., 2008). These studies 
showed a considerable clinical effect of intramuscular EGT in canine patients. GHRH EGT 
resulted in dramatically improved clinical condition of dogs with cancer, resulting in 
prolonged life span and improved quality of life (Bodles-Brakhop et al., 2008; Draghia-Akli 
et al., 2002). In dogs with chronic renal failure the same therapy improved kidney function 
and anemia associated with kidney disease, leading to overall improved health and survival 
rate (Brown et al., 2009). Intramuscular hF.IX EGT led to significant increase in levels of 
hF.IX in dogs, which can be predicted to have therapeutic effect in animal models of 
hemophilia B (Fewell et al., 2001). An important aspect of these studies is the fact that the 
procedure was successfully performed on both healthy and diseased dogs, demonstrating 
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that even debilitated, cachectic and immunocompromised animals are capable of systemic 
shedding of transgenes resulting in clinical effect of intramuscularly delivered therapeutic 
genes. 
IL-12 is a heterodimeric protein composed of two covalently linked subunits, a 35 kDa light 
chain (also known as p35 or IL-12α) and a 40 kDa heavy chain (known as p40 or IL-12). The 
discovery of IL-12 in 1989 revealed its strong effect on both innate immune system through 
induction of IFN-γ production from natural killer (NK) cells as well as on adaptive immune 
system through generation of cytotoxic T Lymphocytes (Kobayashi et al., 1989; Trinchieri et 
al., 1992). Based on these biological actions it was predicted that this cytokine is required for 
resistance to bacterial and intracellular parasites, as well as for the establishment of organ-
specific autoimmunity (Trinchieri, 2003) and was considered that it shows possible 
therapeutic potential for treatment of diseases, which would  favorably respond to its 
immunomodulating actions. With the additional discovery of its antiangiogenic effects 
(Voest et al., 1995), IL-12 became one of the most promising cytokines for treatment of 
malignant diseases. 
A model of mechanisms involved in the antitumor effects of IL-12 predict that IL-12 directly 
activates cells of the adaptive (CD4+ and CD8+ T cells) and innate arm of immunity by 
helping to prime T cells increasing their survival, enhancing T cell, and NK cell effector 
functions as well as promoting induction of IFN-γ secretion. IFN-γ in turn acts directly on 
tumor cells and other cell components within the tumor, by enhancing recognition of tumor 
cells by T cells through MHC class I processing and presentation and by modifications of 
extracellular matrix, which result in reduced antiangiogenesis and tumor invasion. The end 
result of these actions is impediment of tumor growth and ultimately eradication of the 
tumor. The first preclinical studies in the early 1990s with recombinant IL-12 protein in 
cancer treatment indeed showed its antitumor and antimetastatic activity (Brunda et al., 
1993; Nastala et al., 1994). Unfortunately, potent antitumor effect established on preclinical 
level did not translate to clinical setting, demonstrating only limited therapeutic effect with 
serious toxic side-effects in the first clinical studies (Atkins et al., 1997). Therefore new 
therapeutic approaches for in vivo delivery of IL-12 have been investigated, with gene 
transfer of IL-12 introducing safer and more effective treatment method compared to 
systemic application of recombinant protein. 
As one of therapeutic gene delivery methods, IL-12 EGT has been utilized in a number of 
different tumor models both on preclinical level and in clinical trials (Cemazar et al., 2010). 
Using electroporation, the therapeutic gene has been delivered into tumor tissue or skeletal 
muscle and EGT has been used either as a single therapy or in combination with other 
therapeutic genes and agents (e.g. IL-18, IL-27, herpes virus thymidine kinase, tetanus toxin 
fragment C) or different treatment methods, e.g. electrochemotherapy or radiotherapy 
(Cemazar et al., 2010; Kamensek & Sersa, 2008). These studies established that IL-12 EGT 
shows remarkable local and systemic antitumor effects, including significant growth delay 
and even achieving complete long-term regression of treated tumors, induction of long-term 
antitumor immunity, antimetastatic activity and prolongation of survival in treated animals. 
Direct antitumor effect in established tumors is generally better achieved with local 
intratumoral delivery of therapeutic gene, whereas intramuscular delivery results especially 
in good antimetastatic activity (Hanna et al., 2001; Lee et al., 2003; Li et al., 2005; Lucas et al., 
2002; Tevz et al., 2009).  
In preclinical studies the murine tumor models, which favorably responded to  IL-12 EGT, 
were melanoma (L.C. Heller & R. Heller, 2010),  lymphoma (Lee et al., 2003), soft tissue 
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sarcoma (Pavlin et al., 2009; Tevz et al., 2009) and a variety of different carcinomas (Cemazar 
et al., 2010; L.C. Heller et al., 2005). In clinical settings, intratumoral IL-12 EGT has been 
successfully used both in humans (Daud et al., 2008), as well as dogs (Cutrera et al., 2008; 
Pavlin et al., 2011; Reed et al., 2010). In all of presently published studies in tumor-bearing 
dogs, EGT has been performed with intratumoral delivery of IL-12 either alone (Chuang et 
al., 2009; Pavlin et al., 2011), or in combination with electrochemotherapy with bleomycin 
(Cutrera et al, 2008; Reed et al., 2010). The only published intramuscular IL-12 EGT in dogs 
was performed on healthy experimental beagles (Pavlin et al., 2008), showing feasibility, 
efficacy and safety of this approach. However, similar approach to IL-12 gene therapy in 
tumor-bearing companion animals has not yet been described. 
The aim of our study was to evaluate effects of intramuscular EGT with plasmid encoding 
human IL-12 in dogs with spontaneously occurring tumors. For this purpose, 1 mg of 
plasmid encoding human IL-12 was injected into m. semitendinosus of 6 patients with 4 
different tumor types.  Systemic transgene release and induction of IFN-γ response was 
determined by repeated measurements of hIL-12 and canine IFN-γ (cIFN-γ) in patients' sera. 
Possible side effects of the procedure were monitored with regular clinical examinations and 
determination of selected hematology and biochemistry parameters. 
2. Materials and methods 
2.1 Animals 
All animals participating in this study were referred to the Clinic for small animal 
medicine and surgery, Veterinary faculty of Ljubljana, University of Ljubljana, Slovenia, 
for evaluation of different types of spontaneously occurring tumors. Prior to inclusion, 
written consent for participation in the study was obtained from the owners and the study 
was approved by the Ethical Committee at the Ministry of Agriculture, Forestry and Food 
of the Republic of Slovenia (approval No. 323-451/2004-9). Six dogs of five different 
breeds corresponded to the inclusion criteria, their age ranging from 3 - 13 years (Table 1). 
Inclusion criteria for the study comprised at least one cytologically or histologically 
confirmed tumor nodule, good general health status of the animal with the basic 
hematology and biochemistry profile within reference limits and normal renal and 
cardiovascular function. In these animals intramuscular EGT was performed either as an 
adjuvant therapy to conventional therapeutical procedures, specific for each tumor type 
or as single therapy in a patient, where other therapies were not possible or acceptable by 
the owner.  
The study cohort comprised of three dogs with intermediately (i.e. grade II) (Figure 1) and 
poorly differentiated (i.e. grade III)  (Figure 2) mast cell tumors (MCT) in different clinical 
stages, and one dog with each: pulmonary histiocytic sarcoma (PHS) (Figure 3), 
osteosarcoma (OSA) (Figure 4) and mammary adenocarcinoma (MAC) (Table 1).  
One patient with MCT had metastatic disease involving local lymph nodes, and neither of 
patients had clinically detectable distant metastases. Two of the patients, one with MCT and 
one with mammary adenocarcinoma, had recurrent disease after marginal surgery. 
Histological or cytological diagnosis was established with examination of tumor biopsies 
and local lymph node fine needle aspiration in all tumors except OSA. Superficial tumors 
were measured in three perpendicular directions and their volume was calculated using the 
formula: V = a x b x c x π/6. 
 




Fig. 1. Patient no. 2, German boxer with grade II MCT in the gluteal region, which was 
surgically removed and at the same time intramuscular EGT performed in the contralateral 
leg. Arrow indicats the position of the tumor. 
 
 
Fig. 2. Fine needle aspirate of poorly differentiated MCT (gradus III) in patient no. 3 (Giemsa 
stain). A: Tumor aspirate; B: Aspirate of prescapular lymph node with mast cell infiltrations 
(metastases of primary tumor in local lymph nodes) (arrows). 
Before the treatment, staging of the disease according to modified WHO criteria in each 
patient was performed with clinical examinations, abdominal ultrasonography, thoracic 
radiography and basic bloodwork with biochemistry profile. Bloodwork included complete 
blood count with differential white blood cell count, performed with an automated laser 
hematology analyzer (Technicon H*1, Bayer, Germany) with species-specific software (H*1 
Multi-Species V30 Software). Determination of selected biochemistry parameters (serum 
concentrations of urea and creatinine and activity of serum alkaline phosphatase and 
alanine aminotransferase) was performed using automated chemistry analyzer Technicon 
RA-XT (Bayer, Germany).  Basal determinations of serum concentrations of human IL-12 
and canine IFN-γ using ELISA kits (Human IL-12 Quantikine ELISA kit and Canine IFN-γ 
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Fig. 3. Patient no. 4 with pulmonary histiocytic sarcoma. A: Thoracic radiograph of the 
patient depicting a solid mass in caudal lobe of the lungs (arrow); B: Fine needle aspirate of 
the tumor showing large round typically vacuolated histiocytic cells with high degree of 
anisokariosis (Giemsa stain; 400 times magnification). 
 
 
Fig. 4. Radiograph of pelvis in patient no. 5 showing predominantly osteolytic lesions on the 
iliac bone involving pars compacta (arrow), consistent with radiological presentation of 
osteosarcoma. 
Each patient received one EGT treatment. In five of six treated animals, EGT was performed as 
an adjuvant therapy to conventional treatment procedures (Table 1). In all three dogs with 
MCT, tumor nodules were marginally surgically removed prior to or concomitantly with EGT 
and two of these patients also received systemic chemotherapy, which consisted of either 
vincristine and methyprednisolone protocol (0.5 – 0.7 mg/m2 and 1 mg/kg, respectively) or 
CCNU (lomustine, 60 - 90 mg/m2). In the patient with mammary adenocarcinoma, the tumor 
was surgically removed with marginal excision before performing EGT. The patient with 
pulmonary histiocytic sarcoma received one cycle of CCNU chemotherapy (60 mg/m2), 
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applied two weeks after EGT. The only exception, in which EGT was performed as a single 
therapy was the dog with OSA in which location of the tumor (pelvis) precluded surgical 
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approximately 90% genetic identity based on amino acid sequence analysis (Buettner et al., 
1998). Furthermore, it has already been shown that in in vitro settings, human IL-12 activates 
proliferation of canine peripheral blood mononuclear cells (PBMC), consequently triggering 
a number of immune responses in canine PBMCs (Phillips et al., 1999). The plasmid was 
prepared using the Qiagen Maxi Endo-Free kit (Qiagen, Hilden, Germany), according to 
manufacturer's instructions and diluted to concentration of 1 mg/ml. Purified plasmid DNA 
was subjected to quality control and quantity determinations, performed by agarose gel 
electrophoresis and by means of spectrophotometry. 
2.3 Electrogene therapy procedure 
EGT was performed in the patients under general anesthesia, which was induced with 
propofol (Propoven 10 mg/ml, Fresenius Kabi Austria GmbH, Graz, Austria) and maintained 
with isoflurane (Forane, Abbott Laboratories LTD, Queensborough, UK). During the 
anesthesia the animals were receiving Hartmann's solution (B. Braun Melsungen AG, 
Melsunen, Germany) at the rate of 10 ml/kg of bodyweight/h. Hair on the right femoral 
region was clipped and the area surgically prepared, followed by intramuscular injection of 1 
mg of sterile solution of therapeutic plasmid into m. semitendinosus using 1 ml syringe with 22 
G needle (Figure 5). The position of the needle was slightly changed during the emptying of 
syringe, allowing the content of syringe to infiltrate the target tissue more uniformly. Ten 
minutes later, electric pulses were applied to plasmid infiltrated muscle with electric pulses 
generator CliniporatorTM (IGEA s.r.l., Carpi, Italy), using intramuscularly placed needle 
electrodes N-18-4B (IGEA s.r.l., Carpi, Italy), which consist of 2 arrays, each composed of 4 
electrodes with 4 mm distance between them. One HV pulse (600 V/cm, 100 μs) was 
delivered, followed by 4 LV pulses (80 V/cm, 100 ms, 1 Hz), with 1 second lag between the 
HV and LV pulses. Postsurgically, analgesia was provided to all dogs with single intravenous 
application of carprofen (Rimadyl, Pfizer Animal Health, Dundee, United Kingdom; 4mg/kg 
of bodyweight). When they fully recovered from anesthesia, they were released from the 
hospital. The treated femoral area was protected with suitable dressing in order to prevent 
licking and any possible contact of humans or animals with the electroporated region. 
2.4 Evaluation of response to the therapy 
Animals were examined 7, 14 and 28 days after EGT and monthly thereafter until any 
cytokine was detected in three consecutive samples. Each follow-up included the same 
diagnostic procedures as pre-therapy examination. At each examination, response to the 
therapy was evaluated with determination of serum concentrations of both previously 
mentioned cytokines, as described above, measurements of tumor nodules, where 
applicable and notification of possible side effects.  For evaluation of local effects, 
measurements of tumor nodules, where applicable, were performed. 
2.5 Evaluation of possible side effects of the procedure 
The possible occurrence of local and systemic side effects was evaluated at each follow-up 
with clinical examination of the patients, assessment of electroporated area for appearance 
of any adverse effects to either plasmid solution or electroporation of the tissue (e.g. 
swelling, erythema, pain, secretions, tissue necrosis etc). Blood samples were collected at 
each follow-up for the same bloodwork as during the staging of the disease prior to EGT in 
order to evaluate possible systemic toxicity of the procedure. 
 





Fig. 5. Intramuscular EGT procedure. A: Surgically prepared femoral region;  
B: Intramuscular application of plasmid solution; C: Transcutaneous intramuscular 
placement of needle electrodes. 
3. Results 
3.1 Response to the therapy 
In four out of six treated patients, serum concentrations of human IL-12 and/or canine IFN-
γ were detected, among these responders were all three patients with MCT and  the patient 
with PHS (Figure 6). Human IL-12 was detected in serum of a MCT patient 7 days after the 
procedure in concentration 17 pg/ml. IFN-γ was detected in single or multiple samples of 
all four mentioned patients, in concentrations ranging from 6.5 to 246.8 pg/ml, 4 to 28 days 
after the EGT procedure (Table 2). None of the patients had any detectable hIL-12 or IFN-γ 
in samples taken before the EGT procedures. 
In these four patients, surprisingly long survival times after EGT were achieved (Table 2), 
even though intramuscular IL-12 EGT did not have any effect on volumes of measurable 
tumor nodules. The dog with recurrent grade III MCT and lymph node metastases (clinical 
stage III) and the dog with PHS received additional chemotherapy 2 weeks after EGT; 
however the chemotherapeutic protocols were shortly discontinued due to severe side 
effects both patients developed. Even though the delivered chemotherapy in these two 
patients was inadequate to be effective and result in potential systemic antitumor effect, the 
dog with MCT survived 6 and the dog with PHS 8 months after the EGT procedure. The 
other two patients with detected IL-12 and/or IFN-γ had grade II and grade III MCTs. In the 
dog with grade II MCT (clinical stage I), the tumor nodule was marginally surgically 
removed and at the same time intramuscular IL-12 EGT performed, without any additional 
therapy. In the last dog, grade III MCT (clinical stage II) was treated with marginal excision 
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IL-12 EGT. These two patients had complete response to the therapy without local 






















Fig. 6. Graph representing percentage of treated animals, which responded to intramuscular 
EGT with systemic release of either cytokine (i.e. responders) versus animals without 
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Table 2. Response to the therapy in the treated patients. CR: complete response, PD: 
progressive disease, SD: stable disease 
In the other two patients (OSA and recurrent extensive MAC), neither cytokine was detected 
in serum at any time point after surgery. The dog with OSA survived for 165 days without 
17% 67%
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any additional treatment, except pharmacological pain management and was euthanized 
due to progression of pain, unresponsive to analgesic therapy, without any radiologically 
evident distant metastases. The patient with MAC was euthanized 2 months after EGT due 

































WBC 13.64 21.41 15.84 3.29 16.25 19.78 13.51 12.96 6.0-18.0 
RBC 8.45 6.85 6.12 6.55 7.10 6.35 6.89 6.59 5.1-8.5 
HCT 0.57 0.47 0.44 0.47 0.52 0.47 0.51 0.48 0.35-
0.55 
Neutro 8.43 16.48 12.27 1.29 12.31 17.25 10.48 12.2 3.0-11.8 
Urea 10.2 N/D 9.2 12.1 11.9 13.2 8.03 10.5 3.0-12.5 
Crea 107.4 N/D 90.6 111.3 114.9 109.5 96.9 118.1 44.2-
132.6 
SAP 92.6 77.0 113.3 N/D 107.5 112.9 671.1 287.9 25-117 
ALT 65.4 64.6 50.7 N/D 62.1 78.1 312.5 84.1 23-90 
Table 3. Hematological and biochemistry results in the patient No. 3 with high grade MCT, 
receiving IL-12 EGT, followed by two different systemic chemotherapy protocols, applied 
only partially due to induction of marked side effects. Clinically relevant abnormalities in 
the bloodwork subsided after discontinuation of chemotherapy, demonstrating that the 
toxicity was caused by chemotherapy and not IL-12 EGT WBC: white blood cells, RBC: red 
blood cell, HCT: hematocrit, Neutro: neutrophils, Crea: creatinine, SAP: serum alkaline 
phosphatase, ALT: alanine aminotransferase, V+M: vincristine/methylprednosolone 
chemotherapy protocol, N/D: not detected 
3.2 Side effects of the procedure 
In order to evaluate possible side effects at each follow-up, clinical examination as well as 
bloodwork with emphasis on kidney and liver function of patients was performed, due to 
known hepato- and nephrotoxicity of systemic recombinant IL-12 based therapy. We did not 
detect any side effects, which could be attributed to IL-12 toxicity, with hematological and 
biochemistry parameters staying within reference limits immediately after the procedure. In 
two of the patients marked hematological abnormalities were detected after induction of 
chemotherapy after EGT, which were attributed to the used chemotherapeutic agents, rather 
than EGT, since they were typical and well documented side effects of selected 
chemotherapy (i.e. leucopenia due to immunosuppression with vincristine and activation of 
serum alkaline phosphatase and alanin aminotrasferase due to hepatotoxicity of CCNU) 
(Table 3). In these two patients the abnormal values returned within the reference limits 
shortly after discontinuation of chemotherapy. 
EGT procedure also did not cause any local side effects, for example swelling or 
inflammation of the electroporated area despite local invasiveness of the procedure, which 
was performed with intramuscularly placed needle electrodes (Figure 7). 
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any additional treatment, except pharmacological pain management and was euthanized 
due to progression of pain, unresponsive to analgesic therapy, without any radiologically 
evident distant metastases. The patient with MAC was euthanized 2 months after EGT due 
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chemotherapy protocol, N/D: not detected 
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detect any side effects, which could be attributed to IL-12 toxicity, with hematological and 
biochemistry parameters staying within reference limits immediately after the procedure. In 
two of the patients marked hematological abnormalities were detected after induction of 
chemotherapy after EGT, which were attributed to the used chemotherapeutic agents, rather 
than EGT, since they were typical and well documented side effects of selected 
chemotherapy (i.e. leucopenia due to immunosuppression with vincristine and activation of 
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was performed with intramuscularly placed needle electrodes (Figure 7). 
 




Fig. 7. The site of intramuscular EGT (arrow) in patient with mammary adenocarcinoma 2 
days after the procedure without any signs of local side effects following invasive procedure 
4. Discussion 
Results of our study indicate that in canine cancer patients, intramuscular IL-12 EGT is a safe 
procedure, which can result in systemic shedding of human IL-12 and possibly trigger IFN-γ 
response in treated patients, leading to prolonged disease free period and survival of treated 
animals. 
In all of our patients, EGT was performed with a single intramuscular application of 1 mg of 
therapeutic plasmid encoding human IL-12, followed by delivery of one high voltage pulse 
and four low voltage pulses. Four out of six patients responded to the therapy with 
systemically detectable human IL-12 and/or IFN-γ concentrations. Systemic release of 
encoded transgene products in sufficient concentrations to elicit biological effect was 
already demonstrated after intramuscular EGT with different therapeutic genes in dogs 
(Brown et al., 2009; Draghia-Akli et al., 2002; Fewell et al., 2001; Pavlin et al., 2008; Tone et 
al., 2004). In preclinical studies, intramuscular IL-12 EGT displayed systemic antitumor 
effect due to systemic release of IL-12 and IFN-γ in several tumor models (Hanna et al., 2001; 
Lee et al., 2003; Lucas et al., 2002, 2003; Tevz et al., 2009; Zhu & Li, 2008). Compared to these 
studies, we achieved relatively low systemic concentrations of IL-12, whereas the serum 
concentrations of IFN-γ were comparable to concentrations achieved in experimental 
animals (Lucas et al., 2002; Tevz et al., 2009).  
It is possible that more pronounced response to the therapy with higher systemic cytokine 
concentrations in treated patients could be achieved with application of either higher 
plasmid dose or with more repetitions of EGT procedure. Even though Fewell and 
colleagues achieved systemic release of therapeutic concentration of human coagulation 
factor IX with a single intramuscular EGT of therapeutic plasmid, extremely high dose of 
therapeutic plasmid had to be delivered, even up to 3 mg of plasmid/kg of bodyweight 
(Fewell et al., 2001). Similarly, different experiments showed that in large animals the level 
of systemically secreted transgene product is dose and volume dependent with increased 
transgene expression correlating with increase in plasmid dose and volume until a certain 
saturating dose (Khan et al., 2003). On the other hand, in studies where therapeutic plasmid 
encoding GHRH was used, biological effects were achieved after single EGT with plasmid  
doses as low as 10 - 100 μg of plasmid per kg of bodyweight (Brown et al., 2009; Draghia-
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Akli et al., 2002; Tone et al., 2004). As established in preclinical research, size and 
construction of plasmid plays an important role in effectiveness of electroporation-based 
delivery of DNA in vivo (Cemazar & Sersa, 2007). This fact could in part explain such 
striking differences in plasmid doses, which were needed in different studies on dogs to 
exert systemically detectable transgene product release. Therefore in the future, 
optimization of dose with dose escalation studies should be attempted for each therapeutic 
plasmid. 
Another possible improvement of systemic transgene release could be in multiple 
consecutive repetitions of EGT procedure. Several previous studies on different animal 
tumor models demonstrated, that more than one either intratumoral or intramuscular 
application of plasmid encoding IL-12 is necessary to achieve adequate therapeutic response 
in treated animals, even without systemically detectable IL-12 concentrations (Heinzerling et 
al., 2001; L.C. Heller et al., 2006; Lucas & R. Heller, 2003; Tevz et al., 2009). For example in 
melanoma tumor model significantly better therapeutic response was achieved with 
increasing the number of intratumoral applications or with addition of intramuscular gene 
delivery (Lucas & R. Heller, 2003). Similarly, four consecutive intramuscular IL-12 EGTs 
resulted in a significantly better systemic release of IL-12, compared to a single EGT 
procedure (Tevz et al., 2009).  
Another possible explanation for nonresponders is that the timing of the samples collections 
was not optimal, since the samples were collected every 1 to 2 weeks in the first month and 
monthly thereafter. According to published literature, the time of the highest systemic 
release of IL-12 and IFN-γ achieved after intramuscular IL-12 EGT is greatly variable. In 
different studies, the highest serum concentration of IL-12 was achieved between 4 and 17 
days after EGT procedure, followed by the elevation of IFN-γ serum level with 
approximately 4-5 days delay (Lucas et al., 2002; Tevz et al., 2009). Kinetics of systemic IL-12 
release varies even within the same species. In mice intramuscular EGT with the same 
plasmid dose results in significantly different systemic transgene release depending on 
strain of treated animals (Tevz et al., 2009). For example, in C57Bl/6 strain, serum 
concentration of IL-12 reached peak on day 6 (Tevz et al., 2009) or day 10 (Lucas et al., 2002) 
after EGT and abruptly declined to approximately half of peak concentration in the next few 
days. On the other hand, in A/J mice strain, serum concentration of IL-12 reached plateau 
by day 6, which lasted until approximately day 14, followed by a slow decline. Even more 
surprising is the fact, that in C57Bl/6 strain approximately three-times higher serum 
concentrations of IL-12 were achieved compared to A/J strain. The underlying mechanisms 
responsible for these discrepancies in transgene expression are not yet explained. Therefore 
even in a relatively homogenous group of experimental animals, determination of optimal 
serum collection timing is not as straightforward. Based on these findings, in such a 
heterogenic group as dogs, greatly varying in size and other physical attributes, a more 
thorough examination of cytokine release after intramuscular EGT should be attempted. 
Data on kinetics of transgene release in dogs after intramuscular IL-12 EGT would be 
helpful for clinical application to determine the best time intervals for treatment repetitions 
in each individual patient in order to achieve the maximum therapeutic effect. 
In our study, intramuscular EGT did not exert such pronounced local antitumor effect on 
treated tumors compared to direct intratumoral IL-12 EGT (Chuang et al. 2009; Pavlin et al., 
2011). In four of our patients, where tumors were not surgically removed and the size of 
intact tumors could be repeatedly measured, there was no regression in tumor size after 
performed EGT. In comparison, with intratumoral IL-12 EGT volumes of treated canine 
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intact tumors could be repeatedly measured, there was no regression in tumor size after 
performed EGT. In comparison, with intratumoral IL-12 EGT volumes of treated canine 
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mast cell tumors reduced significantly by over 50% (Pavlin et al., 2011) and even complete 
remissions were achieved in experimentally induced transmissible veneral tumors in dogs 
(Chuang et al., 2009). This discrepancy in antitumor effectiveness of intratumoral versus 
intramuscular IL-12 EGT has already been shown in experimentally induced tumors in 
preclinical studies. Usually, intratumoral IL-12 EGT results in better direct antitumor effect, 
demonstrated as growth delay and reduction of treated tumors' size, compared to 
intramuscular route of gene delivery (Lucas et al., 2002, 2003). On the other hand, 
intramuscular IL-12 EGT exhibits pronounced antimetastatic effect with high systemic 
concentrations of IL-12 and stable induction of IFN-γ response (Hanna et al., 2001; Tevz et 
al., 2009). With intramuscular route of therapeutic gene delivery, relatively low proportion 
of complete regressions is achieved, typically around 15-40%, depending on model of 
treated tumor (Lee et al., 2003; Lucas et al., 2003; Tevz et al., 2009), whereas in some of the 
reported studies, complete response with intramuscular IL-12 EGT was not achieved (Hanna 
et al., 2001). In comparison, intratumoral IL-12 EGT generally results in approximately 60-
80% complete response rate in treated tumors (L.C. Heller et al., 2006; Lucas et al., 2003), 
even reaching 100% curability (Pavlin et al., 2009). Based on results of preclinical work it can 
be concluded that the main advantage of intramuscular IL-12 EGT lies in its systemic effects, 
namely antimetastatic activity and consequently prolongation of treated animals survival 
time (Lee et al., 2003; Lucas et al., 2002; Tevz et al., 2009;  Zhu & Li, 2008). 
Even though we treated a relatively small number of animals, their survival times after EGT 
were longer compared to survival times associated with specific tumor types from literature 
review. For example, the patient with PHS was euthanized over 8 months after EGT and a 
single application of CCNU due to progression of clinical signs, namely dispnoa and 
exercise intolerance. According to the literature, median survival time for dogs with PHS, 
treated with full CCNU chemotherapy (four consecutive applications every 3 weeks), is 96-
106 days (Fulmer & Maudlin, 2007; Rassnick et al., 2010; Skropuski et al., 2007). In this 
patient, CCNU therapy was discontinued after one application due to pronounced 
hepatotoxicity, therefore probably exerting only negligible therapeutic effect. The patient 
with OSA survived 5.5 months, whereas reported median survival time for dog with OSA 
without any treatment is 1 - 3 months (Selvarajah et al., 2009). In three patients with higher 
grade MCTs, relatively long survival times were achieved. In canine MCT, survival strongly 
correlates with histological grade of the tumor and clinical stage of the disease (Patnaik et 
al., 1984), with very high recurrence rate after surgical therapy in more aggressive higher 
grade tumors (Fox, 2002; Thamm & Vail, 2007). The patient with grade III MCT in clinical 
stage III of the disease with recurrent growth of tumor tissue immediately after marginal 
resection of MCT and metastases in local lymph nodes survived for 6 months after EGT 
before being euthanized due to progression of the disease. Two weeks after EGT, 
consecutively two different systemic chemotherapies were started, each discontinued 
shortly after induction due to severe side-effects, therefore none of the chemotherapy 
protocol was administered long enough to reach any therapeutic potential.  In comparison 
to these three patients, veterinary literature reports approximately 30% local recurrence of 
incompletely excised grade II MCT (Thamm & Vail, 2007) and only 7% partial response rate, 
without any complete responses, to full chemotherapy protocol utilizing vincristine (McCaw 
et al., 1997). For patients with grade III MCT, median survival time of 3 months after surgery 
without any additional therapy is reported (Thamm & Vail, 2007). 
In preclinical studies intramuscular IL-12 EGT conveyed in successful transgene expression 
and systemic release of significant concentrations of IL-12, therefore raising concerns 
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regarding safety of this therapeutic approach, based on described toxicity of systemic 
application of recombinant IL-12. It has been established that systemic recombinant IL-12 
therapy can exhibit serious adverse effects, including elevated body temperature, 
headaches, nausea and vomiting, nephro- and hepatotoxicity (Leonard et al., 1997) and 
application of high dose of rIL-12 was linked with temporary immunosuppression 
(neutropenia, lymphopenia, thrombocytopenia and anemia) (Motzer et al., 1998), which 
would not be favorable for effective immunotherapy. Therefore monitoring of renal and 
hepatic function in patients receiving any IL-12 based therapy is strongly recommended. 
These adverse effects are presumably due to toxicity of IFN-γ response induced by 
circulating IL-12 (Car et al., 1999; Leonard et al., 1997; Ryffel, 1996). Toxic side effects in 
human patients appeared when serum concentration of IFN-γ exceeded 6.0 ng/ml (Leonard 
et al., 1997), whereas experimental animals tolerated serum concentrations as high as 300 
ng/ml without any severe adverse reactions (Leonard et al., 1997). A comprehensive study 
of intratumoral IL-12 EGT toxicity has been conducted, with evaluation of changes in weight 
and blood biochemistry and haematology parameters, as well as histopatological 
examination of several different tissues of treated animals (L.C. Heller et al., 2006). Even 
though a pronounced antitumor effect was achieved on melanoma tumor model, no 
significant side effects of the procedure were observed (L.C. Heller et al., 2006). Although 
sporadically, significant abnormalities in bloodwork were detected, they were clinically 
irrelevant for the treated animals. The only histopathologic abnormality was late-onset 
inflammation associated with the kidney without any biochemical markers of decreased 
kidney function. Nevertheless, these findings did not reflect in any impairment of general 
health of treated animals. Nevertheless, in this study no systemically detectable 
concentrations of either IL-12 or IFN-γ were achieved. Therefore its conclusions can not 
directly demonstrate safety of intramuscular IL-12 EGT as well, since intramuscular route of 
therapeutic gene administration can result in significant systemic concentrations of both IL-
12 and IFN-γ. In preclinical studies, side-effects of the procedure were not so thoroughly 
investigated, however, available data show that intramuscular IL-12 EGT, compared to 
intratumoral, can exhibit more pronounced, but still tolerable side effects, mainly transient 
significant reduction of bodyweight at the highest serum concentrations of IL-12 and IFN-γ 
(Tevz et al., 2009). 
Clinical status of all animals enrolled in our study remained unaltered for the first 8 weeks 
after the EGT procedure. In the two patients with progressive disease (one patient with MCT 
and a patient with MAC), deterioration of general health was observed after 6 and 2 months, 
respectively, which reflected the increased tumor burden and was not a consequence of any 
toxic effects of the procedure. Hematology as well as biochemistry parameters of collected 
blood samples remained mostly within reference limits throughout the observation period. 
Few clinically significant alterations were observed in two patients receiving systemic 
chemotherapy. In the patient with PHS elevation of serum activities of enzymes ALT and SAP, 
which are biomarkers of liver function, was observed. However, this change occurred a week 
after induction of chemotherapy with CCNU, which exhibits known hepatotoxicity (Kristal et 
al., 2004). In the first two weeks after EGT, before the chemotherapy was started, no 
abnormalities in bloodwork were observed in this patient, despite detecting elevated serum 
levels of IFN-γ in blood samples collected 7 and 14 days after EGT. Furthermore, the increase 
in activities of both enzymes was only transient and their values normalized immediately after 
cessation of systemic chemotherapy. Similarly, transient haematological abnormalities were 
detected in the patient with MCT, receiving first immunosuppressive chemotherapy consisting 
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of vincristine and methylprednisolone and later CCNU. Bloodwork alterations were related to 
toxicity of these chemotherapy protocols, since they were displayed only after induction of 
chemotherapy and not around the time, when elevated levels of IFN-γ in patient's serum was 
detected. Other patients with systemically detectable IFN-γ, even as high as 246.8 pg/ml, did 
not display any abnormalities in their bloodwork assays. Therefore we can conclude, that the 
observed hepatotoxicity and immunosuppression were due to pharmacological agents rather 
than a side effect of IL-12 gene therapy.  
5. Conclusion 
In conclusion, the results of this study indicate, that intramuscular IL-12 EGT in dogs with 
spontaneously occurring tumors, is a feasible, simple and safe procedure, which exerts 
systemic transgene release of IL-12 and induction of IFN-γ response in treated animals, 
making it promising treatment modality in veterinary medicine. In the future, refinement of 
treatment protocols in different canine tumors should be performed, with respect to 
investigating kinetics of cytokine release, defining optimal plasmid dose, number of 
treatment repetitions and effect of combination with other treatment protocols (e.g. local 
intratumoral plasmid delivery or electrochemotherapy) in order to achieve effective long-
term antitumor effect in canine cancer patients. 
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of vincristine and methylprednisolone and later CCNU. Bloodwork alterations were related to 
toxicity of these chemotherapy protocols, since they were displayed only after induction of 
chemotherapy and not around the time, when elevated levels of IFN-γ in patient's serum was 
detected. Other patients with systemically detectable IFN-γ, even as high as 246.8 pg/ml, did 
not display any abnormalities in their bloodwork assays. Therefore we can conclude, that the 
observed hepatotoxicity and immunosuppression were due to pharmacological agents rather 
than a side effect of IL-12 gene therapy.  
5. Conclusion 
In conclusion, the results of this study indicate, that intramuscular IL-12 EGT in dogs with 
spontaneously occurring tumors, is a feasible, simple and safe procedure, which exerts 
systemic transgene release of IL-12 and induction of IFN-γ response in treated animals, 
making it promising treatment modality in veterinary medicine. In the future, refinement of 
treatment protocols in different canine tumors should be performed, with respect to 
investigating kinetics of cytokine release, defining optimal plasmid dose, number of 
treatment repetitions and effect of combination with other treatment protocols (e.g. local 
intratumoral plasmid delivery or electrochemotherapy) in order to achieve effective long-
term antitumor effect in canine cancer patients. 
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1. Introduction 
Heart failure is supposed to be one of the most important causes of morbidity and mortality 
in the developed countries (McMurray JJ, 2000) (Cowie MR, 2000). It is not a disease by itself 
but it is a consequent condition of a number of co-existing factors including arterial 
hypertension, coronary artery heart disease and myocardiopathies. The quality of life of the 
patient is affected in heart failure more than in other diseases (Stewart AL, 1989) and the 
cost for the care providing system is estimated to be 22 billion $ each year in the United 
States (American Heart Association, 2000). Thus, investigating into heart failure causal 
factors and into management possibilities is of high importance in order to provide the 
essential help to the patients. It should be marked that the most important causal factor of 
heart failure is ischemic heart disease, thus we are dealing with heart failure developed after 
an ischemic episode if not mentioned else. 
The currently used drugs can manage effectively the main symptoms of heart failure and 
may control the symptoms of this condition. Nevertheless, judging by the numbers of 
morbidity and especially mortality, which remain high, we can assume that new research 
fields have to be developed in order to provide new effective therapies for heart failure. 
The progress in the technology and in biologic science allows the development of new 
optimized and individualized drugs with the aid of pharmacogenomics. Moreover, novel 
effective therapies emerge from the use of gene therapy and stem cell transplantation in the 
therapeutic strategies against heart failure after an ischemic episode. 
2. Currently available therapy for heart failure 
The main strategy for the currently available therapies used in the management of heart 
failure is to: a) reduce the preload, b) reduce the after load and c) improve the myocardial 
contraction. 
Depending on the New York Heart Association (NYHA) classification for heart failure there 
are four categories based upon the patient’s quality of life due to the symptoms. In NYHA 
Stage I the patient faces no symptoms when performing normal everyday work. In NYHA 
Stage II the patient has mild symptoms in everyday life, which are relieved at rest. In NYHA 
Stage III the patient has moderate symptoms that may affect the physical activity, which are 
only relieved at rest. Finally, in NYHA Stage IV the patients faces severe symptoms which 
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are present even at rest. Table 1 and Fig.1 demonstrate the main pharmaceutical categories 
used taking into consideration the NYHA Stage. 
 
NYHA Stage Stage I Stage II Stage III Stage IV 
Symptoms None Mild Moderate Severe 
ACE inhibitors Yes Yes Yes Yes 
AT1R blockers Alternatively to ACE inhibitors, when adverse reactions present 
(cough) 
beta-blockers After ACS, 
hypertension 
Yes Yes Yes 
Diuretics Hypertension, 
edema 
Yes Yes Yes 
Aldosterone 
antagonists 
Not needed In hypokalemia Yes Yes 
Digoxin In atrial fibrosis In atrial fibrosis Yes Yes 
Table 1. Main pharmaceutical categories used depending on NYHA Stage. (NYHA: New 




Fig. 1. Drugs used in the management of heart failure and their mechanism of action. 
The great and increasing number of patients suffering from heart failure after ischemic 
episodes worldwide provide with the need to improve and individualize existing therapies 
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3. Pharmacogenomics in heart failure 
3.1 Introduction to pharmacogenomics 
In distinction to rare mutations that cause a disease, genetic polymorphisms, which are 
frequently occurring mutations, do not cause disease. Instead, they may affect the disease 
onset and outcome, the clinical cause of a disease or even response to a drug treatment. 
Genetic polymorphisms act either through alteration of the biochemic phenotype of the gene 
products as a mask for other directly involved polymorphisms (linkage disequilibrium). 
The extensive use of drugs in various populations has shown that the efficacy and toxicity 
amongst the users may differ a lot. In the USA it is estimated that 100.000 of patients die and 
2.200.000 suffer from adverse reactions attributed to drugs. The incidence in patients in a 
hospital environment is up to 6-7% and the adverse reaction to drugs is 4th amongst death 
causes (Lazarou J, 1998). 
The adverse reactions and the pharmaceutical targets are the main investigational fields 
with the aid of genetic analysis and computer science. In many cases the efficacy of a drug 
can be attributed to gene polymorphisms that encode enzymes that metabolize the drug 
itself, drug carriers or its targets. The study of genetic diversity the adverse reaction could 
be predicted and the safety and efficacy of the drug could be improved. The most effective 
therapy could be prescribed based on the special genetic alterations that the patient carries 
(March R, 2001) (Veenstra D, 2000). In the future, each patient could have an “individualized 
drug” that would be suitable to the genetic profile. 
3.2 Discovery of new targets 
The discovery of genomic regions of interest requires the DNA of the cell, which contains all 
the essential genetic information. Therefore, we can use the following techniques: 
1. Development of a cDNA library that derives from the mRNA of the studied cellular type. 
This library contains only the expressed gene of the specific tissue. 
2. Extraction of the whole DNA from the chromosomes of the studied cells. In this case the 
derivative DNA contains both introns and exons. Thus, computational tools and biologic 
techniques, such as “western blot” are required in order to define the areas of interest. 
3.2.1 DGE profiling (Differential Gene Expression) 
DGE is a technique which is used to measure the difference of the mRNA that is the product 
of a specific gene or a number of gene between two tissues. Therefore, we can find the 
specific genes expressed in a pathologic tissue, for example an ischemic tissue, and connect 
the gene to the phenotype. Thus, we can define genes responsible for the pathogenesis of a 
certain condition. The most important types of DGE is GeneCalling (Shimkets RA, 1999) and 
SAGE (de Waard V, 1999). GeneCalling has been used in a number of studies in murine 
models involving the Atrial Natriuretic Peptide and the TGF-β  (Shimkets RA, 1999) (Geng 
YJ, 1999). The SAGE method has been used in the identification of genes participating in 
atherogenesis in the myocardial tissue (de Waard V, 1999).  
3.2.2 Database of expressed genes 
The database of expressed genes contains information from cDNA sequences that derive 
from total mRNA of the studied tissue. Therefore, if we know a specific gene that is 
expressed, then we are aware of the proteins that are produced. Special softwares are used 
in the analyses such as PHRED and PHRAP (Ewing B, 1998). In the case of heart failure 
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are present even at rest. Table 1 and Fig.1 demonstrate the main pharmaceutical categories 
used taking into consideration the NYHA Stage. 
 
NYHA Stage Stage I Stage II Stage III Stage IV 
Symptoms None Mild Moderate Severe 
ACE inhibitors Yes Yes Yes Yes 
AT1R blockers Alternatively to ACE inhibitors, when adverse reactions present 
(cough) 
beta-blockers After ACS, 
hypertension 
Yes Yes Yes 
Diuretics Hypertension, 
edema 
Yes Yes Yes 
Aldosterone 
antagonists 
Not needed In hypokalemia Yes Yes 
Digoxin In atrial fibrosis In atrial fibrosis Yes Yes 
Table 1. Main pharmaceutical categories used depending on NYHA Stage. (NYHA: New 




Fig. 1. Drugs used in the management of heart failure and their mechanism of action. 
The great and increasing number of patients suffering from heart failure after ischemic 
episodes worldwide provide with the need to improve and individualize existing therapies 






























Gene Therapy Targets and the Role of Pharmacogenomics in Heart Failure 
 
325 
3. Pharmacogenomics in heart failure 
3.1 Introduction to pharmacogenomics 
In distinction to rare mutations that cause a disease, genetic polymorphisms, which are 
frequently occurring mutations, do not cause disease. Instead, they may affect the disease 
onset and outcome, the clinical cause of a disease or even response to a drug treatment. 
Genetic polymorphisms act either through alteration of the biochemic phenotype of the gene 
products as a mask for other directly involved polymorphisms (linkage disequilibrium). 
The extensive use of drugs in various populations has shown that the efficacy and toxicity 
amongst the users may differ a lot. In the USA it is estimated that 100.000 of patients die and 
2.200.000 suffer from adverse reactions attributed to drugs. The incidence in patients in a 
hospital environment is up to 6-7% and the adverse reaction to drugs is 4th amongst death 
causes (Lazarou J, 1998). 
The adverse reactions and the pharmaceutical targets are the main investigational fields 
with the aid of genetic analysis and computer science. In many cases the efficacy of a drug 
can be attributed to gene polymorphisms that encode enzymes that metabolize the drug 
itself, drug carriers or its targets. The study of genetic diversity the adverse reaction could 
be predicted and the safety and efficacy of the drug could be improved. The most effective 
therapy could be prescribed based on the special genetic alterations that the patient carries 
(March R, 2001) (Veenstra D, 2000). In the future, each patient could have an “individualized 
drug” that would be suitable to the genetic profile. 
3.2 Discovery of new targets 
The discovery of genomic regions of interest requires the DNA of the cell, which contains all 
the essential genetic information. Therefore, we can use the following techniques: 
1. Development of a cDNA library that derives from the mRNA of the studied cellular type. 
This library contains only the expressed gene of the specific tissue. 
2. Extraction of the whole DNA from the chromosomes of the studied cells. In this case the 
derivative DNA contains both introns and exons. Thus, computational tools and biologic 
techniques, such as “western blot” are required in order to define the areas of interest. 
3.2.1 DGE profiling (Differential Gene Expression) 
DGE is a technique which is used to measure the difference of the mRNA that is the product 
of a specific gene or a number of gene between two tissues. Therefore, we can find the 
specific genes expressed in a pathologic tissue, for example an ischemic tissue, and connect 
the gene to the phenotype. Thus, we can define genes responsible for the pathogenesis of a 
certain condition. The most important types of DGE is GeneCalling (Shimkets RA, 1999) and 
SAGE (de Waard V, 1999). GeneCalling has been used in a number of studies in murine 
models involving the Atrial Natriuretic Peptide and the TGF-β  (Shimkets RA, 1999) (Geng 
YJ, 1999). The SAGE method has been used in the identification of genes participating in 
atherogenesis in the myocardial tissue (de Waard V, 1999).  
3.2.2 Database of expressed genes 
The database of expressed genes contains information from cDNA sequences that derive 
from total mRNA of the studied tissue. Therefore, if we know a specific gene that is 
expressed, then we are aware of the proteins that are produced. Special softwares are used 
in the analyses such as PHRED and PHRAP (Ewing B, 1998). In the case of heart failure 
 
Targets in Gene Therapy 
 
326 
genes that are involved in the coagulation and the formation of the vasculature in the 
endothelium have already been scanned. 
3.2.3 ExPg (Expression Pharmacogenomics) 
The ExPg is a tool that can be used to improve the safety and efficacy of the drugs. The most 
time consuming part of a drug development is the toxicity and efficacy tests. The ExPg 
could reduce time in the pharmaceutic development and also predict the possible adverse 
reaction of a novel drug (Gould Rothberg BE, 2001). Moreover, the ExPg could be used for 
the evaluation of known metabolic and signaling pathways of the cell.  
3.2.4 SNPs (Single Nucleotide Polymorphisms) 
The SNPs are changes of a single base that may cause alterations in the protein product and 
having an impact on the functionality of the protein. Genetic polymorphisms may be the 
reason why patients may have a different response to a certain drug therapy, because a 
polymorphism may affect the metabolism of the drug or its receptors. Therefore, a better 
knowledge of possible polymorphisms may give a better prediction of the efficacy of a 
therapy. A map including the main polymorphisms involved in heart failure, atheromatosis, 
thrombosis and dyslipidemia could be produced. 
4. Gene therapy in heart failure 
The biologic progress has provided us with new knowledge regarding the mechanisms 
involved in the restoration of the heart after an ischemic episode. The novel view of the 
disease allows the use of gene therapy in order to a) facilitate revascularization in the 
ischemic myocardium, b) protect from free radicals and oxidative stress and c) improve 
myocardial contraction. 
4.1 Introduction to gene therapy 
The techniques used in gene therapy involve the introduction of a normal allele of a gene 
either because the cell does not express the gene or because the gene is under-expressed in 
that kind of cell. Before performing gene therapy a lot of work is needed to prepare the 
induction of the new gene. More specifically the following steps are followed: 
1. Isolation of the target gene 
2. Development of a specific gene vector 
3. Specification of the target cells 
4. Definition of route of administration 
5. Identification of other potential uses of the gene 
One might wonder what the importance of gene therapy is and why it is not effective to 
produce the protein that is missing and administer it to the patient afterwards. This would be 
available in large scale production schemes by the means of genetically altered bacteria. 
Nevertheless, the infusion of the protein is not curative, because of the half-life of the growth 
factors and the factors helping in angiogenesis that are used in the case of heart failure. 
4.1.1 Isolation of the target gene 
The isolation of a gene can be achieved after the production of a cDNA library that contains 
the total unique genes expressed in a specific tissue. The DNA contained in a cDNA library 
is not genomic, therefore it contains only the encoding sequences of the DNA. 
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The procedure of the construction of a cDNA library consists of the following steps:  
1. Isolation of the total amount of mRNA that is produced in the target cells,  
2. Hybridization using a multi-T promoter,  
3. Synthesis of complementary DNA (cDNA) to the mRNA prototype using the enzyme 
reverse transcriptase,  
4. Degradation of the mRNA by the means of an alkali,  
5. Synthesis of the second DNA strand using nucleotides and the enzyme DNA 
polymerase. 
The cDNA library contains only the exons of the genes that are expressed in the specific 
tissue; therefore the cDNA can show the activity of the studied tissue. 
4.1.2 Development of a specific gene vector 
As soon as the isolation of the gene that is to be administered to the patient is achieved, an 
appropriate vector is needed in order to deliver the gene to the target cells. The methods of 
genetic engineering are utilized and the gene is induced into a special agent (usually a virus 
or a chemical substance) that is used to perform transfection of the targeted cellular 
population. Therefore, the genome of the virus is inserted in the genome of the cell together 
with the gene that was previously inserted in the viral genome. 
A number of chemical agents as well as viruses are used to deliver genes to target cells and 
these are presented in the following table (Table 2). 
 
 Advantages Disadvantages 
Plasmids Well-tolerated 
Safe (Kastrupa J, 2001) 
Transfer towards the nucleus is 
not so easy (Laham RJ, 2001) 
Adeno-virus It may transfect differentiating as 
well as stale cells 
Very good percentage of transfection
It is not inserted in the nucleus 
Possibility of reaction against 
the adeno-virus (Lehrman S, 
1999) 
Retro-virus Inserted in the genome 
Stable during transport 
It can only used in transfection 
of multiplying cells (Flugelman 
MY, 1992) 
Lenti-virus Subtype of retro-virus that may be 
inserted in stable cells 
This type of virus is quite stable 






Inserted in the genome 
This vector is quite stable during the 
procedure 
Stable cells can be transfected as well
Only 4,7 kb can be inserted 





Very easy to use 
Selective for the endothelium 
Special alterations can improve the 
availability and reduce toxicity 
(Felgner PL, 1995) 
 
Table 2. Chemical compounds and virus used in gene therapy. 
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4.1.3 Specification of the target cells 
The target cell has to be defined carefully in order to achieve the best curative result. In the 
case of heart failure, the smooth muscle cells of the heart are targeted, because in most cases 
of heart failure ischemia has already occurred. Soon after ischemia is induced, a number of 
genes alter their expression as a result of changes that take place. Therefore, it is important 
to targeting proteins as these described in the following table (Table 3) in the specified cells 
of the myocardium. 
 
Gene Function 
Heat shock proteins Protection of cellular integrity, metabolism 
and homeostasis after serious injury 
Growth factors:  
Brain-Derived Neurotrophiv factor 
Vascular Endothelial Growth Factor 
Protection and regeneration of neural and 
vascular networks 
Modulators of apoptosis: 
Plasminogen activator inhibitor 1 
Anti-apoptotic factor 
Transcription factors: 
Liver regenerating factor – Atf3 
Regulation of augmentation, anti-apoptotic 
factor 
Cell survival promoters: 
B-cell translocation gene-2 
Growth arrest and DNA-damage inducible 
gene 45a) 
Promote cellular survival, neural protection, 
DNA protection 
Table 3. Genes altering their expression in case of ischemia of the myocardium. 
4.1.4 Definition of route of administration 
The route of administration has to be defined so as the target gene is transported to the 
target cells in order to perform the transfection of the target tissue cells. In the case of heart 
failure after ischemia, the gene can be transported to: a) the epicardium (injection), b) the 
endocardium (catheter), c) the coronary arteries (catheter), d) pericardium (injection). 
4.1.5 Identification of other potential uses of the gene 
The use of a target gene in the therapy of a certain condition such as heart failure does not 
exclude a possible use of the gene in another therapeutic strategy, where there is a similar 
pathophysiology or malfunction of the studied gene or group of genes. Therefore, the 
identification of other potential uses of the target gene is always important. 
4.2 Targets of gene therapy in heart failure 
The most important cause that leads to heart failure is the ischemia of the myocardium, thus 
the post-ischemic myocardium is going to be discussed more extensively. The heart muscle 
fails to keep up to the body needs, because of the ischemia, therefore heart failure symptoms 
present. 
Soon after the crucial period of the ischemia onset in the myocardial tissue, a large number 
of genes alter their expression, as a result to the new environment that lacks oxygen. 
Consequently, only 20 minutes after the induction of ischemia an up-regulation of the 
expression of Heat Shock Protein (HSP) genes is reported, especially HSP 27, 40, 70, 86 and 
105 kDa. These proteins mainly help the ischemic tissue to maintain its integrity and 
homeostasis (Currie RW, 1987). 
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Furthermore, an increase in the expression of growth factors is measured, especially of the 
Vascular Endothelial Growth Factor (VEGF), the Brain-Derived Growth Factor (BDNF), 
which play an important role in the continuation of the stability of the myocardial and 
neural infrastructure of the myocardium (Das DK, 1995). 
The Activating Transcription Factor (Atf-3), that is also known as a factor protecting the 
liver, plays a major role in the activation and the regulation of the growth by controlling the 
expression of genes involved in late response (such as the genes that control the synthesis of 
the DNA) (Nobori K, 2002). Moreover, the Atf-3 can stop the procedure of apoptosis that 
may have been initiated as a response to ischemia (Kwaan HC, 2000).  
Finally, other genes that promote cellular survival are the Btg2 (B-cell translocation gene 2) 
and the Gadd45a (Growth arrest and DNA damage-inducible gene 45 alpha), which can also 
promote the stability of the genome and its resistance in stress conditions (Hollander MC, 
1999). 
4.2.1 Angiogenesis and revascularization in the myocardium 
VEGF (Vascular Endothelial Growth factor) 
The VEGF is an angiogenetic glucoprotein that binds to the heparin and plays a major role 
in the development of new vasculature in the ischemic myocardium (Symes JF, 2001). A 
large number of studies have investigated into the procedure of revascularization and the 
regeneration of the vascular infrastructure of the myocardium that takes place soon after the 
onset of the ischemia, and it is known that the VEGF is facilitated by a transcriptional factor 
that is promoted by hypoxia (hypoxia-inducible factor-1). Six different structural genes of 
the VEGF have already been found, but their efficacy in angiogenesis is comparable. The 
VEGF gene was the first gene to be used in experiments of gene therapy for heart failure. 
Clinical trials has shown so far that the transport of the gene in the target cell is possible by 
the means of plasmid DNA through an direct injection in the ischemic myocardium 
(Losordo DW, 1998) (or with the aid of mini-thoracotomy) (Fortuin Jr FD, 2003). In other 
studies an adeno-virus was used in order to achieve tranfection of the target cellular 
population after the injection of the gene-adeno-viral agent (Rosengart TK, 1999). 
All the studies performed in order to evaluate the use of VEGF gene in gene therapy have 
demonstrated an increase in the level of VEGF in the myocardium without substantial side-
effects that were initially supposed to emerge (such as hemangiomas or reticulopathy) 
(Symes JF, 1999) (Vale PR, 2000). Moreover, the effect of the therapy on the symptoms of 
heart failure was remarkable as angina was significantly reduced and the nitrate-free 
periods were longer (Vale PR, 2001). 
FGF (Fibroblast Growth Factor) 
Apart from the VEGF, the activation of angiogenesis can also be initiated by the Fibroblast 
Growth Factor. Clinical trials so far demonstrate that the administration of FGF-2 gene into 
the coronary artery vasculature can be well tolerated except for episodic hypotension that 
may be present for 1 up to 3 days (Fortuin Jr FD, 2003) (Simons M, 2002). In the patients that 
received the Fibroblast Growth Factor gene, 6 months after the therapy, their score in stress 
test was improved, the angina symptoms were significantly reduced, the ischemic part of 
the heart was smaller and the wall of the myocardium was thickened (Unger EF, 2000). 
The transport of the FGF gene can be achieved using an adeno-virus. The administration can 
be done through intra-coronary artery injection (Grines CL, 2002) (Grines CL, 2003). The 
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Furthermore, an increase in the expression of growth factors is measured, especially of the 
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the means of plasmid DNA through an direct injection in the ischemic myocardium 
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studies an adeno-virus was used in order to achieve tranfection of the target cellular 
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effects that were initially supposed to emerge (such as hemangiomas or reticulopathy) 
(Symes JF, 1999) (Vale PR, 2000). Moreover, the effect of the therapy on the symptoms of 
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FGF (Fibroblast Growth Factor) 
Apart from the VEGF, the activation of angiogenesis can also be initiated by the Fibroblast 
Growth Factor. Clinical trials so far demonstrate that the administration of FGF-2 gene into 
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effect of the therapy on heart failure was remarkable as angina was significantly reduced 
and the nitrate-free periods were longer than before gene therapy. 
4.2.2 Protection from reperfusion injury 
The revascularization after the episode of ischemia is crucial for the myocardium. However, 
the formation of new vasculature towards the right direction is very important, otherwise 
further ischemia may develop either because of oxidative stress products or because of clot 
formation. Possible genes which are involved in the reduction of free radicals and lower the 
oxidative stress impact have already been discovered and investigated. The Superoxide 
Dismutase  gene (SOD) and the Heme Oxygenase-1 gene (HO-1) have been used in trials 
involving animal models. Nevertheless, there are no clinical trials in humans showing the 
possibility of using these target genes for avoiding reperfusion gene in post-ischemic 
myocardium.  
SOD (Superoxide Dismutase) 
It is known that the administration of the superoxide dismutase gene in rabbits soon after 
ischemia of the myocardium can reduce the development of stunning myocardium (Li Q, 
1998). The target gene of SOD, which was acquired from a cDNA library, was inserted in the 
genome of an adenovirus (Ad5/CMV/Ec-SOD) and was injected through a catheter. This 
special vector was selected, because of its selectivity to extracellular binding positions of the 
liver (Karlsson K, 1998), where the gene can be securely “stored” in order to act only when it 
is needed, without causing inflammation to the myocardium. As a result the 
revascularization of the myocardial tissue was improved, without any loss in the 
functionality of the tissue. 
HO-1 (Heme Oxygenase 1) 
The Heme Oxygenase gene 1 (HO-1) has been investigated as a potential target for gene 
therapy in experimental murine models, where reperfusion injury was present due to 
revascularization after an ischemic episode (Melo LG, 2002). A human gene was inserted in 
an adeno-viral vector and then was injected on the epicardium on the wall of the left 
ventricle (Platt JL, 1998). The transportation of the gene resulted in the reduction by 75% of 
the ischemic myocardium and in a reduction of pro-inflammatory and pro-apoptotic factors. 
When planning gene therapy in order to eliminate the oxidative stress it is essential to take 
into consideration the fact that in patients with an ischemic episode there is an increased 
probability of recurrent episodes of ischemia of the myocardium. Therefore, the gene that is 
to be used should be highly expressed in ischemic periods in order to be more effective. The 
HO-1 gene therapy does not seem to have lasting effect on the myocardial tissue, while the 
administration together with the SOD gene may lead to adverse reactions (mitochondrial 
function disruption, CO overproduction) (Tang YL, 2004). 
A special type of vectors called “vigilant vectors” was developed so as to be activated only 
in an ischemic environment (Phillips MI, 2002). The trials were performed in a murine 
model, where a vigilant plasmid containing the HO-1 gene was administrated after an acute 
ischemic episode. This experiment demonstrated less fibrotic regions in the newly 
developed vasculature, an increased expression of the HO-1 gene and improved myocardial 
contraction (Tang YL, 2004). 
Parstatin: a cryptic peptide involved in cardioprotection 
Thrombin activates protease-activated receptor 1 by proteolytic cleavage of the N-terminus. 
Although much research has focused on the activated receptor, little is known about the 41-
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amino acid N-terminal peptide (parstatin). It has been shown that parstatin would protect 
the heart against ischaemia-reperfusion injury (Routhu KV, 2010). 
A single treatment of parstatin administered prior to ischaemia may cause immediate 
cardioprotection by recruiting the Gi-protein activation pathway including p38 MAPK, 
ERK1/2, NOS, and K(ATP) channels. Parstatin acts on both the cardiomyocytes and the 
coronary circulation to induce cardioprotection. This suggests a potential therapeutic role of 
parstatin in the treatment of cardiac injury resulting from ischaemia and reperfusion 
(Strande JL, 2009). 
4.2.3 Improvement of myocardial contraction 
The role of Ca++ and phospholamban 
The intracellular bank of Ca++ in the ischemic myocardium that fails to keep up with the 
heart needs has been another target in gene therapy studies and experiments. It is known 
that the activity of the SERCA2a channel (Sarcoplasmic Reticulum Ca++ adenosine 
trophosphatase 2a channel) is reduced, resulting in decreased myocardial contraction. In 
murine models the gene of SERCA2a channel was inserted in an adeno-viral vector 
(Ad.SERCA2a) and was administered through an injection on the aorta, leading to improved 
myocardial contraction (Miyamoto MI, 2000) (del Monte F, 2001). 
The signaling with the Ca++ levels in myocardial cells also depends on the activity of an 
calcium-binding protein (called S100A1) that shares a positive inotrope action and is found 
to be at low levels in the ischemic tissue (Remppis A, 1996) (Most P, 2004). However, trials 
have shown that the administration of the respective gene can improve the myocardial 
contraction, may increase the levels of Ca++ and facilitate the activity of the SERCA2a 
channel. Thus, the use of this gene may be effective. 
The antagonism of the activity of phospholamban by the means of gene techniques has been 
investigated as well. Phospholamban has an action against SERCA2a channel; therefore its 
blockade can be beneficial for the myocardial tissue. A number of trials both in murine 
models and in humans have been accomplished (Ziolo MT, 2005) (del Monte F, 2002). An 
adenoviral vector was used in the trials. The results demonstrated improved contraction as 
the levels of phospholamban decreased 48 h after the administration of the vector. 
The β-ARs (β-adrenergic receptors) 
The most important actions of the beta-adrenergic receptor are the regulation of the cardiac 
rhythm and the myocardial contraction as a response to catecholamines. The myocardial β-
ARs are equally distributed in the atria and the ventricles (Ahlquist RP, 1948) (Brodde OE, 
1993). There are subtypes β1, β2, β3 and the ratio is β1AR:β2AR=4:1. 
The β-ARs belong to the family of the G protein-coupled receptors (GPCRs), also known as 
seven-transmembrane domain receptors 7TM. Once a catecholamine is recognized, the 
receptor shifts conformation and, thus, mechanically activates the G protein, which detaches 
from the receptor. The receptor can now either activate another G protein or switch back to 
its inactive state. The resulting Gα and Gβγ subunits become active. The Gα activates adenyl 
cyclase towards the formation of cAMP, that controls the ion channels and has a positive 
action on myocardial contraction (Dohlman HG, 1991) (Hartzell HC, 1988). 
The receptor is not active eternally as it is de-activated by the means of GPCR kinase (GRK), 
which are serine/threonine kinases. These are very selective molecules that bind and 
phosphorylate only previously activated receptors. The myocardial sup-types are GRK1 and 
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GRK2 also named as βARK1 and βARK2 respectively (Hausdorff WP, 1990) (Benovic JL, 
1989). 
It is known that in heart failure the density and the sensitivity of the β-adrenergic receptors 
are reduced. Moreover, the levels of the βARK1 are increased which suggests a crucial role 
of the βARK1 in the de-activation of the β-receptor. 
When the myocardial failure commences, the β-adrenergic agonists (epinephrine or nor-
epinephrine ) can be effectively used as they can increase the preload. Nevertheless, in the 
chronic condition of heart failure the myocardial load cannot benefit from the use of β-
agonists due to the decrease in the density and sensitivity of their receptors (Bristow MR, 
1982) (Ungerer M, 1996). 
The blockade of the βARK1 by the means of gene therapy could be effective as in this case 
the de-activating role of the βARK1 would be stopped, thus permitting the β-agonists to 
remain effective even in chronic administration. 
Another view of the matter shows the need to discover the role of β-arrestin. The muscles 
that act under the continuous action of the sympathetic system, β1-adrenergic receptors 
mediate a β-arrestin activation of the EGFR, thus initiating cardioprotective pathways that 
compensate the toxic action of increased catecholes (Noma T, 2007). Therefore, it is 
suggested that there are two signaling pathways, one that is G-protein dependent and 
another one that is b-arrestin dependent. The meaning of these findings is obvious as the 
design of special drugs that selectively activate or block adrenergic action can be achieved. 
5. Stem cell transplantation in heart failure 
The potential use of stem cells for regenerative medicine and for the treatment of genetic 
disease has rarely been out of the news. Discussion has focused mainly on the use of human 
embryonic stem cells, which in culture have the capacity to generate all cell types. However, 
initial hopes for stem-cell therapy have been somewhat dampened by both technical and 
ethical problems. Recent studies have therefore created a great deal of excitement. They 
show that fully differentiated somatic cells (such as skin fibroblasts) can be reprogrammed 
to make cells similar to embryonic stem cells (Douglas R, 2008). 
Experimental studies and clinical trials have revealed that Mesenchymal Stem Cells (MSCs) 
not only differentiate into cardiomyocytes and vascular cells, but also secrete amounts of 
growth factors and cytokines which may mediate endogenous regeneration via activation of 
resident cardiac stem cells and other stem cells, as well as induce neovascularization, anti-
inflammation, anti-apoptosis, anti-remodeling and cardiac contractility in a paracrine 
manner. It has also been postulated that the anti-arrhythmic and cardiac nerve sprouting 
potential of MSCs may contribute to their beneficial effects in cardiac repair. Most molecular 
and cellular mechanisms involved in the MSC-based therapy after myocardial infarction is 
still unclear at present (Wen Z, 2010). 
6. Conclusion 
To sum up, it is clear that the careful study of human genome can lead to new innovative 
views of the pathogenesis of heart failure after an ischemic episode. Therefore, the 
clarification of the genetic mechanisms which are involved in heart failure will give a boost 
to novel genetic therapies and improvement of the existing pharmaceutical therapies. 
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1. Introduction 
To combat ischemic heart disease in the clinical scenarios of open heart surgery, unstable 
coronary syndromes, percutaneous coronary interventions, or thrombolysis, different 
research approaches are used to improve clinical treatments. The most dreaded long term 
consequence of ischemic heart disease – heart failure – is another clinical diagnosis where 
the treatment we have to offer is less than optimal. Some researchers are attempting to omit 
the reason for cardiovascular disease through targeting the process of atherosclerosis. 
Others adress the pathophysiology of restenosis, which may occurr after balloon dilatation 
of atherosclerotic lesions. Yet others adress improved treatment of the myocardium which 
has undergone an infarction, where the building of new blood vessels, strengthening of the 
contractile apparatus, and recruitment of new cells to areas of necrosis may be therapeutical 
end-points. Arrthythmias may occur due to reperfusion injury, after long-term 
morphological changes in the heart, or due to endogenous causes related to changes of the 
conduction system; new therapies are required for improved treatment. Novel treatments 
for dysfunctional, calsified heart valves are subject to other lines of investigations. Gene 
therapy and cell therapy using genetic engineering of stem cells will be the focus of this 
chapter, in particular the current status of treatments directed towards the myocardium 
itself in ischemic heart disease will be discussed. Gene therapy and to a lesser extend cell 
therapy have been used both clinically and experimentally to combat acute ischemia, 
remodeling and heart failure. However, the protected location of the heart of the heart 
inside the thoracic cavity, the nature of cardiac cells with minimal ability of entering cell 
cycle, and the  electrophysiological properties of the heart render this organ with some 
particular challenges for gene therapy. 
2. Gene therapy for myocardial protection 
Delivery of DNA to hearts as well as other organs has been performed in animal 
experiments, and clinical studies in “no-option” patients have been conducted. Many 
clinical trials with gene therapy in cardiovascular patients have recently been reviewed 
(Lavu at al., 2010, Lyon et al., 2011). A general challenge with gene delivery to the heart is 
low transfection efficacy (the cardiomyocyte does not enter cell cycle), cell 
injury/inflammation, and unwanted sideeffects. There are several options on routes of DNA 
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(Lavu at al., 2010, Lyon et al., 2011). A general challenge with gene delivery to the heart is 
low transfection efficacy (the cardiomyocyte does not enter cell cycle), cell 
injury/inflammation, and unwanted sideeffects. There are several options on routes of DNA 
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delivery to the heart. One alternative is intravascular delivery, which can be directed 
through coronary arteries or retrogradely into the coronary sinus. An arterial approach 
which requires open coronary arteries may not be suitable for patients with coronary artery 
disease if the target is treating cardiomyocytes rather than vascular cells. Pericardial gene 
delivery has been attempted, but there are rather few publications with that particular route 
of delivery. Another option is direct intracardiac delivery, which has been tried clinically 
and experimentally (Isner, 2002, Semenza, 2004, Vinge et al., 2008). In general it is difficult to 
achieve a lasting transfection through this invasive approach, which may be delivery of 
naked DNA or DNA ligated to a vector. Viral vectors used for cardiovascular therapy are 
most commonly adenovirus, adenoasscociated virus, and to a lesser extent lentivirus. A 
third possibility is systemic delivery with “something” that directs the DNA/RNA to a 
specific cell. The “something” in question may be adenovirus or adenoassociated virus, 
which have been most extensively used for genetic correction of cardiovascular disorders. 
Adenovirus have the advantage of being easy to manipulate, can be produced in high titers, 
and have a large transgene cloning capacity (Vinge et al., 2008). However, adenovirus elicit 
an inflammatory response. Development of so-called “gutted or gutless” adenovirus, where 
the immunogenic viral epitopes are removed, may become an option in the future (Vinge et 
al., 2008). Adenoassociated virus are not associated with any human disease, produce a 
stable and long-lasting gene expression, and easily transfect cardiac muscle cells. The latter 
is especially the case with some of the newer serotypes, of which serotype 9 is most 
cardiotropic (Bush et al., 2008, Zancarelli et al., 2008). A disadvantage is that only small 
constructs (less than 5 kb) can be packed into adenoassociated virus (AAV). Non-viral 
vectors are also in use and will be briefly discussed.  
Further considerations in cardiac gene therapy are which cells are to be treated and what do 
we want to overexpress or silence (Vinge et al., 2008). The possibilities range from targeting 
the vasculature to stabilize atherosclerotic plaques, prevent neointima formation, reduce 
atherosclerosis, induce angiogenesis, to improve survival of cardiomyocytes, improve 
function of cardiomyocytes, to reduce pathologic remodelling, and to prevent arrhythmia 
generation. Choice of gene construct and delivery route will depend on this. Genes encoding 
for factors which have intracellular effects should be delivered to a large population of cells 
to correct the underlying pathology, while genes encoding for secretory factors require 
fewer successfully transfected cells provided gene expression lasts (Isner, 2002). RNA 
interference or silencing, a possibility for gene knockdown, is predominantly at an animal 
experimental level. Experimentally, RNA interference though short hairpin RNA silencing 
the RNA polymerase of Coxsackie B3 virus packed into AAV2 successfully treated cardiac 
dysfunction in mice with coxsackieB cardiomyopathy (Fechner et al., 2008). In that study, 
the AAV2-construct was given intravenously. The same group have also used 
phospholamban silencing in short hairpin RNA delivered systemically through a AAV9 
vector to normalize left ventricular remodelling after phenylephrine-induced hypertrophy 
(Suckau et al., 2009). RNA silencing will not be discussed further in this chapter. 
2.1 Viral vectors 
The first experimental studies on cardiac gene therapy used intramyocardial delivery with 
plasmid DNA, demonstrating the feasibilty of envisioning cardiac gene transfer (Acsadi et 
al., 1991, Lin et al., 1990, Burrick et al., 1992). Although those studies were successful in 
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the terms of being able to cause transgene expression up to six months later in 
cardiomyocytes, the number of transfected myocytes was estimated to be as low as 60-100 
cells (Ascadi et al., 1991). This lead to the search for vectors to enhance nuclear uptake, 
where viral vectors have been most extensively studied. Adenovirus was first attempted. 
Guzman and coworkers injected an adenoviral vector containing β-galactosidase (1993) 
into the myocardium, and was able to see a stronger signal than that evoked by plasmid 
containing the same molecular marker. However, the expression lasted only one week, 
and was accompanied by an inflammatory response (Guzman et al. 1993). Subsequently 
viral titers and protein production have been extensively studied and optimized,  as have 
anatomic  location and duration of adenoviral based gene expression in the heart (French 
et al., 1994, Magovern et al., 1996, Barr et al., 1994). Delivery of therapeutic genes with 
adenoviral vectors has been performed with success. For instance, adenoviral based 
delivery of DNA encoding for β2-adrenoceptors enhanced cardiac function in hamsters 
with cardiomyopathy (Tomiyasu et al., 2000). However, although adenovirus was the first 
vector to be used for cardiac gene therapy and has been useful for “proof of concept” as 
well as some initial clinical trials (Lavu et al., 2010), it may not be of large scale 
therapeutic use for the future. Adenovirus are double-stranded DNA viruses, with a high 
effeciency of delivery and expression of their genome in nuclei of dividing and non-
dividing cells (Voplers & Kochanek, 2004). They are relatively large viral structures, with 
the capacity to carry constructs of up to 30 kB (Lyon et al., 2011). However, despite the 
fact that they are relatively cheap to produce in high titers and with a reasonably high 
purity, a major issue is that they evoke an immune response. As naturally occurring 
pathogens, patients are likely to have encountered them previously. Thus immune 
responses leading to destruction of cells containing adenovirus in the heart is a likely 
outcome. The latter factor also limits the time frame of therapeutic gene expression (Lyon 
et al., 2011).   However, since work on gene therapy of the heart started with adenoviral 
vectors, the experience in use of this vector is high, and it is an excellent tool for basic 
science studies to evaluate the therapuetic potential of novel genes.    
Attempts are being made to reduce the immunogenicity of adenoviruses, removing the viral 
genome and viral proteins. The third generation of “gutless” adenovirus have low 
immunogenicity, and longer transgene expression (Chen et al., 1997). Direct myocardial 
delivery of gutless adenovirus resulted in less inflammation than the first generation virus, 
but the gene expression was not high and it was short-lasting (Fleury et al., 2004). Another 
still remaining problem with adenovirus in the heart is the affinity for other organs such as 
gastrointestinal tract, liver, respiratory tract, and muscle, causing side effects in clinical trials 
(Lavu et al., 20120, Lyon et al., 2011).  
Adenoassociated viruses (AAV) are currently without comparison the most suitable vectors 
for cardiovascular gene transfer. AAVs are not associated with any human pathology 
although 20-40% of all humans may have antibodies to them, making them attractive and 
safe for clinical treatment. AAVs exist in different seroforms, which have different affinity 
for the heart. The most recent serotyope, AAV9, is more cardiotropic than any other known 
virus and will transfect nearly 100% of all heart cells (Vandendriessche et al., 2007). AAV9 
causes a sustained cardiac expression of the delivered gene, with little leakage to other 
organs (Bish et al., 2008, Inagaki et al., 2006, Zincarelli et al., 2008, Pacak et al., 2006). AAV1, 
6, and 8 also have relatively high tropism to the heart, and since they have been around for a 
longer time, they have come further into clinical studies. AAV have been used for 
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delivery to the heart. One alternative is intravascular delivery, which can be directed 
through coronary arteries or retrogradely into the coronary sinus. An arterial approach 
which requires open coronary arteries may not be suitable for patients with coronary artery 
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naked DNA or DNA ligated to a vector. Viral vectors used for cardiovascular therapy are 
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the terms of being able to cause transgene expression up to six months later in 
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with cardiomyopathy (Tomiyasu et al., 2000). However, although adenovirus was the first 
vector to be used for cardiac gene therapy and has been useful for “proof of concept” as 
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but the gene expression was not high and it was short-lasting (Fleury et al., 2004). Another 
still remaining problem with adenovirus in the heart is the affinity for other organs such as 
gastrointestinal tract, liver, respiratory tract, and muscle, causing side effects in clinical trials 
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Adenoassociated viruses (AAV) are currently without comparison the most suitable vectors 
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safe for clinical treatment. AAVs exist in different seroforms, which have different affinity 
for the heart. The most recent serotyope, AAV9, is more cardiotropic than any other known 
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longer time, they have come further into clinical studies. AAV have been used for 
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intracardiac, intravascular, and systemic gene delivery. Hitherto more than 20 clinical trials 
using AAV vectors have delivered the vectors to hundreds of patients without observing 
any adverse effects (Lyon et al. 2011, Leon et al. 2010). A major advantage of AAV9 is that a 
systemic approach to gene delivery can be used, thus avoiding some of the challenges of the 
other viral vectors. 
Retroviruses are RNA viruses which integrate into the host cell chromosome after enzymatic 
conversion to DNA. Retroviral vectors are modified to retain the part of the genome which 
is neccessary to initiate reverse transcription into the target cell, while the rest of the viral 
genome is removed (Lyon et al., 2011). Integration of virus into the cell requires cell 
division, which is why this vector can be suitable for therapies against endothelial or smooth 
muscle cells such as in avoiding atherosclerosis or restenosis, but less suitable for 
cardiomyocytes which have a low division rate.  However, the insertion of retrovirus into 
the host genome may cause mutations, potentially leading to malignancies which can be 
passed on into the germline to offspring. 
Lentiviruses belong to the retroviridae family, and include vectors derived from the human 
immunodeficiency virus type I (HIV-1). Wild-type HIV-1 have an affinity for T-cell 
subpopulations, limiting their usability for cardiovascular purposes. Hybrid “pseudotyped” 
lentivirus have been produced to expand their tropism for other cell types. In the context of 
transfecting cardiomyocytes, lentiviral-based vectors are as effecient as adenoviruses, with 
transgene expression lasting longer (Yoshimitsu 2006). They can incorporate constructs up 
to 8 kB in size (Yoshimitsu). Lentivirurses are especially favoured in studies targeting 
transfection of endothelial cells or smooth muscle cells (Sakoda et al., 2007). The major 
obstacle towards a large-scale employment of lentivirus is currently uncertainties regarding 
safety. Modifications of the virus to avoid any risk of human disease are being performed, 
and may in the future lead to a larger therapeutic potential (Lyon et al. 2011). 
2.2 Intrapericardial gene delivery 
In theory, injection of DNA into the intrapericardial space may offer an environment which 
is relatively constant (no blood flow), and would be a relatively non-invasive approach for 
getting DNA to the heart. However, an intrapericardial injection can not lead to directed 
gene delivery, in the sense that there is no control over uptake in a specific type of cell or a 
specific area of the heart such as into the border zone of myocardial infarction. It is 
noteworthy that few publications exist using this option. Zhang and coworkers delivered 
adenoviral based LacZ into the pericardium of neonatal mice through a percutaneous 
puncture, and three days later found LacZ activity in the endocardium, epicardium, and 
myocardium (Zhang et al., 1999). However, the same regimen did not lead to wide-spread 
expression in adult hearts, in which hepatic transduction was found in high levels (Zhang et 
al., 1999). Using a transdiagfragmatic approach, Fromes et al. (1999) delivered adenoviral 
based β-galactodase intrapericardially in rats. Positive staining was found exclusively in 
pericardial cells. Mixing the virus with proteolytic enzymes increased transgene expression 
intramyocardially within a short time later, but the expression did not last, and there was 
leakage to other organs (Fromes et al., 1999). In the canine myocardium,  March and 
coworkers (1999) delivered adenovirus based LacZ through a penetrating catheter. This lead 
to a pericardial-located activity of LacZ. The abscence of publications using this delivery 
approach for the last decade suggests that this is not a delivery route for the future. 
 




Fig. 1. The cartoon depicts possible routes of delivery of either stem cells or DNA with or 
without a vector to the heart. Systemic delivery is suitable only when DNA is ligated to a 
cardiotropic vector.  
2.3 Intramyocardial gene delivery 
Gene delivery to the heart of either plasmid DNA or DNA ligated to a vector has been 
performed for decades both in experimental and in clinical trials (Lavu et al., 2010, Katz et 
al., 2010). Regardless of whether the injection is of plasmid DNA or DNA ligated to a vector, 
intramyocardial injections are invasive and do not have a clinical appeal. One can envision 
injection of DNA during open heart surgery when the heart is exposed anyway, or catheter-
based delivery when a patient is undergoing invasive arterial procedures. However, except 
for open heart surgery with direct visualization the accuracy of such an approach is not high 
- if the intention is delivery of genes i.e. into an ischemic border zone to induce 
angiogenesis, it will be very difficult to control where exactly the injection site is in relation 
to where it would be wished to be. The approach has, however, given us invaluable research 
information on the therapeutic potential and limitations of genes thought to correct 
underlying pathologies. Many studies have used intramyocardial injections of DNA to 
induce angiogenesis. Delivery of the transcription factor GATA-4 ligated to an adenoviral 
vector before coronary artery ligation resulted in improved left ventricular function and 
reduced infarct size (Rysä et al., 2010). This was due to increased angiogenesis, decreased 
apoptosis, and mobilization of cardiac stem cells in GATA-4 treated hearts. AAV-based 
transfection with angiogenin in an in vivo infarction model reduced remodelling, induced 
angiogenesis, and attenuated cardiac dysfunction four weeks later (Zhao et al., 2006). 
Therapeutic use of AAV9-vascular endothelial growth factor-B is cardioprotective in canine 
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pacing-induced dilated cardiomyopathy, but not due to formation of new vessels (Pepe et 
al., 2010). Delivery of adenoviral vector-ligated vascular endothelial growth factor B to rats 
with angiotensin II-induced hypertrophy leads to reduction of diastolic dysfunction, 
increasing capillary area but not density (Serpi et al., 2011). In a chronic ischemia model in 
rats, AAV2-based delivery of both vascular endothelial growth factor A and – B were 
protective (Zentilin et al., 2010). Vascular endothelial growth factor B was more protective 
than A, reducing apoptosis and remodelling and preserving heart function in the abscence 
of angiogenesis. Hepatocyte growth factor delivered by adenovirus into the myocardium 
following myocardial infarction preserved cardiac function, reduced remodelling and 
apoptosis, and induced angiogenesis (Jayasankar et al., 2003). Other studies have used 
antiinflammatory agents injected into the myocardium to combat ischemic heart disease and 
its consequences. Adenoviral-based expression of inhibitory kappa B-alpha in a rat 
infarction model improved heart function six weeks later (Trescher et al., 2004). AAV9 based 
delivery of heme oxygenase-1 into the myocardium before myocardial infarction had infarct 
reducing, anti-inflammatory, and antiapoptotic effects (Melo et al., 2002). Intramyocardial 
injection with inducible nitric oxide synthase ligated to adenovirus had an infarct-reducing 
effect both short-term and long-term (Li et al., 2006). This effect was mediated by inducible 
cyclooxygenase and nuclear factor kappa B (Liet al., 2007). Other cardioprotective genes in 
various models of heart disease are the inhibitor of matrix metalloproteinase TIMP-1 
(Jayasankar 2004), the cell cycle regulator cyclin A2 (Woo et al., 2006), the regulator of organ 
development sonic hedgehog (Kusano et al., 2005); Notch1, regulator of cell proliferation 
and  differentiation (Kratsios et al., 2010), the beta adrenoceptor receptor betaARKct (Rengo 
et al., 2009), and sphingosine kinase 1, a protective protein kinase (Duan et al., 2007). Thus, a 
major insight into possible therapeutic genes has been provided by this gene delivery route. 
Intramyocardial gene delivery is likely to remain a powerful research tool for testing the 
therapeutic potiential of genes in experimental models in the future. However, the future 
clinical gene therapies are unlikely to involve intramyocardial delivery at a large scale. 
2.4 Intravascular delivery 
Cardiac intravascular gene delivery has been performed through antegrade coronary artery 
delivery, non-selective intracoronary delivery (i.e. left ventricular injection), and 
retrogradely through the coronary sinus (Katz et al., 2010). Common for these approaches is 
the need to occlude the coronary circulation temporarily to allow virus to migrate into cells. 
The attractive aspect of this approach is the possibility of a  minimally invasive delivery 
procedure through a catheter well within established clinical procedures (at least the 
antegrade technique) and the possibility to deliver into all four heart chambers. The first 
studies using coronary artery delivery resulted in very few transfected cells (Longeart et al., 
2001, Hayase et al., 2005, Kaplitt et al., 1996). Later studies have refined delivery methods to 
some degree. With a recombinant AAV2 vector ligated to deliver enhanced green 
fluorescent protein,  Kaspar and collegues (2005) used rats for indirect intracoronary 
delivery. Rats had transgene expression lasting up to 12 months, with a gradient of 
expression across the left ventricular wall, the epicardium expressing much more than the 
endocardium. There was evidence of AAV2 vector genome in liver and lungs of injected 
animals (Kaspar et al., 2005). Lai and coworkers (2004) delivered DNA encoding for 
adenylyl cyclase 6 ligated to an adenoviral vector into all three major coronary arteries of 
pigs with heart failure, using a vasodilator at the time of delivery, and compared with 
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delivery of saline. Three weeks later left ventricular function was improved in the pigs 
recieving adenylyl cyclase 6. Gene expression in left ventricular biopsies evaluated with 
PCR was increased, although in which cells was not adressed (Lai et al., 2004). The success 
of intravascular gene delivery may depend on the target cell; if it is vascular, the chance of 
success may increase compared with a cardiac cell target. However, anything that enters the 
coronary circulation must enter the general circulation, reducing the clinical appeal of this 
approach. A special situation where this mode of delivery may be attractive is during open 
heart surgery with cardioplegic arrest. 
2.5 Gene therapy using non-viral vectors 
Although improvements are made in modifying viral vectors, reducing immunogenicity 
and increasing duration and amount of gene expression and narrowing the expression to 
target cells, researchers are travelling on alternative routes to deliver genes to the heart. 
Several non-viral techniques are used to improve the transfection efficacy of plasmids such 
as liposomes, polymers, electroporation, and nanotechnology (Holladay et al. 2010, 
Lukyanenko 2007). The status of these approaches are recently reviewed elsewhere 
(Holladay et al. 2010, Lukyanenko 2007).            
3. Cardioprotection by cell therapy  
Stem cell therapy for protecting hearts is a large topic. For readers particularly interested in 
the field, the recent reviews by Novotny et al. (2008), Beeres at al. (2008), and Atoui et al. 
(2008) are excellent. Stem cells are divided into committed and uncommitted cells, where the 
latter are the true stem cells in the sense that they are undifferenciated, capable of self-
renewal, and multipotent (Novotny et al., 2008, Beeres et al., 2008, Atoui et al., 2008). These 
types of cells include multipotent bone marrow or adipose tissue derived mesenchymal 
stem cells and embryonic stem cells. Commited progenitor cells are more differentiated, and 
include endothelial progenitor cells, fetal cardiomyocytes, and autologous skeletal 
myoblasts. Experimental studies have successfully been able to induce neovascularization, 
increase cardiomyocyte survival, and improve postinfarct function through using cell 
transplantation. However, why it works is not completely clarified. Some investigators 
believe that stem cells dedifferentiate into cardiomyocytes, but not all studies confirm this 
finding (Silva et al., 2005, Cinnaird et al., 2004, Cocher et al., 2001, Murry et al., 2004). 
Possibly there is a fusion between the transplanted cells and the endogenous 
cardiomyocytes (Beeres et al., 2008). Possibly also the transplanted cells lead to recruitment 
of resident cardiac progenitor cells (Novotny et al., 2008, Beeres et al., 2008). Paracrine 
effects may be of importance. As transplanted cells have a short life span in their new 
environment, these effects will be transitory. Some suggested mechanisms of action are 
autocrine or paracrine release of cytokines and growth factors that will stimulate new vessel 
formation, inhibit apoptosis, rescue injured cardiomyocytes, and reduce pathologic 
remodelling. Recently, endogenous cardiac stem cells are reported to have even more 
promising potential for correcting cardiac pathologies. These cells are a large topic beyond 
the scope of this chapter (Bolli & Chaudrey, 2010).   
Therapeutic use of stem cells is now a clinical reality, but there is need for more laboratory 
work before this field can become useful in patients at a large scale. At the moment we do 
not know the optimal cell for delivery, the optimal amount of cells, or which route of 
delivery (as for gene therapy, intramyocardial, intravascular through artery or vein, 
pericardial and other approaches have all been performed) that will give the best outcome. 
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adenylyl cyclase 6 ligated to an adenoviral vector into all three major coronary arteries of 
pigs with heart failure, using a vasodilator at the time of delivery, and compared with 
 
Gene Therapy of the Heart through Targeting Non-Cardiac Cells 
 
343 
delivery of saline. Three weeks later left ventricular function was improved in the pigs 
recieving adenylyl cyclase 6. Gene expression in left ventricular biopsies evaluated with 
PCR was increased, although in which cells was not adressed (Lai et al., 2004). The success 
of intravascular gene delivery may depend on the target cell; if it is vascular, the chance of 
success may increase compared with a cardiac cell target. However, anything that enters the 
coronary circulation must enter the general circulation, reducing the clinical appeal of this 
approach. A special situation where this mode of delivery may be attractive is during open 
heart surgery with cardioplegic arrest. 
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and increasing duration and amount of gene expression and narrowing the expression to 
target cells, researchers are travelling on alternative routes to deliver genes to the heart. 
Several non-viral techniques are used to improve the transfection efficacy of plasmids such 
as liposomes, polymers, electroporation, and nanotechnology (Holladay et al. 2010, 
Lukyanenko 2007). The status of these approaches are recently reviewed elsewhere 
(Holladay et al. 2010, Lukyanenko 2007).            
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Stem cell therapy for protecting hearts is a large topic. For readers particularly interested in 
the field, the recent reviews by Novotny et al. (2008), Beeres at al. (2008), and Atoui et al. 
(2008) are excellent. Stem cells are divided into committed and uncommitted cells, where the 
latter are the true stem cells in the sense that they are undifferenciated, capable of self-
renewal, and multipotent (Novotny et al., 2008, Beeres et al., 2008, Atoui et al., 2008). These 
types of cells include multipotent bone marrow or adipose tissue derived mesenchymal 
stem cells and embryonic stem cells. Commited progenitor cells are more differentiated, and 
include endothelial progenitor cells, fetal cardiomyocytes, and autologous skeletal 
myoblasts. Experimental studies have successfully been able to induce neovascularization, 
increase cardiomyocyte survival, and improve postinfarct function through using cell 
transplantation. However, why it works is not completely clarified. Some investigators 
believe that stem cells dedifferentiate into cardiomyocytes, but not all studies confirm this 
finding (Silva et al., 2005, Cinnaird et al., 2004, Cocher et al., 2001, Murry et al., 2004). 
Possibly there is a fusion between the transplanted cells and the endogenous 
cardiomyocytes (Beeres et al., 2008). Possibly also the transplanted cells lead to recruitment 
of resident cardiac progenitor cells (Novotny et al., 2008, Beeres et al., 2008). Paracrine 
effects may be of importance. As transplanted cells have a short life span in their new 
environment, these effects will be transitory. Some suggested mechanisms of action are 
autocrine or paracrine release of cytokines and growth factors that will stimulate new vessel 
formation, inhibit apoptosis, rescue injured cardiomyocytes, and reduce pathologic 
remodelling. Recently, endogenous cardiac stem cells are reported to have even more 
promising potential for correcting cardiac pathologies. These cells are a large topic beyond 
the scope of this chapter (Bolli & Chaudrey, 2010).   
Therapeutic use of stem cells is now a clinical reality, but there is need for more laboratory 
work before this field can become useful in patients at a large scale. At the moment we do 
not know the optimal cell for delivery, the optimal amount of cells, or which route of 
delivery (as for gene therapy, intramyocardial, intravascular through artery or vein, 
pericardial and other approaches have all been performed) that will give the best outcome. 
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Genetically modifed cells may act as transgene carriers and be used to deliver therapeutic 
targets to cardiac tissue. Transfected cells of different origins have been used in animal 
experiments to induce angiogenesis, increase contractility, decrease fibrosis, improve 
remodelling, and improve graft cell survival. 
 
 
Fig. 2. The advantages of using genetically engineered stem cells versus naive stem cells are 
illustrated. Naive stem cells do rescue myocardium, but the effects are much more 
pronounced when stem cells are genetically engineered. 
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3.1 Genetically engineered stem cells as cardioprotective agents 
Based on the assumption that the major effect of stem cells is through their paracrine effects, 
quite a few works have focused on genetically engineered stem cells to produce angiogenic 
factors, with the perspective to both increase survival of the transplanted cell and to enhance 
the formation of new blood vessels in the infarcted heart. For instance, bone-marrow 
derived endothelial progenitor cells were expanded and transduced with AAV to 
overexpress insulin-like growth factor 1. Then the autologous cells were transplanted into 
the infarct area of rats (Sen et al., 2010). Three months later rats receiving insulin-like growth 
factor 1 transduced cells as opposed to LacZ-transduced cells had improved myocardial 
function, reduced apoptosis, increased number of capillaries, and increased cardiomyocyte 
proliferation in the infarct area. There was no dissemination of transduced cells into other 
organs (Sen et al., 2010). In a model of neointima formation in hypercholesterolemic rats, 
endothelial progenitor cells transduced to overexpress hepatocyte growth factor were 
delivered. The transduced cells homed to the vascular site of injury more than untreated 
cells, and this caused a decreased neointima formation and increased endothelialization 
(Song et al., 2009). Colony stimulating factor-1 was used to transfect primary autologous rat 
myoblasts, which were transplanted into the myocardium of rats with postinfarction heart 
failure (Aharinejad et al., 2008). Left ventricular function evaluated by echocardiography 
was improved in hearts of rats treated with with autologous colony stimulating factor 
myoblasts. This protection was not found after delivery of untransduced myoblasts or 
plasmid DNA encoding for colony stimulating factor. In a similar model myoblasts 
transduced with human growth factor were able to improve heart function, increase 
capillary density, and reduced apoptosis (Rong et al., 2008). Mesenchymal stem cells 
engineered to overexpress adrenomedullin transplanted after myocardial infarction 
improved cardiac function more than naive mesenchymal stem cells (Jo et al., 2007). The 
growth factor angiopoietin-1 in modified mesenchymal stem cells has reduced ischemic 
damage when injected shortly after ischemia in rat hearts (Sun et al., 2007). In pigs, 
mononuclear cells were extracted from peripheral blood and induced to overexpress 
vascular endothelial growth factor retrogradely delivered through the coronary sinus. The 
transduced cells induced angiogenesis and reduced postischemic ventricular dysfunction 
four weeks later (Hagikura et al., 2010). Vascular endothelial growth factor ligated to 
mesenchymal stem cells under the control of a hypoxia response element induced ischemia-
responsive production of vascular endothelial growth factor when transplanted into the 
ischemic myocardium (Kim et al., 2010). This caused an increased retainment of genetically 
altered mesenchymal stem cells in the infarcted heart compared with naive cells, reduction 
of apoptosis, and reduced remodelling. Also hypoxia-regulated heme oxygenase-1 
overexpressing mesenchymal stem cells transplanted into the infarcted ventricular wall 
improved survival of transplanted cells, improved heart function, and reduced cell death 
(Tang et al., 2005). 
Genetic modification of stem cells also improves cell survival and outcome of ischemia 
models when the gene in question is not considered to be a secretory molecule. Treatment of 
mesenchymal stem cells to overexpress connexin 43 followed by injection into infarcted 
myocardium improves left ventricular function and reduces cell death (Wang et al., 2010). 
Mesenchymal stem cells overexpressing heat shock protein of the 20 kDa family has similar 
beneficial effects (Wang et al., 2009). In the latter study, the authors provide evidence that 
the protective effect could be through increased secretion of proteins, where vascular 
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endothelial growth factor, insulin-like growth factor, and fibroblast growth factor were 
released from transfected cells. The authors speculate that the relased growth factors were 
due to a detected activation of the protein kinase Akt (Wang et al., 2009). Indeed, 
mesenchymal stem cells overexpressing Akt itself transplanted into the ischemic 
myocardium improved left ventricular function, reduced infarct size, reduced apoptosis, 
increased mobilization of cardiac progenitor cells (c-kit+), and reduced collagen deposition 
(Mangi et al., 2003). The beneficial effects were dependent on the amount of transplanted 
cells. In a follow up study, the authors found that the mechanism for cardioprotection was 
not through stem cell fusion with cardiomyocytes, which occurred infrequently, and not due 
to differentiation of stem cells into cardiomyocytes  (Noiseux et al. 2006). Another protein 
kinase associated with myocardial protection, Pim-1 kinase, was transfected into cardiac 
progenitor cells before injection into ischemic myocardium (Fischer et al., 2009). When 
animals were observed up to 32 weeks later, improved function and reduced infarct size 
was accompanied by increased survival of engrafted cells, increased vascularization, and 
increased number of c-kit+ cells (Fischer et al., 2009). Consequently, secondary secretory 
effects of genetic manipulation with a factor acting intracellularly is indicated. The 
antiapoptotic molecule Bcl2 has been used to transfect cardiomyoblasts (Kutcha et al., 2006) 
and mesenchymal stem cells (Li et al, 2007) before transplantation into infarcted 
myocardium, leading to improved function and survival of both engrafted cells and 
infarcted myocardium. Mesenchymal stem cells transfected with Bcl2 had an increased 
secretion of vascular endothelial growth factor in vitro, and an increased capillary density in 
vivo (Li et al., 2007). Finally, a few studies have used genes coding for antiinflammatory 
factors as enrichment of stem cells to improve survival of engrafted stem cells and the heart. 
Mesenchymal stem cells overexpressing the interleukin-18 binding protein, the naturally 
occurring inhibitor of the proinflammatory cytokine interleukin 18,  improved 
cardioprotection more than that observed with unmodified stem cells (Wang et al., 2009). 
The beneficial effects observed on heart function, remodelling, and infarct size could have 
been due to increased secretion of vascular endothelial growth factor and decreased 
interleukin 6 levels in hearts of animals treated with genetically modified cells. 
Mesenchymal stem cells have also been used to overexpress the chemokine receptors CCR1 
and CXCR2 before intramyocardial injection into infarcted heart (Huang et al., 2010). Stem 
cells with overexpression of CCR1 had increased survival intramyocardially, which was 
accompanied by less cardiac remodelling, increased capillarization, and improved cardiac 
function in both acute and chronic (4 weeks) observation times. The effect was not found 
when cells were overexpressing CXCR2, which lead to similar findings as with naive 
mesenchymal stem cells (Huang et al., 20010).                 
To conclude, we still have a long way to go to fully understand the mechanisms by which 
stem cells may protect hearts and which cell type and number that should be used for future 
therapies. However, it is well documented that genetic engineering of stem cells with both 
secretory factors and primarily intracellularly acting factors improve engrafted cell survival 
as well as survival of the myocardium.  Many of the studies mentioned above using a 
primary intracellularly acting factor have documented secondary secretory effects.  
4. Cardiac gene therapy using a peripheral approach 
A downside with intracardiac delivery of either genes or genetically modified cells is the 
relative invasiveness of the method. It is possible to envision effects in the heart through a 
 
 




Fig. 3. The cartoon depicts the principle of remote gene therapy delivering plasmid DNA 
into the skeletal muscle, increasing nuclear uptake by electroporation, and  achieving 
myocardial protection. 
peripheral approach, building upon the principle of general organ protection evoked by pre- 
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ischemic event (Murry et al., 1986), while postconditioning is the observation that brief 
episodes of ischemia and reperfusion at the start of reperfusion will reduce organ damage 
(Zhao et al., 2003). It is shown that the protection afforded by these brief episodes of 
ischemia and reperfusion provide an universal organ protection termed remote 
preconditioning (Przyklenk et al., 1993). In a series of experiments we have delivered 
plasmid DNA encoding for hypoxia-inducible factor 1alpha (HIF-1α) into an easily 
accessible peripheral organ, the quadriceps skeletal muscle. Others have shown that the 
skeletal muscle may serve as an endocrine organ, stably secreting endocrine factors into the 
blood stream after delivery of plasmid DNA and enhancing nuclear uptake by 
electroporation (Mathisen et al., 1999). This gives a very local increase of gene expression, 
transfecting a few skeletal muscle fibers in the treated muscle and with no leakage to other 
organs (Czibik et al 2009a, 2009b). The skeletal muscle expression of  HIF-1α lasted for 8 
weeks (not investigated longer) (Czibik et al., 2009a). When hearts were isolated and 
Langendorff-perfused with global ischemia and reperfusion, they had improved function 
and reduced infarct size compared with hearts of mice which were not pretreated with HIF-
1α (Czibik et al., 2009a). To attempt to unravel mechanisms underlying the beneficial effects 
of HIF-1α, a Taqman low density array of some 47 HIF-regulated genes was performed on 
samples of the transfected skeletal muscle one week later. Several genes encoding for 
growth factors were increased in the transfected muscle, among them insulin-like growth 
factor 2, heme oxygenase-1, adrenomedullin, and platelet derived growth factor B (Czibik et 
al. 2009a). When these factors were used to protect the cardiomyocyte cell line HL-1 cells 
against injury evoked by hydrogen peroxide, heme oxygenase-1 (HMOX-1) was beyond 
comparison most protective, with effects similar to that of HIF-1α (Czibik et al. 2009b).  
HMOX-1 is an inducible member of the heme oxygenase family of proteins, also consisting 
of the constitutive heme oxygenase-2 and the less well characterized heme oxygenase-3 
(Durante et al., 2010, Wu et al., 2010). HMOX-1 expression is induced by its substrates: 
heme, oxidants, heavy metals, cytokines, growth factors, hemodynamic forces, gases, 
hypoxia, and hormones (Wu et al., 2011). Many transcription factors may be involved in its 
regulation. Some of them are HIF-1α, nuclear factor kappa B, activator protein 1, and 
nuclear factor E2-related factor (Wu et al., 2011). HMOX-1 catalyzes the degradation of heme 
into biliverdin, free iron, and carbon monoxide (Maines et al., 1986). Biliverdin is 
subsequently rapidly reduced to bilirubin by the enzyme biliverdin reductase. HMOX-1 is 
expressed in a plethora of cell types, including cardiac and vascular cells. Carbon monoxide, 
most known as a toxic gas, is recognized as an intracellular signalling molecule (Maines et 
al., 1986, Verma et al., 1993). Carbon monoxide has many cellular effects which have 
recently been reviewed elsewhere (Abraham & Kappas, 2008); in this context, it can be 
summarized that it may have antiinflammatory and antiapoptotic effects, lead to 
vasorelaxation, reduce lipid peroxidation and proliferation of vascular smooth muscle cells, 
and possibly induce angiogenesis. Bilirubin was shown to have antioxidant effects already 
in 1987 (Stocker et al.). Since then evidence supports that bilirubin regulates cellular redox 
states, reduces the formation of reactive oxygen species, and has antiinflammatory effects 
through decreasing the expression leukocyte adhesion molecules and neutrophil adhesion. 
Free iron may induce ferritin expression leading to iron sequestration. Thus, HMOX-1 
through its downstream products is potentially very suitable for protection of 
cardiomyocytes.  
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When the HIF-1α gene was delivered in vivo into skeletal muscle of rats, the expression of 
HMOX-1 was increased, accompanied by increased serum bilirubin (Czibik et al., 2009b, 
Czibik et al., 2011). When a HMOX-1 blocker was given together with plasmid DNA 
encoding for HIF-1α and the hearts isolated and perfused with induced global ischemia, the 
beneficial effect of gene therapy was abolished (Czibik et al., 2009b). Delivery of plasmid 
DNA endocing for HMOX-1 before isolated heart perfusion mimicked the beneficial effects 
of HIF-1α (Czibik et al.,2009b). Gene delivery of HIF-1α  into the skeletal muscle protected 
the heart ex vivo, and in vitro, and was also evaluated to be highly cardioprotective in an in 
vivo model of cardiac ischemia-reperfusion with remodelling six weeks later (Czibik et al., 
2009a, 2009b, 2011). Unfortunately, systemic delivery of HIF-1α induced a general 
angiogenesis evident as increased CD31 positive staining in the electroporated muscle with 
gene delivery, the contralateral muscle, and in the heart (Czibik et al., 2009a, 2009b, 2011). 
Downstream factors to hypoxia inducible factor may turn out to be cardioprotective without 
the unwanted side-effects. Delivery of plasmid DNA encoding for HMOX-1 into the skeletal 
muscle before in vivo infarction protects against postinfarct remodelling without causing 
angiogenesis (manuscript in progress). Thus, these promising results from mice 
experimental studies should now be tested in larger animals as a bridge to human therapy.  
5. Conclusion 
For the treatment of cardiovascular disease, gene therapy may become an alternative in the 
near future. Gene delivery through intravascular approaches, intramyocardial injection, and 
pericardial route have been tried using plasmid DNA, adeno-, retro-, lenti-, and 
adenoassociated viral vectors. Of the viral vectors, adenoassociated virus serotype 9 is the 
most promising, as it is cardiotropic and can be delivered systemically. Stem cells are 
another approach to novel therapies against ischemic heart disease. Stem cells can be 
delivered through the same routes as genes. At the moment the mechanism of stem cell-
induced protection of the heart is not well understood - the cells tend to stay shortly in the 
myocardium, and to a low degree fuse with cardiomyocytes or differentiate into 
cardiomyocytes. Possibly paracrine effects of stem cells are the reason for cardioprotection. 
Genetic engineering of stem cells improves the therapeutic  effect of transplanted cells, both 
when the engineering is for a secretory factor and when it is overexpressing a factor 
primarily working intracellularly, and secondarily secretory. Gene therapy of the heart can 
also be evoked through using the skeletal muscle as a site of gene transfer, where delivery of 
plasmid DNA encoding for both hypoxia-inducible factor 1 alpha and its downstream target 
heme oxygenase-1 protects cardiomyocytes in vivo, ex vivo, and in vitro. 
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most known as a toxic gas, is recognized as an intracellular signalling molecule (Maines et 
al., 1986, Verma et al., 1993). Carbon monoxide has many cellular effects which have 
recently been reviewed elsewhere (Abraham & Kappas, 2008); in this context, it can be 
summarized that it may have antiinflammatory and antiapoptotic effects, lead to 
vasorelaxation, reduce lipid peroxidation and proliferation of vascular smooth muscle cells, 
and possibly induce angiogenesis. Bilirubin was shown to have antioxidant effects already 
in 1987 (Stocker et al.). Since then evidence supports that bilirubin regulates cellular redox 
states, reduces the formation of reactive oxygen species, and has antiinflammatory effects 
through decreasing the expression leukocyte adhesion molecules and neutrophil adhesion. 
Free iron may induce ferritin expression leading to iron sequestration. Thus, HMOX-1 
through its downstream products is potentially very suitable for protection of 
cardiomyocytes.  
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When the HIF-1α gene was delivered in vivo into skeletal muscle of rats, the expression of 
HMOX-1 was increased, accompanied by increased serum bilirubin (Czibik et al., 2009b, 
Czibik et al., 2011). When a HMOX-1 blocker was given together with plasmid DNA 
encoding for HIF-1α and the hearts isolated and perfused with induced global ischemia, the 
beneficial effect of gene therapy was abolished (Czibik et al., 2009b). Delivery of plasmid 
DNA endocing for HMOX-1 before isolated heart perfusion mimicked the beneficial effects 
of HIF-1α (Czibik et al.,2009b). Gene delivery of HIF-1α  into the skeletal muscle protected 
the heart ex vivo, and in vitro, and was also evaluated to be highly cardioprotective in an in 
vivo model of cardiac ischemia-reperfusion with remodelling six weeks later (Czibik et al., 
2009a, 2009b, 2011). Unfortunately, systemic delivery of HIF-1α induced a general 
angiogenesis evident as increased CD31 positive staining in the electroporated muscle with 
gene delivery, the contralateral muscle, and in the heart (Czibik et al., 2009a, 2009b, 2011). 
Downstream factors to hypoxia inducible factor may turn out to be cardioprotective without 
the unwanted side-effects. Delivery of plasmid DNA encoding for HMOX-1 into the skeletal 
muscle before in vivo infarction protects against postinfarct remodelling without causing 
angiogenesis (manuscript in progress). Thus, these promising results from mice 
experimental studies should now be tested in larger animals as a bridge to human therapy.  
5. Conclusion 
For the treatment of cardiovascular disease, gene therapy may become an alternative in the 
near future. Gene delivery through intravascular approaches, intramyocardial injection, and 
pericardial route have been tried using plasmid DNA, adeno-, retro-, lenti-, and 
adenoassociated viral vectors. Of the viral vectors, adenoassociated virus serotype 9 is the 
most promising, as it is cardiotropic and can be delivered systemically. Stem cells are 
another approach to novel therapies against ischemic heart disease. Stem cells can be 
delivered through the same routes as genes. At the moment the mechanism of stem cell-
induced protection of the heart is not well understood - the cells tend to stay shortly in the 
myocardium, and to a low degree fuse with cardiomyocytes or differentiate into 
cardiomyocytes. Possibly paracrine effects of stem cells are the reason for cardioprotection. 
Genetic engineering of stem cells improves the therapeutic  effect of transplanted cells, both 
when the engineering is for a secretory factor and when it is overexpressing a factor 
primarily working intracellularly, and secondarily secretory. Gene therapy of the heart can 
also be evoked through using the skeletal muscle as a site of gene transfer, where delivery of 
plasmid DNA encoding for both hypoxia-inducible factor 1 alpha and its downstream target 
heme oxygenase-1 protects cardiomyocytes in vivo, ex vivo, and in vitro. 
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Ischemic heart disease is one of the major threatens to human heath. Despite great advances in 
the treatment of it, the cardiac infarction caused by heart ischemia still represents a significant 
cause of morbidity and mortality. Recently, MSCs therapy has been emerged as one of the 
potential treatments for ischemic heart disease [1-4]. Although MSCs can differentiate into 
endothelial [5], cardiac cell [6], and secret a range of cytokines [7], there are mounting 
evidences which showed paracrine effect is the major mechanism for the therapeutic effect of 
MSCs in the ischemic heart [8-10]. Thus, the supplement of genes that can enhance 
angiogenesis or cell survival is one of the attractive strategies for MSCs therapy [11]. 
The Ang-1 has been reported to improve angiogenesis in ischemic heart [12,13]. Ang-1 has 
also been found as an apoptotic survival factor [14-16]. Therefore, the combination of Ang-1 
gene and MSCs would be an alternative method to enhance the effects of MSCs. However, 
when performing the combination of Ang-1 gene and MSCs therapy, a vector that has high 
transductive efficiency to MSCs is needed. 
Sendai virus is a murine parainfluenza virus type I, and is a single-stranded RNA virus. 
Sendai virus is considered to be non-pathogenic to humans [17]. Efficient gene transduction 
into various primary cultured cells and tissues by recombinant virus vector has been 
reported [18-22]. Furthermore, it replicates in the cytoplasma and poses no risk of 
integration into the genomic DNA. These characteristics of the Sendai virus make it a 
potential vector for combined gene and cell therapy. 
In our previously study, we found Sendai viral vector (SeV) has high transductive efficiency 
to MSCs even at low MOI [23]. To further investigate its clinical practicality, we infected SeV 
to the MSCs in vitro at low MOI with short time exposure. We also injected MSCs modified 
with SeVhAng-1 into the ischemic heart of rats to investigate its effect on angiogenesis and 
engraftment of MSCs in the ischemic heart. 
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gene and MSCs would be an alternative method to enhance the effects of MSCs. However, 
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into various primary cultured cells and tissues by recombinant virus vector has been 
reported [18-22]. Furthermore, it replicates in the cytoplasma and poses no risk of 
integration into the genomic DNA. These characteristics of the Sendai virus make it a 
potential vector for combined gene and cell therapy. 
In our previously study, we found Sendai viral vector (SeV) has high transductive efficiency 
to MSCs even at low MOI [23]. To further investigate its clinical practicality, we infected SeV 
to the MSCs in vitro at low MOI with short time exposure. We also injected MSCs modified 
with SeVhAng-1 into the ischemic heart of rats to investigate its effect on angiogenesis and 
engraftment of MSCs in the ischemic heart. 
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2. Materials and methods 
2.1 Animals  
Lewis rats were obtained from the Animal Research Centre of the Fourth Military Medical 
University, Xi'an (China) and maintained on a 12-hour light: 12-hour dark in a 20–25°C 
environment. The Ethics Committee for Animal Experiments of the Fourth Military Medical 
University approved all animal work (Permit number: 20531) and the experimental 
protocols strictly complied with the institutional guidelines and the criteria outlined in the 
“Guide for Care and Use of Laboratory Animals”.  
2.2 Sendai virus vectors 
Sendai virus vectors containing the E.coli β-galactosidase gene (SeVLacZ) or the human 
angiopoietin-1 gene (SeVhAng-1) were used [24]. For the construction of genomic cDNA of 
SeVhAng1, the human Ang-1 open reading frame was cloned from a human cDNA library 
and amplified using the polymerase chain reaction with primers containing SeV-specific 
transcriptional regulation signal sequences:  
5’-TTGCGGCCGCCAAAGTTCAATGACAGTTTTCCTTTCCTTTCCTCTCTG-3’a 
nd5’ATTGCGGCCGCGATGAACTTTCACCCTAAGTTTTTCTTACTACGGTCAAAAATCT
AAAGTTCGAATCATCATAGTTGTGGAACG-3’, and was subsequently inserted into the 
NotI site of pSeV18+b(+) [25] to generate pSeVhAng-1. The pSeVhAng-1 was transfected 
into LLC-MK2 cells previously infected with vaccinia virus vTF7-3 [26], which expresses T7 
polymerase. The T7-drived full-length recombinant SeVhAng-1 RNA genomes were 
encapsulated with N, P and L proteins, which were derived from the respective 
cotransfected plasmids. Forty hours later, the transfected cells were injected into 10 day-old 
embryonated chicken eggs to amplify the recovered virus [27]. The Sendai virus titer was 
determined by a hemagglutination assay using chicken red blood cells, and the virus was 
stored at –70 ºC until use. 
2.3 MSCs source 
MSCs cultures were prepared according to the protocol reported previously. Briefly, under 
sterile conditions, the femur and tibia of 2 month-old male Lewis rats were excised, with 
special attention given to remove all connective tissue attached to bones. Bone marrow plugs 
were extracted from the bones by flushing the bone marrow cavity with Dulbecco’s 
modified Eagle’s medium (DMEM). Marrow plug suspension was dispersed by passing it 
through subsequent pipettes of decreasing sizes. After a homogenous cell suspension was 
achieved, the cells were plated, cultured in DMEM containing 10% fetal bovine serum, and 
incubated at 37°C humidified atmosphere with 5% CO2 for 3 days before the first medium 
change. 
2.4 In vitro SeV transduction 
After 70% conflulence of cultured MSCs in the dish, SeVLacZ at 10 MOI were infected to the 
MSCs with different time exposure (1 minute to 60 minutes). After 48 hr, both 
chmiluminescent assay of MSCs infected with SeVLacZ at 10 MOI with different time 
exposure and X-gal staining of MSCs infected with SeVLacZ at 10 MOI with 1 minute 
exposure were performed as previous described [28].  
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2.5 Expression of hAng-1 in MSCs by SeVhAng-1 transduction 
Human Ang-1 expression in MSCs was detected after 2 days of transduction with SeVhAng-
1 by Western blot. MSCs were washed twice with cold PBS and suspended in a cold lysis 
buffer (20 mmol/L HEPES, pH 7.5, 150 mmol/L NaCl, 1 mmol/L EDTA, 0.5% Triton X-100, 
protease inhibitors [complete, Roche]). Similar quantities of the soluble fractions (20µg) were 
separated by SDS-PAGE, transferred onto nitrocellulose membranes, and blocked overnight 
in blocking solution at 4oC. The membranes were incubated for 1 hr with mouse anti-human 
monoclonal antibodies to Ang-1 (Santa Cruz Biotechnology), followed by anti-mouse 
secondary antibody conjugated to horseradish peroxidase (Zymed, Inc., South San 
Francisco, CA) for 1 hr at room temperature. An enhanced chemiluminescence substrate 
system ECL Plus (Amersham Biosciences UK, Little Chalfont, UK) was used to visualize 
HRP. The ß-actin protein levels were assayed as the internal control. 
2.6 Animal model 
Lewis rats (female, weight 200-250 g) were used in the experiment. The rat was anesthetized 
with IP injection of ketamine(100mg/kg) and xylizine (10mg/kg), and intubated with a 17-
gague needle sheath. After intubation, the rat was supported with a rodent respirator. A left 
lateral thoractomy was made, the heart was exposed and LAD was ligated with 6-0 suture 
[12]. Immediately after LAD ligation, 5×106 MSCs were injected into the heart at 2 sites of 
peri-infarct area of the heart. 
2.7 Evaluation of heart function 
After 4 weeks of LAD ligation, the heart function was evaluated by echocardiography as 
previously described [29]. FS was used as a main index for the evaluation of heart function. 
2.8 Evaluation of infarct size 
We evaluated the infarct size of the heart as previously described [12]. Four weeks after 
myocardial infarction, rats were deeply anesthetized with inhalation of diethyl ether, 
injected with a mixture of ketamine hydrochloride (50 mg/kg) and xylazine (4 mg/kg), and 
killed by rapid exision of the heart. The excised hearts were immediately soaked in cold 
saline for 10s to remove excess blood from the ventricles and fixed in neutral-buffered 4% 
formalin for 48 h. Paraffin-embedded samples were sectioned at 10 μm, and Masson's 
trichrome staining was performed to delineate scar tissue from viable myocardium. 
Masson's trichrome-stained sections were captured as digital images and analyzed by NIH 
Image software. 
2.9 Capillary density measurement 
After 28 days of LAD ligation, the heart was harvest and snap-frozen in liquid nitrogen. 
Cryosections of 10 µm were made. The endothelial cells were stained with anti-CD31 
monoclonal antibody (Pharmingen) as first antibody, followed by a biotinylated anti-mouse 
IgG as second antibody, and an avidin-HRP conjugate for color reaction (DAB paraffin IHC 
staining module, Ventana Medical Systems, Inc., Tucson, AZ). The sections were observed 
under microscope, 5 fields were randomly selected in the peri-infarct area of each section, 
and CD31-positive cells were counted in a blinded manner. The number of CD 31-positive 
cells in each field was used as an index of capillary density. 
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2.10 Analysis of Ang-1 expression and its effect on p-Akt in the ischemic heart 
We injected MSCs modified with or without SeVhAng-1 into the ischemic heart of the rats 
and determined the effect of Ang-1 overexpression on p-Akt as previously described. In 
brief, after 2 days injection of MSCs modified with or without SeVhAng-1 into the 
ischemic heart, the heart was harvested and put into 4 ml lysis buffer, and incubated for 5 
min on ice. The cardiac muscle was homogenized with a mixing homogenizer (Kinematica 
AG, Littau switzerland). The homogenates were heated at 95 ºC for 10 min and 
centrifuged at 12,000g for 10 min. After determination of protein concentration in 
supernatants by BCA methods, total protein (40 µg) was subjected to SDS page in 5-20% 
Tris-glycine gels, subsequently transferred to nitrocellulose membranes and blocked 
overnight in blocking solution at 4oC. The membranes were incubated for 1 hr with mouse 
anti-human monoclonal antibodies to Ang-1 (Santa Cruz Biotechnology), p-Akt (ser473) 
and t-Akt (Signaling Technology, Beverly, MA) followed by anti-mouse secondary 
antibody conjugated to horseradish peroxidase (Zymed, Inc., South San Francisco, CA) or 
anti-rabbit secondary antibody conjugated to horseradish peroxidase (Amersham 
Biosciences UK, Buckinghamshire, England) for 1 hr at room temperature. An enhanced 
chemiluminescence substrate system ECL Plus (Amersham Biosciences UK, Little 
Chalfont, UK) was used to visualize HRP. 
2.11 TUNEL staining 
After 2 days injection of MSCs modified with or without SeVhAng-1, the heart was 
harvested, and cryosections were cut and randomly selected for TUNEL staining as 
described by manufacture (Roche).  
2.12 Real-time polymerase chain reaction for MSCs survival in the ischemic heart 
Real-time PCR was performed to detect Y-chromosomal DNA in the ischemic heart of 
female rat injected with male MSCs as previously reported [30]. In brief, after 2 days of 
MSCs injection, the heart was harvested, the DNA of the tissue was extracted with the 
Qiagen Kit (Qiagen, Mississauga, Ontario, Canada). Real-time PCR was performed with 
SYBR-Green (Applied Biosystems, Foster City, Calif). The SYBR-Green I dye binds to the 
double-stranded product, resulting in an increase in fluorescence detected by the ABI 
7900HT Sequence Detection System (Applied Biosystems). A specific sequence of rat Sry3 
gene in the Y chromosome was targeted. The genomic DNA taken from male MSCs was 
used to obtain a standard curve. The primer pairs were 5'-GCA TTT ATG GTG TGG TCC 
CGC GG-3' and 5'-GGC ACT TTA ACC CTT CGA TGA GGC-3'. The cycling conditions 
were 5 minutes at 50°C, 10 minutes at 95°C for activation of polymerase, and then 30 
seconds at 95°C for denaturation, 60 seconds at 62°C inducing annealing, and 30 seconds at 
72°C for extension. Forty-five cycles were used. After amplification, dissociation curves 
were obtained to discriminate between specific and nonspecific products. 
2.13 Statistical analysis 
Data were expressed as means ± standard deviations (SD). Statistical comparisons were 
performed using ANOVA followed by Bonferroni/Dunn testing. A p value less than 0.05 
was considered to be statistically significant. 
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3.1 Transductive efficiency of SeV to the MSCs 
To determine the transductive efficiency of SeV to MSCs, we infected SeVLacZ to MSCs at 
10 MOI with 1 minute exposure, and performed X-Gal staining after 48 h of infection. The 
results showed that Sendai viral vector almost had 100% transductive efficiency to MSCs 
even at 10 MOI with 1 mintue exposure. We also performed time course effect of the Sendai 
viral vector on the transductive efficiency to the MSC by chemiluminescent assay. 
Interestingly, we found that Sendai viral vector almost had the same protein expression at 
every time point checked (1 minute to 60 minutes). This indicates Sendai viral vector is ideal 
candidate for combined gene and cell therapy in clinical practice for its high transductive 
efficiency at low MOI with short time exposure. 
3.2 SeVhAng-1 transduction to MSCs mediated efficient Ang-1 expression 
To determine the expression of hAng-1 by SeVhAng-1-modified MSCs, Western blot were 
performed. We used a human Ang-1 antibody which has cross reaction with rat Ang-1 for 
Western blot. The result showed an obviously increased expression of Ang-1 in MSCs 
modified with SeVhAng-1. 
3.3 SeVhAng-1-modified MSCs injection decreased heart infarction and improved 
cardiac function after LAD ligation 
After 4 weeks of LAD ligation, the cardiac function was evaluated by echo. The FS was 39.0 
± 3.5, 32.0 ± 2.8 and 21.1 ± 3.3 in the SeVhAng-1-modified MSCs-, MSCs- and medium-
treated groups, respectively, and there was a significant difference between the SeVhAng-1-
modified MSCs and the medium (p<0.01), there was also a significant difference between 
SeVhAng-1-modified MSCs and sole MSCs (p<0.05). We then sacrificed rats after 4 weeks, 
the hearts were harvested, and Masson's trichrome staining was performed. The infarct size 
was 24.5 ± 4.8%, 32.5 ± 4.4% and 42.5 ± 5.1% in the SeVhAng-1-modified MSCs-, MSCs- and 
medium-treated groups, respectively, and there was a significant difference between the 
SeVhAng-1-modified MSCs and the medium (p<0.01), there was also a significant difference 
between SeVhAng-1-modified MSCs and sole MSCs (p<0.05). 
3.4 SeVhAng-1-modified MSCs injection increased capillary density in ischemic heart 
After 28 days of SeVhAng-1-modified MSCs injection, the immunostaining of CD31 on the 
cryosections of the cardiac muscle was carried out. The capillary density was  204.8 ± 18.3, 
150.2 ±1 6.2 and 77.4 ± 13.8 per field in the SeVhAng-1-modified MSCs-, MSCs- and 
medium-treated groups, respectively, and there was a significant difference between the 
SeVhAng-1-modified MSCs and the medium(p<0.01), there was also a significant difference 
between SeVhAng-1-modified MSCs and sole MSCs (p<0.05). 
3.5 Overexpression of Ang-1 increased p-Akt and decreased apoptosis in the 
ischemic heart 
MSCs secrete numerous cytokines and growth factors in hypoxic condition. However, the 
Ang-1 secretion is not obvious elevated [10,31]. Thus, we inferred that Ang-1, which is 
secreted by SeVhAng-1-modified MSCs, would play some role during early period of 
cardiac infarction. To prove this, we injected MSCs modified with or without SeVhAng-1 
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± 3.5, 32.0 ± 2.8 and 21.1 ± 3.3 in the SeVhAng-1-modified MSCs-, MSCs- and medium-
treated groups, respectively, and there was a significant difference between the SeVhAng-1-
modified MSCs and the medium (p<0.01), there was also a significant difference between 
SeVhAng-1-modified MSCs and sole MSCs (p<0.05). We then sacrificed rats after 4 weeks, 
the hearts were harvested, and Masson's trichrome staining was performed. The infarct size 
was 24.5 ± 4.8%, 32.5 ± 4.4% and 42.5 ± 5.1% in the SeVhAng-1-modified MSCs-, MSCs- and 
medium-treated groups, respectively, and there was a significant difference between the 
SeVhAng-1-modified MSCs and the medium (p<0.01), there was also a significant difference 
between SeVhAng-1-modified MSCs and sole MSCs (p<0.05). 
3.4 SeVhAng-1-modified MSCs injection increased capillary density in ischemic heart 
After 28 days of SeVhAng-1-modified MSCs injection, the immunostaining of CD31 on the 
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MSCs secrete numerous cytokines and growth factors in hypoxic condition. However, the 
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secreted by SeVhAng-1-modified MSCs, would play some role during early period of 
cardiac infarction. To prove this, we injected MSCs modified with or without SeVhAng-1 
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into the ischemic heart of rats. First, we determined by Western blot whether the 
overexpression of Ang-1 by MSCs had an effect on the expression of p-Akt in the ischemic 
heart. The result showed that p-Akt expression obviously increased in ischemic heart 
treated by SeVhAng-1-modified MSCs, compared with that by sole MSCs. Because activated 
Akt has the effect of anti-apoptosis, we further determined whether increased p-Akt 
decreases apoptosis in the ischemic heart. We found that overexpression of Ang-1 by 
SeVhAng-1-modified MSCs decreased the apoptosis which may include endothelial cells, 
cardiac myocytes or MSCs in the ischemic heart, compared with that by sole MSCs. We 
further determined whether increased p-Akt improves survival of MSCs injected into the 
ischemic heart. By real time detection of sry gene in the female heart tissue samples at 2 days 
after sex-mismatched cell transplantation, We found that overexpression of Ang-1 by 
SeVhAng-1-modified MSCs significantly improved survival of MSCs per se in the ischemic 


















Fig. 1. Transductive efficiency of Sendai viral vector to MSCs. A, MSCs were infected with 
10 MOI SeVLacZ with different time exposure, the chemiluminescent assay showed Sendai 
viral vector had high transductive efficiency to MSCs even with short time exposure, and 1 
minute exposure by SeVLacZ almost had the same transductive efficiency to the MSCs as 60 
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Fig. 2. SeVhAng-1 mediated efficient hAng-1 expression in MSCs. Representative Western 
blot detection of hAng-1 expression after 10 MOI SeVhAng-1 infected to the MSCs with 1 
minute exposure. Lane 1, MSCs without transduction of SeVhAng-1; lane 2, MSCs with 
transduction of SeVhAng-1. The experiments were repeated 3 times. 
Transplantation of Sendai Viral  


















































Fig. 3. Effect of SeVhAng-1 modified MSCs on heart with LAD liagation. A, representive 
echo measurement of cardiac function at 28 days after LAD ligation. left, ischemic heart 
injected with medium; middle, ischemic heart injected with MSCs; right, ischemic heart 
injected with SeVhAng-1 modified MSCs. SeVhAng-1 modified MSCs significantly 
improved cardiac function, *p < 0.05 versus sole MSCs and **p < 0.01 versus medium, n＝5 
in each group. B, Masson's trichrome staining of the heart at 28 days after LAD ligation. left, 
ischemic heart injected with medium; middle, ischemic heart injected with MSCs; right, 
ischemic heart injected with SeVhAng-1 modified MSCs. SeVhAng-1 modified MSCs 
significantly decreased infarct size, *p < 0.05 versus sole MSCs and **p < 0.01 versus 
medium, n＝5 in each group.  
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Fig. 3. Effect of SeVhAng-1 modified MSCs on heart with LAD liagation. A, representive 
echo measurement of cardiac function at 28 days after LAD ligation. left, ischemic heart 
injected with medium; middle, ischemic heart injected with MSCs; right, ischemic heart 
injected with SeVhAng-1 modified MSCs. SeVhAng-1 modified MSCs significantly 
improved cardiac function, *p < 0.05 versus sole MSCs and **p < 0.01 versus medium, n＝5 
in each group. B, Masson's trichrome staining of the heart at 28 days after LAD ligation. left, 
ischemic heart injected with medium; middle, ischemic heart injected with MSCs; right, 
ischemic heart injected with SeVhAng-1 modified MSCs. SeVhAng-1 modified MSCs 
significantly decreased infarct size, *p < 0.05 versus sole MSCs and **p < 0.01 versus 
medium, n＝5 in each group.  
 




Fig. 4. A, capillary density at 28 days after injection of SeVhAng-1 modified MSCs into the 
ischemic heart. Left, heart injected with medium; middle, heart injected with sole MSCs; 
right, heart injected with SeVhAng-1-modified MSCs, magnification, ×400. B, SeVhAng-1 
significantly increased the capillary density compared with controls. *p < 0.01 versus 
medium and *p < 0.05 versus MSCs, n＝5 in each group. 
4. Discussion 
In the present study, we found that Sendai viral vector had high transductive efficiency to 
MSCs even at low MOI with short time exposure. Both MSCs modified with SeVhAng-1 and 
MSCs improved the cardiac function in rats after heart infarction. However, MSCs modified 
with SeVhAng-1 had better improvement of cardiac function, compared with sole MSCs. 
This indicated that SeVhAng-1-modified MSCs could serve as a more effective therapy for 
ischemic heart disease. 
Among various vectors, adenoviral vector is widely used for combination of gene and cell 
therapy in recent years. However, because of lower expression of the CAR receptor for the 
binding of adenovirus in MSCs, the transductive efficiency of adenoviral vector to the MSCs 
is not so satisfactory, especially at low MOI [23, 31]. SeV has been proved to have high 
transductive efficiency in a broad range of tissues, including the airway epithelial cells, 
vasculature tissues, skeletal muscles, activated T cells, stem cells and neural tissues. In our 
previously study, we found Sendai viral vector (SeV) has high transductive efficiency to 
MSCs even at low MOI [23]. In present study, we further found that SeV had high 
transductive efficiency to MSCs at low MOI with short time exposure. This characteristic of 
SeV overcomes the shortcoming of needing relatively long time exposure to the MSCs by 
current available vectors such as adenoviral vector, and makes it an ideal vector for 
combined stem cell and gene therapy in clinical practice. 
Although MSCs can differentiate into cardiomyocytes and endothelial cells, the magnitude 
of incorporation of MSCs into vascular structures or regenerating cardiomycytes is too low 
to explain the functional recovery of ischemic heart by MSCs. Kinnaird et al found that 
MSCs can secret a range of cytokines such as VEGF and bFGF in hypoxic condition and 
Transplantation of Sendai Viral  




suggested the paracrine mechanism of MSCs is one of the major causes of angiogenetic effect 
by MSCs [9,10]. Nevertheless, hypoxic condition does not increase Ang-1 expression in MSCs 
[10, 32]. Because Ang-1 plays an important role in angiogenesis, the supplement of Ang-1 
seems to have significant importance for MSCs in treating ischemic heart disease. In the 
present study, we got a high expression of Ang-1 by transduction of SeVhAng-1 to the MSCs, 
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Fig. 5. Effect of overexpression of Ang-1 on p-Akt and MSCs survival in the ischemic heart. 
A, lane 1, heart injected with MSCs; lane 2, heart injected with SeVhAng-1- modified MSCs. 
SeVhAng-1- modified MSCs obviously increased expression of Ang-1 and p-Akt in the 
ischemic heart. The experiments were repeated 3 times. B, a, heart injected with MSCs; b, 
heart injected with MSCs modified with SeVhAng-1. Apoptotic cell were stained brown, 
magnification, ×400. SeVhAng-1-modified MSCs obviously decreased apoptosis, compared 
with the sole MSCs. C , Real-time polymerase chain reaction for sry gene in the female heart 
muscle samples at 2 days after sex-mismatched cell transplantation. The fold change in sry 
gene expression in different animal groups was calculated. The results showed SeVhAng-1-
modified MSCs significantly improved MSCs survival, compared with the sole MSCs. *p< 
0.01 versus sloe MSCs. 
The high rate of death occurs after MSCs transplantation because of inflammation, loss of 
survival signal from matrix attachments [33] and cytotoxic factors in the ischemic heart [34]. 
For these reasons, the enhancement of MSCs engraftment in hostile circumstance is 
becoming one of attractive strategies to improve its therapeutic effects [35-38]. Ang-1 
prevents endothelial cell apoptosis [16] and promotes cardiac muscle survival [39] via 
activation of Akt pathways. Accordingly, overexpression of Ang-1 by SeVhAng-1-modified 
MSCs may also have protective effect to MSCs per se which is beneficial to the engraftment 
of MSCs in the ischemic heart. Indeed, we found SeVhAng-1-modified MSCs significantly 
 




Fig. 4. A, capillary density at 28 days after injection of SeVhAng-1 modified MSCs into the 
ischemic heart. Left, heart injected with medium; middle, heart injected with sole MSCs; 
right, heart injected with SeVhAng-1-modified MSCs, magnification, ×400. B, SeVhAng-1 
significantly increased the capillary density compared with controls. *p < 0.01 versus 
medium and *p < 0.05 versus MSCs, n＝5 in each group. 
4. Discussion 
In the present study, we found that Sendai viral vector had high transductive efficiency to 
MSCs even at low MOI with short time exposure. Both MSCs modified with SeVhAng-1 and 
MSCs improved the cardiac function in rats after heart infarction. However, MSCs modified 
with SeVhAng-1 had better improvement of cardiac function, compared with sole MSCs. 
This indicated that SeVhAng-1-modified MSCs could serve as a more effective therapy for 
ischemic heart disease. 
Among various vectors, adenoviral vector is widely used for combination of gene and cell 
therapy in recent years. However, because of lower expression of the CAR receptor for the 
binding of adenovirus in MSCs, the transductive efficiency of adenoviral vector to the MSCs 
is not so satisfactory, especially at low MOI [23, 31]. SeV has been proved to have high 
transductive efficiency in a broad range of tissues, including the airway epithelial cells, 
vasculature tissues, skeletal muscles, activated T cells, stem cells and neural tissues. In our 
previously study, we found Sendai viral vector (SeV) has high transductive efficiency to 
MSCs even at low MOI [23]. In present study, we further found that SeV had high 
transductive efficiency to MSCs at low MOI with short time exposure. This characteristic of 
SeV overcomes the shortcoming of needing relatively long time exposure to the MSCs by 
current available vectors such as adenoviral vector, and makes it an ideal vector for 
combined stem cell and gene therapy in clinical practice. 
Although MSCs can differentiate into cardiomyocytes and endothelial cells, the magnitude 
of incorporation of MSCs into vascular structures or regenerating cardiomycytes is too low 
to explain the functional recovery of ischemic heart by MSCs. Kinnaird et al found that 
MSCs can secret a range of cytokines such as VEGF and bFGF in hypoxic condition and 
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seems to have significant importance for MSCs in treating ischemic heart disease. In the 
present study, we got a high expression of Ang-1 by transduction of SeVhAng-1 to the MSCs, 
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Fig. 5. Effect of overexpression of Ang-1 on p-Akt and MSCs survival in the ischemic heart. 
A, lane 1, heart injected with MSCs; lane 2, heart injected with SeVhAng-1- modified MSCs. 
SeVhAng-1- modified MSCs obviously increased expression of Ang-1 and p-Akt in the 
ischemic heart. The experiments were repeated 3 times. B, a, heart injected with MSCs; b, 
heart injected with MSCs modified with SeVhAng-1. Apoptotic cell were stained brown, 
magnification, ×400. SeVhAng-1-modified MSCs obviously decreased apoptosis, compared 
with the sole MSCs. C , Real-time polymerase chain reaction for sry gene in the female heart 
muscle samples at 2 days after sex-mismatched cell transplantation. The fold change in sry 
gene expression in different animal groups was calculated. The results showed SeVhAng-1-
modified MSCs significantly improved MSCs survival, compared with the sole MSCs. *p< 
0.01 versus sloe MSCs. 
The high rate of death occurs after MSCs transplantation because of inflammation, loss of 
survival signal from matrix attachments [33] and cytotoxic factors in the ischemic heart [34]. 
For these reasons, the enhancement of MSCs engraftment in hostile circumstance is 
becoming one of attractive strategies to improve its therapeutic effects [35-38]. Ang-1 
prevents endothelial cell apoptosis [16] and promotes cardiac muscle survival [39] via 
activation of Akt pathways. Accordingly, overexpression of Ang-1 by SeVhAng-1-modified 
MSCs may also have protective effect to MSCs per se which is beneficial to the engraftment 
of MSCs in the ischemic heart. Indeed, we found SeVhAng-1-modified MSCs significantly 
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increased p-AKT expression, which improved survival of MSCs injected into the ischemic 
heart. This protective effect by SeVhAng-1-modified MSCs would be beneficial to the 
enhancement of angiogenesis during the period of heart ischemia. 
Our study indicated that Sendai viral vector has high transductive efficiency to the MSCs 
even at low MOI with short time exposure, and MSCs modified with SeVhAng-1 enhances 
the angiogenetic effect of MSCs. In addition, the SeVhAng-1 modification increases survival 
of MSCs in the ischemic heart. SeVhAng-1-modified MSCs may serve as a more effective 
and practical tool in dealing with ischemic heart disease. 
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1. Introduction 
Human blood at physiological conditions is kept as fluid through precise system called 
homeostasis, if damage to the vessel, causing the system will be restored by vessel wall. 
Cases no regulation or homeostasis disorders, thrombosis (intravascular coagulation) or 
bleeding occur. In normal conditions, the secretion of vascular endothelial heparin-like and 
trmbomodulin molecules prevent blood coagulation and secretion of nitric oxide and 
prostacyclin prevent platelet aggregation and blood brings the liquid keeps. Homeostasis 
has three stages: vasoconstriction, platelet plug formation and blood coagulation, blood 
coagulation are reactions in which plasma zymogens become active enzymes that create the 
clotting reaction. Coagulation reactions will be set with inhibitory and stimulatory 
mechanisms. Coagulation is a regulatory process that keeps the blood flowing. Blood 
coagulation has two external and internal pathways (Figure 1), tissue factor and FVII form 
the external pathway, internal pathway is formed of FVIII, FIX and FXI (Ramanarayana et 
al., 2011; Ellison, 1977). 
2. Hemophilia 
Hemophilia had recognized in the fifth century BC, first the Jews law passed that when a 
woman has two dead boys doing the circumcision her third son should not be circumcised, 
they showed the mother will transmit the disease to her sons (History of hemophilia, 2011). 
Genetic and hereditary pattern of hemophilia was carefully described in 1803 by the American 
physician John Conrad Otto. He supposed that the bleeding was occurring due to lack of 
blood anti hemophilic factor (Cahill & Colvin, 1997). Glossary of hemophilia was developed 
for this disease in 1828 at the University of Zurich. Anti-hemophilia globin was discovered in 
1937 by Patek and Tylor at Harvard University (History of Hemophilia Disease, 2011). The two 
forms of hemophilia A and B were distinguished in 1952 by Pavlosky, the Brazilian physician. 
Both diseases are sex-dependent and occur in males (Cahill & Colvin, 1977). 
3. Causes hemophilia 
Hemophilia is a genetic disorder happens in coagulation FVIII (hemophilia A) or FIX 
(hemophilia B) and are related to the X chromosome. Hemophilia A is a disease due to 
genetic defects in coagulation FVIII (Furie et al., 1994; White & Shoemaker, 1989) It is 
identified by Hoyer and Breckenridge (Hoyer & Breckenridge, 1968) and then by Denson for 
the first time (Denson et al., 1969). They showed that there was not FVIIIa in the plasma of 
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the most people with hemophilia. Hemophilia B caused by genetic defects occur in the 
coagulation FIX; the FIX deficiency will inhibit the activation of FX by FVIIa through 
external coagulation pathway (Furie et al., 1994; Thompson, 1986). About half The patients 
who suffer from severe hemophilia A there is a large inversion in intron 22 of their FVIII 
mRNA (Figure 2) which it is repeated (Arruda et al., 1995; Deutz-Terlouw et al., 1995; 
Okamoto et al., 1995; Pieneman et al., 1995; Van de Water et al., 1995; Goodeve et al., Jenkins 
et al., 1994; 1994; Naylor et al., 1993; Naylor et al., 1992). Different alleles of the VNTR (di 




Fig. 1. External and internal pathways of blood coagulation process. (Reference 
http://www.varnerlab.org/coagulation)Read phonetically 
Hemophilia A is occurring one for 5000-10000 birthday boys and hemophilia B one for 
20,000 to 34,000 birthday boys (Dimitrios et al., 2009). The bleeding in joints of hemophilia 
patients the wound bleeding is longer continued (Petkova et al., 2004). The position of FVIII 
gene is Xq28 and of FIX is Xq27.1 location on distal long arm of chromosome X (Figure 3). 
The FVIII gene has 186 kb organized in 26 exons (about 9 kb) (Figure 4). There are detected 
some gene mutations on FVIII as insertion, deletions or point mutations which involved in 
the reduced or cut up in FVIII activation (Ramanarayana et al., 2011; Salviato et al., 2002; 
Cahill & Colvin, 1997; Arruda et al., 1995; Naylor et al., 1991; Higuchi et al., 1989; 
Youssoufian et al., 1987; Gitschier et al., 1985;). The FVIII organized in A, B and C domains 
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(Figure 5), which B domain is highly glycosylated and do not involve in FVIII activities 
(Eaton et al., 1986). 
 
 
Fig. 2. Genetic mutation in intron 22 of FVIII (Schwartz et al., 2011) 
 
 
Fig. 3. The Map of FVIII on the long arm of chromosome X (Schwartz et al., 2011) 
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Fig. 4. Genetic map of FVIII (White & Shoemaker, 1989) 
 
 
Fig. 5. The domains organization of FVIII (Schwartz et al., 2011) 
4. Diagnosis of hemophilia 
Laboratory diagnosis of hemophilia is done based on activated partial thromboplastin time 
(aPTT), prothrombin time (PT), platelet count and bleeding time. There is an abnormally in 
the initial section of internal coagulation pathway at the prolonged aPTT and normal PT. 
The normal aPTT should not be reject the FVIII deficiencies (hemophilia A), the aPTT is not 
enough sensitive too reduced amount of FVIII C. Prolonged PT alone, or PT and aPTT do 
not specify of hemophilia A, the liver diseases, overdose of warfarin or heparin and the 
distribution intravascular coagulation (DIC) can cause this coagulophaty. 
Thrombocytopenia alone cannot cause of hemophilia A. The nature and severity of bleeding 
is performed with cell blood counts (CBC) and differentiation also check for blood in the 
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stool and urine (Schwartz et al., 2011). Knights and Ingram in 1967 were used 
thromboplastin time assay for hemophilia A and B differentiation. Based on their test when 
alumina is added to normal plasma do not see the harm of FVIII, but FIX is deleted, remove 
the alumina from plasma FIX will re- back up. If thromboplastin time is increased in males 
with a history of prolonged bleeding, test is repeated after adding or removing alumina 
from the plasma. If thromboplastin time is shorter than the control, the patient is suffering 
from hemophilia A, but if thromboplastin time is shortened after the removal of the 
alumina, patient is suffering from hemophilia B (Knights & Ingram, 1967). Stites et al (1971) 
and Essien and Ingram (1967) were distinguished hemophilia A and B by FVIII inhibitory 
antibodies. 
The test results in children and adults are different. Clotting Index and coagulability in 
hemophilia patients significantly lower than non-hemophilia one. In this test, coagulability 
of FVIII treated blood varies by the replaced FVIII type. rFVIII clotting index is lower than of 
derived plasma one (Goldenberg et al., 2006). Firshein and colleagues were diagnosed 
prenatal hemophilia A using radioimmunometric by fetal plasma and fetoscope by amniotic 
fluid at second trimester in pregnancy women (Firshein et al., 1979), other researchers were 
developed radoimmunometric method for measurements of FVIII antibody (Hoyer et al., 
1985; Hellings et al., 1982; Ljung R, Holmberg, 1982). Antonarakis et al were analyzed FVIII 
gene for possibility detection of prenatal and hemophilia carrier through gene cloning 
method (Antonarakis et al., 1985), the problems and limitations of these methods were 
evaluated by other researchers (Graham et al., 1985). The PCR RFLP method was used for 
prenatal diagnosis and hemophilia A carrier for the first time in 1990s (Rudzki et al., 1996; 
Herrmann et al., 1988; Kogan et al., 1987;). Missense and nonsense point mutations in FVIII 
gene of hemophilia A patient, prenatal and carrier hemophilia A were detected using DGGE 
method (Gitschier, 1989). Ball and colleagues were used oral cells, urine and hair follicles 
samples to identify prenatal and carrier hemophilia A (Ball et al., 1990). Various 
polymorphism and mutations have been detected in FVIII gene of hemophilia A patients 
(Wacey et al., 1996’ Antonarakis et al, 1995; Naylor et al., 1991; Baranov et al., 1990; Gécz et 
al., 1990; Jedlicka et al., 1990; Sadler et al., 1990; Surin et al., 1990; Wehnert et al., 1990a; 
Wehnert et al., 1990b). Establishment the PCR technique in diagnostic laboratories was a 
large change in DNA analysis of FVIII gene for detecting carriers and individuals with 
hemophilia A (Song et al., 1993; Feng, 1991; Wadelius et al., 1991; Wu, 1991). Detection of 
unknown mutations is performed by universal mutation detection system methods such as 
SSCP (Arruda et al., 1995; Pieneman et al., 1995; David et al., 1994). Hemophilia diagnosis 
with PGD method was used by Michaelides (2006) and colleagues For the first time in 2006; 
they were diagnosed two point mutations in FVIII gene of donor (IVF) blastomere. Acquired 
hemophilia due to FVIII autoantibody is a rare disease and occurs one in a million, yearly; 
its mortality is 20 percent (Shetty et al., 2010). 
5.1 Treatment of hemophilia A 
Hemophilia treatment doing by replacing the natural (Brackmann & Gormsen, 1977) or 
recombinant FVIII (Kaufman, 1991) via intravenous injection. The half life of transfused 
FVIII in normal individuals or patients with hemophilia is 8 to 12 hours (White & 
Shoemaker, 1989). Using recombinant serum proteins in the treatment of hemophilia began 
in 1990 (Liras, 2008), but Homate P / humate-P is a derived pasteurized human plasma 
which was approved in Germany in 1981 and used administered intravenous injection for 
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25 years to control bleeding in patients with hemophilia A and von Willebrand disease 
(Berntorp, 2009; Carter & Scott, 2007; Czapek et al, 1988). The main presentation following 
hemophilia treatment is creating inhibitory antibodies against the FVIII which observed 5% 
in patients with hemophilia B and 40 -20 percent in patients with severe hemophilia A 
(Hong & Stachnik, 2010; Kempton et al., 2010; Eckhardt et al., 2009; Ghosh & Shetty, 2009; 
von Auer et al., 2005; Sharathkumar wt al., 2003; Scharrer, 1999; de Biasi et al., 1994). 
Complication inhibitory antibodies seem to produce with plasma-derived FVII severe than 
with recombinant one (Lusher, 2002; Lusher, 2000), also with FVIII (Qadura et al., 2009; 
Delignat et al., 2007; Goudemand et al., 2006; Yoshioka et al., 2003; Fijnvandraat et al, 1997). 
The B cell epitopes mutated, produced FVIII inhibitory antibody is reduced, and some one 
proposed that this phenomenon is safe vaccine for people with hemophilia (Parker et al, 
2004). Antibody production against FVIII has been studied in hemophilia patients and 
indicates that most nonsense mutations and large deletions in FVIII gene and chromosomal 
recombination lead to produce FVIII inhibitory antibody (Schwaab et al., 1995). Treatment of 
hemophilia by FVIII overdose administration is effective for producer antibodies 
hemophilia patients (Scandella et al., 2000). 
The OBI (BDD- rpFVIII) was introduced by Ipsen and Inspiration Biopharmaceuticals Inc 
Company and passed clinical trial phases 1 and 2. It shows porcine FVIII biochemical 
properties and procoagulant activity and less immunogenicity than plasma derived pFVIII 
(Toschi, 2010). 
In 1960 Los Angeles Red Cross Blood Center was treated hemophilia patients using anti 
hemophilic globin (Rapaport et al., 1960). 1-Deamino-8-d-arginine vasopressin (DDAVP) (a 
FVII autologous) have been used instead of plasma derived factors for treatment of 
hemophilia A and B (Mannucci et al., 1977). Hultin and colleagues were used 
cyclophosphamide as immunosuppression drug for antibody producer hemophilia patients 
(Hultin et al., 1976). Lian et al. were treated hemophilia using cyclophosphamide, vincristine 
and prednisone (CVP) (Lian et al., 1989). Blatt et al were removed FVIII inhibitory antibody 
with prothrombin complex concentrates (PCC) (Blatt et al., 1977). Paleyanda and colleagues 
were transferred FVIII cDNA into pig lactate system; the pig was produced FVIII more than 
10 times as normal plasma (Paleyanda et al., 1997). Specific thrombin anticoagulant 
Bivalirudin (Krolick, 2005) and monoclonal antibody Retoximab (Franchini, 2007; Wiestner 
et al., 2002) are also used for hemophilia treatment and patients with FVIII autoantibody, 
respectively. Idiotype vaccines will neutralize anti human FVIII antibody in hemophilia A 
patients (Lacroix-Desmazes et al., 2002). 
Production and characterization of recombinant FVIII for the treatment of hemophilia was 
conducted in 1984 for the first time (Toole et al., 1984; Wood et al., 1984). Use of 
recombinant proteins to replace clotting factors and treatment of hemophilia opened a 
new arena in treatment of disease. Circulating blood factors are the first generation 
recombinant proteins and second generation drugs made by recombinant DNA and 
protein engineering technology cause changes in proteins for specific applications, like 
FVIIa (Levy & Levi, 2009; Pipe, 2008). FVII alone or in combination with its analogues 
have been used to reduce bleeding (Lauritzen el al., 2008a; Lauritzen et al., 2008b; Allen et 
al., 2007). Use of recombinant FVIIa for hemophilia patients with FVIII antibody 
(Obergfell et al., 2010; Margaritis, 2010; Margaritis et al., 2010), also people who have 
bleeding into the joint or prevent bleeding in surgery is economically efficient (Stephens 
et al., 2007). 
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5.2 Gene therapy of hemophilia A 
For the first time in 1996, Connelly et al were administrated intravenous hemophilia dog by 
adenovirus containing hFVIII gene in which related protein was detectable in plasma for 
two weeks (Connelly et al., 1996a). Connelly and colleagues were injected adenovirus 
containing BDD- hFVIII gene through the tail artery into mice; hFVIII was detected in 
plasma by ELISA method (Connelly et al., 1999; Connelly et al. 1995). Dwarki and colleagues 
were transfected fibroblast by retrovirus containing BDD- FVIII gene, transfected fibroblasts 
were transferred into mice, human FVIII was observed in plasma after one week (Dwarki et 
al., 1995). Connelly et al were transferred adenovirus containing hFVIII gene into mice, 
hFVIII was stable in mouse for five months. (Connelly et al., 1996b). Ill et al were prepared 
suitable plasmid with necessary elements for FVIII expression in liver cells (Ill et al., 1997). 
Zhang et al were prepared a mini-adenovirus containing FVIII -equipped human albumin 
gene promoter for hemophilia A gene therapy. This structure was transferred to cell line; the 
hFVIII was consistently produced in mouse transferred ell line (Zhang et al., 1999). Gene 
therapy of hemophilia were done by liver cell transfected by adeno associated viruses or 
lentiviral viruses containing FVIII and FIX. Also use non-viral vector is also considered. 
Antibody production in gene therapy of hemophilia with FVIII and FIX can be depended on 
vector serotype (viral), expression rate (a long time, especially in the liver), the promoter 
used, method of gene delivery and transduced cell types (Margaritis et al., 2009; Ohmori et 
al., 2008; VandenDriessche et al., 2003; Chuah et al., 2001).  
To overcome adenovirus toxicity phenomena, Andrews and colleagues were used 
adenovirus defected early genes E1, E2a, E3, E4 (four-generation defected vector), and 
transferred albumin promoter –controlled FVIII gene into mice, but was not suitable for use 
in vivo (Andrews et al., 2001). Chuah et al were inhibited bleeding in hemophilia A SCID 
mice using intravenous injection of adenovirus carrying BDD -FVIII gene (Chuah et al., 
2003). Shi et al believed that platelet/ megakaryocyte is a target for hemophilia A gene 
therapy, they were transferred equipted specific platelet glycoprotein IIb promoter BDD- 
hFVIII to Domi cells, hFVIII was biosynthesised (Shi et al., 2003). Sarkar and colleagues were 
transferred AAV carrying hFVIII to deficient FVIII mice through portal, intravenous and 
spleen injections, they observed secreted hFVIII in transgenic animals but no in neonatal 
animal (Sarkar et al., 2003). Scallan et al were transferred FVIII gene into mice by AAV2 
vector. The construct was equipped with liver cell specific promoter (Scallan et al., 2003). 
Kang and colleagues were used liver specific promoter equipted FIV retrovirus containing 
BDD- hFVIII gen for intravenous injection in hemophilia mice, hFVIII was secreted in mice 
for months without anti FVIII antibody production (Kang et al., 2005). Kumaran et al were 
treated hemophilia mice by cell therapy, a mixture of hepatocytes, liver endothelial 
sinusoids and liver kupffer cells was injected into mice peritoneum, FVIII was observed in 
mouse blood (Kumaran et al., 2005). Jiang et al were transferred FVIII in to hemophilia dog 
by AAV types 2, 5, 6 and 8, their report indicated that the performance of virus types 2 and 5 
for gene therapy is more than viruses type 6 and 8 (Jiang et al., 2006). Sarkar et al believed 
that gene therapy duration in the dog with AAV8 containing FVIII have prolonged up to 
two years (Sarkar et al., 2006). Durable gene therapy based on AAV containing FVIII have 
also been reported by McCormack and colleagues (McCormack et al., 2006). Shi and 
colleagues findings suggest that targeted FVIII gene expression by platelets specific 
promoter is effective in the treatment of hemophilia A (Shi et al., 2006). Shi and colleagues 
were suggested that ectopic expression of FVIII in platelets with lentiviral virus via bone 
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bleeding into the joint or prevent bleeding in surgery is economically efficient (Stephens 
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marrow gene therapy is effective for human hemophilia treatment They were transferred 
lentiviral vector containing FVIII - Induced glycoprotein IIb platelet specific promoter into 
null mice bone marrow, the permanent secretion of FVIII in platelets lysates mice was 
observed. (Shi et al., 2007). Liu and colleagues were targeted rDNA of HL7702 hepatocytes 
by non-viral vector pHrneo containing FVIII gene for treatment of hemophilia (Liu et al., 
2007). Doering has been transferred swine FVIII gene into mouse bone marrow 
mesenchymal cells for hemophilia treatment (Doering, 2008). Ishiwata and colleagues have 
been treated hemophilia mice using AAV8 vector containing canine BDD -FVIII gene 
(Ishiwata et al., 2009). Sabatino and colleagues report indicated that canine BDD- FVIII dogs 
is stable than human BDD- FVIII, it can be considered in the hemophilia treatment (Sabatino 
et al., 2009). Doering et al were transferred hFVIII - sFVIII hybrid in to hematopoietic stem 
cells with lentiviral vector; cells expressed FVIII more than 100-8 times of cells transfected 
with hFVIII only (Doering et al., 2009). Zatloukal and colleagues report suggested that 
expressed FVIII would be observed if the adenovirus containing FVIII -transfected 
fibroblasts or mayoblasts move into liver or spleen cells, but do not observe in the 
transfected muscle cells (Zatloukal et al., 1995). Because there are no acceptable phenotypic 
correction of hemophilia mice, Liars was used induced pluri potent stem cell therapy 
technology, these cells suggested converting into all cells and can be transfected by 
recombinant AAV or lentiviral vectors (Liars, 2011). Studies conducted so far suggest that 
blood factors gene therapy with AAV in animal muscle (dogs and mice) was healthy for FIX, 
but did not sufficiently much success for FVIII (Haurigot et al., 2010; Wang & Herzog, 2005). 
It is believed that the clinical correction of hemophilia B depends on the dose of vector 
transfer into muscular hosts (mice and dogs) (Hagstrom et al., 2000; Kay et al., 2000). 
5.3 Hemophilia gene therapy with factor VII 
Activated FVII is used as recombinant factor VII (rFVII) can go around process dependent 
coagulation FVIII and FIX (Mackman et al., 2007), it helps blood coagulation through extrinsic 
pathway. It is an ideal choice in the treatment of patients with FVIII producing antibodies 
and hemophilia patients to be considered (Johannessen etal., 2000; Lauritzen et al., 2008a). 
FVII is used in patient`s surgery with hemophilia A (Lauritzen et al., 2008a) also effective in 
term of homostatic process (Hedner et al., 2000; Kenet et al., 1999). The VIIa (Novoseven; 
rhFVIIa) has been achieved great success in treating patients with hemophilia. On the FVIII 
or FIX defects or presence of inhibitory antibodies, FVIIa – tissue factor complex will activate 
coagulation FX. FVIIa can activate coagulation cascade which cause clot formation and 
bleeding is inhibited (Hong & Stachnik, 2010; Levy & Levi, 2009). The main drug problems 
are short half-life (3-6 hours) and highly price (Ramanarayana et al., 2011; Puetz, 2010; 
Agersø et al., 2011; ), more than one full dose of medication, especially for homeostasis 
regulation during surgeries are required. Hence, research groups around the world are trying 
different methods of gene transfer to express stable FVIIa in cells without the need to drug re 
administration (Ramanarayana et al., 2011). After biosynthesis of rhFVII as zymogen, it will 
be cut by proteases and biologically active through purification process (Huntington, 2009). 
The produced protein will breaks down at Arg152 and Ile153 to FVIIa. It is proposed that 
FVII gene transfer eliminates short half-life of rFVII and FVIII inhibitory antibody production 
(Ramanarayana et al., 2011). Emamgholipour et al (2009) and Margaritis (2010) established 
furin enzyme digestion site between Arg152 and Ile153 to generate FVIIa from FVII 
zymogene break down inside the targeted cell during FVII gene therapy strategy (Figure 6). 
Margaritis and colleagues were successfully corrected canine hemophilia B with this method 
 
 




Fig. 6. Mutagenesis method to create furin digestion site on the FVII protein (Proposed 
based on Emamgholipour et al., 2009; Margaritis, 2010) 
(Margaritis et al., 2004). Margaritis and colleagues were injected the mice through gene 
therapy by AAV contained FVII gene, FVII was produced in host cells (Margaritis et al., 
2004). Miller et al were injected mice muscle myoblasts with plasmids coding FVIII and FVII 
cDNA (muscle specific elements and poly A were placed on both sides of genes); they were 
observed FVII and related antibody after 4-5 days. They believed that post translation 
modification process was occurred in the muscle cells (Miller et al., 1995). Tomokiyo and 
colleagues showed that the composition of plasma FVIIa and FXa in the treatment of 
monkeys hemophilia B more effective than FVIIa alone (Tomokiyo et al., 2003). Ohmori et al 
have been used ectopic expression FVIIa in platelets to hemophilia A treatment, they were 
transferred SIV containing platelet glycoprotein Ib alpha specific promoter into bone 
marrow cells, was lead to FVII expression on the platelets surface. This construct was 
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corrected mouse hemophilia A phenotype (Ohmori et al., 2008). Margaritis have been 
treated canine hemophilia by AAV containing FVII through the portal vein (Margaritis et al., 
2009). To overcome the repeated injection problem, Obergfell and colleagues were studied 
hemophilia treatment and suggested permanent expression of FVII in canine hemophilia 
model through gene therapy method (Obergfell et al., 2010). 
6. Conclusion 
There are some reported of FVIII and FIX gene transfer by viral vectors in animal models, 
but no evidence so far reported successful treatment of human hemophilia gene therapy by 
this method. Researchers have used FVII to overcome antibody production in treatment of 
FVIII deficiency. Despite several reports of curing hemophilia A with FVII in animals, there 
is no yet successful reported in human. 
Methods proposed for the future: reviewing the history of hemophilia gene therapy by viral 
vectors, identified several reasons that cannot be sure of the viruses used for gene transfer: 
1) Application of viruses is associated with inappropriate chromosomal insertion and makes 
the undesirable point mutations (Nakai et al., 2003; Miller et al., 2002). 2) Viruses are 
carcinogens (Check, 2003). 3) The viruses will cause the host immune response (Lefesvre et 
al., 2003) which is temporarily being transgene. 4) Because viruses genome are great than 
non-viral vectors the sequences of the viruses cannot be controlled by reseaechers. 5) 
Preparation of this vector requires a lot of time and money. Although non-viral gene 
transfer is less efficient than virus vector but have been told no above disadvantages and 
their use for gene transfer in human can be safer than viruses. Vectors are suggested to be 
prepared as non-viral vector for targeting the rDNA locus of human genome by 
homologous recombination method, and as ex vivo gene transfer in humans to be done with 
them. 
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Preparation of this vector requires a lot of time and money. Although non-viral gene 
transfer is less efficient than virus vector but have been told no above disadvantages and 
their use for gene transfer in human can be safer than viruses. Vectors are suggested to be 
prepared as non-viral vector for targeting the rDNA locus of human genome by 
homologous recombination method, and as ex vivo gene transfer in humans to be done with 
them. 
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1. Introduction 
Rupture of anterior cruciate ligament (ACL) is a common knee trauma which leads to 
anterior knee instability. The ACL has long been thought to have poor capacity for healing 
with suture repair. ACL reconstruction is the standard of care which can restore the knee 
stability of ACL deficit knee. Although ACL reconstruction is an excellent operation for 
restoring the sagittal plane stability of the knee, significant problems remain. Studies have 
demonstrated that remodeling of the graft usually takes longer than expected, and many 
patients develop arthritis after an ACL tear, even if they have a reconstruction, with rates as 
high as 78% reported at 14 years post-operatively (1).  
In ACL reconstruction, inflammation and necrosis of the graft can occur immediately after 
transplantation. The graft then undergoes revascularization and cellular repopulation 
from an extrinsic origin, followed by a remodeling period. In the early phase, the 
properties of the grafted tendon are deteriorated and do not recover to physiological 
levels even at 18 months after surgery (2). Therefore, the main goals of ACL 
reconstruction are to prevent the deterioration of grafted tendon and accelerate 
mechanical restoration of the deteriorated graft. New solutions are needed to accelerate 
and improve remodeling of tendon grafts. 
The ACL graft remodeling process is regulated by a complex growth factor network. Many 
growth factors have been evaluated for their ability to stimulate tendon and ligament 
healing in vitro and in vivo. In enhancing ligament repair, the most interesting candidates 
are insulin-like growth factor-I (IGF-I), transforming growth factor β1 (TGFβ1), vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth 
factor (PDGF), and basic fibroblast growth factor (bFGF). PDGF and VEGF appear in the 
early stage of reconstruction, during the stage of graft maturing, the granular tissue becomes 
ligament-like tissue and both PDGF and VEGF are not able to be detected gradually, as the 
replacement, TGFβ1and other cytokines are involving in the reconstruction process to 
mature the ligament. TGFβ1 is the main cytokine for the maturing of ligament. Studies have 
 
Targets in Gene Therapy 
 
388 
Wacey AI, Kemball-Cook G, Kazazian HH, Antonarakis SE, Schwaab R, Lindley P, 
Tuddenham EG (19996) The haemophilia A mutation search test and resource site, 
home page of the factor VIII mutation database: HAMSTeRS. Nucleic Acids Res; 
24(1): 100-102. ISSN: 0305-1048 
Wadelius C, Blombäck M, Goonewardena P, Anvret M, Lindstedt M, Gustavson KH, 
Pettersson U (1991). Evaluation of DNA-based diagnosis for haemophilia A. Scand J 
Clin Lab Invest ; 51(7): 625-633. ISSN: 0036-5513 
Wang L, Herzog RW (2005). AAV-mediated gene transfer for treatment of hemophilia. Curr 
Gene Ther. 2005 Jun; 5(3): 349-360. ISSN: 1566-5232 
Wehnert M, Shukova EL, Surin VL, Schröder W, Solovjev GYa, Herrmann FH (1990a). 
Prenatal diagnosis of haemophilia A by the polymerase chain reaction using the 
intragenic hind III polymorphism. Prenat Diagn; 10(8): 529-532. ISSN: 0197-3851 
Wehnert M, Shukova EL, Surin VL, Schröder W, Solovjev GYa, Grinjeva NI, Herrmann FH 
(1990b). Genomic carrier detection and prenatal diagnosis of haemophilia A in 
families at risk using the polymerase chain reaction (PCR). Folia Haematol Int Mag 
Klin Morphol Blutforsch; 117(4): 617-622. ISSN: 0323-4347 
White GC, Shoemaker CB. (1989). Factor VIII Gene and Hemophilia A. Blood; 73(10): 1-12. 
ISSN 0006-4971 
Wiestner A, Cho HJ, Asch AS, Michelis MA, Zeller JA, Peerschke EI, Weksler BB, Schechter 
GP (2002). Rituximab in the treatment of acquired factor VIII inhibitors. Blood; 
100(9): 3426-3428. ISSN 0006-4971 
Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, 
Hollingshead P, Wion KL, et al. (1984). Expression of active human factor VIII from 
recombinant DNA clones. Nature; 312(5992): 330-337. ISSN : 0028-0836 
Wu G (1991). Prenatal diagnosis of hemophilia A by DNA analysis. Zhongguo Yi Xue Ke Xue 
Yuan Xue Bao; 13(6): 428-434. ISSN: 0376-2491 
Yoshioka A, Fukutake K, Takamatsu J, Shirahata A; Kogenate Post-Marketing Surveillance 
Study Group (2003). Clinical evaluation of a recombinant factor VIII preparation 
(Kogenate) in previously untreated patients with hemophilia A. Int J Hematol; 78(5): 
467-474. ISSN: 0925-5710 
Youssoufian H, Antonarakis SE, Aronis S, Tsiftis G, Phillips DG, Kazazian HH Jr (1987). 
Characterization of five partial deletions of the factor VIII gene. Proc Natl Acad Sci U 
S A; 84(11): 3772-3776. ISSN: 0027-8424.  
Zatloukal K, Cotten M, Berger M, Schmidt W, Wagner E, Birnstiel ML (1994). In vivo 
production of human factor VII in mice after intrasplenic implantation of primary 
fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. 
Proc Natl Acad Sci U S A; 91(11): 5148-5152. ISSN: 0027-8424 
Zhang WW, Josephs SF, Zhou J, Fang X, Alemany R, Balagué C, Dai Y, Ayares D, 
Prokopenko E, Lou YC, Sethi E, Hubert-Leslie D, Kennedy M, Ruiz L, Rockow-
Magnone S (1999). Development and application of a minimal-adenoviral vector 
system for gene therapy of hemophilia A. Thromb Haemost; 82(2): 562-571. ISSN: 
1538-7933 
21 
The Different Effects of TGF-β1, 
 VEGF and PDGF on the  
Remodeling of Anterior Cruciate 
Ligament Graft 
Changlong Yu, Lin Lin and Xuelei Wei 
Institute of Sports Medicine, Peking University Third Hospital,  
No.49, North Garden Road, Haidian District,  
P.R.China 
1. Introduction 
Rupture of anterior cruciate ligament (ACL) is a common knee trauma which leads to 
anterior knee instability. The ACL has long been thought to have poor capacity for healing 
with suture repair. ACL reconstruction is the standard of care which can restore the knee 
stability of ACL deficit knee. Although ACL reconstruction is an excellent operation for 
restoring the sagittal plane stability of the knee, significant problems remain. Studies have 
demonstrated that remodeling of the graft usually takes longer than expected, and many 
patients develop arthritis after an ACL tear, even if they have a reconstruction, with rates as 
high as 78% reported at 14 years post-operatively (1).  
In ACL reconstruction, inflammation and necrosis of the graft can occur immediately after 
transplantation. The graft then undergoes revascularization and cellular repopulation 
from an extrinsic origin, followed by a remodeling period. In the early phase, the 
properties of the grafted tendon are deteriorated and do not recover to physiological 
levels even at 18 months after surgery (2). Therefore, the main goals of ACL 
reconstruction are to prevent the deterioration of grafted tendon and accelerate 
mechanical restoration of the deteriorated graft. New solutions are needed to accelerate 
and improve remodeling of tendon grafts. 
The ACL graft remodeling process is regulated by a complex growth factor network. Many 
growth factors have been evaluated for their ability to stimulate tendon and ligament 
healing in vitro and in vivo. In enhancing ligament repair, the most interesting candidates 
are insulin-like growth factor-I (IGF-I), transforming growth factor β1 (TGFβ1), vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), platelet derived growth 
factor (PDGF), and basic fibroblast growth factor (bFGF). PDGF and VEGF appear in the 
early stage of reconstruction, during the stage of graft maturing, the granular tissue becomes 
ligament-like tissue and both PDGF and VEGF are not able to be detected gradually, as the 
replacement, TGFβ1and other cytokines are involving in the reconstruction process to 
mature the ligament. TGFβ1 is the main cytokine for the maturing of ligament. Studies have 
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demonstrated improved cellular proliferation and migration as well as increased collagen 
production rates with the addition of growth factors. 
2. VEGF 
Angiogenesis is an essential step in the process of tendon healing and tendon graft 
remodeling, in which neovascularization prompts delivery of inammatory cells, broblasts 
and growth factors to the wound site. VEGF plays an essential role in angiogenesis, 
regulating the activation, migration, and proliferation of endothelial cells in various 
pathological conditions. It is well-known that angiogenesis is an essential step in the healing 
process of tendon and tendon graft remodeling. Two studies found that VEGF therapy can 
enhance revascularization in the graft, as well as promoting the infiltration of fibroblasts 
after ACL reconstruction; however, it did not affect the mechanical properties of the in situ 
freeze-thawed ACL model (3). Furthermore, it decreased the stiffness of the grafted tendon 
with increased knee laxity, 12 weeks after ACL reconstruction in a sheep model (4). 
Yoshikawa et al. examined the effects of an application of VEGF to a hamstring graft in a 
sheep ACL reconstruction model and demonstrated that the linear stiffness of the VEGF-
treated graft was significantly lower than that of the PBS-treated group at 12 weeks (4). In 
this study, the stiffness of the VEGF165 group was higher than those of the control group at 
12 weeks, although there was no significant difference (P > 0.05). There are two possible 
reasons for this difference.  
In our study, the stiffness of the VEGF165 group was higher than those of the control 
group at 12 weeks, although there was no significant difference (5). There are two possible 
reasons for this difference. One is the method of applying this factor. In our study, the 
method was transfer of the VEGF165 gene, rather than the gene products. The secretion 
time and quantity of VEGF165 may be suitable for ACL graft remolding. The other 
possible reason is the use of BMSCs in our experiment. BMSCs have the capacity to 
differentiate into various mesenchymal lineages, including ligament, tendon, muscle, 
bone, cartilage and adipose tissue. Kanaya et al. reported that the intra-articular injection 
of BMSCs could accelerate the healing of partially torn knee ACLs in a rat model (6). Our 
study also demonstrated that the application of BMSCs is effective in enhancing collagen 
deposition and changing certain structural properties for improving tendon allograft 
remodeling after ACL reconstruction in a rabbit model (7). The exact reasons for the better 
healing observed in injured ACLs using BMSCs are uncertain. One possibility is that 
BMSCs directly differentiated into ligament fibroblasts within the healing environment. 
Alternatively, another possibility is that injected mesenchymal stromal cells directly 
contribute as a cellular source for ligament healing. BMSCs may also secrete a variety of 
growth factors, which may contribute to the activation and recruitment of local fibroblast 
precursors or enhance extracellular matrix synthesis.  
3. PDGF 
Many studies have also attempted to determine the effects of PDGF-BB on a ligament 
engineering system. It has been demonstrated that it promoted broblast proliferation, 
matrix synthesis, neovascularization, and mechanical properties. In our studies in the gene-
transfected group, more cells and blood vessels could be found at 3 weeks, and more 
collagen was synthesized in the ACL as compared with the control and MSCs group (7). 
The Different Effects of TGF-β1, VEGF and PDGF  
on the Remodeling of Anterior Cruciate Ligament Graft 
 
391 
Similar to our ndings were the results of a study by Nakamuraetal, which described an 
increased vascularity and enhanced collagen deposition in the wound of a patellar ligament 
afte rPDGF-B gene transfer in rats (8). 
The mechanisms by which PDGF affects ligament healing are complex. Kuroda et al. studied 
immunohistochemically the presence and the level of bFGF, TGF-ß, PDGFAA and PDGF-BB 
expression in a model of ACL reconstruction using a free patellar tendon autograft (9). They 
found that all tested growth factors were upregulated with a maximum expression at 3 
weeks and up to 60% of all cells were stained PDGF positive. PDGF is one of the most 
effective growth factors during tendon graft remodeling. 
Tendon grafts are exposed to the reduced PO2 of the intra-articular environment, Petersen 
et al. (10) showed that PDGF as well as hypoxia strongly enhanced VEGF secretion from 
tenocytes. Besides this VEGF-mediated angiogenetic effect, PDGF further more induces the 
synthesis of other growth factors, including IGF, and regulates the presence of other 
receptors (11). Therefore, it could be concluded that the expression of PDGF-BB by the small 
number of transfected cells may activate a cascade of PDGF-BB throughout the wound. 
Some researches (12) showed that there are some growth factors receptors such as PDGFR 
on the surface of MSCs. MSCs from bone marrow might have a better response to PDGF as 
compared with those from the ACL or MCL regarding proliferation and migration. Thus, it 
might be suggested that a tendon graft seeded with MSCs-PDGF-BB is more likely to 
promote MSCs or broblast proliferation and migration and accelerate graft tissue 
remodeling. 
The observations of Kuroda et al. also imply that if a growth factor is administered to the 
tendon graft, its tissue concentration should be highest around the third week to enhance 
the effect of the other intrinsical growth factors (9). In our study at 3 weeks, we found 
signicantly higher vascularity in the PDGF-transfected grafts. The concentration of PDGF-
BB inarticular uid from gene-transfected rabbit increased at 3 week, got to the highest 
point at 6 week and then dropped down. This rapid reduction in the level of their 
localization indicates that once the extrinsic cells inltrate to the graft and revascularization 
is complete, these growth factors may have less signicance for subsequent remodeling. 
Therefore, it is very important to nd the appropriate time point for the administration of 
growth factors to promote healing. 
In vivo study by Hildebrand et al. demonstrated that the improvements in the MCL 
structural properties were dose-dependent to PDGF-BB (13).That is, a higher dose of PDGF-
BB improved more structural properties of the femur–MCL–tibia complex than a lower dose 
of PDGF-BB did. In both the MSCs group and gene-transfected group, although there are 
much more differences in morphology at the early stages, the structure of the ACL in the 
two groups have less signicant differences at the later stages, especially at 12 weeks. For an 
ACL reconstruction model, we don’t know if the dosage we used was appropriate to 
maximally enhance graft remodeling, or this indicates that the growth fact or PDGF may 
have early effect on the ACL reconstruction and have less signicance for subsequent 
remodeling. It is essential to nd an appropriate dosage for ACL reconstruction. 
4. TGFβ1 
Many studies indicate that TGFβ1 plays a key role in the healing process of ligaments. 
TGFβ1 increased both collagen and non-collagenous protein synthesis by the introduction of 
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ACL fibroblasts (14, 15). Furthermore, it has also been shown to increase ACL fibroblast 
proliferation. TGFβ1 enhanced graft remolding in ACL reconstruction by inhibiting 
mechanical deterioration (16).  
In situ freeze-thawed ACL tissues, which were established as an autograft model, 
transfected with TGFβ1 and EGF, significantly reduced the increase in water content and 
cross-sectional area and reduced the deterioration of the ACL (17). However, the results 
were dose- and time-dependent, and of high cost. Furthermore, the clinical application of 
growth factors is hampered by delivery problems. Amiel et al. reported that a high dose of 
TGFβ1 inhibits proliferation of rabbit ACL fibroblasts (18). One study reported that an 
application of low-dose TGFβ1 mixed with fibrin sealant enhanced the remodeling process 
of the in situ freeze-thawed ACL, whereas a high dose of TGFβ1 had no effect (17). We 
demonstrated that TGFβ1 gene-modified BMSCs implanted within the Achilles allograft in 
ACL reconstruction significantly affects the biomechanical properties of the graft. Our 
results suggest that the transfer of the TGFβ1 gene, rather than the gene products, may be 
the most expeditious method of harnessing this factor for the purposes of accelerating ACL 
graft remolding (5). 
Our results showed that the ultimate failure load and the stiffness of the grafted tendon 
were significantly increased in the TGFβ1 treatment group compared with the VEGF165 and 
control groups at 6, 12 and 24 weeks after surgery. Meanwhile toluidine blue staining of the 
grafts appeared positive only in the TGFβ1 group at 12 weeks. ACL has different 
histological characteristics from medical collateral ligament (MCL), which is more cartilage-
like in nature. The normal ACL is positive to toluidine blue staining, so we hypothesized 
that TGFβ1 may promote early maturation of the graft. Histological examination and 
immunohistochemistry showed significantly enhanced cell infiltration and revascularization 
at 3, 6, and 12 weeks in the VEGF165 and the TGFβ1/VEGF165 groups. However, VEGF165 
cDNA-transduced BMSCs exhibited no significant effects on the mechanical properties of 
the ACL graft, while TGFβ1/VEGF165 cDNA-transduced BMSCs showed the best 
biomechanical properties of the ACL graft at 24 weeks after surgery. This work shows that 
the use of TGFβ1 and the co-expression of TGFβ1/VEGF165 of gene therapy may be useful 
for accelerating the remolding of the graft after ACL reconstruction. 
Previous study by Lee et al. demonstrated that VEGF and TGFβ1 were both expressed in 
ACL healing (18). We demonstrate here that the combination of TGFβ1 and VEGF165 gene 
has a synergistic effect on accelerating the remolding of the ACL graft, but few studies have 
defined the exact regulating mechanisms of these two growth factors during ligament 
healing. Several studies have demonstrated that together VEGF and TGFβ1 can enhance 
each the synthesis of one another (19, 20). These studies revealed that the mechanism of 
synergy is probably mediated through Smad3, HIF-1α/β, Smad3/4, PI3K/Akt or ERK1/2 
signaling pathways. 
5. The Effects of TGF-β1, VEGF165 transfer on achilles tendon healing 
The Achilles tendon itself is a dense, regular connective tissue consisting primarily of type I 
collagen and interspersed specializedmesenchymal cells (tenocytes) responsible for the 
maintenance of collagen structure. With respect to reconstruction of the tendon, there are 
three key factors which must be addressed: the cell, the ber, and their arrangement. The 
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properties of the tendon matrix and its regulation by growth factors are largely 
uncharacterized. We examined the effects of implantation of BMSCs transduced with either 
the TGF-β1, VEGF165, or both on experimentally injured Achilles tendons in a rabbit model 
in vivo (21).  
The maximum failure load, the tendon stiffness, and the elastic modular of the healing 
tendons were signicantly increased in the TGF-β1 and the co-expression treatment 
groups compared with the other treatment groups at one, two, four, and eight weeks after 
surgery. Moreover, there was evidence of accelerated remodeling of the lesion in response 
to TGF-β1 and co-expression TGF-β1/VEGF165 treatment, while the size of the ruptured 
callus was increased in the presence of VEGF165. Histological examination showed a 
much more organized and homogeneous pattern of collagen bers at all time points in the 
lesions of the TGF-β1 and the co-expression treatment groups. Both single brils and the 
collagen bers had a greater diameter, with a higher degree of collagen crimp than the 
collagen of the other treatment groups. This was conrmed by Sirius red staining in 
conjunction with polarized light microscopy, which showed a higher shift of small 
yellow-green bers to strong yellow-orange bers after two, four, and eight weeks in the 
TGF-β1 and the co-expression treatment groups. Immunohistochemistry showed more 
vessels after one, two, four, and eight weeks in the VEGF165 treatment group, but only a 
few vessels in the co-expression treatment group. There was also an earlier shift from 
broblasts to brocytes within the healing tendon, with fewer fat cells present in the 
tendons of the TGF-β1 and the co-expression treatment groups compared with intact 
tendon. Thus treatment with TGF-β1 transduced BMSCs resulted in a promising 
acceleration and improvement of tendon healing, particularly inuencing early tissue 
regeneration, leading to quicker recovery and improved biomechanical properties of the 
Achilles tendon. However, VEGF165 transduced BMSCs exhibited a negative role. The 
angiogenesis effects of VEGF165 were diminished by TGF-β1, while the collagen synthesis 
effects of TGF-β1 were only slightly affected by VEGF165. The TGF-β1 and VEGF165 
synthesized of BMSCs with gene transfer were evaluated by ELISA. However, the 
stimulation effect is very weak with heterologous gene transfer in contrast with 
homologous gene transfer. In terms of the broblasts, the mRNA expression of Collagen 
type I, type III and Fibronectin were evaluated. All showed signicant increasing under 
the stimulation of TGF-β1 or TGF-β1/VEGF165 co-existing. Nevertheless, the broblasts 
stimulated by VEGF165 showed no difference with control. 
We demonstrated that gene modied BMSCs implanted within the tendon-repair site 
contributed to early tendon-healing following primary repair, and that growth factor 
signaling can regulate the mechanical properties of the tendon matrix by affecting tendon 
mass and architecture. These data provide a basis for future application of supplementary 
therapy of surgery for tendon and ligaments. Future studies determining the optimal 
growth factor(s), dose, and timing and site of administration are required, along with the 
interactions between different growth factors. 
6. Summary 
The effects of TGF-β1, VEGF and PDGF on the remodeling of anterior cruciate ligament 
graft are different. PDGF, VEGF and TGFβ1transfected MSCs accelerated cellular inltration 
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and enhanced collagen deposition in the graft. PDGF and VEGF promoted the angiogenesis 
of the graft, but did not show any improvement of the biomechanical nature of the graft. 
Only TGFβ1accerated the maturing of graft and improved the biomehchanical nature. 
TGFβ1 co–expression with VEGF165 in gene-transfected BMSCs could accelerate the 
remodeling of the reconstructed ligament. The cross-talk between TGFβ1 and VEGF165 has 
positive consequences, with TGFβ1/VEGF165-gene-transfected BMSCs could significantly 
promote angiogenesis of the reconstructed ligament, while achieving the best mechanical 
properties of the reconstructed ligament. However, the molecular mechanism that regulates 
these two growth factors during ligament healing still needs to be fully elucidated. The 
effects of other growth factors on the remodeling of ACL graft, such as IGF-1, bFGF, need 
further study. 
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of the graft, but did not show any improvement of the biomechanical nature of the graft. 
Only TGFβ1accerated the maturing of graft and improved the biomehchanical nature. 
TGFβ1 co–expression with VEGF165 in gene-transfected BMSCs could accelerate the 
remodeling of the reconstructed ligament. The cross-talk between TGFβ1 and VEGF165 has 
positive consequences, with TGFβ1/VEGF165-gene-transfected BMSCs could significantly 
promote angiogenesis of the reconstructed ligament, while achieving the best mechanical 
properties of the reconstructed ligament. However, the molecular mechanism that regulates 
these two growth factors during ligament healing still needs to be fully elucidated. The 
effects of other growth factors on the remodeling of ACL graft, such as IGF-1, bFGF, need 
further study. 
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1.Introduction 
Recombinant growth hormone (GH) was one of the first proteins to be synthesized via DNA 
recombinant techniques in the late seventies. It was also one of the first proteins to be used 
in studies of animal models for gene therapy, already in the eighties. This was due to the 
real therapeutic need for GH, combined with the fact that its detection by well-known 
immunoassay methods is facile and sensitive. Moreover, evident phenotypic effects can be 
observed and measured in several animal models (e.g., dwarf mice), some of which have 
GH deficiencies that closely resemble their human counterparts. 
GH gene therapy has the potential advantage of circumventing laborious and expensive 
purification processes, quality control procedures and the repetitive injections that are 
required in the conventional treatment. The ideal situation would, of course, be to introduce 
the deficient protein into the circulation via a mechanism that resembles the natural process. 
These treatments have not yet reached the clinical stage for humans, the major challenge 
being to achieve a sustainable and regulated in vivo GH secretion. However, several 
interesting and promising ex vivo and direct in vivo DNA administration strategies for GH 
gene therapy have been developed and studied using animal models. These studies 
obviously open the way for the systemic delivery of other therapeutic proteins in addition to 
GH. 
The various ex vivo models for GH gene therapy are based on the use of target cells, such as 
keratinocytes, fibroblasts, endothelial cells, peritoneal mesothelial cells, or skeletal 
myoblasts. These cells can also be encapsulated to prevent rejection when implanted in 
allogeneic hosts. The majority of the methodologies are carried out via cell isolation and in 
vitro cultivation, genetic modification by viral or non-viral vectors containing the GH gene 
and re-implantation of the secreting cells onto the animal. 
Primary keratinocytes are one of the most attractive vehicles for gene transfer and gene 
therapy. They are among the most accessible cells in the body and can be serially 
propagated in culture; the procedure for their transplantation is already well established, 
e.g., for burn patients, and the therapy can be reversed by excision of the genetically 
modified tissue. Cutaneous gene therapy has already been demonstrated to be a powerful 
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tool for the successful treatment of severe skin disorders such as epidermolysis bullosa 1. 
Keratinocytes can also act as cellular bioreactors, secreting GH or other proteins 
systemically. When primary human keratinocytes were retrovirally transduced with the 
human (hGH) or mouse (mGH) growth hormone genes in our laboratory, they exhibited 
high and stable in vitro secretion. When these hGH-secreting keratinocytes were grafted 
onto immunodeficient dwarf mice (lit/scid), a significant body weight gain was obtained, 
despite low hGH serum levels. When the conventional epithelial sheet grafting 
methodology described by Ian Barrandon and coworkers in 1988 2 was replaced by the 
implantation of an organotypic raft culture, peak values of up to 20 ng mGH/ml were 
observed in the circulation of lit/scid mice. However, this was followed by a rapid decline 
of the levels to a baseline value of ~2 ng/ml 3. For comparison, the mGH serum 
concentration in heterozygous lit/+ mice is of the order of 6 ng/ml. 
Among the various ex vivo methodologies for GH gene therapy, the implantation, by a 
Canadian research group 4, of encapsulated mGH-secreting myoblasts into the peritoneal 
cavity of Snell dwarf mice should be mentioned. Using this procedure, the recombinant 
allogeneic cells were protected from rejection and remained functional for at least 6 months. 
The animals showed a remarkable increase in body weight and the increase in body length 
doubled compared to the control group. 
The GH gene therapy approach based on in vivo gene transfer via adenoviral injection 
developed by a Houston (TX) group led to a complete phenotypic correction of dwarfism in 
little mice (lit/lit) 5. Nonetheless, this strategy suffers from several potentially serious 
problems that require more profound investigation prior to its adaptation to human 
therapy. One of these problems is the high expression of the transgene, mostly by 
hepatocytes, leading to continuously elevated GH and IGF-I circulating levels that may 
cause dysfunctions or cancer. 
A much better option would appear to be the direct administration of naked plasmid 
DNA, a methodology that has been successfully adopted by several authors in the last 
decade. Analysis of growth parameters such as body weight, organ weight (quadriceps 
muscles, liver, kidneys, heart and spleen) and total (nose-to-tail) length of the animals 
have been used to study the endocrine and local (autocrine/paracrine) effects of hGH in 
greater depth after intramuscular DNA administration in immunodeficient dwarf mice 
(lit/scid) 6. Although the majority of the strategies described for GH gene therapy are still 
limited by the absence of an appropriate mechanism for regulating in vivo hormone 
expression and secretion, a number of factors favor in vivo drug generation as the best 
alternative. In particular, this would avoid costly industrial productions, very expensive 
treatments and would improve the quality of life of patients (children and adults) 
suffering from GH deficiency (GHD). 
In this chapter, we review the results reported in five studies from our laboratory, primarily 
involving ex vivo methodologies based on primary human keratinocyte retroviral 
transduction and direct plasmid DNA administration in immunodeficient (lit/scid) and 
immunocompetent (lit/lit) dwarf mice. We also analyze the data reported in nine studies by 
seven other research groups using ex vivo techniques based on transduced fibroblasts and 
myoblasts and in vivo methodologies based on direct adeno and adenoassociated viral 
vectors or on naked DNA administration. The animal models used by these authors include 
lit/lit, Snell dwarf mice, hypophysectomized rats and mice, growth hormone-releasing 
hormone knockout (GHRHKO) mice and growth-retarded swine. 
Different ex Vivo and Direct in Vivo DNA Administration Strategies 
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2. Ex vivo strategies 
In 1995, the Canadian group mentioned above reported that the growth defect of dwarf 
mice (Snell dwarf) could be partially corrected by implanting microencapsulated allogeneic 
myoblasts engineered to secrete mouse growth hormone. The encapsulation of these mouse 
myoblasts into GH-deficient Snell dwarf mice provided a completely homologous system 4. 
The plasmid pKL-mGH, encoding mGH cDNA under the regulation of human β-actin 
promoter and also containing the neomycin resistance gene, was used to transfect the mouse 
myoblast cell line C2C12. G418 resistant clones were selected and screened for the level of 
mGH in the culture medium. Clone Myo-45, which secreted 147 ng of mGH/106 cells/day, 
was selected for encapsulation. Microcapsules were implanted via a 22G catheter into the 
peritoneal cavity and, by the end of the 3rd week, the body weight of the dwarf mice had 
increased about 1.6-fold and the increase in body length had doubled compared to the 
control group. There were also significant increases in the levels of non-esterified free fatty 
acids (a measure of the lipolytic effect of the capsule-delivered mGH), while peripheral 
organ weights and tibial growth plate thickness were also significantly greater. The authors 
hypothesized that most of the capsule-derived mGH was sequestered in the liver through 
the hepatic GH receptors, inducing the secretion of hepatic insulin-like growth factor I (IGF-
I), which mediates most of the GH-dependent systemic metabolic effects. After 5 weeks, 
however, a lack of further growth in weight or length was evident in all of the mice. 
According to the authors, this was not due to the absence of mGH transgene expression by 
the encapsulated cells, but rather to the non-responsiveness of the mice to the hormone at 
this age (13-15 weeks). In fact, a second implantation of freshly-prepared capsules on day 42 
did not result in any further growth enhancement. Moreover, encapsulated cells retrieved at 
the end of the experiment (178 days) continued to secrete in vitro >200 ng/106 cells/day of 
mGH. Interestingly, all the different groups of dwarf mice had low or undetectable GH 
levels in their plasma, i.e. 1.32-1.42 ng/ml at best, comparable to the detection limit of ≤ 0.62 
ng/ml of the mGH RIA. The authors´ assumption was that the capsules probably delivered 
circulating levels of mGH below the detection limit of the assay. Nonetheless, this study 
demonstrated the clinical efficacy of this non-autologous system and its potential for 
widespread application in therapies requiring a continuous systemic supply of recombinant 
gene products. 
Fibroblasts are also a potentially interesting cell type for ex vivo gene delivery because of 
their easy accessibility, facile culture in vitro, convenient re-implantation and their potential 
for delivering proteins to the circulation. In 1995 a research group at the Taiwan National 
University employed hypophysectomized rats as an animal model to explore the feasibility 
of using genetically engineered fibroblasts for growth hormone gene therapy 7. A bicistronic 
retroviral vector controlled by the LTR promoter, which contained a porcine growth 
hormone (pGH) cDNA at the first cistron and a neomycin resistance gene at the second 
cistron, was used to infect primary rat embryo fibroblasts. The transduced cells exhibited an 
in vitro expression level of up to 1.18 µg pGH/106 cells/day and 5 x 106 cells/animal were 
injected directly into the peritoneum of hypophysectomized rats, leading to a significant 
growth of the tibia when tested at days 15 and 57 post-implantation. Alternatively, 1 x 106 
cells were cast in collagen matrices (0.5 cm in diameter) and implanted underneath the skin 
on the back of the rats: a semi-quantitative RT-PCR confirmed that the pGH expression by 
these cells lasted up to 70 days. Unfortunately, a sensitive ELISA system was not available 
and pGH could not be detected in the sera of the animals. However, the tibia growth 
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bioassay in hypophysectomized rats did provide clear evidence for the in vivo activity of 
pGH in a direct functional assay and confirmed that fibroblasts are indeed capable of 
persistently expressing foreign genes in vivo. 
The same Chinese research group subsequently used primary porcine fetal fibroblasts, 
transduced with the same pGH-carrying vector described above, to enhance the weight gain 
of growth-retarded Tao-Yuan Swine, a local breed in Taiwan that is slow growing and fat, 
but palatable8. Immortalized fibroblasts were avoided because of their tumorigenic 
potential, even though they have been used quite successfully in several different studies in 
mice. The transduced primary cells were encapsulated with the same type of alginate-poly-
L-lysine-alginate membranes used previously for mice myoblasts 4 and then implanted into 
the peritoneal cavity of the swine, resulting in a significant increase in weight gain already 
on day 16 post-implantation, even though no increase in serum pGH could be detected. The 
use of immunoprotective microcapsules thus constitutes a simple method of delivering 
recombinant genes in vivo and proved to be a valid approach for the improvement of the 
growth of these animals. Since the microcapsules obviate the need for patient-specific ex vivo 
preparations and are amenable to industrial-scale production and quality control, this 
approach is also potentially economically viable. 
Our research group has focused its ex vivo activities mainly on the use of human primary 
keratinocytes that were retrovirally transduced with the human (hGH) or the mouse (mGH) 
GH genes, implanting them into immunodeficient dwarf (lit/scid) mice 3,9-11. Epidermal 
keratinocytes were chosen as the target of our gene therapy methodology because they are 
among the most accessible cells in the body and can be serially propagated in culture, 
following the pioneering work of Rheinwald and Green 12. When these cells were stably 
transduced with the hGH gene (under control of the retroviral LTR promoter), a high in vitro 
secretion of up to 7 µg hGH/106 cells/day was obtained 9. Their grafting onto lit/scid mice 
led to circulating hGH serum levels of 0.2-0.3 ng/ml during a 12-day assay (peak value, 1.5 
ng/ml at 4h). Grafted mice also showed an increase in body weight (0.060 g/animal/day), 
which was significantly higher (P<0.01) than that of the controls (0.023 g/animal/day). This 
was the first time that continuous in vivo secretion of the hormone and subsequent 
phenotypic alterations due to the grafting of transduced, hGH-secreting primary human 
keratinocytes had been demonstrated in lit/scid mice, an animal model known to be very 
sensitive to low concentrations of hGH 13. 
Conventional epidermal sheets of these mGH-secreting keratinocytes, prepared by us using 
the classical technique of Barrandon et al.2, showed a drop in secretion rates of >80% simply 
due to detachment of the epithelium from its substratum. Replacement of this conventional 
grafting methodology by organotypic raft cultures14 completely overcame this problem. 
Employing a similar ex vivo strategy and this modification of the grafting resulted in a very 
high, stable in vitro secretion of up to 11 µg mGH/106 cells/day. Moreover, the amazing 
value of ~26 µg mGH/106 cells/day could be reached by clonal selection11, performed by 
seeding the mGH-secreting keratinocytes at low densities (~500 cells/10 cm culture dish) 
and isolating colonies with a diameter of ~5 mm by the use of cloning cylinders. Cells were 
expanded four times by serial passage (approximately one passage/week), counted and the 
medium collected for mGH determination by radioimmunoassay. Clonal selection revealed 
that, after four serial passages (equivalent to > 30 cumulative cell doublings or > 107 cells), 
approximately 30% (7 out of 24) of the isolated clones maintained or presented increased 
mGH expression. This percentage represents the fraction of transduced keratinocyte stem 
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cells present, a very important parameter for attaining the desired persistent gene 
therapeutic effect. The stable long-term grafting of such cultures onto lit/scid mice could be 
followed for more than 4 months, with a significant weight increase over the control group 
being observed in the first 40 days. Circulating mGH levels reached a peak of 21 ng/ml just 
1h after grafting but, as already mentioned, these levels fell rapidly (in ~24 h) to baseline 
values 3. Thus, in this study, an animal model for cutaneous gene therapy based on lit/scid 
mice and on the grafting of organotypic raft cultures was developed and the mGH-secreting 
primary human keratinocytes employed exhibited the highest in vitro secretion ever 
reported for any form of GH in these cells. However, the desired sustainability of the in vivo 
secretion of the transgene was not achieved. 
Several hypotheses can be raised as the possible cause(s) of this immediate suppression or 
blocking of exogenous GH in the circulation of lit/scid mice after the grafting. These 
include: (i) a limited mGH circulatory half-life in lit/scid; (ii) a rapid clearance from the 
bloodstream due to a specific binding or selective transfer; (iii) impediments due to poor 
vascularization, to a fast inflammatory process or to an unidentified specific barrier; (iv) the 
occurrence of extremely efficient apoptotic events, transgene inactivation or promoter 
failure; (v) partial immune reactivity spontaneously developed by the immunodeficient 
mice, leading to some production of B and T cells (i.e., “leakiness”). Although several of 
these hypothetical mechanisms could be rationally or even experimentally excluded, so far 
we have been unable to positively prove the existence of any one of them. This led us think 
that comparative tests carried out by injecting mGH-expressing naked DNA, enhanced by in 
vivo electroporation, at approximately the same epidermal site as keratinocyte grafting, 
might prove to be informative. This resulted in studies from our laboratory of the in vivo 
administration of naked DNA to lit/lit and lit/scid mice, with the goal of comparing the 
circulating hormone levels obtained by this type of GH delivery with those obtained via 
implantation of GH-secreting cells. 
3. In vivo approach 
Adenovirus administration is an effective way of delivering therapeutic genes since they can 
be produced and purified in a concentrated form, which facilitates in vivo delivery. Another 
advantage is that potential oncogenic effects resulting from viral integration into critical 
chromosomal regions are unlikely because adenoviruses do not integrate into host 
chromosome DNA 5. Since it is well-known that adenoviruses can elicit multiple innate 
immune responses after systemic administration, there are several approaches under 
investigation that attempt to overcome this limitation. These include modification of the 
adenoviral vector design, the use of tissue specific promoters and local administration 
routes and the utilization of immunosuppressive drugs or specific compounds to block 
important immune pathways known to be induced by adenovirus 15. 
Concerning GH deficiency and dwarf animals, an adenoviral vector containing rat GH 
(rGH) cDNA was used in 1996 by the Houston group mentioned above to induce 
constitutive GH expression in hepatocytes of GH-deficient lit/lit mice 5. When the 
recombinant adenoviral vector, controlled by the human elongation factor 1-α (EF1α) 
promoter, was administered via the tail vein of this animal at a dose of 108 pfu (plaque-
forming units), high levels of GH were detected in the serum for at least 7 weeks. This viral 
dose led to an unbelievably high peak of the serum GH level of 1.9 µg/ml, which then 
decreased to ~125 ng/ml during the next 2 weeks, remaining at that level for the duration of 
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bioassay in hypophysectomized rats did provide clear evidence for the in vivo activity of 
pGH in a direct functional assay and confirmed that fibroblasts are indeed capable of 
persistently expressing foreign genes in vivo. 
The same Chinese research group subsequently used primary porcine fetal fibroblasts, 
transduced with the same pGH-carrying vector described above, to enhance the weight gain 
of growth-retarded Tao-Yuan Swine, a local breed in Taiwan that is slow growing and fat, 
but palatable8. Immortalized fibroblasts were avoided because of their tumorigenic 
potential, even though they have been used quite successfully in several different studies in 
mice. The transduced primary cells were encapsulated with the same type of alginate-poly-
L-lysine-alginate membranes used previously for mice myoblasts 4 and then implanted into 
the peritoneal cavity of the swine, resulting in a significant increase in weight gain already 
on day 16 post-implantation, even though no increase in serum pGH could be detected. The 
use of immunoprotective microcapsules thus constitutes a simple method of delivering 
recombinant genes in vivo and proved to be a valid approach for the improvement of the 
growth of these animals. Since the microcapsules obviate the need for patient-specific ex vivo 
preparations and are amenable to industrial-scale production and quality control, this 
approach is also potentially economically viable. 
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keratinocytes that were retrovirally transduced with the human (hGH) or the mouse (mGH) 
GH genes, implanting them into immunodeficient dwarf (lit/scid) mice 3,9-11. Epidermal 
keratinocytes were chosen as the target of our gene therapy methodology because they are 
among the most accessible cells in the body and can be serially propagated in culture, 
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transduced with the hGH gene (under control of the retroviral LTR promoter), a high in vitro 
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led to circulating hGH serum levels of 0.2-0.3 ng/ml during a 12-day assay (peak value, 1.5 
ng/ml at 4h). Grafted mice also showed an increase in body weight (0.060 g/animal/day), 
which was significantly higher (P<0.01) than that of the controls (0.023 g/animal/day). This 
was the first time that continuous in vivo secretion of the hormone and subsequent 
phenotypic alterations due to the grafting of transduced, hGH-secreting primary human 
keratinocytes had been demonstrated in lit/scid mice, an animal model known to be very 
sensitive to low concentrations of hGH 13. 
Conventional epidermal sheets of these mGH-secreting keratinocytes, prepared by us using 
the classical technique of Barrandon et al.2, showed a drop in secretion rates of >80% simply 
due to detachment of the epithelium from its substratum. Replacement of this conventional 
grafting methodology by organotypic raft cultures14 completely overcame this problem. 
Employing a similar ex vivo strategy and this modification of the grafting resulted in a very 
high, stable in vitro secretion of up to 11 µg mGH/106 cells/day. Moreover, the amazing 
value of ~26 µg mGH/106 cells/day could be reached by clonal selection11, performed by 
seeding the mGH-secreting keratinocytes at low densities (~500 cells/10 cm culture dish) 
and isolating colonies with a diameter of ~5 mm by the use of cloning cylinders. Cells were 
expanded four times by serial passage (approximately one passage/week), counted and the 
medium collected for mGH determination by radioimmunoassay. Clonal selection revealed 
that, after four serial passages (equivalent to > 30 cumulative cell doublings or > 107 cells), 
approximately 30% (7 out of 24) of the isolated clones maintained or presented increased 
mGH expression. This percentage represents the fraction of transduced keratinocyte stem 
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cells present, a very important parameter for attaining the desired persistent gene 
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adenoviral vector design, the use of tissue specific promoters and local administration 
routes and the utilization of immunosuppressive drugs or specific compounds to block 
important immune pathways known to be induced by adenovirus 15. 
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the experiment (7 weeks). A viral dose of 109 pfu induced an even higher serum GH level of 
~35 µg/ml, which then decreased to ~2.5 µg/ml over the next two weeks and stabilized at 1 
µg/ml for the duration of the study. The authors attributed the decrease in GH expression in 
part to the ability of the host’s immune system to recognize and subsequently eliminate the 
virally transduced cells. Little dwarf mice treated with 108 pfu of rGH adenovirus showed 
an increase in circulating IGF-I levels (from 61 to 238 ng/ml in 3 weeks). Although the 
serum GH levels increased dramatically, the serum IGF-I levels did not follow the same 
pattern. This may be due to the presence of reduced IGFBP-3 in GH-deficient humans and 
animals. A rapid weight gain, resulting in a body weight comparable to that of normal age-
matched lit/+ animals, was achieved by 5 weeks of treatment. Total body length was also 
indistinguishable from that of lit/+ mice within 7 weeks of treatment and body composition 
was normal, with a reduction in the percentage of fat and increase in the water and protein 
contents. The animals treated with rGH adenoviruses exhibited slight, but significant, 
increases in liver and kidney sizes and a tendency to increase fasting blood glucose and 
insulin levels, which are known effects in response to prolonged exposure to high levels of 
GH. It was suggested, however, that the induced hepatic and renal hyperplasia warranted 
further investigation. According to the authors, the little mice dwarf phenotype could be 
corrected, with minimal side-effects, by constitutive GH expression achieved through in vivo 
recombinant adenoviral delivery. Because the correction of GH insufficiency by gene 
transfer may represent in the future an alternative to the conventional treatment, the 
importance of this work is undeniable since it was the first study to demonstrate a complete 
phenotypic correction of dwarfism. Nonetheless, a constitutive adenoviral-induced GH 
expression in hepatocytes producing extremely high GH serum concentrations, would meet 
serious obstacles to its application in humans. 
In a subsequent study, carried out in 1999 by groups at the National Institute of Health 
(NIH, Bethesda, MD), an adenovirus encoding mGH cDNA was injected into the quadriceps 
muscle or submandibular ducts of mGH-deficient Snell dwarf mice to obtain a homologous 
system and thus avoid possible side effects resulting from species differences 16. When the 
adenoviral vector was used in vitro to infect SMIE (submandibular immortalized ephitelial) 
cells, an epithelial cell line derived from the adult rat submandibular gland, the highest in 
vitro expression level obtained was ~184 ng mGH/ml at 72h post infection for cells infected 
at a MOI (multiplicity of infection) of 300. To test its in vivo efficacy, the virus was injected 
into the quadriceps muscle of Snell dwarf mice (5 x 109 pfu/animal), resulting in an average 
serum level of 42 ± 29.7 ng mGH/ml at 4 days post injection. Submandibular administration 
provided widely varying serum levels of 64.1, 3.4 and 11 ng mGH/ml in three individual 
animals. The intramuscular protocol was more efficient, providing an average 8% increase 
in body weight of the dwarf mice just 4 days post treatment and close to 100% by 30 days. 
This indicates that skeletal muscle gave a fairly stable transgene expression and suggests 
that it can be a highly useful tissue for the delivery of circulating proteins. To obtain enough 
serum to determine the various metabolic parameters, the adenoviral vector was also 
administered to young rats via the intravenous route. The main effects were an increase of ~ 
35% in serum IGF-I levels, ~60% in cholesterol and ~40% in triglycerides, all changes that 
are consistent with systemic mGH action and anabolic effects. The mice and rats utilized in 
these studies received dexamethasone to limit the host immune response of these 
immunocompetent animals. The authors concluded that the adenoviral vector could be a 
valuable tool in preclinical mouse model studies. Even though administration via muscle is 
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somewhat milder than via other tissues (e.g., the liver), we believe that most of the 
limitations related to adenoviral gene therapy are still present in this approach. 
More recently, in 2008, a new generation of double-stranded adeno-associated viral vectors 
(dsAAV) encoding mGH cDNA driven by a universal promoter (CMV) were used by a 
group coordinated by Johns Hopkins University School of Medicine to prepare viral 
particles that were injected into GHRHKO mice, a model of isolated GH deficiency due to 
generalized ablation (knock-out, KO) of the GHRH gene 17,18. These genetically modified 
dsAAV can infect dividing and non-dividing cells in vitro and in vivo with a long-term 
transgenic expression (up to 1 year) and elicit a lower toxicity and cellular immune 
response, therefore being generally considered to be safer than adenoviral vectors. 
In an initial study, GHRHKO mice were injected intraperitoneally with either a single dose 
(low dose) or two doses (high dose) of 1 x 1011 viral particles at the 10th and 11th days of age 
and were followed up to the 6th or 24th week of life17. Body weight and length of both viral-
treated groups became normal at 6 months of age and normal femoral and tibial lengths, 
body composition and weight of organs (liver, spleen, heart and kidney) were also obtained. 
At week 6, serum GH levels were higher in mice receiving both virus doses compared with 
controls, while they were normal at week 24. This is consistent with the results of previous 
studies showing that long-term expression by this type of viral vector is limited to the liver 
and skeletal and cardiac muscle. This was confirmed by the detection of GH mRNA in these 
same tissues of the GHRHKO mice. Nevertheless, serum IGF levels were significantly 
higher in both virus-treated groups compared to the control group at week 24, showing that 
the expressed GH is still functional in GH-deficient and immunocompetent mice and that no 
resistance to its effect was developed over time, since a species-specific GH cDNA was used. 
The use of a universal promoter is obviously a limitation for any clinical application of this 
approach because of the well-known long-term risks associated with excessive unregulated 
GH secretion. The authors concluded that, while the applicability of these findings is still 
very far from any possible clinical trial in humans, these new AAV vectors offer a good 
starting point for the development of novel regulated viral gene delivery systems for GH 
administration. Such systems could be based on the use of inducible promoters that can be 
regulated at will or of tissue-specific promoters, providing good systemic delivery together 
with limited local expression. 
In a subsequent study, the same group utilized a dsAAV expressing mGH cDNA under the 
control of a muscle creatine kinase regulatory cassette in order to ensure adequate systemic 
delivery in conjunction with muscle-specific expression 18. A low-dose (0.5 x 1011 pfu) and a 
high-dose (1 x 1011 pfu) of virus were injected into the right quadriceps muscle of GHRHKO 
mice at the age of day 10. Virus-injected GHD mice showed a significant (P<0.05) increase in 
body length and weight, however without becoming fully normal, and a significant (P<0.05) 
reduction in visceral fat at week 6 of age. Quantitative RT-PCR showed that GH mRNA 
expression in the quadriceps muscle of animals treated with the high-dose of virus was 
significantly higher than in the gastrocnemius and cardiac muscles or the kidney and liver 
of the same mice. At 6 weeks of age, serum GH and IGF-I levels in both treated groups were 
not significantly higher than those in the control mice. This study showed that, although the 
strategy of vector-mediated GH therapy is still not applicable at the clinical stage, systemic 
GH delivery to GHD animals is possible via a single injection of viral particles derived from 
dsAAV using an approach that limits GH expression to skeletal muscle. In fact, it is known 
that widespread gene expression can result in toxicity 19. 
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An alternative system for delivering genes in vivo is the administration of naked plasmid 
DNA. When carried out in certain tissues, particularly muscle, this is considered to be a 
practical method that can produce significant levels of gene expression, although lower than 
those achieved with viral vectors. The simplicity of this methodology has made it the most 
utilized non-viral system in clinical trials of gene therapy, representing as much as 18% of 
current trials 20. 
A research group from a company in Texas has been a pioneer in GH naked DNA 
administration. They designed a muscle-specific gene medicine, composed of a hGH 
expression plasmid containing the chicken skeletal α-actin promoter complexed with a 
protective, interactive, non-condensing (PINCTM) delivery system, to be administered 
intramuscularly in hypophysectomized rats 21. This polymeric PINC gene delivery system 
consists of polyvinilpyrrolidone (PVP), which protects plasmids from extracellular nuclease 
degradation and facilitates the uptake of the plasmid by muscle cells. To test the in vitro 
hGH expression, C2C12 myoblasts were transfected with the muscle-specific hGH plasmid, 
showing a secretion rate of ~43 ng hGH/ml. The plasmid, formulated in saline or 
complexed to PVP, was then injected into the tibialis cranialis muscle of normal and 
hypophysectomized rats. The levels of hGH in normal rat muscle injected with 150 μg of 
hGH plasmid complexed with PVP were ~ 3 ng/gr muscle, i.e., approximately 10- to 15-fold 
higher than the control (plasmid in saline). Comparable hGH levels were detected in muscle 
extracts for up to 14 days, showing a decline 21 days after the injection. In 
hypophysectomized rats, a single but relatively high intramuscular dose (1.8 mg DNA/rat) 
of the hGH plasmid/PVP complex resulted in ~ 1.5 ng hGH/gr muscle (21 days post 
injection). The animals also showed a significant increase in growth, while serum IGF-I 
levels reached a value of 145.4 ± 77 ng/ml (vs. 34.7 ± 2.0 ng/ml before injection) at 21 days, 
declining thereafter. It is noteworthy that, after a single intra-muscular dose of this gene 
medicine, the increase in growth and the serum IGF-1 levels were comparable to those 
obtained with daily injections of recombinant hGH. Anti-hGH antibodies appeared in the 
serum at 14 days post injection, this antibody response being completely blocked by the 
administration of cyclosporine. hGH was not detectable in the sera of the injected animals, 
in spite of the increases in serum rat IGF-I levels and growth. This was attributed by the 
authors to the possibility that hGH levels were below the detection limit of the 
radioimmunoassay and/or that the human hormone was rapidly cleared from the 
circulation due to its short half-life in rodents. This gene medicine was shown to be effective 
over several weeks at a single intramuscular dose. Future work by the authors will be 
devoted to optimizing both the delivery system and the gene expression plasmid in order to 
produce the sustained levels of therapeutic protein necessary to permit the use of this 
specific gene-therapy approach in humans. 
Another strategy used for in vivo GH delivery by a Danish group with which we are 
collaborating is hydrodynamic gene transfer. This transfer strategy is based on a rapid tail 
vein injection of naked plasmid DNA contained in a volume of buffer that corresponds to 
approximately 10% of the body weight of the animal. Although the exact mechanism is not 
clear, the rapid injection of a large amount of aqueous solution is likely to cause a transient 
right-side congestive heart failure with back-flow to the liver vessels. The liver is thus the 
target organ in this therapy, although the transfected vectors are mainly present as non-
integrated episomes. This methodology was used to deliver hGH into hypophysectomized 
mice 22. The entire plasmid pUC-UBI-hGH solution, containing the ubiquitin C promoter 
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and the genomic hGH sequence, was injected (40-50 μg DNA/1.5-1.9 ml) within 3-9 seconds. 
High levels of hGH were obtained in the circulation of the mice, reaching a peak value of 
67.1 ng/ml 13 days post injection and remaining stable at ~50 ng/ml throughout the study 
(68 days), with a concomitant normalization of circulating IGF-I (from a maximum of 599 
ng/ml on day 13) and IGF-binding protein (IGFBP)-3 levels. Furthermore, longitudinal 
growth became normal in terms of tibia length and tail length, while body weight stabilized 
at a level 4-5 g below that of normal mice. Weights of the liver, spleen and lungs were 
normal, whereas that of the heart was only partially normal, with hGH mRNA being 
expressed exclusively in liver tissue. Although the hGH levels were ~20-fold higher than 
physiological baseline levels, the IGF-I and IGFBP-3 levels were comparable to those found 
in normal mice. The authors suggested that a modification of the hydrodynamic procedure, 
for example by using a catheter-mediated delivery to the isolated liver, could make the 
protocol feasible for future human applications. These data strongly suggest that non-viral 
hGH gene transfer could be a feasible alternative to daily hGH injections in GHD patients, 
but again there are serious obstacles that must be overcome before the procedure can be 
used clinically. Hydrodynamic transfer has been successfully applied in dogs 23, but, as 
pointed out by the authors, other routes for gene transfer can be more convenient for 
humans. 
As already mentioned, our group started working with the administration of naked DNA 
and has described a strategy for in vivo GH gene therapy based on electroporation of hGH-
coding plasmid in the quadriceps muscle of lit/lit and lit/scid mice 6. Muscle was chosen for 
the establishment of the methodology since it has been demonstrated that gene delivery 
vectors can be stably maintained in postmitotic fibers after their injection and that this tissue 
is able to provide a long-term release of the therapeutic protein. The utilization of gene 
electrotransfer must also be emphasized because it is considered to be one of the most 
efficient, safest, most practical and less expensive non-viral methods of DNA delivery and 
also generally decreases the inter-individual variability. Using the pUC-UBI-hGH plasmid 
22, we found the optimal electroporation conditions to be eight 50 V pulses of 20ms each at 
0.5 s intervals. Employing these conditions, various amounts (12.5, 25, 50, 75 and 100 µg) of 
the purified plasmid were administered into the exposed right quadriceps muscle. Serum 
hGH levels, determined 3 days after DNA injection, provided a dose-response curve with a 
highly significant (P<0.01) linear correlation in the range of 0-50 µg of injected plasmid. 
Because 50 µg of DNA produced circulating hGH levels of 2-3 ng/ml for at least 12 days, a 
long-term body weight gain assay was carried out in lit/scid mice. After 60 days of 
continuous secretion of hGH, ranging from 1.5-3 ng/ml, the DNA-treated group increased 
from an average weight of 8.92 ± 1.29 g/mouse to 11.87 ± 0.53 g/mouse, corresponding to 
an average weight gain of 33.1% (P<0.001). In contrast, the control group (mice injected with 
saline followed by electroporation) decreased from 9.08 ± 0.95 g/mouse to 8.70 ±0.88 
g/mouse, for a Statistically non-significant weight loss of 4.2%. 
The DNA-injected quadriceps muscles presented a 48.1 % weight increase versus the saline-
injected control (P<0.001), whereas the weight increase of non-injected quadriceps of treated 
animals was 31.0 % (P<0.005). DNA-injected quadriceps showed a 45.5 % increase compared 
to the non-injected quadriceps of the same treated mice (P<0.001). These data point to local 
(autocrine and/or paracrine) and systemic (endocrine) effects as a result of hGH DNA 
injection. 
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Another long-term experiment carried out with immunocompetent dwarf little mice (lit/lit), 
fail to produce the same degree of statistical significance. The body weight increase was 
somewhat lower (~21%) and the increase in body weight ceased after approximately one 
month. However, up to the 32nd day, the slope of the growth curve was 0.048 ± 0.038 
g/mouse/day and the difference relative to the control curve (slope = 0.038 ± 0.016) was 
statistically significant (P<0.01). 
This treatment with a single injection of 50 µg of pUC-UBI-hGH in lit/scid mice was also 
compared to regular injections of recombinant hGH (5 µg/twice a day/animal) during 30 
days. The two different strategies provided a similar response in terms of weight variation, 
when comparing the body weight gain of 0.094 g/mouse/day for the naked DNA system and 
of 0.095 g/mouse/day for recombinant protein injected daily, while the slope for the control 
(saline injection followed by electroporation) was 0.22 g/mouse/day (manuscript in 
preparation)8.  
We have thus shown that intramuscular naked DNA hGH administration can be effective 
for promoting the growth of dwarf “little” mice, a model of human isolated growth 
hormone deficiency (IGHD). More must still be done, however, especially in terms of 
achieving long-lasting, sustained serum levels of the therapeutic protein. 
4. Conclusions 
As far as we know, the treatment of systemic protein deficiencies via gene therapy has not 
yet reached the stage of successful clinical applications, even for other diseases like 
hemophilia 24. As shown here, however, total or partial correction of growth defects has 
been achieved in several animal models for GH gene therapy by the use of a variety of 
different ex vivo or in vivo methodologies, all of which have the potential for future 
developments. We believe that, among these, the intramuscular administration of hGH-
coding naked DNA, followed by a properly adapted electroporation technique, is probably 
the most promising therapy for GH deficiency due to its simplicity, practicality and safety. 
The fact that the plasmid is maintained in an episomal state results in a lower expression, 
but at the same time it offers the possibility of avoiding dangerously high hormone levels 
and undesirable chromosomal integration. Obviously, more must still be done in the 
direction of obtaining a long-lasting in vivo expression of the transgene. 
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1. Introduction 
Sepsis is the leading cause of death in most intensive care units (Angus et al., 2001; Martin et 
al., 2003). Sepsis results from dysregulation of the normally protective anti-microbial host 
defense mechanism and represents a systemic inflammatory response that is associated with 
hypotension, insufficient tissue perfusion, uncontrolled bleeding, and multiple organ 
failure/dysfunction (Bone et al., 1992; Natanson et al., 1994). Accordingly, a major focus of 
sepsis research has been the development of anti-inflammatory strategies. In clinical trials, 
however, most of the therapies that may modify systemic inflammation have largely failed 
to reduce mortality in patients with severe sepsis (Zeni et al., 1997; Natanson et al., 1998; 
Marshall, 2000). These failed trials include administration of high-dose glucocorticoids; 
polyclonal and monoclonal antibodies against endotoxin and various inflammatory 
mediators such as tumor necrosis factor (TNF)-; anti-inflammatories; nitric oxide (NO) 
inhibitors; anti-oxidants; and others. Hence, new understanding of the pathophysiological 
mechanisms underlying this complex disorder is needed to develop novel therapeutic 
strategies that will impact favorably on septic patient outcome. 
Apoptosis is a second prominent feature of sepsis. This process is a mechanism of tightly 
regulated disassembly of cells caused by activation of certain specialized proteases called 
caspases. A number of laboratories have demonstrated that sepsis induces extensive 
lymphocyte apoptosis, which can impairment of immunoresponses, thereby predisposing 
patients to septic death (Ayala & Chaudry, 1996; Wesche et al., 2005; Hotchkiss et al., 2005; 
Lang & Matute-Bello, 2009; Matsuda et al., 2010a). Parenchymal cells, including intestinal 
and lung epithelial cells, also have increased apoptotic cell death in animal models of sepsis 
(Coopersmith et al., 2002a, 2002b; Perl et al., 2007). An autopsy study comparing samples 
from multiple organ systems in 20 patients who died of sepsis with those from 16 critically 
ill, non-septic patients has shown that gut epithelial apoptosis is increased in septic patients 
(Hotchkiss et al., 1999a). Moreover, it has been suggested that vascular endothelial cells may 
 
Targets in Gene Therapy 
 
408 
[22] Sondergaard M, Dagnaes-Hansen F, Flyvbjerg A, et al. Normalization of growth in 
hypophysectomized mice using hydrodynamic transfer of the human growth 
hormone gene. Am J Physiol Endocrinol Metab 2003; 285: E427-E432. 
[23] Zhang G, Vargo D, Budker V, et al. Expression of naked DNA injected into the afferent 
and efferent vessels of rodent and dog livers. Hum Gene Ther 1997; 8: 1763-1772. 
[24] Doering CB, Spencer HT. Advancements in gene transfer-based therapy for 
hemophilia A. Expert Rev Hematol 2009; 2: 673-683. 
23 
Protection from Lethal Cell Death in Cecal 
Ligation and Puncture-Induced Sepsis Mouse 
Model by In Vivo Delivery of FADD siRNA 
Yuichi Hattori and Naoyuki Matsuda 
Department of Molecular and Medical Pharmacology,  
Graduate School of Medicine and Pharmaceutical Sciences, 
University of Toyama, and 
Department of Emergency and Critical Care Medicine, 
Nagoya University Graduate School of Medicine,  
Japan 
1. Introduction 
Sepsis is the leading cause of death in most intensive care units (Angus et al., 2001; Martin et 
al., 2003). Sepsis results from dysregulation of the normally protective anti-microbial host 
defense mechanism and represents a systemic inflammatory response that is associated with 
hypotension, insufficient tissue perfusion, uncontrolled bleeding, and multiple organ 
failure/dysfunction (Bone et al., 1992; Natanson et al., 1994). Accordingly, a major focus of 
sepsis research has been the development of anti-inflammatory strategies. In clinical trials, 
however, most of the therapies that may modify systemic inflammation have largely failed 
to reduce mortality in patients with severe sepsis (Zeni et al., 1997; Natanson et al., 1998; 
Marshall, 2000). These failed trials include administration of high-dose glucocorticoids; 
polyclonal and monoclonal antibodies against endotoxin and various inflammatory 
mediators such as tumor necrosis factor (TNF)-; anti-inflammatories; nitric oxide (NO) 
inhibitors; anti-oxidants; and others. Hence, new understanding of the pathophysiological 
mechanisms underlying this complex disorder is needed to develop novel therapeutic 
strategies that will impact favorably on septic patient outcome. 
Apoptosis is a second prominent feature of sepsis. This process is a mechanism of tightly 
regulated disassembly of cells caused by activation of certain specialized proteases called 
caspases. A number of laboratories have demonstrated that sepsis induces extensive 
lymphocyte apoptosis, which can impairment of immunoresponses, thereby predisposing 
patients to septic death (Ayala & Chaudry, 1996; Wesche et al., 2005; Hotchkiss et al., 2005; 
Lang & Matute-Bello, 2009; Matsuda et al., 2010a). Parenchymal cells, including intestinal 
and lung epithelial cells, also have increased apoptotic cell death in animal models of sepsis 
(Coopersmith et al., 2002a, 2002b; Perl et al., 2007). An autopsy study comparing samples 
from multiple organ systems in 20 patients who died of sepsis with those from 16 critically 
ill, non-septic patients has shown that gut epithelial apoptosis is increased in septic patients 
(Hotchkiss et al., 1999a). Moreover, it has been suggested that vascular endothelial cells may 
 
Targets in Gene Therapy 
 
410 
be undergoing apoptosis in sepsis (Hotchkiss et al., 2002). In sepsis, endothelial cell 
apoptosis may be associated with microvascular dysfunction with reduced perfusion and 
oxygen, which could result in tissue hypoxia and, ultimately, in the development of organ 
failure (Matsuda & Hattori, 2007). This could explain partly the disappointment in a large 
number of sepsis trials conducted with interventions against individual steps in the 
inflammatory cascade, leading investigators to the question of whether death in septic 
patients stems from uncontrolled inflammation (Hattori et al., 2010). 
To reduce sepsis-induced apoptosis, caspase inhibitors have been examined in mice with 
cecal ligation and puncture (CLP)-induced sepsis. It has been reported that the pan-caspase 
inhibitor N-benzyloxycarbonyl-Val-Ala-Asp (O-methyl) fluoromethyl ketone (z-VAD) 
decreases lymphocyte apoptosis in the thymus and spleen, decreases blood bacterial counts, 
and improves survival in sepsis (Hotchkiss et al., 1999b). In a similar study, the pan-caspase 
inhibitor L-826,920 (M-920) and the selective caspase-3 inhibitor L-826,791 (M-791) have 
shown a survival benefit being the result of the rescue of lymphocytes from apoptosis 
(Hotchkiss et al., 2000). Furthermore, Kawasaki et al. (2000) have demonstrated that z-VAD 
decreases apoptosis on pulmonary endothelial cells and epithelial cells and prolongs the 
survival rate in a lipopolysaccharide (LPS)-induced acute lung injury (ALI) mouse model. 
However, successful anti-apoptotic therapy in sepsis with caspase inhibitors may be 
challenging, because caspase inhibitors themselves can have detrimental effects within the 
cell when large amounts of them must reach the cell cytosol to inhibit apoptosis that is 
initiated only by small amounts of caspases. In fact, survival in z-VAD high-dose group after 
CLP returns toward the level of the control (Hotchkiss et al., 1999b), indicating that there 
appears to be close-limiting toxicity associated with the administration of z-VAD. 
Small interfering RNA (siRNA) is another potential reversible inhibitor of the apoptotic 
death pathways. siRNA therapy may offer a unique alternative sepsis treatment to shorten 
the apoptotic arm of sepsis, revealing a number of targets within the apoptotic death 
pathways, which may be useful in designing stand-alone and/or adjuvant therapies that 
would have a significant impact on septic mortality. Although the causative agents of sepsis 
vary widely as do their traditional anti-microbial treatments, siRNA therapy targeted 
toward salvaging immune effector cells, vascular endothelial cells, and parenchymal cells 
from apoptosis has the potential to be beneficial in sepsis regardless of the source. We have 
generated synthetic double-stranded siRNA targeting Fas-associated death domain (FADD) 
and examined the therapeutic effect of systemic administration of the siRNA in the CLP 
mouse model, regarded as a highly clinically relevant animal model of polymicrobial sepsis. 
As described below, FADD is an essential component of the death-inducing signaling 
complex (DISC) for all death receptors (Thorburn, 2004; Lavrik et al., 2005). Here we present 
that this RNA interference-mediated gene silencing in vivo is effective as gene therapy of the 
septic syndrome. 
2. Apoptotic cell death pathways 
Two major pathways are involved in the initiation of apoptotic cell death (Figure 1) (Roy & 
Nicholson, 2000). The first apoptotic pathway is mediated by specific ligands and surface 
receptors, which are capable of delivering a death signal from the microenvironment and 
can activate the execution of apoptosis in the cell cytoplasm and organelles (Herr & Debatin,  
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the intrinsic pathway is activated by mitochondrial injury (Korsmeyer, 1999). The two 
apoptotic signaling pathways ultimately converge into a common pathway causing the 
activation of effector enzymes termed caspases. 
The extrinsic pathway involves activation of members of the TNF receptor (TNF-R) family 
with an intracellular death domain (DD), including TNF-R1, Fas, DR3, DR4, DR5, and DR6. 
These death receptors transmit apoptotic signals initiated by specific ligands such as TNF-, 
Fas ligand (FasL), and TRAIL. Thus, once activated, death receptors recruit the adaptor 
molecule FADD (plus others in some cases) through the homophilic interaction of their own 
DD to the DD of the adaptor molecule. FADD can then recruit the apoptosis initiator 
enzyme procaspase-8 into the DISC as a consequence of the death effector domain-mediated 
homophilic interaction. Subsequently, procaspase-8 is activated proteolytically into caspase-
8 and further activates the apoptosis effector enzymes caspase-3 and other execuitioner 
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caspases (caspase-6 and caspase-7) (Thorburn, 2004; Lavrik et al., 2005; Green & Kroemer, 
2005). 
The intrinsic pathway is initiated by stress signals through the release of apoptogenic factors 
such as cytochrome c from the mitochondrial intermembrane space. Upon release into the 
cell cytoplasm, cytochrome c promotes the formation of a complex between the caspase 
adaptor molecule APAF-1 and the apoptosis initiator enzyme termed procaspase-9 in a 
caspase-activating structure known as the apoptosome, and consequently triggers the 
apoptotic cascade by activating procaspase-9. Thus, the apoptosome, through newly 
activated caspase-9, activates the effector caspases along the common pathway of apoptosis 
(Korsmeyer, 1999). 
In certain types of cells, there is extensive cross-talk that occurs between the extrinsic and 
intrinsic apoptotic pathways (Roy & Nicholson, 2000). Thus, the extrinsic and intrinsic 
apoptotic pathways are intimately connected. This appears to occur via the proteolysis of 
BID, which normally serves an anti-apoptotic role within the intrinsic mitochondrial-
mediated pathway. BID is truncated to receptor pathway, whereupon tBID promotes 
activation of Bax and Bak and thereby induces cytochrome c release, leading to formation of 
the apoptosome (Esposti, 2002). 
3. Impact of the FADD gene silencing with siRNA in sepsis therapy 
3.1 Sepsis-induced up-regulation of death receptors 
We initially verified the hypothesis that tissue expression of death receptors is up-regulated 
in sepsis. Polymicrobial sepsis was induced by CLP in BALB/c mice (Matsuda et al., 2005). A 
middle abdominal incision was performed under anesthesia. The cecum was mobilized, 
ligated at 5 mm from its top, and then perforated in two locations with a 21-gauge needle, 
allowing expression of feces. The bowel was repositioned, and the abdomen was closed. 
Sham-operated animals underwent the same procedure except for ligation and puncture of 
the cecum. This model has high clinical relevance to humans, because it reproduces many 
hallmarks of sepsis that occur in patients (Hubbard et al., 2005). 
Immunoblot analysis showed that surface expression of the two death receptors TNF-R1 
and Fas were up-regulated in lung tissues with time after CLP induction of sepsis (Figure 
2A). Immunohistochemical studies indicated more abundant TNF-R1 expression in the 
inner wall of microvessels from septic mouse lungs (Figure 2B). Meanwhile, Fas was 
detected mainly in alveolar epithelial Type II cells (Matsuda et al., 2009). Similar to these 
death receptors, DR4 and DR5, both of which mediate TRAIL-induced cell death, were up-
regulated in septic mouse lungs (Matsuda et al., 2009). We also found time-dependent 
increases in surface expression of TNF-R1 and Fas in mouse aortic tissues after CLP sepsis 
(Figure 3A). These death receptors are likely to be up-regulated mainly on endothelial cells, 
because the sepsis-induced up-regulation of TNF-R1 and Fas expression in aortic tissues 
was abolished when the tissues were denuded mechanically. Previous works from other 
laboratory have demonstrated that Fas expression is increased in hepatocytes and in 
selected gastrointestinal-associated lymphoid tissues (Chung et al., 2001, 2003). Moreover, 
splenocytes harvested 24 hours after CLP and stimulated with the T cell mitogen concavalin 
A showed an increase in CD4+ T-cell apoptosis as compared to sham controls, which was 
associated with an increase in Fas expression (Ayala et al., 1999). Based on the findings of  
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(A) Western blots of TNF-R1 and Fas in the membrane fractions of lung tissues from mice that were 
subjected to sham operation (control) and sepsis (10 and 24 hours after CLP). Adaptin- served as 
loading control. (B) Immunohistochemical finding for TNF-R1 in the lung section from the mouse 
subjected to sepsis (24 hours after CLP). Positive staining is indicated by arrows. 
Fig. 2. Increased death receptor expression in lung tissues of septic mice. 
increased death receptor expression in tissues of septic mice, we suggest the importance of 
the extrinsic death receptor pathway in apoptotic cell death in sepsis, although a preeminent 
role for the intrinsic mitochondrial pathway has often been noted (Exline & Crouser, 2008). 
As presented in Figure 1, death receptors, after ligand binding, recruit the adaptor protein 
FADD through hemophilic interaction of their DD with the DD of FADD, and then FADD 
can recruit procaspase-8 to the DISC, thereby causing its activation (Thorburn, 2004; Lavrik 
et al., 2005). When FADD protein levels were assessed by Western blotting, induction of 
sepsis by CLP led to a time-dependent increase in FADD protein expression in aortic 
tissues (Figure 3B). This increase occurred on endothelial cells since FADD protein 
expression was not increased in endothelium-denuded aortic tissues from septic animals. 
For silencing of gene expression of FADD, siRNA oligonucleotides with the following 
sense and antisense sequences were designed: 5’-GCA GUC UUA UUC CUA Att-3’ and 
5’-UUA GGA AUA AGA GGA GUA Ctt-3’ (Matsuda et al., 2009, 2010b). In vivo 
transfection of synthetic siRNAs via tail vein was performed at 10 hours after CLP with 
Lipofectamine RNAiMAX (Invitrogen). We used Opti-MEM I Reduced Serum Medium 
(Invitrogen) to dilute siRNAs and Lipofectamine RNAiMAX before complexing, by which 
50 g of FADD siRNA sequence was usually delivered. Systemic delivery of FADD siRNA 
nearly completely eliminated aortic protein expression of FADD (Figure 3B). We also 
confirmed that the increased levels of FADD mRNA and protein in lungs after CLP 
induction of sepsis were strongly suppressed by systemic application of FADD siRNA but 
not of scrambled siRNA (Matsuda et al., 2009). These findings suggested the successful 
efficacy of systemically administered siRNA for silencing tissue expression of FADD in 
septic mice. 
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Western blots of TNF-R1 and Fas in the membrane fractions (A) and FADD in the total fractions (B) of 
aortic vessels from mice that were subjected to sham-operation (control) and sepsis (10 and 24 hours 
after CLP). -Actin and adaptin- served as loading control. In B, sepsis-induced up-regulation of 
FADD protein expression was eliminated by systemic delivery of FADD siRNA. Note that no increase 
in death receptors and FADD was observed when the endothelium was removed by gently rubbing the 
intimal surface. 
Fig. 3. Endothelium-dependent increases in expression of death receptors and FADD in 
aortic vessels of septic mice. 
3.2 Effect of FADD siRNA on cell apoptosis in sepsis 
To assess whether FADD siRNA treatment has a beneficial effect on sepsis-induced 
apoptotic cell death in lungs, the tissue sections were labeled with an in situ TUNEL assay 
(Figure 4A). Apparently, no TUNEL-positive cells were observed in sham control mice. 
Induction of sepsis by CLP resulted in a striking appearance of TUNEL-positive cells. 
Apoptotic cells were identical morphologically to endothelial cells of capillary vessels in the 
alveolar septa and to epithelial type II cells (Matsuda et al., 2009). In agreement with this 
finding, our recent immunofluorescence studies showed that the cleaved form of caspase-3 
was present in cell types other than CD31-positive endothelial cells in lungs (Takano et al., 
2011). In lungs from CLP mice treated with FADD siRNA, but not with scrambled siRNA, 
TUNEL-positive cells were decreased sharply, providing a protective effect of FADD siRNA 
treatment on pulmonary cell apoptosis mediated by sepsis. 
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Sections of the lung (A) and spleen (B) were prepared from mice that were underwent sham procedure, 
CLP, CLP and FADD siRNA administration, or CLP and scrambled siRNA administration. Tissues 
were harvested 24 hours after surgery. In A, TUNEL-positive apoptotic cells are indicated by arrows. 
Scale bars = 20 m (A) and 200 m (B). 
Fig. 4. Mouse lung and spleen tissue sections showing apoptotic cells by an in situ TUNEL 
assay. 
Physiologic TUNEL-positive cells, morphologically identical to lymphocytes (Matsuda et al., 
2009, 2010a), were sporadically present in the spleen tissues from sham control mice (Figure 
4B). In spleens 24 hours after septic insult, marked apoptosis of follicular lymphocytes were 
observed. Most apoptotic lymphocytes were located in the white pulp of the spleen. 
TUNEL-positive lymphocytes in spleen follicles were greatly reduced when FADD siRNA 
was systemically given after CLP. Administration of scrambled siRNA to septic mice 
showed more frequent TUNEL positivity than no treatment. 
Light microscopic studies of aortic tissue sections from septic mice at 24 hours after CLP 
showed partial detachment of endothelial cells from the basal membrane (Matsuda et al., 
2007, 2010b). When the tissue sections were labeled with an in situ TUNEL assay, a 
significant number of apoptotic endothelial cells was found in aortas of septic mice 
(Matsuda et al., 2007, 2010b). Furthermore, scanning electron microscopic analysis indicated 
that the structure of aortic endothelium displayed a remarkable morphological abnormality: 
most endothelial cells were badly swollen (Figure 5A). Such an endothelial histological 
injury was strikingly prevented by systemic treatment with FADD siRNA but not with 
scrambled siRNA. 
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Mice were underwent sham procedure, CLP, or CLP and FADD siRNA administration. Aortic 
endothelial cells were evaluated by scanning electron microscopy (SEM, A) and by transmission 
electron microscopy (TEM, B) 24 hours after surgry. Septic mice showed anomalous swelling of cells 
(SEM) and autophagy-related vacuolation in the cytoplasm (TEM). These electron-microscopical 
changes were prevented by systemic treatment with FADD siRNA. Scale bars = 2 m. 
Fig. 5. Electron microscopic analysis of mouse aortic endothelial cells. 
3.3 Effect of FADD siRNA on sepsis-induced autophagy in endothelial cells 
A non-apoptotic and non-oncotic type of cell death has been recognized (Clarke, 1990). This 
type of cell death is characterized by the appearance of double- or multi-membrane 
cytoplasmic vesicles engulfing bulk cytoplasm and cytoplasmic organelles, such as 
mitochondria and endoplasmic reticulum, and their delivery to and subsequent degradation 
by the lysosomal system of the same cell (Gozuacik & Kimchi, 2004). This type of cell death 
is referred to as autophagic cell death, but it is still unsettled whether autophagy is the direct 
primary cause of cell death or a compensatory mechanism that tries to rescue a cell from 
dying. In starvation, autophagy provides an internal source of nutrients for energy 
generation, promoting cell survival. Defects in autophagy have been implicated in the 
pathophysiology of cancer and neurodegenerative diseases (Rabinowitz & White, 2010). On 
the other hand, systemic inflammatory response syndrome and multiple organ dysfunction 
syndrome are suggested to be accompanied by increased cell death, including autophagy, in 
the affected organs (Yasuhara et al., 2007). A recent report has shown that LPS induces 
autophagy in human umbilical vein endothelial cells (Meng et al., 2010). Moreover, LPS-
induced systemic inflammation has been demonstrated to exert autophagy of hepatocytes in 
streptozotocin-induced diabetic rats (Hagiwara et al., 2010). 
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Our ultrastructural analysis using transmission electron microscopy indicated the formation 
of autophagy-like vesicles in aortic endothelial cells of CLP septic mice (Figure 5B). 
Microtubule-associated protein 1A/1B-light chain 3 (LC3) is a soluble protein with a 
molecular mass of ~17 kDa that is distributed ubiquitously in mammalian tissues. Cleavage 
of LC3 at the carboxyterminus immediately following synthesis yields the cytosolic LC3-I 
form. LC3-I form is converted to LC3-II during autophagy. Thus, LC3-II is widely used as an 
indicator of autophagy (Kabeya et al., 2000). Western blot analysis revealed significantly 
elevated aortic LC3-II levels in the CLP septic group (Figure 6). Very interestingly, these 
autophagy-related changes were prevented by systemic application of FADD siRNA 
(Figures 5B and 6). 
 
 
Immunoblotting of LC3 usually reveals two bands: the cytosolic form LC3-I and the membrane-bound 
form LC3-II. Sepsis (24 hours after CLP) resulted in a significant conversion of LC3-I to LC3-II. Tracking 
the conversion of LC3-I to LC3-II is indicative of autophagic activity. Systemic administration of FADD 
siRNA prevented this conversion. Summarized data are presented as the mean ± S.E. of five different 
experiments. *P<0.05 vs. sham control. #P<0.05 vs. CLP alone. 
Fig. 6. Immunoblot analysis of LC3 in mouse aortic vessels. 
There are several lines of experimental evidence that apoptosis and autophagy may be 
interconnected in some settings, and in some cases even simultaneously regulated by the 
same trigger resulting in different cellular outcomes (Gozuacik & Kimchi, 2004). Previous 
data supporting the interconnection between the two types of cell death have come from 
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primary cause of cell death or a compensatory mechanism that tries to rescue a cell from 
dying. In starvation, autophagy provides an internal source of nutrients for energy 
generation, promoting cell survival. Defects in autophagy have been implicated in the 
pathophysiology of cancer and neurodegenerative diseases (Rabinowitz & White, 2010). On 
the other hand, systemic inflammatory response syndrome and multiple organ dysfunction 
syndrome are suggested to be accompanied by increased cell death, including autophagy, in 
the affected organs (Yasuhara et al., 2007). A recent report has shown that LPS induces 
autophagy in human umbilical vein endothelial cells (Meng et al., 2010). Moreover, LPS-
induced systemic inflammation has been demonstrated to exert autophagy of hepatocytes in 
streptozotocin-induced diabetic rats (Hagiwara et al., 2010). 
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Our ultrastructural analysis using transmission electron microscopy indicated the formation 
of autophagy-like vesicles in aortic endothelial cells of CLP septic mice (Figure 5B). 
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molecular mass of ~17 kDa that is distributed ubiquitously in mammalian tissues. Cleavage 
of LC3 at the carboxyterminus immediately following synthesis yields the cytosolic LC3-I 
form. LC3-I form is converted to LC3-II during autophagy. Thus, LC3-II is widely used as an 
indicator of autophagy (Kabeya et al., 2000). Western blot analysis revealed significantly 
elevated aortic LC3-II levels in the CLP septic group (Figure 6). Very interestingly, these 
autophagy-related changes were prevented by systemic application of FADD siRNA 
(Figures 5B and 6). 
 
 
Immunoblotting of LC3 usually reveals two bands: the cytosolic form LC3-I and the membrane-bound 
form LC3-II. Sepsis (24 hours after CLP) resulted in a significant conversion of LC3-I to LC3-II. Tracking 
the conversion of LC3-I to LC3-II is indicative of autophagic activity. Systemic administration of FADD 
siRNA prevented this conversion. Summarized data are presented as the mean ± S.E. of five different 
experiments. *P<0.05 vs. sham control. #P<0.05 vs. CLP alone. 
Fig. 6. Immunoblot analysis of LC3 in mouse aortic vessels. 
There are several lines of experimental evidence that apoptosis and autophagy may be 
interconnected in some settings, and in some cases even simultaneously regulated by the 
same trigger resulting in different cellular outcomes (Gozuacik & Kimchi, 2004). Previous 
data supporting the interconnection between the two types of cell death have come from 
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gene expression profiles during steroid-triggered developmental cell death in the Drosophila 
system where several apoptosis-related genes are up-regulated together with autophagy-
related genes (Gorski et al., 2003; Lee et al., 2003). In other cellular settings, autophagy may 
antagonize apoptosis and inhibition of autophagy may increase the sensitivity of the cells to 
apoptotic signals (Gozuacik & Kimchi, 2004). Moreover, apoptosis and autophagy may 
manifest themselves in a mutually exclusive manner. Inhibition of autophasic activity in 
cells may switch responses to death signals from autophagic to apoptotic cell death 
(Gozuacik & Kimchi, 2004). In addition, there are numerous reports showing a direct 
physical interaction between autophagy-inducing proteins and proteins involved in 
apoptosis, especially anti-apoptotic Bcl-2 family members (Liang et al., 1998; Vande Velde et 






















Mortality was monitored 4 times daily, and survival time was recorded for 7 days. Systemic delivery of 
FADD siRNA, but not scrambled siRNA, resulted in a significant survival benefit. Percentage survival 
of mice after CLP is plotted. Ten mice for each group underwent CLP. 
Fig. 7. Kaplan-Meier survival curves after CLP in mice given FADD siRNA. 
3.4 Effect of FADD siRNA on animal survival after CLP 
To evaluate the impact of FADD siRNA on survival benefit in sepsis, we examined mortality 
in mice subjected to CLP (Figure 7). After CLP, mice exhibited signs of sepsis. Thus, they 
showed lack of interest in their environment, displayed piloerection, and had crusty 
exudates around their eyes. Finally, all animals subjected to CLP without treatment died 
within 2 days. Treatment of CLP mice with scrambled siRNA was without effect on 
survival. However, when FADD siRNA was administered to CLP mice, its survival 
advantage was very striking (P<0.0001; Log rank test). Even at the end of 7 days, a greater 
proportion of the animals given FADD siRNA survived CLP with 80%. 
4. Conclusions 
Despite recent advances in antibiotics and critical care therapy, sepsis treatment remains 
clinical conundrum, and its prognosis is still poor, especially when septic shock and/or 
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multiple organ failure develop. Although a host of promising candidates for therapeutic 
intervention in sepsis have been propelled, almost all of these trials have failed to 
demonstrate a mortality benefit for patients suffering from sepsis. Ongoing research into 
this highly lethal disorder has shown that apoptosis is fully associated with an unfavorable 
outcome of sepsis and its inhibition may provide useful therapies for treatment of sepsis. 
Here we propose that FADD siRNA therapy may offer a unique alternative sepsis treatment 
to shorten the apoptotic arm of sepsis. This therapy salvaged immune effector cells, vascular 
endothelial cells, and parenchyma cells from apoptosis, which would arrest the 
development of complications arising from sepsis, including multiple organ failure, and 
ultimately have a beneficial impact on septic mortality. While appreciating that additional 
work is required to optimize preclinical and possibly clinical application, treatment with 
FADD siRNA will hopefully provide novel potential usefulness for gene therapy that could 
improve the survival of critically ill septic patients. 
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1. Introduction  
Charcot-Marie-Tooth disease (CMT) is the most common inherited neurologic disorder. 
Reportedly 10-28 cases exist per 100,000 in Western societies. CMT patients suffer from a 
variable degree of motor dysfunction which adversely affects locomotion and balance. These 
deficits explain by a slowing of impulse conduction in motor and sensory nerves. This 
affects the recruitment of muscle fibres for contraction whereby slow motor units are 
preferentially affected (Gale et al., 1982; Roy et al., 1996). This results in muscle weakness 
and wasting in the extremities of the body.  
The inefficient propagation of excitatory signals in moto neurons towards peripheral muscle 
in CMT disease is caused by a myelination defect which has a genetic origin. Some 20 genes 
for axon proteins and myelin have been implicated in CMT, and allow the classification into 
specific subtypes of the disease. Frequently affected of these genes are peripheral myelin 
protein 22 (pmp22) and myelin protein zero (MPZ) which are mutated in a majority of cases 
(Braathen et al., 2011). CMT subtype 1A (CMT1A) is the most predominant disease type 
being associated with a duplication of the pmp22 gene (Wise et al., 1993; Magyar et al. 1996). 
The pmp22 gene encodes for a factor that is incorporated into the myelin sheet of neurons 
and is thought to control myelin thickness. The pathology on the CMT1A disease types is 
explained by slowed saltatory transduction in moto neurons due to the aberrant nerve 
insulation (Sereda & Griffiths, 1996). 
Currently there is no cure for CMT. There are however a number of occupational 
interventions that can be used to effectively manage its symptoms 
(http://www.ninds.nih.gov/disorders/charcot_marie_tooth/detail_charcot_marie_tooth.ht
m). The most effective treatment consists of a rehabilitation programs with physical therapy 
as an active ingredient. This involves daily heel cord stretching exercises to prevent Achilles 
tendon shortening. Concomitantly, resistant training of CMT patients can lead to impressive 
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increases in maximal voluntary force (Lindeman et al., 1999). Exercise is thus encouraged 
within each individual patient's capability to condition motor performance in this 
neurological disease. Physical activity however only retards the irreversible degeneration 
and may have detrimental consequences if inappropriately administered (Vinci et al., 2003). 
Gene transfer therapy is a promising route for future cures of muscular disorders. However 
major limitations appear regarding the treatment of neurological diseases such as CMT. In 
this case one would normally expect that the therapy must directly target moto neurons to 
initiate a compensatory mechanism that can correct the missing myelination. This is 
currently not feasible. In this regard the important positive influence of exercise on motor 
performance in CMT patients demands consideration as this may offers an indirect means to 
improve neuromuscular function. This relates to the well established feed forward control of 
the muscle phenotype by muscle use (Fluck & Hoppeler, 2003). It has been pointed out that 
the effects of increased muscle recruitment with exercise involve the promotion of the slow-
oxidative expression program (Schmutz et al., 2010; Baumann et al., 1987). Recently, has 
been established that electrically imposed muscle recruitment can re-establish muscle 
functionality in denervated muscle of tetraplegic patients through the remodelling of the 
contractile and metabolic makeup (Boncompagni et al., 2007). The positive influence of 
exercise in CMT patients suggests that the use-dependent pathway importantly affects 
neuro-muscular function. 
We reasoned that altered muscle use combined with gene therapy for focal adhesion kinase 
(FAK), an enzyme that regulates recruitment dependent slow oxidative gene expression, 
would be a suitable venue to promote pmp22 expression in skeletal muscle. Towards this 
end we investigated the use dependence of pmp22 expression in human skeletal muscle and 
assessed the nature of contractile defects in muscles of a mouse model for CMT at the 
molecular, cellular and functional level. Subsequently we tested whether overexpression of 
FAK can enhance pmp22 expression in skeletal muscle (Durieux et al., 2009).  
2. Methods 
Response to exercise in human muscle - A resting biopsy was collected with a conchotome from 
the non-exercising leg after an overnight fast and prior to exercise. Thereafter, each 
participant performed an acute single-legged endurance exercise bout at 60% of their Pmax 
on an Ergoline bicycle ergometer (Jaeger). There was an incremental warm-up period to 
reach their 60% Pmax, and after 20 minutes of cycling at 80 rpm, the resistance was 
increased by 5 W every 10 seconds until volitional exhaustion. A biopsy was collected with 
the ACECUT needle system (UK Surgical Ltd) from the exercised leg 8 hours after the bout 
of exercise. Biopsy position was standardized based on an ultra-sound measurement at 50% 
of femur length. This study was performed at Manchester Metropolitan University (United 
Kingdom) with permission of the institutional ethics Committee, in compliance with the 
Helsinki Convention for research on human subjects. 
Model of altered muscle activity – Hindlimb suspension of rats was performed for 7 days as 
previously described (Fluck et al., 2005) at the Université Lyon 1 (France) and started 2 days 
after transfection. Subsequent reloading was provoked by allowing the animals to return to 
normal cage activity for 1 or 5 days. 
Hindlimb suspension of mice was performed for 3 days as previously described at the 
University of Berne (Switzerland) (Dapp et al., 2004). This was achieved by attaching the tail 
via a swivel hook to a movable X-Y system; thereby preventing the mouse from touching the 
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ground with its hindlimbs while permitting free movement within the entire cage. Soleus 
muscles were extracted from anesthetized animals (5% isoflurane).  
Animal model of CMT - Pmp22-tg mouse (pmp22tg) as CMT model (strain C3Hb6) were bred 
at the University of Fribourg. The original strain was a gift of U. Suter (University of 
Zurich). The pmp22-tg mice carry approximately 16 and 30 copies of the pmp22 gene and 
display a severe congenital hypomyelinating neuropathy due to the accumulation of 
overexpressed pmp22 in the Golgi compartment, and the concomitant interference with 
myelin assembly during Schwann cell differentiation (Niemann et al., 2000). This is 
characterized by an almost complete lack of myelin and marked slowing of nerve 
conductions (Magyar al., 1996). The animals entering the study were between 1.5- and 3-
month of age.  
Somatic transgenesis for FAK - Gene transfer of pCMV-FAK into soleus muscle of 3-month old 
male Wistar rats was essentially carried out as previously described (Durieux et al., 2009). In 
brief, soleus muscles of anaesthetized rats (60 mg of sodium pentobarbital per kg body) 
were surgically exposed. 70 microgram per 70 microliter of endotoxin-free plasmid in Tris-
EDTA buffer (plasmidfactory, Bielefeld, Germany, www.plasmidfactory.de) was injected in 
the belly portion of the soleus muscle and three trains of 80-pulses of 100 microseconds 
duration, each at 100 mA, were delivered using needle electrodes with the GET42generator 
(Electronique et Informatique du Pilat, Jonzieux, France). The wound was closed with 
sutures and animals transferred to single cages. Right soleus muscles were injected with 
cytomegalovirus promoter-driven plasmids for the constitutive overexpression of chicken 
FAK (pCMV-FAK). The plasmid was a gift from Tony Parsons (University of Virginia, 
Charlottesville, USA). The (left) soleus muscles of the contralateral leg were injected with 
empty pCMV plasmid. 
The experiments were performed at the Universities of Berne (Switzerland) and Lyon 
(France) with the permission of the local Animal Care Committee of the Canton of Berne 
(Switzerland) and following the recommendations provided by the European Convention 
for the protection of Vertebrate Animals used for Experimental and Scientific purposes 
(Strasbourg, 18.III.1986). 
Muscle sampling – Collected muscles were frozen in nitrogen cooled isopentane and stored in 
sealed cryotubes at -80°C until use.  
Transcript profiling – Transcript levels were assessed with microarray in total RNA. In brief, 
25 micrometer cross-sections were prepared for 10 mm3 of muscle volume and total RNA 
extracted with the RNeasy mini-protocol (Qiagen, Basel, Switzerland) for skeletal muscle as 
described (Fluck, Schmutz et al. 2005). Integrity of the RNA was checked with denaturing 
agarose gel electrophoresis, and the concentration was quantified against ribosomal 
standard using the RiboGreen RNA quantification kit (Molecular Probes, Eugene, OR). 
Subsequently RNA was labelled during reverse-transcription and hybridized to different 
platforms dependent on the species:  
For human samples this involved the use of a full human genome Affimetrix platform 
through a commercial provider (DNA vision, Gosselies, Belgium). For statistical analysis 
raw signals were normalized to total mRNA signal on the array and assessed with statistical 
analysis of microarrays between pre and 8-hours post samples with T-tests (SAM). 
For studies with rat and mouse soleus muscle, 3 micrograms of total RNA were reverse 
transcribed with SuperScript II (Life Technologies, Basel, Switzerland) using [-32P]dATP 
and gene-specific primers. Radio-labelled target cDNA was hybridised in ExpressHyb 
solution overnight at 68°C to nylon membranes which spotted cDNA probes (BD 
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Biosciences, Allschwil, Switzerland). The membranes were washed (four times for 1 h in 2x 
SSC (0.3 M sodium chloride, 0.03 M sodium citrate), 1% SDS and once for 30 min in 0.1x 
SSC, 0.5% SDS at 68°C and exposed for 5 days to a phosphoimager (Molecular Dynamics, 
Sunnyvale, CA) for quantification with AIDA Array Easy software (Raytest Schweiz, 
Urdorf, Switzerland).  
For the rat experiment cDNA microarrays (Atlas Rat 1.2, no. 7854; Clontech Laboratories, 
Ozyme, France) were used. More details to this cDNA array can be found on Gene 
Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) under GPL153. Data sets 
have been deposited under sample codes GSM10045–GSM10062, and GSM17357–
GSM17361. For statistical analysis, raw signals were normalized to beta actin signal on the 
array and assessed with T-tests. 
For the mouse experiment custom-designed low-density Atlas cDNA expression arrays with 
229 double-spotted probes of mouse cDNAs associated with skeletal muscle form and 
function were employed. More details to this cDNA array can be found on GEO under 
GPL1097. For statistical analysis raw signals were normalized to total mRNA signal on the 
array and assessed with SAM. 
Microscopy - Fibre type analysis of mouse muscle was carried out on cryosections with 
specific antibodies using a two-step detection protocol as described (Fluck et al., 2002). In 
brief, 12 micrometer cryosections were prepared, fixed in cold acetone and wetted in 
phosphate-buffered saline (PBS). Tissue peroxidase activity was then quenched (10 min, 3% 
H2O2 in methanol), sections were washed in PBS and blocked with 3% BSA in PBS for 0.5 h. 
Subsequently the sections were incubated for 1 h at room temperature (20 °C) with 1:100 of a 
monoclonal antibody in 0.3 % BSA/PBS against slow (Chemikon Juro, Lucerne, 
Switzerland) or fast type myosin heavy chain (Sigma Chemicals, (Buchs, Switzerland), 
respectively. Following, 3 brief washing in PBS, the section was reacted for 30 min with 
peroxidase-conjugated goat anti-rabbit IgG (diluted 1:2000 in 0.3 % BSA/PBS; Jackson 
Laboratories, West Grove, PA, USA) and again washed with PBS. Immunoreactivity was 
detected with 3-amino-9-ethylcarbazole substrate (Sigma Chemicals, Buchs, Switzerland); 
the nuclei were counterstained with haematoxylin, and the sections were embedded in 
Aquamount (BDH Laboratory Supplies Poole, UK). The stain was visualised on film 
(Ektachrome 64T, Kodak) using a microscope/photograph system (Vanox-S, Olympus). 
Micrographs were taken from corresponding fields and the fibre types were classified. Slow 
and fast type fibres were differentiated on the basis of the presence of immunoreactivity for 
either type I or type II myosin heavy chain isoforms. Subsequently the percentages of each 
fiber population were counted.  
The overexpression of FAK in muscle fibres was detected out with a Leica TCS SP5 confocal 
microscope on a DMI6000 stage powered by Argon laser and He–Ne lasers (Leica 
Microsystem CMS, Mylton Keynes, UK). In brief, 12 micometer cryosections were reacted 
with a 1 : 100 dilution of rabbit FAK antibody A-17 (Santa Cruz) and MHC2 antibody in 
0.3% BSA in phosphate-buffered saline (PBS) and reacted with fluorescent-labelled 
secondary antibodies (Alexa488-conjugated anti-rabbit IgG, and Alexa555-conjugated anti-
mouse IgG, Molecular Probes/Invitrogen). Sections were embedded in fluorescence-
compatible mounting medium (DAKO, Denmark). Signal for FAK and the co-detected 
myosin protein was inspected with fluorescence after excitation at 458 nm, 476 nm and 488 
nm with sampling in channels between 510–533 nm (Alexa 488) and 593–614 nm (Alexa 555).  
Myography - Soleus muscles were harvested from anesthetized animals (pentobarbital, 50 
microgram/gram body weight) and equilibrated in Tyrod solution (mM/l: 118.0 NaCl, 4.7 
KCl, 2.0 CaCl2, 1.2 MgSO4, 1.1 KH2PO4, 24.0 NaHCO3, 4.5 glucose, pH 7.3–7.4; 5% CO2 / 
95% O2 @ 25°C). Muscles were transferred to Tyrod solution in the contraction chamber, 
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connected to the force transducer (KG7; Muscle tester ORG (SI-Heidelberg, Germany) and 
equilibrated for 5-10 minutes by gazing with 5% CO2 / 95% O2 @ 25°C. Contractions were 
initiated by point stimulation via an Ion Optix myopacer. Signals were recorded using a 
Powerlab system (AD instruments, Germany) and using Chart 5 software. Measurement of 
single twitch, tetanus and fatigue were carried out: First the length of the inserted muscle 
was optimized for maximal force at a stimulation of 1 Hz, 10 V, 0.4 ms. For single twitch 
contractions, the muscle was stimulated at 1 Hz, 10 V, 0.4 ms. For the assessment of fatigue, 
a repeated 3-minute tetanic contraction protocol was used (55/60 Hz, 10 V, 0.4 ms in trains 
of 4 seconds on and off). Fatigue was defined as the contraction cycle when force dropped 
below 50% of original force. Before each measurement the Tyrod solution was exchanged. 
The measured muscles were frozen in liquid nitrogen-cooled isopentane to determine fiber 
size and distribution. Twitch parameters (latency, twitch-time to peak, t1/2 relaxation, 
maximal force) were determined from the digital recording. Measures from contralateral 
muscles were considered as separate biological replica. Statistical analysis was carried out 
with an unpaired t-test (Statistica 6.1). 
2.1 Results 
2.1.1 Regulation of myelin-specific transcripts by muscle activity 
Muscle fibres of anti-gravitational muscles are active for a considerable duration during free 
movement and quiet standing (Hennig & Lomo, 1985). We wished to investigate transcript 
regulation of factors of the myelin sheet by muscle activity. Towards this end we carried out 
an exploratory microarray analysis with the slow oxidative soleus muscle of rats that was 
subjected to changes in muscle activity by hindlimb suspension. The model allows reducing 
load bearing activity to slow oxidative soleus muscle by non-invasive means with the 
suspension of hindlimbs with the option to increase muscle activity with subsequent 
reloading (Morey Holten model as referred by Dapp et al., 2004).  
Transcript profiling of rat soleus muscle showed lowered expression of the myelin-specific 
transcripts, peripheral myelin protein 22 (pmp22), myelin protein zero (MPZ), myelin basic 
protein (mbp) as well as myelin proteolipid protein and myelin-associated glycoprotein 
with reduced muscle activity (Fig. 1). With reloading the abundance of all of these 
transcripts were sizably increased.  
We assessed the response of myelin-specific factors in human knee extensor muscle to 
exhaustive exercise. It has been pointed out before that this exercise stress induces a 
compensatory expression response during the first 24 hours of recovery from exercise 
(Pilegaard et al., 2000; Fluck, 2006). The analysis in the mixed vastus lateralis muscle 
consolidated the observation on the regulation of myelin-specific transcripts by muscle use. 
Pmp22, mpz and mbp transcript levels were increased by 1.2 to 1.8-fold (table 1). 
 
gene abbr mean SE p-value 
myelin basic protein MBP 1.7 0.3 2% 
myelin expression factor 2 MYEF2 1.4 0.2 3% 
peripheral myelin protein 22 PMP22 1.8 0.4 5% 
myelin associated glycoprotein MAG 1.1 0.1 5% 
myelin protein zero MPZ 1.2 0.1 21% 
myelin oligodendrocyte glycoprotein MOG 1.2 0.1 25% 
Table 1. Expressional alterations in myelin-specific transcripts in human vastus lateralis 
muscle after endurance exercise.  
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Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) under GPL153. Data sets 
have been deposited under sample codes GSM10045–GSM10062, and GSM17357–
GSM17361. For statistical analysis, raw signals were normalized to beta actin signal on the 
array and assessed with T-tests. 
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Aquamount (BDH Laboratory Supplies Poole, UK). The stain was visualised on film 
(Ektachrome 64T, Kodak) using a microscope/photograph system (Vanox-S, Olympus). 
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and fast type fibres were differentiated on the basis of the presence of immunoreactivity for 
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Microsystem CMS, Mylton Keynes, UK). In brief, 12 micometer cryosections were reacted 
with a 1 : 100 dilution of rabbit FAK antibody A-17 (Santa Cruz) and MHC2 antibody in 
0.3% BSA in phosphate-buffered saline (PBS) and reacted with fluorescent-labelled 
secondary antibodies (Alexa488-conjugated anti-rabbit IgG, and Alexa555-conjugated anti-
mouse IgG, Molecular Probes/Invitrogen). Sections were embedded in fluorescence-
compatible mounting medium (DAKO, Denmark). Signal for FAK and the co-detected 
myosin protein was inspected with fluorescence after excitation at 458 nm, 476 nm and 488 
nm with sampling in channels between 510–533 nm (Alexa 488) and 593–614 nm (Alexa 555).  
Myography - Soleus muscles were harvested from anesthetized animals (pentobarbital, 50 
microgram/gram body weight) and equilibrated in Tyrod solution (mM/l: 118.0 NaCl, 4.7 
KCl, 2.0 CaCl2, 1.2 MgSO4, 1.1 KH2PO4, 24.0 NaHCO3, 4.5 glucose, pH 7.3–7.4; 5% CO2 / 
95% O2 @ 25°C). Muscles were transferred to Tyrod solution in the contraction chamber, 
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with reduced muscle activity (Fig. 1). With reloading the abundance of all of these 
transcripts were sizably increased.  
We assessed the response of myelin-specific factors in human knee extensor muscle to 
exhaustive exercise. It has been pointed out before that this exercise stress induces a 
compensatory expression response during the first 24 hours of recovery from exercise 
(Pilegaard et al., 2000; Fluck, 2006). The analysis in the mixed vastus lateralis muscle 
consolidated the observation on the regulation of myelin-specific transcripts by muscle use. 
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Fig. 1. Expression of myelin-specific transcripts depends on muscle activity. Bar graphs 
indicating mean ± standard error (SE) of level changes of five transcripts (per beta actin) in 
rat m. soleus with 7 days of hindlimb suspension vs. cage controls (A) and one day of 
reloading vs. hindlimb suspension (B). Asterisks denote significant effect based on a T-test. 
n=6. The line of identity is given. Abbreviations: mpz, myelin protein zero; pmp22, 
peripheral myelin protein 22; plp, myelin proteolipid protein; mag, myelin-associated 
glycoprotein; mbp, myelin basic protein. 
2.2 Contractile defects in a mouse model of pmp22-dependent CMT 
Pmp22-tg mice show reduced pmp22 protein expression, lack myelination, and demonstrate 
neurogenic muscle atrophy (Magyar et al., 1996).  
We compared the muscles of pmp22-tg mice vs. strain matched controls to identify 
contractile defects with pmp22-dependent moto neuron aberration. Soleus muscle of 
pmp22-tg mice demonstrated a shift towards an atrophic, slow phenotype. This was 
indicated by the reduced muscle weight (Fig. 2D) and elevated percentage of slow type 
muscle fibres (Fig. 2A-C). This became manifest in prolonged time-to-peak and half time of 
muscle relaxation (Fig. 2D). The aberrations resulted in a reduction in RNA messengers for 
the slow oxidative expression program concomitantly with the elevated abundance of gene 
transcripts for fast type myogenesis (Fig. 3). The only exceptions were GAPDH and CA3 
being involved in pH regulation of slow type muscle fibres.  
2.3 Aberrant muscle plasticity in CMT mice with altered muscle use 
Towards understanding the functional implication of motor unit recruitment for control of 
muscle gene expression we subjected pmp22-tg mice to 3 days of hindlimb suspension. 
Microarray experiments identified important alterations in transcript expression in soleus 
muscles with 3 days of reduced muscle activity (Fig. 4). The differences between suspended 
and cage control muscle distinguished between wildtype and pmp22-tg mice. This 
concerned gene ontologies defining the contractile and metabolic muscle phenotype of 
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Fig. 2. Contractile aberrations in anti-gravitational muscle of pmp22-transgenic mice. A, B) 
Micrographs visualizing cross sections of soleus muscle from a wildtype (A) and pmp22-tg 
mouse (B) after staining for slow type myosin heavy chain. C, D) Bar graphs indicating 
mean ± SE of percentage of slow type muscle fibres (C) in soleus muscle and weight (D) of 
wildtype (white bar, n=5) and pmp22-transgenic mice (black bar, n=6). E) Mean ± SE and 
standard deviation (SD) of contractile parameters in soleus muscles of wildtype (n=6) and 
pmp22-transgenic mice (n=5). Asterisks denote significant effect based on a T-test. 
skeletal muscle. Thereby transcript levels of factors of myogenesis, fast contraction, 
glycolysis and oxidative metabolism altered in opposite ways between wildtype and 
pmp22-tg muscle. 
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Fig. 2. Contractile aberrations in anti-gravitational muscle of pmp22-transgenic mice. A, B) 
Micrographs visualizing cross sections of soleus muscle from a wildtype (A) and pmp22-tg 
mouse (B) after staining for slow type myosin heavy chain. C, D) Bar graphs indicating 
mean ± SE of percentage of slow type muscle fibres (C) in soleus muscle and weight (D) of 
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standard deviation (SD) of contractile parameters in soleus muscles of wildtype (n=6) and 
pmp22-transgenic mice (n=5). Asterisks denote significant effect based on a T-test. 
skeletal muscle. Thereby transcript levels of factors of myogenesis, fast contraction, 
glycolysis and oxidative metabolism altered in opposite ways between wildtype and 
pmp22-tg muscle. 
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Fig. 3. Aberrant transcript expression in pmp22-transgenic mice. Bar graphs representing the 
mean fold difference in transcript levels between pmp22tg and wildtype mice for gene 
ontologies which set the phenotype of soleus muscle. Data were generated with custom 
mircrarrays for 229 selected factors, normalized to total mRNA and assessed with unpaired 
test using SAM (n=4). Black and grey bars denote significantly up-regulated and 
significantly down-regulated transcripts, respectively. Transcripts reflected by white bars 
were not significant altered. The line of identity is given. Abbreviations: Glut2, facilitative 
glucose transporter member 2; LDH2, lactate dehydrogenase 2; GAPDH; glyceraldehyde-3-
phosphate dehydrogenase; COX IVa, cytochrome c oxidase subunit 4 isoform 1; COX Vb, 
cytochrome c oxidase subunit 5B; COX VIa2; cytochrome c oxidase subunit 6a2; CPTI, 
carnitine O-palmitoyltransferase 1; FAT/CD36, cluster of Differentiation 36/Fatty acid 
transport protein; HADH, 3-hydroxyacyl-CoA dehydrogenase; H-FABP; fatty acid binding 
protein of the heart; LPL, lipoprotein lipase; MCAD, medium-chain specific acyl-CoA 
dehydrogenase; MHC I; myosin heavy chain type I; MHC IIA; myosin heavy chain type IIA; 
MHC IIB; myosin heavy chain type IIB; MHC IIX, myosin heavy chain type IIX; IGF-I, 
Insulin-like growth factor I; SRF, serum response factor; Rb, retinoblastoma-associated 
protein; myoD, Myoblast determination protein 1; p21, cyclin-dependent kinase inhibitor 1; 
myf6/herculin; myogenic factor 6. 
2.4 Muscle-targeted overexpression of the mechano-sensor FAK elevates myelin 
factor expression 
We assessed whether overexpression of the governor of slow-oxidative gene expression, 
focal adhesion kinase (FAK), can control myelin factor expression and pmp22-dependent 
gene transcripts. Using gene electro transfer we introduced a constitutively active 
expression plasmid for FAK, pCMV-FAK, in soleus muscle of the right leg of Wistar rats. 
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Transfection of the contralateral muscle with empty pCMV plasmid served as intra-animal 
control. Immunofluorescence experiments showed that overexpression of FAK was confined 
to muscle fibres but was not observed in contralateral controls (Fig. 5). Microarray analysis 
demonstrated that FAK overexpression increased transcript levels of pmp22 along with the 
one of MBP in soleus muscle of active rats. Concurrently the expression of a battery of slow 
oxidative genes was increased (Durieux et al., 2009). 
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Fig. 4. Anomalous expression response of pmp22-transgenic mice to reduced muscle 
activity. Bar graph representing the mean fold difference in transcript levels in soleus 
muscle between wildtype mice (A, n=8) and pmp22tg (A, n=4) with 3 days of reduced load 
bearing (suspension) vs. cage controls. Data were generated with custom microarrays for 
229 selected factors, normalized to total mRNA and assessed with a paired test between 
values from suspended and cage control muscle using SAM. Black and grey bars denote 
significantly up-regulated and significantly down-regulated transcripts, respectively. 
Transcripts reflected by white bars were not significant altered. The line of identity is given.  
Abbreviations: Glut 4, facilitative glucose transporter member 4; IGF-BP5, Insulin-like 
growth factor binding protein 5. For others consult legend to figure 3. 
2.5 FAK dependent elevation of pmp22 expression is use dependent  
FAK signals mechanical stimuli in muscle to gene expression and protein synthesis (Durieux 
et al. 2009; Klossner et al., 2009). We subjected the FAK-transfected soleus muscles to 7 days 
of hindlimb suspension and subsequent one day of reloading to assess the interaction of 
muscle activity with gene therapy. Pmp22 transcript expression was little affected by 
reduced load bearing. With subsequent reloading however pmp22 levels were reduced. This 
effect was transient and was gone 5 days after reloading 
3. Discussion 
Skeletal muscle is the largest tissue of vertebrate species and most muscle groups rely on 
muscle activity to maintain their phenotype (Booth & Thomason, 1991). This is most 
pronounced in slow oxidative muscle types which are typically involved in control of gait 
and posture (Roy et al., 1996). This resembles the preferential affection of oxidative muscles 
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reduced load bearing. With subsequent reloading however pmp22 levels were reduced. This 
effect was transient and was gone 5 days after reloading 
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pronounced in slow oxidative muscle types which are typically involved in control of gait 
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Fig. 5. FAK driven expression of myelination factors is dependent on muscle activity. A) 
Representative micrograph from a cryosections of a pCMV-FAK transfected soleus muscle 
of a rat after double staining for FAK (red) and fast type myosin heavy chain (MHC, yellow) 
as recorded with a confocal microscope. B) Bar graph representing the mean difference + SE 
of transcripts for three myelination factors pmp22, mpz and mbp between pCMV-FAK vs. 
empty (pCMV) transfected soleus muscle. Black, white and grey bars reflect data from cage 
controls, 7 days suspended and one day reloaded mice. Asterisks denote significant effect 












Fig. 6. Implication of excitation-transcription coupling in muscle control. Sketch summarizes 
a concept whereby moto neuron excitation (feed forward) with muscle use triggers the 
expression of myelination factors which exert feedback control on the muscle-nerve 
interaction. 
in the trembler model of CMT disease (Gale et al., 1982). This use-dependent control of gene 
expression and protein synthesis (Fluck & Hoppeler, 2003; Wilkinson et al., 2008) is not 
taken into consideration in current gene therapy of neurological muscle disorders. 
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Here we prove the concept that muscle fibre targeted somatic transgenesis can affect nerve-
related gene expression. The results point out that muscle activity importantly modifies the 
pre-translational effects of the somatic overexpression of the governor of the slow oxidative 
muscle program, FAK, on the expression of myelin-specific transcripts. This was shown by a 
similar regulation of pmp22, MPZ and MBP transcripts by muscle disuse with reduced load-
bearing (down-regulation) in rats, increased load-bearing muscle activity in rats and with 
endurance exercise (up-regulation) in man (table 1, Fig. 1). The direction of the transcript 
levels points out that that myelin-specific transcript expression is related to fibre 
recruitment. Such a mutual control of the muscle-nerve interaction is known from the action 
of neurotrophic factors during normal development of the slow muscle fiber phenotype 
(Carrasco & English, 2003). These findings support the novel concept that in addition to feed 
forward control of muscle gene expression by muscle use (Calvo et al., 2001) a feedback 
mechanism exists whereby muscle activity in return regulates moto neurons (Fig. 6). 
The functional consequences of use dependent expressional alterations in myelin sheet-
specific factors in skeletal muscle remain to be explored. Pmp22 is a major component of 
myelin expressed in the compact portion of essentially all myelinated fibres in the 
peripheral nervous system and is produced predominantly by Schwann cells. Pmp22 is 
expressed in cranial nerves but not in the mature central nervous system. Studies in injured 
nerve suggested a role during Schwann cell growth and differentiation and maturation of 
the neuromuscular junction (Spreyer et al., 1991; Patel et al., 1992; Magyar et al., 1996). 
Interestingly the identified transcript level changes in our study are in line with the 
degeneration of NMJ with disuse (Deschenes et al., 2001) and neurological adaptation which 
improves fibre recruitment early with exercise (Roy et al., 1996). This supports a hypothesis 
whereby elevated myelin-specific transcript expression may allow the preservation and 
improvement of neuromuscular control of muscle fibres. 
Previous examinations of soleus and EDL muscle in the trembler mouse model of CMT 
revealed that the deep/oxidative and soleus muscles are particularly affected by CMT but 
fibre type differences were not described (Gale et al., 1982). Our measures in the pmp22-tg 
model of CMT emphasize that in addition to altered muscle contractility, slow fibre size and 
transcript expression in the anti-gravitational muscle, m. soleus, is anomalous. The 
reduction in RNA messengers for the slow oxidative expression program (Fig. 3) is possibly 
explained by volumetric alterations in fibre size as suggested by visually larger CSA ratio 
between fast and slow type fibres reflecting atrophy of slow type fibres. Smaller type I fibres 
in animal models for pmp22-dependent motor and sensory neuropathy type has been noted 
before (Schuierer et al., 2005). This would increase the contribution of transcripts in fast type 
muscle fibres. The concomitantly elevated abundance of transcripts for fast type myogenesis 
between pmp22-tg and wildtype mice likely reflects altered regulation in fast muscle fibres 
(Deschenes et al., 2001).  
A main finding of our investigation was that differences between pmp22 and wildtype mice 
were preserved in an ‘opposite’ transcript response of soleus muscle to reduced load-
bearing. Altered transcript expression is a potentially important indicator of pathological 
changes with reduced muscle activity (Bey et al. 2003; Chen et al., 2007). In this regard it is 
important that the response of soleus muscle from wildtype mice to 3 days of unloading 
reproduced the changes reported in a different mouse strain after 7 days of reduced load-
bearing (Dapp, Schmutz et al. 2004). This overlap concerned contractile (MHCIIB) and 
metabolic factors (COXVb, COXVIa2, LDH2). Exceptions concerned those involved in 
myogenesis which were not altered after 3 days in this study. Strikingly, the transcript 
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Fig. 6. Implication of excitation-transcription coupling in muscle control. Sketch summarizes 
a concept whereby moto neuron excitation (feed forward) with muscle use triggers the 
expression of myelination factors which exert feedback control on the muscle-nerve 
interaction. 
in the trembler model of CMT disease (Gale et al., 1982). This use-dependent control of gene 
expression and protein synthesis (Fluck & Hoppeler, 2003; Wilkinson et al., 2008) is not 
taken into consideration in current gene therapy of neurological muscle disorders. 
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Here we prove the concept that muscle fibre targeted somatic transgenesis can affect nerve-
related gene expression. The results point out that muscle activity importantly modifies the 
pre-translational effects of the somatic overexpression of the governor of the slow oxidative 
muscle program, FAK, on the expression of myelin-specific transcripts. This was shown by a 
similar regulation of pmp22, MPZ and MBP transcripts by muscle disuse with reduced load-
bearing (down-regulation) in rats, increased load-bearing muscle activity in rats and with 
endurance exercise (up-regulation) in man (table 1, Fig. 1). The direction of the transcript 
levels points out that that myelin-specific transcript expression is related to fibre 
recruitment. Such a mutual control of the muscle-nerve interaction is known from the action 
of neurotrophic factors during normal development of the slow muscle fiber phenotype 
(Carrasco & English, 2003). These findings support the novel concept that in addition to feed 
forward control of muscle gene expression by muscle use (Calvo et al., 2001) a feedback 
mechanism exists whereby muscle activity in return regulates moto neurons (Fig. 6). 
The functional consequences of use dependent expressional alterations in myelin sheet-
specific factors in skeletal muscle remain to be explored. Pmp22 is a major component of 
myelin expressed in the compact portion of essentially all myelinated fibres in the 
peripheral nervous system and is produced predominantly by Schwann cells. Pmp22 is 
expressed in cranial nerves but not in the mature central nervous system. Studies in injured 
nerve suggested a role during Schwann cell growth and differentiation and maturation of 
the neuromuscular junction (Spreyer et al., 1991; Patel et al., 1992; Magyar et al., 1996). 
Interestingly the identified transcript level changes in our study are in line with the 
degeneration of NMJ with disuse (Deschenes et al., 2001) and neurological adaptation which 
improves fibre recruitment early with exercise (Roy et al., 1996). This supports a hypothesis 
whereby elevated myelin-specific transcript expression may allow the preservation and 
improvement of neuromuscular control of muscle fibres. 
Previous examinations of soleus and EDL muscle in the trembler mouse model of CMT 
revealed that the deep/oxidative and soleus muscles are particularly affected by CMT but 
fibre type differences were not described (Gale et al., 1982). Our measures in the pmp22-tg 
model of CMT emphasize that in addition to altered muscle contractility, slow fibre size and 
transcript expression in the anti-gravitational muscle, m. soleus, is anomalous. The 
reduction in RNA messengers for the slow oxidative expression program (Fig. 3) is possibly 
explained by volumetric alterations in fibre size as suggested by visually larger CSA ratio 
between fast and slow type fibres reflecting atrophy of slow type fibres. Smaller type I fibres 
in animal models for pmp22-dependent motor and sensory neuropathy type has been noted 
before (Schuierer et al., 2005). This would increase the contribution of transcripts in fast type 
muscle fibres. The concomitantly elevated abundance of transcripts for fast type myogenesis 
between pmp22-tg and wildtype mice likely reflects altered regulation in fast muscle fibres 
(Deschenes et al., 2001).  
A main finding of our investigation was that differences between pmp22 and wildtype mice 
were preserved in an ‘opposite’ transcript response of soleus muscle to reduced load-
bearing. Altered transcript expression is a potentially important indicator of pathological 
changes with reduced muscle activity (Bey et al. 2003; Chen et al., 2007). In this regard it is 
important that the response of soleus muscle from wildtype mice to 3 days of unloading 
reproduced the changes reported in a different mouse strain after 7 days of reduced load-
bearing (Dapp, Schmutz et al. 2004). This overlap concerned contractile (MHCIIB) and 
metabolic factors (COXVb, COXVIa2, LDH2). Exceptions concerned those involved in 
myogenesis which were not altered after 3 days in this study. Strikingly, the transcript 
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response of soleus muscle of pmp22-tg mice to suspension “mirrored” the differences seen 
between the pmp22-tg mice and wildtype mice at baseline. These observations imply the 
existence of use-dependent mechanism that “inverts” expression responses in model of 
CMT.  
This observation relates to the effects of current occupational therapy by exercise. We have 
shown before that FAK overexpression controls contractile performance of soleus muscle in 
a activity-dependent manner via the regulation of transcript expression (Durieux et al., 
2009). Intriguingly with FAK overexpression and the resumption of loading bearing muscle 
activity, the transcript level of myelination factors were reduced compared to controls (Fig. 
5). Our previous findings in the suspension model show that reduced myogenic factor RNA 
expression after 24 hours of the reloading stimulus is related to a concomitant increase is the 
encoded protein (Fluck et al., 2008). This relates to the observation that FAK acts as a 
molecular switch for transition between anabolic and catabolic reactions in skeletal muscle 
and controls the protein synthetic pathway via p70S6K (Durieux et al., 2009; Klossner et al., 
2009) . This suggests that transcript level changes in the early phase of reloading may reflect 
inverse alterations in protein synthesis. These relationships imply that the ’muscle activity’ 
is a confounding variable which would be valuable to be considered in somatic gene 
therapy of skeletal muscle. The fact that activity dependent gene regulation is reflected by 
the mechano-regulation of FAK activity by pTyr-397 phosphorylation (Durieux et al., 2009) 
indicates possible venues to stimulate this directly in situations where muscle activity is not 
an option.  
The extent to which differences between slow and fast motor neurons are involved in the 
coupling between muscle excitation and gene expression (excitation-transcription coupling) 
is currently not well understood (Schiaffino & Serrano, 2002; Wakeling & Syme, 2002). Based 
on a preferential atrophy of slow type muscle fibres (Roy et al., 1996; Dapp et al., 2004), 
hindlimb suspension is expected to affect slow motor units more that fast type units. Our 
findings on the distinction of basal and disuse-induced transcript expression with slowed 
signal propagation down the motoneuron (Magyar et al., 1996) highlight the importance of 
correct excitation for control of gene expression (Calvo et al., 2001). 
4. Conclusion  
Our observations indicate that muscle dysfunction with Charcot-Marie-Tooth (CMT) is not 
due to a single, central mechanism. A novel, contraction-dependent feedback mechanism is 
identified that controls myelin-specific transcripts via a muscle fibre-related pathway. 
Somatic transfection of muscle fibres with the mechanosensor FAK prove the concept that 
pmp22 expression which is lowered in CMT can be stimulated when combined with skeletal 
muscle use. This indicates that muscle activity is a confounding variable that warrants 
exploration in future gene therapeutic strategies to treat and manage neuromuscular 
disease.  
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